var images_info;if (!images_info) images_info =[]; images_info["57"]={"57000":{"type":"graphic_figure","displayName":"Efficacy of premixed insulins","title":"Variable serum insulin concentrations with premixed insulins","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Variable serum insulin concentrations with premixed insulins</div><div class=\"cntnt\"><img style=\"width:399px; height:250px;\" src=\"images/ENDO/57000_Efficacy_of_premixed_insuli.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">24-hour serum insulin profiles after the injection of two premixed insulin preparations: one containing a total of 0.3 units/kg of NPH and regular insulin in a 50:50 ratio (dashed line), and one containing the same total amount of NPH and regular insulin in a 70:30 ratio (solid line). Serum insulin concentrations were significantly higher during the first six hours with the 50:50 regimen, which contained more regular insulin. To convert serum insulin values to µU/mL, divide by 6.</div><div class=\"graphic_reference\">Data from: Woodworth JR, Howey DC, Bowsher RR, et al. Comparative pharmacokinetics and glucodynamics of two human insulin mixtures. 70/30 and 50/50 insulin mixtures.&nbsp;Diabetes Care 1994; 17:366.</div><div id=\"graphicVersion\">Graphic 57000 Version 3.0</div></div></div>"},"57001":{"type":"graphic_waveform","displayName":"12 lead ECG common AVNRT","title":"12 lead ECG of the common form of an atrioventricular nodal reentrant tachycardia","html":"<div class=\"graphic normal\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">12 lead ECG of the common form of an atrioventricular nodal reentrant tachycardia</div><div class=\"cntnt\"><img style=\"width:537px; height:352px;\" src=\"images/CARD/57001_12_lead_ECG_common_AVNRT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 12 lead ECG shows a regular narrow complex tachycardia with a rate of 135 beats per minute; no P waves can be seen. The QRS morphology is identical to that seen during sinus rhythm.</div><div class=\"graphic_reference\">Courtesy of Martin Burke, DO.</div><div id=\"graphicVersion\">Graphic 57001 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"57003":{"type":"graphic_figure","displayName":"TPO and cord blood progenitors","title":"Thrombopoietin and flt-3 ligand expand cord blood progenitors","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Thrombopoietin and flt-3 ligand expand cord blood progenitors</div><div class=\"cntnt\"><img style=\"width:533px; height:352px;\" src=\"images/HEME/57003_TPO_and_cord_blood_progenit.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cord blood progenitor cells were cultured ex vivo for up to 25 weeks in the presence of flt-3 ligand (FL), thrombopoietin (TPO), or both. Left panel: The total number of nucleated cells increased only with the combination of hematopoietic growth factors. Middle panel: Both CD34+38- and CD34+38+ cells were markedly expanded by the cytokine combination but the CD34+ cells did not survive in the presence of FL or TPO alone. Right panel: Hematopoietic progenitor cells - granulocyte-macrophage (CFU-GM), megakaryocyte (CFU-Meg), multilineage (CFU- GEMM), and erythroid (BFU-E) - increased exponentially during the period of culture with FL plus TPO.</div><div class=\"graphic_reference\">Data from Piacibello, W, Sanavio, F, Garetto, L, et al, Blood 1997; 89:2644.</div><div id=\"graphicVersion\">Graphic 57003 Version 1.0</div></div></div>"},"57004":{"type":"graphic_picture","displayName":"Diffuse scleritis in RA","title":"Diffuse scleritis in rheumatoid arthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diffuse scleritis in rheumatoid arthritis</div><div class=\"cntnt\"><img style=\"width:398px; height:266px;\" src=\"images/RHEUM/57004_Diffuse_scleritis_in_RA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse scleritis in a patient with rheumatoid arthritis manifested by diffuse injection and scleral thickening, but no nodules.</div><div class=\"graphic_reference\">Courtesy of Reza Dana, MD, MSc, MPH.</div><div id=\"graphicVersion\">Graphic 57004 Version 2.0</div></div></div>"},"57005":{"type":"graphic_table","displayName":"RA versus osteoarthritis","title":"Clinical distinction between rheumatoid arthritis and osteoarthritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical distinction between rheumatoid arthritis and osteoarthritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Feature</td> <td class=\"subtitle1\">Rheumatoid arthritis</td> <td class=\"subtitle1\">Osteoarthritis</td> </tr> <tr> <td rowspan=\"2\">Primary joints affected</td> <td>Metacarpophalangeal</td> <td>Distal interphalangeal</td> </tr> <tr> <td>Proximal interphalangeal</td> <td>Carpometacarpal</td> </tr> <tr> <td>Heberden's nodes</td> <td>Absent</td> <td>Frequently present</td> </tr> <tr> <td>Joint characteristics</td> <td>Soft, warm, and tender</td> <td>Hard and bony</td> </tr> <tr> <td>Stiffness</td> <td>Worse after resting (eg, morning stiffness)</td> <td>If present, worse after effort, may be described as evening stiffness</td> </tr> <tr> <td rowspan=\"3\">Laboratory findings</td> <td>Positive rheumatoid factor</td> <td>Rheumatoid factor-negative</td> </tr> <tr> <td>Positive anti-CCP antibody</td> <td>Anti-CCP antibody-negative</td> </tr> <tr> <td>Elevated ESR and CRP</td> <td>Normal ESR and CRP</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CCP: cyclic citrullinated peptide; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein.</div><div id=\"graphicVersion\">Graphic 57005 Version 5.0</div></div></div>"},"57006":{"type":"graphic_diagnosticimage","displayName":"Pulmonary hypertension MS angio","title":"Pulmonary arteriogram in pulmonary hypertension secondary to mitral stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary arteriogram in pulmonary hypertension secondary to mitral stenosis</div><div class=\"cntnt\"><img style=\"width:278px; height:334px;\" src=\"images/CARD/57006_Pulmonary_hypertension_MS_a.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This pulmonary arteriogram performed in a patient with mitral stenosis demonstrates marking shunting of blood to the pulmonary vasculature of the upper lobes, away from the left and right lower lobes, as a result of constriction of the lower lobe vessels secondary to pulmonary venous hypertension. Also seen is dilation of the left atrium (arrow).</div><div class=\"graphic_reference\">Photo courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 57006 Version 2.0</div></div></div>"},"57007":{"type":"graphic_table","displayName":"Replacement fluid volume","title":"Replacement fluid volume for patients with moderate volume depletion by age and weight","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Replacement fluid volume for patients with moderate volume depletion by age and weight</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Weight</td> <td class=\"subtitle1\">Replacement fluid volume</td> </tr> <tr> <td>&#60;4 months</td> <td>&#60;5 kg</td> <td>200 to 400 mL</td> </tr> <tr> <td>4 to 12 months</td> <td>5 to 8 kg</td> <td>400 to 600 mL</td> </tr> <tr> <td>1 to 2 years</td> <td>8 to 11 kg</td> <td>600 to 800 mL</td> </tr> <tr> <td>2 to 4 years</td> <td>11 to 16 kg</td> <td>800 to 1200 mL</td> </tr> <tr> <td>5 to 14 years</td> <td>16 to 30 kg</td> <td>1200 to 2200 mL</td> </tr> <tr> <td>&#62;14 years</td> <td>&#62;30 kg</td> <td>2200 to 4400 mL</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Patients with moderate volume depletion are estimated to have lost 5 to 10 percent of their body weight (ie, 50 to 100 mL of fluid per kg). The total fluid deficit should be repleted within the first three to four hours of presentation.<br />If weight is known, 100 mL/kg of fluid can be administered. Ongoing losses, if severe, should be incorporated into replacement phase. Fluids should never be restricted. For infants &lt;6 months receiving standard oral rehydration solutions (ORS), provide an additional 100 to 200 mL of water; this is not needed for patients receiving hypo-osmolar ORS.</div><div class=\"graphic_reference\">Data from: World Health Organization. The treatment of diarrhea: A manual for physicians and other senior health workers - 4th revision. World Health Organization, Geneva 2005. Available at: <a href=\"http://whqlibdoc.who.int/publications/2005/9241593180.pdf\" target=\"_blank\">http://whqlibdoc.who.int/publications/2005/9241593180.pdf</a>.</div><div id=\"graphicVersion\">Graphic 57007 Version 6.0</div></div></div>"},"57008":{"type":"graphic_picture","displayName":"Erythema elevatum diutinum - lower extremities","title":"Erythema elevatum diutinum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema elevatum diutinum</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/57008_Eryt_elev_diutin_low_extrem.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nodular lesions are present on the knees in this patient with erythema elevatum diutinum.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 57008 Version 3.0</div></div></div>"},"57009":{"type":"graphic_diagnosticimage","displayName":"Normal postoperative UGI series after gastric bypass","title":"Normal postoperative upper gastrointestinal (UGI) series after gastric bypass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal postoperative upper gastrointestinal (UGI) series after gastric bypass</div><div class=\"cntnt\"><img style=\"width:351px; height:468px;\" src=\"images/SURG/57009_Norm_postop_UGI_series.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Postoperative upper gastrointestinal study showing gastric pouch and gastrojejunal anastomosis.</div><div id=\"graphicVersion\">Graphic 57009 Version 5.0</div></div></div>"},"57011":{"type":"graphic_picture","displayName":"Paracocci sequelae","title":"Sequelae in paracoccidioidomycosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sequelae in paracoccidioidomycosis</div><div class=\"cntnt\"><img style=\"width:387px; height:308px;\" src=\"images/ID/57011_Paracocci_sequelae.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sequelae of paracoccidioidomycosis following treatment. A and B. Microstomia resulting from perioral lesions. C. Tracheal stenosis requiring tracheostomy. D. Chest radiograph demonstrating lung fibrosis.</div><div class=\"graphic_reference\">Reproduced with permission from: Shikanai-Yasuda MA, Queiroz Telles Filho F, Mendes RP, et al. Consenso em paracoccidioidomicose [Guidelines in paracoccidioidomycosis]. Revista da Sociedade Brasileira de Medicina Tropical 2006; 39:297-310. Copyright ©2006 Sociedade Brasileira de Medicina Tropical.</div><div id=\"graphicVersion\">Graphic 57011 Version 3.0</div></div></div>"},"57014":{"type":"graphic_algorithm","displayName":"Treatment algorithm for hepatocellular carcinoma","title":"Treatment algorithm for hepatocellular carcinoma","html":"<div class=\"graphic\"><div style=\"width: 662px\" class=\"figure\"><div class=\"ttl\">Treatment algorithm for hepatocellular carcinoma</div><div class=\"cntnt\"><img style=\"width:642px; height:570px;\" src=\"images/ONC/57014_Rxalgohepatocellularedt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PVE: portal vein embolization; TACE: transcatheter arterial chemoembolization.<br />* Suitability of patients with Child-Pugh B cirrhosis for surgical resection is highly controversial.<br />¶ If not a liver transplantation candidate because disease is outside transplant (Milan) criteria, downstaging therapy (ablation, TACE) could be considered, followed by reassessment for liver transplantation.<br />Δ Options for initial systemic therapy include participation in a clinical trial (preferred), sorafenib, lenvatinib, or cytotoxic chemotherapy. (Refer to text.)</div><div id=\"graphicVersion\">Graphic 57014 Version 8.0</div></div></div>"},"57015":{"type":"graphic_table","displayName":"High fiber diet guidelines PI","title":"High-fiber diet guidelines for children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">High-fiber diet guidelines for children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Why we need fiber</td> </tr> <tr> <td class=\"indent1\">Fiber helps children and adults have regular bowel movements and helps prevent constipation and other health problems. Dietary fiber helps keep the bowel and digestive tract healthy and enhances feelings of fullness after eating.</td> </tr> <tr> <td class=\"subtitle1_single\">How much fiber is needed</td> </tr> <tr> <td class=\"indent1\"> <p>For prevention of constipation, a practical target for fiber intake is the child's age plus 5 to 10 grams per day.<sup>[1]</sup> Giving more than this fiber goal has no proven benefit for management of constipation in children.<sup>[2]</sup></p> <p>Somewhat higher targets for fiber intake (14 grams/1000 kcals in the diet) have been recommended by the Institute of Medicine.<sup>[3]</sup> For children, this translates to an intake of about 20 grams/day in early childhood, rising to 29 grams/day for adolescent girls and young women, and 38 grams/day for adolescent boys and young men.</p> To find out the number of grams of fiber in a certain food, read the label, or see the foods listed in this table. High-fiber foods contain 3 or more grams of fiber per serving.</td> </tr> <tr> <td class=\"subtitle1_single\">How to help your child eat more fiber</td> </tr> <tr> <td class=\"sublist2_start\">A high-fiber diet should be a balanced diet with foods from all the food groups. The most common sources of fiber are whole grain breads and cereals, legumes and nuts, fruits, and vegetables. Include these in your child's balanced diet:</td> </tr> <tr> <td class=\"sublist2\">Offer your child a variety of high-fiber foods during the day rather than giving only one or two high fiber foods.</td> </tr> <tr> <td class=\"sublist2\">Mix a high-fiber cereal with a cereal your child likes.</td> </tr> <tr> <td class=\"sublist2\">Offer fresh fruits with the skin on. Prunes and pears act as natural laxatives.</td> </tr> <tr> <td class=\"sublist2\">Offer raw vegetables, such as carrots, jicama, or cherry tomatoes for snacks and with meals. Offer a salad with dark green lettuce each day.</td> </tr> <tr> <td class=\"sublist2\">Use whole-wheat bread or white bread with added fiber, brown rice, whole-wheat crackers, bran muffins, barley, bran cereals, or oatmeal. Use less refined white flour bread, cereal, and other starches.</td> </tr> <tr> <td class=\"sublist2\">Offer 4 to 6 ounces of prune, apple, orange, or pear juice each day. Remember that fresh fruit has more fiber than juice.</td> </tr> <tr> <td class=\"sublist2\">Offer snacks that have fiber, like granola bars, fruit bars, fig cookies, or popcorn (after age 3 years).</td> </tr> <tr> <td class=\"sublist2\">Help your child develop a taste for bran. Try to include 2 to 4 tablespoons of some form of bran each day.</td> </tr> <tr> <td class=\"sublist2\">Add nuts or seeds to breads and salads, or use them as a snack. This is not recommended for children younger than three years.</td> </tr> <tr> <td class=\"sublist2\">Read labels on foods, and look for foods with 3 or more grams of fiber per serving. Have your child eat 3 or more servings each day of breads and cereals made from whole grains and bran. Have your child eat 5 or more servings of vegetables and fruits, including beans. It is important to increase water in the diet when you increase fiber.</td> </tr> <tr> <td class=\"subtitle1_single\">Preventing constipation</td> </tr> <tr> <td class=\"indent1\">If your child is constipated, follow the dietary guidelines above. Also, encourage your child to drink at least 4 to 8 cups (32 to 64 ounces) of fluid per day, preferably water, low-fat milk, and low-sugar decaffeinated beverages.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Williams CL, Bollella M, Wynder EL. A new recommendation for dietary fiber in childhood. Pediatrics 1995; 96:985.</li>&#xD;&#xA;    <li>Tabbers MM, DiLorenzo C, Berger MY, et al. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr 2014; 58:258.</li>&#xD;&#xA;    <li>Dietary Guidelines for Americans 2005. US Department of Health and Human Services. Available at: <a href=\"http://www.health.gov/dietaryguidelines/pubs.htm\" target=\"_blank\">www.health.gov/dietaryguidelines/pubs.htm</a>.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 57015 Version 8.0</div></div></div>"},"57016":{"type":"graphic_picture","displayName":"Necrotic skin lesion of mucormycosis","title":"Necrotic skin lesion of mucormycosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Necrotic skin lesion of mucormycosis</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/ID/57016_Necr_skin_lesion_mucormyco.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Necrotic skin lesion of disseminated mucormycosis that occurred in a man who was an alcoholic and who initially presented with pneumococcal sepsis.</div><div class=\"graphic_reference\">Courtesy of Carol Kauffman, MD.</div><div id=\"graphicVersion\">Graphic 57016 Version 1.0</div></div></div>"},"57017":{"type":"graphic_picture","displayName":"Psoriatic skin findings in a child with psJIA","title":"Psoriatic skin findings in a child with psoriatic juvenile idiopathic arthritis (psJIA)","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Psoriatic skin findings in a child with psoriatic juvenile idiopathic arthritis (psJIA)</div><div class=\"cntnt\"><img style=\"width:514px; height:342px;\" src=\"images/ALLRG/57017_Psoriatic_skin_find_psJIA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cracking and scale behind the ear of a child with psJIA. As evident from this image, the skin findings of early psoriasis can be subtle and ambiguous.</div><div class=\"graphic_reference\">Reproduced from: Nigrovic PA, Sundel RP, Petty RE. Juvenile psoriatic arthritis. In: Textbook of Pediatric Rheumatology, 6th ed, Cassidy JT, Petty RE, Laxer RM, Lindsley CB (Eds), Saunders, Philadelphia 2011. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 57017 Version 2.0</div></div></div>"},"57018":{"type":"graphic_diagnosticimage","displayName":"Cystogram bladder rupture extraperitoneal","title":"Cystogram of extraperitoneal bladder rupture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cystogram of extraperitoneal bladder rupture</div><div class=\"cntnt\"><img style=\"width:382px; height:382px;\" src=\"images/EM/57018_Bladder_rupture_EP_cysto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This retrograde cystogram reveals an extraperitoneal bladder rupture. Extravasating contrast is seen adjacent to the bladder (arrow).</div><div class=\"graphic_reference\">Courtesy of Michael S Runyon, MD, FAAEM.</div><div id=\"graphicVersion\">Graphic 57018 Version 2.0</div></div></div>"},"57021":{"type":"graphic_diagnosticimage","displayName":"4 chamber view showing circumferential pericardial effusion","title":"4 chamber view showing circumferential pericardial effusion","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">4 chamber view showing circumferential pericardial effusion</div><div class=\"cntnt\"><img style=\"width:491px; height:240px;\" src=\"images/CARD/57021_4_chamber_pericardial_effus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The apical four chamber view shows a moderate to large anterior and posterior pericardial effusion (PE), but the curvature of the right atrium (RA) is normal. In panel B there is diastolic expiratory invagination, compression, or collapse of the RA. Collapse of the right atrium is a highly sensitive, but relatively nonspecific, sign of hemodynamically important tamponade. More importantly, the left atrium (LA) also appears compressed. This latter sign is felt to be more specific for tamponade.</div><div class=\"graphic_footnotes\">RV: right ventricle; LV: left ventricle.</div><div id=\"graphicVersion\">Graphic 57021 Version 3.0</div></div></div>"},"57022":{"type":"graphic_picture","displayName":"Junctional nevus","title":"Junctional nevus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Junctional nevus</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/PEDS/57022_Junctional_nevus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flat junctional nevus with darker pigmentation in the center than at the periphery. This lesion is symmetric with a regular outline.</div><div class=\"graphic_reference\">Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.</div><div id=\"graphicVersion\">Graphic 57022 Version 1.0</div></div></div>"},"57023":{"type":"graphic_form","displayName":"Parent questionnaire A","title":"Questionnaire for parents","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Questionnaire for parents</div><div class=\"cntnt\"><img style=\"width:528px; height:603px;\" src=\"images/PEDS/57023_Parent_questionnaire_A.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Speech-Language Pathology Department, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 57023 Version 2.0</div></div></div>"},"57024":{"type":"graphic_figure","displayName":"B cell dev in germ centers","title":"B cell development in the germinal center","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">B cell development in the germinal center</div><div class=\"cntnt\"><img style=\"width:416px; height:468px;\" src=\"images/RHEUM/57024_B_cell_dev_in_germ_centers.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">One or a few B cell clones colonize the forming germinal center. These clones have been activated elsewhere and are retained via interaction with antigen present in immune complexes (Ag-IC) on the surface of follicular dendritic cells (FDC). They undergo proliferation with class-switching and immunoglobulin V gene somatic hypermutation. If mutation destroys antigen-binding, the cell dies because it cannot interact with FDCs in the basal light zone. High-affinity cells migrate to the apical light zone where, depending on particular cellular signals and/or cytokines provided by T cells, they differentiate either into memory cells or plasma cells. It is possible that some cells may also return to the dark zone for further cycles of division and mutation.</div><div class=\"graphic_footnotes\">Ag-IC: complex of antigen and immune complex; FDC: follicular dendritic cell.</div><div class=\"graphic_reference\">Reproduced with permission from: Bona C, Bonilla F. B Cells and Humoral Immunity. In: Textbook of Immunology, 2nd ed, Harwood Academic Publishers 1996. Page 128, figure 5-16. Original source: Liu et al. Germinal centers in T cell-dependent antibody responses. Immunology Today 1992; 13:17-21. figure 2.</div><div id=\"graphicVersion\">Graphic 57024 Version 3.0</div></div></div>"},"57025":{"type":"graphic_figure","displayName":"QT dispersion tangent method","title":"Tangent method for measurement of QT interval","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Tangent method for measurement of QT interval</div><div class=\"cntnt\"><img style=\"width:460px; height:473px;\" src=\"images/CARD/57025_QT_dispersion_tangent_metho.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The shape of the descending part of the T wave can effect the measurement of the QT interval when using the tangent method. The two hypothetical T waves have the same offset time (vertical solid line). However, the two T waves have a significantly different shape of the descending part; as a result, a tangent to the steepest point may significantly underestimate (top panel, red dash line) or overestimate the T wave offset (bottom panel, black dash line).</div><div id=\"graphicVersion\">Graphic 57025 Version 2.0</div></div></div>"},"57027":{"type":"graphic_table","displayName":"Phases of management for enterocutaneous fistulae","title":"Phases of management for enterocutaneous fistulae","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Phases of management for enterocutaneous fistulae</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Phase</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Timing</td> </tr> <tr> <td>Stabilization</td> <td> <ul> <li>Rehydration</li> <li>Correction of anemia</li> <li>Electrolyte repletion</li> <li>Drainage of sepsis</li> <li>Control of fistula drainage</li> <li>Local skin care measures</li> <li>Commencement of nutritional support</li> </ul> </td> <td>24-48 h</td> </tr> <tr> <td>Investigation</td> <td> <ul> <li>Fistulogram to define anatomy</li> <li>CT/US/MRI to localize collections and guide drainage</li> </ul> </td> <td>7-10 d</td> </tr> <tr> <td>Decision</td> <td> <ul> <li>Assess likelihood of nonoperative closure</li> <li>Plan therapeutic course</li> <li>Decide optimal surgical timing</li> </ul> </td> <td>7-10 d to 4-6 wk</td> </tr> <tr> <td>Definitive therapy</td> <td> <ul> <li>Plan operative approach</li> <li>Bowel resection with end-to-end anastomosis</li> <li>Secure abdominal closure (+/- flap)</li> <li>Gastrostomy</li> <li>Jejunostomy</li> </ul> </td> <td>4-6 wk or if spontaneous closure unlikely</td> </tr> <tr> <td>Healing</td> <td> <ul> <li>Continue nutrition support</li> <li>Transition to total oral/enteral feedings</li> <li>Physical and emotional rehabilitation</li> </ul> </td> <td>5-10 d after closure</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">20.0000000000000</mso:Specialty>\r\n<mso:Publishable_Version msdt:dt=\"string\">0</mso:Publishable_Version>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=91431&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Phases_of_management_for_enterocutaneous_fistulae.htm</title></head></div><div class=\"graphic_footnotes\">CT: computed tomography; US: ultrasound; MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: Fischer JE, Evenson AR. Gastrointestinal-cutaneous fistulae. In: Mastery of Surgery, Fischer JE (Ed), Lippincott Williams &amp; Wilkins 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 57027 Version 7.0</div></div></div>"},"57030":{"type":"graphic_algorithm","displayName":"Diagnostic algorithm CIS","title":"Diagnostic algorithm for patients with typical clinically isolated syndromes (CIS)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diagnostic algorithm for patients with typical clinically isolated syndromes (CIS)</div><div class=\"cntnt\"><img style=\"width:420px; height:289px;\" src=\"images/NEURO/57030_MAGNIMS_dx_algorithm_CIS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm only applies to patients 14 to 50 years old with typical CIS and a complete diagnostic workup.</div><div class=\"graphic_footnotes\">BS: brainstem; DIS: dissemination in space; DIT: dissemination in time; Gd: gadolinium; JC: juxtacortical; PF: posterior fossa; PV: periventricular; SC: spinal cord.</div><div class=\"graphic_reference\">Reproduced with permission from:&nbsp;Montalban X, Tintoré M, Swanton J, et al. MRI criteria for MS in patients with clinically isolated syndromes. Neurology 2010; 74:427. Copyright © 2010 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 57030 Version 13.0</div></div></div>"},"57032":{"type":"graphic_table","displayName":"Acetaminophen toxicity","title":"Stages of acute acetaminophen intoxication","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stages of acute acetaminophen intoxication</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Hours after ingestion</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"3\">I</td> <td rowspan=\"3\">0.5 to 24 hours</td> <td>Nausea, vomiting, diaphoresis, pallor, lethargy, and malaise</td> </tr> <tr> <td>Some patients remain asymptomatic</td> </tr> <tr> <td>Laboratory studies are typically normal</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"7\">II&nbsp;&nbsp;</td> <td rowspan=\"7\">24 to 72 hours</td> <td>Stage I symptoms resolve</td> </tr> <tr> <td>Hepatotoxicity and nephrotoxicity become evident</td> </tr> <tr> <td>Right upper quadrant pain, liver enlargement and tenderness</td> </tr> <tr> <td>Elevation of aminotransferases occurs within 36 hours of ingestion in patients with hepatic injury</td> </tr> <tr> <td>Elevation of prothrombin time (PT) and internationalized ratio of PT</td> </tr> <tr> <td>Oliguria, abnormalities of renal function</td> </tr> <tr> <td>Elevation of serum amylase with or without clinical pancreatitis may occur</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"5\">III</td> <td rowspan=\"5\">72 to 96 hours</td> <td>Liver enzyme and function abnormalities peak (enzymes may be &#62;10,000 IU/L)</td> </tr> <tr> <td>Recurrence of Stage I symptoms</td> </tr> <tr> <td>Jaundice, hepatic encephalopathy, hyperammonemia, bleeding diathesis, hypoglycemia, lactic acidosis</td> </tr> <tr> <td>Renal failure, the incidence of which is related to the severity of intoxication</td> </tr> <tr> <td>Death, from multi-organ failure, occurs most commonly in this stage</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"3\">IV</td> <td rowspan=\"3\">4 to 14 days</td> <td>Recovery phase</td> </tr> <tr> <td>Symptoms and laboratory values may not normalize for several weeks</td> </tr> <tr> <td>Histologic recovery lags behind clinical recovery and may take up to three months</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 57032 Version 2.0</div></div></div>"},"57033":{"type":"graphic_table","displayName":"Differential diagnosis of physical findings sexual abuse 2","title":"Differential diagnosis of physical findings in the evaluation of childhood sexual abuse (part 2)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of physical findings in the evaluation of childhood sexual abuse (part 2)</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Finding</td>\n\n      <td class=\"subtitle1\">Differential diagnosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Female genitalia</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Excoriation, bleeding, vascular lesions</td>\n\n      <td>Nonspecific vulvovaginitis, Group A streptococcal vaginitis,\nlichen sclerosis, lichen simplex chronicus, lichen planus, atopic\ndermatitis</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Erythema of the vestibule</td>\n\n      <td>Irritants, infection, trauma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Increased vascularity of vestibule and hymen</td>\n\n      <td>Local irritants, normal pattern of nonestrogenized state</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Labial adhesion</td>\n\n      <td>Irritation or rubbing</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Apparent scarring</td>\n\n      <td>Linea vestibularis (present in 10 percent of normal newborns)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Vaginal bleeding</td>\n\n      <td>Vaginal foreign body, urethral prolapse (causes apparent vaginal bleeding)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Vaginal discharge</td>\n\n      <td>Sexually transmitted infection, vaginal foreign body</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Friability of the posterior fourchette or commissure</td>\n\n      <td>Irritation, infection, examiner's traction on labia majora</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Perineal bruising or bleeding</td>\n\n      <td>Straddle injury (history is usually readily available;\nstraddle injuries usually are symmetric and involve the anterior\nstructures)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Genital scarring</td>\n\n      <td>Female circumcision</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Genital bleeding</td>\n\n      <td>Trauma, female circumcision</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"3\" class=\"indent1\">Other vaginal findings</td>\n\n      <td>Sarcoma botyroides (unique form of embryonal rhabdomyosarcoma\nthat arises within the wall of the bladder or vagina and protrudes from\nthe vagina resembling a bunch of grapes)</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Ureterocoele</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Caruncle (small, red, papillary growth, highly vascular, sometimes found in the urinary meatus of females)</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Bays, J, Jenny, C. Genital and anal conditions confused with child sexual abuse trauma. Am J Dis Child 1990; 144:1319. Hymel, KP, Jenny, C. Child sexual abuse. Pediatr Rev 1996; 17:236. Adams, JA. Evolution of a classification scale: medical evaluation of suspected child sexual abuse. Child Maltreat 2001; 6:31. Adams, JA. Medical evaluation of suspected child sexual abuse. J Pediatr Adolesc Gynecol 2004; 17:191.</div><div id=\"graphicVersion\">Graphic 57033 Version 2.0</div></div></div>"},"57034":{"type":"graphic_table","displayName":"Differential dx appendagitis","title":"Differential diagnosis in patients with epiploic appendagitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis in patients with epiploic appendagitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Abscess</td> </tr> <tr> <td>Appendicitis</td> </tr> <tr> <td>Colon cancer or metastasis</td> </tr> <tr> <td>Crohn's ileitis</td> </tr> <tr> <td>Ectopic pregnancy</td> </tr> <tr> <td>Gallbladder disease</td> </tr> <tr> <td>Ileitis caused by infection with <em>Yersinia</em>, <em>Campylobacter</em>, or <em>Salmonella</em></td> </tr> <tr> <td>Left- or right-sided diverticulitis</td> </tr> <tr> <td>Mesenteric adenitis</td> </tr> <tr> <td>Mesenteric panniculitis</td> </tr> <tr> <td>Metastases to the omentum</td> </tr> <tr> <td>Ovarian torsion</td> </tr> <tr> <td>Ruptured or hemorrhagic ovarian cyst</td> </tr> <tr> <td>Segmental omental infarction</td> </tr> <tr> <td>Urachal cyst</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 57034 Version 4.0</div></div></div>"},"57035":{"type":"graphic_figure","displayName":"McBurney abdominal incision and closure","title":"McBurney abdominal incision and closure","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">McBurney abdominal incision and closure</div><div class=\"cntnt\"><img style=\"width:491px; height:638px;\" src=\"images/SURG/57035_McBurney_incision_and_closu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Incision through McBurney's point. (B) Fibers of exterior oblique separated. Internal oblique muscle split. (C) Peritoneum and transversalis fascia incised. (D) Internal oblique closed with interrupted suture. (E) External oblique closed with running suture. (F) Delayed closure of skin.</div><div class=\"graphic_reference\">Courtesy of Therese Trenhaile, MD.</div><div id=\"graphicVersion\">Graphic 57035 Version 2.0</div></div></div>"},"57037":{"type":"graphic_table","displayName":"Prevalence of HSV vs bacterial meningitis in neonates","title":"Prevalence of herpes simplex virus (HSV) infection versus bacterial meningitis in neonates with cerebrospinal fluid (CSF) pleocytosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevalence of herpes simplex virus (HSV) infection versus bacterial meningitis in neonates with cerebrospinal fluid (CSF) pleocytosis</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Clinical characteristic(s)\n   </td>\n   <td  class=\"subtitle1\">\n   Number of patients\n   </td>\n   <td  class=\"subtitle1\">\n   HSV percent (95% CI)\n   </td>\n   <td  class=\"subtitle1\">\n   Bacterial meningitis, percent (95% CI)\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\">\n   Neonate (0-28 days)\n   </td>\n   <td>5817</td>\n   <td>0.2 (0.1-0.3)</td>\n   <td>0.4 (0.2-0.6)</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\">\n   CSF pleocytosis\n   </td>\n   <td>472</td>\n   <td>0.6 (0.1-1.9)</td>\n   <td>3.2 (1.8-5.2)</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   &#62;50 percent PMNs*\n   </td>\n   <td>102</td>\n   <td>0 (0-3.6)</td>\n   <td>13.7 (7.7-22)</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   &#62;50 percent mononuclear cells\n   </td>\n   <td>330</td>\n   <td>0.9 (0.2-2.6)</td>\n   <td>0.3 (0-1.7)</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\">\n   CSF pleocytosis and fever\n   </td>\n   <td>204</td>\n   <td>1 (0.1-3.5)</td>\n   <td>5.4 (2.7-9.4)</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   &#62;50 percent PMNs*\n   </td>\n   <td>67</td>\n   <td>0 (0-5.4)</td>\n   <td>14.9 (7.4-25.7)</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   &#62;50 percent mononuclear cells\n   </td>\n   <td>124</td>\n   <td>1.6 (0.2-5.7)</td>\n   <td>0.8 (0.0-4.4)</td>\n   </tr>\n </table></div><div class=\"graphic_footnotes\">PMN: polymorphonuclear cells.<br> * 95 percent confidence intervals do not overlap.</div><div class=\"graphic_reference\">Data from: Caviness AC, Demmler GJ, Almendarez Y, Selwyn BJ. The prevalence of neonatal herpes simplex virus infection compared with serious bacterial illness in hospitalized neonates. J Pediatr 2008; 153:164.</div><div id=\"graphicVersion\">Graphic 57037 Version 2.0</div></div></div>"},"57038":{"type":"graphic_table","displayName":"Common symptoms IEI","title":"Common symptoms in patients with idiopathic environmental intolerance","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common symptoms in patients with idiopathic environmental intolerance</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n    <td class=\"subtitle1\">Organ system</td>\n    <td class=\"subtitle1\">Symptom</td>\n  </tr>\n  <tr>\n    <td>Head, eye, ear, nose, and throat</td>\n    <td>Eye burning or pruritis, tinnitus, buzzing, sudden deafness, visual impairment, rhinorrhea, nasal obstruction, odor sensitivity, glossodynia, pharyngeal irritation, dysphonia, hoarseness</td>\n  </tr>\n  <tr>\n    <td>Pulmonary</td>\n    <td>Dyspnea, cough, chest pain, shortness of breath</td>\n  </tr>\n  <tr>\n    <td>Cardiovascular</td>\n    <td>Palpitations, irregular heartbeat, tachycardia, chest pain</td>\n  </tr>\n  <tr>\n    <td>Gastrointestinal</td>\n    <td>Stomach pain, gastritis, indigestion, dyspepsia, anorexia, constipation, cramps, nausea, vomiting, diarrhea</td>\n  </tr>\n  <tr>\n    <td>Genitourinary</td>\n    <td>Dysmenorrhea, vaginitis, dysuria, urinary frequency, urinary retention</td>\n  </tr>\n  <tr>\n    <td>Musculoskeletal</td>\n    <td>Myalgia, weakness, muscle tension, arthralgia, skin irritation, pruritus</td>\n  </tr>\n  <tr>\n    <td>Endocrine</td>\n    <td>Hot flashes, chills, polydipsia, hair loss</td>\n  </tr>\n  <tr>\n    <td>Lymphatic</td>\n    <td>Change in size of lymph nodes</td>\n  </tr>\n  <tr>\n    <td>Dermatologic</td>\n    <td>Diaphoresis, pruritis, burning, rash, alopecia</td>\n  </tr>\n  <tr>\n    <td>Neurologic</td>\n    <td>Headaches, paresthesias, paralysis, seizures, convulsions, dizziness, light headedness, weakness, pain syndromes, tremor</td>\n  </tr>\n  <tr>\n    <td>Psychiatric</td>\n    <td>Fatigue, drowsiness, irritability, hyperactivity, insomnia, mental slowing or confusion, inattention, poor concentration, memory deficits, depression, anxiety, irritability, anhedonia, mood lability, crying spells</td>\n  </tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 57038 Version 1.0</div></div></div>"},"57040":{"type":"graphic_table","displayName":"Chemical elimination of poisons","title":"Methods for enhanced elimination of poisons","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Methods for enhanced elimination of poisons</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Multiple-dose activated charcoal</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Saline diuresis</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Urinary ion trapping</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Alkalinization</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Acidification</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist1_start\">Extracorporeal methods&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Hemodialysis</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Hemoperfusion</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Hemofiltration</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\"> Peritoneal dialysis</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Plasmapheresis</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Exchange transfusion</td>\n    </tr>\n    <tr>\n\n      <td>Hyperbaric oxygen</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Chelation therapy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cerebrospinal fluid removal</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Specific antibody-toxin binding</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 57040 Version 1.0</div></div></div>"},"57041":{"type":"graphic_picture","displayName":"Diffuse macular edema","title":"Diffuse macular edema: Appearance on fundus photograph and fluorescein angiogram","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Diffuse macular edema: Appearance on fundus photograph and fluorescein angiogram</div><div class=\"cntnt\"><img style=\"width:503px; height:229px;\" src=\"images/ENDO/57041_Diffuse_macular_edema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Color fundus photograph and B) fluorescein angiogram showing diffuse, as opposed to circinate, diabetic macular edema which is difficult to visualize on the color photo.</div><div id=\"graphicVersion\">Graphic 57041 Version 3.0</div></div></div>"},"57042":{"type":"graphic_figure","displayName":"HT dementia WHIMS","title":"Risk of dementia with combined estrogen-progestin therapy versus placebo","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Risk of dementia with combined estrogen-progestin therapy versus placebo</div><div class=\"cntnt\"><img style=\"width:477px; height:449px;\" src=\"images/ENDO/57042_HRT_dementia_WHIMS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the Women's Health Initiative Memory Study, after a mean follow-up of four years, HT was associated with an increased risk of dementia (overall HR 2.05, 95% CI 1.21-3.48). Data shown only through five years of follow-up because numbers at risk are too small after this point for precise estimates.</div><div class=\"graphic_footnotes\">E+P: estrogen + progestin; HR: hazard ratio; HT: hormone therapy.</div><div class=\"graphic_reference\">Data from: Shumaker SA, Legault C, Thal L, et al. Estrogen plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial. JAMA 2003; 289:2651.</div><div id=\"graphicVersion\">Graphic 57042 Version 5.0</div></div></div>"},"57043":{"type":"graphic_figure","displayName":"A2 and autoregulation of GFR","title":"Role of angiotensin II in autoregulation of GFR","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Role of angiotensin II in autoregulation of GFR</div><div class=\"cntnt\"><img style=\"width:446px; height:217px;\" src=\"images/NEPH/57043_A2_and_autoregulation_of_GF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of reducing renal artery pressure (from a baseline value of about 125 mmHg) on&nbsp;glomerular filtration rate (GFR), expressed as a percentage of control values in dogs fed a normal sodium diet. The blue squares represent control animals in which both GFR was maintained until the pressure was markedly reduced. The red circles represent animals given an intrarenal infusion of an angiotensin II antagonist; autoregulation of GFR was less well-regulated. Although not shown, autoregulation also applies to GFR when the renal artery pressure is initially raised and to renal blood flow, which is not impaired by inhibiting the activity of angiotensin II.</div><div class=\"graphic_reference\">Data from: Hall JE, Guyton AC, Jackson TE, et al. Am J Physiol 1977; 233:F366.</div><div id=\"graphicVersion\">Graphic 57043 Version 3.0</div></div></div>"},"57044":{"type":"graphic_picture","displayName":"Ulceronecrotic skin lesions","title":"HIV-positive man with ulceronecrotic skin lesions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">HIV-positive man with ulceronecrotic skin lesions</div><div class=\"cntnt\"><img style=\"width:369px; height:504px;\" src=\"images/ID/57044_Ulceronecrotic_skin_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Necrotic ulcers on the patient's abdomen (A) and arm (B).</div><div class=\"graphic_reference\">Reproduced with permission from: Yanagisawa, N, Imamura, A. HIV-Positive Man with Ulceronecrotic Skin Lesions. Clin Infect Dis 2008; 47:1068. Copyright &#169;2008 University of Chicago Press.</div><div class=\"contractual\"><br/><a href=\"http://www.journals.uchicago.edu/\">http://www.journals.uchicago.edu/</a></div><div id=\"graphicVersion\">Graphic 57044 Version 1.0</div></div></div>"},"57045":{"type":"graphic_waveform","displayName":"Central periph aortic pressures","title":"Central and peripheral aortic pressure tracings","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Central and peripheral aortic pressure tracings</div><div class=\"cntnt\"><img style=\"width:482px; height:272px;\" src=\"images/CARD/57045_Central_periph_aortic_press.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Simultaneously recorded pressures from the aortic root (Ao) and femoral artery (FA) demonstrate delayed transmission and a higher systolic pressure in the femoral artery. There is smoothing of the waveform and loss of the dicrotic notch.</div><div id=\"graphicVersion\">Graphic 57045 Version 2.0</div></div></div>"},"57047":{"type":"graphic_table","displayName":"Healthy People 2020 nutrition objectives","title":"Healthy People 2020: Selected nutrition objectives","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Healthy People 2020: Selected nutrition objectives</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Weight status</td> <td class=\"subtitle1\">2020 targets*</td> </tr> <tr> <td>Reduce the proportion of children 2 to 5 years who are obese</td> <td>9.6 percent</td> </tr> <tr> <td>Reduce the proportion of children 6 to 11 years who are obese</td> <td>15.7 percent</td> </tr> <tr> <td>Reduce the proportion of adolescents who are obese</td> <td>16.1 percent</td> </tr> <tr> <td>Reduce the proportion of adults who are obese</td> <td>30.6 percent</td> </tr> <tr> <td class=\"subtitle1\">Food and nutrient consumption (2 years and older)</td> <td class=\"subtitle1\">2020 targets<sup>&#182;</sup></td> </tr> <tr> <td>Increase the contribution of fruits to the diet</td> <td>0.9 cup-equivalents per 1000 calories</td> </tr> <tr> <td>Increase the contribution of vegetables to the diet, with at least one-third of these servings being dark green or deep yellow vegetables</td> <td>1.1 cup-equivalents total vegetables per 1000 calories</td> </tr> <tr> <td>Increase the contribution of whole grains to the diet</td> <td>0.6 ounce-equivalents of whole grains per 1000 calories</td> </tr> <tr> <td>Reduce the consumption of calories from solid fats and saturated fat</td> <td> <p>Solid fats no more than 16.7 percent of caloric intake</p> <p>Saturated fats no more than 9.5 percent of caloric intake</p> </td> </tr> <tr> <td>Reduce the consumption of calories from added sugars</td> <td>Added sugars no more than 10.8 percent of caloric intake</td> </tr> <tr> <td>Increase consumption of calcium</td> <td>1300 milligrams daily</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Target selected to represent a 10 percent improvement over baseline. In children and adolescents, obesity is defined as &ge;95th percentile of body mass index (BMI) for age and gender. In adults, obesity is defined as BMI &ge;30.<br />&para; Target selected to represent an achievable shift in the population intake, based on past trends and consideration of the target's applicability to subpopulations.</div><div class=\"graphic_reference\">From US DHHS. Healthy People 2020: Nutrition and weight status objectives. Available at: <A spellcheck=true href=\"http://www.healthypeople.gov/2020/topicsobjectives2020/objectiveslist.aspx?topicId=29\"target=_blank>http://www.healthypeople.gov/2020/topicsobjectives2020/objectiveslist.aspx?topicId=29</A> (accessed 3/27/2012).</div><div id=\"graphicVersion\">Graphic 57047 Version 3.0</div></div></div>"},"57048":{"type":"graphic_table","displayName":"Prelim class criteria JSS","title":"Provisional classification criteria for juvenile systemic sclerosis by the Pediatric Rheumatology European Society, the American College of Rheumatology, and the European League against Rheumatism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Provisional classification criteria for juvenile systemic sclerosis by the Pediatric Rheumatology European Society, the American College of Rheumatology, and the European League against Rheumatism</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text\"><strong>Major criterion</strong></td> <td colspan=\"2\">Proximal sclerosis/induration of the skin</td> </tr> <tr> <td class=\"highlight_gray_text\" rowspan=\"20\"><strong>Minor criteria</strong></td> <td>Skin</td> <td>Sclerodactyly</td> </tr> <tr> <td rowspan=\"3\">Vascular</td> <td>Raynaud phenomenon</td> </tr> <tr> <td>Nailfold capillary abnormalities</td> </tr> <tr> <td>Digital tip ulcers</td> </tr> <tr> <td rowspan=\"2\">Gastrointestinal</td> <td>Dysphagia</td> </tr> <tr> <td>Gastroesophageal reflux</td> </tr> <tr> <td rowspan=\"2\">Renal</td> <td>Renal crisis</td> </tr> <tr> <td>New-onset arterial hypertension</td> </tr> <tr> <td rowspan=\"2\">Cardiac</td> <td>Arrhythmias</td> </tr> <tr> <td>Heart failure</td> </tr> <tr> <td rowspan=\"3\">Respiratory</td> <td>Pulmonary fibrosis (seen on HRCT or radiograph of the chest)</td> </tr> <tr> <td>DLCO</td> </tr> <tr> <td>Pulmonary hypertension</td> </tr> <tr> <td rowspan=\"3\">Musculoskeletal</td> <td>Tendon friction rubs</td> </tr> <tr> <td>Arthritis</td> </tr> <tr> <td>Myositis</td> </tr> <tr> <td rowspan=\"2\">Neurologic</td> <td>Neuropathy</td> </tr> <tr> <td>Carpal tunnel syndrome</td> </tr> <tr> <td rowspan=\"2\">Serology</td> <td>Antinuclear antibodies</td> </tr> <tr> <td>SSc selective autoantibodies (anticentromere, antitopoisomerase I, antifibrillarin, anti-PM/Scl, antifibrillin, or anti-RNA polymerase I or III)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">In a patient less than 16 years of age, juvenile systemic sclerosis is diagnosed if the major criterion and at least 2 of 20 minor criteria are present.</div><div class=\"graphic_footnotes\">HRCT: high-resolution computed tomography; DLCO: diffusing capacity of the lung for carbon monoxide; SSc: systemic sclerosis; anti-PM/Scl: anti-polymyositis/scleroderma antinuclear antibodies, also called anti-exosome antibodies.</div><div class=\"graphic_reference\">Reproduced with permission from: Zulian F, Woo P, Athreya BH, et al. The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis. Arthritis Rheum 2007; 57:203. Copyright &copy; 2007 Wiley-Liss, Inc. a subsidiary of John Wiley &amp; Sons Inc.</div><div id=\"graphicVersion\">Graphic 57048 Version 5.0</div></div></div>"},"57049":{"type":"graphic_picture","displayName":"Mallory Weiss tear Endosc","title":"Mallory-Weiss tear","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mallory-Weiss tear</div><div class=\"cntnt\"><img style=\"width:449px; height:269px;\" src=\"images/GAST/57049_Mallory_Weiss_tear_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic diagnosis and treatment of Mallory-Weiss tears. Left panel: A large esophageal laceration extending to the lower esophageal body. Right panel: A large esophageal laceration below the gastroesophageal junction seen by retroflexion of the tip of the gastroscope which also visualized a hiatal hernia; previous bleeding was controlled by multipolar electrocoagulation.</div><div class=\"graphic_reference\">Courtesy of Moises Guelrud, MD.</div><div id=\"graphicVersion\">Graphic 57049 Version 1.0</div></div></div>"},"57050":{"type":"graphic_table","displayName":"Growth factors and stem cells","title":"Action of hematopoietic growth factors on progenitor cells","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Action of hematopoietic growth factors on progenitor cells</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Lineage stem cell</td> <td class=\"subtitle1\">Required growth factors</td> </tr> <tr> <td>CFU-GEMM</td> <td>SCF + IL-3, IL-6, GM-CSF, EPO</td> </tr> <tr> <td>BFU-E</td> <td>SCF + IL-3, GM-CSF, EPO</td> </tr> <tr> <td>CFU-GM</td> <td>SCF + G-CSF or M-CSF plus GM-CSF, IL-3</td> </tr> <tr> <td>CFU-G</td> <td>SCF + G-CSF plus GM-CSF, IL-3</td> </tr> <tr> <td>CFU-M</td> <td>SCF + M-CSF plus GM-CSF, IL-3</td> </tr> <tr> <td>CFU-Meg</td> <td>SCF + IL-3, IL-6, TPO</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CFU-GEMM: colony-forming unit - granulocytes, erythrocytes, monocytes and megakaryocytes; BFU-E: erythroid burst-forming unit; CFU-GM: granulocyte macrophage colony-forming unit; CFU-G: granulocyte colony-forming unit; CFU-M: monocyte colony-forming unit; CFU-Meg: megakaryocyte colony-forming unit; SCF: stem cell factor; IL-3: interleukin-3; IL-6: interleukin-6; GM-CSF: granulocyte-macrophage colony-stimulating factor; EPO: erythropoietin; G-CSF: granulocyte colony-stimulating factor; M-CSF: macrophage colony-stimulating factor; TPO: thrombopoietin.</div><div id=\"graphicVersion\">Graphic 57050 Version 4.0</div></div></div>"},"57051":{"type":"graphic_diagnosticimage","displayName":"Cleavage view","title":"Cleavage view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cleavage view</div><div class=\"cntnt\"><img style=\"width:434px; height:422px;\" src=\"images/PC/57051_Cleavage_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cleavage views of both breasts may be obtained to image the medial tissues adequately. A small nodule in the medial aspect of the&nbsp;left breast is not seen on the original CC view (Panel A) but well seen on the cleavage view (Panel B).</div><div class=\"graphic_footnotes\">CC: craniocaudal.</div><div id=\"graphicVersion\">Graphic 57051 Version 3.0</div></div></div>"},"57052":{"type":"graphic_diagnosticimage","displayName":"Central lung tumor CT","title":"Central bronchogenic carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Central bronchogenic carcinoma</div><div class=\"cntnt\"><img style=\"width:388px; height:299px;\" src=\"images/PULM/57052_Central_lung_tumor_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan confirms the collapse of the right lung with heterogeneous enhancement of the nonaerated lung parenchyma. The right mainstem bronchus is markedly narrowed.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 57052 Version 3.0</div></div></div>"},"57053":{"type":"graphic_table","displayName":"Diagnosis ataxia telangiectasia","title":"Diagnostic criteria for ataxia-telangiectasia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for ataxia-telangiectasia</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Definitive diagnosis*\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Male or female patient with either increased radiation-induced chromosomal breakage in cultured cells or progressive cerebellar ataxia and who has disabling mutations on both alleles of ATM.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Probable diagnosis*\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Male or female patient with progressive cerebellar ataxia and three of the following four findings:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   1. Ocular or facial telangiectasia.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   2. Serum IgA at least 2 SD below normal for age.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   3. Alpha fetoprotein at least 2 SD above normal for age.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   4. Increased radiation-induced chromosomal breakage in cultured cells.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Possible diagnosis*\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Male or female patient with progressive cerebellar ataxia and at least one of the following four findings:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   1. Ocular or facial telangiectasia.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   2. Serum IgA at least 2 SD below normal for age.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   3. Alpha fetoprotein more than 2 SD above normal for age.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   4. Increased chromosomal breakage after exposure to irradiation.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_footnotes\">* Patients with a definitive or probable diagnosis are assumed to have a greater than 98 and 85 percent probability, respectively, that in 20 years they will still have the same diagnosis. Patients with a possible diagnosis are those that have some but not all of the characteristic clinical or laboratory findings of a particular disorder.</div><div class=\"graphic_reference\">From Conley, ME, Notarangelo, LD, Etzioni, A. Clin Immunol 1999; 93:190.</div><div id=\"graphicVersion\">Graphic 57053 Version 2.0</div></div></div>"},"57055":{"type":"graphic_picture","displayName":"Nipple inversion associated with duct ectasia","title":"Nipple inversion associated with duct ectasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nipple inversion associated with duct ectasia</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/SURG/57055_Nipple_invers_duct_ectasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nipple retraction associated with duct ectasia is symmetrical and central, usually involving the nipple but not the areola.</div><div id=\"graphicVersion\">Graphic 57055 Version 1.0</div></div></div>"},"57056":{"type":"graphic_figure","displayName":"Standard cricothyrotomy step nine","title":"Standard cricothyrotomy step nine","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Standard cricothyrotomy step nine</div><div class=\"cntnt\"><img style=\"width:372px; height:322px;\" src=\"images/EM/57056_Cric_standard_step_nine.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><FONT class=red><FONT color=black>Attach ventilator tubing, confirm proper placement, and secure the tube with a circumferential tie around the patient's neck.</FONT></FONT></div><div class=\"graphic_reference\">Reproduced with permission from: Custalow CB. Color Atlas of Emergency Department Procedures, Elsevier Saunders, Philadelphia 2005. Copyright &#169;2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 57056 Version 2.0</div></div></div>"},"57059":{"type":"graphic_figure","displayName":"Percent ideal body weight","title":"Determination of percent ideal body weight for a 9-month-old boy who weighs 7.6 kg and is 70 cm long","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Determination of percent ideal body weight for a 9-month-old boy who weighs 7.6 kg and is 70 cm long</div><div class=\"cntnt\"><img style=\"width:405px; height:537px;\" src=\"images/PEDS/57059_Percent_ideal_body_weight.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To determine ideal body weight (IBW), plot the child's length on the length curve (point A) and the weight on the weight curve (point B). Determine the child's length percentile (in this example, 25th). Draw a vertical line from the length point to the same percentile curve for weight (point C). Draw a horizontal line to the weight scale to determine ideal body weight (point D). Percent IBW = actual weight/IBW x 100. In this example, IBW = 8.6 kg, and percent IBW = 88 percent.</div><div class=\"graphic_reference\">Data from: The National Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000). Available at www.cdc.gov/growthcharts.</div><div id=\"graphicVersion\">Graphic 57059 Version 1.0</div></div></div>"},"57061":{"type":"graphic_figure","displayName":"Incidence of myocardial infarction in men and women","title":"Incidence of myocardial infarction in men and women","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Incidence of myocardial infarction in men and women</div><div class=\"cntnt\"><img style=\"width:482px; height:284px;\" src=\"images/CARD/57061_MIincidenceinmenandwom.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Incidence of myocardial infarction by age and sex in a 26-year follow-up in the Framingham study. The incidence increases with age in both sexes, but occurs later (primarily after menopause) in women.</div><div class=\"graphic_reference\">Data from: Lerner DJ, Kannel WB. Am Heart J 1986; 111:383.</div><div id=\"graphicVersion\">Graphic 57061 Version 4.0</div></div></div>"},"57064":{"type":"graphic_figure","displayName":"Lap adjustable gastric band","title":"Laparoscopic adjustable gastric band (LAGB)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laparoscopic adjustable gastric band (LAGB)</div><div class=\"cntnt\"><img style=\"width:422px; height:365px;\" src=\"images/GAST/57064_Lap_adjustable_gastric_band.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows how the stomach will look after lap banding.</div><div id=\"graphicVersion\">Graphic 57064 Version 2.0</div></div></div>"},"57066":{"type":"graphic_waveform","displayName":"RNS in myasthenia gravis","title":"Repetitive nerve stimulation pre and post exercise in a patient with myasthenia gravis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Repetitive nerve stimulation pre and post exercise in a patient with myasthenia gravis</div><div class=\"cntnt\"><img style=\"width:421px; height:687px;\" src=\"images/NEURO/57066_RNS_myasthenia_gravis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stimulating the ulnar nerve at the wrist, recording the first dorsal interosseous. Maximal decrement noted to the right of traces.<br> (A) Baseline<br> (B) Immediately after 10 seconds of exercise (postexercise facilitation)<br> (C, D) Two and three minutes after 60 seconds of exercise (postexercise exhaustion)<br> (E) Immediately after 10 seconds of exercise again (postexercise facilitation and repair of the decrement)</div><div class=\"graphic_reference\">Reproduced from: Preston DC, Shapiro BE. Electromyography and neuromuscular disorders: Clinical-electrophysiologic correlations, 2nd edition, Butterworth-Heinemann, 2005. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 57066 Version 2.0</div></div></div>"},"57067":{"type":"graphic_figure","displayName":"Comparing child and parent head circumference","title":"Comparing child and parent head circumference","html":"<div class=\"graphic\"><div style=\"width: 656px\" class=\"figure\"><div class=\"ttl\">Comparing child and parent head circumference</div><div class=\"cntnt\"><img style=\"width:636px; height:812px;\" src=\"images/PEDS/57067_Comp_child_parent_head_circ.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">It is helpful to simultaneously plot the child's and parents' occipitofrontal circumference (OFC) measurements to compare the percentile or standard deviation. For most normal children, the child's OFC percentile is between that of the parents. In the example above, the child's OFC is certainly small relative to that of his parents.</div><div class=\"graphic_reference\">Original figure modified for this publication. Rollins JD, Collins JS, Holden KR. United States head circumference growth reference charts: birth to 21 years. J Pediatr 2010; 156:907. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 57067 Version 1.0</div></div></div>"},"57068":{"type":"graphic_figure","displayName":"Acidosis and K balance","title":"Acidemia and the plasma potassium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acidemia and the plasma potassium</div><div class=\"cntnt\"><img style=\"width:273px; height:264px;\" src=\"images/NEPH/57068_AcidosisKbalanceedt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Change in the plasma K+ concentration in relation to the arterial pH in experimentally induced hydrochloric acidosis (HCl is a mineral acid) and lactic acidosis in dogs. Only HCl induced hyperkalemia.</div><div class=\"graphic_reference\">Data from: Perez GO, Oster JR, Vaamonde CA. Serum potassium concentration in acidemic states. Nephron 1981; 27:233.</div><div id=\"graphicVersion\">Graphic 57068 Version 7.0</div></div></div>"},"57069":{"type":"graphic_figure","displayName":"Brachial artery tethering","title":"Brachial artery tethering in a supracondylar fracture","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Brachial artery tethering in a supracondylar fracture</div><div class=\"cntnt\"><img style=\"width:498px; height:379px;\" src=\"images/EM/57069_Brachial_artery_tethering.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The branchial artery may be tethered to the sharp edge of the proximal supracondylar fracture fragment by the supratrochlear branch of the anterior ulnar recurrent artery, thereby increasing the risk of brachial artery injury during movement of the injured arm or fracture manipulation</div><div id=\"graphicVersion\">Graphic 57069 Version 1.0</div></div></div>"},"57070":{"type":"graphic_table","displayName":"Pneumococcal immunization in patients with recurrent infections","title":"Pneumococcal immunization in patients with recurrent infections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pneumococcal immunization in patients with recurrent infections</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Vaccine</td> </tr> <tr> <td class=\"subtitle2\">Conjugate (CV)*</td> <td class=\"subtitle2\">Polysaccharide (PV)</td> </tr> <tr> <td><strong>Normal infants</strong></td> <td>2, 4, 6, 12 to 15 months</td> <td>Not given to patients this age</td> </tr> <tr> <td><strong>7 to 11 months</strong></td> <td>3 doses<sup>&#182;</sup></td> <td>Not given to patients this age</td> </tr> <tr> <td><strong>12 to 23 months</strong></td> <td>2 doses</td> <td>Not given to patients this age<sup>&#916;</sup></td> </tr> <tr> <td><strong>2 to 5 years</strong></td> <td>1 dose<sup>&#9674;</sup></td> <td>1 dose</td> </tr> <tr> <td><strong>&#62;5 years</strong></td> <td>&nbsp;</td> <td>1 dose<sup>&#167;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The measurement of preimmunization immunoglobulin and serotype-specific antibody concentrations, as well as four- to six-week postimmunization serotype-specific antibody concentrations are recommended.</div><div class=\"graphic_footnotes\">* Recommendations for the use of CV are based upon the recommendations of the Centers for Disease Control and Prevention (CDC) Advisory Committee (press release 10/22/99), US Food and Drug Administration (FDA) (HHS News release 2/17/00), and of the American Council on Immunization Practices (CDC 2002 [ACIP] MMWR 2002; 51:31).<br />¶ Intervals between doses of any vaccine combination should be ≥2 months.<br />Δ One study showed excellent serologic responses to 22 of the 23 serotypes in the PV vaccine in 56 12-month-old children. (Balloch A, Licciardi P, Russell F, et al. J Allergy Clin Immunol 2010; 126:395). These results support personal observations (Sorensen RU) of good responses to PV in younger children. The use of PV in patients 12 to 24 months of age could be considered when CVs are not available.<br /><FONT class=lozenge>◊</FONT> Patients with immunoglobulin G2 (IgG2) deficiency may require two doses at any age. (Zielen S, Buhring I, Strand N, et al. Infect Immun 2000; 68:1435).<br />§ If there is no antibody response to PV, give CV. Repeating PV is not effective. (Sorensen RU, Leiva LE, Giangrosso PA, et al. Pediatr Infect Dis J 1998; 17:685).</div><div class=\"graphic_reference\">Adapted from: Sorensen RU, Moore C. Peds Clin N A 2000; 42:1225.</div><div id=\"graphicVersion\">Graphic 57070 Version 7.0</div></div></div>"},"57072":{"type":"graphic_table","displayName":"Low tidal volume vent","title":"Low tidal volume ventilation in patients with acute respiratory distress syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Low tidal volume ventilation in patients with acute respiratory distress syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_left\" colspan=\"9\">Initial ventilator settings </td> </tr> <tr> <td colspan=\"9\">Calculate predicted body weight (PBW) </td> </tr> <tr> <td rowspan=\"2\">Male = </td> <td colspan=\"8\">50 + 2.3 [height (inches) - 60] <strong>OR</strong> </td> </tr> <tr> <td colspan=\"8\">50 + 0.91 [height (cm) - 152.4] </td> </tr> <tr> <td rowspan=\"2\">Female = </td> <td colspan=\"8\">45.5 + 2.3 [height (inches) - 60] <strong>OR</strong> </td> </tr> <tr> <td colspan=\"8\">45.5 + 0.91 [height (cm) - 152.4] </td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"9\">Set mode to volume assist-control </td> </tr> <tr> <td class=\"sublist1\" colspan=\"9\">Set initial tidal volume to&nbsp;6 mL/kg PBW </td> </tr> <tr> <td colspan=\"9\">Set initial ventilator rate &#8804;35 breaths/min to match baseline minute ventilation </td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"9\">Subsequent tidal volume adjustment </td> </tr> <tr> <td colspan=\"9\">Plateau pressure goal: Pplat &#8804;30 cm H<sub>2</sub>O </td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"9\">Check inspiratory plateau pressure with 0.5 second inspiratory pause at least every four hours and after each change in PEEP or tidal volume. </td> </tr> <tr> <td class=\"sublist1\" colspan=\"9\">If Pplat &#62;30 cm H<sub>2</sub>O, decrease tidal volume in 1 mL/kg PBW steps to 5 or if necessary to 4 mL/kg PBW. </td> </tr> <tr> <td class=\"sublist1\" colspan=\"9\">If Pplat &#60;25 cm H<sub>2</sub>O and tidal volume &#60;6 mL/kg, increase tidal volume by 1 mL/kg PBW until Pplat &#62;25 cm H<sub>2</sub>O or tidal volume = 6 mL/kg. </td> </tr> <tr> <td class=\"sublist1\" colspan=\"9\">If breath stacking (autoPEEP) or severe dyspnea occurs, tidal volume may be increased to 7 or 8 mL/kg PBW if Pplat remains &#8804;30 cm H<sub>2</sub>O. </td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"9\">Arterial oxygenation and PEEP </td> </tr> <tr> <td colspan=\"9\">Oxygenation goal: PaO<sub>2</sub> 55 to 80 mmHg or SpO<sub>2</sub> 88 to 95 percent </td> </tr> <tr> <td colspan=\"9\">Use these FiO<sub>2</sub>/PEEP combinations to achieve oxygenation goal: </td> </tr> <tr> <td class=\"subtitle2_left\">FiO<sub>2</sub> </td> <td>0.3</td> <td>0.4</td> <td>0.5</td> <td>0.6</td> <td>0.7</td> <td>0.8</td> <td>0.9</td> <td>1.0</td> </tr> <tr> <td class=\"subtitle2_left\">PEEP </td> <td>5</td> <td>5 to 8</td> <td>8 to 10</td> <td>10</td> <td>10 to 14</td> <td>14</td> <td>14 to 18</td> <td>18 to 24</td> </tr> <tr> <td colspan=\"9\">PEEP should be applied starting with the minimum value for a given FiO<sub>2</sub>. </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Pplat: plateau pressure; PaO<SUB>2</SUB>: arterial oxygen tension; SpO<SUB>2</SUB>: oxyhemoglobin saturation; PEEP: positive end-expiratory pressure; FiO2: fraction of inspired oxygen.</div><div class=\"graphic_reference\">Adapted from: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000; 342:1301.</div><div id=\"graphicVersion\">Graphic 57072 Version 4.0</div></div></div>"},"57073":{"type":"graphic_diagnosticimage","displayName":"Periph nodule sampling I","title":"Endobronchial ultrasound (EBUS) peripheral nodule sampling","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endobronchial ultrasound (EBUS) peripheral nodule sampling</div><div class=\"cntnt\"><img style=\"width:357px; height:542px;\" src=\"images/PULM/57073_Periph_nodule_sampling_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Computed tomography demonstrates a right middle lobe lesion. B) The radial probe and guide sheath are advanced until the lesion is visualized (arrow).</div><div id=\"graphicVersion\">Graphic 57073 Version 3.0</div></div></div>"},"57074":{"type":"graphic_picture","displayName":"Circumcision PI","title":"Circumcision","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Circumcision</div><div class=\"cntnt\"><img style=\"width:377px; height:518px;\" src=\"images/PI/57074_Circumcision_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Circumcision is a surgery that removes the skin that covers the tip of the penis, called the &quot;foreskin.&quot; Picture A shows a boy who has not been circumcised. Picture B shows a boy who has been circumcised.</div><div class=\"graphic_reference\">Courtesy of David G Weismiller, MD.</div><div id=\"graphicVersion\">Graphic 57074 Version 3.0</div></div></div>"},"57075":{"type":"graphic_table","displayName":"Revised cardiac risk index","title":"Revised cardiac risk index (RCRI)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Revised cardiac risk index (RCRI)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Six independent predictors of major cardiac complications<sup>[1]</sup></td> </tr> <tr> <td class=\"indent1\">High-risk type of surgery (examples include vascular surgery and any open intraperitoneal or intrathoracic procedures)</td> </tr> <tr> <td class=\"indent1\">History of ischemic heart disease (history of&nbsp;myocardial infarction&nbsp;or a positive exercise test, current complaint of chest pain considered to be secondary to myocardial ischemia, use of nitrate therapy, or ECG with pathological Q waves; do not count prior coronary revascularization procedure unless one of the other criteria for ischemic heart disease is present)</td> </tr> <tr> <td class=\"indent1\">History of heart failure</td> </tr> <tr> <td class=\"indent1\">History of cerebrovascular disease</td> </tr> <tr> <td class=\"indent1\">Diabetes mellitus requiring treatment with insulin</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Preoperative serum creatinine &#62;2.0 mg/dL (177 micromol/L)</td> </tr> <tr> <td class=\"subtitle1_single\">Rate of cardiac death, nonfatal myocardial infarction, and nonfatal cardiac arrest according to the number of predictors<sup>[2]</sup></td> </tr> <tr> <td class=\"indent1\">No risk factors&nbsp;<span style=\"font-size: 10.5pt; font-family: 'Cambria',serif;\">&ndash;</span> 0.4% (95% CI: 0.1-0.8)</td> </tr> <tr> <td class=\"indent1\">One risk factor&nbsp;<span style=\"font-size: 10.5pt; font-family: 'Cambria',serif;\">&ndash;</span> 1.0% (95% CI: 0.5-1.4)</td> </tr> <tr> <td class=\"indent1\">Two risk factors&nbsp;<span style=\"font-size: 10.5pt; font-family: 'Cambria',serif;\">&ndash;</span> 2.4% (95% CI: 1.3-3.5)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Three or more risk factors&nbsp;<span style=\"font-size: 10.5pt; font-family: 'Cambria',serif;\">&ndash;</span> 5.4% (95% CI: 2.8-7.9)</td> </tr> <tr> <td class=\"subtitle1_single\">Rate of myocardial infarction, pulmonary edema, ventricular fibrillation, primary cardiac arrest, and complete heart block<sup>[1]</sup></td> </tr> <tr> <td class=\"indent1\">No risk factors&nbsp;<span style=\"font-size: 10.5pt; font-family: 'Cambria',serif;\">&ndash;</span> 0.5% (95% CI: 0.2-1.1)</td> </tr> <tr> <td class=\"indent1\">One risk factor&nbsp;<span style=\"font-size: 10.5pt; font-family: 'Cambria',serif;\">&ndash;</span> 1.3% (95% CI: 0.7-2.1)</td> </tr> <tr> <td class=\"indent1\">Two risk factors&nbsp;<span style=\"font-size: 10.5pt; font-family: 'Cambria',serif;\">&ndash;</span> 3.6% (95% CI: 2.1-5.6)</td> </tr> <tr> <td class=\"indent1\">Three or more risk factors&nbsp;<span style=\"font-size: 10.5pt; font-family: 'Cambria',serif;\">&ndash;</span> 9.1% (95% CI: 5.5-13.8)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999; 100:1043.</LI>&#xD;&#xA;<LI>Devereaux PJ, Goldman L, Cook DJ, et al. Perioperative cardiac events in patients undergoing noncardiac surgery:&nbsp;A review of the magnitude of the problem, the pathophysiology of the events, and methods to estimate and communicate risk. CMAJ 2005; 173:627.</LI></OL></div><div id=\"graphicVersion\">Graphic 57075 Version 13.0</div></div></div>"},"57076":{"type":"graphic_figure","displayName":"Effect of elbow flexion on the ulnar nerve","title":"Effect of elbow flexion on the ulnar nerve","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Effect of elbow flexion on the ulnar nerve</div><div class=\"cntnt\"><img style=\"width:518px; height:349px;\" src=\"images/NEURO/57076_Effect-of-elbow-flexion-on-the-ulnar-nerve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates the effect of elbow flexion on the ulnar nerve. Note that with flexion (B), the distance between the olecranan and median epicondyle increases, thus resulting in compression of the nerve by the attached aponeurosis.</div><div id=\"graphicVersion\">Graphic 57076 Version 4.0</div></div></div>"},"57078":{"type":"graphic_figure","displayName":"Epinephrine and plasma K","title":"Epinephrine lowers the plasma potassium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Epinephrine lowers the plasma potassium</div><div class=\"cntnt\"><img style=\"width:393px; height:256px;\" src=\"images/NEPH/57078_Epinephrine_and_plasma_K.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plasma potassium concentration during an infusion of epinephrine (in physiologic doses) in six patients pretreated with a placebo or a thiazide diuretic for seven days. The plasma potassium concentration fell in both groups, but reached potentially dangerous levels in the diuretic-treated patients who had mild baseline hypokalemia.</div><div class=\"graphic_reference\">Data from Struthers, AD, Whitesmith, R, Reid, JL, Lancet 1983; 1:1358.</div><div id=\"graphicVersion\">Graphic 57078 Version 1.0</div></div></div>"},"57079":{"type":"graphic_table","displayName":"Hodgkin immunophenotype","title":"Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) and classical Hodgkin lymphoma (HL): Morphologic and immunophenotypic features","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) and classical Hodgkin lymphoma (HL): Morphologic and immunophenotypic features</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">&nbsp;</td>\r\n                    <td class=\"subtitle1\">Classical HL</td>\r\n                    <td class=\"subtitle1\">NLPHL</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Pattern</td>\r\n                    <td>Diffuse, interfollicular, nodular</td>\r\n                    <td>Nodular, at least in part</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Tumor cells</td>\r\n                    <td>Diagnostic RS cells; mononuclear or lacunar cells</td>\r\n                    <td>\"L&#38;H\" or \"popcorn\" cells</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Background</td>\r\n                    <td>Lymphocytes, histiocytes, eosinophils, plasma cells</td>\r\n                    <td>Lymphocytes, histiocytes</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Fibrosis</td>\r\n                    <td>Common</td>\r\n                    <td>Rare</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>CD15</td>\r\n                    <td>+</td>\r\n                    <td>-</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>CD30</td>\r\n                    <td>+</td>\r\n                    <td>-</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>CD20</td>\r\n                    <td>-/+</td>\r\n                    <td>+</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>CD45</td>\r\n                    <td>-</td>\r\n                    <td>+</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>EMA</td>\r\n                    <td>-</td>\r\n                    <td>+</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>EBV (in RS cells)</td>\r\n                    <td>+ (&sim;50%)</td>\r\n                    <td>-</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Oct2</td>\r\n                    <td>-/+</td>\r\n                    <td>+</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>BOB.1</td>\r\n                    <td>-/+</td>\r\n                    <td>+</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Background lymphocytes</td>\r\n                    <td>T cells &#62; B cells</td>\r\n                    <td>B cells &#62; T cells</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>CD57+ Tcells</td>\r\n                    <td>-</td>\r\n                    <td>+</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Ig genes (single-cell PCR)</td>\r\n                    <td>Rearranged, clonal, mutated, \"crippled\", no ongoing somatic hypermutation</td>\r\n                    <td>Rearranged, clonal, mutated, productive, ongoing somatic hypermutation</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 57079 Version 2.0</div></div></div>"},"57081":{"type":"graphic_table","displayName":"Avoiding bias in screening","title":"Avoiding bias in screening","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Avoiding bias in screening</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Bias</td> <td class=\"subtitle1\">Effect</td> <td class=\"subtitle1\">How to avoid</td> </tr> <tr> <td>Lead time</td> <td>Appears to improve survival time but actually increases \"disease\" time after disease detection.</td> <td>Use mortality rather than survival rates.</td> </tr> <tr> <td>Length time</td> <td>Outcome appears better in screened group because more cancers with a good prognosis are detected.</td> <td>Compare outcomes in randomized controlled trial with control group and one offered screening. Count <strong>all</strong> outcomes regardless of method of detection.</td> </tr> <tr> <td>Compliance</td> <td>Outcome in screened group appears better due to compliance, not screening.</td> <td>Compare outcomes in randomized controlled trial with control group and one offered screening. Count <strong>all</strong> outcomes regardless of compliance.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Fletcher RH, Fletcher SW, Fletcher GS. Clinical Epidemiology: The Essentials, 5th Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 57081 Version 14.0</div></div></div>"},"57082":{"type":"graphic_figure","displayName":"External ear anatomy","title":"Ear anatomy","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Ear anatomy</div><div class=\"cntnt\"><img style=\"width:537px; height:404px;\" src=\"images/PC/57082_External_ear_anatomy_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The external auditory canal is a cylinder measuring approximately 2.5 cm in length and 7 to 9 mm in width, extending from the conchal cartilage of the auricle to the tympanic membrane. It is divided into a lateral (outer) cartilaginous portion that occupies approximately one-third of the canal, and a medial (inner) bony portion that occupies the other two-thirds. Their junction is termed the isthmus and is the narrowest region of the ear canal. The outer cartilaginous portion is lined by thicker skin with numerous adnexal structures, including cerumen glands (a modified apocrine type gland), sebaceous glands, and hair follicles. Cerumen is formed here. The inner osseous portion of the canal contains thin skin without subcutaneous tissue. The inferior tympanic recess is a small depression in the inferior medial aspect of the ear canal, adjacent to the tympanic membrane. Debris can collect in this area and cause or perpetuate infection.</div><div class=\"graphic_reference\">Adapted with permission from: Cantor RM, Emerg Med 1999; 31:40. Copyright Quadrant HealthCom, Inc, 1999.</div><div id=\"graphicVersion\">Graphic 57082 Version 7.0</div></div></div>"},"57083":{"type":"graphic_figure","displayName":"Precut from pancreatic duct","title":"Precut sphincterotomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Precut sphincterotomy</div><div class=\"cntnt\"><img style=\"width:389px; height:257px;\" src=\"images/GAST/57083_Precut_from_pancreatic_duct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The nose of the pull-type papillotome is left in the pancreatic duct and the common channel is then unroofed in the biliary direction with the cutting wire.</div><div class=\"graphic_reference\">Courtesy of Douglas A Howell, MD and David J Desilets, MD.</div><div id=\"graphicVersion\">Graphic 57083 Version 2.0</div></div></div>"},"57084":{"type":"graphic_table","displayName":"Cervical cancer risk with OCs","title":"Risk of cervical cancer among oral contraceptive users compared to nonusers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk of cervical cancer among oral contraceptive users compared to nonusers</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Use less than&nbsp;five years</td> <td>Relative risk 1.1 (95% CI 1.1-1.2)</td> </tr> <tr> <td class=\"subtitle1_single\">Use&nbsp;five to&nbsp;nine years</td> <td>Relative risk 1.6 (95% CI 1.4-1.7)</td> </tr> <tr> <td class=\"subtitle1_single\">Use 10 or more years</td> <td>Relative risk 2.2 (95% CI 1.9-2.4)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Smith JS, Green J, Berrington de Gonzalez A, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003; 361:1159.</div><div id=\"graphicVersion\">Graphic 57084 Version 4.0</div></div></div>"},"57085":{"type":"graphic_picture","displayName":"Plasmacytoma variants","title":"Plasmacytoma","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Plasmacytoma</div><div class=\"cntnt\"><img style=\"width:464px; height:311px;\" src=\"images/HEME/57085_Plasmacytoma_variants.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates two variants of plasmacytoma. The tumor on the left is the plasmacytic variant, showing collection of mature-looking plasma cells with eccentric round nuclei, condensed, coarsely clumped &quot;clock-face&quot; chromatin, basophilic cytoplasm, and a prominent, pale Golgi zone. The tumor on the right is the plasmablastic variant, with cells showing striking variation in size. Their blastic nature is apparent from the coarsely clumped chromatin and basophilic cytoplasm.</div><div class=\"graphic_reference\">From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 57085 Version 1.0</div></div></div>"},"57086":{"type":"graphic_figure","displayName":"Prominent U waves tutorial","title":"Prominent U waves","html":"<div class=\"graphic normal\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Prominent U waves</div><div class=\"cntnt\"><img style=\"width:461px; height:110px;\" src=\"images/CARD/57086_Prominent_U_waves_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A prominent U wave (&gt;0.2 mV) is usually suggestive of hypokalemia, although it may be seen in other circumstances.</div><div id=\"graphicVersion\">Graphic 57086 Version 1.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"57087":{"type":"graphic_picture","displayName":"Split-thickness skin graft and skin mesher","title":"Split-thickness skin graft and skin mesher","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Split-thickness skin graft and skin mesher</div><div class=\"cntnt\"><img style=\"width:432px; height:289px;\" src=\"images/SURG/57087_Split_thick_graft_mesher.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A split-thickness skin graft is processed through a skin mesher that creates apertures in the graft. This allows for expansion and coverage of a greater wound surface area.</div><div class=\"graphic_reference\">Courtesy of Jorge Leon-Villapalos, MD, FRCS.</div><div id=\"graphicVersion\">Graphic 57087 Version 2.0</div></div></div>"},"57088":{"type":"graphic_figure","displayName":"Troponin predicts outcome in unstable angina","title":"Cardiac troponins are predictive of outcome in unstable angina","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cardiac troponins are predictive of outcome in unstable angina</div><div class=\"cntnt\"><img style=\"width:434px; height:256px;\" src=\"images/CARD/57088_Troponin_ECG_unstable_angin.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among patients with class IIIB unstable angina (primary acute rest angina within the preceding 48 hours), both ST segment depression and serum troponins have independent predictive value. Serum troponins can distinguish between patients at high risk for a cardiac event at 30 days and those at low risk (20 percent if troponin-positive versus less than 2 percent if troponin-negative).</div><div class=\"graphic_footnotes\">TnI: troponin I; TnT: troponin T.</div><div class=\"graphic_reference\">Data from Hamm CW, Braunwald E. Circulation 2000; 102:118.</div><div id=\"graphicVersion\">Graphic 57088 Version 3.0</div></div></div>"},"57089":{"type":"graphic_picture","displayName":"Air cushioned leg splint","title":"Air cushioned lower leg splint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Air cushioned lower leg splint</div><div class=\"cntnt\"><img style=\"width:226px; height:350px;\" src=\"images/EM/57089_Air_cushioned_leg_splint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A light weight air cushioned lower leg splint with self adhesive straps may be used for various lower leg injuries.</div><div class=\"graphic_reference\">Reproduced with permission from Aircast. Copyright &#169; Aircast.</div><div id=\"graphicVersion\">Graphic 57089 Version 1.0</div></div></div>"},"57090":{"type":"graphic_picture","displayName":"Angioedema lip 2","title":"Angioedema of the lips","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Angioedema of the lips</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/ALLRG/57090_Angioedema_lip_2_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 57090 Version 6.0</div></div></div>"},"57092":{"type":"graphic_table","displayName":"Prevalence of gallstones","title":"The prevalence of gallstone disease in selected populations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The prevalence of gallstone disease in selected populations</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Population</td> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Age (years)</td> <td class=\"subtitle1\">Female percent GSD</td> <td class=\"subtitle1\">Male percent GSD</td> </tr> <tr> <td rowspan=\"3\"> <p>Mexican-American</p> <p>1982-1984</p> (n = 1388)</td> <td rowspan=\"3\">Ultrasonography</td> <td>20-39</td> <td>13.8</td> <td>2.6</td> </tr> <tr> <td>40-59</td> <td>26.4</td> <td>9.7</td> </tr> <tr> <td>60-74</td> <td>44.4</td> <td>15.5</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\"> <p>Puerto Ricans</p> <p>1982-1984</p> (n = 582)</td> <td rowspan=\"3\">Ultrasonography</td> <td>20-39</td> <td>9.0</td> <td>2.0</td> </tr> <tr> <td>40-49</td> <td>21.2</td> <td>3.3</td> </tr> <tr> <td>60-74</td> <td>12.1</td> <td>11.1</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\"> <p>Rome, Italy</p> <p>1981-1982</p> (n = 2320)</td> <td rowspan=\"5\">Ultrasonography</td> <td>20-29</td> <td>2.5</td> <td>2.3</td> </tr> <tr> <td>30-39</td> <td>5.9</td> <td>2.0</td> </tr> <tr> <td>40-49</td> <td>10.9</td> <td>6.7</td> </tr> <tr> <td>50-59</td> <td>17.8</td> <td>14.7</td> </tr> <tr> <td>&#62;65</td> <td>25</td> <td>14.4</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\"> <p>Bristol, England<sup>[1]</sup></p> <p>1987-1989</p> (n = 1896)</td> <td rowspan=\"5\">Ultrasonography</td> <td>20-29</td> <td>3.9</td> <td>&ndash;</td> </tr> <tr> <td>30-39</td> <td>6.4</td> <td>&ndash;</td> </tr> <tr> <td>40-49</td> <td>6.5</td> <td>4.7</td> </tr> <tr> <td>50-59</td> <td>14.2</td> <td>22.4</td> </tr> <tr> <td>60-69</td> <td>22.4</td> <td>11.5</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\"> <p>Pima Indians</p> <p>1967-1968</p> (n = 596)</td> <td rowspan=\"6\">Oral cholecystogram</td> <td>15-25</td> <td>12.7</td> <td>0</td> </tr> <tr> <td>25-34</td> <td>73.2</td> <td>4.4</td> </tr> <tr> <td>35-44</td> <td>70.8</td> <td>11.1</td> </tr> <tr> <td>45-54</td> <td>75.8</td> <td>31.9</td> </tr> <tr> <td>55-64</td> <td>62.0</td> <td>66.3</td> </tr> <tr> <td>&#62;65</td> <td>89.5</td> <td>67.8</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"7\"> <p>Okinawa, Japan<sup>[2]</sup></p> <p>1984</p> (n = 2727)</td> <td rowspan=\"7\">Ultrasonography</td> <td>0-19</td> <td>0</td> <td>1.0</td> </tr> <tr> <td>20-29</td> <td>3.0</td> <td>1.0</td> </tr> <tr> <td>30-39</td> <td>3.5</td> <td>2.5</td> </tr> <tr> <td>40-49</td> <td>3.0</td> <td>2.0</td> </tr> <tr> <td>50-59</td> <td>4.0</td> <td>1.5</td> </tr> <tr> <td>60-69</td> <td>9.0</td> <td>4.5</td> </tr> <tr> <td>&#62;70</td> <td>9.5</td> <td>15.0</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\"> <p>United States<sup>[3]</sup></p> <p>1988-1991</p> (n = 14,000)</td> <td rowspan=\"5\">Ultrasonography</td> <td>20-29</td> <td>4.4</td> <td>1.3</td> </tr> <tr> <td>30-39</td> <td>5.2</td> <td>1.1</td> </tr> <tr> <td>40-49</td> <td>8.2</td> <td>5.9</td> </tr> <tr> <td>50-59</td> <td>11.9</td> <td>7.3</td> </tr> <tr> <td>60-74</td> <td>16.4</td> <td>17.2</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\"> <p>China<sup>[4]</sup></p> <p>2008</p> (n = 54,584)</td> <td rowspan=\"6\">Ultrasonography</td> <td>20-29</td> <td>1.1</td> <td>1.2</td> </tr> <tr> <td>30-39</td> <td>2.6</td> <td>2.6</td> </tr> <tr> <td>40-49</td> <td>3.6</td> <td>5.1</td> </tr> <tr> <td>50-59</td> <td>8.2</td> <td>7.9</td> </tr> <tr> <td>60-69</td> <td>8.8</td> <td>8.0</td> </tr> <tr> <td>70+</td> <td>12.2</td> <td>10.7</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">GSD: gallstone disease.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Adapted from: Heaton IW, Braddon FEM, Mountford RA, et al. Gut 1991; 32:316.</li>&#xD;&#xA;    <li>Adapted from: Nomura H, Kashiwagi S, Hayashi J, et al. Am J Epidemiol 1992; 136:787.</li>&#xD;&#xA;    <li>Adapted from: Everhart JE, Khare M, Hill M, Maurer KR. Gastroenterology 1999; 117:632.</li>&#xD;&#xA;    <li>Adapted from: Zeng Q, He Y, Qiang DC, Wu LX. Eur J Gastroenterol Hepatol 2012; 24:1459.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 57092 Version 5.0</div></div></div>"},"57093":{"type":"graphic_picture","displayName":"Truncal rash in measles","title":"Measles exanthem","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Measles exanthem</div><div class=\"cntnt\"><img style=\"width:332px; height:240px;\" src=\"images/ID/57093_Truncal_rash_in_measles.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blanching erythematous macules with some confluent areas on the trunk in a patient with measles.</div><div class=\"graphic_reference\">Copyright Dr. Michael Bennish; reproduced with his permission.</div><div id=\"graphicVersion\">Graphic 57093 Version 4.0</div></div></div>"},"57096":{"type":"graphic_picture","displayName":"RPGN IF Fibrin","title":"Immunofluorescence microscopy showing fibrin deposition","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Immunofluorescence microscopy showing fibrin deposition</div><div class=\"cntnt\"><img style=\"width:396px; height:253px;\" src=\"images/NEPH/57096_RPGN_IF_Fibrin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunofluorescence microscopy showing intense deposition (bright areas in the upper right portion of the glomerulus) of fibrin within a circumferential crescent surrounding the glomerular tuft in any form of crescentic or rapidly progressive glomerulonephritis, including that due to anti-GBM antibody disease.</div><div class=\"graphic_footnotes\">GBM: glomerular basement membrane.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 57096 Version 3.0</div></div></div>"},"57097":{"type":"graphic_picture","displayName":"CA ex-pleomorphic adenoma light micro","title":"Carcinoma ex-pleomorphic adenoma of the salivary gland","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Carcinoma ex-pleomorphic adenoma of the&nbsp;salivary gland</div><div class=\"cntnt\"><img style=\"width:406px; height:584px;\" src=\"images/ONC/57097_CA_ex-pleomorphic_adenoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Carcinoma ex-pleomorphic adenoma. A hyalinized nodule of pleomorphic adenoma adjacent to a nested, malignant proliferation of poorly differentiated epithelial cells with central necrosis.<br />(B) A high-power field of carcinoma ex-pleomorphic adenoma consisting of sheets and nests of large cells with nuclear pyknosis and pleomorphism.</div><div class=\"graphic_reference\">Image B courtesy of G Kenneth Haines, MD.</div><div id=\"graphicVersion\">Graphic 57097 Version 5.0</div></div></div>"},"57098":{"type":"graphic_table","displayName":"Differential dx NLPHL","title":"Differential diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) </div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">&nbsp;</td>\n\t\t\t\t\t<td class=\"subtitle1\">NLPHL</td>\n\t\t\t\t\t<td class=\"subtitle1\">LRCHL</td>\n\t\t\t\t\t<td class=\"subtitle1\">T/HRBCL</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td rowspan=\"5\">Clinical presentation</td>\n\t\t\t\t\t<td>53 percent Stage I</td>\n\t\t\t\t\t<td>46 percent Stage I</td>\n\t\t\t\t\t<td>8 percent Stage I</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>28 percent Stage II</td>\n\t\t\t\t\t<td>24 percent Stage II</td>\n\t\t\t\t\t<td>8 percent Stage II</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>14 percent Stage III</td>\n\t\t\t\t\t<td>24 percent Stage III</td>\n\t\t\t\t\t<td>15 percent Stage III</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>6 percent Stage IV</td>\n\t\t\t\t\t<td>6 percent Stage IV</td>\n\t\t\t\t\t<td>69 percent Stage IV</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>10 percent B symptoms</td>\n\t\t\t\t\t<td>10 percent B symptoms</td>\n\t\t\t\t\t<td>54 percent B symptoms</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Neoplastic cells</td>\n\t\t\t\t\t<td>L&amp;H cell</td>\n\t\t\t\t\t<td>Reed-Sternberg cell which can resemble L&amp;H cells or lacunar cells</td>\n\t\t\t\t\t<td>Can resemble the L&amp;H cell, centroblast, immunoblast, or Reed-Sternberg cell</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Background cells</td>\n\t\t\t\t\t<td>B cells &#62;T cells small B cells, CD3+CD4+CD57+ T cells and follicular dendritic cells</td>\n\t\t\t\t\t<td>Variable. In nodular cases, Reed-Sternberg cells may be found adjacent to B cell follicles</td>\n\t\t\t\t\t<td>T cells &#62;B cells CD8+ cytotoxic T cells and histiocytes</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Growth pattern</td>\n\t\t\t\t\t<td>Nodular, at least in part</td>\n\t\t\t\t\t<td>Usually nodular but can be diffuse</td>\n\t\t\t\t\t<td>Usually diffuse</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\" colspan=\"4\">Tumor cell immunophenotype</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">CD15</td>\n\t\t\t\t\t<td>-</td>\n\t\t\t\t\t<td>+</td>\n\t\t\t\t\t<td>-</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">CD30</td>\n\t\t\t\t\t<td>-/+</td>\n\t\t\t\t\t<td>+/-</td>\n\t\t\t\t\t<td>-/+</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">CD20</td>\n\t\t\t\t\t<td>+</td>\n\t\t\t\t\t<td>-/+</td>\n\t\t\t\t\t<td>+</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">CD45</td>\n\t\t\t\t\t<td>+</td>\n\t\t\t\t\t<td>-</td>\n\t\t\t\t\t<td>+</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">EMA</td>\n\t\t\t\t\t<td>+/-</td>\n\t\t\t\t\t<td>-</td>\n\t\t\t\t\t<td>+/-</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">BOB-1</td>\n\t\t\t\t\t<td>+</td>\n\t\t\t\t\t<td>-/+</td>\n\t\t\t\t\t<td>+</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">OCT-2</td>\n\t\t\t\t\t<td>+</td>\n\t\t\t\t\t<td>-/+</td>\n\t\t\t\t\t<td>+</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">BLC6</td>\n\t\t\t\t\t<td>+</td>\n\t\t\t\t\t<td>-/+</td>\n\t\t\t\t\t<td>+/-</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div class=\"graphic_footnotes\">NLPHL: Nodular lymphocyte-predominant Hodgkin lymphoma; LRCHL: Lymphocyte-rich classical Hodgkin lymphoma; T/HRBCL: T-cell/histiocyte-rich B-cell lymphoma.<br> +: all cases positive.<br> +/-: majority of cases positive.<br> -/+: minority of cases positive.<br> -: all cases negative.</div><div id=\"graphicVersion\">Graphic 57098 Version 2.0</div></div></div>"},"57099":{"type":"graphic_table","displayName":"Second CA after treatment HL","title":"Site-specific risk of second primary malignancy according to treatment of Hodgkin lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Site-specific risk of second primary malignancy according to treatment of Hodgkin lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"8\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Site</td> <td class=\"subtitle1\" colspan=\"4\">Chemotherapy only</td> <td class=\"subtitle1\" colspan=\"4\">Chemotherapy plus radiotherapy</td> </tr> <tr> <td class=\"subtitle2\"># of patients</td> <td class=\"subtitle2\">SIR</td> <td class=\"subtitle2\">95% CI</td> <td class=\"subtitle2\">AER</td> <td class=\"subtitle2\"># of patients</td> <td class=\"subtitle2\">SIR</td> <td class=\"subtitle2\">95% CI</td> <td class=\"subtitle2\">AER</td> </tr> <tr> <td>All malignancies, except nonmelanoma skin cancer and Hodgkin lymphoma*</td> <td>157</td> <td>2.0<sup>&#182;</sup></td> <td>1.7 to 2.4</td> <td>32.9</td> <td>302</td> <td>3.9<sup>&#182;</sup></td> <td>3.5 to 4.4</td> <td>65.3</td> </tr> <tr> <td>Lung</td> <td>40</td> <td>2.9<sup>&#182;</sup></td> <td>2.0 to 3.9</td> <td>10.7</td> <td>60</td> <td>5.1<sup>&#182;</sup></td> <td>3.8 to 6.5</td> <td>14.0</td> </tr> <tr> <td>Non-Hodgkin lymphoma</td> <td>31</td> <td>11.5<sup>&#182;</sup></td> <td>7.8 to 16.3</td> <td>11.6</td> <td>51</td> <td>17.1<sup>&#182;</sup></td> <td>12.7 to 22.5</td> <td>13.9</td> </tr> <tr> <td>Leukemia, excluding CLL</td> <td>33</td> <td>26.7<sup>&#182;</sup></td> <td>18.4 to 37.5</td> <td>13.0</td> <td>42</td> <td>30.6<sup>&#182;</sup></td> <td>22.1 to 41.4</td> <td>11.8</td> </tr> <tr> <td>Leukemia</td> <td>33</td> <td>18.4<sup>&#182;</sup></td> <td>12.7 to 25.9</td> <td>12.8</td> <td>42</td> <td>22.7<sup>&#182;</sup></td> <td>16.3 to 30.7</td> <td>11.7</td> </tr> <tr> <td>Nonmelanoma skin cancer</td> <td>6</td> <td>0.5</td> <td>0.2 to 1.0</td> <td>&ndash;2.8</td> <td>30</td> <td>2.4<sup>&#182;</sup></td> <td>1.6 to 3.4</td> <td>5.1<sup>&#916;</sup></td> </tr> <tr> <td>Breast (female)</td> <td>5</td> <td>0.5</td> <td>0.2 to 1.2</td> <td>&ndash;1.8</td> <td>30</td> <td>2.4<sup>&#182;</sup></td> <td>1.6 to 3.4</td> <td>5.1<sup>&#916;</sup></td> </tr> <tr> <td>Unspecified primary</td> <td>2</td> <td>0.5</td> <td>0.1 to 1.9</td> <td>&ndash;0.7</td> <td>16</td> <td>4.7<sup>&#182;</sup></td> <td>2.7 to 7.6</td> <td>3.7</td> </tr> <tr> <td>Colon, rectum</td> <td>10</td> <td>1.1</td> <td>0.5 to 1.9</td> <td>0.2</td> <td>17</td> <td>2.0<sup>&#9674;</sup></td> <td>1.2 to 3.2</td> <td>2.4</td> </tr> <tr> <td>Esophagus</td> <td>1</td> <td>0.5</td> <td>0.01 to 2.9</td> <td>&ndash;0.4</td> <td>7</td> <td>4.1<sup>&#167;</sup></td> <td>1.6 to 8.4</td> <td>1.5</td> </tr> <tr> <td>Stomach</td> <td>4</td> <td>1.1</td> <td>0.3 to 2.9</td> <td>0.2</td> <td>8</td> <td>2.7<sup>&#9674;</sup></td> <td>1.2 to 5.3</td> <td>1.5</td> </tr> <tr> <td>Soft tissue</td> <td>0</td> <td>0</td> <td>0 to 7.9</td> <td>&ndash;0.2</td> <td>5</td> <td>8.9<sup>&#182;</sup></td> <td>2.9 to 20.7</td> <td>1.3</td> </tr> <tr> <td>Melanoma</td> <td>1</td> <td>0.5</td> <td>0.01 to 2.8</td> <td>&ndash;0.4</td> <td>7</td> <td>2.7<sup>&#9674;</sup></td> <td>1.1 to 5.5</td> <td>1.3</td> </tr> <tr> <td>Tongue, mouth, pharynx</td> <td>2</td> <td>1.3</td> <td>0.2 to 4.6</td> <td>0.2</td> <td>6</td> <td>3.5<sup>&#9674;</sup></td> <td>1.3 to 7.7</td> <td>1.2</td> </tr> <tr> <td>Nervous system</td> <td>3</td> <td>1.2</td> <td>0.2 to 3.5</td> <td>0.2</td> <td>7</td> <td>2.3</td> <td>0.9 to 4.8</td> <td>1.2</td> </tr> <tr> <td>Cervix</td> <td>2</td> <td>1.4</td> <td>0.2 to 4.9</td> <td>0.2</td> <td>6</td> <td>2.7</td> <td>1.0 to 5.8</td> <td>1.1</td> </tr> <tr> <td>Pancreas</td> <td>2</td> <td>1.0</td> <td>0.1 to 3.7</td> <td>0.0</td> <td>5</td> <td>2.9</td> <td>0.9 to 6.7</td> <td>0.9</td> </tr> <tr> <td>Small intestine</td> <td>0</td> <td>0</td> <td>0 to 20.1</td> <td>&ndash;0.1</td> <td>3</td> <td>16.2<sup>&#167;</sup></td> <td>3.3 to 47.3</td> <td>0.8</td> </tr> <tr> <td>Thyroid</td> <td>1</td> <td>2.3</td> <td>0.1 to 12.9</td> <td>0.2</td> <td>3</td> <td>5.1<sup>&#9674;</sup></td> <td>1.1 to 15.0</td> <td>0.7</td> </tr> <tr> <td>Prostate</td> <td>4</td> <td>0.7</td> <td>0.2 to 1.9</td> <td>&ndash;0.6</td> <td>6</td> <td>1.5</td> <td>0.5 to 3.2</td> <td>0.6</td> </tr> <tr> <td>Bone</td> <td>0</td> <td>0</td> <td>0 to 20.7</td> <td>&ndash;0.1</td> <td>2</td> <td>9.0<sup>&#9674;</sup></td> <td>1.1 to 32.5</td> <td>0.5</td> </tr> <tr> <td>Liver</td> <td>2</td> <td>3.4</td> <td>0.4 to 12.5</td> <td>0.6</td> <td>2</td> <td>3.7</td> <td>0.4 to 13.3</td> <td>0.4</td> </tr> <tr> <td>Pleura</td> <td>3</td> <td>6.3<sup>&#9674;</sup></td> <td>1.3 to 18.5</td> <td>1.0</td> <td>2</td> <td>4.4</td> <td>0.5 to 15.9</td> <td>0.4</td> </tr> <tr> <td>Corpus uteri</td> <td>0</td> <td>0</td> <td>0 to 3.1</td> <td>&ndash;0.5</td> <td>2</td> <td>1.5</td> <td>0.2 to 5.5</td> <td>0.2</td> </tr> <tr> <td>Testis</td> <td>2</td> <td>1.7</td> <td>0.2 to 6.2</td> <td>0.3</td> <td>1</td> <td>0.6</td> <td>0.01 to 3.3</td> <td>&ndash;0.2</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Second primary malignancies identified in a cohort of 3564 men and 2234 women treated for Hodgkin lymphoma in Britain from 1963 to 2001.</div><div class=\"graphic_footnotes\">AER: absolute excess risk per 10,000 person-years; CLL: chronic lymphocytic leukemia; SIR: standardized incidence ratio.<br />* In addition to specified sites, one laryngeal, one gallbladder, two ovarian, two bladder, and two kidney cancers occurred in chemotherapy-only patients, and one laryngeal, one heart, one adrenal, two ovarian, two bladder, and three kidney cancers and one myeloma and three cancers of ill-defined site occurred in mixed-modality patients.<br />&para; p&lt;0.001.<br />&Delta; By coincidence, results for nonmelanoma skin cancer and for breast (female) cancer after chemotherapy plus radiotherapy are the same with one digit after the decimal point. This is not a typographical error.<br /><span class=\"lozenge\">&loz;</span> p&lt;0.05.<br />&sect; p&lt;0.01.</div><div class=\"graphic_reference\">From: Swerdlow AJ, Higgins CD, Smith P, et al. Second Cancer Risk After Chemotherapy for Hodgkin's Lymphoma: A Collaborative British Cohort Study. J Clin Oncol 2011; 29(31):4096-4104. Reprinted with permission. Copyright &copy; 2011 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 57099 Version 5.0</div></div></div>"},"57100":{"type":"graphic_table","displayName":"Survival by histology","title":"Survival of paranasal sinus cancer according to tumor site and histologic type","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Survival of paranasal sinus cancer according to tumor site and histologic type</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Tumor site</td> <td class=\"subtitle1\" colspan=\"2\">Maxillary sinus<sup>[1]</sup></td> <td class=\"subtitle1\" colspan=\"2\">Maxillary sinus<sup>[2]</sup></td> <td class=\"subtitle1\" colspan=\"2\">Ethmoid sinus<sup>[1]</sup></td> <td class=\"subtitle1\" colspan=\"2\">PNS<sup>[3]</sup></td> </tr> <tr> <td class=\"subtitle2_left\">Characteristic</td> <td class=\"subtitle2_left\">N (n = 399)</td> <td class=\"subtitle2_left\">5-year OS</td> <td class=\"subtitle2_left\">N (n = 650)</td> <td class=\"subtitle2_left\">5-year OS</td> <td class=\"subtitle2_left\">N (n = 305)</td> <td class=\"subtitle2_left\">5-year OS</td> <td class=\"subtitle2_left\">N (n = 650)</td> <td class=\"subtitle2_left\">5-year OS</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"9\">Histology</td> </tr> <tr> <td class=\"indent2\">Adenocarcinoma</td> <td>18</td> <td>53.8</td> <td>31</td> <td>47.7</td> <td>153</td> <td>43.6</td> <td>107</td> <td>44.8</td> </tr> <tr> <td class=\"indent2\">Esthesioneuroblastoma</td> <td>0</td> <td>NE</td> <td>NA</td> <td>NA</td> <td>27</td> <td>81.7</td> <td>NA</td> <td>NA</td> </tr> <tr> <td class=\"indent2\">Adenoid cystic carcinoma</td> <td>91</td> <td>53.1</td> <td>64</td> <td>57.5</td> <td>24</td> <td>64.1</td> <td>32*</td> <td>65</td> </tr> <tr> <td class=\"indent2\">Melanoma</td> <td>0</td> <td>NE</td> <td>23</td> <td>25.9</td> <td>11</td> <td>0</td> <td>21</td> <td>0</td> </tr> <tr> <td class=\"indent2\">Sarcoma</td> <td>59</td> <td>48.7</td> <td>46</td> <td>44.8</td> <td>15</td> <td>NE</td> <td>18<sup>&#182;</sup></td> <td>46.4</td> </tr> <tr> <td class=\"indent2\">Squamous cell carcinoma</td> <td>156</td> <td>45.2</td> <td>401</td> <td>29.2</td> <td>33</td> <td>18.7</td> <td>101</td> <td>43</td> </tr> <tr> <td class=\"indent2\">Undifferentiated carcinoma</td> <td>26</td> <td>30.5</td> <td>NA</td> <td>NA</td> <td>17</td> <td>0</td> <td>14</td> <td>0</td> </tr> <tr> <td class=\"indent2\">Mucoepidermoid carcinoma</td> <td>27</td> <td>61.9</td> <td>15</td> <td>35.9</td> <td>1</td> <td>NE</td> <td>NA</td> <td>NA</td> </tr> <tr> <td class=\"indent2\">Other</td> <td>22</td> <td>35.8</td> <td>70</td> <td>38.7</td> <td>24</td> <td>32.1</td> <td>18</td> <td>92.3</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">N: number of patients; NA: not available; NE: not estimated; OS: overall survival; PNS: paranasal sinuses (including maxillary, ethmoid, sphenoid, and frontal sinuses; esthesioneuroblastoma excluded).<br />* Minor salivary malignancies, including adenoid cystic carcinoma.<br />¶ High-grade sarcomas only.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Cantu, G, et al. Arch Otolaryngol Head Neck Surg 2008; 134:170.</LI>&#xD;&#xA;<LI>Bhattacharyya, N. J Oral Maxillofac Surg 2003; 61:1016.</LI>&#xD;&#xA;<LI>Ganly, I, et al. Head Neck 2005; 27:575.</LI></OL></div><div id=\"graphicVersion\">Graphic 57100 Version 2.0</div></div></div>"},"57102":{"type":"graphic_figure","displayName":"Incidence colon ca family hx","title":"Incidence of colorectal cancer according to age and family history","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Incidence of colorectal cancer according to age and family history</div><div class=\"cntnt\"><img style=\"width:419px; height:302px;\" src=\"images/PC/57102_Incidence_colon_ca_family_h.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Graphic representation of the cumulative incidence of colorectal cancer demonstrates that in people with a family history, colorectal cancers occur earlier in life, not uncommonly in the 40s or even the 30s.</div><div class=\"graphic_reference\">Data from Fuchs, CS, Giovannucci, EL, Colditz, GA, et al, N Engl J Med 1994; 331:1669.</div><div id=\"graphicVersion\">Graphic 57102 Version 1.0</div></div></div>"},"57103":{"type":"graphic_picture","displayName":"Purpura fulminans large lesion","title":"Purpura fulminans","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Purpura fulminans</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/57103_Purp_fulminans_large_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large, retiform, purpuric lesion is present on the leg. Purpura fulminans is characterized by the presence of extensive purpura.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 57103 Version 3.0</div></div></div>"},"57104":{"type":"graphic_diagnosticimage","displayName":"Tracheobronchopathia osteochondroplastica 2","title":"Tracheobronchopathia osteochondroplastica","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tracheobronchopathia osteochondroplastica</div><div class=\"cntnt\"><img style=\"width:432px; height:432px;\" src=\"images/PULM/57104_Tracheobronch_osteochondr_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The computed tomographic (CT) scan of the distal trachea demonstrates corrugation and polypoid projections into the tracheal lumen in a patient with tracheobronchopathia osteochondroplastica.</div><div id=\"graphicVersion\">Graphic 57104 Version 2.0</div></div></div>"},"57105":{"type":"graphic_table","displayName":"AASLD guideline Rx Wilson","title":"AASLD recommendations for treatment of Wilson disease (WD)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">AASLD recommendations for treatment of Wilson disease (WD)</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td>Initial treatment for symptomatic patients should include a chelating agent (D-penicillamine or trientine). Trientine may be better tolerated.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Patients should avoid intake of foods and water with high concentrations of copper, especially during the first year of treatment.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Treatment of presymptomatic patients or those on maintenance therapy can be accomplished with a chelating agent or with zinc. Trientine may be better tolerated.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Patients with acute liver failure due to WD should be referred for and treated with liver transplantation immediately.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Patients with decompensated cirrhosis unresponsive to chelation treatment should be evaluated promptly for liver transplantation.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Treatment for WD should be continued during pregnancy, but dosage reduction is advisable for D-penicillamine and trientine.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Treatment is lifelong and should not be discontinued, unless a liver transplant has been performed.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>For routine monitoring, serum copper and ceruloplasmin, liver biochemistries and international normalized ratio, complete blood count and urinalysis (especially for those on chelation therapy), and physical examination should be performed regularly, at least twice annually. Patients receiving chelation therapy require a complete blood count and urinalysis regularly, no matter how long they have been on treatment.</td>\r\n  \r\n   </tr>\r\n\r\n   <tr>\r\n\t\r\n\t<td>The 24-hour urinary excretion of copper while on medication should be measured yearly, or more frequently if there are questions on compliance or if dosage of medications is adjusted. The estimated serum non-ceruloplasmin bound copper may be elevated in situations of nonadherence and extremely low in situations of overtreatment.</td>\r\n\t\r\n\t</tr>\r\n\t\r\n </table></div><div class=\"graphic_reference\">Data from: Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: an update. Hepatology 2008; 47:2089.</div><div id=\"graphicVersion\">Graphic 57105 Version 2.0</div></div></div>"},"57109":{"type":"graphic_table","displayName":"Measuring temperature PI","title":"Frequently asked questions about fever in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequently asked questions about fever in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">What is a fever?</td> </tr> <tr> <td>In general, a fever means a temperature above 100.4&ordm;F (38&ordm;C). You might get slightly different numbers depending on how you take your child's temperature &ndash; oral (mouth), armpit, ear, forehead, or rectal.</td> </tr> <tr> <td class=\"subtitle1_single\">How do I measure my child's temperature?</td> </tr> <tr> <td>The best method to measure temperature depends upon several factors. In all cases, rectal temperatures are the most accurate. However, measurements of temperature in the mouth (for children older than&nbsp;four or&nbsp;five years) is accurate when done properly. Temperatures measured in the armpit, in the ear, and on the forehead are least accurate, but may be useful as a first test.</td> </tr> <tr> <td>Glass thermometers are not recommended due to the potential risks of exposure to mercury, which is toxic. If another (digital) thermometer is not available, be sure to carefully \"shake down\" the glass thermometer before use. Instructions for disposing of glass thermometers are available online (www.epa.gov/mercury/spills/index.htm).</td> </tr> <tr> <td class=\"subtitle1_single\">Measuring a rectal temperature</td> </tr> <tr> <td>The child or infant should lie down on his or her stomach across an adult's lap.</td> </tr> <tr> <td>Apply a small amount of petroleum jelly (sample brand name: Vaseline) to the end of the thermometer.</td> </tr> <tr> <td>Gently insert the thermometer into the child's anus. The silver tip of the thermometer should be 1/4 to 1/2 inch inside the rectum.</td> </tr> <tr> <td>Hold the thermometer in place. A glass thermometer requires&nbsp;two minutes, while most digital thermometers need less than&nbsp;one minute.</td> </tr> <tr> <td class=\"subtitle1_single\">Measuring an oral temperature</td> </tr> <tr> <td>Clean the thermometer with cool water and soap. Rinse with water.</td> </tr> <tr> <td>Do not measure the temperature in a child's mouth if he or she has consumed a hot or cold food or drink in the last 30 minutes.</td> </tr> <tr> <td>Place the tip of the thermometer under the child's tongue toward the back. Ask the child to hold the thermometer with his or her lips.</td> </tr> <tr> <td>Keep the lips sealed around the thermometer. A glass thermometer requires about&nbsp;three minutes, while most digital thermometers need less than&nbsp;one minute.</td> </tr> <tr> <td class=\"subtitle1_single\">Measuring an armpit temperature</td> </tr> <tr> <td>Place the tip of the thermometer in the child's dry armpit.</td> </tr> <tr> <td>Hold the thermometer in place by holding the child's elbow against the chest for&nbsp;four to&nbsp;five minutes.</td> </tr> <tr> <td class=\"subtitle1_single\">Measuring an ear temperature</td> </tr> <tr> <td>To measure temperature in the ear, the parent must pull the child's outer ear backward before inserting the thermometer.</td> </tr> <tr> <td>The ear probe is held in the child's ear for about&nbsp;two seconds.</td> </tr> <tr> <td>If the child has been outside on a cold day, wait 15 minutes before measuring the ear temperature.</td> </tr> <tr> <td>Ear tubes and ear infections do <strong>NOT</strong> affect the accuracy of an ear temperature.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 57109 Version 7.0</div></div></div>"},"57110":{"type":"graphic_figure","displayName":"Tympanic membrane anatomy","title":"Anatomy of the tympanic membrane","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Anatomy of the tympanic membrane</div><div class=\"cntnt\"><img style=\"width:541px; height:331px;\" src=\"images/PEDS/57110_Tympanic_membrane-_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Otoscopic image (panel A) and schematic diagram (panel B) of a left tympanic membrane. A line drawn along the manubrium of the malleus divides the tympanic membrane into anterior and posterior halves (dashed line). A line drawn through the umbo (perpendicular to the first line) divides the tympanic membrane into superior and inferior halves (solid line). </div><div class=\"graphic_footnotes\">I: incudostapedial joint; L: lateral process; LR: light reflex; M: manubrium of the malleus; PF: pars flaccida; PT: pars tensa; U: umbo.</div><div class=\"graphic_reference\">Panel A courtesy of Glenn Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 57110 Version 3.0</div></div></div>"},"57111":{"type":"graphic_figure","displayName":"Differences in cystatin C according to demographic factors","title":"Variations in cystatin C based upon sex, race, and ethnicity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Variations in cystatin C based upon sex, race, and ethnicity</div><div class=\"cntnt\"><img style=\"width:414px; height:600px;\" src=\"images/NEPH/57111_Diff_cystatinC_demograph_5.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Serum cystatin C percentiles (5th, 50th, and 95th) by age and (A) sex and (B) race/ethnicity graphed by using an inverse transformation. (-1/cystatin C) is analyzed and the corresponding values for serum cystatin C are shown on the y-axis. The horizontal line at a serum cystatin C value of 1.12 mg/L indicates the cutoff value for increased serum cystatin C level.</div><div class=\"graphic_reference\">From: K&#246;ttgen A, Selvin E, Stevens LA, et al. Serum cystatin C in the United States: the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2008; 51:385. Illustrations used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 57111 Version 1.0</div></div></div>"},"57112":{"type":"graphic_table","displayName":"Normal salivary cortisol","title":"Salivary cortisol concentrations in normal subjects, according to analytic method","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Salivary cortisol concentrations in normal subjects, according to analytic method</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n      <td class=\"subtitle1\">Mean (SE), ng/mL</td>\n\n      <td class=\"subtitle1\">Range, ng/mL</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">Radioimmunoassay of\nunextracted saliva</td>\n\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Men (7 AM)</td>\n\n      <td>5.0 &plusmn; 0.4</td>\n\n      <td>&nbsp;</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Women (7 AM)</td>\n\n      <td>5.8 &plusmn; 0.5</td>\n\n      <td>&nbsp;</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Men and women (11 PM)</td>\n\n      <td>0.4 &plusmn; 0.1</td>\n\n      <td>&nbsp;</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">Radioimmunoassay of\nunextracted saliva</td>\n\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Men and women (9 AM)</td>\n\n      <td>6.0 &plusmn; 0.4</td>\n\n      <td>1.9-10.4</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Men and women (11 PM)</td>\n\n      <td>1.0 &plusmn; 0.1</td>\n\n      <td>0.6-2.3</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Obese men and women (9 AM)</td>\n\n      <td>5.3 &plusmn; 1.0</td>\n\n      <td>0.9-16.0</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Obese men and women (11 PM)</td>\n\n      <td>1.3 &plusmn; 0.2</td>\n\n      <td>0.6-3.9</td>\n </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">To convert salivary cortisol values to nmol/L multiply by 2.76.</div><div class=\"graphic_reference\">Data from: Raff, H, Raff, JL, Findling, JW, J Clin Endocrinol Metab 1998; 83:2681 and Castro, M, Elias, PC, Quidute, AR, et al, J Clin Endocrinol Metab 1999; 84:878.</div><div id=\"graphicVersion\">Graphic 57112 Version 1.0</div></div></div>"},"57113":{"type":"graphic_picture","displayName":"Tissue bag for laparoscopy","title":"Tissue bag for laparoscopy","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Tissue bag for laparoscopy</div><div class=\"cntnt\"><img style=\"width:468px; height:140px;\" src=\"images/OBGYN/57113_Tissue_bag_for_laparoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tissue bags such as this are used for removal of tissue fragments, ovarian masses, or fallopian tubes.</div><div id=\"graphicVersion\">Graphic 57113 Version 2.0</div></div></div>"},"57115":{"type":"graphic_figure","displayName":"Primary graft dysfunction","title":"Primary lung graft dysfunction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary lung graft dysfunction</div><div class=\"cntnt\"><img style=\"width:265px; height:605px;\" src=\"images/PULM/57115_Primary_graft_dysfunction.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 57115 Version 1.0</div></div></div>"},"57116":{"type":"graphic_diagnosticimage","displayName":"Angulated radial neck fracture","title":"Angulated radial neck fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Angulated radial neck fracture</div><div class=\"cntnt\"><img style=\"width:324px; height:329px;\" src=\"images/EM/57116_Angulatedradialneckfract.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radial neck fracture angulated 45 degrees in a 14-year-old female.</div><div class=\"graphic_reference\">Reproduced with permission from: Erickson M, Garg S. Radial Neck and Olecranon Fractures. In: Rockwood and Wilkins' Fractures in Children, 8th ed, Flynn JM, Skaggs DL, Waters PM (Eds), Lippincott Williams &amp; Wilkins 2014. Copyright © 2014 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 57116 Version 9.0</div></div></div>"},"57118":{"type":"graphic_picture","displayName":"Petechiae in infective endocarditis","title":"Petechiae in infective endocarditis","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Petechiae in infective endocarditis</div><div class=\"cntnt\"><img style=\"width:468px; height:351px;\" src=\"images/DERM/57118_Petechiae_subacute_bac_endo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Petechiae (nonblanching, pinpoint reddish brown macules) are present on the toe in this patient with subacute bacterial endocarditis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 57118 Version 4.0</div></div></div>"},"57119":{"type":"graphic_diagnosticimage","displayName":"FAST subxiphoid effusion","title":"FAST: Subxiphoid view with pericardial effusion","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">FAST: Subxiphoid view with pericardial effusion</div><div class=\"cntnt\"><img style=\"width:504px; height:382px;\" src=\"images/EM/57119_FAST_subxiphoid_effus_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image reveals a large pericardial effusion (E) seen using a subxiphoid view as part of the FAST examination.</div><div class=\"graphic_footnotes\">FAST: Focused Assessment with Sonography for Trauma; LV: left ventricle.</div><div class=\"graphic_reference\">Courtesy of Greg Snead, MD.</div><div id=\"graphicVersion\">Graphic 57119 Version 3.0</div></div></div>"},"57120":{"type":"graphic_table","displayName":"Classification of local anesthetics","title":"Classification of local anesthetics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of local anesthetics</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Group I. Benzoic acid esters</td> </tr> <tr> <td>Benzocaine (Americaine, Lanacane)</td> </tr> <tr> <td>Chloroprocaine (Nesacaine)</td> </tr> <tr> <td>Cocaine</td> </tr> <tr> <td>Procaine (Novocaine)</td> </tr> <tr> <td>Proparacaine (Alcaine, Ophthetic, Paracain)</td> </tr> <tr> <td>Tetracaine (Pontocaine)</td> </tr> <tr> <td class=\"subtitle1_single\">Group II. Amides</td> </tr> <tr> <td>Articaine (Septocaine, Zorcaine)</td> </tr> <tr> <td>Bupivacaine (Marcaine, Sensorcaine)</td> </tr> <tr> <td>Levobupivacaine</td> </tr> <tr> <td>Dibucaine (Nupercainal)</td> </tr> <tr> <td>Etidocaine (Duranest)</td> </tr> <tr> <td>Lidocaine (Xylocaine)</td> </tr> <tr> <td>Mepivacaine (Carbocaine)</td> </tr> <tr> <td>Prilocaine (Citanest)</td> </tr> <tr> <td>Ropivacaine (Naropin)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 57120 Version 5.0</div></div></div>"},"57122":{"type":"graphic_table","displayName":"Epidemiologic and historic clues encephalitis","title":"Epidemiologic and historic clues to the etiology of encephalitis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Epidemiologic and historic clues to the etiology of encephalitis in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Epidemiologic clues</td> <td class=\"subtitle1_single\">Potential etiologies</td> </tr> <tr> <td>Age (0 to 28 days)</td> <td> <p>Infectious: CMV, HSV-2 or HSV-1, rubella virus</p> Noninfectious: Inborn error of metabolism (eg, organic acidemia, urea cycle disorder)</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Season:</td> </tr> <tr> <td class=\"sublist1\">Summer</td> <td class=\"sublist_other\">Enterovirus, free living amebae</td> </tr> <tr> <td class=\"sublist1\">Late summer/fall</td> <td class=\"sublist_other\">Arbovirus</td> </tr> <tr> <td class=\"sublist1\">Winter</td> <td class=\"sublist_other\">Postinfectious encephalitis in countries with low rates of MMR immunization</td> </tr> <tr> <td>Infection in horses, birds</td> <td>Arbovirus, Hendra virus</td> </tr> <tr> <td>Blood transfusion or transplant recipient</td> <td>CMV, EBV, HIV, rabies, tick-borne encephalitis, WNV</td> </tr> <tr> <td>Immunodeficiency</td> <td>CMV, enterovirus, HHV6, HSV, VZV, WNV</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Historical clues</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Rash</td> </tr> <tr> <td class=\"indent2\">Vesicular</td> <td>HSV, VZV, enterovirus (hand, foot, and mouth disease), herpes B virus</td> </tr> <tr> <td class=\"indent2\">Hand, foot, mouth</td> <td>Enterovirus</td> </tr> <tr> <td class=\"indent2\">Erythematous macules and papules with cephalocaudad spread</td> <td>Measles</td> </tr> <tr> <td class=\"indent2\">Maculopapular</td> <td>WNV</td> </tr> <tr> <td class=\"indent2\">Maculopapular/petechial begins on ankles and wrists</td> <td>Rocky Mountain spotted fever</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Exposures</td> </tr> <tr> <td class=\"indent2\">Mosquitoes</td> <td>Arbovirus</td> </tr> <tr> <td class=\"indent2\">Ticks</td> <td><em>Borrelia burgdorferi</em>, Powassan virus, <em>Rickettsia rickettsii</em>, tick-borne encephalitis</td> </tr> <tr> <td class=\"indent2\">Animal bite/exposure (dog, bat, cat, birds, livestock, others)</td> <td>Rabies, arboviruses, cat scratch disease, Q fever</td> </tr> <tr> <td class=\"indent2\">Blood transfusion or transplant recipient</td> <td>CMV, EBV, HIV, rabies, tick-borne encephalitis, WNV</td> </tr> <tr> <td class=\"indent2\">Recent infectious illness</td> <td>ADEM</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Recreational activity</td> </tr> <tr> <td class=\"indent2\">Swimming</td> <td>Enteroviruses, free-living amebae</td> </tr> <tr> <td class=\"indent2\">Spelunking</td> <td>Rabies</td> </tr> <tr> <td class=\"indent2\">Sexual activity</td> <td>HIV, <em>Treponema pallidum</em></td> </tr> <tr> <td class=\"subtitle3_left\">Travel</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Immunization</td> </tr> <tr> <td class=\"indent2\">Lack of immunization for specific agent</td> <td>Japanese encephalitis, MMR, VZV, polio, TBEV</td> </tr> <tr> <td class=\"indent2\">Recent immunization</td> <td>ADEM</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CMV: cytomegalovirus; HSV: herpes simplex virus; MMR: measles, mumps, rubella; EBV: Epstein-Barr virus; HIV: human immunodeficiency virus; WNV: West Nile virus; HHV6: human herpesvirus 6; VZV: varicella zoster virus; ADEM: acute disseminated encephalomyelitis; TBEV: Tick-borne encephalitis virus.</div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Willoughby RE, Long SS. Encephalitis, meningoencephalitis, acute disseminated encephalomyelitis, and acute necrotizing encephalopathy. In: Principles and Practice of Pediatric Infectious Diseases, 2nd ed, Long SS, Pickering LK, Prober CG (Eds), Churchill Livingstone, New York 2008. p.310. </LI>&#xD;&#xA;<LI>Tunkel AR, Glaser CA, Bloch KC, et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2008; 47:303. </LI>&#xD;&#xA;<LI>Bronstein DE, Shields WD, Glaser CA. Encephalitis and meningoencephalitis. In: Feigin and Cherry’s Textbook of Pediatric Infectious Diseases, 7th, Cherry JD, Harrison GJ, Kaplan SL, et al. (Eds), Elsevier Saunders, Philadelphia 2014. p.492.&nbsp;</LI></OL></div><div id=\"graphicVersion\">Graphic 57122 Version 9.0</div></div></div>"},"57123":{"type":"graphic_table","displayName":"Termination of exercise testing in children","title":"Indications for terminating pediatric exercise testing before reaching maximal voluntary capacity level","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for terminating pediatric exercise testing before reaching maximal voluntary capacity level</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Decrease in&nbsp;heart rate with increasing workload associated with extreme fatigue, dizziness, or other symptoms suggestive of insufficient cardiac output</td> </tr> <tr> <td>Failure of heart rate to increase with exercise, and extreme fatigue, dizziness, or other symptoms suggestive of insufficient cardiac output</td> </tr> <tr> <td>Progressive fall in systolic blood pressure with increasing workload</td> </tr> <tr> <td>Severe hypertension (ie, &#62;250 mmHg systolic or &#62;125 mm Hg diastolic), or blood pressures higher than can be measured by the laboratory equipment</td> </tr> <tr> <td>Dyspnea that the patient finds intolerable</td> </tr> <tr> <td>Symptomatic tachycardia that the patient finds intolerable</td> </tr> <tr> <td>Progressive fall in oxygen saturation to &#60;90% or a 10-point drop from resting saturation in a patient who is symptomatic</td> </tr> <tr> <td>Presence of &#8805;3 mm flat or downward sloping ST-segment depression</td> </tr> <tr> <td>Increasing ventricular ectopy with increasing workload, including a &#62;3-beat run</td> </tr> <tr> <td>Patient requests termination of the study</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Source: Paridon SM, Alpert BS, Boas SR, et al. Clinical stress testing in the pediatric age group: a statement from the American Heart Association Council on Cardiovascular Disease in the Young, Committee on Atherosclerosis, Hypertension, and Obesity in Youth. Circulation 2006; 113:1905.</div><div id=\"graphicVersion\">Graphic 57123 Version 4.0</div></div></div>"},"57124":{"type":"graphic_table","displayName":"Burn depth","title":"Burn depth","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Burn depth</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Depth </td> <td class=\"subtitle1\">Cause </td> <td class=\"subtitle1\">Appearance </td> <td class=\"subtitle1\">Sensation </td> <td class=\"subtitle1\">Healing time </td> </tr> <tr> <td>Superficial</td> <td> <p>Ultraviolet exposure (eg, sunburn)</p> <p>Very short flash</p> </td> <td> <p>Dry, red</p> <p>Blanches with pressure</p> </td> <td>Painful</td> <td>3 to 6 days</td> </tr> <tr> <td>Superficial partial-thickness</td> <td> <p>Scald (spill or splash)</p> <p>Short flash</p> </td> <td> <p>Blisters</p> <p>Moist, red, weeping</p> <p>Blanches with pressure</p> </td> <td>Painful to temperature and air</td> <td>7 to 20 days</td> </tr> <tr> <td>Deep partial-thickness</td> <td> <p>Scald (spill)</p> <p>Flame</p> <p>Oil</p> <p>Grease</p> </td> <td> <p>Blisters (easily unroofed)</p> <p>Wet or waxy dry</p> <p>Variable color (patchy to cheesy white to red)</p> <p>Does not blanch with pressure</p> </td> <td>Perceptive of pressure only</td> <td>&#62;21 days</td> </tr> <tr> <td>Full-thickness</td> <td> <p>Scald (immersion)</p> <p>Flame</p> <p>Steam</p> <p>Oil</p> <p>Grease</p> <p>Chemical</p> <p>Electrical</p> </td> <td> <p>Waxy white to leathery gray to charred and black</p> <p>Dry and inelastic</p> <p>No blanching with pressure</p> </td> <td>Deep pressure only</td> <td>Never (if &#62;2% total body surface area)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: <br /><OL>&#xD;&#xA;<LI>Mertens DM, Jenkins ME, Warden GD. Out patient burn management.&nbsp;Nurs Clin North Am 1997; 32:343.</LI>&#xD;&#xA;<LI>Peate WF. Outpatient management of burns. Am Fam Physician 1992; 45:1321.</LI>&#xD;&#xA;<LI>Clayton MC, Solem LD. No ice, no butter. Advice on management of burns for primary care physicians.&nbsp;Postgrad Med 1995; 97:151.</LI></OL></div><div id=\"graphicVersion\">Graphic 57124 Version 4.0</div></div></div>"},"57125":{"type":"graphic_picture","displayName":"LV noncompaction autopsy","title":"Left ventricular noncompaction","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Left ventricular noncompaction</div><div class=\"cntnt\"><img style=\"width:504px; height:329px;\" src=\"images/CARD/57125_LV_noncompaction_autopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Isolated left ventricular noncompaction in an autopsy specimen, shown in short-axis view. Note the compacted epicardial layer and noncompacted endocardial layer with marked hypertrabeculation and deep recesses.</div><div class=\"graphic_reference\">Courtesy of William D. Edwards, MD, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.</div><div id=\"graphicVersion\">Graphic 57125 Version 2.0</div></div></div>"},"57127":{"type":"graphic_figure","displayName":"Mechanism of angulation of middle phalangeal shaft fractures","title":"Mechanism of angulation of middle phalangeal shaft fractures","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Mechanism of angulation of middle phalangeal shaft fractures</div><div class=\"cntnt\"><img style=\"width:517px; height:327px;\" src=\"images/SURG/57127_Mech_angl_mid_phal_shaft_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The reduction of middle/proximal fractures is achieved by axial traction and reversing the effects of the deforming forces acting on the fracture. The deforming forces that act on the middle phalanx are the flexor digitorum superficialis (FDS) and the intrinsic tendons. Fractures proximal to the FDS insertion will have an apex dorsal angulation (A), whereas fractures distal to the FDS insertion will have an apex volar angulation (B).</div><div id=\"graphicVersion\">Graphic 57127 Version 3.0</div></div></div>"},"57128":{"type":"graphic_table","displayName":"DES-B","title":"Dissociative Experiences Scale (Brief)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dissociative Experiences Scale (Brief)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup span=\"6\" width=\"10%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Name:</strong></td> <td><strong>Age:</strong></td> <td colspan=\"2\"><strong>Sex:</strong> <p class=\"indent1\"><strong><span class=\"primarybox_left\">&nbsp;</span>Male</strong><br /> <strong><span class=\"primarybox_left\">&nbsp;</span>Female</strong></p> </td> <td><strong>Date:</strong></td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"8\"><strong>Instructions:</strong> For each statement below, please check (✓) the box that best answers each question to show how much each thing has happened to you in the past SEVEN (7) DAYS.</td> </tr> <tr> <td class=\"subtitle2 highlight_gray_text\" colspan=\"7\">&nbsp;</td> <td class=\"subtitle2 highlight_blue_text\">CLINICIAN USE</td> </tr> <tr> <td class=\"subtitle2 highlight_gray_text\" colspan=\"2\">&nbsp;</td> <td class=\"subtitle2 highlight_gray_text\" style=\"text-align: left;\">Not at all</td> <td class=\"subtitle2 highlight_gray_text\" style=\"text-align: left;\">Once or twice</td> <td class=\"subtitle2 highlight_gray_text\" style=\"text-align: left;\">Almost every day</td> <td class=\"subtitle2 highlight_gray_text\" style=\"text-align: left;\">About once a day</td> <td class=\"subtitle2 highlight_gray_text\" style=\"text-align: left;\">More than once a day</td> <td class=\"subtitle2 highlight_blue_text\">ITEM SCORE</td> </tr> <tr> <td colspan=\"2\">1. I find myself staring into space and thinking of nothing.</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>0</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>1</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>2</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>3</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>4</td> <td class=\"centered\"><strong>&nbsp;</strong></td> </tr> <tr class=\"highlight_gray_text\"> <td colspan=\"2\">2. People, objects, or the world around me seem strange or unreal.</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>0</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>1</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>2</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>3</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>4</td> <td class=\"centered\"><strong>&nbsp;</strong></td> </tr> <tr> <td colspan=\"2\">3. I find that I did things that I do not remember doing.</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>0</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>1</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>2</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>3</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>4</td> <td class=\"centered\"><strong>&nbsp;</strong></td> </tr> <tr class=\"highlight_gray_text\"> <td colspan=\"2\">4. When I am alone, I talk out loud to myself.</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>0</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>1</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>2</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>3</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>4</td> <td class=\"centered\"><strong>&nbsp;</strong></td> </tr> <tr> <td colspan=\"2\">5. I feel as though I were looking at the world through a fog so that people and things seem far away or unclear.</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>0</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>1</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>2</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>3</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>4</td> <td class=\"centered\"><strong>&nbsp;</strong></td> </tr> <tr class=\"highlight_gray_text\"> <td colspan=\"2\">6. I am able to ignore pain.</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>0</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>1</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>2</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>3</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>4</td> <td class=\"centered\"><strong>&nbsp;</strong></td> </tr> <tr> <td colspan=\"2\">7. I act so differently from one situation to another that it is almost as if I were two different people.</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>0</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>1</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>2</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>3</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>4</td> <td class=\"centered\"><strong>&nbsp;</strong></td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td colspan=\"2\">8. I can do things very easily that would usually be hard for me.</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>0</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>1</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>2</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>3</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>4</td> <td class=\"centered\"><strong>&nbsp;</strong></td> </tr> <tr class=\"divider_bottom highlight_blue_text\"> <td style=\"text-align: right;\" colspan=\"7\"><strong>Total/partial raw score:</strong></td> <td class=\"centered\"><strong>&nbsp;</strong></td> </tr> <tr class=\"divider_bottom highlight_blue_text\"> <td style=\"text-align: right;\" colspan=\"7\"><strong>Prorated total raw score: (if 1-2 items left unanswered)</strong></td> <td class=\"centered\"><strong>&nbsp;</strong></td> </tr> <tr class=\"highlight_blue_text\"> <td style=\"text-align: right;\" colspan=\"7\"><strong>Average total score:</strong></td> <td class=\"centered\"><strong>&nbsp;</strong></td> </tr> </tbody></table></div><div class=\"graphic_reference\">DES-B (Dalenberg C, Carlson E, 2010) modified for DSM-5 by C. Dalenberg and E. Carlson.</div><div id=\"graphicVersion\">Graphic 57128 Version 1.0</div></div></div>"},"57129":{"type":"graphic_diagnosticimage","displayName":"Xray of distal clavicle fracture Type II","title":"Xray of distal clavicle fracture: Type II","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Xray of distal clavicle fracture: Type II</div><div class=\"cntnt\"><img style=\"width:432px; height:257px;\" src=\"images/EM/57129_Clav_fx_distal_type2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain radiograph shows a type II fracture of the distal third of the clavicle, with characteristic upward displacement of the proximal fragment.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 57129 Version 3.0</div></div></div>"},"57130":{"type":"graphic_diagnosticimage","displayName":"Metatarsal fracture nonunion","title":"Metatarsal fracture with nonunion and growth arrest","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Metatarsal fracture with nonunion and growth arrest</div><div class=\"cntnt\"><img style=\"width:468px; height:586px;\" src=\"images/EM/57130_Metatarsalfxnonunion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple metatarsal neck fractures were complicated by nonunion and growth arrest in this 11-year-old boy. A) Initial x-ray shows fractures of the second, third, and fourth metatarsals with dorsal displacement. B) Patient was treated in a molded short-leg cast. Early remodeling is evident after cast removal. C) At 4.5 years after injury, the patient has growth arrest of the second metatarsal with shortening, hallux valgus, and clawing of the second toe. D) Clinical appearance.</div><div class=\"graphic_reference\">Reproduced with permission from: Jarvis JG, Moroz PJ. Fractures and Dislocations of the Foot. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 57130 Version 11.0</div></div></div>"},"57131":{"type":"graphic_figure","displayName":"Actions antiulcer drugs","title":"Actions of antiulcer medications","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Actions of antiulcer medications</div><div class=\"cntnt\"><img style=\"width:546px; height:328px;\" src=\"images/GAST/57131_Actions_antiulcer_drugs.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">H2 receptor antagonists inhibit acid secretion by blocking histamine H2 receptors on the parietal cell. The proton pump inhibitors (PPIs; eg, omeprazole, lansoprazole, pantoprazole, esomeprazole, and rabeprazole) effectively block acid secretion by irreversibly binding to and inhibiting the hydrogen-potassium ATPase pump that resides on the luminal surface of the parietal cell membrane. The mechanism involved in antacid healing of peptic ulcers may include neutralizing gastric acid, but probably also includes a number of other factors.</div><div id=\"graphicVersion\">Graphic 57131 Version 2.0</div></div></div>"},"57133":{"type":"graphic_figure","displayName":"Water soluble vitamins B","title":"Chemical structure of folate, vitamin C, pantothenate, biotin and niacin","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Chemical structure of folate, vitamin C, pantothenate, biotin and niacin</div><div class=\"cntnt\"><img style=\"width:480px; height:540px;\" src=\"images/PC/57133_Water_soluble_vitamins_B.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 57133 Version 4.0</div></div></div>"},"57134":{"type":"graphic_diagnosticimage","displayName":"Lepidic adenocarcinoma CT","title":"Lepidic adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lepidic&nbsp;adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:335px; height:199px;\" src=\"images/PULM/57134_Bronchioalveolar_carcinoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) scan of&nbsp;lepidic adenocarcinoma demonstrates a right lower lobe mass, measuring 3.5 cm in diameter with thickened lines extending to the pleura (also known as pleural tails, pleural tags,&nbsp;or rabbit ear sign) and with central lucencies that probably represent air bronchograms rather than cavitation.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 57134 Version 4.0</div></div></div>"},"57136":{"type":"graphic_figure","displayName":"Smoking in pulm histiocytosis X","title":"Proposed pathogenetic role of smoking in pulmonary Langerhans cell histiocytosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proposed pathogenetic role of smoking in pulmonary Langerhans cell histiocytosis</div><div class=\"cntnt\"><img style=\"width:320px; height:235px;\" src=\"images/PULM/57136_Smoking_in_pulm_histiocytos.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Proposed pathogenetic scheme showing how cigarette smoke-induced neuroendocrine cell hyperplasia may contribute to airway infiltration by mononuclear phagocytes and fibrosis in pulmonary Langerhans cell histiocytosis. The degree of neuroendocrine cell hyperplasia demonstrated in this condition does not occur in most smokers without this disease. Presumably, patients with pulmonary Langerhans cell histiocytosis are either innately more susceptible to cigarette smoke or are exposed to other stimuli which interact synergistically to induce neuroendocrine cell hyperplasia.</div><div class=\"graphic_reference\">Redrawn from Aguayo, SM, King TE Jr, Waldron, JA Jr, et al, J Clin Invest 1990; 86:838.</div><div id=\"graphicVersion\">Graphic 57136 Version 1.0</div></div></div>"},"57137":{"type":"graphic_figure","displayName":"Vertical band gastroplasty","title":"Vertical band gastroplasty","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vertical band gastroplasty</div><div class=\"cntnt\"><img style=\"width:418px; height:370px;\" src=\"images/SURG/57137_Vertical_band_gastroplasty.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vertical banded gastroplasty is a purely restrictive procedure in which the upper part of the stomach is partitioned by a vertical staple line with a tight outlet wrapped by a prosthetic mesh or band. The small upper stomach pouch gets filled quickly by solid food and prevents consumption of a large meal. Weight loss occurs because of decreased caloric intake of solid food.</div><div class=\"graphic_reference\">Reproduced with permission from: Jones DB, Schneider BE, Olbers T. Atlas of Metabolic and Weight Loss Surgery. Cine-Med, North Woodbury, Connecticut 2010. Copyright &#169; 2010 Cine-Med.</div><div id=\"graphicVersion\">Graphic 57137 Version 3.0</div></div></div>"},"57138":{"type":"graphic_diagnosticimage","displayName":"Fluoroscopic image of tumor ingrowth into a metal biliary stent","title":"Fluoroscopic image of tumor ingrowth into a metal biliary stent","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fluoroscopic image of tumor ingrowth into a metal biliary stent</div><div class=\"cntnt\"><img style=\"width:432px; height:432px;\" src=\"images/GAST/57138_Fluor_tum_ingrow_metal_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image reveals a filling defect (arrow) within a metal biliary stent due to tumor ingrowth.</div><div class=\"graphic_reference\">Courtesy of Douglas G. Adler, MD, FACS, FASGE.</div><div id=\"graphicVersion\">Graphic 57138 Version 3.0</div></div></div>"},"57140":{"type":"graphic_picture","displayName":"Beta hemolysis 1","title":"<em>Listeria monocytogenes</em> on blood agar","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><em>Listeria monocytogenes</em> on blood agar</div><div class=\"cntnt\"><img style=\"width:365px; height:246px;\" src=\"images/ID/57140_Beta_hemolysis_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The clear areas around each colony of <EM>Listeria monocytogenes</EM> are characteristic small zones of beta hemolysis.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 57140 Version 5.0</div></div></div>"},"57141":{"type":"graphic_table","displayName":"Specimens for anaerobic culture","title":"Specimens appropriate for anaerobic culture","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Specimens appropriate for anaerobic culture</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Specimen and collection method</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Normally sterile body fluids</td> <td>Includes blood, pleural fluid, peritoneal fluid, bile, cerebrospinal fluid</td> </tr> <tr> <td>Abscess contents</td> <td>Needle aspirates are preferred</td> </tr> <tr> <td>Wound*</td> <td>Exudate, preferably collected by syringe aspiration using care to decontaminate the adjacent surface</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Pulmonary</td> </tr> <tr> <td class=\"indent1\">Pleural fluid</td> <td>Antecedent antibiotics will reduce yield</td> </tr> <tr> <td class=\"indent1\">Transtracheal aspirate*</td> <td>The only likely specimen source now is pleural fluid</td> </tr> <tr> <td class=\"indent1\">Transthoracic needle aspirate</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Thoracotomy specimen</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Bronchoscopic aspirate*</td> <td>Requires double-lumen catheter brush with distal occluding plug or bronchoalveolar lavage, each combined with quantitative culture</td> </tr> <tr> <td class=\"indent1\">Tracheostomy aspirate*</td> <td>Validity is not well established; one-third of patients without evidence of infection yield anaerobes, and quantitative cultures may be required</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Urinary tract</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Suprapubic aspirate</td> <td>Rare source of anaerobic infections</td> </tr> <tr> <td>Suspect when positive Gram stain and negative culture</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Female genital tract</td> </tr> <tr> <td class=\"indent1\">Culdocentesis</td> <td>Experience is varied, seldom done now</td> </tr> <tr> <td class=\"indent1\">Specimens obtained above pelvic reflection at surgery or laparoscopy </td> <td>Seldom done</td> </tr> <tr> <td class=\"indent1\">Transabdominal needle aspirates of uterus</td> <td>Seldom done</td> </tr> <tr> <td class=\"indent1\">Intrauterine brush using double catheter with a distal occluding plug*</td> <td>Requires quantitative culture; seldom done</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Intraabdominal</td> </tr> <tr> <td class=\"indent1\">Aspirates, biopsy specimens</td> <td>Specimen must be devoid of gastrointestinal flora</td> </tr> <tr> <td class=\"indent1\">Small bowel aspirate</td> <td>Quantitative culture is necessary to detect bacterial overgrowth syndromes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Oral-dental</td> </tr> <tr> <td class=\"indent1\">Aspirate of closed spaces</td> <td>Collected from endodontal canal and preferably transported in conditions that preserve hydration and anaerobiosis</td> </tr> <tr> <td class=\"indent1\">Paper point specimen</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Paranasal sinuses</td> </tr> <tr> <td class=\"indent1\">Aspirate using catheter or syringe*</td> <td>Plastic catheter inserted into depths of sinus track is preferred</td> </tr> <tr> <td class=\"indent1\">Middle-ear aspirate</td> <td>Optimal specimens are obtained with intact tympanic membrane</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Soft tissue</td> </tr> <tr> <td class=\"indent1\">Aspirate of closed spaces (eg, abscesses)</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Biopsies using 3 mm dermal punch*</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Because contamination with normal flora is common, broth cultures are inappropriate; interpretation is facilitated with quantitative or semiquantitative culture.</div><div id=\"graphicVersion\">Graphic 57141 Version 3.0</div></div></div>"},"57143":{"type":"graphic_diagnosticimage","displayName":"Peripelvic cysts","title":"Peripelvic cysts","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peripelvic cysts</div><div class=\"cntnt\"><img style=\"width:288px; height:256px;\" src=\"images/NEPH/57143_Peripelvic_cysts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Longitudinal sonogram of the left kidney showing peripelvic cysts in the renal sinus. Note the rim of echogenic (bright) sinus fat between the fluid and the parenchyma. These can usually distinguished from hydronephrosis by the lack of dilatation of the minor calyces and the proximal ureter.</div><div class=\"graphic_reference\">Courtesy of W Charles O'Neill, MD.</div><div id=\"graphicVersion\">Graphic 57143 Version 2.0</div></div></div>"},"57148":{"type":"graphic_figure","displayName":"Paragard IUD sliding tube back","title":"Paragard IUD sliding tube back","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">Paragard IUD sliding tube back</div><div class=\"cntnt\"><img style=\"width:495px; height:231px;\" src=\"images/OBGYN/57148_ParagardIUDslidingtubeb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With the device stabilized by the rod, the insertion tube is slid back over the rod and slightly out of the uterus to the point where it meets the ring of the plastic rod.</div><div class=\"graphic_reference\">Reproduced with permission from: FEI Women's Health. Copyright ©FEI Women's Health.</div><div id=\"graphicVersion\">Graphic 57148 Version 3.0</div></div></div>"},"57149":{"type":"graphic_table","displayName":"CAM discussion points","title":"How to talk with caregivers/patients about therapeutic options for children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">How to talk with caregivers/patients about therapeutic options&nbsp;for children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>Do</strong> talk about the different kinds of therapies families may have tried to help their child.</td> </tr> <tr> <td>Do <strong>not</strong> wait for families to bring it up.</td> </tr> <tr> <td>Ask in an open-minded, nonjudgmental fashion. Avoid using potentially pejorative terms such as \"unproven,\" \"unconventional,\" or \"alternative.\"</td> </tr> <tr> <td class=\"sublist1_start\">Elicit further information with questions about specific therapies:</td> </tr> <tr> <td class=\"sublist1\">- Have you tried any <strong>herbal</strong> therapies, such as echinacea or ginkgo?</td> </tr> <tr> <td class=\"sublist1\">- Have you tried any <strong>dietary</strong> therapies, like avoiding wheat or milk?</td> </tr> <tr> <td class=\"sublist1\">- Have you sought care from any <strong>other health professionals</strong>, such as acupuncturists or chiropractors?</td> </tr> <tr> <td class=\"sublist1_start\">Elicit the values, beliefs, and influences that led parents to these therapies:</td> </tr> <tr> <td class=\"sublist1\">- Suggested by family members?</td> </tr> <tr> <td class=\"sublist1\">- Consistent with their religious, spiritual, or cultural beliefs?</td> </tr> <tr> <td class=\"sublist1\">- Value of natural or organic approaches?</td> </tr> <tr> <td class=\"sublist1\">- Fear of side effects of mainstream treatments?</td> </tr> <tr> <td>Whenever possible, join with the parents and support their decision to pursue avenues that may help their child; be an ally rather than a tyrant.</td> </tr> <tr> <td>Ask how well the family thinks the therapies worked or didn't work <strong>before</strong> offering your opinion.</td> </tr> <tr> <td>Offer to talk with other therapists involved in the child's care to better maintain coordinated, comprehensive care.</td> </tr> <tr> <td>Offer to learn more to help answer the family's questions.</td> </tr> <tr> <td>Offer families additional information and resources to address their questions about alternative and complementary therapies.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 57149 Version 8.0</div></div></div>"},"57150":{"type":"graphic_table","displayName":"Specific rx pneumonia children","title":"Specific antibiotic therapy for pneumonia in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Specific antibiotic therapy for pneumonia in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Pathogen</td> <td class=\"subtitle1\">Parenteral therapy</td> <td class=\"subtitle1\">Oral therapy<br /> (step-down therapy or mild infection)</td> </tr> <tr class=\"divider_bottom\"> <td><em>Streptococcus pneumoniae</em> with MICs for penicillin &#8804;2.0 mcg/mL</td> <td> <p><strong>Preferred:</strong> Ampicillin (150 to 200 mg/kg/day every 6 hours) or penicillin (200,000 to 250,000 units/kg/day every 4 to 6 hours)</p> <strong>Alternatives:</strong> Ceftriaxone (50 to 100 mg/kg/day every 12 to 24 hours) (preferred for parenteral outpatient therapy) or cefotaxime (150 mg/kg/day every 8 hours); may also be effective: clindamycin* (40 mg/kg/day every 6 to 8 hours) or vancomycin (40 to 60 mg/kg/day every 6 to 8 hours)</td> <td> <p><strong>Preferred:</strong> Amoxicillin (90 mg/kg/day in&nbsp;two doses or 45 mg/kg/day in&nbsp;three doses)</p> <strong>Alternatives:</strong> Second- or third-generation cephalosporin (cefpodoxime, cefuroxime, cefprozil); levofloxacin, if susceptible (16 to 20 mg/kg/day in&nbsp;two doses for children 6 months to 5 years old and 8 to 10 mg/kg/day once daily for children 5 to 16 years old; maximum daily dose 750 mg) or linezolid (30 mg/kg/day in&nbsp;three doses for children &#60;12 years old and 20 mg/kg/day in two doses for children &#8805;12 years old)</td> </tr> <tr class=\"divider_bottom\"> <td><em>S. pneumoniae</em> resistant to penicillin, with MICs &#8805;4.0 mcg/mL</td> <td> <p><strong>Preferred:</strong> Ceftriaxone (100 mg/kg/day every 12 to 24 hours)</p> <strong>Alternatives:</strong> Ampicillin (300 to 400 mg/kg/day every 6 hours), levofloxacin (16 to 20 mg/kg/day every 12 hours for children 6 months to 5 years old and 8 to 10 mg/kg/day once daily for children 5 to 16 years old; maximum daily dose 750 mg), or linezolid (30 mg/kg/day every 8 hours for children &#60;12 years old and 20 mg/kg/day every 12 hours for children &#8805;12 years old); may also be effective: clindamycin* (40 mg/kg/day every 6 to 8 hours) or vancomycin (40 to 60 mg/kg/day every 6 to 8 hours)</td> <td> <p><strong>Preferred:</strong> Levofloxacin (16 to 20 mg/kg/day in&nbsp;two doses for children 6 months to 5 years and 8 to 10 mg/kg/day once daily for children 5 to 16 years, maximum daily dose 750 mg), if susceptible, or linezolid (30 mg/kg/day in&nbsp;three doses for children &#60;12 years and 20 mg/kg/day in&nbsp;two doses for children &#8805;12 years)</p> <strong>Alternative:</strong> Clindamycin* (30 to 40 mg/kg/day in&nbsp;three doses)</td> </tr> <tr class=\"divider_bottom\"> <td>Group A <em>Streptococcus</em></td> <td> <p><strong>Preferred:</strong> Penicillin (100,000-250,000 units/kg/day every 4 to 6 hours) or ampicillin (200 mg/kg/day every 6 hours)</p> <strong>Alternatives:</strong> Ceftriaxone (50 to 100 mg/kg/day every 12 to 24 hours) or cefotaxime (150 mg/kg/day every 8 hours); may also be effective: clindamycin, if susceptible (40 mg/kg/day every 6 to 8 hours) or vancomycin<sup>&#182;</sup> (40 to 60 mg/kg/day every 6 to 8 hours)</td> <td> <p><strong>Preferred:</strong> Amoxicillin (50 to 75 mg/kg/day in&nbsp;two doses), or penicillin V (50 to 75 mg/kg/day in&nbsp;three or&nbsp;four doses)</p> <strong>Alternative:</strong> Clindamycin if susceptible (40 mg/kg/day in 3 doses)</td> </tr> <tr class=\"divider_bottom\"> <td><em>Staphylococcus aureus</em>, methicillin susceptible (combination therapy not well studied)</td> <td> <p><strong>Preferred:</strong> Cefazolin (150 mg/kg/day every 8 hours) or semisynthetic penicillin (eg, oxacillin or nafcillin 150 to 200 mg/kg/day every 6 to 8 hours)</p> <strong>Alternatives:</strong> Cindamycin* (40 mg/kg/day every 6 to 8 hours) or vancomycin (40 to 60 mg/kg/day every 6 to 8 hours)</td> <td> <p><strong>Preferred:</strong> Cephalexin (75 to 100 mg/kg/day in&nbsp;three or&nbsp;four doses)</p> <strong>Alternative:</strong> Clindamycin* (30 to 40 mg/kg/day in&nbsp;three or&nbsp;four doses)</td> </tr> <tr class=\"divider_bottom\"> <td><em>S. aureus</em>, methicillin resistant, susceptible to clindamycin (combination therapy not well studied)</td> <td> <p><strong>Preferred:</strong> Vancomycin (40 to 60 mg/kg/day every 6 to 8 hours or dosing to achieve an AUC/MIC ratio of &#62;400) or clindamycin (40 mg/kg/day every 6 to 8 hours)</p> <strong>Alternatives:</strong> Linezolid (30 mg/kg/day every 8 hours for children &#60;12 years old and 20 mg/kg/day every 12 hours for children &#8805;12 years old)</td> <td> <p><strong>Preferred:</strong> Clindamycin (30 to 40 mg/kg/day in&nbsp;three or&nbsp;four doses)</p> <strong>Alternatives:</strong> Linezolid (30 mg/kg/day in&nbsp;three doses for children &#60;12 years and 20 mg/kg/day in&nbsp;two doses for children &#8805;12 years)</td> </tr> <tr class=\"divider_bottom\"> <td><em>S. aureus</em>, methicillin resistant, resistant to clindamycin (combination therapy not well studied)</td> <td> <p><strong>Preferred:</strong> Vancomycin (40 to 60 mg/kg/day every 6 to 8 hours or dosing to achieve an AUC/MIC ratio of &#62;400)</p> <strong>Alternatives:</strong> Linezolid (30 mg/kg/day every 8 hours for children &#60;12 years old and 20 mg/kg/day every 12 hours for children &#8805;12 years old)</td> <td> <p><strong>Preferred:</strong> Linezolid (30 mg/kg/day in&nbsp;three doses for children &#60;12 years and 20 mg/kg/day in&nbsp;two doses for children &#8805;12 years old)</p> <strong>Alternatives:</strong> None; entire treatment course with parenteral therapy may be required</td> </tr> <tr class=\"divider_bottom\"> <td><em>Haemophilus influenzae</em>, typeable (A-F) or nontypeable</td> <td> <p><strong>Preferred:</strong> Ampicillin (150 to 200 mg/kg/day every 6 hours) if &#946;-lactamase negative; ceftriaxone (50 to 100 mg/kg/day every 12 to 24 hours) or cefotaxime (150 mg/kg/day every 8 hours) if &#946;-lactamase positive</p> <strong>Alternatives:</strong> Ciprofloxacin (30 mg/kg/day every 12 hours) or levofloxacin (16 to 20 mg/kg/day every 12 hours for children 6 months to 5 years old and 8 to 10 mg/kg/day once daily for children 5 to 16 years old; maximum daily dose 750 mg)</td> <td> <p><strong>Preferred:</strong> Amoxicillin (75 to 100 mg/kg/day in&nbsp;three doses) if &#946;-lactamase negative or amoxicillin clavulanate (amoxicillin component, 45 mg/kg/day in&nbsp;three doses or 90 mg/kg/day in&nbsp;two doses) if &#946;-lactamase positive</p> <strong>Alternatives:</strong> Cefdinir, cefixime, cefpodoxime, or ceftibuten</td> </tr> <tr class=\"divider_bottom\"> <td><em>Mycoplasma pneumoniae</em></td> <td> <p><strong>Preferred:</strong> Azithromycin (10 mg/kg on days 1 and 2 of therapy; transition to oral therapy if possible)</p> <strong>Alternatives:</strong> Erythromycin lactobionate (20 mg/kg/day every 6 hours) or levofloxacin (16 to 20 mg/kg/day every 12 hours for children 6 months to 5 years old and 8 to 10 mg/kg/day once daily for children 5 to 16 years old; maximum daily dose 750 mg)</td> <td> <p><strong>Preferred:</strong> Azithromycin (10 mg/kg on day 1, followed by 5 mg/kg/day once daily on days 2 to 5)</p> <strong>Alternatives:</strong> Clarithromycin (15 mg/kg/day in&nbsp;two doses) or erythromycin (40 mg/kg/day in&nbsp;four doses); for children &#62;7 years old, doxycycline (2 to 4 mg/kg/day in&nbsp;two doses); for adolescents with skeletal maturity, levofloxacin (500 mg once daily) or moxifloxacin (400 mg once daily)</td> </tr> <tr> <td><em>Chlamydia trachomatis</em> or <em>Chlamydia pneumoniae</em></td> <td> <p><strong>Preferred:</strong> Azithromycin (10 mg/kg on days 1 and 2 of therapy; transition to oral therapy if possible)</p> <strong>Alternatives:</strong> Erythromycin lactobionate (20 mg/kg/day every 6 hours) or levofloxacin (16 to 20 mg/kg/day in&nbsp;two doses for children 6 months to 5 years old and 8 to 10 mg/kg/day once daily for children 5 to 16 years old; maximum daily dose 750 mg)</td> <td> <p><strong>Preferred:</strong> Azithromycin (10 mg/kg on day 1, followed by 5 mg/kg/day once daily days 2 to 5)</p> <strong>Alternatives:</strong> Clarithromycin (15 mg/kg/day in&nbsp;two doses) or erythromycin (40 mg/kg/day in&nbsp;four doses); for children &#62;7 years old, doxycycline (2 to 4 mg/kg/day in&nbsp;two doses); for adolescents with skeletal maturity, levofloxacin (500 mg once daily) or moxifloxacin (400 mg once daily)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Doses for oral therapy should not exceed adult doses.</div><div class=\"graphic_footnotes\">MIC: minimum inhibitory concentration; AUC: area under the time versus serum concentration curve.<br />* Clindamycin resistance appears to be increasing in certain geographic areas among <EM>S. pneumoniae</EM> and <EM>S. aureus</EM> infections.<br />¶ For β-lactam-allergic children.</div><div class=\"graphic_reference\">From: Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25. By permission of the Infectious Diseases Society of America. Copyright &copy; 2013 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 57150 Version 23.0</div></div></div>"},"57151":{"type":"graphic_figure","displayName":"Left and right axis deviation","title":"Left and right axis deviation","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Left and right axis deviation</div><div class=\"cntnt\"><img style=\"width:518px; height:241px;\" src=\"images/CARD/57151_Left_and_right_axis_deviati.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the QRS complex in leads I and II in left and right axis deviation. The net QRS area is normally positive in leads I and II. An axis more negative than -30&#186; is referred to as left axis deviation, which produces a negative net area in lead II with a positive QRS area in lead I. In comparison, an axis more positive than +100&#186; is referred to as right axis deviation, which produces a negative net area in lead I (a left-right lead) with a positive QRS area in lead II.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 57151 Version 1.0</div></div></div>"},"57153":{"type":"graphic_table","displayName":"Injury severity","title":"Examples of injury severity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of injury severity</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Anatomic region</td> <td class=\"subtitle1\">Mild</td> <td class=\"subtitle1\">Moderate</td> <td class=\"subtitle1\">Severe</td> </tr> <tr> <td>Head</td> <td> <p>Fall &#60;3 feet or from standing height</p> <p>Blow to head with no LOC and small hematoma</p> </td> <td> <p>Blow to head with brief LOC</p> <p>Superficial penetrating injury to the scalp (BB gunshot wound)</p> </td> <td> <p>Blunt head trauma with GCS &#8804;12</p> <p>Intracranial penetrating head trauma</p> </td> </tr> <tr> <td>Neck</td> <td>Restrained passenger of MVC with &#60;20 mph (32 kph) force</td> <td> <p>Pedestrian hit by a car</p> <p>Bicyclist hit by a car</p> <p>Fall &#62;10 feet or 3x standing height</p> <p>Penetrating injury not deep to the platysma muscle</p> </td> <td> <p>Blunt neck trauma with palpable stepoff or neurologic deficit</p> <p>Diving injury with neck pain and paresthesias down both arms</p> <p>Penetrating neck trauma deep to the platysma muscle</p> </td> </tr> <tr> <td>Thorax</td> <td>Punch to chest wall with superficial bruise and normal respirations</td> <td>Pleuritic pain or significant bony tenderness after blunt trauma</td> <td> <p>Blunt trauma with hypoxemia or dyspnea</p> <p>Penetrating chest trauma with shock</p> </td> </tr> <tr> <td>Abdomen</td> <td>Hit in the stomach by a soccer ball kicked by a playmate</td> <td> <p>Blunt trauma with abdominal tenderness or hematuria</p> <p>Restrained MVC passenger with a contusion from the seat belt</p> <p>Penetrating wound superficial to the peritoneum</p> </td> <td> <p>Blunt trauma with shock</p> <p>Penetrating trauma deep to the peritoneum</p> </td> </tr> <tr> <td>Extremities</td> <td> <p>Fall on outstretched hand with no deformity</p> <p>Inverted&nbsp;ankle with lateral malleolar swelling but no deformity</p> </td> <td>Extremity injury with obvious deformity</td> <td> <p>Crush injury with pallor and pain</p> <p>Penetrating injury with vascular compromise</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LOC: loss of consciousness; GCS: Glasgow coma scale; MVC: motor vehicle collision.</div><div id=\"graphicVersion\">Graphic 57153 Version 2.0</div></div></div>"},"57154":{"type":"graphic_picture","displayName":"Storz C Mac video laryngoscope","title":"Storz C-Mac video laryngoscope","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Storz C-Mac video laryngoscope</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/EM/57154_Storz_overview.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Video laryngoscopes like the model pictured above use a camera positioned deep to the tongue and oropharynx to provide an excellent, wide angle view of the glottis.</div><div class=\"graphic_footnotes\">Image courtesy of KARL STORZ Endoskope, Germany.</div><div id=\"graphicVersion\">Graphic 57154 Version 2.0</div></div></div>"},"57155":{"type":"graphic_table","displayName":"Clinical syndromes Lyme","title":"Pathophysiology of clinical syndromes with neuroborreliosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pathophysiology of clinical syndromes with neuroborreliosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Manifestation</td> <td class=\"subtitle1\">Antimicrobial response</td> <td class=\"subtitle1\">Organisms demonstrable</td> <td class=\"subtitle1\">Multifocal inflammatory</td> </tr> <tr> <td>Meningitis</td> <td class=\"centered\">+</td> <td class=\"centered\">Minority</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Neuropathy</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> </tr> <tr> <td>Encephalomyelitis</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> </tr> <tr> <td>Encephalopathy</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 57155 Version 3.0</div></div></div>"},"57159":{"type":"graphic_figure","displayName":"Needle position","title":"Relationship of motor unit action potential (MUAP) amplitude to needle position","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Relationship of motor unit action potential (MUAP) amplitude to needle position</div><div class=\"cntnt\"><img style=\"width:507px; height:336px;\" src=\"images/NEURO/57159_Needle_position.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Of all MUAP parameters, amplitude is most dependent on needle position. Only muscle fibers very close to the needle contribute to amplitude, as opposed to duration, wherein most muscle fibers contribute. Note change in amplitude as needle is moved to different locations within the same motor unit.</div><div class=\"graphic_reference\">Reproduced with permission from: Preston, DC, Shapiro, BE. Electromyography and neuromuscular disorders, Butterworth-Heinemann, Boston 1998. Copyright &#169; 1998 Elsevier.</div><div id=\"graphicVersion\">Graphic 57159 Version 1.0</div></div></div>"},"57160":{"type":"graphic_table","displayName":"Perinatal autopsy procedure","title":"Detailed procedure for perinatal autopsy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Detailed procedure for perinatal autopsy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Hints for dissection of the intact fetus: </td> </tr> <tr> <td>1. Make generous incisions.</td> </tr> <tr> <td>2. Examine organs in situ before evisceration&nbsp;<span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">&ndash;</span> photograph any anomalies and pertinent negative findings.</td> </tr> <tr> <td>3. Remove and set aside the thymus and gonads before evisceration because they are small and often difficult to find after dissection.</td> </tr> <tr> <td>4. Place the brain into a large, preweighed vessel filled with fixative. Weigh the vessel with the fixative and brain to determine brain weight.</td> </tr> <tr> <td>5. After each organ is removed, compare the organ weight with standards.</td> </tr> <tr> <td>6. Dissect the heart and great vessels with the descending aorta and lungs after fixation. Document venous return and the ductus arteriosus before dissecting the heart off of the lungs. When opening the heart, open the appendage side from the inferior to the superior vena cava and look immediately for the foramen ovale and the coronary sinus. Probe the coronary sinus to document whether there is a persistent left superior vena cava. Open the right heart along the lines of flow and continue through the main pulmonary artery through the ductus arteriosus and into the descending aorta. Open the left atrium between the left and right pulmonary veins, and then open&nbsp;the left&nbsp;ventricle posteriorly following&nbsp;the posterior descending coronary and then turning anteriorly and opening along the anterior descending coronary keeping in the left ventricular chamber, left of the septum, continuing up through the aortic valve. This will put the papillary muscles on the free wall, give a clean view of the septum (easy to see common ventricular septal defects this way), and maintains the mitral valve intact. Examine carefully for number of valve leaflets in the great vessels.</td> </tr> <tr> <td class=\"subtitle1_single\">Procedure </td> </tr> <tr> <td class=\"indent1\">&#8226; Proper respect for the fetus should be maintained during the procedure. Eviscerate by using the classic \"Y\"-shaped incision. Reflect back the skin, remove the chest plate after cutting through the soft ribs and clavicle. Obtain lung tissue for microbiology. Examine the organs in situ for any situs malformations, ensure all organs are present, and look for any malformations (photograph abnormalities in situ, if identified). </td> </tr> <tr> <td class=\"indent1\">&#8226; Remove and weigh the thymus, and then submit for histology. Identify gonads, remove, and process. Bluntly dissect up through the neck to the tongue (above the larynx at a minimum), remove as a block from the tongue to anus. Once removed, use a thin probe to document tracheal and esophageal patency (examine for tracheoesophageal fistula). </td> </tr> <tr> <td class=\"indent1\">&#8226; The organ bloc can be dissected fresh or fixed overnight if tissues are autolyzed. Before tissues are fixed, obtain fresh tissue if needed for special studies. Remove and save the vertebral column. Remove the brain and spinal cord, eyes (intracranially), and pituitary. The brain and spinal cord&nbsp;are best removed by a dorsal approach, which is especially useful in identifying spina bifida and in cases with meningocele, meningomyelocele, and other neural tube defects. </td> </tr> <tr> <td class=\"indent1\">&#8226; After the scalp is reflected, the cranium can be opened along suture lines. It is sometimes helpful to keep the dura intact. By cradling the head and holding it over a preweighed vessel filled with fixative, the fetal brain can be allowed to fall slowly into the fixative while the cranial vessels and tentoriums are cut. A deep cut into the spinal canal will allow the brain to \"slip\" into the fixative. Fetal and infantile brains contains more water than adult brains and can therefore be floated in formalin more concentrated than 10 percent. This is achieved by adding undiluted formalin to the formalin solution slowly until the brain floats, thereby avoiding distortion due to fixation. As the brain is being fixed over the following two to three days, it will attain the same density as the formalin and sink. By then, the sunken brain will not distort further and it will not be necessary to add additional formalin. The body should be stitched closed. It is best to ensure the body is presentable. Fetuses who will be buried are rarely embalmed. </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 57160 Version 3.0</div></div></div>"},"57161":{"type":"graphic_figure","displayName":"Lg airway obstruct PFT","title":"Large airway obstruction noted on pulmonary function","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Large airway obstruction noted on pulmonary function</div><div class=\"cntnt\"><img style=\"width:398px; height:461px;\" src=\"images/ONC/57161_Lg_airway_obstruct_PFT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flow volume loop showing flattening of the expiratory portion and normal contour to the inspiratory<br>portion (variable intra-thoracic obstruction). The curve improved after bronchoscopic treatment.</div><div class=\"graphic_reference\">Reproduced with permission from: Midthun, DE, et al. Clinical presentation of lung cancer. Lung Cancer 1996; :421. Copyright &#169; Elsevier Science, Inc.</div><div id=\"graphicVersion\">Graphic 57161 Version 1.0</div></div></div>"},"57162":{"type":"graphic_figure","displayName":"Related food allergies PI","title":"Risk of clinical reactivity among related fruits and vegetables","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Risk of clinical reactivity among related fruits and vegetables</div><div class=\"cntnt\"><img style=\"width:481px; height:235px;\" src=\"images/PI/57162_Related_food_allergies_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The numeric risks cited here are based upon findings in limited series of patients and may not be generalizable to all populations.</div><div class=\"graphic_reference\">Adapted from: Sicherer SH. Clinical implications of cross-reactive food allergens. J Allergy Clin Immunol 2001; 108:881.</div><div id=\"graphicVersion\">Graphic 57162 Version 2.0</div></div></div>"},"57164":{"type":"graphic_table","displayName":"Phytophotodermatitis agents","title":"Plants causing phytophotodermatitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Plants causing phytophotodermatitis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Limes</td>\n\n\n</tr>\n<tr>\n<td>Lemons</td>\n\n\n</tr>\n<tr>\n<td>Celery</td>\n\n\n</tr>\n<tr>\n<td>Grasses</td>\n\n\n</tr>\n<tr>\n<td>Oranges</td>\n\n\n</tr>\n<tr>\n<td>Parsley</td>\n\n\n</tr><tr><td>Parsnips</td></tr><tr><td>Sagebrush</td></tr><tr><td>Goldenrod</td></tr><tr><td>Chrysanthemum</td></tr><tr><td>Ragweed</td></tr><tr><td>Cocklebur</td></tr><tr><td>Tobacco</td></tr><tr><td>Figs</td></tr><tr><td>Garlic</td></tr><tr><td>Hot peppers</td></tr><tr><td>Hyacinth bulbs</td></tr><tr><td>Daffodil bulbs</td></tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Bergeson, PS, Weiss, JC. Arch Pediatr Adolesc Med 2000; 154:201.</div><div id=\"graphicVersion\">Graphic 57164 Version 1.0</div></div></div>"},"57165":{"type":"graphic_figure","displayName":"Delorme procedure for rectal procidentia","title":"Delorme procedure for rectal procidentia","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Delorme procedure for rectal procidentia</div><div class=\"cntnt\"><img style=\"width:540px; height:720px;\" src=\"images/SURG/57165_Delorme-procedure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These figures depict the Delorme procedure, a perineal approach for repair of rectal procidentia. The procedure is performed by dissecting within the submucosal layer of the rectal prolapse.<BR>Figure A: Injection of a dilute saline-epinephrine solution in the submucosa.<BR>Figure B: Mucosa is incised using electrocautery.<BR>Figure C: Circumferential stripping of the mucosa.<BR>Figure D: Plicating sutures placed in the seromuscular layer of the rectum. Rectal mucosa is excised.<BR>Figure E: Plication of the seromuscular layer.<BR>Figure F: Completed anastomosis just proximal to the dentate line.</div><div id=\"graphicVersion\">Graphic 57165 Version 1.0</div></div></div>"},"57167":{"type":"graphic_figure","displayName":"Forceps of aftercoming head 1","title":"Forceps applied to after-coming head","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Forceps applied to after-coming head</div><div class=\"cntnt\"><img style=\"width:408px; height:301px;\" src=\"images/OBGYN/57167_Forceps_of_aftercoming_head.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The head has entered the pelvis and forceps have been applied.</div><div class=\"graphic_reference\">Reproduced with permission from: Pritchard, JA, MacDonald, PC. Williams Obstetrics, 16th Edition, Appleton-Century-Crofts, New York 1980. Copyright &#169;1980 McGraw Hill. p.1071.</div><div id=\"graphicVersion\">Graphic 57167 Version 1.0</div></div></div>"},"57168":{"type":"graphic_table","displayName":"Compare melanoma subtypes","title":"Comparison of histologic patterns of four major subtypes of melanoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of histologic patterns of four major subtypes of melanoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Superficial spreading melanoma</td> <td class=\"subtitle1\">Lentigo maligna melanoma</td> <td class=\"subtitle1\">Acral lentiginous melanoma</td> <td class=\"subtitle1\">Nodular melanoma</td> </tr> <tr> <td>Pattern of RGP</td> <td>Diffuse pagetoid</td> <td>Lentiginous</td> <td>Lentiginous</td> <td>Absent</td> </tr> <tr> <td>Dominant cell type in RGP</td> <td>Epithelioid</td> <td>Epithelioid, spindle, and uncommonly dendritic</td> <td>Spindle, epithelioid, or dendritic</td> <td>Not applicable</td> </tr> <tr> <td>Epidermis of RGP</td> <td>Normal to hyperplastic</td> <td>Atrophic</td> <td>Hyperplastic</td> <td>Not applicable</td> </tr> <tr> <td>Dominant cell type of VGP</td> <td>Epithelioid</td> <td>Spindle and epithelioid</td> <td>Spindle and epithelioid</td> <td>Epithelioid</td> </tr> <tr> <td>Desmoplasia</td> <td>Rare</td> <td>Common</td> <td>Common</td> <td>Uncommon</td> </tr> <tr> <td>Neurotropism</td> <td>Rare</td> <td>Common</td> <td>Common</td> <td>Uncommon</td> </tr> <tr> <td>Frequency of regression</td> <td>Often partial regression</td> <td>Common</td> <td>Variable</td> <td>Uncommon</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RGP: radial growth phase; VGP: vertical growth phase.</div><div id=\"graphicVersion\">Graphic 57168 Version 4.0</div></div></div>"},"57169":{"type":"graphic_table","displayName":"Tobacco associated cancers","title":"Cancers associated with smoking tobacco","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cancers associated with smoking tobacco</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Causation proven</td> </tr> <tr> <td>Colorectal</td> </tr> <tr> <td>Head and neck cancers, including esophagus</td> </tr> <tr> <td>Kidney</td> </tr> <tr> <td>Liver</td> </tr> <tr> <td>Lower urinary tract, including renal pelvis, ureter, and bladder</td> </tr> <tr> <td>Lung</td> </tr> <tr> <td>Mesothelioma</td> </tr> <tr> <td>Myeloid leukemia</td> </tr> <tr> <td>Nasal cavity and paranasal sinuses</td> </tr> <tr> <td>Pancreas</td> </tr> <tr> <td>Penis</td> </tr> <tr> <td>Stomach</td> </tr> <tr> <td>Uterine cervix</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Evidence equivocal</td> </tr> <tr> <td>Breast</td> </tr> <tr> <td>Skin (including squamous cell carcinoma and basal cell carcinoma)</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Vineis P, et al. Tobacco and cancer: recent epidemiological evidence. J Natl Cancer Inst 2004; 96:99.</div><div id=\"graphicVersion\">Graphic 57169 Version 5.0</div></div></div>"},"57170":{"type":"graphic_table","displayName":"FTT historical clues of organic disease ","title":"Historical clues to potential organic causes of failure to thrive (undernutrition) in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Historical clues to potential organic causes of failure to thrive (undernutrition) in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Historical clues</td> <td class=\"subtitle1\">Potential significance</td> </tr> <tr> <td>Diarrhea</td> <td>Malabsorption (celiac disease, inflammatory bowel disease, cystic fibrosis, secondary lactase deficiency, food allergy, short bowel syndrome)</td> </tr> <tr> <td>Chronic constipation</td> <td>May cause decreased appetite</td> </tr> <tr> <td>Abdominal pain</td> <td>Gastroesophageal reflux, esophagitis, chronic constipation</td> </tr> <tr> <td>Vomiting or spitting up</td> <td>Gastroesophageal reflux, delayed gastric emptying, intestinal obstruction</td> </tr> <tr> <td>Gagging, tactile hypersensitivity, prolonged feeding time</td> <td>Oral motor dysfunction</td> </tr> <tr> <td>Decreased appetite</td> <td>Excessive juice&nbsp;(or other nonnutritious liquid) intake, chronic disease, medications, stressful psychosocial conditions&nbsp;</td> </tr> <tr> <td>Recent travel to developing country, camping, housing in shelter, day care</td> <td>Infectious diarrhea (eg, giardiasis, nematodes, enteric pathogens)</td> </tr> <tr> <td>Chronic otitis media</td> <td>Immune deficiency, structural abnormality that impairs intake</td> </tr> <tr> <td>Snoring or mouth breathing</td> <td>Adenoidal hypertrophy</td> </tr> <tr> <td>History of wheezing</td> <td>Mechanical obstruction (eg, vascular ring), chronic pulmonary disease</td> </tr> <tr> <td>Polyuria, polydipsia, polyphagia</td> <td>Diabetes</td> </tr> <tr> <td>Frequent infections</td> <td>Immune deficiency</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Frank D, Silva M, Needlman R. Failure to thrive: Mystery, myth and method. Contemp Pediatr 1993; 10:114.</LI>&#xD;&#xA;<LI>American Academy of Pediatrics Committee on Nutrition. Failure to thrive. In: Pediatric Nutrition, 7<SUP>th</SUP> ed, Kleinman RE, Greer FR (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2014. p.663.</LI></OL></div><div id=\"graphicVersion\">Graphic 57170 Version 6.0</div></div></div>"},"57171":{"type":"graphic_table","displayName":"Reading difficulty tests","title":"Selected tests in the evaluation of a child with reading difficulty","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected tests in the evaluation of a child with reading difficulty</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Age groups <span style=\"color: black;\">or grade levels</span></td> <td class=\"subtitle1\">Description/comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Screening tests</td> </tr> <tr> <td class=\"indent1\">Parents' Evaluation of Developmental Status: Developmental Milestones (PEDS:DM)</td> <td>0 to 8 years</td> <td>Screens developmental skills including reading and math skills</td> </tr> <tr> <td class=\"indent1\">Safety Word Inventory and Literacy Screener</td> <td>6 to 14 years</td> <td>Screens overall academic performance with a special focus on reading</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"3\">Psychometric tests</td> </tr> <tr> <td class=\"indent1\">Comprehensive Test of Phonological Processing in Reading, <span style=\"color: black;\">second edition</span></td> <td><span style=\"color: black;\">4 through 24 years</span></td> <td>Measures phonologic awareness, phonologic memory, and rapid naming</td> </tr> <tr> <td class=\"indent1\">Woodcock-Johnson <span style=\"color: black;\">IV</span></td> <td><span style=\"color: black;\">Prekindergarten through grade 12</span></td> <td><span style=\"color: black;\">Measures cognitive abilities, achievement, and oral language</span></td> </tr> <tr> <td class=\"indent1\">Woodcock Reading Mastery<span style=\"color: black;\"> Tests, third edition</span></td> <td><span style=\"color: black;\">Kindergarten through grade 12</span></td> <td><span style=\"color: black;\">Measures phonologic awareness, listening comprehension, letter and word identification, rapid automatic naming, oral reading fluency, word attack, and word and passage comprehension; provides scores for total reading, readiness, basic skills, and reading comprehension </span></td> </tr> <tr> <td class=\"indent1\">Gray Oral Reading Test (GORT),<span style=\"color: black;\"> fifth edition</span></td> <td>6<span style=\"color: black;\">&nbsp;through 23</span>&nbsp;years</td> <td><span style=\"color: black;\">16&nbsp;increasingly </span><span style=\"color: black;\">difficult </span>passages, each followed by 5 comprehension questions; provides scores for accuracy, rate, fluency, comprehension, <span style=\"color: black;\">and oral reading index (combining scores for fluency and comprehension</span>)</td> </tr> <tr> <td class=\"indent1\">Test of Word Reading Efficiency (TOWRE) - <span style=\"color: black;\">second edition</span></td> <td>6 through 24 years</td> <td>Test of speed of oral reading of individual words; measures sight word efficiency and <span style=\"color: black;\">phonemic </span>decoding efficiency</td> </tr> <tr> <td class=\"indent1\">DIBELS Oral Reading Fluency<span style=\"color: black;\"> and Retell Fluency, sixth edition</span></td> <td><span style=\"color: black;\">Administered in the beginning, middle, and end of grade 1 through grade 6</span></td> <td>Assesses <span style=\"color: #ff0000;\"><span style=\"color: black;\">accuracy, fluency, and comprehension&nbsp;through oral reading and retelling of</span>&nbsp;</span>standardized passages; identifies children who may need additional instructional support; monitors progress toward instructional goals</td> </tr> <tr> <td class=\"indent1\">Nelson-Denny Reading Test</td> <td>Grade 9 through college</td> <td>Silent reading test administered under timed and untimed conditions; assesses reading fluency, vocabulary and comprehension</td> </tr> <tr> <td class=\"indent1\">Wilson Assessment of Decoding and Encoding (WADE)</td> <td>7 years to adult</td> <td>Measures phonologic awareness, decoding, sight words, and spelling</td> </tr> <tr> <td class=\"indent1\">Rapid Automatized Naming and Rapid Alternating Stimulus Test (RAN/RAS)</td> <td>5 years to adult</td> <td>Measures ability to recognize a visual symbol and name it accurately and rapidly</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 57171 Version 6.0</div></div></div>"},"57172":{"type":"graphic_figure","displayName":"Crowe-Davis gag","title":"Crowe-Davis mouth gag for tonsillectomy","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Crowe-Davis mouth gag for tonsillectomy</div><div class=\"cntnt\"><img style=\"width:523px; height:306px;\" src=\"images/PC/57172_Crowe_Davis_gag.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 57172 Version 2.0</div></div></div>"},"57173":{"type":"graphic_picture","displayName":"Stable UCL","title":"Ulnar collateral ligament: Stable","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ulnar collateral ligament: Stable</div><div class=\"cntnt\"><img style=\"width:396px; height:354px;\" src=\"images/EM/57173_Stable_UCL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An abduction stress placed upon the ulnar collateral ligament in this photograph reveals a stable endpoint without increased motion.</div><div id=\"graphicVersion\">Graphic 57173 Version 1.0</div></div></div>"},"57174":{"type":"graphic_figure","displayName":"Mechanism of dissecting aneurysm formation","title":"Mechanism of dissecting aneurysm formation","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Mechanism of dissecting aneurysm formation</div><div class=\"cntnt\"><img style=\"width:464px; height:561px;\" src=\"images/NEURO/57174_Mech_dissect_aneur_form.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral and cross-sectional schematic view of the carotid artery.<br> (A) Aneurysmal dilatation of the vessel related to a hemorrhage between the media and the adventitia (subadventitial dissection).<br> (B) Communication between the arterial lumen and the dissection cavity or disappearance of the hematoma may lead to the formation of an extraluminal pouch or a fusiform dilatation.</div><div class=\"graphic_reference\">Reproduced with permission from: Guillon B, Brunereau L, Biousse V, et al. Long-term follow-up of aneurysms developed during extracranial internal carotid artery dissection. Neurology 1999; 53:117. Copyright © 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 57174 Version 4.0</div></div></div>"},"57175":{"type":"graphic_table","displayName":"ERAS protocol for colorectal surgery","title":"Enhanced recovery after surgery protocol for colorectal procedures in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Enhanced recovery after surgery&nbsp;protocol for colorectal procedures in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Preoperative period</td> </tr> <tr> <td>Patient education (including stoma site selection)</td> </tr> <tr> <td>Optimization of medical comorbidities</td> </tr> <tr> <td>Mechanical bowel preparation and oral antibiotics</td> </tr> <tr> <td>Fasting from fried or fatty foods or meat for eight hours</td> </tr> <tr> <td>Fasting from light meals and non-clear liquids (eg, tea and toast, juice with pulp, milk) for six hours</td> </tr> <tr> <td>Fasting from clear liquids (excludes alcoholic beverages, beverages with milk, juice with pulp) for two hours</td> </tr> <tr> <td>No premedication</td> </tr> <tr> <td>Carbohydrate drink two hours prior to the procedure (optional)</td> </tr> <tr> <td class=\"subtitle1_single\">Intraoperative period</td> </tr> <tr> <td>Thromboprophylaxis</td> </tr> <tr> <td>Antibiotic prophylaxis</td> </tr> <tr> <td>Normothermia</td> </tr> <tr> <td>Fluid optimization</td> </tr> <tr> <td>Minimally invasive surgical approach</td> </tr> <tr> <td>Avoid nasogastric tubes</td> </tr> <tr> <td>Avoid intra-abdominal or perineal drains (except in settings such as colonic spillage or purulent drainage)</td> </tr> <tr> <td class=\"subtitle1_single\">Postoperative period</td> </tr> <tr> <td>Enteral nutrition beginning on postoperative day 1</td> </tr> <tr> <td>High-calorie supplements twice daily</td> </tr> <tr> <td>Multimodal analgesia (eg, transverse abdominis block and opioid-sparing pain medications)</td> </tr> <tr> <td>Multimodal antiemetic regimen</td> </tr> <tr> <td>Early removal of urinary catheter, typically on postoperative day 1</td> </tr> <tr> <td>Early mobilization using a structured program, typically on the evening of the procedure</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This&nbsp;ERAS protocol is an example of a protocol that is used for patients after elective colorectal surgery. </div><div class=\"graphic_footnotes\">ERAS: enhanced recovery after surgery.</div><div id=\"graphicVersion\">Graphic 57175 Version 4.0</div></div></div>"},"57176":{"type":"graphic_picture","displayName":"Saw palmetto","title":"Saw palmetto","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Saw palmetto</div><div class=\"cntnt\"><img style=\"width:324px; height:491px;\" src=\"images/PC/57176_Saw_palmetto.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Martin Wall/herbslides.com.</div><div id=\"graphicVersion\">Graphic 57176 Version 1.0</div></div></div>"},"57177":{"type":"graphic_table","displayName":"Clinical interaction with NMBAs","title":"Clinical interactions with neuromuscular blocking agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical interactions with neuromuscular blocking agents</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\">Potentiating conditions</td></tr>\n\t\t\t\t\t\t<tr><td>Acidosis</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1_start\">Electrolyte abnormalities</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Hypermagnesemia</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Hypocalcemia</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Hypokalemia</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Hyponatremia</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Hypothermia</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1_start\">Neuromuscular diseases</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Myasthenia gravis</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Amyotrophic lateral sclerosis</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Poliomyelitis</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Multiple sclerosis</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Eaton-Lambert syndrome</td></tr>\n\t\t\t\t\t\t<tr><td>Acute intermittent porphyria</td></tr>\n\t\t\t\t\t\t<tr><td>Renal failure</td></tr>\n\t\t\t\t\t\t<tr><td>Hepatic failure</td></tr></tbody></table></td>\n\n      <td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\">Inhibiting conditions</td></tr>\n\t\t\t\t\t\t<tr><td>Alkalosis</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1_start\">Electrolyte abnormalities</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Hypercalcemia</td></tr>\n\t\t\t\t\t\t<tr><td>Demyelinating lesions</td></tr>\n\t\t\t\t\t\t<tr><td>Peripheral neuropathies</td></tr>\n\t\t\t\t\t\t<tr><td>Diabetes mellitus</td></tr>\n\t\t\t\t\t\t<tr><td>Massive trauma</td></tr>\n\t\t\t\t\t\t<tr><td>Major burns</td></tr></tbody></table></td>\n\n    </tr>\n\n    \n\n    \n\n    \n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 57177 Version 1.0</div></div></div>"},"57178":{"type":"graphic_diagnosticimage","displayName":"Miliary tuberculosis PA","title":"Miliary tuberculosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Miliary tuberculosis</div><div class=\"cntnt\"><img style=\"width:360px; height:372px;\" src=\"images/PULM/57178_Miliary_tuberculosis_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows multiple faint miliary nodules scattered diffusely in both lungs.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 57178 Version 3.0</div></div></div>"},"57179":{"type":"graphic_figure","displayName":"Tolerance to chronic B agonist","title":"Tolerance to chronic beta agonist therapy in asthma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tolerance to chronic beta agonist therapy in asthma</div><div class=\"cntnt\"><img style=\"width:420px; height:286px;\" src=\"images/PULM/57179_Tolerance_to_chronic_B_agon.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Number of patients without an exacerbation of asthma over time in patients treated with as needed or regular (continuous) beta agonist therapy. The likelihood of exacerbation was greater in the patients treated with continuous beta agonist, suggesting the development of tolerance.</div><div class=\"graphic_reference\">Redrawn from Taylor, DR, Sears, MR, Herbison, GP, et al, Thorax 1993; 48:134.</div><div id=\"graphicVersion\">Graphic 57179 Version 1.0</div></div></div>"},"57180":{"type":"graphic_picture","displayName":"Small vessel vasculitis EGPA (Churg-Strauss)","title":"Histopathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histopathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)</div><div class=\"cntnt\"><img style=\"width:360px; height:235px;\" src=\"images/RHEUM/57180_Sm_ves_vasculitis_Churg_Str.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small artery in a patient with&nbsp;eosinophilic granulomatosis with polyangiitis (Churg-Strauss) showing intimal fibrinoid necrosis and mural infiltration by histiocytes consistent with a necrotizing granulomatous vasculitis. There is marked extravascular eosinophilia.</div><div id=\"graphicVersion\">Graphic 57180 Version 3.0</div></div></div>"},"57181":{"type":"graphic_table","displayName":"Revised RECIST criteria only","title":"Revised Response Evaluation Criteria in Solid Tumors (RECIST) for assessing clinical tumor response","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Revised Response Evaluation Criteria in Solid Tumors (RECIST) for assessing clinical tumor response</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Response assessment</td> <td class=\"subtitle1\">RECIST guideline, version 1.1<sup>[1]</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Target lesions</td> </tr> <tr> <td class=\"indent1\">CR</td> <td>Disappearance of all target lesions and reduction in the short axis measurement of all pathologic lymph nodes to &#8804;10 mm</td> </tr> <tr> <td class=\"indent1\">PR</td> <td>&#8805;30 percent decrease in the sum of the longest diameter of the target lesions compared with baseline</td> </tr> <tr> <td class=\"indent1\">PD</td> <td> <p>&#8805;20 percent increase of at least 5 mm in the sum of the longest diameters of the target lesions compared with the smallest sum of the longest diameter recorded</p> <p><strong>OR</strong></p> <p>The appearance of new lesions including those detected by FDG-PET</p> </td> </tr> <tr> <td class=\"indent1\">SD</td> <td>Neither PR nor PD</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Non-target lesions</td> </tr> <tr> <td class=\"indent1\">CR</td> <td>Disappearance of all non-target lesions and normalization of tumor marker levels</td> </tr> <tr> <td class=\"indent1\">IR, SD</td> <td>Persistence of one or more non-target lesions and/or the maintenance of tumor marker levels above normal limits</td> </tr> <tr> <td class=\"indent1\">PD</td> <td> <p>The appearance of one of more new lesions or unequivocal progression.</p> <p>If patient has measurable disease, an increase in the overall level, or substantial worsening in non-target lesions, such that tumor burden has increased, even if there is a SD or PR in target lesions.</p> <p>If no measurable disease, an increase in the overall tumor burden comparable in magnitude to the increase that would be required to declare PD in measurable disease (eg, an increase in pleural effusions from trace to large, or an increase in lymphangitic disease from localized to widespread).</p> </td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">11.0000000000000</mso:Specialty>\r\n<mso:Publishable_Version msdt:dt=\"string\">0</mso:Publishable_Version>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=81211&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Revised_RECIST_criteria_only.htm</title></head></div><div class=\"graphic_footnotes\">CR: complete response; PR: partial response; PD: progressive disease; IR: incomplete response; SD: stable disease.</div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>Eisenhauer E, et al. Eur J Cancer 2009; 45:228. </LI></OL></div><div id=\"graphicVersion\">Graphic 57181 Version 3.0</div></div></div>"},"57182":{"type":"graphic_table","displayName":"Antibiotic prophylaxis for endocarditis","title":"Antibiotic regimens for prevention of endocarditis prior to dental and respiratory procedures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antibiotic regimens for prevention of endocarditis prior to dental and respiratory procedures</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Situation</td> <td class=\"subtitle1\" rowspan=\"2\">Agent</td> <td class=\"subtitle1\" colspan=\"2\">Regimen: Single dose*</td> </tr> <tr> <td class=\"subtitle2\">Adults</td> <td class=\"subtitle2\">Children<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Oral</td> <td>Amoxicillin</td> <td>2 g</td> <td>50 mg/kg</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Unable to take oral medication</td> <td>Ampicillin</td> <td>2 g IM or IV</td> <td>50 mg/kg IM or IV</td> </tr> <tr> <td colspan=\"3\"><strong>OR</strong></td> </tr> <tr class=\"divider_bottom\"> <td>Cefazolin or ceftriaxone<sup>&#916;</sup></td> <td>1 g IM or IV</td> <td>50 mg/kg IM or IV</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Allergic to penicillins - oral</td> <td>Cephalexin<sup>&#916;&#9674;</sup></td> <td>2 g</td> <td>50 mg/kg</td> </tr> <tr> <td colspan=\"3\"><strong>OR</strong></td> </tr> <tr> <td>Clindamycin</td> <td>600 mg</td> <td>20 mg/kg</td> </tr> <tr> <td colspan=\"3\"><strong>OR</strong></td> </tr> <tr class=\"divider_bottom\"> <td>Azithromycin or clarithromycin</td> <td>500 mg</td> <td>15 mg/kg</td> </tr> <tr> <td rowspan=\"5\">Allergic to penicillins and unable to take oral medication</td> <td>Cefazolin or ceftriaxone<sup>&#916;</sup></td> <td>1 g IM or IV</td> <td>50 mg/kg IM or IV</td> </tr> <tr> <td colspan=\"3\"><strong>OR</strong></td> </tr> <tr> <td>Clindamycin</td> <td>600 mg IM or IV</td> <td>20 mg/kg IM or IV</td> </tr> <tr> <td colspan=\"3\"><strong>OR</strong></td> </tr> <tr> <td>Vancomycin</td> <td>15 to 20 mg/kg, not to exceed 2 g per dose</td> <td>15 mg/kg to a maximum dose of 1 g</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IM: intramuscular; IV: intravenous.<br />* In general, antibiotics should be administered 30 to 60 minutes prior to the procedure; an exception is intravenous vancomycin, which should be administered 120 minutes prior to the procedure. (Refer to the UpToDate topic on antimicrobial prophylaxis for bacterial endocarditis for further discussion.)<br />¶ The maximal dose in children should not exceed the dose recommended for adults.<br />Δ&nbsp;Cephalosporins should not be used in an individual with a history of anaphylaxis, angioedema, or urticaria with penicillins.<br />◊&nbsp;Or other first- or second-generation oral cephalosporin in equivalent adult or pediatric dose.</div><div class=\"graphic_reference\">Reproduced with permission from: Wilson W, Taubert KA, Gewitz M, Lockhart PB, et al. Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 116:1736. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 57182 Version 18.0</div></div></div>"},"57183":{"type":"graphic_picture","displayName":"Retinal examination showing severe hypertensive retinopathy II","title":"Retinal examination showing severe hypertensive retinopathy II","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retinal examination showing severe hypertensive retinopathy II</div><div class=\"cntnt\"><img style=\"width:397px; height:334px;\" src=\"images/NEPH/57183_Grade_IV_HTN_retinopathy_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Retinal examination in a patient with severe hypertension and grade IV hypertensive retinopathy. The optic disc is swollen with indistinct borders. There is venous tortuosity with multiple cotton wool spots and numerous flame-shaped (arrows) and punctate hemorrhages (arrowhead).</div><div class=\"graphic_reference\">Reproduced by permission from: Gallasch G, Ritz E. The fundus in malignant hypertension. Nephrol Dial Trans 1997; 12:1518.</div><div id=\"graphicVersion\">Graphic 57183 Version 7.0</div></div></div>"},"57187":{"type":"graphic_table","displayName":"Dx criteria atopic dermatitis","title":"Diagnostic criteria for atopic dermatitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for atopic dermatitis</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Major criteria</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Pruritus</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Dermatitis affecting flexural surfaces in adults and the face and extensors in infants</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Chronic or relapsing dermatitis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Personal or family history of cutaneous or respiratory atopy</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Minor criteria</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1_start\">Features of the so-called \"atopic facies\"</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Facial pallor or erythema</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Hypopigmented patches</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Infraorbital darkening</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Infraorbital folds or wrinkles</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Cheilitis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Recurrent conjunctivitis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Anterior neck folds</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1_start\">Triggers of atopic dermatitis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Foods</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Emotional factors</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Environmental factors</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Skin irritants such as wool, solvents and sweat</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1_start\">Complications of atopic dermatitis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Susceptibility to cutaneous viral and bacterial infections</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Impaired cell-mediated immunity</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Immediate skin-test reactivity</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Raised serum IgE</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Keratoconus</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Anterior subcapsular cataracts</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1_start\">Others</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Early age of onset</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Dry skin</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Ichthyosis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Hyperlinear palms</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Keratosis pilaris (plugged hair follicles of proximal extremities)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Hand and foot dermatitis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Nipple eczema</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">White dermatographism</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Perifollicular accentuation</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_lgnd\">Diagnosis requires the presence of at least three major and three minor criteria.</div><div class=\"graphic_reference\">Adapted from: Hanifin JM, Rajka G, Acta Dermatol Venereol 1980; 92(Suppl):44.</div><div id=\"graphicVersion\">Graphic 57187 Version 3.0</div></div></div>"},"57189":{"type":"graphic_figure","displayName":"Acute inferior MI tutorial","title":"Acute inferior transmural myocardial infarction","html":"<div class=\"graphic normal\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Acute inferior transmural myocardial infarction</div><div class=\"cntnt\"><img style=\"width:525px; height:220px;\" src=\"images/CARD/57189_Acute_inferior_MI_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">ST segment elevation in leads II, III, and aVF is characteristic of an acute inferior infarct. Reciprocal ST segment depression is present in this case in leads V1 to V4, and aVL.</div><div id=\"graphicVersion\">Graphic 57189 Version 1.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"57190":{"type":"graphic_diagnosticimage","displayName":"LUL atelectasis PA","title":"Left upper lobe atelectasis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left upper lobe atelectasis</div><div class=\"cntnt\"><img style=\"width:352px; height:355px;\" src=\"images/PULM/57190_LUL_atelectasis_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior (PA) view of&nbsp;left upper lobe atelectasis due to an endobronchial squamous cell carcinoma. An ill-defined opacity is superimposed on the upper half of the left hemithorax, making it appear&nbsp;more opaque&nbsp;than the comparable region in the right hemithorax. The trachea is deviated to the left, the left hilum is retracted cephalad, and the left pulmonary artery fills the aortopulmonary window. Vascular branches to the superior segment of the left lower lobe form an array of linear and tubular opacities (ALTO). A vertical lucency separates the aortic arch from the medial margin of the collapsed lobe and forms an air crescent (\"Luftsichel\") (arrow). This finding probably represents an incomplete left major fissure with parts of the lower lobe pulled forward by the upper lobe, which collapses anteriorly.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 57190 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"57191":{"type":"graphic_diagnosticimage","displayName":"Knee fat fluid level","title":"Fat-fluid level in intraarticular fracture of the knee","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fat-fluid level in intraarticular fracture of the knee</div><div class=\"cntnt\"><img style=\"width:259px; height:351px;\" src=\"images/RHEUM/57191_Knee_fat_fluid_level.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This standing lateral view of the knee demonstrates the presence of a fat-fluid level (arrow) which is indicative of an intraarticular fracture.</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD and Cecilia M Jude, MD.</div><div id=\"graphicVersion\">Graphic 57191 Version 2.0</div></div></div>"},"57193":{"type":"graphic_picture","displayName":"Closed oblique proximal phalanx shaft fracture","title":"Closed oblique proximal phalanx shaft fracture with rotational deformity treated by percutaneous K-wire fixation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Closed oblique proximal phalanx shaft fracture with rotational deformity treated by percutaneous K-wire fixation</div><div class=\"cntnt\"><img style=\"width:334px; height:442px;\" src=\"images/SURG/57193_Unstable_prox_phal_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients with an unstable fracture pattern require surgical intervention. Displaced oblique and comminuted fractures are typically unstable as illustrated here.</div><div id=\"graphicVersion\">Graphic 57193 Version 6.0</div></div></div>"},"57194":{"type":"graphic_algorithm","displayName":"CDC algorithm for prenatal GBS screening","title":"Algorithm for recommended laboratory testing for prenatal screening for group B streptococcal (GBS) colonization","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Algorithm for recommended laboratory testing for prenatal screening for group B streptococcal (GBS) colonization</div><div class=\"cntnt\"><img style=\"width:598px; height:544px;\" src=\"images/OBGYN/57194_CDC_algo_prenatal_GBS.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Direct plating with appropriate media may be done in addition to enriched culture. Direct plating should not be used as the sole means to identify GBS.</div><div class=\"graphic_reference\">Reproduced from: Verani JR, McGee L, Schrag SJ. Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. MMWR Recomm Rep 2010; 59:1.</div><div id=\"graphicVersion\">Graphic 57194 Version 2.0</div></div></div>"},"57198":{"type":"graphic_figure","displayName":"Formula for reverse osmosis","title":"Formulae for calculating the performance characteristics of a reverse osmosis unit for hemodialysis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Formulae for calculating the performance characteristics of a reverse osmosis unit for hemodialysis</div><div class=\"cntnt\"><img style=\"width:413px; height:126px;\" src=\"images/NEPH/57198_Formula_for_reverse_osmosis.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Feed flow rate = Product flow rate + Reject flow rate.</div><div id=\"graphicVersion\">Graphic 57198 Version 3.0</div></div></div>"},"57200":{"type":"graphic_figure","displayName":"Physical activities PI","title":"Examples of moderate physical activity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Examples of moderate physical activity</div><div class=\"cntnt\"><img style=\"width:447px; height:549px;\" src=\"images/PI/57200_Physical_activities_PI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A moderate amount of physical activity is roughly equivalent to physical activity that uses approximately 150 calories (kcal) of energy per day, or 1000 calories per week. Some activities can be performed at various intensities; the suggested durations correspond to the expected intensity of effort.</div><div id=\"graphicVersion\">Graphic 57200 Version 3.0</div></div></div>"},"57201":{"type":"graphic_picture","displayName":"Complicated crown fracture","title":"Complicated crown fracture","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Complicated crown fracture</div><div class=\"cntnt\"><img style=\"width:504px; height:246px;\" src=\"images/PEDS/57201_Complicated_crown_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This fracture of the upper central incisor exposes the neurovascular pulp.</div><div class=\"graphic_reference\">Reproduced with permission from: McTigue, DJ. Managing traumatic injuries in the young permanent dentition. In: Pediatric Dentistry: Infancy through adolescence, 4th ed, WB Saunders, Philadelphia 2005. Copyright &#169; 2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 57201 Version 1.0</div></div></div>"},"57202":{"type":"graphic_table","displayName":"Portals of entry for fusariosis","title":"Portals of entry for fusariosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Portals of entry for fusariosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Airborne</td> </tr> <tr> <td class=\"subtitle2_single\">Immunocompetent host</td> </tr> <tr> <td class=\"indent1\">Keratitis</td> </tr> <tr> <td class=\"indent1\">Sinusitis</td> </tr> <tr> <td class=\"subtitle2_single\">Immunocompromised host</td> </tr> <tr> <td class=\"indent1\">Sinusitis</td> </tr> <tr> <td class=\"indent1\">Pneumonia</td> </tr> <tr> <td class=\"indent1\">Disseminated</td> </tr> <tr> <td class=\"subtitle1_single\">Direct contact</td> </tr> <tr> <td class=\"subtitle2_single\">Immunocompetent host</td> </tr> <tr> <td class=\"indent1\">Onychomycosis</td> </tr> <tr> <td class=\"indent1\">Cutaneous</td> </tr> <tr> <td class=\"indent1\">Peritonitis (CAPD catheter)</td> </tr> <tr> <td class=\"indent1\">Thrombophlebitis</td> </tr> <tr> <td class=\"indent1\">Keratitis (traumatic inoculation, contaminated contact lens solution)</td> </tr> <tr> <td class=\"subtitle2_single\">Immunocompromised host</td> </tr> <tr> <td class=\"indent1\">Cellulitis at site of onychomycosis</td> </tr> <tr> <td class=\"indent1\">Arthritis at sites of cutaneous damage</td> </tr> <tr> <td class=\"indent1\">Osteomyelitis at sites of cutaneous damage</td> </tr> <tr> <td class=\"indent1\">Bloodstream infection and cellulitis at central venous catheter site</td> </tr> <tr> <td class=\"indent1\">Disseminated</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CAPD: continuous ambulatory peritoneal dialysis.</div><div id=\"graphicVersion\">Graphic 57202 Version 1.0</div></div></div>"},"57203":{"type":"graphic_diagnosticimage","displayName":"MRI migrainous infarction","title":"Brain MRI migrainous infarction","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">Brain MRI migrainous infarction</div><div class=\"cntnt\"><img style=\"width:475px; height:581px;\" src=\"images/NEURO/57203_MRI_migrainous_infarction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffusion-weighted imaging lesion patterns of 11 patients with migrainous infarction. Patients 1 through 4 have multiple small lesions, patients 5 through 8 have isolated lesions in the posterior circulation territory, and patients 9 through 11 have isolated lesions in the middle cerebral artery territory.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: Wolf ME, Szabo K, Griebe M, et al. Clinical and MRI characteristics of acute migrainous infarction. Neurology 2011; 76:1911. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 57203 Version 9.0</div></div></div>"},"57204":{"type":"graphic_algorithm","displayName":"Algorithm - acute abdominal pain boys and premenarchal girls","title":"Acute abdominal pain: Males and premenarchal females","html":"<div class=\"graphic\"><div style=\"width: 715px\" class=\"figure\"><div class=\"ttl\">Acute abdominal pain: Males and premenarchal females</div><div class=\"cntnt\"><img style=\"width:695px; height:1794px;\" src=\"images/EM/57204_Algoacuteabdpainchild.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bold text: Life-threatening conditions.<br />Italic text: Common conditions.</div><div id=\"graphicVersion\">Graphic 57204 Version 4.0</div></div></div>"},"57205":{"type":"graphic_picture","displayName":"Pigmented nails in Addison's","title":"Hyperpigmentation of nails in primary adrenal insufficiency","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hyperpigmentation of nails in primary adrenal insufficiency</div><div class=\"cntnt\"><img style=\"width:360px; height:232px;\" src=\"images/ENDO/57205_Pigmented_nails_in_Addisons.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fingers of a 28-year-old white woman with Addison's disease (underneath) compared with those of a normal woman (top). There is hyperpigmentation of the skin and increased pigmentation of the distal half of the nails that occurred during the period of adrenal insufficiency. The proximal half of the nails are hypopigmented, a reflection of the reduction in corticotropin (ACTH) secretion after the institution of glucocorticoid therapy.</div><div class=\"graphic_reference\">Courtesy of David N Orth, MD.</div><div id=\"graphicVersion\">Graphic 57205 Version 2.0</div></div></div>"},"57206":{"type":"graphic_table","displayName":"Terms used for intellectual disability","title":"Terminology used to describe intellectual disability in different countries","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Terminology used to describe intellectual disability in different countries</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Country and/or language</td> <td class=\"subtitle1\">Term</td> </tr> <tr> <td>United States</td> <td>Intellectual disability</td> </tr> <tr> <td>Australia</td> <td>Intellectual disability</td> </tr> <tr> <td>Canada (English, French)</td> <td>Mental deficiency, intellectual handicap</td> </tr> <tr> <td>England</td> <td>Learning disability,* intellectual disability, developmental disability<sup>&#182;</sup></td> </tr> <tr> <td>France</td> <td>Mental deficiency, mental apraxia</td> </tr> <tr> <td>Germany</td> <td>Mental handicap, mental retardation</td> </tr> <tr> <td>Italy</td> <td>Mental delay, mentally deficient</td> </tr> <tr> <td>Estonia</td> <td>Mental retardation</td> </tr> <tr> <td>Puerto Rico</td> <td>Mentally slowed down</td> </tr> <tr> <td>Spain</td> <td>Mental delay</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* In the United States, the term \"learning disability\" usually denotes a specific learning disability (eg, dyslexia) rather than intellectual disability.<br />¶ In the United States, the term \"developmental disability\" does not necessarily involve intellectual disability. For example, a developmental disability could be limited to motor dysfunction or developmental-behavioral dysfunction, in the absence of intellectual disability.</div><div class=\"graphic_reference\">Schroeder SR, Gerry M, Gertz G, Velazquez F. Usage of the Term \"Mental Retardation:\" Language, Image and Public Education. Kansas University Center on Developmental Disabilities; Center for the Study of Family, Neighborhood and Community Policy, The University of Kansas. 2002. p.86.</div><div id=\"graphicVersion\">Graphic 57206 Version 8.0</div></div></div>"},"57207":{"type":"graphic_table","displayName":"Antidepressants in older adults and medically ill","title":"Drug properties and doses of antidepressants in older adults and medically ill","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drug properties and doses of antidepressants in older adults and medically ill</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"35%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Starting dose</td> <td class=\"subtitle1\">Suggested dose range</td> <td class=\"subtitle1\">Precautions*</td> <td class=\"subtitle1\">Potential advantages</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Selective serotonin reuptake inhibitors (SSRIs)<sup>&#182;</sup></td> </tr> <tr> <td>Escitalopram</td> <td>5 mg every morning or every evening</td> <td>5 to 20 mg daily</td> <td>Mild discontinuation symptoms may occur absent tapering.</td> <td rowspan=\"2\"> <p>Applies to escitalopram and citalopram:</p> <p>Generally well tolerated. Non-sedating, low risk of sleep disturbance, comparatively few significant drug interactions.</p> Good choice for initial treatment of depression in most older adults.</td> </tr> <tr> <td>Citalopram</td> <td>10 mg every morning or every evening</td> <td>10 to 20 mg<sup>&#916;</sup> daily</td> <td> <p>Dose related risk of QT prolongation<sup>&#182;</sup><sup>&#916;</sup>.</p> Mild discontinuation symptoms may occur absent tapering.</td> </tr> <tr> <td>Sertraline</td> <td>12.5 to 25 mg every morning</td> <td>25 to 200 mg daily</td> <td>More frequent gastrointestinal symptoms including diarrhea. Variable oral bioavailability. Oral solution contains alcohol. Discontinuation symptoms may occur absent tapering.</td> <td> <p>Non-sedating, low risk of insomnia, lacks significant cardiovascular effects.</p> Good choice for initial treatment of depression in most older adults.</td> </tr> <tr> <td>Fluoxetine</td> <td>5 to 10 mg every morning</td> <td>5 to 60 mg daily</td> <td> <p>Activating.</p> <p>Significant drug interactions. </p> Prolonged half-life and active metabolites require weeks to reach steady-state, prolonging time needed to evaluate effect of dose adjustment and complicating wash-out and withdrawal.</td> <td>Activating effect may be useful for treatment of depressed patients with low energy or hypersomnia. Tapering upon discontinuation is not needed due to long half-life.</td> </tr> <tr> <td>Paroxetine</td> <td>10 mg every evening</td> <td>10 to 40 mg every evening</td> <td> <p>Weakly anticholinergic. May cause constipation, dry mouth or drowsiness.</p> Associated with more severe discontinuation symptoms in absence of tapering.</td> <td>Useful for patients with insomnia. Moderate half-life with no active metabolites.</td> </tr> <tr class=\"divider_bottom\"> <td>Fluvoxamine</td> <td>25 mg every evening</td> <td>25 to 200 mg every evening</td> <td>Significant drug interactions. Short half-life associated with discontinuation symptoms in absence of tapering.</td> <td>May be useful for patients with insomnia. </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Serotonin-norepinephrine reuptake inhibitors (SNRIs)<sup>&#9674;</sup></td> </tr> <tr> <td>Venlafaxine (extended release)</td> <td>37.5 mg once daily</td> <td>75 to 225 mg once daily</td> <td rowspan=\"3\"> <p>Applies to venlafaxine and desvenlafaxine:</p> <p>Activating.</p> <p>May cause dose-dependent increases in blood pressure (primarily diastolic) and heart rate. Monitor blood pressure regularly.</p> <p>Gastrointestinal symptoms (eg, nausea) may be more prominent with immediate release venlafaxine.</p> Associated with discontinuation symptoms absent tapering. Taper desvenlafaxine by increasing interval between doses.</td> <td rowspan=\"3\"> <p>Applies to venlafaxine and desvenlafaxine: activating effect may be useful for treatment of melancholic depressed patients with low energy or hypersomnia.</p> Useful for patients with co-morbid painful conditions such as diabetic neuropathy.</td> </tr> <tr> <td>Venlafaxine (immediate release)</td> <td>18.75 to 37.5 mg every morning or twice daily</td> <td>75 to 150 mg twice daily</td> </tr> <tr> <td>Desvenlafaxine</td> <td> <p>50 mg every morning</p> CrCl &#60; 30 mL/min: 50 mg every other day</td> <td> <p>50 mg every morning</p> CrCl &#60; 30 mL/min: 50 mg every other day</td> </tr> <tr class=\"divider_bottom\"> <td>Duloxetine</td> <td>10 to 20 mg daily</td> <td>20 to 60 mg once daily</td> <td>Significant drug interactions.</td> <td> <p>Mildy sedating. Low risk of insomnia.</p> Useful for patients with comorbid painful conditions such as diabetic neuropathy or chronic pain.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Atypical antidepressants<sup>&#9674;</sup></td> </tr> <tr> <td>Mirtazapine</td> <td>7.5 mg every evening</td> <td>15 to 60 mg every evening</td> <td> <p>Prolonged half-life and active metabolites. Risk of accumulation with renal and/or hepatic insufficiency. Dose reductions necessary.</p> Drowsiness, weight gain. Rare reports of agranulocytosis.</td> <td> <p>Sedating. Low risk of sexual dysfunction.</p> <p>Appetite stimulant and anti-nausea effects can be noted within days.</p> Useful for patients with insomnia or who may benefit from weight gain.</td> </tr> <tr> <td>Bupropion sustained release</td> <td>75 mg in morning initially then twice daily</td> <td>150 mg in morning and mid-afternoon (twice daily)</td> <td>Avoid in seizure disorders and depressed patients with agitation. Dose-dependent increase in diastolic blood pressure. May worsen insomnia.</td> <td>Stimulant effect may be useful for treatment of depressed patients with low energy and apathy. Low risk of cognitive toxicity. Dopaminergic action may be advantageous for depressed patients with Parkinson disease.</td> </tr> <tr> <td>Vilazodone</td> <td>10 mg once daily with food for 7 days or more</td> <td>20 to 40 mg once daily with food</td> <td> <p>Take with food to assure bioavailability.</p> <p>Diarrhea, nausea, vomiting, dizziness, insomnia.</p> Significant drug interactions via CYP 3A4 require dose adjustment.</td> <td> <p>Low incidence of weight gain or sexual dysfunction.</p> Role in therapy for treatment of depressed older adults or adults with comorbid illness is not yet defined.</td> </tr> <tr class=\"divider_bottom\"> <td>Trazodone</td> <td>12.5 to 25 mg taken 30 to 60 minutes before bedtime for hypnotic effects</td> <td>25 to 100 mg taken 30 to 60 minutes before bedtime for hypnotic effects; antidepressant effects require higher doses.</td> <td>Sedation, orthostatic hypotension, nausea. Residual daytime sedation and cognitive impairment. Reports of hyponatremia.</td> <td>Used in low doses as adjunct to SSRI for treatment of insomnia.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Tricyclic antidepressants (TCAs)<sup>&#167;</sup></td> </tr> <tr> <td>Nortriptyline</td> <td>10 mg every evening</td> <td>10 to 100 mg every evening or in two divided doses</td> <td rowspan=\"2\"> <p>Applies to nortriptyline and desipramine:</p> <p>May be poorly tolerated by medically ill and older adults due to anticholinergic effects which include dry mouth, constipation, urinary retention or altered vision (eg, avoid in prostatic disease or narrow angle glaucoma).</p> <p>May be fatal in overdose. </p> <p>Potentially cardiotoxic, can cause arrhythmia or orthostatic hypotension.</p> Significant drug interactions.</td> <td> <p>Applies to nortriptyline:</p> <p>Established therapeutic serum concentration 50 to 150 ng/mL.</p> <p>Mildly sedating. Taken at bed time for depressed patients with insomnia.</p> May be useful for melancholic, anxious depressed patients who have not responded to first and second line antidepressants.</td> </tr> <tr> <td>Desipramine</td> <td>10 mg every morning</td> <td>25 to 150 mg every morning or in two divided doses</td> <td> <p>Applies to desipramine:</p> <p>Established therapeutic serum concentration 125 to 300 ng/mL.</p> Mild stimulant effects may be useful for depressed patients with low energy and hypersomnia who have not responded to first and second line antidepressants.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Specific interactions of antidepressants with other medications may be determined using the Lexi-Interact&trade; drug interactions program included with UpToDate.<br />&para; For additional information refer to topic on unipolar depression in adults and SSRIs.<br />&Delta; Maximum recommended daily dose of citalopram is 20 mg for patients &gt;60 years of age, with significant hepatic insufficiency, or taking interacting medications that can increase citalopram levels.<br />&loz; For additional information refer to topic on SNRIs and other antidepressants for treating depressed adults.<br />&sect; For additional information refer to topic on tricyclic and tetracyclic antidepressants for treating depressed adults.</div><div id=\"graphicVersion\">Graphic 57207 Version 7.0</div></div></div>"},"57208":{"type":"graphic_diagnosticimage","displayName":"Parasternal long axis color flow Doppler I","title":"Parasternal long axis view with color flow Doppler","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Parasternal long axis view with color flow Doppler</div><div class=\"cntnt\"><img style=\"width:456px; height:355px;\" src=\"images/CARD/57208_Long_axis_color_flow_Dop_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The long axis parasternal view with superimposed color flow Doppler mapping of the left ventricular inflow and outflow tracts was obtained during diastole. The color bar in the left side of the image indicates that red designates flow towards the transducer and that orange shades of red indicate velocities at the preset Nyquist limit of 0.75 m/sec; blue identifies flow that is away from the transducer. Normal diastolic mitral inflow from the left atrium (LA) to the left ventricle (LV) is color coded in shades of red. As the point flow crosses the mitral valve (MV) plane it becomes bright orange, ie, flow accelerates as it crosses the narrower diameter of the mitral valve ring, reaching a velocity that is at the upper limits of the instrument's ability to measure. There is a small diastolic signal in blue that arises from the central portion of the coapted aortic valve leaflets and represents mild aortic regurgitation (AI); at its point of origin, this flow is characterized by red, white, and blue dots that, by convention, identify the flow as being \"disturbed\" or chaotic and high velocity. As the flow decelerates it becomes blue, identifying it as flow that is away from the transducer.</div><div id=\"graphicVersion\">Graphic 57208 Version 8.0</div></div></div>"},"57209":{"type":"graphic_diagnosticimage","displayName":"Lipoma arborescens MRI","title":"Magnetic resonance imaging of lipoma arborescens explaining dry tap","html":"<div class=\"graphic\"><div style=\"width: 637px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance imaging of lipoma arborescens explaining dry tap</div><div class=\"cntnt\"><img style=\"width:617px; height:360px;\" src=\"images/RHEUM/57209_Lipoma_arborescens_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Failed arthrocentesis due to chronic synovitis with lipoma arborescens in a patient with psoriatic arthritis. T1 weighted (left) and T2 weighted (right) axial images through the mid-pole of the patella show massive frond-like, fatty proliferation of the synovium both on the medial and lateral sides of the joint (short arrows). Although a large joint effusion is present (E), placement of a needle, particularly from the medial side (long arrow), would probably enter the hypertrophied synovium and would fail to yield fluid. Aspiration of 10 mL of low-viscosity, inflammatory fluid was achieved by the lateral approach.</div><div class=\"graphic_footnotes\">M: medial; L: lateral.</div><div class=\"graphic_reference\">Reproduced with permission from: Roberts WN, Hayes CW, Breitbach SA, et al. Am J Med 1996; 100:461.</div><div id=\"graphicVersion\">Graphic 57209 Version 3.0</div></div></div>"},"57210":{"type":"graphic_movie","displayName":"Atheroma 2D TEE","title":"Atheroma on 2D TEE","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atheroma on 2D TEE</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SURG/57210_Atheroma2DTEEconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:414px; height:285px;\" src=\"images/SURG/57210_Atheroma2DTEE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Complex atherosclerotic plaque with multiple mobile components visualized in the descending thoracic aorta by 2D TEE. In the video clip to the left, the aorta is visualized first in its short axis (transversely) then in its long axis (longitudinally).</div><div class=\"graphic_reference\">Courtesy of Dr. Muhamed Saric and Dr. Itzhak Kronzon.</div><div id=\"graphicVersion\">Graphic 57210 Version 2.0</div></div></div>"},"57211":{"type":"graphic_waveform","displayName":"12-lead ECG right posteroseptal WPW II","title":"12-lead electrocardiogram (ECG) of a right posteroseptal accessory AV pathway","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) of a right posteroseptal accessory AV pathway</div><div class=\"cntnt\"><img style=\"width:514px; height:311px;\" src=\"images/CARD/57211_Right_posteroseptal_WPW_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram during rapid atrial pacing from a patient with Wolff-Parkinson-White syndrome. The QRS complex is maximally excited; the PR interval is short, and there is a left bundle branch morphology, left axis deviation, and early transition across the anterior precordial leads. The delta waves are positive in the lateral leads I, aVL, and V6 and negative in the inferior leads, localizing the pathway to the posteroseptal region. The negative delta wave in lead II places the pathway on the right, in the area between the coronary sinus os and middle cardiac vein.</div><div id=\"graphicVersion\">Graphic 57211 Version 3.0</div></div></div>"},"57212":{"type":"graphic_picture","displayName":"Arthritis in RRV infection","title":"Knee arthritis in Ross River virus infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Knee arthritis in Ross River virus infection</div><div class=\"cntnt\"><img style=\"width:206px; height:306px;\" src=\"images/ID/57212_Arthritis_in_RRV_infection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Swelling and pain in large joints such as the knees may accompany or follow a rash or occur in its absence in patients with Ross River virus infection.</div><div class=\"graphic_reference\">Courtesy of Michael Richards, MB, BS, FRACP.</div><div id=\"graphicVersion\">Graphic 57212 Version 3.0</div></div></div>"},"57215":{"type":"graphic_table","displayName":"Cutaneous reactions EGFR inhibitors","title":"Cutaneous reactions associated with epidermal growth factor receptor inhibitors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cutaneous reactions associated with epidermal growth factor receptor inhibitors</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drugs</td> <td class=\"subtitle1\">Reported cutaneous effects</td> </tr> <tr> <td>Cetuximab</td> <td rowspan=\"8\"> <p>Papulopustular (acneiform) rash</p> <p>Abnormal scalp, facial hair, and/or eyelash growth</p> <p>Paronychia with or without pyogenic granuloma</p> <p>Telangiectasias</p> <p>Xerosis</p> <p>Pruritus</p> <p>Purpuric xerotic dermatitis</p> <p>Alopecia</p> Hand-foot skin reaction</td> </tr> <tr> <td>Panitumumab</td> </tr> <tr> <td>Necitumumab</td> </tr> <tr> <td>Erlotinib</td> </tr> <tr> <td>Gefitinib</td> </tr> <tr> <td>Lapatinib</td> </tr> <tr> <td>Afatinib</td> </tr> <tr> <td>Osimertinib</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 57215 Version 11.0</div></div></div>"},"57216":{"type":"graphic_table","displayName":"ICD-10 dx borderline type","title":"ICD-10 diagnostic criteria for emotionally unstable personality disorder, borderline type","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ICD-10 diagnostic criteria for emotionally unstable personality disorder, borderline type</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n    <td>1. Emotionally instability and unpredictable outbursts</td>\n  </tr>\n  <tr>\n    <td>2. Impulsivity</td>\n  </tr>\n  <tr>\n    <td>3. Intense, unstable, and conflicted interpersonal relationships</td>\n  </tr>\n  <tr>\n    <td>4. Disturbed self-image, aims, and preferences</td>\n  </tr>\n  <tr>\n    <td>5. Chronic feelings of emptiness</td>\n  </tr>\n  <tr>\n    <td>6. Tendency for self-destructive behavior, including suicide gestures and behavior</td>\n  </tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: World Health Organization, International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Version for 2007. http://www.who.int/classifications/apps/icd/icd10online/. Accessed January 5, 2009.</div><div id=\"graphicVersion\">Graphic 57216 Version 1.0</div></div></div>"},"57217":{"type":"graphic_figure","displayName":"Average intrapleural distance","title":"Pneumothorax size estimated by the average intrapleural distance","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pneumothorax size estimated by the average intrapleural distance</div><div class=\"cntnt\"><img style=\"width:288px; height:432px;\" src=\"images/PULM/57217_Collins_ptx_percentage_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The schematic diagram details the use of the average intrapleural distance (in millimeters) to estimate the size of a pneumothorax from a frontal chest radiograph.</div><div class=\"graphic_footnotes\">Ptx: pneumothorax.</div><div class=\"graphic_reference\">Courtesy of Helga E Stark, MD, PhD.</div><div id=\"graphicVersion\">Graphic 57217 Version 8.0</div></div></div>"},"57218":{"type":"graphic_diagnosticimage","displayName":"Maisonneuve stress view","title":"Maisonneuve stress view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Maisonneuve stress view</div><div class=\"cntnt\"><img style=\"width:356px; height:480px;\" src=\"images/RHEUM/57218_Maisonneuve_stress_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stress radiographs may reveal injuries not apparent on standard views. In the x-ray above, the application of an external rotation force to the foot reveals a widening of the medial tibiotalar space (arrow). This is indicative of a sprain or rupture of the tibiofibular syndesmosis. There may also be an associated fracture (Maisonneuve fracture) of the proximal fibula (not seen on this view).</div><div class=\"graphic_reference\">Courtesy of Scott Koehler, MD.</div><div id=\"graphicVersion\">Graphic 57218 Version 4.0</div></div></div>"},"57219":{"type":"graphic_figure","displayName":"Lines of Blaschko","title":"Lines of Blaschko","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Lines of Blaschko</div><div class=\"cntnt\"><img style=\"width:469px; height:576px;\" src=\"images/PEDS/57219_Lines_of_Blaschko.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pattern assumed by many different nevoid and acquired skin diseases on the human skin and mucosae. The cause of the pattern of Blaschko lines is unknown; they do not follow nerves, vessels, or lymphatics. The lines described by these conditions not only did not correspond to any known anatomical basis, but were remarkably consistent both from patient to patient and even from one disease to another. The lines may represent a clinical expression of a genetically programmed clone of altered cells, perhaps first expressed during embryogenesis.</div><div class=\"graphic_reference\">Reproduced with permission from: Med Art (www.med-ars.it). Copyright © 2010.</div><div id=\"graphicVersion\">Graphic 57219 Version 3.0</div></div></div>"},"57220":{"type":"graphic_picture","displayName":"Aspergillus bronchopneumonia histopathology","title":"<em>Aspergillus</em> bronchopneumonia histopathology","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\"><em>Aspergillus</em> bronchopneumonia histopathology</div><div class=\"cntnt\"><img style=\"width:512px; height:398px;\" src=\"images/ID/57220_Aspergillbronchopneumonia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) Magnified view of a slice of lower lobe shows multiple foci of necrosis, some clearly centered on airways (arrows) as indicated by their intimate association with pulmonary arteries. The lung parenchyma adjacent to the necrotic regions is hemorrhagic.<br />(Panel B) Photomicrograph shows small colonies of <EM>Aspergillus</EM> (arrow) within a bronchial lumen (L) and wall (W). Extension of fungus can also be seen into the adjacent pulmonary artery, which is partly occluded by thrombus (T). An infiltrate of neutrophils (N) is evident in the adjacent lung.</div><div class=\"graphic_reference\">Reproduced with permission from: Müller NL, Fraser RS, Lee KS, Johkoh T. Pulmonary infections. In: Diseases of the Lung, Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright © 2002 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 57220 Version 12.0</div></div></div>"},"57221":{"type":"graphic_picture","displayName":"Sarcoidosis alopecia","title":"Alopecia secondary to sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Alopecia secondary to sarcoidosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/57221_Sarcoidosis_alopecia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sarcoidal alopecia. Erythematous plaques with areas of follicular loss and scarring are present on the frontal scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 57221 Version 3.0</div></div></div>"},"57222":{"type":"graphic_table","displayName":"Strategies rx depression IFN","title":"Algorithm for pretreatment vs. symptomatic treatment of neuropsychiatric side effects","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Algorithm for pretreatment vs. symptomatic treatment of neuropsychiatric side effects</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td class=\"container\">\r\n\t\t\t\t\t<table cellspacing=\"0\">\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td class=\"subtitle1_single\">Prophylaxis</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\t\r\n\t\t\t\t\t<td>Mild or greater depressive/anxiety symptoms just prior to IFN-alfa initiation</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Receiving ongoing treatment for a psychiatric condition</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Developed psychiatric symptoms during prior IFN-alfa treatment</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Patient requests pretreatment</td>\r\n\t\t\t\t</tr>\r\n\t\t\t</table>\r\n\t\t\t</td>\r\n\t\t\t\t\t<td class=\"container\">\r\n\t\t\t\t\t<table cellspacing=\"0\">\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td class=\"subtitle1_single\">Symptomatic Rx</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t<td>No depressive/anxiety symptoms prior to IFN-alfa treatment</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>No past psychiatric history</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Tolerated prior IFN-alfa treatment without psychiatric side effects</td>\r\n\t\t\t\t</tr>\r\n\t\t\t</table>\r\n\t\t\t</td>\r\n\t\t\t</tr>\r\n\t\t\t</table></div><div class=\"graphic_reference\">Courtesy of Charles Raison, MD.</div><div id=\"graphicVersion\">Graphic 57222 Version 1.0</div></div></div>"},"57223":{"type":"graphic_table","displayName":"ACC AHA skills internal CV I","title":"Cognitive skills necessary to perform internal DC cardioversion","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cognitive skills necessary to perform internal DC cardioversion</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Physicians should have knowledge of the following:</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Cognitive and technical skills for performing intracardiac electrophysiologic study</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Principles of intracavitary cardioversion with\ncatheter technology, catheters, chest electrodes, or whatever variant\nthe operator plans to use</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Indications and complications associated with transvenous catheterization and with the intracavitary delivery of DC shock</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>The safe delivery of DC shock and the limit of energy that can be delivered via electrode catheters</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>The use of conscious sedation or, when appropriate, anesthesia</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>The use of intravenous antiarrhythmic medications</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Cognitive skills necessary for external DC cardioversion</td>\n\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">2.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=2028&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>ACC_AHA_skills_internal_CV.htm</title></head></div><div class=\"graphic_reference\">Data from Tracy CM, Akhtar M, DiMarco JP, et al. Circulation 2000; 102:2309.</div><div id=\"graphicVersion\">Graphic 57223 Version 2.0</div></div></div>"},"57224":{"type":"graphic_picture","displayName":"Rash in infectious mono","title":"Rash in infectious mononucleosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rash in infectious mononucleosis</div><div class=\"cntnt\"><img style=\"width:385px; height:252px;\" src=\"images/ID/57224_Rash_in_infectious_mono.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A generalized, erythematous, maculopapular eruption is often seen in patients with infectious mononucleosis after the administration of ampicillin.</div><div class=\"graphic_reference\">Courtesy of Lee T Nesbitt, Jr. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 57224 Version 5.0</div></div></div>"},"57228":{"type":"graphic_table","displayName":"Clinical conditions UIP","title":"Clinical conditions associated with usual interstitial pneumonia pattern","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical conditions associated with usual interstitial pneumonia pattern</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td>Idiopathic pulmonary fibrosis/cryptogenic fibrosing alveolitis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Collagen vascular disease</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Drug toxicity</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Chronic hypersensitivity pneumonitis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Asbestosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Familial idiopathic pulmonary fibrosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Hermansky-Pudlak syndrome</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 57228 Version 1.0</div></div></div>"},"57231":{"type":"graphic_figure","displayName":"Circadian rhythm of plasma ACTH","title":"Circadian rhythm of corticotropin (ACTH) secretion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Circadian rhythm of corticotropin (ACTH) secretion</div><div class=\"cntnt\"><img style=\"width:320px; height:395px;\" src=\"images/ENDO/57231_Pulse_analysis_plasma_ACTH.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Top panel: Pulse analysis of plasma ACTH concentrations in samples obtained at 10-minute intervals for 24 hours. The line represents the plasma ACTH concentration at any moment as predicted by a computer-generated deconvolution program. Bottom panel: Computer-calculated ACTH secretion rate at any moment. The circadian rhythm in plasma ACTH concentrations and, therefore, of cortisol secretion and plasma cortisol concentrations is a function of the variation in the amplitude, not the frequency, of ACTH secretory pulses. To convert pg/mL to pmol/L, multiply by 0.22.</div><div class=\"graphic_reference\">Data from: Veldhuis JD, Iranmanesh A, Johnson ML, et al. Amplitude, but not frequency, modulation of adrenocorticotropin secretory bursts gives rise to the nyctohemeral rhythm of the corticotropic axis in man.&nbsp;J Clin Endocrinol Metab 1990; 71:452.</div><div id=\"graphicVersion\">Graphic 57231 Version 4.0</div></div></div>"},"57235":{"type":"graphic_table","displayName":"Zoonoses from Cats A","title":"Zoonoses cats","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Zoonoses cats</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Transmission</td> <td class=\"subtitle1\">Organism</td> <td class=\"subtitle1\">Human symptoms</td> <td class=\"subtitle1\">Feline symptoms</td> <td class=\"subtitle1\">Geographic distribution</td> </tr> <tr> <td rowspan=\"5\">Infectious saliva</td> <td>Bartonella henselae</td> <td>Cat scratch disease, lymphadenopathy</td> <td>Asymptomatic even with bacteremia</td> <td>Worldwide</td> </tr> <tr> <td>Pasteurella </td> <td>Skin and soft-tissue infections, septic arthritis, osteomyelitis</td> <td>Asymptomatic</td> <td>Worldwide</td> </tr> <tr> <td>Rabies</td> <td>Acute progressive encephalitis</td> <td>Stages: prodromal, furious, and paralytic</td> <td>Worldwide</td> </tr> <tr> <td>Capnocytophaga </td> <td>Skin and soft-tissue infections, sepsis, meningitis</td> <td>Asymptomatic</td> <td>Worldwide</td> </tr> <tr> <td>Cowpox</td> <td>Painful, hemorrhagic pustules or black eschars</td> <td>Ulcerated, crusted focal skin lesions; systemic illness possible</td> <td>Europe</td> </tr> <tr> <td rowspan=\"7\">Fecal</td> <td>Salmonella Campylobacter Cryptosporidium Giardia</td> <td>Asymptomatic or gastroenteritis</td> <td>Asymptomatic or gastroenteritis</td> <td>Worldwide</td> </tr> <tr> <td>Multidrug-resistant bacteria (eg, Escherichia coli)</td> <td>Asymptomatic or gastroenteritis</td> <td>Asymptomatic or gastroenteritis&nbsp;</td> <td>Worldwide</td> </tr> <tr> <td>Toxocara cati</td> <td>Visceral larva migrans and ocular larva migrans</td> <td>Asymptomatic</td> <td>Worldwide</td> </tr> <tr> <td>Ancylostoma caninum</td> <td>Cutaneous larva migrans</td> <td>Hookworm</td> <td>Worldwide</td> </tr> <tr> <td>Echinococcus granulosus</td> <td>Hydatid cysts, echinococcosis</td> <td>Hydatid cysts, echinococcosis</td> <td>Worldwide</td> </tr> <tr> <td>Toxoplasma gondii</td> <td>Lymphadenopathy, cerebral, congenital infection</td> <td>Asymptomatic, may be associated with co-infection with feline leukemia virus or feline immuno- deficiency virus</td> <td>Worldwide</td> </tr> <tr> <td>Dipylidium caninum</td> <td>Asymptomatic to abdominal pain, diarrhea, pruritus ani, and urticaria</td> <td>Tapeworm</td> <td>Most common in ranching areas of the Mediterranean, South America, and Australia</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 57235 Version 2.0</div></div></div>"},"57237":{"type":"graphic_diagnosticimage","displayName":"Complete cleft lip and palate","title":"Complete cleft lip and palate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Complete cleft lip and palate</div><div class=\"cntnt\"><img style=\"width:363px; height:320px;\" src=\"images/OBGYN/57237_Complete_cleft_lip_and_pala.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal view of a late second trimester fetal face demonstrating the fetal nose, lips, and chin. A unilateral complete cleft lip is shown.</div><div class=\"graphic_reference\">Courtesy of Thomas Shipp, MD.</div><div id=\"graphicVersion\">Graphic 57237 Version 2.0</div></div></div>"},"57238":{"type":"graphic_diagnosticimage","displayName":"Electroanatomic map MI","title":"Typical electroanatomic map of infarcted myocardium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Typical electroanatomic map of infarcted myocardium</div><div class=\"cntnt\"><img style=\"width:318px; height:307px;\" src=\"images/CARD/57238_Electroanatomic_map_MI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The electroanatomic map of a patient with a myocardial infarction shows large regions of abnormal electromechanical activity and reduced local shortening (red, abnormally contracting regions with values &lt;4 percent). In contrast, a region in which function remains unhindered is a color-coded blue/purple, normal contractile function &gt;12 percent.</div><div class=\"graphic_reference\">Reprinted with permission from: the American College of Cardiology (Journal of the American College of Cardiology, 2001, 37:1590-7).</div><div class=\"contractual\"><br/><a href=\"http://www.elsevier.com/locate/jacc\">http://www.elsevier.com/locate/jacc</a><br/><a href=\"http://www.sciencedirect.com/\"> http://www.sciencedirect.com</a></div><div id=\"graphicVersion\">Graphic 57238 Version 3.0</div></div></div>"},"57240":{"type":"graphic_picture","displayName":"Acute seasonal conjunctivitis","title":"Acute seasonal conjunctivitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute seasonal conjunctivitis</div><div class=\"cntnt\"><img style=\"width:201px; height:213px;\" src=\"images/RHEUM/57240_Acute_seasonal_conjunctivit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acute seasonal conjunctivitis classically presents with eyelid and conjunctival erythema and swelling. It is almost always bilateral.</div><div id=\"graphicVersion\">Graphic 57240 Version 2.0</div></div></div>"},"57241":{"type":"graphic_figure","displayName":"Occiput posterior and occiput transverse positions","title":"Occiput posterior and occiput transverse positions","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Occiput posterior and occiput transverse positions</div><div class=\"cntnt\"><img style=\"width:509px; height:554px;\" src=\"images/OBGYN/57241_Occiput-post-trans-new.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Right occiput posterior (ROP).<br> (B) Right occiput transverse (ROT).</div><div id=\"graphicVersion\">Graphic 57241 Version 4.0</div></div></div>"},"57242":{"type":"graphic_picture","displayName":"Toxic epidermolytic erosion","title":"Erosions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erosions</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/57242_Toxic_epidermolytic_eros_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple shallow erosions are present in areas of sloughed skin in this patient with toxic epidermal necrolysis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 57242 Version 5.0</div></div></div>"},"57243":{"type":"graphic_diagnosticimage","displayName":"Hill Sachs lesion AP radiograph","title":"Hill Sachs lesion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hill Sachs lesion</div><div class=\"cntnt\"><img style=\"width:360px; height:343px;\" src=\"images/EM/57243_Hill_Sachs_lesion_AP_XR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A Hill-Sachs deformity is a cortical depression (arrows) in the humeral head made by the glenoid rim with dislocation. They occur in 35 to 40 percent of anterior dislocations and are seen on the AP radiograph with the arm in internal rotation.</div><div class=\"graphic_reference\">Courtesy of Mary Hochman, MD.</div><div id=\"graphicVersion\">Graphic 57243 Version 4.0</div></div></div>"},"57244":{"type":"graphic_diagnosticimage","displayName":"Ulnar styloid","title":"Fracture of the base of the ulnar styloid (anteroposterior radiograph)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fracture of the base of the ulnar styloid (anteroposterior radiograph)</div><div class=\"cntnt\"><img style=\"width:396px; height:345px;\" src=\"images/EM/57244_Ulnar_styloid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extraarticular (Colles) distal radial fracture in frontal projection associated with a fracture of the base of the ulnar styloid which indicates disruption of the trianglar fibrocartilage complex (curved arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Harris JH, Harris WH, Novelline RA. The Radiology of Emergency Medicine, 3rd ed. Williams &amp; Wilkins, Baltimore 1993. Copyright © 1993 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 57244 Version 5.0</div></div></div>"},"57246":{"type":"graphic_diagnosticimage","displayName":"Air bronchogram CT I","title":"Pneumonia with air bronchogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pneumonia with air bronchogram</div><div class=\"cntnt\"><img style=\"width:360px; height:269px;\" src=\"images/PULM/57246_Air_bronchogram_CT_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe pneumonia with&nbsp;homogenous consolidation of the right upper lobe and marked air bronchogram formation, characteristic of air space disease.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 57246 Version 3.0</div></div></div>"},"57248":{"type":"graphic_picture","displayName":"Continuous oral NPPV","title":"Continuous oral NPPV","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Continuous oral NPPV</div><div class=\"cntnt\"><img style=\"width:276px; height:504px;\" src=\"images/PULM/57248_Continuous_oral_NPPV.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of John R Bach, MD.</div><div id=\"graphicVersion\">Graphic 57248 Version 2.0</div></div></div>"},"57249":{"type":"graphic_algorithm","displayName":"Hemodynamically stable PE treatment algorithm","title":"Treatment algorithm for hemodynamically stable patients with suspected pulmonary embolism (PE)","html":"<div class=\"graphic\"><div style=\"width: 664px\" class=\"figure\"><div class=\"ttl\">Treatment algorithm for hemodynamically stable patients with suspected pulmonary embolism (PE)</div><div class=\"cntnt\"><img style=\"width:644px; height:742px;\" src=\"images/PULM/57249_PE_treatment_algorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Patients at high risk of bleeding are considered as having a contraindication to anticoagulation; patients at low risk of bleeding are considered as having no contraindications to anticoagulation. Patients at moderate risk of bleeding should be considered for anticoagulation on a case-by-case basis. Please refer to the UpToDate topic text for details.<br />&para; For most patients with hemodynamically stable PE, we recommend against thrombolytic therapy. However, in rare circumstances, thrombolysis can be considered on a case-by-case basis. Please refer to the UpToDate topic text for details.</div><div id=\"graphicVersion\">Graphic 57249 Version 8.0</div></div></div>"},"57250":{"type":"graphic_diagnosticimage","displayName":"Subpulmonic effusion I PA","title":"Right subpulmonic pleural effusion","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right subpulmonic pleural effusion</div><div class=\"cntnt\"><img style=\"width:324px; height:337px;\" src=\"images/PULM/57250_Subpulmonic_effusion_I_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph of a right subpulmonic pleural effusion. The right lung base is slightly elevated. A small pneumoperitoneum outlines the actual level of the right hemidiaphragm. Left pleural effusion has spilled over into the left lateral costophrenic sulcus.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 57250 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"57251":{"type":"graphic_movie","displayName":"VSD small four chamber color Doppler echo","title":"Echocardiogram (four-chamber view) of a small ventricular septal defect","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echocardiogram (four-chamber view) of a small ventricular septal defect</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/57251_4chcsvsdconv.mp4\" style=\"width:312px;height:224px\"></div><img style=\"width:263px; height:208px;\" src=\"images/CARD/57251_4chcsvsd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The apical four-chamber view from a 2D echocardiogram with color flow Doppler shows a small muscular ventricular septal defect (VSD) associated with left to right shunting of blood.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 57251 Version 4.0</div></div></div>"},"57255":{"type":"graphic_picture","displayName":"Bullous pemphigoid vulva2","title":"Bullous pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bullous pemphigoid</div><div class=\"cntnt\"><img style=\"width:432px; height:287px;\" src=\"images/OBGYN/57255_Bullous_pemphigoid_vulva2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 57255 Version 2.0</div></div></div>"},"57257":{"type":"graphic_table","displayName":"Peak expiratory flow in men","title":"Predicted average peak expiratory flow (PEF) for normal males (L/min)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Predicted average peak expiratory flow (PEF)&nbsp;for normal males (L/min)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Age</td> <td class=\"subtitle1\" colspan=\"6\">Height</td> </tr> <tr> <td class=\"subtitle2\">60 inches/152 cm</td> <td class=\"subtitle2\">65 inches/165 cm</td> <td class=\"subtitle2\">70 inches/178 cm</td> <td class=\"subtitle2\">75 inches/191 cm</td> <td class=\"subtitle2\">80 inches/203 cm</td> </tr> <tr> <td>20</td> <td>554</td> <td>602</td> <td>649</td> <td>693</td> <td>740</td> </tr> <tr> <td>25</td> <td>543</td> <td>590</td> <td>636</td> <td>679</td> <td>725</td> </tr> <tr> <td>30</td> <td>532</td> <td>577</td> <td>622</td> <td>664</td> <td>710</td> </tr> <tr> <td>35</td> <td>521</td> <td>565</td> <td>609</td> <td>651</td> <td>695</td> </tr> <tr> <td>40</td> <td>509</td> <td>552</td> <td>596</td> <td>636</td> <td>680</td> </tr> <tr> <td>45</td> <td>498</td> <td>540</td> <td>583</td> <td>622</td> <td>665</td> </tr> <tr> <td>50</td> <td>486</td> <td>527</td> <td>569</td> <td>607</td> <td>649</td> </tr> <tr> <td>55</td> <td>475</td> <td>515</td> <td>556</td> <td>593</td> <td>634</td> </tr> <tr> <td>60</td> <td>463</td> <td>502</td> <td>542</td> <td>578</td> <td>618</td> </tr> <tr> <td>65</td> <td>452</td> <td>490</td> <td>529</td> <td>564</td> <td>603</td> </tr> <tr> <td>70</td> <td>440</td> <td>477</td> <td>515</td> <td>550</td> <td>587</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">14</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=67369&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_lgnd\">These values represent average normal values within 100 L/min. Predicted values for African American and Hispanic minorities are approximately 10 percent lower.</div><div class=\"graphic_reference\">From: Leiner GC, Abramowitz S, Small MJ, et al. Expiratory peak flow rate. Standard values for normal subjects. Use as a clinical test of ventilatory function. Am Rev Respir Dis 1963; 88:644.</div><div id=\"graphicVersion\">Graphic 57257 Version 7.0</div></div></div>"},"57258":{"type":"graphic_figure","displayName":"Base of the first metacarpal fracture types","title":"Base of the first metacarpal fracture types","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Base of the first metacarpal fracture types</div><div class=\"cntnt\"><img style=\"width:445px; height:424px;\" src=\"images/EM/57258_1stmetacarpalbasefxtype.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Type I (Bennet's fracture-dislocation) and type II (Rolando's fracture) are intraarticular. Type III fractures are extraarticular, either transverse (IIIA) or oblique (IIIB). Type IV fractures are seen only in children and involve the proximal epiphysis.</div><div class=\"graphic_reference\">Reproduced with permission from: Eiff MP, Hatch RL, Calmbach WL. Fracture Management for Primary Care, 2nd ed., W.B. Saunders 2002. Copyright © 2002 Elsevier.</div><div id=\"graphicVersion\">Graphic 57258 Version 8.0</div></div></div>"},"57259":{"type":"graphic_table","displayName":"Oral medications for pediatric hypertensive urgencies","title":"Oral drugs for treatment of hypertensive urgencies in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oral drugs for treatment of hypertensive urgencies in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Route*</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Onset of action</td> <td class=\"subtitle1\">Duration of action</td> <td class=\"subtitle1\">Mechanism of action</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Clonidine<sup>&#182;</sup></td> <td>Oral</td> <td>2 to 5&nbsp;mcg/kg/dose every hour up to maximum total dose of 10 mcg/kg/dose or 0.8 mg </td> <td>15-30 minutes</td> <td>6-8 hours</td> <td>Central alpha2 adrenergic and imidazoline agonist</td> <td>Effective dose for acute hypertension in infants and toddlers is <strong>not</strong> known</td> </tr> <tr> <td>Hydralazine</td> <td>Oral</td> <td>0.25 mg/kg per dose up to 25 mg maximum single dose</td> <td>30 min</td> <td>2-8 hours</td> <td>Direct vasodilator</td> <td>Variable response</td> </tr> <tr> <td>Isradipine</td> <td>Oral</td> <td>0.05-0.1 mg/kg per dose up to 5 mg maximum single dose</td> <td>&#60;1 hour</td> <td>6-8 hours</td> <td>Calcium channel blocker</td> <td>Stable oral suspension can be compounded</td> </tr> <tr> <td>Minoxidil</td> <td>Oral</td> <td>0.1-0.2 mg/kg per dose up to 10 mg maximum single dose</td> <td>1 hour</td> <td>8-12 hours</td> <td>Direct arterial vasodilator</td> <td>Most potent oral vasodilator with longest duration of action</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* All of this drugs can be compounded to make liquid formulations although stability will vary.<br />¶ This dosing regimen is for older children and adolescents.</div><div class=\"graphic_reference\">Adapted from: Flynn, JT, Tullus, K. Severe hypertension in children and adolescents: pathophysiology and treatment. Pediatr Nephrol 2009; 24: 1101.</div><div id=\"graphicVersion\">Graphic 57259 Version 4.0</div></div></div>"},"57263":{"type":"graphic_figure","displayName":"Mechanism of statins","title":"Statins and cholesterol synthesis","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Statins and cholesterol synthesis</div><div class=\"cntnt\"><img style=\"width:520px; height:578px;\" src=\"images/CARD/57263_Mechanismofstatins.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inhibition of HMG CoA reductase reduces intracellular cholesterol levels; this activates a protease, which in turn cleaves SREBPs from the endoplasmic reticulum. The SREBPs translocate to the nucleus where they upregulate expression of the LDL receptor gene. Enhanced LDL receptor expression increases receptor-mediated endocytosis of LDL and thus lowers serum LDL. Inhibition of HMG CoA reductase also reduces intracellular levels of isoprenoids, which are intermediates in cholesterol biosynthesis.</div><div class=\"graphic_footnotes\">HMG: hydroxymethylglutaryl; LDL: low-density lipoprotein; LDLR: LDL receptor; SRE: sterol regulatory element; SREBP: SRE binding proteins.</div><div class=\"graphic_reference\">Reprinted with permission from: Vaughan, CJ, Gotto, AM, Basson, CT. J Am Coll Cardiol 2000; 35:1. Copyright © 2000 American College of Cardiology.</div><div id=\"graphicVersion\">Graphic 57263 Version 2.0</div></div></div>"},"57264":{"type":"graphic_table","displayName":"Alpha-1 antitrypsin genotypes","title":"Characteristics of alpha-1 antitrypsin deficiency genotypes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of alpha-1 antitrypsin deficiency genotypes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Genotype</td> <td class=\"subtitle1\">Risk for emphysema</td> <td class=\"subtitle1\">True plasma level, micromol/L (SI units)</td> <td class=\"subtitle1\">Commercial standard plasma level, mg/dL</td> </tr> <tr> <td>MM (normal)</td> <td>No increase</td> <td>20 to 48</td> <td>80 to 220</td> </tr> <tr> <td>MZ</td> <td>Possible mild increase</td> <td>17 to 33</td> <td>90 to 210</td> </tr> <tr> <td>SS</td> <td>No increase</td> <td>15 to 33</td> <td>100 to 200</td> </tr> <tr> <td>SZ*</td> <td>Mild increase (20 to 50 percent)</td> <td>8 to 16</td> <td>75 to 120<sup>&#182;</sup></td> </tr> <tr> <td>ZZ</td> <td>High risk (80 to 100 percent)</td> <td>2.5 to 7</td> <td>20 to 45</td> </tr> <tr> <td>Null</td> <td>High risk (100 percent by age 30)</td> <td>0</td> <td>0</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Pulmonary and plasma features of the different genotypes of alpha-1 antitrypsin (AAT)&nbsp;deficiency. Measurement of&nbsp;AAT serum levels can be done by enzyme-linked immunosorbent assay (ELISA)&nbsp;or&nbsp;nephelometry.</div><div class=\"graphic_footnotes\">* Heterozygotes with the SZ genotype rarely have evidence of clinical pulmonary disease.<br />¶ Protective threshold of 11 micromol/L (ELISA)&nbsp;is approximately equal to 57 mg/dL by nephelometry.</div><div class=\"graphic_reference\">Adapted from: American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168:818.</div><div id=\"graphicVersion\">Graphic 57264 Version 9.0</div></div></div>"},"57265":{"type":"graphic_table","displayName":"Complications of TBNA","title":"Complications of TBNA*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complications of TBNA*</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Fever</td>\n</tr>\n<tr>\n<td>Transient bacteremia</td>\n</tr>\n<tr>\n<td>Oozing of blood</td>\n</tr>\n<tr>\n<td>Inadvertent puncture of mediastinal structures</td>\n</tr>\n<tr>\n<td>Pneumothorax/pneumomediastinum</td>\n</tr>\n<tr>\n<td>Damage to the working channel of the fiberoptic bronchoscope</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_footnotes\">* Rare if the proper technique is used and the appropriate precautions are taken.</div><div class=\"graphic_reference\">Reproduced with permission from Dasgupta, A, Mehta, AC, Clin Chest Med 1999; 20:39 andMinai, OA, Dasgupta, A, Mehta, AC. Transbronchial needle aspiration of central and peripheral lesions. In: Bolliger, CT, Mathur, PN (Eds), Progress in Respiratory Research-Interventional Bronchoscopy. Karger, Basel, Switzerland, 1999.</div><div id=\"graphicVersion\">Graphic 57265 Version 1.0</div></div></div>"},"57267":{"type":"graphic_figure","displayName":"AHT drugs and proteinuria in DM","title":"Antihypertensive drugs and urinary protein excretion in diabetic nephropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Antihypertensive drugs and urinary protein excretion in diabetic nephropathy</div><div class=\"cntnt\"><img style=\"width:419px; height:207px;\" src=\"images/NEPH/57267_AHT_drugs_and_proteinuria_i.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Protein excretion at baseline (black columns) and after one year of antihypertensive therapy (hatched columns) in patients with type 2 diabetes treated with lisinopril (mean dose 29 mg/day), verapamil (mean dose 360 mg/day), half-dose lisinopril plus verapamil, or hydrochlorothiazide plus guanfacine (which has a mechanism of action similar to methyldopa). The last regimen had little or no antiproteinuric effect while the fall in protein excretion with the lisinopril-verapamil combination (75 percent) was additive to the action of either drug alone (roughly 50 percent).</div><div class=\"graphic_reference\">Data from: Bakris GL, Barnhill BW, Sadler R. Kidney Int 1992; 41:912.</div><div id=\"graphicVersion\">Graphic 57267 Version 2.0</div></div></div>"},"57270":{"type":"graphic_figure","displayName":"Stone recurrence rate","title":"Recurrence rate after first kidney stone","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Recurrence rate after first kidney stone</div><div class=\"cntnt\"><img style=\"width:396px; height:239px;\" src=\"images/NEPH/57270_Stone_recurrence_rate.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cumulative incidence of stone recurrence after a first kidney stone in men and women. The data represent a summary of six studies.</div><div class=\"graphic_reference\">Data from Uribarri, J, Oh, MS, Carroll, HJ, Ann Intern Med 1989; 111:1006.</div><div id=\"graphicVersion\">Graphic 57270 Version 1.0</div></div></div>"},"57271":{"type":"graphic_diagnosticimage","displayName":"Blood in fetal bowel","title":"Echogenic fetal bowel at 15 weeks' gestational age in 33-year-old woman with vaginal bleeding","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echogenic fetal bowel at 15 weeks' gestational age in 33-year-old woman with vaginal bleeding</div><div class=\"cntnt\"><img style=\"width:367px; height:310px;\" src=\"images/OBGYN/57271_Blood_in_fetal_bowel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sonogram revealed subchorionic hemorrhage (not shown). Sagittal scan through fetal abdomen reveals hyperechoic loops of bowel (arrow) as echogenic as adjacent bone. Cytomegalovirus titers and karyotype were normal, and findings of prenatal screening for cystic fibrosis were negative. Normal bowel echotexture was seen on follow-up two weeks later (not shown).</div><div class=\"graphic_reference\">Reproduced with permission from: Trop I, Levine D. Hemorrage During Pregnancy: Sonography and MR Imaging. AJR Am J Roentgenol 2001; 176:607.</div><div id=\"graphicVersion\">Graphic 57271 Version 4.0</div></div></div>"},"57272":{"type":"graphic_figure","displayName":"Normal uterine position","title":"Normal gravid uterus","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Normal gravid uterus</div><div class=\"cntnt\"><img style=\"width:485px; height:588px;\" src=\"images/OBGYN/57272_Normal_uterine_position.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 57272 Version 2.0</div></div></div>"},"57273":{"type":"graphic_table","displayName":"Weaning technique success","title":"Rate of successful weaning with various weaning techniques","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rate of successful weaning with various weaning techniques</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Weaning technique</td>\n\n      <td class=\"subtitle1\">Relative rate of successful\nweaning (95% confidence interval)</td>\n\n      <td class=\"subtitle1\">P value</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Once daily trial of spontaneous breathing vs\nintermittent mandatory ventilation</td>\n\n      <td>2.83 (1.36-5.89)</td>\n\n      <td>&#60;0.006</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Once daily trial of spontaneous breathing vs\npressure-support ventilation</td>\n\n      <td>2.05 (1.04-4.04)</td>\n\n      <td>&#60;0.04</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Once daily trial of spontaneous breathing vs\nintermittent trials of spontaneous breathing</td>\n\n      <td>1.24 (0.64-2.41)</td>\n\n      <td>0.54</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">Proportional-hazards regression analysis was used to estimate the 95 percent confidence interval of the relative rate of successful weaning.</div><div class=\"graphic_reference\">Data from Esteban, A, Frutos, F, Tobin, MJ, et al, N Engl J Med 1995; 332:345.</div><div id=\"graphicVersion\">Graphic 57273 Version 2.0</div></div></div>"},"57275":{"type":"graphic_figure","displayName":"Risk of rupture of AAA","title":"AAA rupture primarily occurs in larger aneurysms","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">AAA rupture primarily occurs in larger aneurysms</div><div class=\"cntnt\"><img style=\"width:420px; height:347px;\" src=\"images/CARD/57275_Risk_of_rupture_of_AAA_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Risk of rupture of an abdominal aortic aneurysm (AAA) over time according to the first measurement of aneurysm diameter in 1792 men and 465 women. The risk of rupture increased markedly in aneurysms larger than 5.5 cm in diameter.</div><div class=\"graphic_reference\">Data from: Powell, JT, Greenhalgh, RM, N Engl J Med 2003; 348:1895.</div><div id=\"graphicVersion\">Graphic 57275 Version 4.0</div></div></div>"},"57277":{"type":"graphic_picture","displayName":"Glottic view with external laryngeal manipulation","title":"Laryngeal inlet photograph with external laryngeal manipulation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laryngeal inlet photograph with external laryngeal manipulation</div><div class=\"cntnt\"><img style=\"width:297px; height:295px;\" src=\"images/EM/57277_GlottiswithELM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph of the glottis was obtained while the airway manager performed ELM.</div><div class=\"graphic_footnotes\">ELM: external laryngeal manipulation.</div><div class=\"graphic_reference\">Reproduced with permission from: Orebaugh SL. Direct laryngoscopy. In: Atlas of Airway Management: Techniques and Tools, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 57277 Version 12.0</div></div></div>"},"57278":{"type":"graphic_table","displayName":"Management of life-threatening acute respiratory compromise","title":"Management of life-threatening causes of acute respiratory compromise in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management of life-threatening causes of acute respiratory compromise in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Maneuver</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>Complete upper airway obstruction*</td> <td>Needle cricothyrotomy</td> <td>This is a temporizing measure that can provide oxygenation, but not ventilation</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Foreign body<sup>&#182;</sup></td> <td>Back blows/chest thrusts (&#60;1 year of age)</td> <td>Maneuvers should only be used for patients who are unable to phonate</td> </tr> <tr> <td>Abdominal thrusts (&#8805;1 year of age)</td> <td>Maneuvers should only be used for patients who are unable to phonate</td> </tr> <tr> <td>Manual removal with finger sweep</td> <td>Perform this maneuver only when foreign body is visible in the oropharynx</td> </tr> <tr class=\"divider_bottom\"> <td>Laryngoscopy and removal with Magill forceps</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Laryngospasm<sup>&#916;</sup></td> <td>Positive pressure with a ventilation bag and tight fitting mask</td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Soft tissue upper airway obstruction<sup>&#916;</sup></td> <td>Head tilt/chin lift</td> <td>&nbsp;</td> </tr> <tr> <td>Jaw thrust</td> <td>Use for patients who may have cervical spine injury</td> </tr> <tr> <td>Nasopharyngeal airway</td> <td>May be tolerated by a conscious patient</td> </tr> <tr class=\"divider_bottom\"> <td>Oropharyngeal airway</td> <td>Use only in an unconscious patient</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Respiratory failure<sup>&#916;</sup></td> <td>Bag-mask ventilation</td> <td>Suspect upper airway obstruction if unable to ventilate with proper size equipment and technique</td> </tr> <tr class=\"divider_bottom\"> <td>Endotracheal intubation<sup>&#9674;</sup></td> <td>Use for patient who requires more than a few minutes of assisted ventilation or those with complete subglottic upper airway obstruction</td> </tr> <tr class=\"divider_bottom\"> <td>Tension pneumothorax</td> <td>Needle thoracentesis</td> <td>Patients will require chest tube placement following emergent decompression</td> </tr> <tr> <td>Cardiac tamponade</td> <td>Pericardiocentesis<sup>&#167;</sup></td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* See topic on \"Needle cricothyroidotomy with percutaneous transtracheal ventilation\".<br />¶ See topic on \"Emergent evaluation of acute upper airway obstruction in children\", section on 'Suspected foreign body'.<br />Δ See topic on \"Basic airway management in children\".<br /><FONT class=lozenge>◊</FONT> See topic on \"Emergent endotracheal intubation in children\".<br />§ See topic on \"Emergency pericardiocentesis\".</div><div id=\"graphicVersion\">Graphic 57278 Version 7.0</div></div></div>"},"57280":{"type":"graphic_figure","displayName":"Anatomy of thoracic duct","title":"Anatomy of the thoracic duct","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Anatomy of the thoracic duct</div><div class=\"cntnt\"><img style=\"width:494px; height:691px;\" src=\"images/PULM/57280_Anatomy_thoracic_duct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Course of the thoracic duct from cisterna chyli to left subclavian vein. The right lymphatic duct drains into the right subclavian vein.</div><div id=\"graphicVersion\">Graphic 57280 Version 8.0</div></div></div>"},"57282":{"type":"graphic_table","displayName":"Less common causes of cough","title":"Less common causes of chronic cough","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Less common causes of chronic cough</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td>Bronchiectasis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Angiotensin-converting enzyme inhibitors</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Nonasthmatic eosinophilic bronchitis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Bronchogenic carcinoma</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Interstitial lung disease</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Occult pulmonary infection</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Occult heart failure</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Occult aspiration</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Tracheobronchial foreign body or mass (other than bronchogenic carcinoma)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Occupational asthma</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Nasal polyps</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Disorders of the external auditory canals, pharynx, larynx, diaphragm, pleura pericardium, esophagus, stomach, or thyroid</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Psychogenic</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Adapted from Pratter, MR, Bartter, T, Akers, S, DuBois, J, Ann Intern Med 1993; 119:977, Poe, RH, Israel, RH, J, Respir Dis 1997; 18:629, Irwin, RS, Boulet, LP, Cloutier, MM, et al, Chest 1998; 114(suppl):133S.</div><div id=\"graphicVersion\">Graphic 57282 Version 1.0</div></div></div>"},"57284":{"type":"graphic_figure","displayName":"Jet or pneumatic nebulizers","title":"Pneumatic (jet) nebulizer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pneumatic (jet) nebulizer</div><div class=\"cntnt\"><img style=\"width:377px; height:390px;\" src=\"images/PULM/57284_Pneumatic_nebulizer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A jet flow of driving gas creates an area of low pressure above the medication reservoir, generating an aerosol. The baffle helps ensure the formation of respirable particles, and prevents inhalation of oversized droplets of medication. Most nebulizers require a flow rate of 6 to 8 liters per minute for optimum performance.</div><div id=\"graphicVersion\">Graphic 57284 Version 4.0</div></div></div>"},"57290":{"type":"graphic_figure","displayName":"Changes in BUN","title":"Changes in blood urea nitrogen measured at different times after dialysis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Changes in blood urea nitrogen measured at different times after dialysis</div><div class=\"cntnt\"><img style=\"width:361px; height:223px;\" src=\"images/NEPH/57290_Time_of_postdialysis_BUN.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sequential changes in BUN measured at the end of and after hemodialysis. A is the immediate postdialysis sample; B is an immediate postdialysis sample taken from the limb opposite the vascular access to eliminate access recirculation; C is delayed for two minutes to eliminate the effect of cardiopulmonary recirculation; and D is delayed for one hour when urea equilibration should be complete.</div><div class=\"graphic_footnotes\">BUN: blood urea nitrogen.</div><div class=\"graphic_reference\">Data from Depner TA. Assessing adequacy of hemodialysis: Urea modeling.&nbsp;Kidney Int 1994; 45:1522.</div><div id=\"graphicVersion\">Graphic 57290 Version 3.0</div></div></div>"},"57291":{"type":"graphic_figure","displayName":"Intrinsic muscles of the hand","title":"Intrinsic muscles of the hand","html":"<div class=\"graphic\"><div style=\"width: 636px\" class=\"figure\"><div class=\"ttl\">Intrinsic muscles of the hand</div><div class=\"cntnt\"><img style=\"width:616px; height:574px;\" src=\"images/EM/57291_Handmusclesintrinsicpict.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The diagrams above depict the location of the muscles involved in finger and hand movement. Red represents a muscle's origin and blue a muscle's insertion.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AR. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 57291 Version 12.0</div></div></div>"},"57292":{"type":"graphic_table","displayName":"Laboratory studies for pediatric hypertensive emergencies","title":"Recommended studies in children with hypertensive emergencies*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended studies in children with hypertensive emergencies*</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   All patients\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Serum BUN, creatinine, electrolytes, and glucose</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Complete blood count with reticulocyte count</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Microscopic urinalysis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>EKG</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Chest radiograph</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Selected patients\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Urine toxicology screen for amphetamines, PCP, cocaine metabolites</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Urine pregnancy test</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Head CT</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_footnotes\">BUN: blood urea nitrogen; EKG: electrocardiogram; PCP: phencyclidine; CT: computed tomography.<br>* Additional specialized diagnostic testing may be deferred until blood pressure is controlled.</div><div id=\"graphicVersion\">Graphic 57292 Version 3.0</div></div></div>"},"57293":{"type":"graphic_table","displayName":"High risk trauma mechanisms","title":"Trauma mechanisms associated with a high risk of injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Trauma mechanisms associated with a high risk of injury</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Blunt</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_single\">Motor vehicle collision</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Ejection from the automobile</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Death of  another passenger in same vehicle compartment</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Vehicle roll over</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">High speed automobile crash</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">&#8226; Initial speed &#62;40 mph (64 kph)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">&#8226; Auto deformity &#62;20 inches (50 cm)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">&#8226; Intrusion into passenger compartment &#62;12 inches (30 cm)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Extrication time &#62;20 minutes</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Motorcycle crash &#62;20 mph (32 kph) or with separation of rider from bike</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_single\">Motor vehicle pedestrian injury</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Pedestrian thrown or run over</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Automobile-pedestrian injury with &#62;5 mph (8 kph) impact</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_single\">Falls</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Adult: &#62;20 ft (6 m)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Child: &#62;10 ft (3 m) or more than 2 to 3 times patient height</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Penetrating</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Any penetrating trauma to head, neck, chest, abdomen, or extremities proximal to elbow or knee</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Reference: American College of Surgeons Committee on Trauma. Resources for Optimal Care of the Injured Patient. American College of Surgeons Chicago, IL 2006, p. 22.</div><div id=\"graphicVersion\">Graphic 57293 Version 2.0</div></div></div>"},"57294":{"type":"graphic_diagnosticimage","displayName":"Massive cerebral air embolism","title":"Massive cerebral air embolism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Massive cerebral air embolism</div><div class=\"cntnt\"><img style=\"width:269px; height:381px;\" src=\"images/PULM/57294_Massive_cerebral_air_emboli.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gas is present throughout both hemispheres, and there is evidence of diffuse cerebral edema.</div><div class=\"graphic_reference\">Reproduced with permission from: Valentino, R, Hilbert, G, Vargas, F, Gruson, D. Computed tomographic scan of massive cerebral air embolism. Lancet 2003; 361:1848. Copyright © 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 57294 Version 2.0</div></div></div>"},"57296":{"type":"graphic_waveform","displayName":"Posthyperventilation apnea","title":"Posthyperventilation apnea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posthyperventilation apnea</div><div class=\"cntnt\"><img style=\"width:435px; height:277px;\" src=\"images/SLEEP/57296_Posthyperventilation_apnea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nasal mechanical ventilation for three minutes was used to induce hypocapnia, which causes a 6 mmHg decrease in exhaled CO<SUB>2</SUB> [PeCO<SUB innerHtml>2</SUB>] during stable non-rapid eye movement (NREM) sleep. Central apnea occurs upon cessation of mechanical hyperventilation.</div><div id=\"graphicVersion\">Graphic 57296 Version 3.0</div></div></div>"},"57297":{"type":"graphic_figure","displayName":"Survival by diagnosis","title":"Kaplan-Meier survival by diagnosis for adult lung transplant recipients","html":"<div class=\"graphic\"><div style=\"width: 727px\" class=\"figure\"><div class=\"ttl\">Kaplan-Meier survival by diagnosis for adult lung transplant recipients</div><div class=\"cntnt\"><img style=\"width:707px; height:491px;\" src=\"images/PULM/57297_Survivalbydiagnosisedt2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Survival was calculated using the Kaplan-Meier method, which incorporates information from all transplants for whom any follow-up has been provided. Since many patients are still alive and some patients have been lost to follow-up, the survival rates are estimates rather than exact rates because the time of death is not known for all patients. The median survival is the estimated time point at which 50% of all of the recipients have died. Survival rates were compared using the log-rank test statistic. Adjustments for multiple comparisons were done using Scheffe's method. Only pair-wise comparisons statistically significant at p&lt;0.05 are shown.</div><div class=\"graphic_footnotes\">COPD: chronic obstructive pulmonary disease; A1ATD: alpha-1 antitrypsin deficiency emphysema; CF: cystic fibrosis; IIP: idiopathic interstitial pneumonia; ILD: interstitial lung disease.</div><div class=\"graphic_reference\">Reproduced from: Yusen RD, Edwards LB, Dipchand AI, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Lung and Heart-Lung Transplant Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. J Heart Lung Transplant. 2016; 35:1170. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 57297 Version 7.0</div></div></div>"},"57299":{"type":"graphic_figure","displayName":"Acetabular fracture general classification","title":"Letournel and Judet classification for acetabular fractures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Letournel and Judet classification for acetabular fractures</div><div class=\"cntnt\"><img style=\"width:337px; height:684px;\" src=\"images/EM/57299_Acetabularfxscheme.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Moed BR, Reilly MC. Lower extremity: Acetabulum fractures. In: Rockwood and Green's Fractures in Adults, vol 2, 7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 57299 Version 13.0</div></div></div>"},"57300":{"type":"graphic_algorithm","displayName":"Diagnosis neurosyphilis no HIV","title":"Algorithm for diagnosis of neurosyphilis in a patient without HIV infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Algorithm for diagnosis of neurosyphilis in a patient without HIV infection</div><div class=\"cntnt\"><img style=\"width:384px; height:616px;\" src=\"images/NEURO/57300_Diag_neurosyphilis_no_HIV.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CSF: cerebrospinal fluid; EIA: syphilis enzyme immunoassay; FTA-ABS: fluorescent treponemal antibody-absorbed test; HIV: human immunodeficiency virus; LP: lumbar puncture; NS: neurosyphilis; RPR: rapid plasma reagin test; TPPA: treponema pallidum particle agglutination test; VDRL: Venereal Disease Research Laboratory test; WBC: white blood cell count.<br />* A reactive serum EIA should be confirmed with a different treponemal test.</div><div class=\"graphic_reference\">Courtesy of Christina M Marra, MD.</div><div id=\"graphicVersion\">Graphic 57300 Version 7.0</div></div></div>"},"57301":{"type":"graphic_figure","displayName":"Myometrial and endometrial arteries ","title":"Stereographic representation of myometrial and endometrial arteries in the macaque","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Stereographic representation of myometrial and endometrial arteries in the macaque</div><div class=\"cntnt\"><img style=\"width:512px; height:328px;\" src=\"images/OBGYN/57301_Basal_arteries.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Above are shown parts of myometrial arcuate arteries from which myometrial radial arteries course toward the endometrium. There are found larger endometrial coiled arteries and smaller endometrial basal arteries.</div><div class=\"graphic_reference\">From Okkels and Engle. Acta Pathol Microbiol Scand 15:150, 1930. Reproduced with permission from: Pritchard, JA, MacDonald, PC. Williams Obstetrics, 16th Edition, Appleton-Century-Crofts, New York 1980. Copyright &#169; 1980 McGraw Hill. p.25.</div><div id=\"graphicVersion\">Graphic 57301 Version 2.0</div></div></div>"},"57304":{"type":"graphic_figure","displayName":"Effect of PGI2 and NO on PaO2","title":"Effects of inhaled prostacyclin and inhaled nitric oxide on oxygenation and shunt fraction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Effects of inhaled prostacyclin and inhaled nitric oxide on oxygenation and shunt fraction</div><div class=\"cntnt\"><img style=\"width:381px; height:233px;\" src=\"images/PULM/57304_Effect_of_PGI2_and_NO_on_Pa.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Both inhaled prostacyclin (PGI2) and inhaled nitric oxide (NO) improved arterial oxygenation and shunt fraction (QsQt) in patients with severe ARDS who were treated sequentially with both agents.</div><div class=\"graphic_reference\">Redrawn from Zwissler, B, Kemming, G, Habler, O, et al, Am J Respir Crit Care Med 1996; 154:1671.</div><div id=\"graphicVersion\">Graphic 57304 Version 1.0</div></div></div>"},"57305":{"type":"graphic_diagnosticimage","displayName":"LLL atelectasis I","title":"Left lower lobe atelectasis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left lower lobe atelectasis</div><div class=\"cntnt\"><img style=\"width:374px; height:375px;\" src=\"images/PULM/57305_LLL_atelectasis_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left lower lobe atelectasis due to an aspirated foreign body in a small child. A wedge-shaped opacity is seen in retrocardiac location (arrow). Its oblique lateral border is formed by the major fissure. The left hilum is obscured partially and displaced caudad. The residual left upper lobe is hyperexpanded, accounting for the increased lucency in the left hemithorax.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 57305 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"57307":{"type":"graphic_table","displayName":"Steps in management of postpartum hemorrhage","title":"Steps in management of postpartum hemorrhage","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Steps in management of postpartum hemorrhage</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>Assemble team and notify appropriate departments (obstetrics, nursing, anesthesiology, blood bank, laboratory).</strong></td> </tr> <tr> <td><strong>Initiate uterine massage and/or manual compression and establish large-bore (two 16- or 18-gauge, ideally 14-gauge) intravenous access.</strong></td> </tr> <tr> <td><strong>Tamponade bleeding from the uterine cavity.</strong> Balloon tamponade should be initiated early if bleeding is brisk, particularly if the patient is not hemodynamically stable, and blood products are not readily available. Both balloon tamponade or packing can be performed prior to, or in conjunction with, preparations for laparotomy or transarterial embolization. Balloon tamponade may reduce blood loss while initiating carboprost or ergot drugs, if used after oxytocin has failed. Early use of a balloon tamponade with or after use of these agents may reduce the incidence of heavy blood loss and the need for blood products.</td> </tr> <tr> <td><strong>Administer oxygen (10 to 15 liters/minute) by face mask. Anesthesia team should evaluate airway and breathing; intubate if indicated.</strong></td> </tr> <tr> <td><strong>Fluid resuscitation:</strong> Infuse isotonic crystalloid to prevent hypotension (target systolic pressure 90 mmHg) and maintain urine output at &#62;30 mL/hour.</td> </tr> <tr> <td><strong>Transfusion:</strong> If hemodynamics do not improve with 2 to 3 liters of crystalloid administration and bleeding continues, administer blood products, initially two units packed red blood cells. Aggressive use of plasma replacement is also important to reverse dilutional coagulopathy. Coagulation factor concentrates may also be needed. For patients with massive hemorrhage, red blood cells, fresh frozen plasma, and apheresis platelets are best administered according to an established massive transfusion protocol.</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Administer uterotonic drugs</strong>* <strong>to reverse atony:</strong> It should be possible to determine within 30 minutes whether uterotonic treatment will reverse atony. If it does not, prompt invasive intervention is usually warranted.</td> </tr> <tr> <td class=\"sublist1\"><strong>Initiate oxytocin:</strong> <ul class=\"decimal_heading\"> <li>Begin with oxytocin 40 units in 1 liter of normal saline or Ringer's lactate. Using an intravenous infusion pump, start at 10 to 40 milliunits per minute. Adjust rate to achieve and maintain uterine contraction<sup>[1]</sup>; 15 units in 250 mL normal saline or Ringer's lactate may be given if a high concentration must be administered rapidly. Expect rapid response. </li> <li>Avoid rapid intravenous bolus injection of oxytocin. </li> <li>If no intravenous access, give 10 units intramuscularly; expect response within three to five minutes. </li> <li>There are no absolute contraindications to oxytocin for PPH; oxytocin is the uterotonic of choice, even if it was already given as prophylaxis. </li> <li>Carbetocin (where available<sup>&#916;</sup>) 100 micrograms slow intravenous injection as single dose. A long-acting analogue of oxytocin, carbetocin is a potential alternative if titrable oxytocin intravenous infusion is not feasible. </li> </ul> </td> </tr> <tr> <td class=\"sublist1\"><strong>If oxytocin is not immediately available or does not control PPH:</strong><br /> <ul class=\"decimal_heading\"> <li><strong>Add ergot:</strong> <ul> <li>Methylergonovine (methylergometrine) 200 micrograms intramuscularly (including intramyometrial) every two to four hours up to a maximum of 1 mg (five doses). Expect response within two to five minutes. <ul> <li>Do <strong>not</strong> give intravenously. </li> <li>Avoid in women with hypertension, Raynaud's phenomenon, or scleroderma. </li> <li>If first dose ineffective, quickly add a different uterotonic agent (eg, carboprost tromethamine). </li> </ul> </li> <li>Ergonovine (ergometrine), where available<sup>&#916;</sup>, is an alternative to methylergonovine; its actions and contraindications are similar to methylergonovine (see above).<sup>[2]</sup> <ul> <li>Ergonovine (ergometrine) 200 micrograms intramuscularly; may be repeated once in 15 minutes. </li> <li>If required, additional doses of 200 micrograms intramuscularly may be given every four hours up to a maximum of 1 mg (five doses).<sup>[2]</sup> </li> </ul> </li> </ul> </li> </ul> <ul class=\"decimal_heading\"> <li><strong>Add carboprost:</strong> <ul> <li>Carboprost tromethamine (PGF<sub>2</sub>alpha, Hemabate) 250 micrograms intramuscularly every 15 to 90 minutes, as needed, to a maximum of 2 mg (eight doses). Peak plasma level is approximately 30 minutes after injection. <ul> <li>Do <strong>not</strong> give intravenously. </li> <li>Avoid in women with asthma/bronchospasm or hypertension. </li> <li>Relatively contraindicated in renal or hepatic insufficiency or reduced cardiac output. </li> <li>Can cause tachycardia, pyrexia, diarrhea. </li> <li>If no response after one or two doses, quickly move to a different uterotonic agent. </li> </ul> </li> </ul> </li> </ul> </td> </tr> <tr> <td><strong>Inspect the vagina and cervix for lacerations; repair as necessary. Evacuate any retained products of conception. Replace uterus if inverted.</strong></td> </tr> <tr> <td><strong>Perform transarterial embolization if the woman is stable and there is time for personnel and facilities to mobilize.</strong></td> </tr> <tr> <td class=\"sublist1_start\"><strong>Perform laparotomy if the above measures fail.</strong> Surgical approaches that are quick, relatively easy, and effective should be tried first. In utilizing these measures, the surgeon should be cognizant of the amount of blood loss and the stability of the patient, and should perform hysterectomy rather than resort to temporizing measures if her cardiovascular status is unstable or if it appears that the anesthesiologist will not be able to keep up with her fluid needs. Options include:</td> </tr> <tr> <td class=\"sublist1\">Ligate bleeding sites.</td> </tr> <tr> <td class=\"sublist1\">Perform uterine artery ligation, including the utero-ovarian arcade.</td> </tr> <tr> <td class=\"sublist1\">Place a B-Lynch stitch or other uterine compression suture.</td> </tr> <tr> <td class=\"sublist1\">Perform hysterectomy - Hysterectomy is the last resort for atony, but should not be delayed in women who have disseminated intravascular coagulation and require prompt control of uterine hemorrhage to prevent death. Planned hysterectomy is often the appropriate first-line approach for placenta creta.</td> </tr> <tr> <td class=\"sublist1\">Suture deep pelvic bleeders.</td> </tr> <tr> <td class=\"sublist1\">Tamponade pelvic bleeding with pelvic packing.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Simultaneous use of misoprostol with oxytocin is unlikely to have added benefit, but where other uterotonic drugs are unavailable, misoprostol (PGE1) can be useful. Give misoprostol 400 micrograms sublingually or rectally as a single dose. Maximum dose 800 micrograms. The mean time to peak concentration is approximately 30 minutes after sublingual administration versus 40 to 60 minutes after rectal administration. Misoprostol can be given to women with hypertension or asthma/bronchospasm. Monitor for pyrexia. Acetaminophen (paracetamol) is useful for reducing fever.<br />Dinoprostone (PGE2) 20 mg vaginal or rectal suppository is an alternative to misoprostol. Its actions and contraindications are similar to misoprostol; it can be repeated at two hours.</div><div class=\"graphic_footnotes\">PG: prostglandin; PPH: postpartum hemorrhage.<br />* All uterotonic agents can cause nausea and vomiting.<br />Δ Not available in United States. Available in Canada, United Kingdom, Europe, and elsewhere.<br /><FONT class=lozenge>◊</FONT> Oral tablets may be given per rectum or as a micro-enema prepared from oral misoprostol tablets dissolved in 5 mL saline<SUP>[3]</SUP>.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>American College of Obstetricians and Gynecologists Committee on Practice Bulletins&mdash;Obstetrics Postpartum hemorrhage (ACOG Practice Bulletin, number 76, issued October 2006). Obstet Gynecol 2006; 108:1039.</li>&#xD;&#xA;    <li>WHO guidelines for the management of postpartum haemorrhage and retained placenta (issued 2009).</li>&#xD;&#xA;    <li>Bugalho A, Daniel A, Faundes A, et al. Misoprostol for prevention of postpartum hemorrhage. Int J Gynecol Obstet 2001; 73:1.</li>&#xD;&#xA;</ol>&#xD;&#xA;With additional data from:<br /><ul>&#xD;&#xA;    <li>Ramanathan G, Arulkumaran S. Postpartum hemorrhage. J Obstet Gynaecol Can 2006; 28:967.</li>&#xD;&#xA;    <li>Tun&ccedil;alp O, Souza JP, G&uuml;lmezoglu M. New WHO recommendations on prevention and treatment of postpartum hemorrhage. Int J Gynaecol Obstet 2013; 123:254.</li>&#xD;&#xA;    <li>Hofmeyr GJ, G&uuml;lmezoglu M, Novikova N, Lawrie TA. Postpartum misoprostol for preventing maternal mortality and morbidity. Cochrane Database Syst Rev 2013: 7:CD008982.</li>&#xD;&#xA;    <li>International Federation of Gynecology and Obstetrics. Treatment of postpartum hemorrhage with misoprostol. Int J Gynaecol Obstet 2012; 119:215.</li>&#xD;&#xA;</ul></div><div id=\"graphicVersion\">Graphic 57307 Version 13.0</div></div></div>"},"57308":{"type":"graphic_algorithm","displayName":"Dysuria adolescent male","title":"Diagnostic approach to the adolescent male with dysuria","html":"<div class=\"graphic\"><div style=\"width: 725px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to the adolescent male with dysuria</div><div class=\"cntnt\"><img style=\"width:705px; height:857px;\" src=\"images/EM/57308_Dysuriaadolescntmaleedt2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">UTI may coexist with noninfectious etiologies. Unless the cause of dysuria is obvious on physical examination (eg, balanoposthitis, obvious local trauma, or viral exanthem) a urine specimen for rapid dipstick should be obtained in all patients. Urinalysis and urine culture should also be obtained if the urine dipstick suggests a UTI (refer to UpToDate topics on diagnosis of UTI in children).</div><div class=\"graphic_footnotes\">PCR: polymerase chain reaction; UTI: urinary tract infection.<br />* Testing for <em>Neisseria gonorrhoeae</em> and <em>Chlamydia trachomatis</em> is warranted. Refer to UpToDate topics on urethritis in men.<br />&para; In addition to Stevens-Johnson, varicella infection, Beh&ccedil;et syndrome, and reactive arthritis with urethritis and conjunctivitis, potential causes include inflammatory bowel disease and urinary tuberculosis. Refer to appropriate UpToDate topics.<br />&Delta; Refer to UpToDate topics and algorithms on symptomatic microscopic hematuria in children.</div><div id=\"graphicVersion\">Graphic 57308 Version 8.0</div></div></div>"},"57309":{"type":"graphic_table","displayName":"Food prot GI diseases","title":"Food protein-induced gastrointestinal disease in childhood","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Food protein-induced gastrointestinal disease in childhood</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Target</td> <td class=\"subtitle1\">IgE-mediated?</td> <td class=\"subtitle1\">Symptoms</td> </tr> <tr> <td>Immediate hypersensitivity</td> <td>Systemic</td> <td>Yes</td> <td>Rapid onset of nausea, abdominal pain, vomiting, and/or diarrhea; often with hives and wheezing.</td> </tr> <tr> <td>Oral allergy syndrome</td> <td>Oral</td> <td>Yes</td> <td>Mild tingling or angioedema of the lips or oropharynx; occasional sensation of tightness in the throat.</td> </tr> <tr> <td>Eosinophilic esophagitis</td> <td>Esophagus</td> <td>Yes, and/or cell-mediated</td> <td>Gastroesophageal reflux, dysphagia, abdominal pain, lack of histological response to acid suppression; &#177; esophageal strictures.</td> </tr> <tr> <td>Eosinophilic gastroenteritis</td> <td>Stomach, small bowel</td> <td>Yes, and/or cell-mediated</td> <td>Recurrent abdominal pain, intermittent vomiting, failure to thrive or weight loss; &#177; ascites.</td> </tr> <tr> <td>Food protein-induced allergic proctocolitis</td> <td>Rectum, sigmoid colon</td> <td>No</td> <td>Gross or occult blood in stool; otherwise typically asymptomatic.</td> </tr> <tr> <td>Food protein-induced enteropathy</td> <td>Small bowel</td> <td>No</td> <td>Diarrhea or steatorrhea, abdominal distension, failure to thrive, nausea or vomiting.</td> </tr> <tr> <td>Food protein-induced enterocolitis syndrome (FPIES)</td> <td>Small bowel, colon</td> <td>No</td> <td>Protracted vomiting and diarrhea (&#177; blood), dehydration, shock, failure to thrive.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Alan M Lake, MD.</div><div id=\"graphicVersion\">Graphic 57309 Version 2.0</div></div></div>"},"57310":{"type":"graphic_picture","displayName":"Slumped posture","title":"The slumped posture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The slumped posture</div><div class=\"cntnt\"><img style=\"width:335px; height:306px;\" src=\"images/EM/57310_Slumped_posture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the forward-slumped shoulders and protruding chin.</div><div class=\"graphic_reference\">Courtesy of Jason E Decker, MD.</div><div id=\"graphicVersion\">Graphic 57310 Version 3.0</div></div></div>"},"57311":{"type":"graphic_picture","displayName":"Shave biopsy","title":"Shave biopsy technique","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Shave biopsy technique</div><div class=\"cntnt\"><img style=\"width:422px; height:252px;\" src=\"images/PC/57311_Shave_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Half of a double-edge razor is curved with the thumb and forefinger to perform a shave biopsy.</div><div class=\"graphic_reference\">Reprinted with permission from Alguire, PC, Mathes, BM, J Gen Intern Med 1998; 13:46.</div><div id=\"graphicVersion\">Graphic 57311 Version 2.0</div></div></div>"},"57312":{"type":"graphic_figure","displayName":"Tilt table test PI","title":"Tilt table test","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Tilt table test</div><div class=\"cntnt\"><img style=\"width:542px; height:451px;\" src=\"images/PI/57312_Tilt_table_test_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During a tilt table test, a doctor or nurse tilts your body at different angles. At the same time, he or she monitors your blood pressure and your heart's electrical activity. Your body's response to the changes in position can help your doctor or nurse figure out what, if anything, is wrong with your heart.</div><div id=\"graphicVersion\">Graphic 57312 Version 5.0</div></div></div>"},"57313":{"type":"graphic_picture","displayName":"Pemphigus foliaceus histopathology","title":"Pemphigus foliaceus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pemphigus foliaceus</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/57313_Pemphi_foliaceus_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blister formation within the superficial granular layer in pemphigus foliaceus.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 57313 Version 3.0</div></div></div>"},"57315":{"type":"graphic_picture","displayName":"Esophageal inlet patch","title":"Esophageal inlet patch","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Esophageal inlet patch</div><div class=\"cntnt\"><img style=\"width:481px; height:227px;\" src=\"images/GAST/57315_Esophageal_inlet_patch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic views showing inlet patches in two different patients. Both show well-circumscribed areas of salmon-colored mucosa in the proximal esophagus. The patient on the right had two areas (11 and 6 o'clock).</div><div class=\"graphic_reference\">Courtesy of Daniel Wild, MD, and Moises Guelrud, MD.</div><div id=\"graphicVersion\">Graphic 57315 Version 1.0</div></div></div>"},"57316":{"type":"graphic_figure","displayName":"Clamping broad ligament","title":"Clamping of the remaining portion of the broad ligament during vaginal hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Clamping of the remaining portion of the broad ligament during vaginal hysterectomy</div><div class=\"cntnt\"><img style=\"width:461px; height:332px;\" src=\"images/OBGYN/57316_Clamping_broad_ligament.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">It is important to make certain that all branches of the uterine vasculature have been ligated.</div><div id=\"graphicVersion\">Graphic 57316 Version 2.0</div></div></div>"},"57320":{"type":"graphic_diagnosticimage","displayName":"Skin biopsy findings in RV","title":"Skin biopsy findings in rheumatoid vasculitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Skin biopsy findings in rheumatoid vasculitis</div><div class=\"cntnt\"><img style=\"width:504px; height:329px;\" src=\"images/RHEUM/57320_Skin_biopsy_findings_in_RV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This biopsy from the border of a lower-extremity ulcer shows fibrinoid necrosis within the vessel wall.</div><div class=\"graphic_reference\">Courtesy of John Stone, MD, MPH.</div><div id=\"graphicVersion\">Graphic 57320 Version 3.0</div></div></div>"},"57322":{"type":"graphic_diagnosticimage","displayName":"Pulmonic stenosis Doppler II","title":"Pulmonary valve stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary valve stenosis</div><div class=\"cntnt\"><img style=\"width:241px; height:217px;\" src=\"images/CARD/57322_Pulmonic_stenosis_Doppler1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The continuous wave Doppler shows a peak systolic velocity across the pulmonary valve of 4.5 m/sec or a gradient of 81 mmHg.</div><div class=\"graphic_reference\">Provided by Thomas Binder, MD, et al. Interactive Echocardiography. A Clinical Atlas. Futura, 1997.</div><div id=\"graphicVersion\">Graphic 57322 Version 3.0</div></div></div>"},"57323":{"type":"graphic_figure","displayName":"Gene therapy SCID X","title":"Principles of ex vivo gene therapy for X-linked severe combined immunodeficiency (SCID-X)","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Principles of ex vivo gene therapy for X-linked severe combined immunodeficiency (SCID-X)</div><div class=\"cntnt\"><img style=\"width:538px; height:444px;\" src=\"images/ALLRG/57323_Gene_therapy_SCID_X.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CD34<sup>+</sup> cells are incubated ex vivo with supernatant that contains retrovirus encoding the interleukin-2 receptor gamma-chain gene (<em>IL2RG</em>), also called the common cytokine-receptor gamma chain (gamma-c or &gamma;c). Binding of the virus to a cell is followed by viral entry. Viral RNA is retrotranscribed into DNA, which, as a preintegration complex, can recombine with the cell's genome. The <em>IL2RG</em> (&gamma;c) gene can be transcribed, being under the control of the viral LTR, which leads to protein synthesis, membrane expression, and function.</div><div class=\"graphic_footnotes\">LTR: long terminal repeat; RNA: ribonucleic acid; DNA: deoxyribonucleic acid; mRNA: messenger RNA.</div><div class=\"graphic_reference\">Reprinted by permission from MacMillan Publishers Ltd: Fischer A, Hacein-Bey S, Cavazzana-Calvo M. Gene therapy of severe combined immunodeficiencies. Nature Reviews Immunology 2002; 8:615. Copyright &copy; 2002 MacMillan Publishers Ltd.</div><div class=\"contractual\"><br/><a href=\"http://www.nature.com/\">http://www.nature.com</a></div><div id=\"graphicVersion\">Graphic 57323 Version 4.0</div></div></div>"},"57326":{"type":"graphic_table","displayName":"Child abuse neglect resources A","title":"Child abuse and neglect resources","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Child abuse and neglect resources</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_left\">Child Welfare Information Gateway </td> <td rowspan=\"2\">Child Welfare Information Gateway helps professionals locate information related to child abuse and neglect and related child welfare issues. It is a service of the Children's Bureau, within the Administration on Children, Youth, and Families, Administration for Children and Families, U.S. Department of Health and Human Services.</td> </tr> <tr> <td>Children's Bureau/ACYF<br /> 1250 Maryland Avenue, SW<br /> Eighth Floor<br /> Washington, DC 20224<br /> <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">800.394.3366<a href=\"#\" title=\"Call: 800.394.3366\"><img alt=\"\" title=\"Call: 800.394.3366\" style=\"overflow: hidden; cursor: hand; height: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; width: 16px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span> or <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">703.385.7565<a href=\"#\" title=\"Call: 703.385.7565\"><img alt=\"\" title=\"Call: 703.385.7565\" style=\"overflow: hidden; cursor: hand; height: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; width: 16px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span><br /> <a href=\"http://www.childwelfare.gov/\" target=\"_blank\">www.childwelfare.gov</a></td> </tr> <tr> <td class=\"subtitle1_left\">American Professional Society on the Abuse of Children (APSAC) </td> <td rowspan=\"2\">The APSAC is a nonprofit organization of professionals who work with maltreated children and their families. Members include professionals working in mental health, child welfare, law enforcement, health care, and prevention.</td> </tr> <tr> <td>940 NE 13th Street CHO 3B--3406<br /> Oklahoma City, OK 73104<br /> <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">(405) 271-8202<a href=\"#\" title=\"Call: (405) 271-8202\"><img alt=\"\" title=\"Call: (405) 271-8202\" style=\"overflow: hidden; cursor: hand; height: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; width: 16px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span><br /> <a href=\"http://www.apsac.org/\" target=\"_blank\">www.apsac.org</a></td> </tr> <tr> <td class=\"subtitle1_left\">Chadwick Center for Children and Families </td> <td rowspan=\"2\">The Chadwick Center for Children and Families addresses the prevention, investigation, diagnosis, treatment, and prosecution of child maltreatment, and conducts professional education and research.</td> </tr> <tr> <td>Children's Hospital and Health Center<br /> 3020 Children's Way MC 5017<br /> San Diego, CA 92123<br /> <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">(619) 576-5803<a href=\"#\" title=\"Call: (619) 576-5803\"><img alt=\"\" title=\"Call: (619) 576-5803\" style=\"overflow: hidden; cursor: hand; height: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; width: 16px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span><br /> <a href=\"http://www.rchsd.org/\">www.rchsd.org</a></td> </tr> <tr> <td class=\"subtitle1_left\">Child Welfare League of America (CWLA) </td> <td rowspan=\"2\">The Child Welfare League of America is a federation of public and private non-profit agencies and organizations that serve vulnerable children and youths and their families. CWLA provides training, consultation, and technical assistance to child welfare professionals and agencies while also educating the public about emerging issues affecting abused, neglected, and at-risk children.</td> </tr> <tr> <td>440 First St., NW, Third Floor<br /> Washington, DC 20001-2085<br /> <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">(202) 638-2952<a href=\"#\" title=\"Call: (202) 638-2952\"><img alt=\"\" title=\"Call: (202) 638-2952\" style=\"overflow: hidden; cursor: hand; height: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; width: 16px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span><br /> <a href=\"http://www.cwla.org/\" target=\"_blank\">www.cwla.org</a></td> </tr> <tr> <td class=\"subtitle1_left\">Childhelp USA </td> <td rowspan=\"2\">Childhelp USA is a national organization that provides crisis assistance 24 hours a day, 7 days a week, as well as other counseling and referral services. Childhelp USA is dedicated to meeting the physical, emotional, educational, and spiritual needs of abused and neglected children.</td> </tr> <tr> <td>15757 North 78th St.<br /> Scottsdale, AZ 85260<br /> (800) 4-A-CHILD (National Child Abuse Hotline)<br /> <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">(480) 922-8212<a href=\"#\" title=\"Call: (480) 922-8212\"><img alt=\"\" title=\"Call: (480) 922-8212\" style=\"overflow: hidden; cursor: hand; height: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; width: 16px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span><br /> TDD:(800) 2-A-CHILD<br /> <a href=\"https://www.childhelp.org/\"><span style=\"color: #3966bf;\">https://www.childhelp.org/</span></a></td> </tr> <tr> <td class=\"subtitle1_left\">Domestic Violence Institute (DVI) </td> <td rowspan=\"2\">The Institute is an international membership organization that provides research, public information, education, and training programs in the area of domestic violence, including child abuse.</td> </tr> <tr> <td>50 South Steele St.<br /> Suite 850<br /> Denver, CO 80209<br /> <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">(303) 322-1831<a href=\"#\" title=\"Call: (303) 322-1831\"><img alt=\"\" title=\"Call: (303) 322-1831\" style=\"overflow: hidden; cursor: hand; height: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; width: 16px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABAAAAAQCAYAAAAf8/9hAAABcklEQVR4XpXTPUvDUBTH4aR2c2hBQXGpTiIORhBcBOvgYKf0Awi+4Ggr1MVPIIrYdnEpShddHIyLi6AVXVxsRRDRwbi4KNgu4lCIv8i/i6QRDzycy+09555LqOl5nhEUptPoJe1iDHU8oYlrlDw79m4QEbSLPexzsIc8hDRm8YBjLpj4q8EgxQdab+MNd4ghhQ2adIc1+ORAFEnWWfTDRp7GDfImlsIavKALLuqoqMGUCs4wHtagiQ5uc8kDyCOBKlP1k78QNTOZnMXCQRxWsbjl6iuskV41SQG2Gj9rikvcR1WcgKFDBa1LOEUK56hqv8BUFV3SGWkVS9JQ6Dsv4wQ1DKMPORUvkm78BhdQMI1CTa5I0yrcwSFqFD+SZ7DQesIkCG5S/JpkHYERQRmuNsrZ7Grc+Ef8/Bcoslkfae8Wc7CUHZ++TuAEBj86pHntjaDKXllPy6PW/gkKFaThwp/K87N8hDcQTTKKFTioSxqB8Q2BNX5JtAljwgAAAABJRU5ErkJggg==\" /></a></span></td> </tr> </tbody></table></div><div class=\"graphic_reference\">Additional resources are available at the Child Welfare Information Gateway: <A spellcheck=true href=\"https://www.childwelfare.gov/\" target=_blank>https://www.childwelfare.gov/</A> (Accessed on July 20, 2017).</div><div id=\"graphicVersion\">Graphic 57326 Version 3.0</div></div></div>"},"57328":{"type":"graphic_picture","displayName":"Injection superior trochanter","title":"Injection at the superior trochanter","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Injection at the superior trochanter</div><div class=\"cntnt\"><img style=\"width:516px; height:342px;\" src=\"images/EM/57328_Injection_superior_trochant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A local anesthetic block placed just under the gluteus medius tendon and just short of the periosteum of the superior aspect of the trochanteric process can be used to confirm the presence of bursitis of the deeper trochanteric or gluteus medius bursa. The patient is placed in the lateral decubitus position with the affected side up and the knees flexed to 90 degrees. The superior, posterior, and anterior edges of the trochanteric process are palpated and marked. The point of entry for injection of the superficial bursa is approximately 2 to 2.5 cm (0.75 to 1 in)&nbsp;above the midpoint of the most superior portion of the trochanter. Topical anesthetic (eg, ethyl chloride) is&nbsp;applied to&nbsp;the skin. Local anesthetic is placed at the gluteus medius tissue plane (1 mL) and at the periosteum of the femur (0.5 to 1 mL). A&nbsp;4 cm (1.5&nbsp;in), 22-gauge or 22-gauge spinal needle is inserted at a 45 degree&nbsp;angle in direct alignment with the femur; the depth is 2.5 to 6.4 cm (1 to 2.5 in)&nbsp;to the gluteus medius tendon, and 4 to 7.5 cm (1.5 to 3 in)&nbsp;to the superior trochanter. The needle is held lightly and advanced through the low resistance of the subcutaneous fat to the firm, rubbery resistance of the gluteus medius tissue plane. Following anesthesia at this level, the needle is advanced with firm pressure approximately 1.3 cm (0.5 in) farther to the periosteum of the femur. The patient will usually experience sharp pain as the needle touches the periosteum. Injection at this deeper level requires firm pressure. The needle should be rotated 180 degrees&nbsp;or withdrawn slightly if excessive pressure is encountered. If the trochanter tenderness is significantly relieved with anesthetic injection, 1 mL of triamcinolone acetonide 40 mg/mL can be injected through the same needle.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 57328 Version 4.0</div></div></div>"},"57329":{"type":"graphic_figure","displayName":"Central obstruction types","title":"Schematic illustration of the three main types of malignant central airway obstruction shown at the tracheal level, with identical degrees of narrowing of the lumen","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schematic illustration of the three main types of malignant central airway obstruction shown at the tracheal level, with identical degrees of narrowing of the lumen</div><div class=\"cntnt\"><img style=\"width:446px; height:173px;\" src=\"images/PULM/57329_Central_obstruction_types.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) intraluminal; B) extraluminal; C) mixed obstruction.</div><div class=\"graphic_reference\">Reproduced with permission from: Bolliger, CT, Mathur, PN, Beamis, JF, et al. Eur Respir J 2002; 19:368. Copyright &#169; 2002 European Respiratory Society Journals Ltd.</div><div id=\"graphicVersion\">Graphic 57329 Version 1.0</div></div></div>"},"57330":{"type":"graphic_figure","displayName":"Placement of Thal-Quick thoracostomy tube","title":"Placement of Thal-Quick thoracostomy tube","html":"<div class=\"graphic\"><div style=\"width: 622px\" class=\"figure\"><div class=\"ttl\">Placement of Thal-Quick thoracostomy tube</div><div class=\"cntnt\"><img style=\"width:602px; height:649px;\" src=\"images/SURG/57330_PlaceThalquikthoracostomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Permission for use granted by Cook Medical Incorporated, Bloomington, Indiana.</div><div id=\"graphicVersion\">Graphic 57330 Version 3.0</div></div></div>"},"57331":{"type":"graphic_waveform","displayName":"LV - aorta pullback","title":"LV - aorta pullback","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">LV - aorta pullback</div><div class=\"cntnt\"><img style=\"width:442px; height:351px;\" src=\"images/CARD/57331_LV_aorta_pullback.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal LV and aortic pressures. Note pattern of LV diastolic pressure with lowest pressure earliest in diastole and gradual filling across diastole until the 'a' wave after which is the end diastolic pressure point (arrow).</div><div class=\"graphic_reference\">Courtesy of Dr. Morton Kern.</div><div id=\"graphicVersion\">Graphic 57331 Version 3.0</div></div></div>"},"57336":{"type":"graphic_table","displayName":"Infections by immune deficit","title":"Organisms associated with infection in individuals with various immune deficits","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Organisms associated with infection in individuals with various immune deficits</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Immune deficit</td> <td class=\"subtitle1\">Common causes</td> <td class=\"subtitle1\">Organisms</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Neutrophil disorders</td> </tr> <tr> <td class=\"sublist1\">Neutropenia</td> <td class=\"sublist_other\"> <p>Chemotherapy</p> <p>Leukemia</p> <p>AIDS</p> <p>Felty's syndrome</p> <p>Viral infections</p> </td> <td class=\"sublist_other\"> <p>Gram-negative bacilli (enteric and nonenteric)</p> <p><em>Staphylococcus aureus</em></p> <p>Coagulase-negative <em>Staphylococcus</em></p> <p>Streptococci</p> <p>Fungi (<em>Aspergillus</em> spp, <em>Candida </em>spp)</p> </td> </tr> <tr> <td class=\"sublist1\">Neutrophil chemotaxis</td> <td class=\"sublist_other\"> <p>Diabetes mellitus</p> <p>Cirrhosis, alcoholism</p> <p>Uremia</p> <p>Hodgkin's disease</p> <p>Trauma, burns</p> <p>Lazy leukocyte syndrome</p> </td> <td class=\"sublist_other\"> <p><em>S. aureus</em></p> <p><em>Candida spp</em></p> <p>Streptococci</p> <p>Mucorales</p> </td> </tr> <tr> <td class=\"sublist1\">Neutrophil killing</td> <td class=\"sublist_other\"> <p>Chronic granulomatous disease</p> <p>Myeloperoxidase deficiency</p> </td> <td class=\"sublist_other\"> <p><em>S. aureus</em></p> <p><em>Escherichia coli</em></p> <p>Fungi (<em>Aspergillus</em> spp, <em>Candida</em> spp)</p> </td> </tr> <tr> <td>T lymphocyte deficiency</td> <td> <p>HIV/AIDS</p> <p>Lymphoma</p> <p>Chemotherapy</p> <p>Transplantation</p> <p>Glucocorticoids</p> <p>Viral infection</p> <p>T cell-depleting antibodies</p> </td> <td> <p>Viruses (latent herpesviruses, papillomaviruses, respiratory viruses)</p> <p>Intracellular bacteria (<em>Legionella</em> spp, mycobacteria)</p> <p><em>Nocardia</em> spp</p> <p>Fungi (<em>Pneumocystis jirovecii</em>, <em>Cryptococcus</em> spp, <em>Histoplasma capsulatum</em>)</p> <p>Parasites (<em>Strongyloides</em> spp, <em>Toxoplasma</em> spp)</p> </td> </tr> <tr> <td>B lymphocyte deficiency</td> <td> <p>Multiple myeloma</p> <p>Acute leukemia</p> <p>Burns</p> <p>Congenital</p> <p>Drugs (anti-B-cell therapies, azathioprine, mycophenylate)</p> <p>Enteropathies</p> <p>Plasmapheresis</p> <p>Glucocorticoids</p> </td> <td> <p>Encapsulated bacteria (<em>Pneumococcus</em>, <em>Haemophilus influenzae</em>, <em>Neisseria meningitides</em>)</p> <p><em>Salmonella</em> spp</p> <p><em>Campylobacter</em></p> <p><em>Giardia</em></p> </td> </tr> <tr> <td>Spleen</td> <td> <p>Splenectomy</p> <p>Sickle cell disease</p> <p>Cirrhosis</p> </td> <td> <p>Encapsulated bacteria (<em>Pneumococcu</em>s, <em>H. influenzae</em>, <em>N. meningitidis</em>)</p> <p><em>Capnocytophaga</em></p> </td> </tr> <tr> <td>Complement</td> <td>Congenital/acquired deficiencies</td> <td> <p><em>S. aureus</em></p> <p>Encapsulated bacteria (<em>Pneumococcus, H. influenzae, N. meningitidis</em>)</p> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 57336 Version 4.0</div></div></div>"},"57338":{"type":"graphic_figure","displayName":"MVP complication and MR severity","title":"Complications in MVP related to mitral regurgitation","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Complications in MVP related to mitral regurgitation</div><div class=\"cntnt\"><img style=\"width:457px; height:319px;\" src=\"images/CARD/57338_Complix_and_MR_severity_in.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 229 patients with mitral valve prolapse (MVP), the incidence of complications was directly related to the severity of mitral regurgitation. Complications included atrial fibrillation, heart failure, chordal rupture, infective endocarditis, the need for mitral valve replacement, cerebral embolism, and cardiac death.</div><div class=\"graphic_reference\">Data from Kim S, Kuroda T, Nishinaga M, et al. Am Heart J 1996; 132:348.</div><div id=\"graphicVersion\">Graphic 57338 Version 2.0</div></div></div>"},"57339":{"type":"graphic_table","displayName":"Miscarriage rate after amnio","title":"Miscarriage rate after amniocentesis in series utilizing ultrasound guidance during the procedure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Miscarriage rate after amniocentesis in series utilizing ultrasound guidance during the procedure</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Author </td> <td class=\"subtitle1\" colspan=\"2\">Spontaneous abortions </td> <td class=\"subtitle1\" rowspan=\"2\">Difference in rates (95% confidence interval) </td> </tr> <tr> <td class=\"subtitle2\">Cases (numbers) </td> <td class=\"subtitle2\">Controls (number) </td> </tr> <tr> <td>Tabor (1986)</td> <td>1.7% (38/2242)</td> <td>0.7% (17/2270)</td> <td>0.9% (0.3%; 1.5%)</td> </tr> <tr> <td>Andreasen (1989)</td> <td>2.3% (30/1318)</td> <td>1.4% (4/276)</td> <td>0.8% (-1.3%; 1.9%)</td> </tr> <tr> <td>Tongsong (1998)</td> <td>1.8% (36/2045)</td> <td>1.4% (29/2045)</td> <td>0.3% (-0.4%; 1.1%)</td> </tr> <tr> <td>Antsaklis (2000)</td> <td>2.1% (79/3696)</td> <td>1.5% (80/5324)</td> <td>0.6% (0.1%; 1.2%)</td> </tr> <tr> <td>Muller (2002)</td> <td>0.9% (31/3472)</td> <td>0.4% (197/47,004)</td> <td>0.5% (0.2%; 0.8%)</td> </tr> <tr> <td>Eddleman (2006)</td> <td>1.0% (31/3096)</td> <td>0.9% (300/31,907)</td> <td>0.1% (-0.3%; 0.5%)</td> </tr> <tr> <td>Kong (2006)</td> <td>2.0% (68/3466)</td> <td>1.2% (13/1125)</td> <td>0.8% (-0.2%; 1.5%)</td> </tr> <tr> <td>Towner (2007)</td> <td>0.5% (69/15,005)</td> <td>0.5% (90/17,045)</td> <td>-0.1% (-0.2%; 0.1%)</td> </tr> <tr> <td>Pitukkijronnakorn (2011)</td> <td>0.4% (11/2990)</td> <td>0.2% (3/1495)</td> <td>0.2% (-0.3%; 0.4%)</td> </tr> <tr> <td>Corrado (2012)</td> <td>1.0% (30/2990)</td> <td>0.8% (4/487)</td> <td>0.2% (-0.1%; 0.8%)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">An increase in rate of spontaneous abortion compared with controls was seen in all study groups following amniocentesis, although the difference did not reach significance in four series.</div><div class=\"graphic_footnotes\">%: percent.</div><div id=\"graphicVersion\">Graphic 57339 Version 2.0</div></div></div>"},"57340":{"type":"graphic_picture","displayName":"Accommodative esotropia","title":"Refractive-type accommodative esotropia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Refractive-type accommodative esotropia</div><div class=\"cntnt\"><img style=\"width:364px; height:520px;\" src=\"images/PEDS/57340_Accommodative_esotropia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Esotropia of the left eye. B) Esotropia is eliminated with the use of hyperopic glasses.</div><div class=\"graphic_reference\">Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2e. Lippincott Williams &amp; Wilkins, 2001. Copyright &#169;2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 57340 Version 1.0</div></div></div>"},"57341":{"type":"graphic_table","displayName":"Fondaparinux in ACS","title":"Study drug administration during PCI","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Study drug administration during PCI</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup span=\"3\" width=\"28%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"3\">Time since last injection(s)</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">&#8804;6 hours</td> <td class=\"subtitle2\">&#62;6 hours</td> </tr> <tr> <td> <p>Last injection</p> <p><strong>Double</strong></p> (fonda/placebo + enox/placebo)</td> <td> <p>Last injection</p> <p><strong>Single</strong></p> (enox/placebo <strong>only</strong>)</td> <td> <p>Last injection</p> <strong>Double or single</strong></td> </tr> <tr> <td><strong>With GP IIb/IIIa</strong></td> <td>No study drug</td> <td>Fonda/placebo 2.5 mg IV</td> <td>Fonda/placebo 2.5 mg IV + UFH/placebo 0.013 mL/kg IV (65 units/kg)</td> </tr> <tr> <td><strong>Without GP IIb/IIIa</strong></td> <td>Fonda/placebo 2.5 mg IV</td> <td>Fonda/placebo 5.0 mg IV</td> <td>Fonda/placebo 5.0 mg IV + UFH/placebo 0.02 mL/kg IV (100 units/kg)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GP: glycoprotein; IV: intravenous; UFH: unfractionated heparin.</div><div class=\"graphic_reference\">Reproduced with permission from: The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes. N Engl J Med 2006; 354(14):464. Copyright &copy; 2006 Dr. Salim Yusuf.</div><div id=\"graphicVersion\">Graphic 57341 Version 3.0</div></div></div>"},"57342":{"type":"graphic_figure","displayName":"Fetal development weeks three to five","title":"Umbilical cord development third to fifth week gestation","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Umbilical cord development third to fifth week gestation</div><div class=\"cntnt\"><img style=\"width:542px; height:562px;\" src=\"images/PEDS/57342_Fetal_development_weeks_3-5.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">GI: gastrointestinal.</div><div id=\"graphicVersion\">Graphic 57342 Version 3.0</div></div></div>"},"57343":{"type":"graphic_figure","displayName":"Scleral buckle","title":"Scleral buckle","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Scleral buckle</div><div class=\"cntnt\"><img style=\"width:487px; height:238px;\" src=\"images/PC/57343_Scleral_buckle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Following cryoretinopexy, an exoplant is sutured to the outside of the sclera that indents the wall of the eye and closes the retinal breaks.</div><div class=\"graphic_reference\">Reproduced with permission from: Wilkinson CP, Rice TA. Mitchel's Retinal Detachment, 2nd ed, Mosby-Year Book, Inc., Louis 1997. Copyright © Charles P Wilkinson, MD.</div><div id=\"graphicVersion\">Graphic 57343 Version 3.0</div></div></div>"},"57344":{"type":"graphic_algorithm","displayName":"Rx algorithm tracheomalacia","title":"Treatment algorithm for tracheomalacia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Treatment algorithm for tracheomalacia</div><div class=\"cntnt\"><img style=\"width:433px; height:442px;\" src=\"images/PULM/57344_Rx_Algorithm_Tracheomalacia.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Treatment algorithm for adult tracheomalacia.</div><div class=\"graphic_footnotes\">TM: tracheomalacia; CT: computed tomography; PFTs: pulmonary function tests; 6MWT: six-minute walk test; QOL: quality of life.</div><div class=\"graphic_reference\">Adapted with permission from: Carden KA, Boiselle PM, Waltz D, Ernst A. Tracheomalacia and tracheobronchomalacia in children and adults: An in-depth review. Chest 2005; 127:984. Copyright &copy; 2005 American College of Chest Physicians.</div><div id=\"graphicVersion\">Graphic 57344 Version 4.0</div></div></div>"},"57345":{"type":"graphic_picture","displayName":"Severe retinal hemorrhage","title":"Severe retinal hemorrhage from central retinal vein obstruction associated with a direct cavernous-carotid fistula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe retinal hemorrhage from central retinal vein obstruction associated with a direct cavernous-carotid fistula</div><div class=\"cntnt\"><img style=\"width:360px; height:339px;\" src=\"images/NEURO/57345_Severe_retinal_hemorrhage.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Jeffrey L Bennett, MD, PhD.</div><div id=\"graphicVersion\">Graphic 57345 Version 1.0</div></div></div>"},"57346":{"type":"graphic_table","displayName":"Mechanisms of anaphylaxis and pseudoallergic syndromes","title":"Mechanisms of anaphylaxis and pseudoallergic syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mechanisms of anaphylaxis and pseudoallergic syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Proposed mechanism(s)</td> <td class=\"subtitle1\">Characteristics</td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>IgE-mediated activation of mast cells and basophils</strong></p> Examples: Reactions to penicillin and other beta-lactams and to neuromuscular-blocking agents</td> <td> <ul> <li>Can be evaluated with skin test and/or in vitro tests for allergen-specific IgE </li> <li>Requires prior exposure to allergen or cross-reacting allergen </li> <li>Amenable to desensitization in some situations </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>Immunologic mechanisms NOT involving IgE (mediated by IgG or IgM, antigen:antibody complexes, and/or complement)</strong></p> Examples: Reactions to dextran, protamine</td> <td> <ul> <li>Formerly called anaphylactoid reactions </li> <li>Skin testing and in vitro IgE testing are <strong>NOT</strong> useful </li> <li>Pretreatment with glucocorticoids and/or antihistamines may be helpful </li> </ul> </td> </tr> <tr> <td> <p><strong>Direct (nonimmunologic) activation of mast cells and basophils</strong></p> Examples: Reactions to radiocontrast agents, opioids, and to neuromuscular-blocking agents</td> <td> <ul> <li>Formerly called anaphylactoid reactions </li> <li>Skin testing and in vitro IgE testing are <strong>NOT</strong> useful </li> <li>Pretreatment with glucocorticoids and/or antihistamines may be helpful </li> <li>Slow administration of responsible agent generally minimizes reactions </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgE: immunoglobulin E; IgG: immunoglobulin G; IgM: immunoglobulin M.</div><div id=\"graphicVersion\">Graphic 57346 Version 10.0</div></div></div>"},"57348":{"type":"graphic_table","displayName":"Summary of results from FASTER and SURUSS trials","title":"Detection rate and false positive rate for Down syndrome screening tests - First and Second Trimester Evaluation of Risk Trial (FASTER) and Serum, Urine and Ultrasound Screening Study (SURUSS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Detection rate and false positive rate for Down syndrome screening tests - First and Second Trimester Evaluation of Risk Trial (FASTER) and Serum, Urine and Ultrasound Screening Study (SURUSS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Test</td> <td class=\"subtitle1\" colspan=\"2\">FASTER*</td> <td class=\"subtitle1\" colspan=\"3\">SURUSS<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2\">Detection rate, percent</td> <td class=\"subtitle2\">FPR, percent</td> <td class=\"subtitle2\">Detection rate, percent</td> <td class=\"subtitle2\">FPR, percent</td> <td class=\"subtitle2\">Procedure related losses per 100,000 women screened</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Full integrated</td> <td>85</td> <td>0.8</td> <td>85</td> <td>0.9</td> <td>6</td> </tr> <tr class=\"divider_bottom\"> <td>95</td> <td>5</td> <td>90</td> <td>2.1</td> <td>15</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Serum integrated</td> <td>85</td> <td>4.4</td> <td>85</td> <td>3.9</td> <td>28</td> </tr> <tr class=\"divider_bottom\"> <td>95</td> <td>17</td> <td>90</td> <td>7.4</td> <td>53</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Combined</td> <td>85</td> <td>4.8</td> <td>85</td> <td>4.3</td> <td>35</td> </tr> <tr class=\"divider_bottom\"> <td>95</td> <td>21</td> <td>90</td> <td>8.4</td> <td>60</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Quadruple</td> <td>85</td> <td>7.3</td> <td>85</td> <td>6.2</td> <td>45</td> </tr> <tr class=\"divider_bottom\"> <td>95</td> <td>22</td> <td>90</td> <td>10.6</td> <td>76</td> </tr> <tr> <td rowspan=\"2\">Triple</td> <td>85</td> <td>14</td> <td>85</td> <td>9.3</td> <td>67</td> </tr> <tr> <td>95</td> <td>32</td> <td>90</td> <td>14.7</td> <td>106</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FPR: false positive rate.<br />* For FASTER, the first trimester combined test or first trimester component of the integrated test was done at 12 completed weeks of gestation.<br />&para; For SURUSS, the first trimester combined test or first trimester component of the integrated test was done at 11 completed weeks of gestation.</div><div class=\"graphic_reference\">Adapted from: Wald NJ, Rodeck C, Hackshaw AK, et al. Health Technol Assess 2003; 7:1.</div><div id=\"graphicVersion\">Graphic 57348 Version 6.0</div></div></div>"},"57349":{"type":"graphic_table","displayName":"Organ function change age","title":"Age-related organ function changes relevant to colorectal cancer treatment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Age-related organ function changes relevant to colorectal cancer treatment</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">Organ system </td>\r\n                    <td class=\"subtitle1\">Age-related change </td>\r\n                    <td class=\"subtitle1\">Potential CRC relevance </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Bone Marrow</td>\r\n                    <td>&#8595; Cellularity and reserve</td>\r\n                    <td>&#8593; Risk of leukopenia: dose reduction and growth factor often needed</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Liver</td>\r\n                    <td>&#8595; Parenchymal volume</td>\r\n                    <td>Less able to tolerate oxaliplatin steatohepatitis, metastasectomy</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Kidney</td>\r\n                    <td>&#8595; Glomerular filtration rate</td>\r\n                    <td>&#8593; Risk of prerenal azotemia</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Cardiovascular</td>\r\n                    <td>&#8593; CAD, valvular disease, HTN</td>\r\n                    <td>\r\n                    <p>Fluoropyrimidine coronary vasospasm </p>\r\n                    <p>Greater risk from bevacizumab-related hypertension and arterial thromboembolism</p>\r\n                    </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Central nervous system</td>\r\n                    <td>\r\n                    <p>&#8595; Cerebral perfusion</p>\r\n                    <p>&#8593; Autonomic disturbance</p>\r\n                    </td>\r\n                    <td>5-FU-associated cerebellar toxicity, with greater effect on balance, gait</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 57349 Version 2.0</div></div></div>"},"57350":{"type":"graphic_picture","displayName":"Verrucous carcinoma","title":"Verrucous carcinoma of the oral cavity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Verrucous carcinoma of the oral cavity</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/ONC/57350_Verrucous_carcinoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Verrucous carcinoma of the oral cavity.</div><div class=\"graphic_reference\">Courtesy of Vaibhav Parekh, MD MBA.</div><div id=\"graphicVersion\">Graphic 57350 Version 3.0</div></div></div>"},"57351":{"type":"graphic_algorithm","displayName":"Secretory diarrhea child","title":"Algorithm for evaluation of a child with secretory diarrhea","html":"<div class=\"graphic\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">Algorithm for evaluation of a child with secretory diarrhea</div><div class=\"cntnt\"><img style=\"width:640px; height:508px;\" src=\"images/PEDS/57351_Secretorydiarrheachedt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm shows a typical diagnostic pathway for many patients in this age group. Other sequences of testing may be appropriate in some cases.</div><div class=\"graphic_footnotes\">CT: computerized tomography; VIP: vasoactive intestinal polypeptide; 5-HIAA: 5-hydroxyindoleacetic acid; TSH: thyroid stimulating hormone; ACTH: adrenocorticotropic hormone.</div><div id=\"graphicVersion\">Graphic 57351 Version 6.0</div></div></div>"},"57354":{"type":"graphic_figure","displayName":"Cardiotocography showing calculation of Montevideo units","title":"Cardiotocography showing calculation of Montevideo units","html":"<div class=\"graphic\"><div style=\"width: 634px\" class=\"figure\"><div class=\"ttl\">Cardiotocography showing calculation of Montevideo units</div><div class=\"cntnt\"><img style=\"width:614px; height:387px;\" src=\"images/OBGYN/57354_Cardiotographshowingcalc.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Montevideo units are calculated by subtracting the baseline uterine pressure from the peak contraction pressure of each contraction (arrows) in a 10-minute window and adding the pressures generated by each contraction.</div><div class=\"graphic_footnotes\">FHR: fetal heart rate; bpm: beats per minute; mmHg: millimeters of mercury; kPa: kilopascals; UA: uterine activity.</div><div id=\"graphicVersion\">Graphic 57354 Version 6.0</div></div></div>"},"57355":{"type":"graphic_picture","displayName":"Erythema gyratum repens lesions","title":"Erythema gyratum repens","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema gyratum repens</div><div class=\"cntnt\"><img style=\"width:432px; height:282px;\" src=\"images/DERM/57355_Eryth_gyrat_repens_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Concentric erythematous plaques are present on the skin of this patient with erythema gyratum repens.</div><div id=\"graphicVersion\">Graphic 57355 Version 1.0</div></div></div>"},"57356":{"type":"graphic_diagnosticimage","displayName":"Reduced Salter II fracture","title":"Reduced Salter II fracture","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Reduced Salter II fracture</div><div class=\"cntnt\"><img style=\"width:453px; height:388px;\" src=\"images/EM/57356_Reduced_Salter_II_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fracture reduced with improved alignment.</div><div class=\"graphic_reference\">Courtesy of Paula Schweich, MD.</div><div id=\"graphicVersion\">Graphic 57356 Version 2.0</div></div></div>"},"57357":{"type":"graphic_diagnosticimage","displayName":"Coxa profunda in osteomalacia","title":"Coxa profunda abnormality in osteomalacia: Radiographic findings","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Coxa profunda abnormality in osteomalacia: Radiographic findings</div><div class=\"cntnt\"><img style=\"width:360px; height:273px;\" src=\"images/ENDO/57357_Coxa_profunda_in_osteomalac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone film in a patient with vitamin D-resistant rickets showing hip deformity with coxa profunda (in which the femoral head comes deeply into the pelvis), coxa vara (in which the angle between the femoral neck and the femoral shaft is diminished) (arrow), and rods representing surgical treatment of pathologic fractures.</div><div class=\"graphic_reference\">Courtesy of CJ Menkes, MD.</div><div id=\"graphicVersion\">Graphic 57357 Version 4.0</div></div></div>"},"57358":{"type":"graphic_picture","displayName":"Cap polyposis Endosc IV","title":"Cap polyposis","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Cap polyposis</div><div class=\"cntnt\"><img style=\"width:480px; height:360px;\" src=\"images/GAST/57358_Cap_polyposis_Endosc_IV.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Jerome D Waye, MD.</div><div id=\"graphicVersion\">Graphic 57358 Version 1.0</div></div></div>"},"57359":{"type":"graphic_table","displayName":"Fontaine stages and Rutherford categories PAD","title":"Fontaine stages and Rutherford categories PAD","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fontaine stages and Rutherford categories PAD</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody><tr>\n<td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">Fontaine</td>\n<td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">Rutherford</td>\n</tr>\n<tr><td class=\"subtitle2\">Stage</td>\n<td class=\"subtitle2\">Clinical</td>\n<td class=\"subtitle2\">Grade</td>\n<td class=\"subtitle2\">Category</td>\n<td class=\"subtitle2\">Clinical</td>\n</tr><tr>\n<td>I</td>\n<td>Asymptomatic</td>\n<td>0</td>\n<td>0</td>\n<td colspan=\"1\">Asymptomatic</td>\n</tr><tr>\n<td>IIa</td>\n<td>Mild claudication</td>\n<td>I</td>\n<td>1</td>\n<td colspan=\"1\">Mild claudication</td>\n</tr><tr>\n<td colspan=\"1\" rowspan=\"2\">IIb</td>\n<td colspan=\"1\" rowspan=\"2\">Moderate to severe\nclaudication</td>\n<td>I</td>\n<td>2</td>\n<td colspan=\"1\">Moderate claudication</td>\n</tr><tr><td>I</td><td>3</td><td>Severe\nclaudication</td></tr><tr>\n<td>III</td>\n<td>Ischemic rest pain</td>\n<td>II</td>\n<td>4</td>\n<td colspan=\"1\">Ischemic rest pain</td>\n</tr><tr>\n<td colspan=\"1\" rowspan=\"2\">IV</td>\n<td colspan=\"1\" rowspan=\"2\">Ulceration or gangrene</td>\n<td>III</td>\n<td>5</td>\n<td colspan=\"1\">Minor tissue loss</td>\n</tr><tr><td>III</td><td>6</td><td>Major tissue loss</td></tr>\n</tbody></table></div><div class=\"graphic_reference\">Reprinted from Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Concensus (TASC). J Vasc Surg 2000; 31:S1.</div><div id=\"graphicVersion\">Graphic 57359 Version 3.0</div></div></div>"},"57360":{"type":"graphic_picture","displayName":"T1 oral tongue SCC","title":"Stage T1 oral tongue squamous cell carcinoma (SCC)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stage T1 oral tongue squamous cell carcinoma (SCC)</div><div class=\"cntnt\"><img style=\"width:319px; height:396px;\" src=\"images/ONC/57360_T1_oral_tongue_SCC.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Neil D Gross, MD.</div><div id=\"graphicVersion\">Graphic 57360 Version 2.0</div></div></div>"},"57361":{"type":"graphic_table","displayName":"Age of fontanelle closure","title":"Age of fontanelle closure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Age of fontanelle closure</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Fontanelle</td>\n\n      <td class=\"subtitle1\">Closure</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Posterior</td>\n\n      <td>Two months</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Anterior lateral</td>\n\n      <td>Three months</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Posterior lateral</td>\n\n      <td>One year</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Anterior</td>\n\n      <td>Two years</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=49793&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Age_of_fontanelle_closure.htm</title></head></div><div id=\"graphicVersion\">Graphic 57361 Version 2.0</div></div></div>"},"57362":{"type":"graphic_picture","displayName":"ILS gross pathology","title":"Gross pathology of an intralobar pulmonary sequestration (ILS)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gross pathology of an intralobar pulmonary sequestration (ILS)</div><div class=\"cntnt\"><img style=\"width:263px; height:388px;\" src=\"images/PEDS/57362_ILS_gross_pathology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large distended systemic artery is present at one border (red arrow). A dilated, mucus filled bronchus (blue arrow) is evident adjacent to the artery. The lung parenchyma has a microcystic appearance, distinguishing it from the adjacent normal parenchyma.</div><div class=\"graphic_reference\">Courtesy of Claire Langston, MD and Christopher Oermann, MD.</div><div id=\"graphicVersion\">Graphic 57362 Version 3.0</div></div></div>"},"57363":{"type":"graphic_algorithm","displayName":"Management foreign body ingestion","title":"Algorithm for management of suspected foreign body ingestion in children","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Algorithm for management of suspected foreign body ingestion in children</div><div class=\"cntnt\"><img style=\"width:487px; height:659px;\" src=\"images/PEDS/57363_Manage_foreign_body_edt1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AP: anteroposterior; CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Mark Gilger, MD.</div><div id=\"graphicVersion\">Graphic 57363 Version 8.0</div></div></div>"},"57364":{"type":"graphic_figure","displayName":"Ovarian steroid biosynthesis","title":"Ovarian steroid biosynthetic pathways","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Ovarian steroid biosynthetic pathways</div><div class=\"cntnt\"><img style=\"width:560px; height:567px;\" src=\"images/PEDS/57364_Ovarian_steroid_biosynthesi.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Outline of the organization of the major steroid biosynthetic pathways in the small antral follicle of the ovary, depicted according to the two-gonadotropin, two-cell model of ovarian steroidogenesis. LH stimulates androgen formation within theca cells via the steroidogenic pathway common to the gonads and adrenal glands. FSH regulates estradiol biosynthesis from androgen by granulosa cells. Long-loop negative feedback of estradiol on gonadotropin secretion does not suppress LH at follicular phase levels of estradiol, nor do modest elevations of androgen suppress LH. Androgen formation in response to LH appears to be modulated by intraovarian feedback, mainly at the levels of 17-hydroxylase and 17, 20-lyase, both of which are activities of cytochrome P450c17. The quantitative importance of androstenedione formation from 17-hydroxyprogesterone (thin grey arrow) in the intact follicle is unknown. Androgens and estradiol inhibit (minus signs) and inhibin, insulin, and insulin-like growth factors (IGF) stimulate (plus signs) 17-hydroxylase and 17, 20-lyase activities. The steroidogenic enzymes appear in red.</div><div class=\"graphic_footnotes\">StAR: steroidogenic acute regulatory protein; scc: side chain cleavage; 3&beta;: &Delta; 5-isomerase-3&beta;-hydroxysteroid dehydrogenase; 17&beta;-HSD: 17&beta;-hydroxysteroid dehydrogenase types 1 and 5; 5&alpha;-R: 5&alpha;-reductase.</div><div class=\"graphic_reference\">Reproduced with permission from: Rosenfield RL. Ovarian and adrenal function in polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999; 28:265. Copyright &copy; 1999 WB Saunders.</div><div id=\"graphicVersion\">Graphic 57364 Version 4.0</div></div></div>"},"57365":{"type":"graphic_figure","displayName":"Taxonomy cereal grains","title":"Taxonomic relationships of major cereal grains","html":"<div class=\"graphic\"><div style=\"width: 573px\" class=\"figure\"><div class=\"ttl\">Taxonomic relationships of major cereal grains</div><div class=\"cntnt\"><img style=\"width:553px; height:530px;\" src=\"images/GAST/57365_Taxonomy_cereal_grains_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from: Kasarda DD. Nucleic acid (cDNA) and amino acid sequences of alpha-type gliadins from wheat (Triticum aestivum). Proc Natl Acad Sci U S A 1984; 81:4712.</div><div id=\"graphicVersion\">Graphic 57365 Version 3.0</div></div></div>"},"57366":{"type":"graphic_picture","displayName":"Burkitt lymphoma","title":"Burkitt lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Burkitt lymphoma</div><div class=\"cntnt\"><img style=\"width:349px; height:288px;\" src=\"images/HEME/57366_Burkitts_lymphoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel: Lymph node touch inprint from a patient with Burkitt lymphoma shows multiple small noncleaved cells with a thin rim of basophilic cytoplasm containing numerous vacuoles. The macrophage in the center (yellow arrow) contains abundant cellular debris (ie, tingible body macrophage). Right panel: Bone marrow from the same patient shows two small noncleaved cells with eccentric nuclei, a thin rim of basophilic cytoplasm, and vacuoles aggregated at one pole of the cell (red arrows).</div><div class=\"graphic_reference\">From Warnke RA, Weiss LM, Chan JK, Cleary ML, Dorfman RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 57366 Version 3.0</div></div></div>"},"57367":{"type":"graphic_figure","displayName":"Pulm embolism and air travel","title":"Incidence of pulmonary embolism according to distance traveled by air","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Incidence of pulmonary embolism according to distance traveled by air</div><div class=\"cntnt\"><img style=\"width:491px; height:402px;\" src=\"images/HEME/57367_Pulm_embolism_and_air_trave.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure indicates the incidence of pumonary embolism per <strong>million</strong> passenger arrivals, arranged according to flight distance in kilometers. Error bars indicate 95 percent confidence limits. To convert kilometers to miles, multiply by 0.62.</div><div class=\"graphic_reference\">Data from Lapastolle, F, et al. N Engl J Med 2001; 345:779.</div><div id=\"graphicVersion\">Graphic 57367 Version 1.0</div></div></div>"},"57368":{"type":"graphic_figure","displayName":"Benefit of supervised exercise therapy in claudication","title":"Benefit of supervised exercise therapy in claudication","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Benefit of supervised exercise therapy in claudication</div><div class=\"cntnt\"><img style=\"width:535px; height:395px;\" src=\"images/SURG/57368_Exercise_claudication_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ACD: absolute claudication distance; FCD: functional claudication distance.</div><div class=\"graphic_reference\">Data from: Nicolai, SP, Teijink, JA, Prins, MH, et al. Multicenter randomized clinical trial of supervised exercise therapy with or without feedback versus walking advice for intermittent claudication. J Vasc Surg 2010; 52:348.</div><div id=\"graphicVersion\">Graphic 57368 Version 3.0</div></div></div>"},"57369":{"type":"graphic_picture","displayName":"Peripheral IV placement 4","title":"Peripheral IV placement: Approach","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peripheral IV placement: Approach</div><div class=\"cntnt\"><img style=\"width:432px; height:288px;\" src=\"images/EM/57369_Peripheral_IV_placement_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Using your nondominant hand, stabilize the vein and area around the venipuncture site. Insert the needle at a shallow angle (approximately 10 to 30 degrees from the skin surface) to enter the vein.</div><div class=\"graphic_reference\">Courtesy of Robert Frank, MD.</div><div id=\"graphicVersion\">Graphic 57369 Version 2.0</div></div></div>"},"57370":{"type":"graphic_table","displayName":"Laboratory findings in catatonia","title":"Laboratory findings in catatonia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory findings in catatonia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Laboratory finding</td> <td class=\"subtitle1\">Implication</td> </tr> <tr> <td>Leukocytosis</td> <td>Non-specific; levels between 15,000 and 25,000 per mL correlate with malignant catatonia</td> </tr> <tr> <td>Increased creatinine kinase (CK)</td> <td>Non-specific; levels exceeding 1000 IU/L (normal range &#60;150 IU/L) strongly correlate with malignant catatonia</td> </tr> <tr> <td>Low serum iron</td> <td>Observed in 40 percent of persons with malignant catatonia</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:<br> <ol> <li>Northoff G, Wenke J, Pflug B. Increase of serum creatine phosphokinase in catatonia: an investigation in 32 acute catatonic patients. Psychol Med 1996; 26:547. </li> <li>Lee JW. Serum iron in catatonia and neuroleptic malignant syndrome. Biol Psychiatry 1998; 44:499. </li> <li>Carroll BT, Goforth HW. Serum iron in catatonia. Biol Psychiatry 1995; 38:776. </li> <li>Singerman B, Raheja R. Malignant catatonia - a continuing reality. Ann Clin Psychiatry 1994; 6:259. </li> </ol></div><div id=\"graphicVersion\">Graphic 57370 Version 1.0</div></div></div>"},"57371":{"type":"graphic_diagnosticimage","displayName":"Parasternal long view of normal heart","title":"Parasternal long view of normal heart","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Parasternal long view of normal heart</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/EM/57371_Parasternal_long_norm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image, obtained using a parasternal long view, shows normal anatomy.</div><div class=\"graphic_footnotes\">LV: left ventricle; RV: right ventricle.</div><div class=\"graphic_reference\">Courtesy of Greg Snead, MD.</div><div id=\"graphicVersion\">Graphic 57371 Version 3.0</div></div></div>"},"57375":{"type":"graphic_table","displayName":"Maintenance dose aminoglycoside","title":"Maintenance dose nomogram for traditional, intermittent dosing of gentamicin and tobramycin in adults*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Maintenance dose nomogram for traditional, intermittent dosing of gentamicin and tobramycin in adults*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Creatinine clearance<sup>&#182;</sup><br /> conventional unit (mL/minute)</td> <td class=\"subtitle1\">Creatinine clearance<sup>&#182;</sup><br /> SI unit (mL/second)</td> <td class=\"subtitle1\">Maintenance dose<br /> (% of loading dose<sup>&#916;</sup>)</td> <td class=\"subtitle1\">Dose interval<br /> (hours)</td> </tr> <tr> <td>&#62;90</td> <td>&#62;1.5</td> <td>84</td> <td>8</td> </tr> <tr> <td>80 to 90</td> <td>1.3 to 1.5</td> <td>80</td> <td>8</td> </tr> <tr> <td>70 to 79</td> <td>1.2 to &#60;1.3</td> <td>76</td> <td>8</td> </tr> <tr> <td>60 to 69</td> <td>1 to &#60;1.2</td> <td>84</td> <td>12</td> </tr> <tr> <td>50 to 59</td> <td>0.8 to &#60;1</td> <td>79</td> <td>12</td> </tr> <tr> <td>40 to 49</td> <td>0.7 to &#60;0.8</td> <td>72</td> <td>12</td> </tr> <tr> <td>30 to 39</td> <td>0.5 to &#60;0.7</td> <td>86</td> <td>24</td> </tr> <tr> <td>20 to 29</td> <td>0.33 to &#60;0.5</td> <td>75</td> <td>24 to 36</td> </tr> <tr> <td>&#60;20<sup>&#9674;</sup></td> <td>&#60;0.33<sup>&#9674;</sup></td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* For many patients, the preferred dosing strategy is extended-interval. Refer to the aminoglycosides topic discussion of selection of dosing strategy. Although the dosing adjustments listed in this table should be applicable for amikacin dosing, they have not been validated for use with that agent.<br />¶ Creatinine clearance may be estimated using the Cockcroft-Gault equation. Calculators for estimation of creatinine clearance are available in UpToDate.<br />Δ Loading dose recommendations are provided in a separate table.<br /><FONT class=lozenge>◊</FONT> When the creatinine clearance is below 20 mL/min, a loading dose is recommended with subsequent doses guided by monitoring of the serum aminoglycoside concentration.</div><div class=\"graphic_reference\">This table lists dosing adjustments recommended by UpToDate contributors based on pharmacokinetic data and institutional experience.</div><div id=\"graphicVersion\">Graphic 57375 Version 7.0</div></div></div>"},"57376":{"type":"graphic_table","displayName":"Kadish staging ONB","title":"Kadish staging of olfactory neuroblastomas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Kadish staging of olfactory neuroblastomas</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Definition</td> </tr> <tr> <td class=\"centered\">A</td> <td>Confined to nasal cavity</td> </tr> <tr> <td class=\"centered\">B</td> <td>Involves the nasal cavity and one or more paranasal sinuses</td> </tr> <tr> <td class=\"centered\">C</td> <td>Extending beyond the nasal cavity or paranasal sinuses</td> </tr> <tr> <td class=\"centered\">D</td> <td>Regional lymph node or distant metastasis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Kadish S, Goodman M, Wang CC, Cancer 1976; 37:1571.</div><div id=\"graphicVersion\">Graphic 57376 Version 3.0</div></div></div>"},"57379":{"type":"graphic_table","displayName":"Rx serious MSSA child","title":"Parenteral antimicrobial regimens for definitive treatment of bacteremia and other serious methicillin-susceptible <EM>Staphylococcus aureus</EM> infections outside the central nervous system in children older than 30 days","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Parenteral antimicrobial regimens for definitive treatment of bacteremia and other serious methicillin-susceptible <EM>Staphylococcus aureus</EM> infections outside the central nervous system in children older than 30 days</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Antimicrobial regimen</td> <td class=\"subtitle1\">Dose</td> </tr> <tr> <td rowspan=\"2\">Regimens of choice</td> <td> <p>Nafcillin* &#177;</p> <p>Gentamicin<sup>&#182;</sup></p> </td> <td> <p>Nafcillin: 150 to 200 mg/kg per day in 4 doses; maximum daily dose 12 g</p> <p>Gentamicin: 3 mg/kg per day in 3 doses for 5 days</p> </td> </tr> <tr> <td> <p>Oxacillin* &#177;</p> <p>Gentamicin<sup>&#182;</sup></p> </td> <td> <p>Oxacillin: 150 to 200 mg/kg per day in 4 doses; maximum daily dose 12 g</p> <p>Gentamicin: 3 mg/kg per day in 3 doses for 5 days</p> </td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Alternatives</td> <td>Cefazolin*</td> <td>100 mg/kg per day in 3 doses; maximum daily dose 6 g</td> </tr> <tr> <td>Clindamycin<sup>&#916;</sup></td> <td>40 mg/kg per day in 3 to 4 doses; maximum daily dose 2.7 g</td> </tr> <tr> <td>Vancomycin<sup>&#9674;</sup></td> <td>60 mg/kg per day in 4 doses; maximum daily dose 4 g</td> </tr> <tr> <td>Ampicillin-sulbactam<sup>&#167;</sup></td> <td>200 mg/kg of ampicillin component per day in 4 doses; maximum daily dose 8g</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Patients allergic to penicillins and cephalosporins should receive vancomycin for serious infection with methicillin-susceptible <EM>Staphylococcus aureus</EM> (MSSA). Clindamycin may be used if the organism is susceptible and the infection is not endovascular.<br />¶&nbsp;Gentamicin may be added for endocarditis, although there are no data from controlled trials to indicate that combination therapy is advantageous. It is recommended that both rifampin and gentamicin be added to nafcillin/oxacillin for MSSA prosthetic valve endocarditis. Consultation with an expert in infectious diseases may be warranted to determine which agent to use and duration of use.<br />Δ Clindamycin should only be used for patients with serious penicillin allergy and clindamycin-susceptible strain. It should not be used in patients with ongoing bacteremia or endocarditis.<br /><FONT class=lozenge>◊</FONT> Only for patients with allergy to penicillins and cephalosporins.<br />§ For polymicrobial infections that include MSSA.</div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Staphylococcal infections. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.715.&nbsp;</LI>&#xD;&#xA;<LI>American Academy of Pediatrics. Tables of antibacterial drug dosages. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.881. </LI></OL></div><div id=\"graphicVersion\">Graphic 57379 Version 5.0</div></div></div>"},"57380":{"type":"graphic_figure","displayName":"APOC countries in Africa","title":"African Programme for Onchocerciasis Control (APOC) and ex-Onchocerciasis Control Programme (OCP) countries","html":"<div class=\"graphic\"><div style=\"width: 591px\" class=\"figure\"><div class=\"ttl\">African Programme for Onchocerciasis Control (APOC) and ex-Onchocerciasis Control Programme (OCP) countries</div><div class=\"cntnt\"><img style=\"width:571px; height:640px;\" src=\"images/ID/57380_APOC_countries.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: World Health Organization. African Programme for Onchocerciasis Control (APOC). Available at: <a href=\"http://www.who.int/apoc/countries/en/\" target=\"_blank\">http://www.who.int/apoc/countries/en/</a>.</div><div id=\"graphicVersion\">Graphic 57380 Version 3.0</div></div></div>"},"57381":{"type":"graphic_figure","displayName":"Child insulin injection sites PI","title":"Where to give your child an insulin shot","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Where to give your child an insulin shot</div><div class=\"cntnt\"><img style=\"width:440px; height:559px;\" src=\"images/PI/57381_Child-insulin-injection-sites-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The shaded areas of the body (as shown above) can be used for insulin shots. You should change areas so that you don't give your child an insulin shot in the same part of the body each time. In children who are school-age and older, you can also give an insulin shot in the belly.</div><div id=\"graphicVersion\">Graphic 57381 Version 3.0</div></div></div>"},"57382":{"type":"graphic_algorithm","displayName":"Dx ileal pouch disorders","title":"Diagnostic algorithm of ileal pouch disorders","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Diagnostic algorithm of ileal pouch disorders</div><div class=\"cntnt\"><img style=\"width:458px; height:478px;\" src=\"images/GAST/57382_Dx_ileal_pouch_disorders.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Shen B, Remzi FH, Lavery IC, et al. A Proposed Classification of Ileal Pouch Disorders and Associated Complications After Restorative Proctocolectomy. Clin Gastroenterol Hepatol 2008; 6:145. Copyright ©2008 Elsevier.</div><div id=\"graphicVersion\">Graphic 57382 Version 3.0</div></div></div>"},"57384":{"type":"graphic_picture","displayName":"Myelofibrosis bone marrow","title":"Myelofibrosis bone marrow biopsy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Myelofibrosis bone marrow biopsy</div><div class=\"cntnt\"><img style=\"width:360px; height:241px;\" src=\"images/HEME/57384_Myelofibrosis_bone_marrow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow biopsy in myelofibrosis shows replacement of the marrow with fibrous tissue.</div><div class=\"graphic_reference\">Courtesy of Stanley L Schrier, MD.</div><div id=\"graphicVersion\">Graphic 57384 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal bone marrow biopsy at low power</div><div class=\"cntnt\"><img style=\"width:360px; height:239px;\" src=\"images/HEME/68384_Normal_bone_marrow_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of a normal bone marrow biopsy. The overall cellularity is between 30 and 70 percent, with the remainder of the space being occupied by fat and stroma.</div><div class=\"graphic_reference\">Courtesy of Stanley L Schrier, MD.</div><div id=\"graphicVersion\">Graphic 68384 Version 2.0</div></div></div>"},"57386":{"type":"graphic_picture","displayName":"Spurling maneuver","title":"Spurling maneuver to detect cervical radiculopathy","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Spurling maneuver to detect cervical radiculopathy</div><div class=\"cntnt\"><img style=\"width:470px; height:395px;\" src=\"images/PC/57386_Spurling_maneuver.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Spurling maneuver is used to detect cervical radiculopathy. Several positions of the head may be tested to provoke nerve irritation. First, the maneuver is performed with the head held in a neutral position. The examiner taps or presses down on the top of the head. If this fails to reproduce the patient's pain, the procedure is repeated with the head rotated to the affected side and hyperextended.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 57386 Version 3.0</div></div></div>"},"57387":{"type":"graphic_picture","displayName":"Vasculitic neuropathy","title":"Vasculitic neuropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vasculitic neuropathy</div><div class=\"cntnt\"><img style=\"width:376px; height:576px;\" src=\"images/RHEUM/57387_Vasculitic_neuropathy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Wasting of muscles of the left leg secondary to mononeuritis multiplex and nerve infarctions.</div><div class=\"graphic_reference\">Courtesy of John Stone, MD, MPH.</div><div id=\"graphicVersion\">Graphic 57387 Version 2.0</div></div></div>"},"57388":{"type":"graphic_picture","displayName":"Circinate balanitis in reactive arthritis","title":"Circinate balanitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Circinate balanitis</div><div class=\"cntnt\"><img style=\"width:432px; height:288px;\" src=\"images/DERM/57388_Circinate_balanitis_arth.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shallow erythematous erosions in a circinate distribution are present on the glans.</div><div class=\"graphic_reference\">Courtesy of Jeffrey Callen, MD, FACP.</div><div id=\"graphicVersion\">Graphic 57388 Version 2.0</div></div></div>"},"57390":{"type":"graphic_waveform","displayName":"ECG atrial tachycardia from pulmonary vein","title":"Electrocardiogram (ECG) showing atrial tachycardia originating from the left superior pulmonary vein.","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram (ECG) showing atrial tachycardia originating from the left superior pulmonary vein.</div><div class=\"cntnt\"><img style=\"width:492px; height:461px;\" src=\"images/CARD/57390_Atrial_tachycardia_ECG_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiographic tracing showing a narrow complex tachycardia with uniform P waves consistent with atrial tachycardia originating from the left superior pulmonary vein. The initial QRS complex shows a normal sinus beat, followed by the development of atrial tachycardia.</div><div class=\"graphic_reference\">Courtesy of Dr. Peter Kistler.</div><div id=\"graphicVersion\">Graphic 57390 Version 3.0</div></div></div>"},"57394":{"type":"graphic_table","displayName":"Congenital anomaly terminology","title":"Terms used to describe congenital abnormalities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Terms used to describe congenital abnormalities</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Term</td> <td class=\"subtitle1\">Definition</td> </tr> <tr> <td>Malformation</td> <td>Defects of organs or body parts due to an intrinsically abnormal developmental process</td> </tr> <tr> <td>Deformation</td> <td>Abnormalities of the position of body parts due to extrinsic intrauterine mechanical forces that modify a normally formed structure</td> </tr> <tr> <td>Disruption</td> <td>Defects of organs or body parts that result from destruction of or interference with normal vascular development</td> </tr> <tr> <td>Dysplasia</td> <td>Anomalies that result from the abnormal organization of cells into tissues</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 57394 Version 3.0</div></div></div>"},"57396":{"type":"graphic_picture","displayName":"Inferior segmental atrophy","title":"Inferior segmental optic disc atrophy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inferior segmental optic disc atrophy</div><div class=\"cntnt\"><img style=\"width:291px; height:349px;\" src=\"images/PEDS/57396_Inferior_segmental_atrophy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inferior segmental optic disc atrophy typical of previous ischemic insult.</div><div class=\"graphic_reference\">Courtesy of Karl C Golnik, MD.</div><div id=\"graphicVersion\">Graphic 57396 Version 1.0</div></div></div>"},"57398":{"type":"graphic_figure","displayName":"Ovarian cancer types pregnancy","title":"Proportion of histologic types of ovarian cancers among all patients compared to proportions in pregnant women","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Proportion of histologic types of ovarian cancers among all patients compared to proportions in pregnant women</div><div class=\"cntnt\"><img style=\"width:493px; height:381px;\" src=\"images/OBGYN/57398_Ovarian_cancer_types_pregna.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 57398 Version 1.0</div></div></div>"},"57399":{"type":"graphic_table","displayName":"Classification of AIHA","title":"Classification of autoimmune hemolytic anemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of autoimmune hemolytic anemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Warm-reactive AIHA</td> </tr> <tr> <td>Primary (idiopathic)*</td> </tr> <tr> <td> <p>Secondary<sup>&#182;</sup></p> <ul id=\"_telerik_insertedList_id\"> <li>Autoimmune or inflammatory disorders (eg, systemic lupus erythematosus, Sj&#246;gren syndrome, scleroderma,&nbsp;juvenile idiopathic&nbsp;arthritis, dermatomyositis, vitiligo, ulcerative colitis, autoimmune hepatitis, type 1 diabetes mellitus, autoimmune thyroiditis) </li> <li>​Evans syndrome </li> <li>Primary immunodeficiency (eg, common variable immune deficiency, Wiskott-Aldrich syndrome) </li> <li>Acquired immunodeficiency (eg, HIV) </li> <li>Malignancy (eg, acute leukemia, lymphoma) </li> <li>Infection<sup>&#916;</sup> </li> <li>Post-transplant </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Cold agglutinin disease</td> </tr> <tr> <td>Primary (idiopathic)*</td> </tr> <tr> <td> <p>Secondary<sup>&#182;</sup></p> <ul id=\"_telerik_insertedList_id\"> <li>​Infection (eg, Mycoplasma pneumoniae, EBV)<sup>&#916;</sup> </li> <li>Malignancy (eg, lymphoma) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Paroxysmal cold hemoglobinuria</td> </tr> <tr> <td>Primary (idiopathic)</td> </tr> <tr> <td>Post-infectious<sup>&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AIHA: autoimmune hemolytic anemia; HIV: human immunodeficiency anemia.<br />* Primary AIHA refers to disorders with only immune-mediated hemolytic anemia and no evidence of an underlying systemic disorder.<br />¶&nbsp;Secondary AIHA refers to disorders with immune-mediated hemolytic anemia in the presence of another condition. Common secondary causes are listed in this table. For further details, refer to UpToDate content on AIHA in children.<br />Δ Infectious and post-infectious causes of AIHA are most commonly associated with cold agglutinins disease and paroxysmal cold hemoglobinuria.</div><div id=\"graphicVersion\">Graphic 57399 Version 7.0</div></div></div>"},"57400":{"type":"graphic_table","displayName":"PMN granule contents","title":"Content of human neutrophil granules ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Content of human neutrophil granules </div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Granule</td> <td class=\"subtitle1\">Azurophil</td> <td class=\"subtitle1\">Specific</td> <td class=\"subtitle1\">Gelatinase</td> <td class=\"subtitle1\">Secretory vesicles</td> </tr> <tr> <td class=\"subtitle2_left topBorder_single\">Marker enzyme</td> <td>Myeloperoxidase</td> <td>Lactoferrin</td> <td>Gelantinase</td> <td>Alkaline phosphatase</td> </tr> <tr> <td class=\"subtitle3_left topBorder_single\" rowspan=\"2\">Membrane</td> <td class=\"topBorder_single\">CD63 granulophysin</td> <td class=\"topBorder_single\">CD15, CD66, CD67</td> <td class=\"topBorder_single\">CD11b/CD18</td> <td class=\"topBorder_single\">CD10, CD13, CD45,&nbsp;CD35 (CR1)</td> </tr> <tr> <td>CD68</td> <td>CD11b/CD18</td> <td>&nbsp;</td> <td>CD11b/CD18</td> </tr> <tr> <td class=\"indent2\" rowspan=\"9\">Oxidase receptors</td> <td rowspan=\"9\">&nbsp;&nbsp;</td> <td>Cytochrome b</td> <td>Cytochrome b&nbsp;</td> <td>Cytochrome b&nbsp;</td> </tr> <tr> <td>Rap1A</td> <td>Rap1A</td> <td>Rap1A</td> </tr> <tr> <td>fMLP R</td> <td>fMLP R</td> <td>fMLP R</td> </tr> <tr> <td>C3bi R</td> <td>C3bi R</td> <td>CR1</td> </tr> <tr> <td>Fibronectin R</td> <td rowspan=\"5\">&nbsp;</td> <td>C3bi R (CR3) </td> </tr> <tr> <td>Laminin R</td> <td>CR4</td> </tr> <tr> <td>Vitronectin R</td> <td>C1q R</td> </tr> <tr> <td rowspan=\"2\">&nbsp;</td> <td>Fc-gamma-RIII (CD16)</td> </tr> <tr> <td>Plasminogen activator R</td> </tr> <tr> <td class=\"indent2\" rowspan=\"2\">Signal transduction </td> <td>Thrombospondin R</td> <td rowspan=\"2\">Diacylglycerol deacylating enzyme</td> <td rowspan=\"2\">Decay-accelerating factor</td> <td rowspan=\"2\">&nbsp;</td> </tr> <tr> <td>Gi2 protein subunit</td> </tr> <tr> <td class=\"indent2\" rowspan=\"2\">Others</td> <td>Nb antigen</td> <td rowspan=\"2\">&nbsp;</td> <td rowspan=\"2\">&nbsp;</td> <td rowspan=\"2\">&nbsp;</td> </tr> <tr> <td>9 kd and 155 kd&nbsp;proteins</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Matrix</td> </tr> <tr> <td class=\"indent2\" rowspan=\"11\">Microbicidal</td> <td class=\"topBorder_single\">Myeloperoxidase</td> <td class=\"topBorder_single\">Lactoferrin</td> <td class=\"topBorder_single\">Lysozyme</td> <td class=\"topBorder_single\" rowspan=\"11\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td> </tr> <tr> <td>Nitric oxide&nbsp;synthase</td> <td>Lysozyme</td> <td rowspan=\"10\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td> </tr> <tr> <td>Lysozyme</td> <td rowspan=\"9\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td> </tr> <tr> <td>BPI protein</td> </tr> <tr> <td>Defensins</td> </tr> <tr> <td>Serprocidins</td> </tr> <tr> <td class=\"indent1\">Elastase</td> </tr> <tr> <td class=\"indent1\">Cathepsin G</td> </tr> <tr> <td class=\"indent1\">Proteinase 3</td> </tr> <tr> <td class=\"indent1\">Azurocidin</td> </tr> <tr> <td>(CAP37)</td> </tr> <tr> <td class=\"indent2\" rowspan=\"6\">Hydrolases</td> <td>Acid beta glycero-phosphatase alpha</td> <td>Gelatinase</td> <td>Gelatinase</td> <td rowspan=\"6\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td> </tr> <tr> <td>Mannosidase beta</td> <td>Collagenase</td> <td>Acetyltransferase</td> </tr> <tr> <td>Glucuronidase beta</td> <td>Histaminase</td> <td rowspan=\"4\">&nbsp;<br /> &nbsp;&nbsp;&nbsp;</td> </tr> <tr> <td>Glycerophosphatase</td> <td>Heparanase</td> </tr> <tr> <td>N-acetyl-beta&nbsp;glucosaminidase</td> <td>NGAL</td> </tr> <tr> <td>Sialidase</td> <td>Sialidase</td> </tr> <tr> <td class=\"indent2\" rowspan=\"3\">Other</td> <td>Acid mucopolysaccharide</td> <td>Beta-2 microglobulin</td> <td>Beta-2 microglobulin</td> <td>Plasma proteins</td> </tr> <tr> <td>Heparin-binding protein</td> <td>Plasminogen activator </td> <td rowspan=\"2\">&nbsp;&nbsp;</td> <td rowspan=\"2\">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>Vitamin B12 binding protein</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CD: cluster of differentiation; CR: complement receptor; Rap: Ras-related protein; fMLP: formyl-Methionyl-Leucyl-Phenylalanine; R: receptor; C3bi: complement protein fragment 3bi; C1q: complement 1 subcomponent q; Fc-gamma-RIII: low affinity receptor for the crystallizable fragment of immunoglobulin G; Gi2: guanosine nucleotide-binding regulatory protein i2; Nb: Nippostrongylus brasiliensis; kd: kilodalton; BPI: bactericidal/permeability-increasing; CAP37: cationic antimicrobial protein-37; NGAL: neutrophil gelatinase-associated lipocalin.</div><div class=\"graphic_reference\">Adapted from Borregaard N, Kledsen L, Lollike K, Sengelov H. Granules and secretory vesicles of the human neutrophil.&nbsp;Clin Exp Immunol 1995; 101:6.</div><div id=\"graphicVersion\">Graphic 57400 Version 5.0</div></div></div>"},"57401":{"type":"graphic_picture","displayName":"Pyoderma faciale","title":"Pyoderma faciale (rosacea fulminans)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pyoderma faciale (rosacea fulminans)</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/57401_Pyoderma_faciale.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An intensely inflammatory large plaque with pustules and sinus tracts is present on the cheek.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 57401 Version 3.0</div></div></div>"},"57402":{"type":"graphic_table","displayName":"Diagnostic pemphigoid testing","title":"Diagnostic pemphigoid testing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic pemphigoid testing</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Specimen</td> <td class=\"subtitle1\">Site</td> <td class=\"subtitle1\">Procedure</td> <td class=\"subtitle1\">Transport</td> </tr> <tr class=\"divider_bottom\"> <td>Histology (H&#38;E)</td> <td>Skin or mucous membrane</td> <td>Lesional or part lesional</td> <td>At least 4 mm punch biopsy* <ul class=\"decimal_heading\"> <li>Specimen should contain intact epidermis/epithelium, basement membrane zone, and upper dermis/subepithelium </li> <li>Avoid torsion and crushing to prevent separation artifact </li> </ul> </td> <td>In <strong>formalin</strong> to a dermatopathology laboratory</td> </tr> <tr class=\"divider_bottom\"> <td>Direct immunofluorescence</td> <td>Skin or mucous membrane</td> <td>Perilesional <ul class=\"decimal_heading\"> <li>For cutaneous lesions, an erythematous or urticarial area next to a blister from a proximal anatomical location is ideal </li> <li>For mucous membrane lesions, avoid areas of scarring; since perilesional tissue may be friable, normal-appearing epithelium may be obtained </li> </ul> </td> <td>At least 4 mm punch biopsy* <ul class=\"decimal_heading\"> <li>Specimen should contain intact epidermis/epithelium, basement membrane zone, and upper dermis/subepithelium </li> <li>Avoid torsion and crushing to prevent separation artifact </li> </ul> </td> <td>In <strong>Michel's or Zeus medium</strong> to an immunodermatology laboratory<sup>&#916;</sup></td> </tr> <tr> <td>Indirect immunofluorescence and ELISA</td> <td>Serum</td> <td>Peripheral blood</td> <td>At least 5 mL of blood by venipuncture in serum tube (red top, NO anticoagulant); separate serum from clot and send serum<sup>&#9674;</sup></td> <td>In <strong>serum tube</strong> to an immunodermatology laboratory</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">If questions about specimen site selection or acceptable specimen handling conditions, contact an immunodermatology laboratory.</div><div class=\"graphic_footnotes\">H&amp;E: hematoxylin and eosin pathology stain; ELISA: enzyme-linked immunosorbent assay.<br />* An alternative to two biopsies, one each for H&amp;E and direct immunofluorescence, as indicated above, is to obtain one 5 or 6 mm punch biopsy or one deep shave biopsy specimen that contains both lesional and perilesional tissue. The specimen is split into two pieces with a scalpel. Care should be taken to avoid disrupting the epidermis or crushing the specimen during splitting. The lesional portion is placed in formalin for H&amp;E histology and the perilesional portion is placed in Michel's or Zeus transport medium for direct immunofluorescence.<br />&Delta; Some immunodermatology laboratories will accept tissue on saline-saturated gauze if it is transported to the laboratory within six hours (the sooner the better and to be received during working hours) and will also accept tissue specimens flash frozen in liquid nitrogen and transported on dry ice.<br /><span class=\"lozenge\">&loz;</span> The serum can be separated without a centrifuge by allowing whole blood to clot in a tube for 1/2 hour to 2 hours. The serum on top of the clotted blood is then carefully transferred into a serum tube with a disposable pipette and sent to an immunodermatology laboratory. Alternatively, some immunodermatology laboratories accept whole blood if it is transported to the laboratory promptly (within six hours).</div><div id=\"graphicVersion\">Graphic 57402 Version 3.0</div></div></div>"},"57403":{"type":"graphic_table","displayName":"TTS endoclips","title":"Through-the-scope endoclips","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Through-the-scope endoclips</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Manufacturer</td> <td class=\"subtitle1\">Name</td> <td class=\"subtitle1\">Open clip size (mm)</td> <td class=\"subtitle1\">Minimum endoscope channel size (mm)</td> <td class=\"subtitle1\">Special characteristics</td> <td class=\"subtitle1\">MRI compatibility</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Olympus</td> <td>QuickClip2</td> <td>8</td> <td>2.8</td> <td>Rotatable. Available in 165 cm and 230 cm lengths.</td> <td>Not compatible</td> </tr> <tr class=\"divider_bottom\"> <td>QuickClip2Long</td> <td>12</td> <td>2.8</td> <td>Rotatable. Available in 165 cm and 230 cm lengths.</td> <td>Not compatible</td> </tr> <tr class=\"divider_bottom\"> <td>Boston Scientific</td> <td>Resolution</td> <td>11</td> <td>2.8</td> <td>Jaws can be re-opened to reposition. Available in 165 cm and 235 cm lengths.</td> <td>Conditional approval</td> </tr> <tr> <td rowspan=\"3\">Cook Medical</td> <td>Instinct</td> <td>16</td> <td>2.8</td> <td>Rotatable. Jaws can be re-opened to reposition.</td> <td>Conditional approval</td> </tr> <tr> <td>TriClip</td> <td>12</td> <td>2.8</td> <td>&nbsp;</td> <td>Not compatible</td> </tr> <tr> <td>TriClip</td> <td>12</td> <td>3.2</td> <td>Integrated flush port.</td> <td>Not compatible</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Dennis M Jensen, MD.</div><div id=\"graphicVersion\">Graphic 57403 Version 4.0</div></div></div>"},"57406":{"type":"graphic_picture","displayName":"Complex endometrial hyperplasia","title":"Complex endometrial hyperplasia","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Complex endometrial hyperplasia</div><div class=\"cntnt\"><img style=\"width:504px; height:375px;\" src=\"images/OBGYN/57406_Complex_hyperplasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Silverberg SG, Kurman RJ. Tumors of the Uterine Corpus and Gestational Trophoblastic Disease. AFIP Atlas of Tumor Pathology, version 2.0, American Registry of Pathology, Washington DC 1995.</div><div id=\"graphicVersion\">Graphic 57406 Version 3.0</div></div></div>"},"57407":{"type":"graphic_table","displayName":"Metabolic causes hydrops","title":"Metabolic causes of hydrops","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Metabolic causes of hydrops</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Mucopolysaccharidosis type VII (MPS VII, Sly disease)</td> </tr> <tr> <td>Mucopolysaccharidosis type IVA (MPS IVA, Morquio type A)</td> </tr> <tr> <td>Mucolipidosis I (sialidosis)</td> </tr> <tr> <td>Mucolipidosis II (I-cell disease)</td> </tr> <tr> <td>Gaucher disease</td> </tr> <tr> <td>Niemann-Pick C</td> </tr> <tr> <td>Farber disease</td> </tr> <tr> <td>GM1 gangliosidosis</td> </tr> <tr> <td>Sialic acid storage disease</td> </tr> <tr> <td>Primary carnitine deficiency</td> </tr> <tr> <td>Fumarase deficiency</td> </tr> <tr> <td>Respiratory chain disorders</td> </tr> <tr> <td>Congenital disorders of glycosylation</td> </tr> <tr> <td>Neonatal haemochromatosis</td> </tr> <tr> <td>Zellweger</td> </tr> <tr> <td>Glycogen storage disease type IV (GSD IV)</td> </tr> <tr> <td>Deficiencies of red cell glycolytic/pentose phosphate pathway enzymes (eg, G6PDH deficiency, pyruvate kinase deficiency)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GM1: monosialotetrahexosylganglioside; G6PDH: glucose-6-phosphate dehydrogenase.</div><div class=\"graphic_reference\">Courtesy of V Reid Sutton, MD.</div><div id=\"graphicVersion\">Graphic 57407 Version 5.0</div></div></div>"},"57408":{"type":"graphic_table","displayName":"Ophthalmologic dilating agents abusive head trauma","title":"Dilating drops recommended for fundus examination for abusive head injury (shaken baby syndrome)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dilating drops recommended for fundus examination for abusive head injury (shaken baby syndrome)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Name</td> <td class=\"subtitle1\">Efficacy/advantages</td> <td class=\"subtitle1\">Duration of large pupil*</td> <td class=\"subtitle1\">Disadvantages</td> </tr> <tr> <td>Tropicamide 1/2 or 1 percent</td> <td>Good in less pigmented eyes</td> <td>4 to 6 hours</td> <td>Works less well in brown eyes</td> </tr> <tr> <td>Cyclopentolate 1/2 or 1 percent</td> <td>Good in all eyes</td> <td>1 to 2 days</td> <td>Long duration 2 percent solution can cause hallucinations</td> </tr> <tr> <td>Phenylephrine 2.5 percent</td> <td> <p>Poor by itself</p> Very helpful combined with tropicamide or cyclopentolate</td> <td>3 to 4 hours</td> <td> <p>Systemic hypertension in higher strengths</p> Used alone, pupil still constricts during examination</td> </tr> <tr> <td>Cyclomydril (0.2 percent cyclopentolate and 1 percent phenylephrine, Alcon Laboratories)</td> <td> <p>Good in less pigmented eyes</p> <p>Commonly used for ROP examinations</p> Convenient combination drop</td> <td>3 to 4 hours</td> <td>Often needs to be repeated for darker eyes</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ROP: retinopathy of prematurity.<br />* Repeat dosage will prolong duration by up to 50 percent.</div><div class=\"graphic_reference\">Reproduced with permission from: Kivlin JD. Ophthalmic manifestations of shaken baby syndrome. Journal of Aggression, Maltreatment &amp; Trauma 2001; 5:137. &copy; 2001 The Haworth Press, Inc.</div><div id=\"graphicVersion\">Graphic 57408 Version 6.0</div></div></div>"},"57411":{"type":"graphic_figure","displayName":"Right winged scapula","title":"Right winged scapula","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Right winged scapula</div><div class=\"cntnt\"><img style=\"width:504px; height:395px;\" src=\"images/EM/57411_Rightwingedscapula.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF, Agur AMR. Clinically Oriented Anatomy, 7th Edition. Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 57411 Version 9.0</div></div></div>"},"57412":{"type":"graphic_picture","displayName":"Nevus central hyperpigmentation","title":"Dermoscopic image of a nevus with a peripheral reticular and central hyperpigmented pattern","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of a nevus with a peripheral reticular and central hyperpigmented pattern</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/57412_Nevus_central_hyperpigment.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 57412 Version 3.0</div></div></div>"},"57414":{"type":"graphic_picture","displayName":"Erythema migrans uniform","title":"Erythema migrans lesion with uniform erythema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema migrans lesion with uniform erythema</div><div class=\"cntnt\"><img style=\"width:300px; height:238px;\" src=\"images/PEDS/57414_Erythema_migrans_uniform.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema migrans lesion with uniform erythema. Note that the lesion is not a perfect circle.</div><div class=\"graphic_reference\">Courtesy of Eugene D Shapiro, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 57414 Version 1.0</div></div></div>"},"57415":{"type":"graphic_picture","displayName":"Anterior laryngeal web","title":"Anterior laryngeal web (type 3 laryngeal atresia)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior laryngeal web (type 3 laryngeal atresia)</div><div class=\"cntnt\"><img style=\"width:363px; height:270px;\" src=\"images/PEDS/57415_Laryngeal_atresia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A perforated membrane (*) partially obstructs the glottis (G).</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 57415 Version 3.0</div></div></div>"},"57416":{"type":"graphic_table","displayName":"PERT preparations","title":"Oral preparations for pancreatic enzyme replacement therapy (PERT)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oral preparations for pancreatic enzyme replacement therapy (PERT)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup width=\"25%\"></colgroup><colgroup span=\"3\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Pancrelipase preparations<br /> (US trade name)</td> <td class=\"subtitle1\">Description and US manufacturer<br /> (see NOTE)</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Lipase<br /> (USP units)</td> <td class=\"subtitle1\">Amylase<br /> (USP units)</td> <td class=\"subtitle1\">Protease<br /> (USP units)</td> </tr> <tr> <td>Pancreaze 2600</td> <td class=\"divider_bottom\" rowspan=\"5\">Delayed release capsule containing enteric coated microtablets, porcine origin.(Janssen Pharmaceuticals, Inc)</td> <td class=\"divider_bottom\" rowspan=\"17\"> <p>Applies to Pancreaze, Creon, Zenpep:</p> <p>Preparation is suitable&nbsp;for use in adults, children, and infants.</p> <p>Swallow capsules whole or sprinkle capsule contents on small amount of acidic soft food with pH of 4.5 or less (eg, applesauce, yogurt, commercially prepared bananas or pears), consume immediately and follow with water, juice, or other liquid. Do not crush or chew capsule shell or contents.</p> <p>For infants, contents of the capsule may also be administered directly into the mouth followed by breast milk or formula.*</p> </td> <td>2600</td> <td>10,850</td> <td>6200</td> </tr> <tr> <td>Pancreaze 4200</td> <td>4200</td> <td>17,500</td> <td>10,000</td> </tr> <tr> <td>Pancreaze 10,500</td> <td>10,500</td> <td>43,750</td> <td>25,000</td> </tr> <tr> <td>Pancreaze 16,800</td> <td>16,800</td> <td>70,000</td> <td>40,000</td> </tr> <tr class=\"divider_bottom\"> <td>Pancreaze 21,000</td> <td>21,000</td> <td>61,000</td> <td>37,000</td> </tr> <tr> <td>Creon 3</td> <td class=\"divider_bottom\" rowspan=\"5\"> <p>Delayed release capsule containing enteric coated mini-microspheres, porcine origin.</p> (AbbVie, Inc)</td> <td>3000</td> <td>15,000</td> <td>9500</td> </tr> <tr> <td>Creon 6</td> <td>6000</td> <td>30,000</td> <td>19,000</td> </tr> <tr> <td>Creon 12</td> <td>12,000</td> <td>60,000</td> <td>38,000</td> </tr> <tr> <td>Creon 24</td> <td>24,000</td> <td>120,000</td> <td>76,000</td> </tr> <tr class=\"divider_bottom\"> <td>Creon 36</td> <td>36,000</td> <td>180,000</td> <td>114,00</td> </tr> <tr> <td>Zenpep 3</td> <td class=\"divider_bottom\" rowspan=\"7\"> <p>Delayed release capsule containing enteric coated beads, porcine origin.</p> (Aptalis Pharma)</td> <td>3000</td> <td>16,000</td> <td>10,000</td> </tr> <tr> <td>Zenpep 5</td> <td>5000</td> <td>27,000</td> <td>17,000</td> </tr> <tr> <td>Zenpep 10</td> <td>10,000</td> <td>55,000</td> <td>34,000</td> </tr> <tr> <td>Zenpep 15</td> <td>15,000</td> <td>82,000</td> <td>51,000</td> </tr> <tr> <td>Zenpep 20</td> <td>20,000</td> <td>109,000</td> <td>68,000</td> </tr> <tr> <td>Zenpep 25&nbsp;</td> <td>25,000&nbsp;</td> <td>136,000&nbsp;</td> <td>85,000&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Zenpep 40</td> <td>40,000</td> <td>218,000</td> <td>136,000</td> </tr> <tr> <td>Ultresa 13,800</td> <td class=\"divider_bottom\" rowspan=\"3\"> <p>Delayed release capsule containing enteric coated minitablets, porcine origin.</p> (Aptalis Pharma)</td> <td class=\"divider_bottom\" rowspan=\"3\"> <p>Not recommended for infants or children aged &#60;4 years who weigh less than 14 kg.</p> Swallow capsules whole or sprinkle capsule contents on small amount of acidic soft food with pH of 4.5 or less (eg, applesauce, yogurt, commercially prepared bananas or pears), consume immediately and follow with water, juice, or other liquid. Do not crush or chew capsule shell or contents.</td> <td>13,800</td> <td>27,600</td> <td>27,600</td> </tr> <tr> <td>Ultresa 20,700</td> <td>20,700</td> <td>41,400</td> <td>41,400</td> </tr> <tr class=\"divider_bottom\"> <td>Ultresa 23,000</td> <td>23,000</td> <td>46,000</td> <td>46,000</td> </tr> <tr> <td>Viokace 10,440</td> <td class=\"divider_bottom\" rowspan=\"2\"> <p>Regular release (NON enteric coated) tablet, porcine origin.</p> (Aptalis Pharma)</td> <td class=\"divider_bottom\" rowspan=\"2\"> <p>Only indicated for use in adult patients also treated with a proton pump inhibitor.</p> <p>Swallow tablets whole with sufficient liquid. Do not crush or chew.</p> Preparation is not suited for infants or children who do not readily swallow whole pills.</td> <td>10,440</td> <td>39,150</td> <td>39,150</td> </tr> <tr class=\"divider_bottom\"> <td>Viokace 20,880</td> <td>20,880</td> <td>78,300</td> <td>78,300</td> </tr> <tr> <td>Pertzye 4</td> <td rowspan=\"3\"> <p>Delayed release capsule containing bicarbonate buffered enteric coated microspheres.</p> (Digestive Care, Inc)</td> <td rowspan=\"3\"> <p>Preparation is suitable for use in adults, children, and infants.</p> <p>Swallow capsules whole or sprinkle capsule contents on small amount of acidic soft food with pH of 4.5 or less (eg, applesauce, yogurt, commercially prepared bananas or pears), consume immediately and follow with water, juice, formula, or breast milk as appropriate. Do not crush or chew capsule shell or contents. Do not mix contents of capsule in formula or breast milk.</p> </td> <td>4000</td> <td>15,125</td> <td>14,375</td> </tr> <tr> <td>Pertzye 8</td> <td>8000</td> <td>30,250</td> <td>28,750</td> </tr> <tr> <td>Pertzye 16</td> <td>16,000</td> <td>60,500</td> <td>57,500</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table shows USP (US pharmacopeial) units of enzyme activity for product brands available in the United States. Individual product contents, preparation type, and units of activity vary by country. The units of activity used in other countries are not equivalent to the USP units shown in this table (unless the data are specifically given as USP units). Consult local prescribing information before use or changing products.<br /><strong>NOTE: Products are not equivalent to one another and are not automatically interchangeable with any other pancreatic enzyme replacement product.</strong></div><div class=\"graphic_footnotes\">* Care should be taken to be sure that the&nbsp;capsule contents (pellets)&nbsp;are not crushed or retained in the mouth, to avoid irritation of the oral mucosa.&nbsp;Do not mix directly into infant formula or breast milk, as this may diminish efficacy. </div><div class=\"graphic_reference\">Data from: US licensed prescribing information accessed on October 21, 2016, at <a href=\"http://dailymed.nlm.nih.gov/dailymed/about.cfm\" target=\"_blank\">http://dailymed.nlm.nih.gov/dailymed/about.cfm</a>.</div><div id=\"graphicVersion\">Graphic 57416 Version 24.0</div></div></div>"},"57419":{"type":"graphic_table","displayName":"MHC class II deficiency","title":"Diagnostic criteria for MHC class II deficiency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for MHC class II deficiency</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Definitive diagnosis*</td> </tr> <tr> <td>Male or female patient with decreased intensity of expression (less than 5% of normal) of HLA-DR or DP on B cells or monocytes and a mutation in one of the following genes: <em>CIITA</em>, <em>RFXB</em>, <em>RFX5</em>, or <em>RFXAP</em>.</td> </tr> <tr> <td class=\"subtitle1_single\">Probable diagnosis</td> </tr> <tr> <td class=\"sublist1_start\">Male or female patient with decreased intensity of expression (less than 5% of normal) of HLA-DR or DP on B cells and monocytes and all of the following:</td> </tr> <tr> <td class=\"sublist1\">1. Failure to thrive, opportunistic infections, or persistent viral infections.</td> </tr> <tr> <td class=\"sublist1\">2. Normal numbers of T cells and B cells.</td> </tr> <tr> <td class=\"sublist1\">3. Normal proliferative responses to mitogens.</td> </tr> <tr> <td class=\"subtitle1_single\">Possible diagnosis*</td> </tr> <tr> <td class=\"sublist1_start\">Male or female patient with decreased intensity of expression (less than 5% of normal) of HLA-DR or DP on B cells or monocytes, and normal numbers of T cells and B cells, who has at least one of the following:</td> </tr> <tr> <td class=\"sublist1\">1. Hypogammaglobulinemia.</td> </tr> <tr> <td class=\"sublist1\">2. Normal mitogen responses but absent T cell proliferation to antigens.</td> </tr> <tr> <td class=\"sublist1\">3. Reduced numbers of CD4+ cells.</td> </tr> <tr> <td class=\"sublist1\">4. Failure of mononuclear cells to stimulate a mixed lymphocyte culture.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HLA: human leukocyte antigen; CIITA: class II transactivator; <EM innerHtml>RFXB</EM>: regulatory factor X, B; <EM innerHtml>RFX5</EM>: regulatory factor X, 5; <EM innerHtml>RFXAP</EM>: regulatory factor X-associated protein.<br />* Patients with a definitive or probable diagnosis are assumed to have a greater than 98 and 85% probability, respectively, that in 20 years they will still have the same diagnosis. Patients with a possible diagnosis are those that have some but not all of the characteristic clinical or laboratory findings of a particular disorder.</div><div class=\"graphic_reference\">From Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 1999; 93:190.</div><div id=\"graphicVersion\">Graphic 57419 Version 2.0</div></div></div>"},"57420":{"type":"graphic_diagnosticimage","displayName":"Ectop preg hemoperit Doppl","title":"Ectopic pregnancy with hemoperitoneum (Doppler color ultrasound)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ectopic pregnancy with hemoperitoneum (Doppler color ultrasound)</div><div class=\"cntnt\"><img style=\"width:354px; height:262px;\" src=\"images/OBGYN/57420_Ectop_preg_hemoperit_Doppl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal imaging of the adnexa was limited in this patient due to the presence of hemoperitoneum. Color Doppler assisted in identifying the site of ectopic pregnancy (E) in this patient.</div><div class=\"graphic_reference\">Courtesy of Tejas S Mehta, MD, MPH.</div><div id=\"graphicVersion\">Graphic 57420 Version 2.0</div></div></div>"},"57421":{"type":"graphic_figure","displayName":"Retaining ovary at hysterectomy","title":"Hysterectomy without oophorectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hysterectomy without oophorectomy</div><div class=\"cntnt\"><img style=\"width:355px; height:362px;\" src=\"images/OBGYN/57421_Retaining_ovary_at_hysterec.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clamp placement when the ovaries are to be retained.</div><div id=\"graphicVersion\">Graphic 57421 Version 1.0</div></div></div>"},"57422":{"type":"graphic_table","displayName":"Acute porphyrias drug interactions","title":"Examples of drugs known to be safe or unsafe in the acute porphyrias","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of drugs known to be safe or unsafe in the acute porphyrias</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"3\">Safe</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Acetaminophen (paracetamol)</p> <p>Aminoglycosides</p> <p>Anesthetic (eg, propofol)</p> <p>Antiemetics* (ondansetron); refer to note</p> <p>Aspirin</p> <p>Atropine</p> Benzodiazepines<sup>&#182;</sup> (eg, lorazepam, midazolam); refer to note</td> <td> <p>Cephalosporins; refer to note</p> <p>Erythropoietin<sup>&#916;</sup></p> <p>Gabapentin</p> <p>Glucocorticoids</p> <p>Histamine<sub>2</sub> receptor antagonists<sup>&#916;</sup> (eg, cimetidine, famotidine, ranitidine)</p> <p>Insulin</p> Levetiracetam</td> <td> <p>Local anesthetics<sup>&#182;</sup> (eg, lidocaine, bupivacaine)</p> <p>Opioid analgesics<sup>&#182;</sup></p> <p>Penicillin and derivatives</p> <p>Phenothiazines (eg, chlorpromazine, prochlorperazine, promethazine)</p> <p>Proton pump inhibitors (eg, lansoprazole, omeprazole, pantoprazole)</p> Vigabatrin</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"3\">Unsafe</td> </tr> <tr> <td class=\"indent1\"> <p>Alcohol</p> <p>Anesthetics<sup>&#182;</sup> (eg, etomidate, ketamine, thiopental)</p> <p>Antipyrine (phenazone)</p> <p>Barbiturates<sup>&#916;</sup></p> <p>Carbamazepine<sup>&#916;</sup></p> <p>Carisoprodol<sup>&#916;</sup></p> <p>Clonazepam (high doses)</p> <p>Danazol<sup>&#916;</sup></p> <p>Diclofenac<sup>&#916;</sup> and possibly other NSAIDs</p> <p>Efavirenz</p> <p>Ergot derivatives (including dihydroergotamine)</p> Estrogens<sup>&#916;</sup></td> <td> <p>Ethosuximide and methsuximide</p> <p>Griseofulvin<sup>&#916;</sup></p> <p>Hydralazine</p> <p>Hydroxyzine</p> <p>Meprobamate<sup>&#916;</sup></p> <p>Nifedipine</p> <p>Nitrofurantoin</p> <p>Oxcarbazepine</p> <p>Pentazocine</p> <p>Phenytoin<sup>&#916;</sup></p> Phenobarbital<sup>&#916;</sup></td> <td> <p>Primidone<sup>&#916;</sup></p> <p>Progesterone and synthetic progestins<sup>&#916;</sup></p> <p>Pyrazinamide<sup>&#916;</sup></p> <p>Rifampin<sup>&#916;</sup></p> <p>Spironolactone</p> <p>Sulfasalazine</p> <p>Sulfonamide antibiotics<sup>&#916;</sup> (including trimethoprim-sulfamethoxazole [cotrimoxazole])</p> <p>Tamoxifen</p> <p>Topiramate</p> Valproic acid<sup>&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table includes examples of commonly used drugs known to be safe or unsafe in the acute porphyrias (ie, porphyrias associated with acute neurovisceral attacks).<br />NOTE: <strong>This list is incomplete and includes drugs for which there is general agreement among experts.</strong> It is recommended that clinicians consult the websites of the <a href=\"http://www.porphyriafoundation.com/\" target=\"_blank\">American Porphyria Foundation</a> and the <a href=\"http://www.porphyria-europe.com/\" target=\"_blank\">European Porphyria Network</a>, which are frequently updated; list many other drugs, including those that are not classified with certainty; and provide evidence for these classifications. Because the evidence base is inadequate, expert assessments of the safety of drugs in porphyria may differ. Refer to the UpToDate topics on individual porphyrias for more information.</div><div class=\"graphic_footnotes\">NSAIDs: nonsteroidal anti-inflammatory drugs.<br />* Serotonin 5HT3 antagonists are probably safe. Classification of metoclopramide is controversial but is generally a less effective antiemetic.<br />¶ Not all agents within the same class will necessarily have the same risk. For example, though opioids are generally considered safe, pentazocine may be unsafe. Benzodiazepines that are rapidly metabolized or administered in low doses are considered safe, but the safety of high doses or prolonged use of long-acting agents is less certain. There are conflicting reports on the safety of cephalosporins.<br />Δ In United States labeling for these drugs, porphyria is listed as a contraindication, warning, precaution, or adverse effect. Erythropoietin and ranitidine are regarded as safe by other sources. Estrogens are unsafe for porphyria cutanea tarda but can be used with caution in the acute porphyrias, especially in low doses or by the transdermal route.</div><div class=\"graphic_reference\">Adapted from: Anderson KE, Bloomer JR, Bonkovsky HL, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 2005; 142:439.</div><div id=\"graphicVersion\">Graphic 57422 Version 17.0</div></div></div>"},"57423":{"type":"graphic_figure","displayName":"Sickle endothelial interactions","title":"Model of sickle cell-endothelial cell adhesion","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Model of sickle cell-endothelial cell adhesion</div><div class=\"cntnt\"><img style=\"width:540px; height:334px;\" src=\"images/HEME/57423_Sickle_endothelial_interact.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sickle red cells (RBCs) are shown here as red biconcave ovals and the vascular endothelium as a layer of gray elongated flat cells. Three steps of adhesion are shown: (A) Initial contact, (B) Rolling adhesion, and (C) Firm adhesion. Initial contact of sickle RBCs with endothelium is through binding of an erythroid P-selectin ligand with endothelial cell P-selectin. The interaction of E-selectin with a sialylated carbohydrate RBC ligand also participates in initial adhesion. These same molecules that initially slow flowing sickle cells also mediate their rolling along the vascular wall. Several ligand-receptor cognate pairs are involved in firm adhesion, which creates an adhesive nidus behind which rigid, sickled RBCs become trapped. Some of these are shown in this diagram. CD36 on the sickle RBC binds to alphaVbeta3 integrin on the endothelial cell by using plasma thrombospondin (TSP) as a bridging molecule. The RBC integrin alpha4beta1 binds directly to vascular cell adhesion molecule-1 (VCAM-1). Activated endothelial cells express alpha5beta1 and additional alphaVbeta3 to which sickle cells stick. Gaps are created between activated endothelial cells, which expose adhesive subendothelial matrix proteins (laminin, TSP, von Willebrand Factor) that also bind sickle cells.</div><div id=\"graphicVersion\">Graphic 57423 Version 1.0</div></div></div>"},"57424":{"type":"graphic_table","displayName":"Headache triggers","title":"Headache triggers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Headache triggers</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Diet</td> </tr> <tr> <td class=\"indent1\">Alcohol</td> </tr> <tr> <td class=\"indent1\">Chocolate</td> </tr> <tr> <td class=\"indent1\">Aged cheeses</td> </tr> <tr> <td class=\"indent1\">Monosodium glutamate</td> </tr> <tr> <td class=\"indent1\">Aspartame</td> </tr> <tr> <td class=\"indent1\">Caffeine</td> </tr> <tr> <td class=\"indent1\">Nuts</td> </tr> <tr> <td class=\"indent1\">Nitrites, nitrates</td> </tr> <tr> <td class=\"subtitle1_single\">Hormones</td> </tr> <tr> <td class=\"indent1\">Menses</td> </tr> <tr> <td class=\"indent1\">Ovulation</td> </tr> <tr> <td class=\"indent1\">Hormone replacement (progesterone)</td> </tr> <tr> <td class=\"subtitle1_single\">Sensory stimuli</td> </tr> <tr> <td class=\"indent1\">Strong light</td> </tr> <tr> <td class=\"indent1\">Flickering lights</td> </tr> <tr> <td class=\"indent1\">Odors</td> </tr> <tr> <td class=\"indent1\">Sounds, noise</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Stress</td> </tr> <tr> <td class=\"indent1\">Let-down periods</td> </tr> <tr> <td class=\"indent1\">Times of intense activity</td> </tr> <tr> <td class=\"indent1\">Loss or change (death, separation, divorce, job change)</td> </tr> <tr> <td class=\"indent1\">Moving</td> </tr> <tr> <td class=\"indent1\">Crisis</td> </tr> <tr> <td class=\"subtitle1_single\">Changes of environment or habits</td> </tr> <tr> <td class=\"indent1\">Weather</td> </tr> <tr> <td class=\"indent1\">Travel (crossing time zones)</td> </tr> <tr> <td class=\"indent1\">Seasons</td> </tr> <tr> <td class=\"indent1\">Altitude</td> </tr> <tr> <td class=\"indent1\">Schedule changes</td> </tr> <tr> <td class=\"indent1\">Sleeping patterns</td> </tr> <tr> <td class=\"indent1\">Dieting</td> </tr> <tr> <td class=\"indent1\">Skipping meals</td> </tr> <tr> <td class=\"indent1\">Irregular physical activity</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 57424 Version 4.0</div></div></div>"},"57425":{"type":"graphic_picture","displayName":"Metatarsus adductus","title":"Metatarsus adductus (medial deviation of the forefoot)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Metatarsus adductus (medial deviation of the forefoot)</div><div class=\"cntnt\"><img style=\"width:216px; height:288px;\" src=\"images/PEDS/57425_Metatarsus_adductus.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Hart ES. Pediatric Orthopaedic Ailments. Department of Pediatric Orthopaedics, Massachusetts General Hospital. Available at: www2.massgeneral.org/ortho/pediatric_intoe.htm.</div><div id=\"graphicVersion\">Graphic 57425 Version 2.0</div></div></div>"},"57426":{"type":"graphic_table","displayName":"Initial blood lead testing of neonates","title":"Initial blood lead testing of neonates","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Initial blood lead testing of neonates</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Initial venous blood lead level* (BLL; &#181;g/dL)</td> <td class=\"subtitle1\">Perform follow-up test(s)<sup>&#182;</sup></td> </tr> <tr> <td>&#60;5</td> <td>According to local lead screening guidelines for children.</td> </tr> <tr> <td>5-24</td> <td>Within 1 month (at first newborn visit)<sup>&#916;</sup>.</td> </tr> <tr> <td>25-44</td> <td>Within 2 weeks. Consultation with a clinician experienced in the management of children with BLLs in this range is strongly advised<sup>&#9674;</sup>.</td> </tr> <tr> <td>&#8805;45</td> <td>Within 24 hours and then at frequent intervals depending on clinical interventions and trend in BLLs. Prompt consultation with a clinician experienced in the management of children withd BLLs in this range is strongly advised<sup>&#9674;</sup>.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BLL: blood lead level.<br />* The initial blood lead level may be either from an umbilical cord sample at the time of delivery or an infant venous BLL. A venous blood sample is preferred over a capillary sample. Decisions to initiate or stop breastfeeding or initiate chelation therapy should be based on venous blood lead test results only.<br />¶ If infants are breastfeeding, also follow recommendations in Chapter 9.<br />Δ According to pediatric health supervision guidelines (well-baby visit schedule) or as clinically indicated based on trends in blood lead levels.<br /><FONT class=lozenge>◊</FONT> The higher the BLL on the initial test, the more urgent the need for confirmatory testing.</div><div class=\"graphic_reference\">Reproduced from: Ettinger AS, Gurthrie Wengrovitz A (Eds). Guidelines for the identification and management of lead exposure in pregnant and lactating women. National Center for Environmental Health/Agency for Toxic Substances and Disease Registry; Centers for Disease Control and Prevention, Atlanta, GA, 2010. Available at <A spellcheck=true href=\"http://www.cdc.gov/nceh/lead/publications/LeadandPregnancy2010.pdf\" target=_blank>http://www.cdc.gov/nceh/lead/publications/LeadandPregnancy2010.pdf</A>.</div><div id=\"graphicVersion\">Graphic 57426 Version 6.0</div></div></div>"},"57427":{"type":"graphic_table","displayName":"Treatment of onchocerciasis","title":"Treatment of individuals with onchocerciasis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of individuals with onchocerciasis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Individuals in endemic areas with high levels of ongoing transmission</td> </tr> <tr> <td class=\"indent1\">Ivermectin 150 mcg/kg orally (single dose); repeat every&nbsp;three to&nbsp;six months until asymptomatic</td> </tr> <tr> <td class=\"subtitle1_single\">Individuals outside endemic areas or in areas with low transmission</td> </tr> <tr> <td class=\"indent1\">Ivermectin 150 mcg/kg orally (single dose), PLUS</td> </tr> <tr> <td class=\"indent1\">Doxycycline* 200 mg orally once daily for&nbsp;six weeks (start&nbsp;one week after administration of ivermectin)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Several studies support use of doxycycline, although it is not standard therapy. Treatment with ivermectin should be administered one week prior to treatment with doxycycline to provide symptom relief. Doxycycline is contraindicated during pregnancy and in children &lt;9 years of age or &lt;15 kg.</div><div class=\"graphic_reference\">Source: Hoerauf A. Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis. Curr Opin Infect Dis 2008; 21:673.</div><div id=\"graphicVersion\">Graphic 57427 Version 7.0</div></div></div>"},"57429":{"type":"graphic_figure","displayName":"Surgical treatment of acute paronychia","title":"Surgical treatment of acute paronychia","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Surgical treatment of acute paronychia</div><div class=\"cntnt\"><img style=\"width:560px; height:399px;\" src=\"images/SURG/57429_Surgical_treat_acute_paron.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surgical drainage is indicated for patients with acute paronychia who present late and have an abscess cavity. The drawings illustrate the appropriate drainage procedure.<br />(Left) Preoperative appearance.<br />(Center) Elevation and excision of lateral third of nail.<br />(Right) Incision of perionychial fold with the blade directed away from the nail bed and matrix.</div><div id=\"graphicVersion\">Graphic 57429 Version 3.0</div></div></div>"},"57431":{"type":"graphic_table","displayName":"Causes of long QT syndrome","title":"Some reported causes and potentiators of the long QT syndrome*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Some reported causes and potentiators of the long QT syndrome*</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Congenital</td> </tr> <tr> <td class=\"indent1\">Jervell and Lange-Nielsen syndrome (including \"channelopathies\")</td> </tr> <tr> <td class=\"indent1\">Romano-Ward syndrome</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Idiopathic</td> </tr> <tr> <td class=\"subtitle1_single\">Acquired</td> </tr> <tr> <td class=\"indent1\"><strong>Metabolic disorders</strong></td> </tr> <tr> <td class=\"indent2\">Hypokalemia</td> </tr> <tr> <td class=\"indent2\">Hypomagnesemia</td> </tr> <tr> <td class=\"indent2\">Hypocalcemia</td> </tr> <tr> <td class=\"indent2\">Starvation</td> </tr> <tr> <td class=\"indent2\">Anorexia nervosa</td> </tr> <tr> <td class=\"indent2\">Liquid protein diets</td> </tr> <tr> <td class=\"indent2\">Hypothyroidism</td> </tr> <tr> <td class=\"indent1\"><strong>Bradyarrhythmias</strong></td> </tr> <tr> <td class=\"indent2\">Sinus node dysfunction</td> </tr> <tr> <td class=\"indent2\">Atrioventricular (AV) block: second- or third-degree</td> </tr> <tr> <td class=\"indent1\"><strong>Antiarrhythmic drugs</strong></td> </tr> <tr> <td class=\"indent2\">Quinidine, procainamide, disopyramide</td> </tr> <tr> <td class=\"indent2\">Flecainide, propafenone</td> </tr> <tr> <td class=\"indent2\">Amiodarone<sup>&#182;</sup>, dronedarone, vernakalant<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent2\">Sotalol</td> </tr> <tr> <td class=\"indent2\">Dofetilide, ibutilide</td> </tr> <tr> <td class=\"indent1\"><strong>Antianginal drugs</strong></td> </tr> <tr> <td class=\"indent2\">Ranolazine, ivabradine<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\"><strong>Anticholinergic drugs (antimuscarinics)</strong></td> </tr> <tr> <td class=\"indent2\">Solifenacin, tolterodine</td> </tr> <tr> <td class=\"indent1\"><strong>Anti-infective drugs</strong></td> </tr> <tr> <td class=\"indent2\">Antimalarial: <ul class=\"decimal_heading\"> <li>Known risk: Artemether, artemether-lumefantrine, chloroquine, halofantrine, lumefantrine, quinidine </li> <li>Possible or conditional risk: Delamanid<sup>&#916;</sup>, hydroxychloroquine, mefloquine, primaquine, quinine </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Antituberculous: Bedaquiline</td> </tr> <tr> <td class=\"indent2\">Azole antifungals: Fluconazole, itraconazole, ketoconazole (systemic), posaconazole, voriconazole</td> </tr> <tr> <td class=\"indent2\">Clofazimine (possible or conditional risk)</td> </tr> <tr> <td class=\"indent2\">Fluoroquinolones (systemic): Ciprofloxacin, gatifloxacin<sup>&#916;</sup>, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent2\">HIV antiretrovirals: <ul class=\"decimal_heading\"> <li>Known risk: Efavirenz, lopinavir-ritonavir, saquinavir </li> <li>Possible or conditional risk: Atazanavir, nelfinavir, rilpivirine </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Macrolide antibiotics: Azithromycin, erythromycin, clarithromycin, roxithromycin, telithromycin</td> </tr> <tr> <td class=\"indent2\">Metronidazole</td> </tr> <tr> <td class=\"indent2\">Pentamidine (intravenous)</td> </tr> <tr> <td class=\"indent2\">Pentavalent antimonials (antiparasitic/antiprotozoal): Meglumine antimoniate, sodium stibogluconate</td> </tr> <tr> <td class=\"indent2\">Telavancin</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Acquired (continued)</td> </tr> <tr> <td class=\"indent1\"><strong>Antihistamines</strong></td> </tr> <tr> <td class=\"indent2\">Astemizole<sup>&#9674;</sup>, bilastine<sup>&#916;</sup>,&nbsp;hydroxyzine, terfenadine<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\"><strong>Antineoplastic drugs</strong></td> </tr> <tr> <td class=\"indent2\">Arsenic trioxide, bendamustine, capecitabine, ceritinib, cesium chloride<sup>&#9674;</sup>, crizotinib, dasatinib, eribulin, fluorouracil, inotuzumab ozogamicin, nilotinib, lapatinib, lenvatinib, osimertinib, oxaliplatin, panobinostat, pazopanib, ribociclib, romidepsin, sorafenib, sunitinib, tegafur<sup>&#916;</sup>, toremifene, trifluridine-tipiracil<span style=\"font-family: Calibri; color: #1f497d;\">, </span>vandetanib, vemurafenib, vorinostat</td> </tr> <tr> <td class=\"indent1\"><strong>Analgesic, anesthetic, and sedative drugs</strong></td> </tr> <tr> <td class=\"indent2\">Anesthetic/sedative: Chloral hydrate, propofol</td> </tr> <tr> <td class=\"indent2\">Opioids: Buprenorphine<sup>&#167;</sup>, hydrocodone, loperamide<sup>&#165;</sup> (in overdose), methadone</td> </tr> <tr> <td class=\"indent1\"><strong>Bronchodilators (beta<sub>2</sub>-agonists)</strong></td> </tr> <tr> <td class=\"indent2\">Arformoterol, albuterol, formoterol, levalbuterol, indacaterol, olodaterol, salmeterol, terbutaline, vilanterol</td> </tr> <tr> <td class=\"indent1\"><strong>Diuretics</strong></td> </tr> <tr> <td class=\"indent2\">Via electrolyte changes (especially hypokalemia or hypomagnesemia)</td> </tr> <tr> <td class=\"indent1\"><strong>Gastrointestinal drugs</strong></td> </tr> <tr> <td class=\"indent2\">Antidiarrheal: Loperamide<sup>&#165;</sup> (in overdose)</td> </tr> <tr> <td class=\"indent2\">Antiemetics: Ondansetron, granisetron, dolasetron, droperidol (may be safe at the low doses used by anesthesiologists [0.625 to 1.25 mg]), hydroxyzine, tropisetron<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent2\">Promotility: Cisapride (restricted availability), domperidone<sup>&#916;</sup>, metoclopramide</td> </tr> <tr> <td class=\"indent2\">Proton pump inhibitors: Chronic use leading to hypomagnesemia (rare)</td> </tr> <tr> <td class=\"indent1\"><strong>Gonadotropin-releasing hormone agonists and antagonists</strong></td> </tr> <tr> <td class=\"indent2\">Buserelin, degarelix, goserelin, histrelin, leuprolide, triptorelin</td> </tr> <tr> <td class=\"indent1\"><strong>Neurologic drugs</strong></td> </tr> <tr> <td class=\"indent2\">Apomorphine, deutetrabenazine, donepezil, ezogabine, fingolimod, pimavanserin, tetrabenazine</td> </tr> <tr> <td class=\"indent1\"><strong>Psychotropic drugs</strong></td> </tr> <tr> <td class=\"indent2\">Antipsychotics: <ul class=\"decimal_heading\"> <li>Known risk: Chlorpromazine, haloperidol, levosulpiride<sup>&#916;</sup>,&nbsp;methotrimeprazine (levomepromazine)<sup>&#916;</sup>, pimozide, sulpiride<sup>&#916;</sup>, thioridazine </li> <li>Possible or conditional risk: Amisulpride<sup>&#916;</sup>, aripiprazole, asenapine, clozapine, cyamemazine<sup>&#916;</sup>, flupentixol<sup>&#916;</sup>, iloperidone, melperone<sup>&#916;</sup>, olanzapine, paliperidone, perphenazine, pimavanserin,&nbsp;pipamperone<sup>&#916;</sup>, quetiapine, risperidone, sertindole<sup>&#916;</sup>, tiapride<sup>&#916;</sup>, ziprasidone </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Tricyclic and tetracyclic antidepressants (TCAs)<sup>&#135;</sup></td> </tr> <tr> <td class=\"indent2\">Selective serotonin reuptake inhibitors (lower risk than TCAs): Citalopram, escitalopram, fluoxetine&nbsp;(less than citalopram)</td> </tr> <tr> <td class=\"indent2\">Others: Atomoxetine, trazodone, valbenazine</td> </tr> <tr> <td class=\"indent1\"><strong>Vasodilator drugs</strong></td> </tr> <tr> <td class=\"indent2\">Bepridil<sup>&#9674;</sup>, cilostazol</td> </tr> <tr> <td class=\"indent1\"><strong>Other drugs and herbs</strong></td> </tr> <tr> <td class=\"indent2\">Miscellaneous: Anagrelide, alfuzosin, cocaine, eliglustat, mifepristone, papaverine (intracoronary), pasireotide, probucol<sup>&#9674;</sup>, terlipressin<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent2\">Herbs: Cinchona (contains quinine), licorice extract (glycyrrhizin) in overuse leading to electrolyte changes</td> </tr> <tr> <td class=\"indent1\"><strong>Other factors</strong></td> </tr> <tr> <td class=\"indent2\">Myocardial ischemia or infarction, especially with prominent T-wave inversions</td> </tr> <tr> <td class=\"indent2\">Intracranial disease</td> </tr> <tr> <td class=\"indent2\">Human immunodeficiency virus (HIV) infection</td> </tr> <tr> <td class=\"indent2\">Hypothermia</td> </tr> <tr> <td class=\"indent2\">Toxic exposure: Organophosphate insecticides</td> </tr> <tr> <td class=\"indent2\">Connective tissue diseases with anti-Ro/SSA antibodies</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">This is not a complete list of all corrected QT interval (QTc)-prolonging drugs and does not include drugs with either a minor&nbsp;degree or&nbsp;isolated&nbsp;association(s)&nbsp;with QTc prolongation&nbsp;that appear to be safe in most patients, but may need to be avoided in patients with congenital long QT syndrome depending upon clinical circumstances.&nbsp;A&nbsp;more complete&nbsp;list of such drugs is available at the <A spellcheck=true href=\"https://crediblemeds.org/index.php/login/dlcheck\">Credible Meds </A>website.<br />* The long and growing list of medications and other factors capable of prolonging the QTc represents an evolving area of clinical research. In some cases of long QTc, two or more factors may be involved.<br />¶ In contrast with other class III antiarrhythmic drugs, amiodarone is rarely associated with torsades de pointes (TdP); refer to accompanying text within UpToDate topic reviews of acquired long QT syndrome.<br />Δ Not available in the United States.<br /><FONT class=lozenge>◊</FONT> Removed from market in most countries due to adverse cardiovascular effects.<br />§ Although product labeling for buprenorphine analgesics warn of QTc prolongation at doses exceeding those recommended, data for buprenorphine in usual doses for treatment of opioid use disorder are reassuring, and it appears to be a suitable alternative for patients with significant QTc prolongation due to methadone. Refer to the UpToDate topic reviews of opioid intoxication and opioid use disorder for detail.<br />¥ Over-the-counter; available without a prescription.<br />‡ Although amoxapine and protriptyline are not included on the AZCERT list of drugs associated with acquired QT prolongation, overdose of these tricyclic antidepressants has been associated with cardiovascular toxicity and fatalities.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Nielsen J, Graff C, Kanters J, et al. Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs 2011; 25:473.</LI>&#xD;&#xA;<LI>Li E, Esterly J, Pohl S, et al. Drug-induced QT interval prolongation: Considerations for clinicians. Pharmacotherapy 2010; 30:684.</LI>&#xD;&#xA;<LI>CredibleMeds QT drugs list website sponsored by Science Foundation of the University of Arizona. Available at <A href=\"http://crediblemeds.org/\" target=_blank>http://crediblemeds.org/</A> (Accessed&nbsp;December 18, 2017).</LI>&#xD;&#xA;<LI>Lexicomp Online. Copyright ©1978-2018 Lexicomp, Inc. All Rights Reserved.</LI></OL></div><div id=\"graphicVersion\">Graphic 57431 Version 87.0</div></div></div>"},"57434":{"type":"graphic_table","displayName":"BRCA testing USPSTF guidelines","title":"Recommendations from the United States Preventive Services Task Force on who should be offered genetic testing for BRCA mutations*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations from the United States Preventive Services Task Force on who should be offered genetic testing for BRCA mutations*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">For non-Ashkenazi Jewish women:</td> </tr> <tr> <td>Two first-degree relatives with breast cancer, one of whom was diagnosed at age 50 or younger</td> </tr> <tr> <td>A combination of three or more first- or second-degree relatives with breast cancer regardless of age at diagnosis</td> </tr> <tr> <td>A combination of both breast and ovarian cancer among first- and second-degree relatives</td> </tr> <tr> <td>A first-degree relative with bilateral breast cancer</td> </tr> <tr> <td>A combination of two or more first- or second-degree relatives with ovarian cancer, regardless of age at diagnosis</td> </tr> <tr> <td>A first- or second-degree relative with both breast and ovarian cancer at any age</td> </tr> <tr> <td>History of breast cancer in a male relative</td> </tr> <tr> <td class=\"subtitle1_single\">For women of Ashkenazi Jewish descent:</td> </tr> <tr> <td>Any first-degree relative (or two second-degree relatives on the same side of the family) with breast or ovarian cancer</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* These recommendations do not apply to women with a family history of breast or ovarian cancer that includes a relative with a known deleterious BRCA mutation.</div><div class=\"graphic_reference\">U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 2005; 143:355.</div><div id=\"graphicVersion\">Graphic 57434 Version 4.0</div></div></div>"},"57437":{"type":"graphic_figure","displayName":"Link disease gene location","title":"Linkage to resolve location of disease gene","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Linkage to resolve location of disease gene</div><div class=\"cntnt\"><img style=\"width:532px; height:290px;\" src=\"images/PC/57437_Link_disease_gene_location.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With successive meioses, recombination narrows chromosomal region harboring disease locus (+).</div><div id=\"graphicVersion\">Graphic 57437 Version 1.0</div></div></div>"},"57439":{"type":"graphic_picture","displayName":"RA hand 1","title":"Synovial thickening of the metacarpophalangeal joint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Synovial thickening of the metacarpophalangeal joint</div><div class=\"cntnt\"><img style=\"width:432px; height:264px;\" src=\"images/RHEUM/57439_RA_hand_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral swelling of the MCP joints is evident in this patient with rheumatoid arthritis. Note also the mild swan neck deformities present in several fingers, particularly the left middle and fifth fingers.</div><div class=\"graphic_footnotes\">MCP: metacarpophalangeal.</div><div class=\"graphic_reference\">Courtesy of Patrick J Venables, MD.</div><div id=\"graphicVersion\">Graphic 57439 Version 2.0</div></div></div>"},"57440":{"type":"graphic_picture","displayName":"Bullous cutaneous small vessel vasculitis","title":"Bullous cutaneous small vessel vasculitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bullous cutaneous small vessel vasculitis</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/DERM/57440_Leukocyto_vascu_close_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vesicles overlying purpuric macules are present on the lower leg.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 57440 Version 4.0</div></div></div>"},"57443":{"type":"graphic_figure","displayName":"Carvedilol LVEF dose response","title":"Dose-related increase in LVEF with carvedilol in nonischemic cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Dose-related increase in LVEF with carvedilol in nonischemic cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:524px; height:295px;\" src=\"images/CARD/57443_Carvedilol_LVEF_dose_respon.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Change in left ventricular ejection fraction (LVEF) among patients with dilated cardiomyopathy after the administration of carvedilol. There is a dose-related increase in LVEF in those with nonischemic cardiomyopathy; no such dose-relationship is seen in patients with ischemic cardiomyopathy.</div><div class=\"graphic_reference\">Data from Bristow MR, Gilbert EM, Abraham WT, et al. Circulation 1996; 94:2807.</div><div id=\"graphicVersion\">Graphic 57443 Version 2.0</div></div></div>"},"57445":{"type":"graphic_figure","displayName":"Down screening test performance","title":"Performance of maternal age and various second trimester maternal serum combinations in screening for Down syndrome","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Performance of maternal age and various second trimester maternal serum combinations in screening for Down syndrome</div><div class=\"cntnt\"><img style=\"width:474px; height:300px;\" src=\"images/OBGYN/57445_Down_screening_test_prfrmnc.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The bar graphs describe the detection rate attained at a fixed 5% false positive rate for each of the screening tests. </div><div class=\"graphic_reference\">Data adapted from: Wald, NJ, Kennard, A, Hackshaw, A, et al. J Med Screen1997; 4:181.</div><div id=\"graphicVersion\">Graphic 57445 Version 2.0</div></div></div>"},"57447":{"type":"graphic_table","displayName":"MGH screening VHL","title":"Criteria for referral to Massachusetts General Hospital VHL clinic","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for referral to Massachusetts General Hospital VHL clinic</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td>Any blood relative of an individual diagnosed with VHL disease</td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1_start\">\n   Any individual with <strong>TWO</strong> VHL-associated lesions:\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist3\">\n   Hemangioblastoma\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist3\">\n   Clear cell renal carcinoma\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist3\">\n   Pheochromocytoma\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist3\">\n   Endolymphatic sac tumor\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist3\">\n   Epididymal or adnexal papillary cystadenoma\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist3\">\n   Pancreatic serous cystadenomas\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist3\">\n   Pancreatic neuroendocrine tumors\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1_start\">\n   Any individual with <strong>ONE</strong> or more of the following:\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist2\">\n   CNS hemangioblastoma\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist2\">\n   Pheochromocytoma or paraganglioma\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist2\">\n   Endolymphatic sac tumor\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist2\">\n   Epididymal papillary cystadenoma\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1_start\">\n   Any individual with:\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist2\">\n   Clear cell renal carcinoma diagnosed at age &#60;40 years\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist2\">\n   Bilateral and/or multiple clear cell RCCs\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist2\">\n   &#62;1 Pancreatic serous cystadenoma\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist2\">\n   &#62;1 Pancreatic neuroendocrine tumor\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist2\">\n   Multiple pancreatic cysts + any VHL associated lesion\n   </td>\n   </tr>\n </table></div><div class=\"graphic_footnotes\">VHL: von Hippel-Lindau.</div><div id=\"graphicVersion\">Graphic 57447 Version 1.0</div></div></div>"},"57448":{"type":"graphic_table","displayName":"Clinical manifestations of infectious mononucleosis","title":"Clinical manifestations of infectious mononucleosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of infectious mononucleosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Symptoms and signs</td> <td class=\"subtitle1\">Frequency, percent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Symptoms</td> </tr> <tr> <td class=\"indent1\">Malaise and fatigue</td> <td>90 to 100</td> </tr> <tr> <td class=\"indent1\">Sweats</td> <td>80&nbsp;to 95</td> </tr> <tr> <td class=\"indent1\">Sore throat, dysphagia</td> <td>80&nbsp;to 85</td> </tr> <tr> <td class=\"indent1\">Anorexia</td> <td>50&nbsp;to 80</td> </tr> <tr> <td class=\"indent1\">Nausea</td> <td>50&nbsp;to 70</td> </tr> <tr> <td class=\"indent1\">Headache</td> <td>40&nbsp;to 70</td> </tr> <tr> <td class=\"indent1\">Chills</td> <td>40&nbsp;to 60</td> </tr> <tr> <td class=\"indent1\">Cough</td> <td>30&nbsp;to 50</td> </tr> <tr> <td class=\"indent1\">Myalgia</td> <td>12&nbsp;to 30</td> </tr> <tr> <td class=\"indent1\">Ocular muscle pain</td> <td>10&nbsp;to 20</td> </tr> <tr> <td class=\"indent1\">Chest pain</td> <td>5&nbsp;to 20</td> </tr> <tr> <td class=\"indent1\">Arthralgia</td> <td>5&nbsp;to 10</td> </tr> <tr> <td class=\"indent1\">Photophobia</td> <td>5&nbsp;to 10</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Signs</td> </tr> <tr> <td class=\"indent1\">Adenopathy</td> <td>100</td> </tr> <tr> <td class=\"indent1\">Fever</td> <td>80&nbsp;to 95</td> </tr> <tr> <td class=\"indent1\">Pharyngitis</td> <td>65&nbsp;to 85</td> </tr> <tr> <td class=\"indent1\">Splenomegaly</td> <td>50&nbsp;to 60</td> </tr> <tr> <td class=\"indent1\">Bradycardia</td> <td>35&nbsp;to 50</td> </tr> <tr> <td class=\"indent1\">Periorbital edema</td> <td>25&nbsp;to 40</td> </tr> <tr> <td class=\"indent1\">Palatal enanthem</td> <td>25&nbsp;to 35</td> </tr> <tr> <td class=\"indent1\">Liver and spleen tenderness</td> <td>15&nbsp;to 30</td> </tr> <tr> <td class=\"indent1\">Hepatomegaly</td> <td>15&nbsp;to 25</td> </tr> <tr> <td class=\"indent1\">Rhinitis</td> <td>10&nbsp;to 25</td> </tr> <tr> <td class=\"indent1\">Jaundice</td> <td>5&nbsp;to 10</td> </tr> <tr> <td class=\"indent1\">Skin rash</td> <td>3&nbsp;to 6 </td> </tr> <tr> <td class=\"indent1\">Pneumonitis</td> <td>&#60;3</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified from Chervenik PA. Dis Mon 1974; 1:29.</div><div id=\"graphicVersion\">Graphic 57448 Version 3.0</div></div></div>"},"57450":{"type":"graphic_figure","displayName":"Three by three grid POP-Q","title":"Three-by-three grid used to express the quantified pelvic organ prolapse (POP-Q) system","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Three-by-three grid used to express the quantified pelvic organ prolapse (POP-Q) system</div><div class=\"cntnt\"><img style=\"width:214px; height:152px;\" src=\"images/OBGYN/57450_Three_by_three_grid_POP-Q.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">Aa: point A of the anterior wall; Ba: point B of the anterior wall; C: cervix or cuff; D: posterior fornix; gh: genital hiatus; pb: perineal body; tvl: total vaginal length; Ap: point A of the posterior wall; Bp: point B of the posterior wall.</div><div class=\"graphic_reference\">Reproduced with permission from: Harvey, M-A, Versi, E. Urogynecology and pelvic floor dysfunction. In: Kistner's Gynecology and Women's Health, 7th ed, Ryan, KJ, Berkowitz, RS, Barbieri, RL, Dunaif, A (Eds), St. Louis, Mosby 1999. Copyright &#169; 1999 Elsevier.</div><div id=\"graphicVersion\">Graphic 57450 Version 3.0</div></div></div>"},"57451":{"type":"graphic_figure","displayName":"Lymph node groups body","title":"Lymph node regions in the body","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Lymph node regions in the body</div><div class=\"cntnt\"><img style=\"width:544px; height:477px;\" src=\"images/PC/57451_Lymph_node_groups_body.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 57451 Version 2.0</div></div></div>"},"57452":{"type":"graphic_diagnosticimage","displayName":"False positive radiograph","title":"False positive abdominal radiograph","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">False positive abdominal radiograph</div><div class=\"cntnt\"><img style=\"width:500px; height:336px;\" src=\"images/PULM/57452_False_positive_radiograph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An admitted body packer presented to the Emergency Department for medical clearance, and a plain abdominal radiograph demonstrated a radiolucency overlying the L1 vertebral body. Although suspicious for a drug packet, the lucency was subsequently determined to be due to intra-abdominal calcifications, in this case in the pancreas.</div><div class=\"graphic_reference\">Courtesy of Stephen Traub, MD.</div><div id=\"graphicVersion\">Graphic 57452 Version 2.0</div></div></div>"},"57453":{"type":"graphic_algorithm","displayName":"Approach to oral appliances for OSA","title":"Multidisciplinary approach to oral appliances for obstructive sleep apnea (OSA)","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Multidisciplinary approach to oral appliances for obstructive sleep apnea (OSA)</div><div class=\"cntnt\"><img style=\"width:596px; height:460px;\" src=\"images/SLEEP/57453_Multidisciplinary_approach.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TMJ: temporomandibular joint.</div><div id=\"graphicVersion\">Graphic 57453 Version 5.0</div></div></div>"},"57454":{"type":"graphic_figure","displayName":"Cumulative two-year mortality rates in CKD pts","title":"Cumulative two-year mortality rates in chronic kidney disease patients","html":"<div class=\"graphic\"><div style=\"width: 578px\" class=\"figure\"><div class=\"ttl\">Cumulative two-year mortality rates in chronic kidney disease patients</div><div class=\"cntnt\"><img style=\"width:558px; height:269px;\" src=\"images/NEPH/57454_Mort_rates_CKD_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The long-term mortality of patients with different stages of CKD is displayed. Thus, the cumulative mortality rates at two years after stroke and TIA in patients with CKD or with hemodialysis were dramatically higher than in the control cohort without CKD.</div><div class=\"graphic_footnotes\">CKD: chronic kidney disease; TIA: transitory ischemic attacks.</div><div class=\"graphic_reference\">Reproduced with permission from: Reinecke H, Brand E, Mesters R, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009; 20:705. Copyright &copy; 2009 American Society of Nephrology.</div><div id=\"graphicVersion\">Graphic 57454 Version 7.0</div></div></div>"},"57455":{"type":"graphic_figure","displayName":"Femoral artery puncture site and position","title":"Positioning and pertinent anatomy for femoral artery puncture or cannulation","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Positioning and pertinent anatomy for femoral artery puncture or cannulation</div><div class=\"cntnt\"><img style=\"width:518px; height:589px;\" src=\"images/EM/57455_Femoral_artery_puncture_site_position.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient should be positioned with a towel roll placed under the buttocks with the leg exernally rotated at the hip and flexed at the knee as shown.&#160;The femoral artery is palpated approximately midway between the symphysis pubis and superior iliac spine and punctured 2 cm below the inguinal ligament.</div><div id=\"graphicVersion\">Graphic 57455 Version 1.0</div></div></div>"},"57456":{"type":"graphic_algorithm","displayName":"Approach to patients with an elevated serum amylase","title":"Approach to patients with an elevated serum amylase","html":"<div class=\"graphic\"><div style=\"width: 581px\" class=\"figure\"><div class=\"ttl\">Approach to patients with an elevated serum amylase</div><div class=\"cntnt\"><img style=\"width:561px; height:548px;\" src=\"images/GAST/57456_Approach_elevated_amylase.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography; MRCP: magnetic resonance cholangiopancreatography; ERCP: endoscopic retrograde cholangiopancreatography; EUS: endoscopic ultrasound.</div><div id=\"graphicVersion\">Graphic 57456 Version 2.0</div></div></div>"},"57457":{"type":"graphic_table","displayName":"Disseminated histo rx recs","title":"Treatment recommendations for disseminated histoplasmosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment recommendations for disseminated histoplasmosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Manifestation</td> <td class=\"subtitle1\">Treatment</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">Progressive disseminated histophasmosis</td> </tr> <tr> <td class=\"indent1\">Moderately severe to severe</td> <td>Liposomal AmB* (3 mg/kg daily), AmB lipid complex* (5 mg/kg daily), or AmB deoxycholate* (0.7 to 1 mg/kg daily) for one to two weeks followed by itraconazole<sup>&#182;</sup> (200 mg twice daily for at least 12 months)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Mild to moderate</td> <td>Itraconazole (200 mg twice daily for at least 12 months)</td> </tr> <tr> <td>CNS histoplasmosis</td> <td>Liposomal AmB* (5 mg/kg daily for four to six weeks) followed by itraconazole<sup>&#182;</sup> (200 mg two to three times daily for at least 12 months)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">With regard to pregnancy, all azoles are contraindicated because of the risk of teratogenicity. Otherwise, the indications for treatment are not different in pregnancy, and lipid formulations of AmB are preferred. AmB deoxycholate is preferred for use in children because it is effective, well-tolerated, and less costly. The dosage of itraconazole for children is 5 to 10 mg/kg in two divided doses, not to exceed 400 mg daily.</div><div class=\"graphic_footnotes\">AmB: amphotericin B; CNS: central nervous system.<br />* Liposomal AmB (3 mg/kg daily) or AmB lipid complex (5 mg/kg daily) are recommended for one to two weeks, except in patients with meningitis for whom the dosage of liposomal AmB is 5 mg/kg daily for four to six weeks. The deoxycholate formulation of AmB (0.7 to 1 mg/kg daily) is an alternative to a lipid formulation in patients who are at low risk for nephrotoxicity.<br />¶ Itraconazole should be given as a loading dose of 200 mg three times daily for the first three days, followed by 200 mg twice daily thereafter. Itraconazole (200 mg once daily) may be sufficient in patients with less severe manifestations of histoplasmosis. If used for prophylaxis, a dosage of 200 mg daily is recommended. Concentrations of itraconazole in serum should be monitored in patients being treated for chronic pulmonary, disseminated, or CNS histoplasmosis; a random serum concentration &gt;1.0 mcg/mL should be sought. Drug monitoring is infrequently needed for patients receiving shorter courses of therapy for acute pulmonary histoplasmosis and its complications.</div><div class=\"graphic_reference\">Modified with permission from: Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45:807. Copyright &copy;2007 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 57457 Version 6.0</div></div></div>"},"57459":{"type":"graphic_table","displayName":"Atypical features JIA","title":"Atypical features of juvenile idiopathic arthritis that should prompt consideration of leukemia*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Atypical features of juvenile idiopathic arthritis that should prompt consideration of leukemia*</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Nocturnal pain that may cause waking</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Severe pain, requiring opiate analgesia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pain out of proportion to severity of arthritis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Systemic symptoms out of proportion to severity of arthritis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Nonarticular bone pain</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* Particularly before the initiation of corticosteroid or cytotoxic therapy.</div><div class=\"graphic_reference\">Adapted from Murray, MJ, Tang, T, Ryder, C, et al. BMJ 2004; 329:959.</div><div id=\"graphicVersion\">Graphic 57459 Version 1.0</div></div></div>"},"57463":{"type":"graphic_figure","displayName":"Mobilization of the hepatic flexure","title":"Mobilization of the hepatic flexure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mobilization of the hepatic flexure</div><div class=\"cntnt\"><img style=\"width:427px; height:460px;\" src=\"images/SURG/57463_Mobilize-hepatic-flex.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates a mobilized hepatic flexure of the right colon. The second portion of&#160;the duodenum and the head of the pancreas are exposed.</div><div id=\"graphicVersion\">Graphic 57463 Version 2.0</div></div></div>"},"57465":{"type":"graphic_table","displayName":"Normal hematologic values in children and adolescents","title":"Hemoglobin, hematocrit, red blood cells, mean corpuscular volume, and white blood cells in children 1 to 14 years of age, by age group and sex: The Third National Health and Nutrition Examination Survey (1988 to 1991)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hemoglobin, hematocrit, red blood cells, mean corpuscular volume, and white blood cells in children 1 to 14 years of age, by age group and sex: The Third National Health and Nutrition Examination Survey (1988 to 1991)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Characteristic</td> <td class=\"subtitle1\" colspan=\"4\">Male* (n = 5070)</td> <td class=\"subtitle1\" colspan=\"4\">Female* (n = 5175)</td> </tr> <tr> <td class=\"subtitle2\">Mean</td> <td class=\"subtitle2\">SD</td> <td class=\"subtitle2\" colspan=\"2\">95% CI</td> <td class=\"subtitle2\">Mean</td> <td class=\"subtitle2\">SD</td> <td class=\"subtitle2\" colspan=\"2\">95% CI</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">Hemoglobin, g/dL<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">1 to 2 years</td> <td>12.01</td> <td>0.82</td> <td>10.37</td> <td>13.65</td> <td>12.02</td> <td>0.8</td> <td>10.42</td> <td>13.62</td> </tr> <tr> <td class=\"indent1\">3 to 5 years</td> <td>12.35</td> <td>0.77</td> <td>10.81</td> <td>13.89</td> <td>12.39</td> <td>0.77</td> <td>10.85</td> <td>13.93</td> </tr> <tr> <td class=\"indent1\">6 to 8 years</td> <td>12.88</td> <td>0.8</td> <td>11.28</td> <td>14.48</td> <td>12.82</td> <td>0.77</td> <td>11.28</td> <td>14.36</td> </tr> <tr> <td class=\"indent1\">9 to 11 years</td> <td>13.28</td> <td>0.84</td> <td>11.6</td> <td>14.96</td> <td>13.1</td> <td>0.78</td> <td>11.54</td> <td>14.66</td> </tr> <tr> <td class=\"indent1\">12 to 14 years</td> <td>14.14</td> <td>1.08</td> <td>11.98</td> <td>16.3</td> <td>13.29</td> <td>1</td> <td>11.29</td> <td>15.29</td> </tr> <tr> <td class=\"indent1\">15 to 19 years</td> <td>15.07</td> <td>1.03</td> <td>13.01</td> <td>17.13</td> <td>13.15</td> <td>1</td> <td>11.15</td> <td>15.15</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">Hematocrit, percent</td> </tr> <tr> <td class=\"indent1\">1 to 2 years</td> <td>36</td> <td>2</td> <td>32</td> <td>40</td> <td>36</td> <td>2</td> <td>32</td> <td>40</td> </tr> <tr> <td class=\"indent1\">3 to 5 years</td> <td>37</td> <td>2</td> <td>33</td> <td>41</td> <td>37</td> <td>2</td> <td>33</td> <td>41</td> </tr> <tr> <td class=\"indent1\">6 to 8 years</td> <td>38</td> <td>2</td> <td>34</td> <td>42</td> <td>38</td> <td>2</td> <td>34</td> <td>42</td> </tr> <tr> <td class=\"indent1\">9 to 11 years</td> <td>39</td> <td>2</td> <td>35</td> <td>43</td> <td>39</td> <td>2</td> <td>35</td> <td>43</td> </tr> <tr> <td class=\"indent1\">12 to 14 years</td> <td>42</td> <td>3</td> <td>36</td> <td>48</td> <td>40</td> <td>3</td> <td>34</td> <td>46</td> </tr> <tr> <td class=\"indent1\">15 to 19 years</td> <td>45</td> <td>3</td> <td>39</td> <td>51</td> <td>39</td> <td>3</td> <td>33</td> <td>45</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">Red blood cells, 10<sup>12</sup> cells per liter</td> </tr> <tr> <td class=\"indent1\">1 to 2 years</td> <td>4.55</td> <td>0.34</td> <td>3.87</td> <td>5.23</td> <td>4.5</td> <td>0.34</td> <td>3.82</td> <td>5.18</td> </tr> <tr> <td class=\"indent1\">3 to 5 years</td> <td>4.51</td> <td>0.34</td> <td>3.83</td> <td>5.19</td> <td>4.49</td> <td>0.32</td> <td>3.85</td> <td>5.13</td> </tr> <tr> <td class=\"indent1\">6 to 8 years</td> <td>4.6</td> <td>0.29</td> <td>4.02</td> <td>5.18</td> <td>4.56</td> <td>0.31</td> <td>3.94</td> <td>5.18</td> </tr> <tr> <td class=\"indent1\">9 to 11 years</td> <td>4.71</td> <td>0.32</td> <td>4.07</td> <td>5.35</td> <td>4.62</td> <td>0.3</td> <td>4.02</td> <td>5.22</td> </tr> <tr> <td class=\"indent1\">12 to 14 years</td> <td>4.93</td> <td>0.39</td> <td>4.15</td> <td>5.71</td> <td>4.59</td> <td>0.32</td> <td>3.95</td> <td>5.23</td> </tr> <tr> <td class=\"indent1\">15 to 19 years</td> <td>5.06</td> <td>0.37</td> <td>4.32</td> <td>5.8</td> <td>4.47</td> <td>0.35</td> <td>3.77</td> <td>5.17</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">Mean corpuscular volume (femtoliters)</td> </tr> <tr> <td class=\"indent1\">1 to 2 years</td> <td>79.2</td> <td>4.5</td> <td>70.2</td> <td>88.2</td> <td>79.8</td> <td>4.5</td> <td>70.8</td> <td>88.8</td> </tr> <tr> <td class=\"indent1\">3 to 5 years</td> <td>81.8</td> <td>4.3</td> <td>73.2</td> <td>90.4</td> <td>82.3</td> <td>4</td> <td>74.3</td> <td>90.3</td> </tr> <tr> <td class=\"indent1\">6 to 8 years</td> <td>83.2</td> <td>4</td> <td>75.2</td> <td>91.2</td> <td>83.6</td> <td>3.6</td> <td>76.4</td> <td>90.8</td> </tr> <tr> <td class=\"indent1\">9 to 11 years</td> <td>83.9</td> <td>3.7</td> <td>76.5</td> <td>91.3</td> <td>84.2</td> <td>3.9</td> <td>76.4</td> <td>92</td> </tr> <tr> <td class=\"indent1\">12 to 14 years</td> <td>85.3</td> <td>4</td> <td>77.3</td> <td>93.3</td> <td>86.2</td> <td>4.2</td> <td>77.8</td> <td>94.6</td> </tr> <tr> <td class=\"indent1\">15 to 19 years</td> <td>88.3</td> <td>3.9</td> <td>80.5</td> <td>96.1</td> <td>87.8</td> <td>4.7</td> <td>78.4</td> <td>97.2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">White blood cells, 10<sup>9</sup> cells per liter</td> </tr> <tr> <td class=\"indent1\">1 to 2 years</td> <td>8.74</td> <td>2.53</td> <td>3.68</td> <td>13.8</td> <td>8.66</td> <td>2.41</td> <td>3.84</td> <td>13.48</td> </tr> <tr> <td class=\"indent1\">3 to 5 years</td> <td>7.68</td> <td>2.26</td> <td>3.16</td> <td>12.2</td> <td>7.9</td> <td>2.12</td> <td>3.66</td> <td>12.14</td> </tr> <tr> <td class=\"indent1\">6 to 8 years</td> <td>7.45</td> <td>2.02</td> <td>3.41</td> <td>11.49</td> <td>7.63</td> <td>2.1</td> <td>3.43</td> <td>11.83</td> </tr> <tr> <td class=\"indent1\">9 to 11 years</td> <td>7.01</td> <td>2.07</td> <td>2.87</td> <td>11.15</td> <td>7.2</td> <td>1.98</td> <td>3.24</td> <td>11.16</td> </tr> <tr> <td class=\"indent1\">12 to 14 years</td> <td>7.02</td> <td>2.07</td> <td>2.88</td> <td>11.16</td> <td>7.3</td> <td>2.06</td> <td>3.18</td> <td>11.42</td> </tr> <tr> <td class=\"indent1\">15 to 19 years</td> <td>7.15</td> <td>2.11</td> <td>2.93</td> <td>11.37</td> <td>7.58</td> <td>2.18</td> <td>3.22</td> <td>11.94</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The 95% confidence interval (+/– 2 SD) defines the normal range, and corresponds to the 2.5<SUP>th</SUP> through 97.5<SUP>th</SUP> percentiles.</div><div class=\"graphic_footnotes\">SD: standard deviation; 95% CI: 95 percent confidence interval.<br />* Includes all race/ethnic groups.<br />¶&nbsp;Hemoglobin is sometimes reported as grams/liter (g/L), in which case the values are 10 times those reported as g/dL (13.5 g/dL = 135 g/L).</div><div class=\"graphic_reference\">Adapted from: Hollowell JG, van Assendelft OW, Gunter EW, et al. Hematological and iron-related analytes-reference data for persons aged 1 year and over: United States, 1988-94. Vital Health Stat 2005; 11:1.</div><div id=\"graphicVersion\">Graphic 57465 Version 13.0</div></div></div>"},"57466":{"type":"graphic_picture","displayName":"Superficial spreading melanoma","title":"Superficial spreading melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superficial spreading melanoma</div><div class=\"cntnt\"><img style=\"width:288px; height:206px;\" src=\"images/PC/57466_Superficial_spreading_melan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Asymmetry and color variegation are characteristic of superficial spreading melanomas.</div><div class=\"graphic_reference\">Courtesy of James C Shaw, MD.</div><div id=\"graphicVersion\">Graphic 57466 Version 2.0</div></div></div>"},"57469":{"type":"graphic_table","displayName":"Lexicomp clinical abbreviations","title":"Lexicomp clinical abbreviations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lexicomp clinical abbreviations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Abbreviation</td> <td class=\"subtitle1\">Meaning</td> <td class=\"subtitle1\">Abbreviation</td> <td class=\"subtitle1\">Meaning</td> <td class=\"subtitle1\">Abbreviation</td> <td class=\"subtitle1\">Meaning</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Abbreviations, acronyms, and symbols that may be used in Lexicomp*</td> </tr> <tr> <td class=\"centered\">&#189;NS</td> <td>0.45% sodium chloride</td> <td class=\"centered\">EEG</td> <td>Electroencephalogram</td> <td class=\"centered\">NS</td> <td>Normal saline (0.9% sodium chloride)</td> </tr> <tr> <td class=\"centered\">5-HT</td> <td>5-hydroxytryptamine (serotonin)</td> <td class=\"centered\">EF</td> <td>Ejection fraction</td> <td class=\"centered\">NSAID</td> <td>Nonsteroidal anti-inflammatory drug</td> </tr> <tr> <td class=\"centered\">AAP</td> <td>American Academy of Pediatrics</td> <td class=\"centered\">EG</td> <td>Ethylene glycol</td> <td class=\"centered\">NSF</td> <td>Nephrogenic systemic fibrosis</td> </tr> <tr> <td class=\"centered\">AAPC</td> <td>Antibiotic-associated pseudomembranous colitis</td> <td class=\"centered\">EGA</td> <td>Estimated gestational age</td> <td class=\"centered\">NSCLC</td> <td>Non-small cell lung cancer</td> </tr> <tr> <td class=\"centered\">ABCB1</td> <td>ATP-binding cassette sub-family B member 1 (also known as P-gP or MDR1)</td> <td class=\"centered\">EIA</td> <td>Enzyme immunoassay</td> <td class=\"centered\">NSTEMI</td> <td>Non-ST-elevation myocardial infarction</td> </tr> <tr> <td class=\"centered\">ABCC2</td> <td>ATP-binding cassette sub-family C member 2 (also known as MRP2)</td> <td class=\"centered\">ELBW</td> <td>Extremely low birth weight</td> <td class=\"centered\">NYHA</td> <td>New York Heart Association</td> </tr> <tr> <td class=\"centered\">ABCG2</td> <td>ATP-binding cassette sub-family G member 2 (also known as BCRP)</td> <td class=\"centered\">ELISA</td> <td>Enzyme-linked immunosorbent assay</td> <td class=\"centered\">OA</td> <td>Osteoarthritis</td> </tr> <tr> <td class=\"centered\">ABG</td> <td>Arterial blood gases</td> <td class=\"centered\">EPS</td> <td>Extrapyramidal side effects</td> <td class=\"centered\">OAT</td> <td>Organic anion transporter</td> </tr> <tr> <td class=\"centered\">ABMT</td> <td>Autologous bone marrow transplant</td> <td class=\"centered\">ESR</td> <td>Erythrocyte sedimentation rate</td> <td class=\"centered\">OCD</td> <td>Obsessive-compulsive disorder</td> </tr> <tr> <td class=\"centered\">ABW</td> <td>Adjusted body weight</td> <td class=\"centered\">ESRD</td> <td>End stage renal disease</td> <td class=\"centered\">OCT</td> <td>Organic cation transporter</td> </tr> <tr> <td class=\"centered\">AACT</td> <td>American Academy of Clinical Toxicology</td> <td class=\"centered\">E.T.</td> <td>Endotracheal</td> <td class=\"centered\">OHSS</td> <td>Ovarian hyperstimulation syndrome</td> </tr> <tr> <td class=\"centered\">ACC</td> <td>American College of Cardiology</td> <td class=\"centered\">EtOH</td> <td>Alcohol</td> <td class=\"centered\">O.R.</td> <td>Operating room</td> </tr> <tr> <td class=\"centered\">ACE</td> <td>Angiotensin-converting enzyme</td> <td class=\"centered\">FDA</td> <td>Food and Drug Administration (United States)</td> <td class=\"centered\">OTC</td> <td>Over-the-counter (nonprescription)</td> </tr> <tr> <td class=\"centered\">ACLS</td> <td>Advanced cardiac life support</td> <td class=\"centered\">FEV<sub>1</sub></td> <td>Forced expiratory volume exhaled after 1 second</td> <td class=\"centered\">PABA</td> <td>Para-aminobenzoic acid</td> </tr> <tr> <td class=\"centered\">ACOG</td> <td>American College of Obstetricians and Gynecologists</td> <td class=\"centered\">FMO</td> <td>Flavin-containing monooxygenase</td> <td class=\"centered\">PACTG</td> <td>Pediatric AIDS Clinical Trials Group</td> </tr> <tr> <td class=\"centered\">ACTH</td> <td>Adrenocorticotrophic hormone</td> <td class=\"centered\">FSH</td> <td>Follicle-stimulating hormone</td> <td class=\"centered\">PALS</td> <td>Pediatric advanced life support</td> </tr> <tr> <td class=\"centered\">ADH</td> <td>Antidiuretic hormone</td> <td class=\"centered\">FTT</td> <td>Failure to thrive</td> <td class=\"centered\">PAT</td> <td>Paroxysmal atrial tachycardia</td> </tr> <tr> <td class=\"centered\">ADHD</td> <td>Attention-deficit/hyperactivity disorder</td> <td class=\"centered\">FVC</td> <td>Forced vital capacity</td> <td class=\"centered\">PCA</td> <td>Patient-controlled analgesia</td> </tr> <tr> <td class=\"centered\">ADI</td> <td>Adequate daily intake</td> <td class=\"centered\">G-6-PD, G6PD</td> <td>Glucose-6-phosphate dehydrogenase</td> <td class=\"centered\">PCI</td> <td>Percutaneous coronary intervention</td> </tr> <tr> <td class=\"centered\">ADLs</td> <td>Activities of daily living</td> <td class=\"centered\">GA</td> <td>Gestational age</td> <td class=\"centered\">PCP</td> <td><em>Pneumocystis jiroveci</em> pneumonia (also called <em>Pneumocystis carinii</em> pneumonia)</td> </tr> <tr> <td class=\"centered\">AED</td> <td>Antiepileptic drug</td> <td class=\"centered\">GABA</td> <td>Gamma-aminobutyric acid</td> <td class=\"centered\">PCWP</td> <td>Pulmonary capillary wedge pressure</td> </tr> <tr> <td class=\"centered\">AHA</td> <td>American Heart Association</td> <td class=\"centered\">GAD</td> <td>Generalized anxiety disorder</td> <td class=\"centered\">PD</td> <td>Parkinson's disease; peritoneal dialysis</td> </tr> <tr> <td class=\"centered\">AHCPR</td> <td>Agency for Health Care Policy and Research</td> <td class=\"centered\">GE</td> <td>Gastroesophageal</td> <td class=\"centered\">PDA</td> <td>Patent ductus arteriosus</td> </tr> <tr> <td class=\"centered\">AIDS</td> <td>Acquired immunodeficiency syndrome</td> <td class=\"centered\">GERD</td> <td>Gastroesophageal reflux disease</td> <td class=\"centered\">PDE-5</td> <td>Phosphodiesterase-5</td> </tr> <tr> <td class=\"centered\">AIMS</td> <td>Abnormal Involuntary Movement Scale</td> <td class=\"centered\">GFR</td> <td>Glomerular filtration rate</td> <td class=\"centered\">PE</td> <td>Pulmonary embolism</td> </tr> <tr> <td class=\"centered\">ALL</td> <td>Acute lymphoblastic leukemia</td> <td class=\"centered\">GGT</td> <td>Gamma-glutamyltransferase</td> <td class=\"centered\">PEG tube</td> <td>Percutaneous endoscopic gastrostomy tube</td> </tr> <tr> <td class=\"centered\">ALS</td> <td>Amyotrophic lateral sclerosis</td> <td class=\"centered\">GI</td> <td>Gastrointestinal</td> <td class=\"centered\">P-gP</td> <td>P-glycoprotein</td> </tr> <tr> <td class=\"centered\">ALT</td> <td>Alanine aminotransferase (formerly called SGPT)</td> <td class=\"centered\">GIST</td> <td>Gastrointestinal stromal tumor</td> <td class=\"centered\">PHN</td> <td>Post-herpetic neuralgia</td> </tr> <tr> <td class=\"centered\">AMA</td> <td>American Medical Association</td> <td class=\"centered\">GU</td> <td>Genitourinary</td> <td class=\"centered\">PICU</td> <td>Pediatric Intensive Care Unit</td> </tr> <tr> <td class=\"centered\">AML</td> <td>Acute myeloblastic leukemia</td> <td class=\"centered\">GVHD</td> <td>Graft versus host disease</td> <td class=\"centered\">PID</td> <td>Pelvic inflammatory disease</td> </tr> <tr> <td class=\"centered\">ANA</td> <td>Antinuclear antibodies</td> <td class=\"centered\">HAM-A</td> <td>Hamilton Anxiety Scale</td> <td class=\"centered\">PIP</td> <td>Peak inspiratory pressure</td> </tr> <tr> <td class=\"centered\">ANC</td> <td>Absolute neutrophil count</td> <td class=\"centered\">HAM-D</td> <td>Hamilton Depression Scale</td> <td class=\"centered\">PMA</td> <td>Postmenstrual age</td> </tr> <tr> <td class=\"centered\">ANLL</td> <td>Acute nonlymphoblastic leukemia</td> <td class=\"centered\">HARS</td> <td>HIV-associated adipose redistribution</td> <td class=\"centered\">PMDD</td> <td>Premenstrual dysphoric disorder</td> </tr> <tr> <td class=\"centered\">APL</td> <td>Acute promyelocytic leukemia</td> <td class=\"centered\">HCAHPS</td> <td>Hospital Consumer Assessment of Healthcare Providers and Systems</td> <td class=\"centered\">PNA</td> <td>Postnatal age</td> </tr> <tr> <td class=\"centered\">aPTT</td> <td>Activated partial thromboplastin time</td> <td class=\"centered\">HCM</td> <td>Hypertrophic cardiomyopathy</td> <td class=\"centered\">PONV</td> <td>Postoperative nausea and vomiting</td> </tr> <tr> <td class=\"centered\">ARB</td> <td>Angiotensin receptor blocker</td> <td class=\"centered\">Hct</td> <td>Hematocrit</td> <td class=\"centered\">PPHN</td> <td>Persistent pulmonary hypertension of the neonate</td> </tr> <tr> <td class=\"centered\">ARDS</td> <td>Acute respiratory distress syndrome</td> <td class=\"centered\">HCV</td> <td>Hepatitis C virus</td> <td class=\"centered\">PPN</td> <td>Peripheral parenteral nutrition</td> </tr> <tr> <td class=\"centered\">ASA-PS</td> <td> <p>American Society of Anesthesiologists - Physical Status (ASA-PS)</p> <p>I: Normal, healthy patient</p> <p>II: Patient having mild systemic disease</p> <p>III: Patient having severe systemic disease</p> <p>IV: Patient having severe systemic disease which is a constant threat to life</p> <p>V: Moribund patient; not expected to survive without the procedure</p> VI: Patient declared brain-dead; organs being removed for donor purposes</td> <td class=\"centered\">HDL-C</td> <td>High density lipoprotein cholesterol</td> <td class=\"centered\">PROM</td> <td>Premature rupture of membranes</td> </tr> <tr> <td class=\"centered\">AST</td> <td>Aspartate aminotransferase (formerly called SGOT)</td> <td class=\"centered\">HF</td> <td>Heart failure</td> <td class=\"centered\">PSVT</td> <td>Paroxysmal supraventricular tachycardia</td> </tr> <tr> <td class=\"centered\">ATP</td> <td>Adenosine triphosphate</td> <td class=\"centered\">HFA</td> <td>Hydrofluoroalkane</td> <td class=\"centered\">PT</td> <td>Prothrombin time</td> </tr> <tr> <td class=\"centered\">AUC</td> <td>Area under the curve (area under the serum concentration-time curve)</td> <td class=\"centered\">HFSA</td> <td>Heart Failure Society of America</td> <td class=\"centered\">PTH</td> <td>Parathyroid hormone</td> </tr> <tr> <td class=\"centered\">A-V</td> <td>Atrial-ventricular</td> <td class=\"centered\">Hgb</td> <td>Hemoglobin</td> <td class=\"centered\">PTSD</td> <td>Post-traumatic stress disorder</td> </tr> <tr> <td class=\"centered\">AVNRT</td> <td>Atrioventricular nodal reentrant tachycardia</td> <td class=\"centered\">HIV</td> <td>Human immunodeficiency virus</td> <td class=\"centered\">PTT</td> <td>Partial thromboplastin time</td> </tr> <tr> <td class=\"centered\">AVRT</td> <td>Atrioventricular reentrant tachycardia</td> <td class=\"centered\">HMG-CoA</td> <td>3-hydroxy-3-methylglutaryl-coenzyme A</td> <td class=\"centered\">PUD</td> <td>Peptic ulcer disease</td> </tr> <tr> <td class=\"centered\">BCRP</td> <td>Breast cancer resistance protein</td> <td class=\"centered\">HOCM</td> <td>Hypertrophic obstructive cardiomyopathy</td> <td class=\"centered\">PVC</td> <td>Premature ventricular contraction</td> </tr> <tr> <td class=\"centered\">BDI</td> <td>Beck Depression Inventory</td> <td class=\"centered\">HPA</td> <td>Hypothalamic-pituitary-adrenal</td> <td class=\"centered\">PVD</td> <td>Peripheral vascular disease</td> </tr> <tr> <td class=\"centered\">BEC</td> <td>Blood ethanol concentration</td> <td class=\"centered\">HPLC</td> <td>High performance liquid chromatography</td> <td class=\"centered\">PVR</td> <td>Peripheral vascular resistance</td> </tr> <tr> <td class=\"centered\">BLS</td> <td>Basic life support</td> <td class=\"centered\">HSV</td> <td>Herpes simplex virus</td> <td class=\"centered\">QTc</td> <td>Corrected QT interval</td> </tr> <tr> <td class=\"centered\">BMI</td> <td>Body mass index</td> <td class=\"centered\">HTC</td> <td>Hematopoietic cell transplantation</td> <td class=\"centered\">QTc-F</td> <td>Corrected QT interval - Fridericia</td> </tr> <tr> <td class=\"centered\">BMT</td> <td>Bone marrow transplant</td> <td class=\"centered\">HTN</td> <td>Hypertension</td> <td class=\"centered\">R</td> <td>Ringer's injection</td> </tr> <tr> <td class=\"centered\">BP</td> <td>Blood pressure</td> <td class=\"centered\">HUS</td> <td>Hemolytic uremic syndrome</td> <td class=\"centered\">RA</td> <td>Rheumatoid arthritis</td> </tr> <tr> <td class=\"centered\">BPD</td> <td>Bronchopulmonary disease or dysplasia</td> <td class=\"centered\">IBD</td> <td>Inflammatory bowel disease</td> <td class=\"centered\">RAP</td> <td>Right arterial pressure</td> </tr> <tr> <td class=\"centered\">BPH</td> <td>Benign prostatic hyperplasia</td> <td class=\"centered\">IBS</td> <td>Irritable bowel syndrome</td> <td class=\"centered\">RDA</td> <td>Recommended daily allowance</td> </tr> <tr> <td class=\"centered\">BPRS</td> <td>Brief Psychiatric Rating Scale</td> <td class=\"centered\">IBW</td> <td>Ideal body weight</td> <td class=\"centered\">REM</td> <td>Rapid eye movement</td> </tr> <tr> <td class=\"centered\">BSA</td> <td>Body surface area</td> <td class=\"centered\">ICD</td> <td>Implantable cardioverter defibrillator</td> <td class=\"centered\">REMS</td> <td>Risk evaluation and mitigation strategies</td> </tr> <tr> <td class=\"centered\">BSEP</td> <td>Bile salt export pump</td> <td class=\"centered\">ICH</td> <td>Intracranial hemorrhage</td> <td class=\"centered\">RIA</td> <td>Radioimmunoassay</td> </tr> <tr> <td class=\"centered\">BUN</td> <td>Blood urea nitrogen</td> <td class=\"centered\">ICP</td> <td>Intracranial pressure</td> <td class=\"centered\">RNA</td> <td>Ribonucleic acid</td> </tr> <tr> <td class=\"centered\">CABG</td> <td>Coronary artery bypass graft</td> <td class=\"centered\">IDDM</td> <td>Insulin-dependent diabetes mellitus</td> <td class=\"centered\">RPLS</td> <td>Reversible posterior leukoencephalopathy syndrome</td> </tr> <tr> <td class=\"centered\">CAD</td> <td>Coronary artery disease</td> <td class=\"centered\">IDSA</td> <td>Infectious Diseases Society of America</td> <td class=\"centered\">RSV</td> <td>Respiratory syncytial virus</td> </tr> <tr> <td class=\"centered\">CADD</td> <td>Computer ambulatory drug delivery</td> <td class=\"centered\">IgG</td> <td>Immune globulin G</td> <td class=\"centered\">SA</td> <td>Sinoatrial</td> </tr> <tr> <td class=\"centered\">cAMP</td> <td>Cyclic adenosine monophosphate</td> <td class=\"centered\">IM</td> <td>Intramuscular</td> <td class=\"centered\">SAD</td> <td>Seasonal affective disorder</td> </tr> <tr> <td class=\"centered\">CAN</td> <td>Canadian</td> <td class=\"centered\">ILCOR</td> <td>International Liaison Committee on Resuscitation</td> <td class=\"centered\">SAH</td> <td>Subarachnoid hemorrhage</td> </tr> <tr> <td class=\"centered\">CAPD</td> <td>Continuous ambulatory peritoneal dialysis</td> <td class=\"centered\">INR</td> <td>International normalized ratio</td> <td class=\"centered\">SBE</td> <td>Subacute bacterial endocarditis</td> </tr> <tr> <td class=\"centered\">CAS</td> <td>Chemical abstract service</td> <td class=\"centered\">Int. unit</td> <td>International unit</td> <td class=\"centered\">SBP</td> <td>Systolic blood pressure</td> </tr> <tr> <td class=\"centered\">CBC</td> <td>Complete blood count</td> <td class=\"centered\">I.O. or IO</td> <td>Intraosseous</td> <td class=\"centered\">Scr</td> <td>Serum creatinine</td> </tr> <tr> <td class=\"centered\">CBT</td> <td>Cognitive behavioral therapy</td> <td class=\"centered\">I &#38; O</td> <td>Input and output</td> <td class=\"centered\">SCLC</td> <td>Small cell lung cancer</td> </tr> <tr> <td class=\"centered\">CDC</td> <td>Centers for Disease Control and Prevention</td> <td class=\"centered\">IOP</td> <td>Intraocular pressure</td> <td class=\"centered\">SERM</td> <td>Selective estrogen receptor modulator</td> </tr> <tr> <td class=\"centered\">CF</td> <td>Cystic fibrosis</td> <td class=\"centered\">IQ</td> <td>Intelligence quotient</td> <td class=\"centered\">SGA</td> <td>Small for gestational age</td> </tr> <tr> <td class=\"centered\">CFC</td> <td>Chlorofluorocarbons</td> <td class=\"centered\">I.T. or IT</td> <td>Intrathecal</td> <td class=\"centered\">SGOT</td> <td>Serum glutamic oxaloacetic aminotransferase</td> </tr> <tr> <td class=\"centered\">CGI</td> <td>Clinical Global Impression</td> <td class=\"centered\">ITP</td> <td>Immune thrombocytopenia</td> <td class=\"centered\">SGPT</td> <td>Serum glutamic pyruvate transaminase</td> </tr> <tr> <td class=\"centered\">CHD</td> <td>Coronary heart disease</td> <td class=\"centered\">IUGR</td> <td>Intrauterine growth retardation</td> <td class=\"centered\">SI</td> <td>International System of Units or Systeme international d'Unites</td> </tr> <tr> <td class=\"centered\">CHF</td> <td>Congestive heart failure; chronic heart failure</td> <td class=\"centered\">IV</td> <td>Intravenous</td> <td class=\"centered\">SIADH</td> <td>Syndrome of inappropriate antidiuretic hormone secretion</td> </tr> <tr> <td class=\"centered\">CI</td> <td>Cardiac index</td> <td class=\"centered\">IVH</td> <td>Intraventricular hemorrhage</td> <td class=\"centered\">SIDS</td> <td>Sudden infant death syndrome</td> </tr> <tr> <td class=\"centered\">CIE</td> <td>Chemotherapy-induced emesis</td> <td class=\"centered\">IVP</td> <td>Intravenous push</td> <td class=\"centered\">SL</td> <td>Sodium lactate</td> </tr> <tr> <td class=\"centered\">C-II</td> <td>Schedule two controlled substance</td> <td class=\"centered\">IVPB</td> <td>Intravenous piggyback</td> <td class=\"centered\">SLCO1B1</td> <td>Solute carrier organic anion transporter family member 1B1</td> </tr> <tr> <td class=\"centered\">C-III</td> <td>Schedule three controlled substance</td> <td class=\"centered\">JIA</td> <td>Juvenile idiopathic arthritis</td> <td class=\"centered\">SLE</td> <td>Systemic lupus erythematosus</td> </tr> <tr> <td class=\"centered\">C-IV</td> <td>Schedule four controlled substance</td> <td class=\"centered\">JNC</td> <td>Joint National Committee</td> <td class=\"centered\">SLEDD</td> <td>Sustained low-efficiency daily diafiltration</td> </tr> <tr> <td class=\"centered\">C-V</td> <td>Schedule five controlled substance</td> <td class=\"centered\">JRA</td> <td>Juvenile rheumatoid arthritis</td> <td class=\"centered\">SNRI</td> <td>Serotonin norepinephrine reuptake inhibitor</td> </tr> <tr> <td class=\"centered\">CIV</td> <td>Continuous intravenous infusion</td> <td class=\"centered\">kg</td> <td>Kilogram</td> <td class=\"centered\">SSKI</td> <td>Saturated solution of potassium iodide</td> </tr> <tr> <td class=\"centered\">Cl<sub>cr</sub></td> <td>Creatinine clearance</td> <td class=\"centered\">KIU</td> <td>Kallikrein inhibitor unit</td> <td class=\"centered\">SSRIs</td> <td>Selective serotonin reuptake inhibitors</td> </tr> <tr> <td class=\"centered\">CLL</td> <td>Chronic lymphocytic leukemia</td> <td class=\"centered\">KOH</td> <td>Potassium hydroxide</td> <td class=\"centered\">STD</td> <td>Sexually transmitted disease</td> </tr> <tr> <td class=\"centered\">C<sub>max</sub></td> <td>Maximum plasma concentration</td> <td class=\"centered\">LAMM</td> <td>L-&#945;-acetyl methadol</td> <td class=\"centered\">STEMI</td> <td>ST-elevation myocardial infarction</td> </tr> <tr> <td class=\"centered\">C<sub>min</sub></td> <td>Minimum plasma concentration</td> <td class=\"centered\">LDH</td> <td>Lactate dehydrogenase</td> <td class=\"centered\">SubQ</td> <td>Subcutaneous</td> </tr> <tr> <td class=\"centered\">CML</td> <td>Chronic myelogenous leukemia</td> <td class=\"centered\">LDL-C</td> <td>Low density lipoprotein cholesterol</td> <td class=\"centered\">SVR</td> <td>Systemic vascular resistance</td> </tr> <tr> <td class=\"centered\">CMV</td> <td>Cytomegalovirus</td> <td class=\"centered\">LE</td> <td>Lupus erythematosus</td> <td class=\"centered\">SVT</td> <td>Supraventricular tachycardia</td> </tr> <tr> <td class=\"centered\">CNS</td> <td>Central nervous system or coagulase negative staphylococcus</td> <td class=\"centered\">LFT</td> <td>Liver function test</td> <td class=\"centered\">SWFI</td> <td>Sterile water for injection</td> </tr> <tr> <td class=\"centered\">COLD</td> <td>Chronic obstructive lung disease</td> <td class=\"centered\">LGA</td> <td>Large for gestational age</td> <td class=\"centered\">SWI</td> <td>Sterile water for injection</td> </tr> <tr> <td class=\"centered\">COMT</td> <td>Catechol-<em>O</em>-methyltransferase</td> <td class=\"centered\">LH</td> <td>Luteinizing hormone</td> <td class=\"centered\">T&#189;</td> <td>Half-life</td> </tr> <tr> <td class=\"centered\">COPD</td> <td>Chronic obstructive pulmonary disease</td> <td class=\"centered\">LP</td> <td>Lumbar posture</td> <td class=\"centered\">T<sub>3</sub></td> <td>Triiodothyronine</td> </tr> <tr> <td class=\"centered\">COX</td> <td>Cyclooxygenase</td> <td class=\"centered\">LR</td> <td>Lactated Ringer's solution</td> <td class=\"centered\">T<sub>4</sub></td> <td>Thyroxine</td> </tr> <tr> <td class=\"centered\">CPK</td> <td>Creatine phosphokinase</td> <td class=\"centered\">LV</td> <td>Left ventricular</td> <td class=\"centered\">TB</td> <td>Tuberculosis</td> </tr> <tr> <td class=\"centered\">CPR</td> <td>Cardiopulmonary resuscitation</td> <td class=\"centered\">LVEF</td> <td>Left ventricular ejection fraction</td> <td class=\"centered\">TC</td> <td>Total cholesterol</td> </tr> <tr> <td class=\"centered\">CRF</td> <td>Chronic renal failure</td> <td class=\"centered\">LVH</td> <td>Left ventricular hypertrophy</td> <td class=\"centered\">TCA</td> <td>Tricyclic antidepressant</td> </tr> <tr> <td class=\"centered\">CRP</td> <td>C-reactive protein</td> <td class=\"centered\">MAC</td> <td><em>Mycobacterium avium</em> complex</td> <td class=\"centered\">TD</td> <td>Tardive dyskinesia</td> </tr> <tr> <td class=\"centered\">CrCl</td> <td>Creatinine clearance</td> <td class=\"centered\">MADRS</td> <td>Montgomery Asbery Depression Rating Scale</td> <td class=\"centered\">TG</td> <td>Triglyceride</td> </tr> <tr> <td class=\"centered\">CRRT</td> <td>Continuous renal replacement therapy</td> <td class=\"centered\">MAO</td> <td>Monoamine oxidase</td> <td class=\"centered\">TIA</td> <td>Transient ischemic attack</td> </tr> <tr> <td class=\"centered\">CSF</td> <td>Cerebrospinal fluid</td> <td class=\"centered\">MAOIs</td> <td>Monamine oxidase inhibitors</td> <td class=\"centered\">TIBC</td> <td>Total iron binding capacity</td> </tr> <tr> <td class=\"centered\">CSII</td> <td>Continuous subcutaneous insulin infusion</td> <td class=\"centered\">MAP</td> <td>Mean arterial pressure</td> <td class=\"centered\">TMA</td> <td>Thrombotic microangiopathy</td> </tr> <tr> <td class=\"centered\">CT</td> <td>Computed tomography</td> <td class=\"centered\">MDD</td> <td>Major depressive disorder</td> <td class=\"centered\">T<sub>max</sub></td> <td>Time to maximum observed concentration, plasma</td> </tr> <tr> <td class=\"centered\">CVA</td> <td>Cerebrovascular accident</td> <td class=\"centered\">MDR1</td> <td>Multidrug resistence protein 1</td> <td class=\"centered\">TNF</td> <td>Tumor necrosis factor</td> </tr> <tr> <td class=\"centered\">CVP</td> <td>Central venous pressure</td> <td class=\"centered\">MDRD</td> <td>Modification of diet in renal disease</td> <td class=\"centered\">TPN</td> <td>Total parenteral nutrition</td> </tr> <tr> <td class=\"centered\">CVVH</td> <td>Continuous venovenous hemofiltration</td> <td class=\"centered\">MDRSP</td> <td>Multidrug resistant <em>streptococcus pneumoniae</em></td> <td class=\"centered\">TSH</td> <td>Thyroid stimulating hormone</td> </tr> <tr> <td class=\"centered\">CVVHD</td> <td>Continuous venovenous hemodialysis</td> <td class=\"centered\">MI</td> <td>Myocardial infarction</td> <td class=\"centered\">TT</td> <td>Thrombin time</td> </tr> <tr> <td class=\"centered\">CVVHDF</td> <td>Continuous venovenous hemodiafiltration</td> <td class=\"centered\">MMSE</td> <td>Mini mental status examination</td> <td class=\"centered\">UA</td> <td>Urine analysis</td> </tr> <tr> <td class=\"centered\">CYP</td> <td>Cytochrome</td> <td class=\"centered\">M/P</td> <td>Milk to plasma ratio</td> <td class=\"centered\">UC</td> <td>Ulcerative colitis</td> </tr> <tr> <td class=\"centered\">D5&#188;NS</td> <td>Dextrose 5% in sodium chloride 0.2%</td> <td class=\"centered\">MPS I</td> <td>Mucopolysaccharidosis I</td> <td class=\"centered\">UGT</td> <td>UDP-glucuronosyltransferase</td> </tr> <tr> <td class=\"centered\">D5&#189;NS</td> <td>Dextrose 5% in sodium chloride 0.45%</td> <td class=\"centered\">MRHD</td> <td>Maximum recommended human dose</td> <td class=\"centered\">ULN</td> <td>Upper limits of normal</td> </tr> <tr> <td class=\"centered\">D5LR</td> <td>Dextrose 5% in lactated Ringer's</td> <td class=\"centered\">MRI</td> <td>Magnetic resonance imaging</td> <td class=\"centered\">URI</td> <td>Upper respiratory infection</td> </tr> <tr> <td class=\"centered\">D5NS</td> <td>Dextrose 5% in sodium chloride 0.9%</td> <td class=\"centered\">MRP2</td> <td>Multidrug resistance-associated protein 2</td> <td class=\"centered\">USAN</td> <td>United States Adopted Names</td> </tr> <tr> <td class=\"centered\">D5W</td> <td>Dextrose 5% in water</td> <td class=\"centered\">MRSA</td> <td>Methicillin-resistant <em>Staphylococcus aureus</em></td> <td class=\"centered\">USP</td> <td>United States Pharmacopeia</td> </tr> <tr> <td class=\"centered\">D10W</td> <td>Dextrose 10% in water</td> <td class=\"centered\">MUGA</td> <td>Multiple gated acquisition scan</td> <td class=\"centered\">UTI</td> <td>Urinary tract infection</td> </tr> <tr> <td class=\"centered\">DBP</td> <td>Diastolic blood pressure</td> <td class=\"centered\">NAEPP</td> <td>National Asthma Education and Prevention Program</td> <td class=\"centered\">UV</td> <td>Ultraviolet</td> </tr> <tr> <td class=\"centered\">DEHP</td> <td>Di(3-ethylhexyl)phthalate</td> <td class=\"centered\">NAS</td> <td>Neonatal abstinence syndrome</td> <td class=\"centered\">V<sub>d</sub></td> <td>Volume of distribution</td> </tr> <tr> <td class=\"centered\">DIC</td> <td>Disseminated intravascular coagulation</td> <td class=\"centered\">NCI</td> <td>National Cancer Institute</td> <td class=\"centered\">V<sub>dss</sub></td> <td>Volume of distribution at steady-state</td> </tr> <tr> <td class=\"centered\">DLco</td> <td>Pulmonary diffusion capacity for carbon monoxide</td> <td class=\"centered\">ND</td> <td>Nasoduodenal</td> <td class=\"centered\">VEGF</td> <td>Vascular endothelial growth factor</td> </tr> <tr> <td class=\"centered\">DM</td> <td>Diabetes mellitus</td> <td class=\"centered\">NF</td> <td>National Formulary</td> <td class=\"centered\">VF</td> <td>Ventricular fibrillation</td> </tr> <tr> <td class=\"centered\">DMARD</td> <td>Disease modifying antirheumatic drug</td> <td class=\"centered\">NFD</td> <td>Nephrogenic fibrosing dermopathy</td> <td class=\"centered\">VLBW</td> <td>Very low birth weight</td> </tr> <tr> <td class=\"centered\">DNA</td> <td>Deoxyribonucleic acid</td> <td class=\"centered\">NG</td> <td>Nasogastric</td> <td class=\"centered\">VMA</td> <td>Vanillylmandelic acid</td> </tr> <tr> <td class=\"centered\">DSC</td> <td>Discontinued</td> <td class=\"centered\">NHL</td> <td>Non-Hodgkin lymphoma</td> <td class=\"centered\">VT</td> <td>Ventricular tachycardia</td> </tr> <tr> <td class=\"centered\">DSM-IV</td> <td>Diagnostic and Statistical Manual</td> <td class=\"centered\">NIDDM</td> <td>Noninsulin-dependent diabetes mellitus</td> <td class=\"centered\">VTE</td> <td>Venous thromboembolism</td> </tr> <tr> <td class=\"centered\">DVT</td> <td>Deep vein thrombosis</td> <td class=\"centered\">NIOSH</td> <td>National Institute for Occupational Safety and Health</td> <td class=\"centered\">vWD</td> <td>Von Willebrand disease</td> </tr> <tr> <td class=\"centered\">EBV</td> <td>Epstein-Barr virus</td> <td class=\"centered\">NIH</td> <td>National Institute of Health</td> <td class=\"centered\">VZV</td> <td>Varicella zoster virus</td> </tr> <tr> <td class=\"centered\">ECG</td> <td>Electrocardiogram</td> <td class=\"centered\">NKA</td> <td>No known allergies</td> <td class=\"centered\">WHO</td> <td>World Health Organization</td> </tr> <tr> <td class=\"centered\">ECHO</td> <td>Echocardiogram</td> <td class=\"centered\">NKDA</td> <td>No known drug allergies</td> <td class=\"centered\">w/v</td> <td>Weight&nbsp;in volume</td> </tr> <tr> <td class=\"centered\">eGFR</td> <td>Estimated glomerular filtration rate</td> <td class=\"centered\">NMDA</td> <td>N-methyl-d-aspartate</td> <td class=\"centered\">w/w</td> <td>Weight&nbsp;in weight</td> </tr> <tr> <td class=\"centered\">ECMO</td> <td>Extracorporeal membrane oxygenation</td> <td class=\"centered\">NMS</td> <td>Neuroleptic malignant syndrome</td> <td class=\"centered\">YBOC</td> <td>Yale Brown Obsessive-Compulsive Scale</td> </tr> <tr> <td class=\"centered\">ECT</td> <td>Electroconvulsive therapy</td> <td class=\"centered\">NNRTI</td> <td>Non-nucleoside reverse transcriptase inhibitor</td> <td class=\"centered\">YMRS</td> <td>Young Mania Rating Scale</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">ED</td> <td>Emergency department</td> <td class=\"centered\">NRTI</td> <td>Nucleoside reverse transcriptase inhibitor</td> <td class=\"centered\">&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Country abbreviations used in \"International Brand Names\" field of Lexicomp</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Argentina (AR)</td> <td class=\"centered\" colspan=\"2\">Guinea (GN)</td> <td class=\"centered\" colspan=\"2\">Oman (OM)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Australia (AU)</td> <td class=\"centered\" colspan=\"2\">Guyana (GY)</td> <td class=\"centered\" colspan=\"2\">Pakistan (PK)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Austria (AT)</td> <td class=\"centered\" colspan=\"2\">Honduras (HN)</td> <td class=\"centered\" colspan=\"2\">Panama (PA)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Bahamas (BS)</td> <td class=\"centered\" colspan=\"2\">Hong Kong (HK)</td> <td class=\"centered\" colspan=\"2\">Paraguay (PY)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Bahrain (BH)</td> <td class=\"centered\" colspan=\"2\">Hungary (HU)</td> <td class=\"centered\" colspan=\"2\">Peru (PE)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Bangladesh (BD)</td> <td class=\"centered\" colspan=\"2\">Iceland (IS)</td> <td class=\"centered\" colspan=\"2\">Philippines (PH)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Barbados (BB)</td> <td class=\"centered\" colspan=\"2\">India (IN)</td> <td class=\"centered\" colspan=\"2\">Poland (PL)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Belgium (BE)</td> <td class=\"centered\" colspan=\"2\">Indonesia (ID)</td> <td class=\"centered\" colspan=\"2\">Portugal (PT)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Belize (BZ)</td> <td class=\"centered\" colspan=\"2\">Iran (IR)</td> <td class=\"centered\" colspan=\"2\">Puerto Rico (PR)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Benin (BJ)</td> <td class=\"centered\" colspan=\"2\">Iraq (IQ)</td> <td class=\"centered\" colspan=\"2\">Qatar (QA)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Bermuda (BM)</td> <td class=\"centered\" colspan=\"2\">Ireland (IE)</td> <td class=\"centered\" colspan=\"2\">Russia (RU)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Bolivia (BO)</td> <td class=\"centered\" colspan=\"2\">Israel (IL)</td> <td class=\"centered\" colspan=\"2\">Saudi Arabia (SA)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Brazil (BR)</td> <td class=\"centered\" colspan=\"2\">Italy (IT)</td> <td class=\"centered\" colspan=\"2\">Senegal (SN)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Bulgaria (BG)</td> <td class=\"centered\" colspan=\"2\">Ivory Coast (CI)</td> <td class=\"centered\" colspan=\"2\">Seychelles (SC)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Burkina Faso (BF)</td> <td class=\"centered\" colspan=\"2\">Jamaica (JM)</td> <td class=\"centered\" colspan=\"2\">Sierra Leone (SL)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Canada (CA)</td> <td class=\"centered\" colspan=\"2\">Japan (JP)</td> <td class=\"centered\" colspan=\"2\">Singapore (SG)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Chile (CL)</td> <td class=\"centered\" colspan=\"2\">Jordan (JO)</td> <td class=\"centered\" colspan=\"2\">Slovakia (SK)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">China (CN)</td> <td class=\"centered\" colspan=\"2\">Kenya (KE)</td> <td class=\"centered\" colspan=\"2\">Slovenia (SI)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Colombia (CO)</td> <td class=\"centered\" colspan=\"2\">Korea (KP)</td> <td class=\"centered\" colspan=\"2\">South Africa (ZA)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Costa Rica (CR)</td> <td class=\"centered\" colspan=\"2\">Kuwait (KW)</td> <td class=\"centered\" colspan=\"2\">Spain (ES)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Croatia (HR)</td> <td class=\"centered\" colspan=\"2\">Lebanon (LB)</td> <td class=\"centered\" colspan=\"2\">Sudan (SD)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Cyprus (CY)</td> <td class=\"centered\" colspan=\"2\">Liberia (LR)</td> <td class=\"centered\" colspan=\"2\">Surinam (SR)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Czech Republic (CZ)</td> <td class=\"centered\" colspan=\"2\">Libya (LY)</td> <td class=\"centered\" colspan=\"2\">Sweden (SE)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Denmark (DK)</td> <td class=\"centered\" colspan=\"2\">Luxembourg (LU)</td> <td class=\"centered\" colspan=\"2\">Switzerland (CH)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Dominican Republic (DO)</td> <td class=\"centered\" colspan=\"2\">Malawi (MW)</td> <td class=\"centered\" colspan=\"2\">Syria (SY)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Ecuador (EC)</td> <td class=\"centered\" colspan=\"2\">Malaysia (MY)</td> <td class=\"centered\" colspan=\"2\">Taiwan (TW)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Egypt (EG)</td> <td class=\"centered\" colspan=\"2\">Mali (ML)</td> <td class=\"centered\" colspan=\"2\">Tanzania (TZ)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">El Salvador (SV)</td> <td class=\"centered\" colspan=\"2\">Malta (MT)</td> <td class=\"centered\" colspan=\"2\">Thailand (TH)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Estonia (EE)</td> <td class=\"centered\" colspan=\"2\">Mauritania (MR)</td> <td class=\"centered\" colspan=\"2\">Trinidad and Tobago (TT)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Ethiopia (ET)</td> <td class=\"centered\" colspan=\"2\">Mauritius (MU)</td> <td class=\"centered\" colspan=\"2\">Tunisia (TN)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Finland (FI)</td> <td class=\"centered\" colspan=\"2\">Mexico (MX)</td> <td class=\"centered\" colspan=\"2\">Turkey (TR)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">France (FR)</td> <td class=\"centered\" colspan=\"2\">Morocco (MA)</td> <td class=\"centered\" colspan=\"2\">Uganda (UG)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Gambia (GM)</td> <td class=\"centered\" colspan=\"2\">Netherlands (NL)</td> <td class=\"centered\" colspan=\"2\">United Arab Emirates (AE)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Germany (DE)</td> <td class=\"centered\" colspan=\"2\">New Zealand (NZ)</td> <td class=\"centered\" colspan=\"2\">Uruguay (UY)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Ghana (GH)</td> <td class=\"centered\" colspan=\"2\">Nicaragua (NI)</td> <td class=\"centered\" colspan=\"2\">Venezuela (VE)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Great Britain [UK] (GB)</td> <td class=\"centered\" colspan=\"2\">Niger (NE)</td> <td class=\"centered\" colspan=\"2\">Yemen (YE)</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">Greece (GR)</td> <td class=\"centered\" colspan=\"2\">Nigeria (NG)</td> <td class=\"centered\" colspan=\"2\">Zambia (ZM)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\" colspan=\"2\">Guatemala (GT)</td> <td class=\"centered\" colspan=\"2\">Norway (NO)</td> <td class=\"centered\" colspan=\"2\">Zimbabwe (ZW)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Common weights, measures, or apothecary abbreviations that may be used in Lexicomp*</td> </tr> <tr> <td class=\"centered\">&#60;<sup>&#182;</sup></td> <td>Less than</td> <td class=\"centered\">F</td> <td>Fahrenheit</td> <td class=\"centered\">pc, post cib</td> <td>After meals</td> </tr> <tr> <td class=\"centered\">&#62;<sup>&#182;</sup></td> <td>Greater than</td> <td class=\"centered\">g</td> <td>Gram</td> <td class=\"centered\">PM</td> <td>Afternoon or evening</td> </tr> <tr> <td class=\"centered\">&#8804;</td> <td>Less than or equal to</td> <td class=\"centered\">gr</td> <td>Grain</td> <td class=\"centered\">P.O.</td> <td>By mouth</td> </tr> <tr> <td class=\"centered\">&#8805;</td> <td>Greater than or equal to</td> <td class=\"centered\">gtt</td> <td>One drop</td> <td class=\"centered\">P.R.</td> <td>Rectally</td> </tr> <tr> <td class=\"centered\">ac</td> <td>Before meals or food</td> <td class=\"centered\">h</td> <td>Hour</td> <td class=\"centered\">prn</td> <td>As needed</td> </tr> <tr> <td class=\"centered\">ad</td> <td>To, up to</td> <td class=\"centered\">hs<sup>&#182;</sup></td> <td>At bedtime</td> <td class=\"centered\">pulv</td> <td>A powder</td> </tr> <tr> <td class=\"centered\">ad lib</td> <td>At pleasure</td> <td class=\"centered\">kcal</td> <td>Kilocalorie</td> <td class=\"centered\">q</td> <td>Every</td> </tr> <tr> <td class=\"centered\">AM</td> <td>Morning</td> <td class=\"centered\">kg</td> <td>Kilogram</td> <td class=\"centered\">qad</td> <td>Every other day</td> </tr> <tr> <td class=\"centered\">AMA</td> <td>Against medical advice</td> <td class=\"centered\">L</td> <td>Liter</td> <td class=\"centered\">qd<sup>&#182;</sup></td> <td>Every day, daily</td> </tr> <tr> <td class=\"centered\">amp</td> <td>Ampul</td> <td class=\"centered\">liq</td> <td>A liquor, solution</td> <td class=\"centered\">qh</td> <td>Every hour</td> </tr> <tr> <td class=\"centered\">amt</td> <td>Amount</td> <td class=\"centered\">M</td> <td>Molar</td> <td class=\"centered\">qid</td> <td>Four times a day</td> </tr> <tr> <td class=\"centered\">aq</td> <td>Water</td> <td class=\"centered\">mcg</td> <td>Microgram</td> <td class=\"centered\">qod<sup>&#182;</sup></td> <td>Every other day</td> </tr> <tr> <td class=\"centered\">aq. dest.</td> <td>Distilled water</td> <td class=\"centered\">m. dict</td> <td>As directed</td> <td class=\"centered\">qs</td> <td>A sufficient quantity</td> </tr> <tr> <td class=\"centered\">ASAP</td> <td>As soon as possible</td> <td class=\"centered\">mEq</td> <td>Milliequivalent</td> <td class=\"centered\">qs ad</td> <td>A sufficient quantity to make</td> </tr> <tr> <td class=\"centered\">a.u.<sup>&#182;</sup></td> <td>Each ear</td> <td class=\"centered\">mg</td> <td>Milligram</td> <td class=\"centered\">Rx</td> <td>Take, a recipe</td> </tr> <tr> <td class=\"centered\">bid</td> <td>Twice daily</td> <td class=\"centered\">microL</td> <td>Microliter</td> <td class=\"centered\">S.L.</td> <td>Sublingual</td> </tr> <tr> <td class=\"centered\">bm</td> <td>Bowel movement</td> <td class=\"centered\">min</td> <td>Minute</td> <td class=\"centered\">stat</td> <td>At once, immediately</td> </tr> <tr> <td class=\"centered\">C</td> <td>Celsius, centigrade</td> <td class=\"centered\">mL</td> <td>Milliliter</td> <td class=\"centered\">SubQ</td> <td>Subcutaneous</td> </tr> <tr> <td class=\"centered\">cal</td> <td>Calorie</td> <td class=\"centered\">mm</td> <td>Millimeter</td> <td class=\"centered\">supp</td> <td>Suppository</td> </tr> <tr> <td class=\"centered\">cap</td> <td>Capsule</td> <td class=\"centered\">mM</td> <td>Millimole</td> <td class=\"centered\">syr</td> <td>Syrup</td> </tr> <tr> <td class=\"centered\">cc<sup>&#182;</sup></td> <td>Cubic centimeter</td> <td class=\"centered\">mmHg</td> <td>Millimeters of mercury</td> <td class=\"centered\">tab</td> <td>Tablet</td> </tr> <tr> <td class=\"centered\">cm</td> <td>Centimeter</td> <td class=\"centered\">mo</td> <td>Month</td> <td class=\"centered\">tal</td> <td>Such</td> </tr> <tr> <td class=\"centered\">comp</td> <td>Compound</td> <td class=\"centered\">mOsm</td> <td>Milliosmoles</td> <td class=\"centered\">tid</td> <td>Three times a day</td> </tr> <tr> <td class=\"centered\">cont</td> <td>Continue</td> <td class=\"centered\">ng</td> <td>Nanogram</td> <td class=\"centered\">tr, tinct</td> <td>Tincture</td> </tr> <tr> <td class=\"centered\">d</td> <td>Day</td> <td class=\"centered\">nmol</td> <td>Nanomole</td> <td class=\"centered\">trit</td> <td>Triturate</td> </tr> <tr> <td class=\"centered\">d/c<sup>&#182;</sup></td> <td>Discharge</td> <td class=\"centered\">no.</td> <td>Number</td> <td class=\"centered\">tsp</td> <td>Teaspoon</td> </tr> <tr> <td class=\"centered\">dil</td> <td>Dilute</td> <td class=\"centered\">noc</td> <td>In the night</td> <td class=\"centered\">u.d.</td> <td>As directed</td> </tr> <tr> <td class=\"centered\">disp</td> <td>Dispense</td> <td class=\"centered\">non rep</td> <td>Do not repeat, no refills</td> <td class=\"centered\">ung</td> <td>Ointment</td> </tr> <tr> <td class=\"centered\">div</td> <td>Divide</td> <td class=\"centered\">NPO</td> <td>Nothing by mouth</td> <td class=\"centered\">v.o.</td> <td>Verbal order</td> </tr> <tr> <td class=\"centered\">dtd</td> <td>Give of such a dose</td> <td class=\"centered\">NV</td> <td>Nausea and vomiting</td> <td class=\"centered\">w.a.</td> <td>While awake</td> </tr> <tr> <td class=\"centered\">Dx</td> <td>Diagnosis</td> <td class=\"centered\">O, Oct</td> <td>One pint</td> <td class=\"centered\">x3</td> <td>Three times</td> </tr> <tr> <td class=\"centered\">elix, el</td> <td>Elixir</td> <td class=\"centered\">o.d.<sup>&#182;</sup></td> <td>Right eye</td> <td class=\"centered\">x4</td> <td>Four times</td> </tr> <tr> <td class=\"centered\">emp</td> <td>As directed</td> <td class=\"centered\">o.l.</td> <td>Left eye</td> <td class=\"centered\">y</td> <td>Year</td> </tr> <tr> <td class=\"centered\">et</td> <td>And</td> <td class=\"centered\">o.s.<sup>&#182;</sup></td> <td>Left eye</td> <td class=\"centered\">&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"centered\">ex aq</td> <td>In water</td> <td class=\"centered\">o.u.<sup>&#182;</sup></td> <td>Each eye</td> <td class=\"centered\">&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Definitions for the two letter country codes used in \"International Brand Names\" field of Lexicomp are also available at the International Standards Organization (ISO) website: <a href=\"https://www.iso.org/obp/ui/#search\" target=\"_blank\">https://www.iso.org/obp/ui/#search</a>.</div><div class=\"graphic_footnotes\">* Additional abbreviations used and defined within a specific drug monograph or text piece may only apply to that text.<br />&para; These abbreviations are considered error-prone according to the Institute for Safe Medicine Practices.<sup>[1]</sup></div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>The Institute for Safe Medication Practices (ISMP) list of Error-Prone Abbreviations, Symbols, and Dose Designations. Available at <A href=\"http://www.ismp.org/Tools/errorproneabbreviations.pdf\" target=_blank>http://www.ismp.org/Tools/errorproneabbreviations.pdf</A>.</LI></OL>Reproduced with permission from: Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 57469 Version 30.0</div></div></div>"},"57470":{"type":"graphic_table","displayName":"Ampicillin and aminoglycoside resistance in enterococci","title":"Mechanisms of ampicillin and aminoglycoside resistance in enterococci","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mechanisms of ampicillin and aminoglycoside resistance in enterococci</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Resistance</td> <td class=\"subtitle1\">Typical MIC (mcg/mL)</td> <td class=\"subtitle1\">Mechanism or enzyme</td> <td class=\"subtitle1\">Species</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"2\">Ampicillin</td> <td>4&nbsp;to &#62;128</td> <td>Beta-lactamase production</td> <td><em>E. faecalis</em></td> <td>Rare. Specific&nbsp;beta-lactamase test is required (eg, nitrocefin)</td> </tr> <tr> <td>&#8805;16</td> <td>Low-affinity PBP, increased production of PBP5, or penicillin-insensitive transpeptidation</td> <td><em>E. faecium</em></td> <td>For isolates with MIC &#8804;64, high-dose ampicillin might be effective</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Aminoglycosides*</td> </tr> <tr> <td class=\"indent1\" rowspan=\"8\">HLR gentamicin</td> <td rowspan=\"2\">&#62;500</td> <td rowspan=\"2\">Bifunctional enzyme AAC(6')-Ie-APH(2\")-Ia</td> <td><em>E. faecium</em></td> <td rowspan=\"2\">Common; streptomycin remains active<sup>&#182;</sup></td> </tr> <tr> <td><em>E. faecalis</em></td> </tr> <tr> <td rowspan=\"2\">&#62;500</td> <td rowspan=\"2\">APH(2\")-Id</td> <td><em>E. faecium</em></td> <td rowspan=\"2\">Rare; streptomycin remains active<sup>&#182;</sup></td> </tr> <tr> <td><em>E. casseliflavus</em></td> </tr> <tr> <td rowspan=\"3\">64&nbsp;to 256</td> <td rowspan=\"3\">APH(2\")-Ic</td> <td><em>E. gallinarum</em></td> <td>It may not be detected by routine screening tests</td> </tr> <tr> <td><em>E. faecium</em></td> <td rowspan=\"2\">Streptomycin remains active<sup>&#182;</sup></td> </tr> <tr> <td><em>E. faecalis</em></td> </tr> <tr> <td>&#62;500</td> <td>APH(2\")-Ib</td> <td><em>E. faecium</em></td> <td>Streptomycin remains active<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">HLR streptomycin</td> <td rowspan=\"2\">&#62;1000</td> <td rowspan=\"2\">Adenylyltransferase (ANT), ribosomal mutation</td> <td><em>E. faecium</em></td> <td rowspan=\"2\">Gentamicin remains active<sup>&#916;</sup></td> </tr> <tr> <td><em>E. faecalis</em></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MIC: minimum inhibitory concentration; PBP: penicillin-binding protein; HLR: high-level resistance; APH: aminoglycoside phosphotransferase; AAC: aminoglycoside acetyltransferase.<br />* Screening for HLR to aminoglycosides should be performed on a routine bases when a synergistic effect is required following the National Committee for Clinical Laboratory Standards (NCCLS) recommendations<SUP>[1]</SUP>&nbsp;(Refer to UpToDate topic on mechanisms of antibiotic resistance in enterococci).<br />¶&nbsp;Testing for HLR to streptomycin should be performed.<br />Δ Testing for HLR to gentamicin should be performed.</div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>​National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: Approved standard. Document M7-A6. NCCLS, Pennsylvania.</LI></OL></div><div id=\"graphicVersion\">Graphic 57470 Version 6.0</div></div></div>"},"57474":{"type":"graphic_table","displayName":"Other lacunar syndromes","title":"Other lacunar syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Other lacunar syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Modified pure motor hemiparesis with motor aphasia</td> </tr> <tr> <td>Pure motor hemiparesis sparing face</td> </tr> <tr> <td>Mesencephalo-thalamic syndrome</td> </tr> <tr> <td>Thalamic dementia</td> </tr> <tr> <td>Pure motor hemiparesis with horizontal gaze palsy</td> </tr> <tr> <td>Pure motor hemiparesis with crossed third-nerve palsy (Weber syndrome)</td> </tr> <tr> <td>Pure motor hemiparesis with crossed sixth-nerve palsy</td> </tr> <tr> <td>Pure motor hemiparesis with confusion</td> </tr> <tr> <td>Cerebellar ataxia with crossed third-nerve palsy (Claude syndrome)</td> </tr> <tr> <td>Hemiballismus</td> </tr> <tr> <td>Lower basilar branch syndrome -- dizziness, diplopia, gaze palsy, dysarthria, cerebellar ataxia, trigeminal numbness</td> </tr> <tr> <td>Lateral medullary syndrome</td> </tr> <tr> <td>Lateral pontomedullary syndrome</td> </tr> <tr> <td>Locked-in syndrome (bilateral pure motor hemiparesis)</td> </tr> <tr> <td>Pure dysarthria</td> </tr> <tr> <td>Acute dystonia of thalamic origin</td> </tr> <tr> <td>Lacunar state</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Fisher CM, Neurology 1982; 32:871.</div><div id=\"graphicVersion\">Graphic 57474 Version 3.0</div></div></div>"},"57475":{"type":"graphic_table","displayName":"Foods and drugs to avoid in CID","title":"Foods and medications to avoid in chemotherapy-induced diarrhea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Foods and medications to avoid in chemotherapy-induced diarrhea</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Food products</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Milk and dairy products (since lactase deficiency may be induced by mucosal injury)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Spicy foods</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Alcohol</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Caffeine-containing products</td>\n\n    </tr>\n\n    <tr>\n\n      <td>High fiber and high fat foods</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Some fruit juices (eg, prune juice, orange juice)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Medications</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Bulk laxatives</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Stool softeners</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Promotility drugs (eg, metoclopramide)</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">11.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=46204&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Foods_and_drugs_to_avoid_in.htm</title></head></div><div class=\"graphic_reference\">Adapted from: Wadler S, Benson AB, Engelking C, et al. J Clin Oncol 1998; 16:3169.</div><div id=\"graphicVersion\">Graphic 57475 Version 2.0</div></div></div>"},"57476":{"type":"graphic_table","displayName":"Anticoagulants in children with cancer","title":"Advantages and disadvantages of various anticoagulant agents in children with cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Advantages and disadvantages of various anticoagulant agents in children with cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"13%\"></colgroup><colgroup span=\"2\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Anticoagulant</td> <td class=\"subtitle1\">Monitoring</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages/complications</td> <td class=\"subtitle1\">Special considerations for children with cancer</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Unfractionated heparin (UFH)</td> <td class=\"divider_bottom\" rowspan=\"4\"> <p>aPTT</p> Anti-Xa</td> <td class=\"divider_bottom\" rowspan=\"4\">Easy reversal</td> <td>Bleeding<sup>[1]</sup></td> <td>Bleeding may be exaggerated due to thrombocytopenia and coagulopathy<sup>[2]</sup></td> </tr> <tr> <td>Difficult to monitor aPTT</td> <td class=\"divider_bottom\" rowspan=\"3\">Osteoporosis may be exaggerated in children treated with glucocorticoids (eg, ALL, NHL)<sup>[6-8]</sup></td> </tr> <tr> <td>Osteoporosis<sup>[3-5]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Heparin-induced thrombocytopenia</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Low molecular weight heparin (LMWH)</td> <td class=\"divider_bottom\" rowspan=\"3\">Anti-Xa levels</td> <td>Compared with UFH more efficacious and safe</td> <td>Subcutaneous administration</td> <td>Target anti-Xa levels in children are unknown<sup>[9]</sup></td> </tr> <tr> <td>Cost effective</td> <td class=\"divider_bottom\" rowspan=\"2\">Therapeutic range is not established so that bleeding may occur (0 to 5.6 percent)</td> <td class=\"divider_bottom\" rowspan=\"2\">Difficult to reverse anticoagulation in emergency situation</td> </tr> <tr class=\"divider_bottom\"> <td>Easy to monitor</td> </tr> <tr> <td rowspan=\"4\">Oral anticoagulants</td> <td>INR</td> <td>Oral administration</td> <td>Dose requirements strongly influenced by age<sup>[10]</sup></td> <td>Dietary alterations (due to mucositis, TPN) and antibacterial therapy (PCP prophylaxis or treatment for fever and neutropenia) leads to unpredictable exogenous and endogenous vitamin K levels</td> </tr> <tr> <td rowspan=\"3\">Difficult monitoring</td> <td rowspan=\"3\">Low cost</td> <td>Efficacy affected by diet*<sup>[11]</sup></td> <td rowspan=\"3\">Warfarin metabolism by cytochrome P450 system leading to numerous drug interactions with anticancer agents (eg, corticosteroids)<sup>[1]</sup></td> </tr> <tr> <td>Difficult to adjust dose around time of invasive procedures</td> </tr> <tr> <td>No stability data on solution or suspension making dosing in young children and in children unable to swallow tablets difficult<sup>[12]</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ALL: acute lymphoblastic leukemia; aPTT: activated partial thromboplastin time; INR: international normalization ratio; LMWH: low molecular weight heparin; PCP: pneumocystis carinii; NHL: non-Hodgkin lymphoma; TPN: total parenteral nutrition; UFH: unfractionated heparin.<br />* Infants may have resistance to warfarin if formula fed (vitamin K enriched), whereas breastfed infants may be oversensitive due to poor vitamin K content in breast milk.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Monagle P, Chan A, Massicotte P, et al. Antithrombotic therapy in children: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:645S. </li>&#xD;&#xA;    <li>Athale UH, Wiernikowaski J. Thromboembolic complications in children with cancer. Thromb Res 2006; 118:137. </li>&#xD;&#xA;    <li>Murphy MS, John PR, Mayer AD, et al. Heparin therapy and bone fractures. Lancet 1992; 340:1098. </li>&#xD;&#xA;    <li>Avioli LV. Heparin-induced osteopenia: an appraisal. Adv Exp Med Biol 1975; 52:375. </li>&#xD;&#xA;    <li>Sackler JP, Liu L. Heparin-induced osteoporosis. Br J Radio 1973; 46:548. </li>&#xD;&#xA;    <li>Roebuck DJ. Skeletal complications in pediatric oncology patients. Radiographics 1999; 19:873. </li>&#xD;&#xA;    <li>Halton JM, Atkinson SA, Fraher L, et al. Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia. J Bone Miner Res 1996; 11:1774. </li>&#xD;&#xA;    <li>Arikoski P, Komulainen J, Riikonen P, et al. Impaired development of bone mineral density during chemotherapy: a prospective analysis of 46 children newly diagnosed with cancer. J Bone Miner Res 1999; 14:2002. </li>&#xD;&#xA;    <li>Revel-Vilk S, Chan AKC. Anticoagulation therapy in children. Semin Thromb Hemost 2003; 29:425. </li>&#xD;&#xA;    <li>Streif W, Andrew M, Marzinotto V, et al. Analysis of warfarin therapy in pediatric patients: A prospective cohort study of 319 patients. Blood 1999; 94:3007.</li>&#xD;&#xA;    <li>Andrew M, Monagle P, Brooker L. Oral anticoagulant therapy in pediatric patients. Thromboembolic Complications During Infancy and Childhood, BC Decker Inc, Hamilton 2000. p.321. </li>&#xD;&#xA;    <li>Buck ML. Anticoagulation with warfarin in infants and children. Ann Pharmacother 1996; 30:1316. </li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from: Athale UH, Chan AKC. Thromboembolic complications in pediatric hematologic malignancies. Semin Thromb Hemost 2007; 33:416. Copyright &copy; 2007 Thieme Publishers.</div><div id=\"graphicVersion\">Graphic 57476 Version 8.0</div></div></div>"},"57477":{"type":"graphic_table","displayName":"Docetaxel and prednisone for prostate cancer","title":"Docetaxel and prednisone for metastatic hormone-refractory prostate cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Docetaxel and prednisone for metastatic hormone-refractory prostate cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Docetaxel</td> <td>75 mg/m<sup>2</sup> IV*</td> <td>Dilute in 250 mL normal saline and administer over one hour.</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Prednisone</td> <td>5 mg orally</td> <td>Twice daily.</td> <td>Days 1 to 21</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>LOW (10 to 30% frequency of emesis). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reaction and fluid retention</strong></td> <td colspan=\"3\"> <ul> <li>Premedicate with dexamethasone prior to docetaxel administration.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Docetaxel is an irritant but can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with hematopoietic growth factors is not recommended (incidence of febrile neutropenia approximately 3%<sup>[1]</sup>). </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Docetaxel should not be administered to patients with a serum bilirubin above the ULN or to patients with transaminase elevations &#62;1.5 times the ULN in conjunction with alkaline phosphatase &#62;2.5 times the ULN.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for known drug interactions</strong></td> <td colspan=\"3\"> <ul> <li>Caution is needed when administering docetaxel with strong CYP3A4 inhibitors. Although specific dose recommendations are not available, the United States Prescribing Information suggests close monitoring for toxicity and consideration of docetaxel dose reduction if coadministration with a strong CYP3A4 inhibitor cannot be avoided.<sup>[2]</sup> </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential at least every three weeks during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Renal and liver function testing at least every three weeks during treatment. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for neurologic function and gastrointestinal toxicities. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Docetaxel should only be administered if the absolute neutrophil count is &#62;1500 cells/microL. Reduce docetaxel to 60 mg/m<sup>2</sup> for subsequent cycles for severe prolonged neutropenia (&#60;500 cells/microL lasting seven days or more), febrile neutropenia, or an infection with life-threatening consequences.<sup>[2]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Cutaneous, mucosal, and neurologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>For severe or cumulative cutaneous reactions (erythema, desquamation), grade 3 or 4 stomatitis or &#62;grade 2 neurosensory signs and/or symptoms, reduce docetaxel dose to 60 mg/m<sup>2</sup>.<sup>[1]</sup> Discontinue docetaxel if toxicity persists at the lower dose. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Hepatotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Docetaxel dose reduction may be needed for patients who develop significant alterations in transaminases and alkaline phosphatase during therapy. Docetaxel should not be administered to patients with a serum bilirubin above the ULN or to patients with transaminase elevations &#62;1.5 times the ULN in conjunction with alkaline phosphatase &#62;2.5 times the ULN. </li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; ULN: upper limit of normal; CBC: complete blood count.<br />* Some clinicians use a dose of 70 to 75 mg/m<SUP>2</SUP> to minimize toxicity.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Tannock IF, et al. N Engl J Med 2004; 351:1502.</LI>&#xD;&#xA;<LI>Docetaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on January 13, 2012).</LI></OL></div><div id=\"graphicVersion\">Graphic 57477 Version 11.0</div></div></div>"},"57479":{"type":"graphic_diagnosticimage","displayName":"Occult supracondylar and radius fractures","title":"Occult ipsilateral fractures","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Occult ipsilateral fractures</div><div class=\"cntnt\"><img style=\"width:514px; height:370px;\" src=\"images/EM/57479_Occultfx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Type II supracondylar fracture (arrowhead) with an occult distal radial fracture (arrows).<br />(B) Type II supracondylar fracture (arrowheads) with an occult proximal humeral fracture (arrows).</div><div class=\"graphic_reference\">Reproduced with permission from: Skaggs DL, Flynn JM. Supracondylar Fractures of the Distal Humerus. In: Rockwood and Wilkins' Fractures in Children, 8th ed, Flynn JM, Skaggs DL, Waters PM (Eds), Lippincott Williams &amp; Wilkins 2014. Copyright &copy; 2014 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 57479 Version 15.0</div></div></div>"},"57480":{"type":"graphic_table","displayName":"HDL-C and cardiovascular risk","title":"HDL-C and cardiovascular risk","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">HDL-C and cardiovascular risk</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n      <td colspan=\"1\" rowspan=\"2\" class=\"subtitle1\">HDL, mg/dL</td>\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1\">Multiplier for cardiovascular risk</td>\n    </tr>\n    <tr>\n      \n      <td class=\"subtitle2\">Men</td>\n      <td class=\"subtitle2\">Women</td>\n    </tr>\n    <tr>\n\n      <td>30</td>\n\n      <td>1.82&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>\n\n      <td>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>\n\n    </tr>\n\n    <tr>\n\n      <td>35</td>\n\n      <td>1.49</td>\n\n      <td>-</td>\n\n    </tr>\n\n    <tr>\n\n      <td>40</td>\n\n      <td> 1.22</td>\n\n      <td>1.94</td>\n\n    </tr>\n\n    <tr>\n\n      <td>45</td>\n\n      <td>1.00</td>\n\n      <td>1.55</td>\n\n    </tr>\n\n    <tr>\n\n      <td>50</td>\n\n      <td>0.82</td>\n\n      <td>1.25</td>\n\n    </tr>\n\n    <tr>\n\n      <td>55 </td>\n\n      <td>0.67</td>\n\n      <td>1.00</td>\n\n    </tr>\n\n    <tr>\n\n      <td>60</td>\n\n      <td>0.55</td>\n\n      <td>0.80</td>\n\n    </tr>\n\n    <tr>\n\n      <td>65</td>\n\n      <td>0.45</td>\n\n      <td>0.64</td>\n\n    </tr>\n\n    <tr>\n\n      <td>70 </td>\n\n      <td>-</td>\n\n      <td>0.52</td>\n\n    </tr>\n\n    <tr>\n\n      <td>75</td>\n\n      <td>Longevity syndrome</td>\n\n      <td> Longevity syndrome</td>\n\n    </tr>\n\n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">Inverse relation between plasma HDL-cholesterol levels and cardiovascular risk in men and women. Multiply values by 38.5 to convert to mmol/L.</div><div class=\"graphic_reference\">Data from Castelli WP. Am Heart J 1983; 106:1191.</div><div id=\"graphicVersion\">Graphic 57480 Version 3.0</div></div></div>"},"57481":{"type":"graphic_figure","displayName":"Risk of intracranial bleed with thrombolytic therapy","title":"Risk of intracranial hemorrhage from thrombolytic therapy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Risk of intracranial hemorrhage from thrombolytic therapy</div><div class=\"cntnt\"><img style=\"width:450px; height:163px;\" src=\"images/CARD/57481_Intracranial_bleed_thrombol.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the GUSTO-I trial, increasing age and systolic pressure and, not shown, increasing diastolic pressure and decreasing body weight were associated with an increased probability of intracranial hemorrhage in patients who received thrombolytic therapy.</div><div class=\"graphic_reference\">Data from Gore JM, Granger CB, Simoons ML, et al for the GUSTO-I Investigators. Circulation 1995; 92:2811.</div><div id=\"graphicVersion\">Graphic 57481 Version 3.0</div></div></div>"},"57483":{"type":"graphic_table","displayName":"Causes of NPE","title":"Causes of neurogenic pulmonary edema","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of neurogenic pulmonary edema</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Major causes</td> </tr> <tr> <td>Epileptic seizures, particularly status epilepticus</td> </tr> <tr> <td>Cerebral hemorrhage</td> </tr> <tr> <td>Head injury</td> </tr> <tr> <td class=\"subtitle1_single\">Minor causes</td> </tr> <tr> <td>Guillain-Barr&#233; syndrome</td> </tr> <tr> <td>Multiple sclerosis with medullary involvement</td> </tr> <tr> <td>Nonhemorrhagic strokes</td> </tr> <tr> <td>Trigeminal nerve block</td> </tr> <tr> <td>Bulbar poliomyelitis</td> </tr> <tr> <td>Vertebral artery ligation</td> </tr> <tr> <td>Ruptured spinal arteriovenous malformation</td> </tr> <tr> <td>Air embolism</td> </tr> <tr> <td>Brain tumors</td> </tr> <tr> <td>Electroconvulsive therapy</td> </tr> <tr> <td>Induction of general anesthesia</td> </tr> <tr> <td>Colloid cyst</td> </tr> <tr> <td>Hydrocephalus</td> </tr> <tr> <td>Reye syndrome</td> </tr> <tr> <td>Bacterial meningitis</td> </tr> <tr> <td>Viral meningoencephalitis</td> </tr> <tr> <td>Cervical spinal cord injury</td> </tr> <tr> <td>Cryptococcal meningoencephalitis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 57483 Version 3.0</div></div></div>"},"57484":{"type":"graphic_diagnosticimage","displayName":"Pulmonary AVM PA","title":"Pulmonary arteriovenous malformation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary arteriovenous malformation</div><div class=\"cntnt\"><img style=\"width:360px; height:234px;\" src=\"images/PULM/57484_Pulmonary_AVM_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph showing a single, bilobed pulmonary arteriovenous malformation (PAVM)&nbsp;with smooth borders (arrow). There is an area of infiltrate from a recent episode of acute respiratory distress syndrome that lies inferior and lateral to the PAVM.</div><div class=\"graphic_reference\">Gossage, JR, Ghassan, K. Pulmonary arteriovenous malformations. American Journal of Respiratory and Critical Care Medicine 1998; 158:643. Official Journal of the American Thoracic Society. © American Lung Association.</div><div id=\"graphicVersion\">Graphic 57484 Version 3.0</div></div></div>"},"57488":{"type":"graphic_table","displayName":"Travel symptoms Australia NZ Oceania","title":"Infectious causes of symptoms in travelers to Australia, New Zealand, and Oceania","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infectious causes of symptoms in travelers to Australia, New Zealand, and Oceania</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Condition or pathogen</td> <td class=\"subtitle1\">Temperate Australia or New Zealand</td> <td class=\"subtitle1\">Tropical Australia</td> <td class=\"subtitle1\">Papua New Guinea (PNG) and Oceania</td> </tr> <tr> <td rowspan=\"7\">Acute fever</td> <td>Malaria</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> </tr> <tr> <td>Enteric fever</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> </tr> <tr> <td>Amoebic liver abscess</td> <td>&nbsp;</td> <td>+</td> <td>+</td> </tr> <tr> <td>Leptospirosis</td> <td>+</td> <td>+</td> <td>+</td> </tr> <tr> <td>Q fever*</td> <td>+</td> <td>+</td> <td>&nbsp;</td> </tr> <tr> <td>Scrub typhus and tick typhus*</td> <td>+</td> <td>+</td> <td>+ (PNG)</td> </tr> <tr> <td>Melioidosis</td> <td>&nbsp;</td> <td>+</td> <td>+</td> </tr> <tr> <td rowspan=\"6\">Acute diarrhea</td> <td>Enteropathogenic <em>Escherichia coli</em></td> <td>+</td> <td>+</td> <td>+</td> </tr> <tr> <td>Rotavirus, Norwalk, other viruses</td> <td>+</td> <td>+</td> <td>+</td> </tr> <tr> <td><em>Campylobacter</em></td> <td>+</td> <td>+</td> <td>+</td> </tr> <tr> <td><em>Salmonella</em>, <em>Shigella</em></td> <td>+</td> <td>+</td> <td>+</td> </tr> <tr> <td>Amoebiasis (<em>Entamoeba histolytica</em>)</td> <td>&nbsp;</td> <td>+</td> <td>+</td> </tr> <tr> <td>Ciguatera poisoning</td> <td>&nbsp;</td> <td>+</td> <td>+</td> </tr> <tr> <td rowspan=\"5\">Rash</td> <td>Ross River virus*</td> <td>+</td> <td>+</td> <td>+</td> </tr> <tr> <td>Barmah forest virus*</td> <td>+</td> <td>+</td> <td>&nbsp;</td> </tr> <tr> <td>Dengue</td> <td>&nbsp;</td> <td>+</td> <td>+</td> </tr> <tr> <td>Tick typhus*</td> <td>&nbsp;</td> <td>+</td> <td>+ (PNG)</td> </tr> <tr> <td>Scrub typhus*</td> <td>&nbsp;</td> <td>+</td> <td>+</td> </tr> <tr> <td rowspan=\"3\">Pneumonia</td> <td><em>Streptococcus pneumoniae </em>and other common respiratory pathogens</td> <td>+</td> <td>+</td> <td>+</td> </tr> <tr> <td>Psittacosis</td> <td>+</td> <td>+</td> <td>&nbsp;</td> </tr> <tr> <td>Q fever*</td> <td>&nbsp;</td> <td>+</td> <td>+</td> </tr> <tr> <td rowspan=\"7\">Neurologic problems</td> <td>Bacterial meningitis due to common pathogens</td> <td>+</td> <td>+</td> <td>+</td> </tr> <tr> <td>Eosinophilic meningitis</td> <td>&nbsp;</td> <td>+</td> <td>+</td> </tr> <tr> <td>Murray Valley encephalitis*</td> <td>+</td> <td>+</td> <td>+</td> </tr> <tr> <td>Japanese B encephalitis</td> <td>&nbsp;</td> <td>+</td> <td>+ (PNG)</td> </tr> <tr> <td>Cryptococcosis</td> <td>+</td> <td>+</td> <td>+</td> </tr> <tr> <td>Ciguatera fish poisoning</td> <td>&nbsp;</td> <td>+</td> <td>+</td> </tr> <tr> <td>Tick paralysis</td> <td>&nbsp;</td> <td>+</td> <td>&nbsp;</td> </tr> <tr> <td rowspan=\"3\">Acute polyarthritis</td> <td>Ross River virus*</td> <td>+</td> <td>+</td> <td>+</td> </tr> <tr> <td>Barmah forest virus*</td> <td>+</td> <td>+</td> <td>&nbsp;</td> </tr> <tr> <td>Chikungunya</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> </tr> <tr> <td rowspan=\"2\">Jaundice</td> <td>Hepatitis A or B</td> <td>+</td> <td>+</td> <td>+</td> </tr> <tr> <td>Malaria</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> </tr> <tr> <td rowspan=\"5\">Skin ulcer</td> <td>Tropical ulcer infected with <em>Streptococcus pyogenes </em>or <em>S. aureus</em></td> <td>&nbsp;</td> <td>+</td> <td>+</td> </tr> <tr> <td>Infected coral injury&nbsp;</td> <td>&nbsp;</td> <td>+</td> <td>+</td> </tr> <tr> <td><em>Mycobacterium ulcerans</em>*</td> <td>+</td> <td>+</td> <td>&nbsp;</td> </tr> <tr> <td>Melioidosis</td> <td>&nbsp;</td> <td>+</td> <td>+</td> </tr> <tr> <td>Cutaneous diphtheria</td> <td>&nbsp;</td> <td>+</td> <td>+</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* These infections are not present in New Zealand.</div><div id=\"graphicVersion\">Graphic 57488 Version 5.0</div></div></div>"},"57489":{"type":"graphic_table","displayName":"Causes of metabolic alkalosis","title":"Major causes of metabolic alkalosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of metabolic alkalosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\"><span class=\"sublist3_start\"></span>Gastrointestinal hydrogen loss</td> </tr> <tr> <td>Vomiting or nasogastric suction</td> </tr> <tr> <td>Congenital chloride diarrhea</td> </tr> <tr> <td class=\"subtitle1_single\">Renal hydrogen loss</td> </tr> <tr> <td>Primary mineralocorticoid excess</td> </tr> <tr> <td>Mineralocorticoid excess-like states</td> </tr> <tr> <td class=\"indent1\">Licorice ingestion</td> </tr> <tr> <td class=\"indent1\">Liddle syndrome</td> </tr> <tr> <td class=\"indent1\">Apparent mineralocorticoid excess</td> </tr> <tr> <td><span class=\"indent1\"></span>Loop or thiazide diuretics</td> </tr> <tr> <td>Bartter or Gitelman syndrome</td> </tr> <tr> <td>Posthypercapnic alkalosis</td> </tr> <tr> <td>Hypercalcemia and the milk-alkali syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Intracellular shift of hydrogen</td> </tr> <tr> <td>Severe hypokalemia</td> </tr> <tr> <td class=\"indent1\">Villous adenoma</td> </tr> <tr> <td class=\"indent1\">Laxative abuse</td> </tr> <tr> <td class=\"subtitle1_single\">Alkali administration with reduced renal function</td> </tr> <tr> <td class=\"subtitle1_single\">Contraction alkalosis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 57489 Version 3.0</div></div></div>"},"57491":{"type":"graphic_table","displayName":"Nonskeletal causes LS radiculopathy","title":"Nonskeletal causes of lumbosacral radiculopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nonskeletal causes of lumbosacral radiculopathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Diabetes mellitus</td> </tr> <tr> <td class=\"indent1\">Single or multiple radiculopathies</td> </tr> <tr> <td class=\"subtitle1_single\">Inflammatory disorders</td> </tr> <tr> <td class=\"indent1\">Acute inflammatory demyelinating polyradiculoneuropathy (AIDP; Guillain-Barr&#233; syndrome)</td> </tr> <tr> <td class=\"indent1\">Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> <tr> <td class=\"subtitle1_single\">Infectious diseases</td> </tr> <tr> <td class=\"indent1\">Borrelia burgdorferi (Lyme disease)</td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus</td> </tr> <tr> <td class=\"indent1\">Epstein-Barr</td> </tr> <tr> <td class=\"indent1\">Herpes simplex virus</td> </tr> <tr> <td class=\"indent1\">Human immunodeficiency virus (HIV)</td> </tr> <tr> <td class=\"indent1\">Mycobacterium</td> </tr> <tr> <td class=\"indent1\">Mycoplasma</td> </tr> <tr> <td class=\"indent1\">Syphilis</td> </tr> <tr> <td class=\"indent1\">Varicella zoster virus (Herpes zoster or shingles)</td> </tr> <tr> <td class=\"subtitle1_single\">Malignancy</td> </tr> <tr> <td class=\"indent1\">Lymphoma</td> </tr> <tr> <td class=\"indent1\">Metastasis</td> </tr> <tr> <td class=\"indent1\">Multiple myeloma</td> </tr> <tr> <td class=\"subtitle1_single\">Vascular</td> </tr> <tr> <td class=\"indent1\">Arteriovenous malformation</td> </tr> <tr> <td class=\"indent1\">Radiation-induced vascular occlusion</td> </tr> <tr> <td class=\"indent1\">Vasculitis (nerve root infarction)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 57491 Version 3.0</div></div></div>"},"57492":{"type":"graphic_table","displayName":"Cocaine kinetics","title":"Cocaine kinetics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cocaine kinetics</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Route of exposure</td>\n\t\t\t\t\t<td class=\"subtitle1\">Onset of action</td>\n\t\t\t\t\t<td class=\"subtitle1\">Peak action</td>\n\t\t\t\t\t<td class=\"subtitle1\">Duration of action</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Intravenous</td>\n\t\t\t\t\t<td>&#60;1 minute</td>\n\t\t\t\t\t<td>3-5 minutes</td>\n\t\t\t\t\t<td>30-60 minutes</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Nasal</td>\n\t\t\t\t\t<td>1-5 minutes</td>\n\t\t\t\t\t<td>20-30 minutes</td>\n\t\t\t\t\t<td>60-120 minutes</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Smoking</td>\n\t\t\t\t\t<td>&#60;1 minute</td>\n\t\t\t\t\t<td>3-5 minutes</td>\n\t\t\t\t\t<td>30-60 minutes</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Gastrointestinal</td>\n\t\t\t\t\t<td>30-60 minutes</td>\n\t\t\t\t\t<td>60-90 minutes</td>\n\t\t\t\t\t<td>Unknown</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 57492 Version 1.0</div></div></div>"},"57493":{"type":"graphic_figure","displayName":"EtCO2 wave interpretation b","title":"Capnographic airway assessment for procedural sedation and analgesia, continued","html":"<div class=\"graphic\"><div style=\"width: 621px\" class=\"figure\"><div class=\"ttl\">Capnographic airway assessment for procedural sedation and analgesia, continued</div><div class=\"cntnt\"><img style=\"width:601px; height:666px;\" src=\"images/EM/57493_EtCO2_wave_interpretation_b.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Varying waveform amplitutde and width.<br> <span class=bullet>&#8226;</span> Depending on duration and severity of bronchospasm.<br> &#916; Depending on duration of episode.</div><div class=\"graphic_reference\">Reproduced with permission from: Krauss, B, Hess, DR. Capnography for Procedural Sedation and Analgesia in the Emergency Department. Annals of Emergency Medicine 2007; 50:172. Copyright &#169; 2007 The American College of Emergency Physicians.</div><div id=\"graphicVersion\">Graphic 57493 Version 2.0</div></div></div>"},"57494":{"type":"graphic_picture","displayName":"Night splint","title":"Night splint applied to the right foot","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Night splint applied to the right foot</div><div class=\"cntnt\"><img style=\"width:502px; height:364px;\" src=\"images/EM/57494_Night_splint_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Jill Ferrari, PhD, BSc.</div><div id=\"graphicVersion\">Graphic 57494 Version 2.0</div></div></div>"},"57495":{"type":"graphic_figure","displayName":"Proximal humerus intraosseous site","title":"Proximal humeral intraosseous access site","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Proximal humeral intraosseous access site</div><div class=\"cntnt\"><img style=\"width:534px; height:558px;\" src=\"images/EM/57495_Proximal_humerus_IO_site.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For proximal humeral intraosseous placement in the skeletally mature adolescent or adult, adduct and internally rotate the arm (hand on abdomen) to make damage to the medial structures of the axillary plexus unlikely. Find the greater tubercle of the proximal humerus approximately 2 cm below the acromion process. Alternatively, palpate the greater tubercle from below. Access the intraosseous space using a battery operated drill.</div><div id=\"graphicVersion\">Graphic 57495 Version 3.0</div></div></div>"},"57496":{"type":"graphic_diagnosticimage","displayName":"EUS hyperechoic cloud","title":"EUS hyperechoic cloud","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">EUS hyperechoic cloud</div><div class=\"cntnt\"><img style=\"width:396px; height:346px;\" src=\"images/GAST/57496_EUS_hyperechoic_cloud.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The needle has been advanced through the gastric wall immediately lateral and beyond the anterior wall of the aorta. Injection of absolute ethanol results in an echodense cloud.</div><div class=\"graphic_reference\">Copyrighted and used with permission of Mayo Foundation for Medical Education and Research.</div><div id=\"graphicVersion\">Graphic 57496 Version 11.0</div></div></div>"},"57497":{"type":"graphic_table","displayName":"Toxic optic neuropathies","title":"Toxins and drugs associated with an optic neuropathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Toxins and drugs associated with an optic neuropathy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Toxins</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Carbon monoxide</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Ethylene glycol</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Methanol</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Perchloroethylene</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Tobacco</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Toluene</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Styrene</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\"><p>Drug reactions (direct effect on the optic nerve)</p>\n\t\t\t\t\t<p>Antimicrobials</p></td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Clioquinol</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Chloramphenicol</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Dapsone</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Ethambutol</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Isoniazid</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Iodochlorhydroxyquinoline</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Linezolid</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Immune modulators and suppressants</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Cyclosporine</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Tacrolimus (FK506)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Alpha interferon-2b</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Cancer chemotherapy</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>5-Fluorouracil</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Cisplatin</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Carboplatin</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Nitrosureas: BCNU (carmustine), CCNU (lomustine), and methyl-CCN (semustine)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Paclitaxel</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Vincristine</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Other</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Amiodarone</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Chlorpropamide</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Benoxaprofen</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Cimetidine</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Disulfiram</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Melatonin, sertraline hydrochloride (Zoloft), and a high-protein diet</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Drug reactions (indirect effect on the optic nerve)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Sildenafil (Viagra)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Infliximab</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Kerrison, JB. Optic neuropathies caused by toxins and adverse drug reactions. Opthalmol Clin North Am 2004; 17:481. Copyright &#169;2004 Elsevier Science, Inc.</div><div id=\"graphicVersion\">Graphic 57497 Version 1.0</div></div></div>"},"57499":{"type":"graphic_figure","displayName":"Transportation young CSHCN","title":"General guidelines for safe transportation of infants and young children with special health care needs*","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">General guidelines for safe transportation of infants and young children with special health care needs*</div><div class=\"cntnt\"><img style=\"width:525px; height:583px;\" src=\"images/PEDS/57499_Transportation_young_CSHCN.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">FMVSS: Federal Motor Vehicle Safety Standards; NHTSA; National Highway Traffic Safety Administration; CSHCN: children with special health care needs.<br />* Consultation with a child passenger safety technician may be helpful; additional information and a national list of child passenger safety technicians can be found at <A href=\"http://www.preventinjury.org/Special-Needs-Transportation\" target=_blank>www.preventinjury.org/Special-Needs-Transportation</A>.</div><div class=\"graphic_reference\">Data from: Bull M, Agran P, Laraque D, et al. American Academy of Pediatrics. Committee on Injury and Poison Prevention. Transporting children with special health care needs. Pediatrics 1999; 104:988. (Reaffirmed March 2013).</div><div id=\"graphicVersion\">Graphic 57499 Version 7.0</div></div></div>"},"57500":{"type":"graphic_table","displayName":"Diagnosis posttraumatic stress disorder","title":"Diagnostic criteria for posttraumatic stress disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for posttraumatic stress disorder</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Criterion A: The\nperson has been exposed to a traumatic event in which both of the\nfollowing were present:</td>\n\n    </tr>\n\n    <tr>\n\n      <td>1. The person experienced, witnessed or was confronted\nwith an event or events that involved actual or threatened death or serious injury,\nor a threat to the physical integrity of self or others.</td>\n\n    </tr>\n\n\n\n    <tr>\n\n      <td>2. The person's response involved intense fear,\nhelplessness or horror. Note: in children this may be expressed instead by disorganized\nor agitated behavior.</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Criterion B: The\ntraumatic event is persistently reexperienced in one (or more) of the\nfollowing ways:</td>\n\n    </tr>\n\n    <tr>\n\n      <td>1. Recurrent and intrusive distressing recollections of\nthe event, including images, thoughts, or perceptions. Note: in young children,\nrepetitive play may occur in which themes or aspects of the trauma are expressed.</td>\n\n    </tr>\n\n\n\n    <tr>\n\n      <td>2. Recurrent distressing dreams of the event. Note: in\nchildren there may be frightening dreams without recognizable content.</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>3. Acting or feeling as if the traumatic event were\nrecurring (including a sense of reliving the experience, illusions, hallucinations and\ndissociative flashback episodes, including those that occur on wakening or when intoxicated).\nNote: in young children trauma-specific reenactment may occur.</td>\n\n    </tr>\n\n\n\n\n    <tr>\n\n      <td>4. Intense psychological distress and/or physiological\nreactivity on exposure to internal or external cues that symbolize or resemble an aspect\nof the traumatic event.</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Criterion C:\nPersistent avoidance of stimuli associated with the trauma and numbing\nof general responsiveness (not present before the trauma), as indicated\nby three (or more) of the following:</td>\n\n    </tr>\n\n    <tr>\n\n      <td>1. Efforts to avoid thoughts, feelings or conversations\nassociated with the trauma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>2. Efforts to avoid activities, places or people that\narouse recollections of the trauma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>3. Inability to recall an important aspect of the trauma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>4. Markedly diminished interest in participating in\nsignificant activities</td>\n\n    </tr>\n\n    <tr>\n\n      <td>5. Feeling detached or estranged from others</td>\n\n    </tr>\n\n    <tr>\n\n      <td>6. Restricted range of effect (eg, unable to have\nloving feelings)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>7. Sense of a foreshortened future (eg, does not expect\nto have a career, marriage, children, or a normal life span)</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Criterion D:\nPersistent symptoms of increased arousal (not present before trauma),\nas indicated by two (or more) of the following:</td>\n\n    </tr>\n\n    <tr>\n\n      <td>1. Difficulty falling or staying asleep</td>\n\n    </tr>\n\n    <tr>\n\n      <td>2. Irritability or outbursts of anger</td>\n\n    </tr>\n\n    <tr>\n\n      <td>3. Difficulty concentrating</td>\n\n    </tr>\n\n    <tr>\n\n      <td>4. Hypervigilance</td>\n\n    </tr>\n\n    <tr>\n\n      <td>5. Exaggerated startle response</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Criterion E:\nDuration of the disturbance (symptoms in criteria B, C, and D) is more\nthan one month.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Criterion F:\nDisturbance causes clinically significant distress or impairment in\nsocial, occupational, or other important areas of functioning.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Specify if:</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Acute: if duration of symptoms is less than three months</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Chronic: if duration of symptoms is three months or more</td>\n\n    </tr>\n\n    <tr>\n\n      <td>With delayed onset: if onset of symptoms is at least\nsix months after the stressor</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: Diagnostic and Statistical Manual of Mental Disorders, 4th ed, American Psychiatric Association, Washington, DC 1994.</div><div id=\"graphicVersion\">Graphic 57500 Version 4.0</div></div></div>"},"57501":{"type":"graphic_picture","displayName":"Mature teratoma Low","title":"Mediastinal mature teratoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mediastinal mature teratoma</div><div class=\"cntnt\"><img style=\"width:370px; height:243px;\" src=\"images/PULM/57501_Mature_teratoma_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adult-type squamous epithelium and skin appendages, such as sebaceous glands, are frequent components of mature teratomas in the mediastinum (hematoxylin and eosin, magnification 10x).</div><div class=\"graphic_reference\">Courtesy of William Travis, MD.</div><div id=\"graphicVersion\">Graphic 57501 Version 2.0</div></div></div>"},"57502":{"type":"graphic_diagnosticimage","displayName":"Pulmonary osteoarthropathy I","title":"Pulmonary osteoarthropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary osteoarthropathy</div><div class=\"cntnt\"><img style=\"width:283px; height:288px;\" src=\"images/PULM/57502_Pulmonary_osteoarthropathy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain film of the hand in a 41-year-old woman who presented with severe hand and ankle pain demonstrates marked periosteal new bone formation adjacent to the first metacarpal bone (arrows). A chest radiograph revealed a large solitary mass subsequently shown to represent an adenocarcinoma.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 57502 Version 3.0</div></div></div>"},"57503":{"type":"graphic_waveform","displayName":"Basic case 4 with answer","title":"Sinus rhythm with ventricular bigeminy","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm with ventricular bigeminy</div><div class=\"cntnt\"><img style=\"width:520px; height:142px;\" src=\"images/CARD/57503_Basic_case_4_with_answer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sinus rhythm with ventricular bigeminy. Each sinus beat is followed by a uniform premature complex with prolonged duration and no apparent preceding P wave; these findings are indicative of ventricular ectopic beats.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 57503 Version 2.0</div></div></div>"},"57504":{"type":"graphic_diagnosticimage","displayName":"Osteo diabetic foot ulcer","title":"Osteomyelitis in the setting of a diabetic foot ulcer","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Osteomyelitis in the setting of a diabetic foot ulcer</div><div class=\"cntnt\"><img style=\"width:505px; height:404px;\" src=\"images/ID/57504_Osteo_diabetic_foot_ulcer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Sagittal fluid-sensitive short inversion time inversion recovery (STIR) image demonstrates high signal fluid collection along the plantar surface of the calcaneus (arrow).<br />(B) Sagittal post-contrast T1-weighted image with fat saturation demonstrates the peripherally enhancing fluid collection (arrow).<br />(C) Sagittal T1-weighted pre-contrast image demonstrates some cortical interruption (arrow).<br />(D) Lateral radiograph demonstrates soft tissue loss overlying the plantar aspect of the calcaneus (arrow). Osseous remodeling and periosteal reaction about the posterior calcaneus (asterisk) reflect changes associated with longstanding chronic osteomyelitis.</div><div class=\"graphic_reference\">Courtesy of Perry Horwich, MD.</div><div id=\"graphicVersion\">Graphic 57504 Version 6.0</div></div></div>"},"57505":{"type":"graphic_picture","displayName":"Triple sugar iron agar slant","title":"Shigella on triple sugar iron agar slant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Shigella on triple sugar iron agar slant</div><div class=\"cntnt\"><img style=\"width:229px; height:288px;\" src=\"images/ID/57505_Triple_sugar_iron_agar_slan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Triple sugar iron agar slant shows the reaction pattern of Shigella. This pattern is designated alkaline (red) over acid (yellow), indicating the absence of lactose fermentation by the test organism. In addition, there is no gas or the black color indicative of hydrogen sulfide visible.</div><div class=\"graphic_reference\">Courtesy of Michael S Glickman, MD.</div><div id=\"graphicVersion\">Graphic 57505 Version 1.0</div></div></div>"},"57508":{"type":"graphic_picture","displayName":"Marcus Gunn Jaw winking","title":"Child with Marcus Gunn Jaw winking ptosis of the right eye","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Child with Marcus Gunn Jaw winking ptosis of the right eye</div><div class=\"cntnt\"><img style=\"width:394px; height:432px;\" src=\"images/NEURO/57508_Marcus_Gunn_Jaw_winking.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">As the child sucks on a bottle, the right upper lid opens due to aberrant innervation of the levator by the mandibular branch of CN V.</div><div class=\"graphic_reference\">Courtesy of C Gail Summers, MD.</div><div id=\"graphicVersion\">Graphic 57508 Version 3.0</div></div></div>"},"57509":{"type":"graphic_picture","displayName":"Blood lymphocyte - Normal and Wiskott-Aldrich syndrome","title":"Blood lymphocyte of a normal subject (left) and WAS patient (right), analyzed by scanning electron microscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Blood lymphocyte of a normal subject (left) and WAS patient (right), analyzed by scanning electron microscopy</div><div class=\"cntnt\"><img style=\"width:450px; height:227px;\" src=\"images/ALLRG/57509_Blood_lymphocyte.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note \"bald\" appearance of WAS lymphocyte.</div><div class=\"graphic_reference\">Reproduced with permission from: Kenney K, Cairns L, Remold-O'Donnell E, et al. Morphological abnormalities in the lymphocytes of patients with the Wiskott-Aldrich syndrome. Blood 1986; 68:1329. Copyright © 1986 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 57509 Version 5.0</div></div></div>"},"57510":{"type":"graphic_diagnosticimage","displayName":"Hydrocephalus due to a Chiari II malformation","title":"Hydrocephalus due to a Chiari II malformation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hydrocephalus due to a Chiari II malformation</div><div class=\"cntnt\"><img style=\"width:413px; height:353px;\" src=\"images/PEDS/57510_Hydro_Chiari_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal T1 weighted magnetic resonance imaging (MRI) showing acquired hydrocephalus due to a Chiari II malformation in a child with spina bifida. Note the shallow posterior fossa and descent of cerebellar tonsils past the foramen magnum. Other findings include large massa intermedia, low lying torcula, and partial agenesis of the corpus callosum.</div><div class=\"graphic_reference\">Courtesy of Drs. Abilash Haridas and Tadanori Tomita.</div><div id=\"graphicVersion\">Graphic 57510 Version 2.0</div></div></div>"},"57511":{"type":"graphic_waveform","displayName":"ECG ventricular premature beat tutorial","title":"Single lead electrocardiogram (ECG) showing a ventricular premature beat (VPB)","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Single lead electrocardiogram (ECG) showing a ventricular premature beat (VPB)</div><div class=\"cntnt\"><img style=\"width:438px; height:150px;\" src=\"images/CARD/57511_Ventric_premature_beat_tuto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The fourth beat is a ventricular premature beat (VPB). It has a wide, bizarre morphology, with a duration &gt;0.16 seconds.</div><div id=\"graphicVersion\">Graphic 57511 Version 3.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"57512":{"type":"graphic_algorithm","displayName":"Abnormal adult behavior management algorithm","title":"Management approach to the patient with confusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Management approach to the patient with confusion</div><div class=\"cntnt\"><img style=\"width:284px; height:569px;\" src=\"images/EM/57512_Abnrmadultbehvrmgmtalgo.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ED: emergency department; CBC: complete blood count; UA: urinalysis; ECG: electrocardiogram; CT: computed tomography; ABG: arterial blood gas; EEG: electroencephalogram.</div><div id=\"graphicVersion\">Graphic 57512 Version 3.0</div></div></div>"},"57513":{"type":"graphic_picture","displayName":"Spica cast application","title":"Spica cast application","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Spica cast application</div><div class=\"cntnt\"><img style=\"width:463px; height:460px;\" src=\"images/EM/57513_Spicacastapplicationedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Application of a 90 degree/90 degree spica cast.<br> (A) Generous padding is applied over the foot, and a pad is placed on the popliteal fossa to prevent injury to the peroneal nerve and popliteal vessels.<br> (B) A long leg cast is applied with the knee flexed 90 degrees. Longitudinal traction should NOT be applied while extending the long leg cast to the spica component to avoid the risk of an acute compartment syndrome.<br> (C) A mold is placed over the apex of the fracture, generally correcting a varus deformity into slight valgus.<br> (D) Using a standard spica table, the spica cast is applied with the hip flexed 90 degrees and abducted 30 degrees.</div><div class=\"graphic_reference\">Reproduced with permission from: Kasser JR, Beaty JH. Femoral Shaft Fractures. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 57513 Version 16.0</div></div></div>"},"57514":{"type":"graphic_picture","displayName":"Sticky colloid FNA","title":"Papillary carcinoma with sticky colloid: Appearance on fine needle aspirate of the thyroid","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Papillary carcinoma with sticky colloid: Appearance on fine needle aspirate of the thyroid</div><div class=\"cntnt\"><img style=\"width:360px; height:237px;\" src=\"images/ENDO/57514_Sticky_colloid_FNA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fine needle aspirate of a papillary carcinoma showing scant colloid which appears to &quot;stick&quot; to laminated psammoma bodies instead of smearing across the slide.</div><div id=\"graphicVersion\">Graphic 57514 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Colloid from a macrofollicular nodule: Findings on fine needle aspirate</div><div class=\"cntnt\"><img style=\"width:360px; height:239px;\" src=\"images/ENDO/52463_Thyroid_colloid_FNA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Papanicolaou stain showing colloid, which is usually abundant in the background of macrofollicular lesions.</div><div id=\"graphicVersion\">Graphic 52463 Version 3.0</div></div></div>"},"57517":{"type":"graphic_waveform","displayName":"Pericarditis tutorial","title":"Pericarditis","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Pericarditis</div><div class=\"cntnt\"><img style=\"width:529px; height:220px;\" src=\"images/CARD/57517_Pericarditis_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">J point and concave ST segment elevation seen diffusely in most of the precordial and limb leads are the hallmarks of pericarditis. There are no reciprocal ST changes. PR depression is evident in some leads.</div><div id=\"graphicVersion\">Graphic 57517 Version 2.0</div></div></div>"},"57518":{"type":"graphic_table","displayName":"Cyclosporine FK506 preparations","title":"Cyclosporine and tacrolimus preparations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cyclosporine and tacrolimus preparations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Cyclosporine non-modified</td> </tr> <tr> <td class=\"indent1\"><strong>Oral</strong></td> </tr> <tr> <td class=\"indent2\">Capsules: Liquid filled&nbsp;<span style=\"font-size: 10.5pt; font-family: 'Cambria',serif;\">&ndash;</span> 25 mg, 50 mg, 100 mg (Sandimmune and generics)</td> </tr> <tr> <td class=\"indent2\">Solution: 100 mg/mL in 50 mL bottles</td> </tr> <tr> <td class=\"indent1\"><strong>Topical</strong></td> </tr> <tr> <td class=\"indent2\">Ophthalmic emulsion: 0.05% in 0.4 mL vials (Restasis)</td> </tr> <tr> <td class=\"indent1\"><strong>Parenteral</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Concentrate for injection: For IV infusion 50 mg/mL in 5 mL ampules</td> </tr> <tr> <td class=\"subtitle1_single\">Cyclosporine modified (microemulsion)</td> </tr> <tr> <td class=\"indent1\"><strong>Oral</strong></td> </tr> <tr> <td class=\"indent2\">Capsules: 25 mg, 100 mg (Neoral and generics)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Solution: 100 mg/mL in 50 mL bottles</td> </tr> <tr> <td class=\"subtitle1_single\"><strong>Tacrolimus</strong></td> </tr> <tr> <td class=\"indent1\"><strong>Oral</strong></td> </tr> <tr> <td class=\"indent2\">Immediate-release capsules: 0.5 mg, 1 mg, 5 mg (Prograf)</td> </tr> <tr> <td class=\"indent2\">Extended-release capsules: 0.5 mg, 1 mg, 5 mg (Astagraf XL)</td> </tr> <tr> <td class=\"indent2\">Extended-release tablet: 0.75 mg, 1 mg, 4 mg (Envarsus XR)</td> </tr> <tr> <td class=\"indent1\"><strong>Topical</strong></td> </tr> <tr> <td class=\"indent2\">Ointment: 0.03 and 0.1% in 30 g, 60 g, 100 g tubes (Protopic)</td> </tr> <tr> <td class=\"indent1\"><strong>Parenteral</strong></td> </tr> <tr> <td class=\"indent2\">Concentrate for injection: For IV infusion 5 mg/mL in 1 mL ampules</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Formulation descriptions are for products available in the United States, Canada, and some other countries. Consult local product information before use.</div><div class=\"graphic_reference\">Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 57518 Version 6.0</div></div></div>"},"57519":{"type":"graphic_diagnosticimage","displayName":"Neuropathic disease of foot","title":"Neuropathic disease of foot","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Neuropathic disease of foot</div><div class=\"cntnt\"><img style=\"width:237px; height:322px;\" src=\"images/RHEUM/57519_Neuropathic_disease_of_foot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain radiograph of the foot demonstrating features typical of neuropathic joint disease involving the tarsometatarsal joint spaces (arrows); there is destruction of the joints and adjacent bones, infralateral subluxation of the metatarsal bones with respect to the tarsal bones, and proliferative new bone formation, including extensive intertarsal degenerative change.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 57519 Version 2.0</div></div></div>"},"57520":{"type":"graphic_figure","displayName":"Abdominal aortic aneurysm repair PI","title":"Abdominal aortic aneurysm repair","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Abdominal aortic aneurysm repair</div><div class=\"cntnt\"><img style=\"width:464px; height:705px;\" src=\"images/PI/57520_AAArepairPI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For open surgery repair, the doctor cuts open your belly and replaces the bulging part of the aorta with a tube called a \"graft.\" This tube is made from manmade materials. It is sewn into place. Blood can flow normally through it.<br />To repair the aorta with an endovascular stent graft, the doctor cuts into a blood vessel in your thigh (at the spot where your thigh meets the rest of your body) and inserts a folded graft. Then the doctor threads the graft up to the bulging part of the aorta and unfolds it. This type of graft is not sewn into place. Blood flows through the graft.</div><div id=\"graphicVersion\">Graphic 57520 Version 7.0</div></div></div>"},"57522":{"type":"graphic_diagnosticimage","displayName":"Echo assessment rt ventricle2","title":"Echocardiographic estimate of right ventricular pressure in an infant with congenital diaphragmatic hernia","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Echocardiographic estimate of right ventricular pressure in an infant with congenital diaphragmatic hernia</div><div class=\"cntnt\"><img style=\"width:540px; height:213px;\" src=\"images/OBGYN/57522_Echo_assessment_rt_ventri1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Estimates of right ventricular pressure are obtained by measuring the tricuspid regurgitation (TR) jet and adding this to right atrial pressure. The presence of a TR jet suggests increased pulmonary vascular resistance.</div><div class=\"graphic_reference\">Courtesy of Holly L Hedrick, MD.</div><div id=\"graphicVersion\">Graphic 57522 Version 3.0</div></div></div>"},"57523":{"type":"graphic_diagnosticimage","displayName":"U-S complete hydatid mole","title":"Ultrasound complete hydatid mole","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Ultrasound complete hydatid mole</div><div class=\"cntnt\"><img style=\"width:504px; height:530px;\" src=\"images/OBGYN/57523_U-S_complete_hydatid_mole.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Complete hydatidiform mole: Ultrasound shows a 20 week size uterus. The endometrial cavity is filled with vesicular echogenic material. No fetus is seen.</div><div class=\"graphic_reference\">Courtesy of Department of Radiology, Santa Clara Valley Medical Center.</div><div id=\"graphicVersion\">Graphic 57523 Version 3.0</div></div></div>"},"57524":{"type":"graphic_figure","displayName":"ETT HR recovery prognosis","title":"Heart rate recovery after exercise predicts mortality","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Heart rate recovery after exercise predicts mortality</div><div class=\"cntnt\"><img style=\"width:430px; height:292px;\" src=\"images/CARD/57524_ETT_HR_recovery_prognosis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a study of 2428 patients without known heart disease, an abnormal value for the recovery of heart rate, defined as a reduction of &#8804;12 beats per minute (bpm) from the heart rate at peak exercise, was associated with an increased risk of death. Circles represent the relative risk of death for each of the quintiles as compared with the fifth quintile which had the lowest risk of death; red lines represent the 95 percent confidence interval.</div><div class=\"graphic_reference\">Data from: Cole CR, Blackstone EH, Pashkow FJ, et al. N Engl J Med 1999; 341:1351</div><div id=\"graphicVersion\">Graphic 57524 Version 2.0</div></div></div>"},"57527":{"type":"graphic_figure","displayName":"Organophos carbamate structure","title":"General structures of organophosphate (left) and carbamate (right) agents","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">General structures of organophosphate (left) and carbamate (right) agents</div><div class=\"cntnt\"><img style=\"width:427px; height:124px;\" src=\"images/PULM/57527_Organophos_carbamate_struct.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The variable R1 and R2 groups are composed of either methyl (CH3) or ethyl (CH3CH2) moieties. The leaving group is generally an oxime or an aromatic group. Organophosphorones are similar to organophosphates, but they lack a sulfur atom, and are instead bound to four oxygen molecules.</div><div id=\"graphicVersion\">Graphic 57527 Version 1.0</div></div></div>"},"57530":{"type":"graphic_table","displayName":"Symptoms of rotavirus infection","title":"Frequency of symptoms and signs in children with rotavirus gastroenteritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of symptoms and signs in children with rotavirus gastroenteritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Study</td> <td class=\"subtitle1\">Rodriguez, 1977</td> <td class=\"subtitle1\">Gurwith, 1981</td> <td class=\"subtitle1\">Kovacs, 1987</td> <td class=\"subtitle1\">Staat, 2002&nbsp;</td> </tr> <tr> <td>Vomiting</td> <td>46</td> <td>48</td> <td>86</td> <td>&nbsp;88</td> </tr> <tr> <td>Dehydration</td> <td>83</td> <td>Not stated</td> <td>87</td> <td>&nbsp;Not stated</td> </tr> <tr> <td>Fever</td> <td>46</td> <td>34</td> <td>63</td> <td>&nbsp;69</td> </tr> <tr> <td>Respiratory symptoms</td> <td>34</td> <td>52</td> <td>22</td> <td>&nbsp;Not stated</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Reported as percentages.</div><div id=\"graphicVersion\">Graphic 57530 Version 3.0</div></div></div>"},"57531":{"type":"graphic_table","displayName":"Clinical manifestations of Fabry disease","title":"Clinical manifestations of Fabry disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of Fabry disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Childhood</td> </tr> <tr> <td>Pain, numbness of fingers and toes</td> </tr> <tr> <td>Telangiectasias on ears, conjunctiva</td> </tr> <tr> <td>Blue-black angiomatous macules or papules</td> </tr> <tr> <td>Edematous upper eyelids</td> </tr> <tr> <td>Raynaud phenomenon</td> </tr> <tr> <td>Ophthalmologic abnormalities</td> </tr> <tr> <td class=\"subtitle1_single\">Early adulthood</td> </tr> <tr> <td>Extensive telangiectasias, angiokeratomas</td> </tr> <tr> <td>Albuminuria, hematuria, oval fat bodies in urine</td> </tr> <tr> <td>Edema</td> </tr> <tr> <td>Fever, heat collapse, anhidrosis</td> </tr> <tr> <td>Lymphadenopathy</td> </tr> <tr> <td>Isothermia</td> </tr> <tr> <td class=\"subtitle1_single\">30 to 40 years of age</td> </tr> <tr> <td>Cardiac disease: Coronary conduction defects, mitral insufficiency</td> </tr> <tr> <td>Renal insufficiency</td> </tr> <tr> <td>Cerebrovascular attacks</td> </tr> <tr> <td>Neurologic findings suggesting multiple sclerosis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from: Cho ME, Kopp JB. Fabry disease in the era of enzyme replacement therapy: a renal perspective. Pediatr Nephrol 2004; 19:583. Copyright © 2004 Springer Science and Business Media.</div><div id=\"graphicVersion\">Graphic 57531 Version 4.0</div></div></div>"},"57534":{"type":"graphic_table","displayName":"Signs of adrenal insufficiency","title":"Clinical manifestations of chronic adrenal insufficiency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of chronic adrenal insufficiency</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Symptom</td>\n\n      <td class=\"subtitle1\">Frequency, percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Weakness, tiredness, fatigue</td>\n\n      <td>100</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Anorexia</td>\n\n      <td>100</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Gastrointestinal symptoms</td>\n\n      <td class=\"sublist_other_start\">92</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Nausea</td>\n\n      <td class=\"sublist_other\">86</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Vomiting</td>\n\n      <td class=\"sublist_other\">75</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Constipation</td>\n\n      <td class=\"sublist_other\">33</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Abdominal pain</td>\n\n      <td class=\"sublist_other\">31</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Diarrhea</td>\n\n      <td class=\"sublist_other\">16</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Salt craving</td>\n\n      <td>16</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Postural dizziness</td>\n\n      <td>12</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Muscle or joint pains</td>\n\n      <td>6-13</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1\">Sign</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Weight loss</td>\n\n      <td>100</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hyperpigmentation</td>\n\n      <td>94</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hypotension (systolic BP &#60;110 mmHg)</td>\n\n      <td>88-94</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Vitiligo</td>\n\n      <td>10-20</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Auricular calcification</td>\n\n      <td>5</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1\">Laboratory abnormality</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Electrolyte disturbances</td>\n\n      <td class=\"sublist_other_start\">92</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Hyponatremia</td>\n\n      <td class=\"sublist_other\">88</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Hyperkalemia</td>\n\n      <td class=\"sublist_other\">64</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Hypercalcemia</td>\n\n      <td class=\"sublist_other\">6</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Azotemia</td>\n\n      <td>55</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Anemia</td>\n\n      <td>40</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Eosinophilia</td>\n\n      <td>17</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 57534 Version 1.0</div></div></div>"},"57536":{"type":"graphic_figure","displayName":"Deglutitive UES relaxation","title":"Deglutitive UES relaxation","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Deglutitive UES relaxation</div><div class=\"cntnt\"><img style=\"width:456px; height:605px;\" src=\"images/GAST/57536_Deglutitive_UES_relaxation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A color isobaric contour representing the pressure changes of the upper esophageal sphincter (UES) during deglutitive relaxation and esophageal contractions is shown with the high resolution manometry system. <BR>(B) A linear tracing representing pressure changes is shown as well.</div><div class=\"graphic_reference\">Courtesy of Anthony J Lembo, MD.</div><div id=\"graphicVersion\">Graphic 57536 Version 2.0</div></div></div>"},"57537":{"type":"graphic_diagnosticimage","displayName":"Tetralogy Fallot RV angiogram","title":"Right ventricular angiogram in tetralogy of fallot","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right ventricular angiogram in tetralogy of fallot</div><div class=\"cntnt\"><img style=\"width:338px; height:311px;\" src=\"images/CARD/57537_Tetralogy_Fallot_RV_angiogr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The right ventricular (RV) angiogram in a patient with tetralogy of Fallot was obtained with the camera angled cranially and in a slight left anterior oblique projection. The subvalvar (*) obstruction is so severe that with systole there is absence of contrast in the RV outflow tract. The pulmonary valve annulus is small with a thickened valve. There is a small ridge of supravalvar narrowing (black arrow) and mild proximal left pulmonary artery (LPA) stenosis (red arrow).</div><div class=\"graphic_footnotes\">MPA: main pulmonary artery; RPA: right pulmonary artery.</div><div class=\"graphic_reference\">Photo courtesy of Thomas Doyle, MD.</div><div id=\"graphicVersion\">Graphic 57537 Version 2.0</div></div></div>"},"57538":{"type":"graphic_figure","displayName":"Valvular regurgitation dexfen","title":"Prevalence of aortic regurgitation is increased with dexfenfluramine","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">Prevalence of aortic regurgitation is increased with dexfenfluramine</div><div class=\"cntnt\"><img style=\"width:495px; height:269px;\" src=\"images/CARD/57538_Valvularregurgitationdexf.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 223 patients treated with dexfenfluramine (Dexfen), there is an increase in the presence of 2+ aortic regurgitation (AR) (6.3 versus 1.6 percent for control, p&lt;0.02*) and any degree of AR (21.5 versus 11 percent, p = 0.005•). Additionally, there is a significant increase in any FDA-grade regurgitation of either the aortic or mitral valve in the dexfenfluramine patients (7.6 versus 2 percent, p = 0.01Δ).</div><div class=\"graphic_reference\">Data from Shively BK, Roldan CA, Gill EA, et al. Circulation 1999; 100:2161.</div><div id=\"graphicVersion\">Graphic 57538 Version 2.0</div></div></div>"},"57539":{"type":"graphic_picture","displayName":"Black widow spider 2","title":"Widow spider C","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Widow spider C</div><div class=\"cntnt\"><img style=\"width:432px; height:289px;\" src=\"images/EM/57539_Black_widow_spider_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Julian White, MD.</div><div id=\"graphicVersion\">Graphic 57539 Version 2.0</div></div></div>"},"57540":{"type":"graphic_picture","displayName":"Scapular manipulation for shoulder reduction","title":"Scapular manipulation for reduction of anterior shoulder dislocation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scapular manipulation for reduction of anterior shoulder dislocation</div><div class=\"cntnt\"><img style=\"width:324px; height:489px;\" src=\"images/EM/57540_Shoulder_reduct_scap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient sits upright and leans the unaffected shoulder against the stretcher. The physician stands behind the patient and palpates the tip of the scapula with his thumbs and directs a force medially. The assistant stands in front of the patient and provides gentle downward traction on the humerus as shown. The patient is encouraged to relax the shoulder as much as possible.</div><div class=\"graphic_reference\">Courtesy of Scott C Sherman, MD.</div><div id=\"graphicVersion\">Graphic 57540 Version 3.0</div></div></div>"},"57542":{"type":"graphic_picture","displayName":"Hashimotos thyroiditis","title":"Hashimoto's thyroiditis: Findings on surgical histology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hashimoto's thyroiditis: Findings on surgical histology</div><div class=\"cntnt\"><img style=\"width:360px; height:237px;\" src=\"images/ENDO/57542_Hashimotos_thyroiditis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surgical specimen from a patient with Hashimoto's thyroiditis. Some areas show normal appearing follicles with minimal lymphocytic infiltrates, while other areas have complete destruction of follicles with a dense lymphocytic infiltrate, in which the lymphocytes form germinal centers.</div><div id=\"graphicVersion\">Graphic 57542 Version 2.0</div></div></div>"},"57543":{"type":"graphic_figure","displayName":"Brachial artery anatomy","title":"Brachial artery anatomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brachial artery anatomy</div><div class=\"cntnt\"><img style=\"width:301px; height:207px;\" src=\"images/PULM/57543_Brachial_artery_anatomy.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the relationship of the brachial artery to the antecubital crease and the median nerve. The artery should be entered just above the antecubital crease.</div><div id=\"graphicVersion\">Graphic 57543 Version 1.0</div></div></div>"},"57544":{"type":"graphic_table","displayName":"Sleep patterns in elderly","title":"Normal changes in sleep with aging","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal changes in sleep with aging</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Increased</td>\n</tr>\n<tr>\n<td>Daytime napping</td>\n</tr>\n<tr>\n<td>Nocturnal awakenings</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Decreased</td>\n</tr>\n<tr>\n<td>Total sleep time</td>\n</tr>\n<tr>\n<td>Sleep efficiency</td>\n</tr>\n<tr>\n<td>REM latency</td>\n</tr>\n<tr>\n<td>Slow wave sleep</td>\n</tr>\n<tr>\n<td>Daytime sleep latency</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 57544 Version 1.0</div></div></div>"},"57546":{"type":"graphic_table","displayName":"B cell surface markers II","title":"Surface markers during B cell development-II","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Surface markers during B cell development-II</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td rowspan=\"2\" class=\"subtitle1\" colspan=\"1\">&nbsp;</td><td class=\"subtitle1\" rowspan=\"1\" colspan=\"5\">Antigen-independent phase</td>\n\n\n\n<td colspan=\"4\" class=\"subtitle1\">Antigen-dependent phase</td>\n\n</tr>\n<tr>\n\n<td class=\"subtitle2\">Pre-pro B cell</td>\n<td class=\"subtitle2\">Pro-B cell</td>\n<td class=\"subtitle2\">Pre B cell</td>\n<td class=\"subtitle2\">Immature B cell</td>\n<td class=\"subtitle2\">Mature B cell</td>\n<td class=\"subtitle2\">Activated B cell</td>\n<td class=\"subtitle2\">Blast B cell</td>\n<td class=\"subtitle2\">Memory B cell</td>\n<td class=\"subtitle2\">Plasma B cell</td>\n</tr>\n<tr>\n<td>CD121, IL-1R</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>+</td>\n<td>+</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>CD122, IL-2R beta</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>+</td>\n<td>+</td>\n<td>+</td>\n<td>+</td>\n<td>+</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>CD123, IL-3R alpha</td>\n<td>+</td>\n<td>+</td>\n<td>+</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>CD124, IL-4R alpha</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>+</td>\n<td>+</td>\n<td>+</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>CD125, IL-5R alpha</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>+</td>\n<td>+</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>CD126, IL-6R alpha</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>+</td>\n<td>+</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>CD127, IL-7R alpha</td>\n<td>+</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n</tr>\n\n</tbody>\n</table></div><div class=\"graphic_footnotes\">IL: interleukin; R: receptor; alpha: alpha chain.</div><div class=\"graphic_reference\">Data from Bona, CA, Bonilla, FA, Textbook of Immunology, 2nd edition, Harwood Academic Publishers, Amsterdam, 1996. page 102</div><div id=\"graphicVersion\">Graphic 57546 Version 1.0</div></div></div>"},"57547":{"type":"graphic_diagnosticimage","displayName":"Osteochondral knee fract","title":"Osteochondral fracture of the medial femoral condyle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Osteochondral fracture of the medial femoral condyle</div><div class=\"cntnt\"><img style=\"width:351px; height:396px;\" src=\"images/RHEUM/57547_Osteochondral_knee_fract.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This coronal T2 weighted magnetic resonance image of the knee demonstrates abnormally increased signal in the lateral aspect of the medial femoral condyle (arrow) due to an osteochondral fracture.</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD, and Cecilia M Jude, MD.</div><div id=\"graphicVersion\">Graphic 57547 Version 2.0</div></div></div>"},"57549":{"type":"graphic_diagnosticimage","displayName":"Kidney stone detected by ultrasonography","title":"Kidney stone detected by ultrasonography","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">Kidney stone detected by ultrasonography</div><div class=\"cntnt\"><img style=\"width:475px; height:428px;\" src=\"images/RADIOL/57549_Renal_stone_Echo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The sagittal view of the right kidney reveals a 7 mm shadowing stone in mid-portion of the kidney, characteristic of a non-obstructing stone. The echogenic focus (arrow) represents the stone. The calcified stone inhibits transmission of sound waves, resulting in a shadow behind the stone (arrowheads).</div><div id=\"graphicVersion\">Graphic 57549 Version 4.0</div></div></div>"},"57550":{"type":"graphic_figure","displayName":"Migraine prevalence","title":"Migraine prevalence","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Migraine prevalence</div><div class=\"cntnt\"><img style=\"width:499px; height:370px;\" src=\"images/NEURO/57550_Migraine_prevalence.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Lipton, RB, Bigal, ME, Diamond, M, et al. Migrane prevalence, disease burden, and the need for preventative therapy. Neurology 2007; 68:343.</div><div id=\"graphicVersion\">Graphic 57550 Version 1.0</div></div></div>"},"57551":{"type":"graphic_figure","displayName":"Tx post vaginal wall def 9","title":"Example of a left lateral posterior vaginal wall support defect","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Example of a left lateral posterior vaginal wall support defect</div><div class=\"cntnt\"><img style=\"width:372px; height:404px;\" src=\"images/OBGYN/57551_Tx_post_vaginal_wall_def_9.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Walters, MD, Karram, MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright ©2007 Elsevier.</div><div id=\"graphicVersion\">Graphic 57551 Version 2.0</div></div></div>"},"57553":{"type":"graphic_waveform","displayName":"Intermediate case 5","title":"Intermediate case 5","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intermediate case 5</div><div class=\"cntnt\"><img style=\"width:422px; height:127px;\" src=\"images/CARD/57553_Intermediate_case_5.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 57553 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"57556":{"type":"graphic_picture","displayName":"CHS smear giant granules","title":"Bone marrow from a male patient with Chediak-Higashi syndrome after cord blood transplantation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bone marrow from a male patient with Chediak-Higashi syndrome after cord blood transplantation</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/ALLRG/57556_CHS_smear_giant_granules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note chimerism, with CHS cells with&nbsp;giant azurophilic&nbsp;granules and normal cells.</div><div class=\"graphic_footnotes\">CHS: Chediak-Higashi syndrome.</div><div class=\"graphic_reference\">Courtesy of Robert L Roberts, MD, PhD.</div><div id=\"graphicVersion\">Graphic 57556 Version 4.0</div></div></div>"},"57557":{"type":"graphic_movie","displayName":"Mitral valve prolapse apical long axis echocardiogram","title":"Mitral valve prolapse apical long axis echocardiogram","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mitral valve prolapse apical long axis echocardiogram</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/57557_aplaxmvpconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:342px; height:234px;\" src=\"images/CARD/57557_aplaxmvp.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 57557 Version 2.0</div></div></div>"},"57558":{"type":"graphic_table","displayName":"Claassen SAH CT grading scale","title":"Claassen subarachnoid hemorrhage CT rating scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Claassen subarachnoid hemorrhage CT rating scale</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Grade</td>\n\n      <td class=\"subtitle1\">Head CT criteria</td>\n\n    </tr>\n\n    <tr>\n\n      <td>1</td>\n\n      <td>No SAH or IVH</td>\n\n    </tr>\n\n    <tr>\n      <td>2</td>\n      <td>Minimal SAH and no IVH</td>\n    </tr>\n    <tr>\n      <td>3</td>\n      <td>Minimal SAH with bilateral IVH</td>\n    </tr>\n    <tr>\n      <td>4</td>\n      <td>Thick SAH (completely filling one or more cistern or fissure) without bilateral IVH</td>\n    </tr>\n    <tr>\n\n      <td>5</td>\n\n      <td>Thick SAH (completely filling one or more cistern or fissure) with bilateral IVH</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">SAH: subarachnoid hemorrhage; IVH: intraventricular hemorrhage.</div><div class=\"graphic_reference\">From: Claassen, J, Bernardini, GL, Kreiter, K, et al. Effect of cisternal and ventricular blood on risk of delayed cerebral ischemia after subarachnoid hemorrhage: the Fisher scale revisited. Stroke 2001; 32:2012.</div><div id=\"graphicVersion\">Graphic 57558 Version 1.0</div></div></div>"},"57559":{"type":"graphic_picture","displayName":"Polyvinyl alcohol particles","title":"Polyvinyl Alcohol (PVA) particles","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Polyvinyl Alcohol (PVA) particles</div><div class=\"cntnt\"><img style=\"width:468px; height:346px;\" src=\"images/OBGYN/57559_Polyvinyl_alcohol_particles.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 57559 Version 2.0</div></div></div>"},"57560":{"type":"graphic_diagnosticimage","displayName":"Chondroblastoma knee","title":"Chondroblastoma of the knee","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chondroblastoma of the knee</div><div class=\"cntnt\"><img style=\"width:350px; height:511px;\" src=\"images/PEDS/57560_Chondroblastoma_knee.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intercondylar (Tunnel), Knee, Chondroblastoma. A well-defined radiolucent lesion is present within the medial femoral condyle (arrows). This lesion was almost non-detectable on the routine AP view but is shown more clearly on the intercondylar view, because the femoral surface is less tangential to the incident beam.</div><div class=\"graphic_reference\">Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 57560 Version 3.0</div></div></div>"},"57561":{"type":"graphic_table","displayName":"Major functions of nephron segments","title":"Major functions of nephron segments","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major functions of nephron segments</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"subtitle1\">Nephron segment</td>\n\n\t\t\t<td class=\"subtitle1\">Major functions</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Glomerulus</td>\n\n\t\t\t<td>Forms an ultrafiltrate of plasma</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Proximal tubule</td>\n\n\t\t\t<td><p>Reabsorbs isosmotically 60 to 65 percent of the filtered NaCl and H2O</p>\n\t\t\t<p>Reabsorbs 90 percent of the filtered HCO3-</p>\n\t\t\t<p>Major site of ammonia production in the nephron</p>\n\t\t\t<p>Reabsorbs almost all of filtered glucose and amino acids</p>\n\t\t\t<p>Reabsorbs K+, phosphate, calcium, magnesium, urea, and uric acid</p>\n\t\t\t<p>Secretes organic anions (such as urate) and cations (such as creatine); this pathway is also used for excretion of protein-bound drugs and toxins</p></td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Loop of Henle</td>\n\n\t\t\t<td><p>Reabsorbs 25 to 35 percent of filtered NaCl</p>\n\t\t\t<p>Countercurrent multiplier as NaCl reabsorbed in excess of water</p>\n\t\t<p>\tMajor site of active regulation of magnesium excretion</p></td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Distal tubule</td>\n\n\t\t\t<td><p>Reabsorbs about 5 percent of filtered NaCl but almost no water</p>\n\t\t\t<p>Major site, with connecting segment, of active regulation of calcium excretion</p></td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Connecting segment and cortical collecting tubule</td>\n\n\t\t\t<td><p>Principal cells reabsorb Na+ and Cl- and secrete K+ under the influence of aldosterone</p>\n\t\t<p>\tIntercalated cells secrete H+, reabsorb K+, and, in metabolic alkalosis, secrete HCO3-</p>\n\t\t\t<p>Reabsorb water in the presence of antidiuretic hormone</p></td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Medullary collecting tubule</td>\n\n\t\t\t<td><p>Site of final modification of the urine</p>\n\t\t\t<p>Reabsorb NaCl, the concentration of which can be reduced to less than 1 meq/L</p>\n\t\t\t<p>Reabsorb water and urea relative to the amount of antidiuretic hormone present, allowing a concentrated or dilute urine to be excreted</p>\n\t\t\t<p>Secrete H+ and NH3; urine pH can be reduced to as low as 4.5 to 5.0</p>\n\t\t\t<p>Can contribute to potassium balance by reabsorption or secretion of K+</p></td>\n\t\t</tr>\n\t</tbody>\n</table></div><div class=\"graphic_lgnd\">Contribution of the different nephron segments to solute and water homeostasis.</div><div id=\"graphicVersion\">Graphic 57561 Version 2.0</div></div></div>"},"57562":{"type":"graphic_picture","displayName":"Lichen sclerosus lost architecture","title":"Loss of architecture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Loss of architecture</div><div class=\"cntnt\"><img style=\"width:258px; height:393px;\" src=\"images/OBGYN/57562_Lichen_sclers_lost_archecte.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The distinction between the labia majora and minora is lost, and the clitoris becomes buried under the fused prepuce.</div><div class=\"graphic_reference\">Reproduced with permission from Ridley CM, Neill SM (Eds), The Vulva, 2nd ed, Blackwell Science, Oxford 1999. Copyright © 1999 Blackwell Science. <A spellcheck=true href=\"http://www.wiley.com/wiley-blackwell\" target=_blank>http://www.blackwell-science.com</A>.</div><div id=\"graphicVersion\">Graphic 57562 Version 5.0</div></div></div>"},"57565":{"type":"graphic_diagnosticimage","displayName":"Malignant pleural effs I CT","title":"Malignant pleural effusions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Malignant pleural effusions</div><div class=\"cntnt\"><img style=\"width:324px; height:310px;\" src=\"images/PULM/57565_Malignant_pleural_effs_I_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral malignant pleural effusions in patient with carcinoma of the breast and bilateral mastectomies. CT scan shows a free right pleural effusion and two left-sided collections of pleural liquid, loculated medially and anterolaterally.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 57565 Version 3.0</div></div></div>"},"57566":{"type":"graphic_figure","displayName":"Whole body Langers lines","title":"Whole body Langer's lines","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Whole body Langer's lines</div><div class=\"cntnt\"><img style=\"width:436px; height:480px;\" src=\"images/SURG/57566_Whole_body_langers_lines.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic drawing of the cleavage (Langer's) lines in the skin. Surgical incisions made in the direction of these lines, which run parallel to the predominant direction of the collagen fiber bundles in the dermis, have less tendency to gape.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley II AF. Clinical Oriented Anatomy, Fourth Edition. Baltimore, Lippincott Williams &amp; Wilkins 1999. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 57566 Version 3.0</div></div></div>"},"57568":{"type":"graphic_picture","displayName":"Pityriasis rosea trailing scale","title":"Pityriasis rosea","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pityriasis rosea</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/57568_Pityr_rosea_trailing_scale.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous plaques with trailing collarettes of scale.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 57568 Version 4.0</div></div></div>"},"57569":{"type":"graphic_picture","displayName":"Bullosis diabeticorum","title":"Bullous disease of diabetes (bullosis diabeticorum)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Bullous disease of diabetes (bullosis diabeticorum)</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/57569_Bulllous_diabeticorum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A noninflammatory bulla is present on the lower leg in this patient with bullosis diabeticorum.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 57569 Version 5.0</div></div></div>"},"57570":{"type":"graphic_table","displayName":"Cholestatic causes jaundice","title":"Cholestatic conditions that can produce jaundice","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cholestatic conditions that can produce jaundice</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Intrahepatic</td> </tr> <tr> <td>Viral hepatitis</td> </tr> <tr> <td>Alcoholic hepatitis</td> </tr> <tr> <td class=\"sublist1_start\">Drug toxicity</td> </tr> <tr> <td class=\"sublist1\">Pure cholestasis - anabolic and contraceptive steroids</td> </tr> <tr> <td class=\"sublist1\">Mixed cholestasis/hepatitis - chlorpromazine, erythromycin estolate</td> </tr> <tr> <td class=\"sublist1\">Chronic cholestasis - chlorpromazine and prochlorperazine</td> </tr> <tr> <td>Primary biliary cholangitis</td> </tr> <tr> <td>Primary sclerosing cholangitis</td> </tr> <tr> <td class=\"sublist1_start\">Vanishing bile duct syndrome</td> </tr> <tr> <td class=\"sublist1\">Chronic rejection of liver transplants</td> </tr> <tr> <td class=\"sublist1\">Sarcoidosis</td> </tr> <tr> <td class=\"sublist1\">Drugs</td> </tr> <tr> <td class=\"sublist1_start\">Inherited</td> </tr> <tr> <td class=\"sublist1\">Benign recurrent cholestasis</td> </tr> <tr> <td class=\"sublist1\">Progressive intrahepatic familial cholestasis</td> </tr> <tr> <td class=\"sublist1\">Gilbert syndrome</td> </tr> <tr> <td class=\"sublist1\">Crigler-Najjar syndrome types 1 and 2</td> </tr> <tr> <td class=\"sublist1\">Dubin-Johnson syndrome</td> </tr> <tr> <td class=\"sublist1\">Rotor syndrome</td> </tr> <tr> <td class=\"sublist1\">Alagille syndrome</td> </tr> <tr> <td>Cholestasis of pregnancy</td> </tr> <tr> <td>Total parenteral nutrition</td> </tr> <tr> <td>Non-hepatobiliary sepsis</td> </tr> <tr> <td>Benign postoperative cholestasis</td> </tr> <tr> <td>Paraneoplastic syndrome (Stauffer's syndrome)</td> </tr> <tr> <td class=\"subtitle1_single\">Extrahepatic</td> </tr> <tr> <td class=\"sublist1_start\">Malignant</td> </tr> <tr> <td class=\"sublist1\">Cholangiocarcinoma</td> </tr> <tr> <td class=\"sublist1\">Pancreatic cancer</td> </tr> <tr> <td class=\"sublist1\">Gallbladder cancer</td> </tr> <tr> <td class=\"sublist1\">Ampullary cancer</td> </tr> <tr> <td class=\"sublist1\">Malignant involvement of the porta hepatis lymph nodes</td> </tr> <tr> <td class=\"sublist1_start\">Benign</td> </tr> <tr> <td class=\"sublist1\">Choledocholithiasis</td> </tr> <tr> <td class=\"sublist1\">Primary sclerosing cholangitis</td> </tr> <tr> <td class=\"sublist1\">Chronic pancreatitis</td> </tr> <tr> <td class=\"sublist1\">AIDS cholangiopathy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AIDS: acquired immunodeficiency syndrome.</div><div id=\"graphicVersion\">Graphic 57570 Version 4.0</div></div></div>"},"57571":{"type":"graphic_picture","displayName":"Koplik spots in measles","title":"Koplik spots","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Koplik spots</div><div class=\"cntnt\"><img style=\"width:319px; height:234px;\" src=\"images/ID/57571_Kopliks_spots_in_measles.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Koplik spots, seen as whitish papules on an erythematous background opposite the molars (arrows), are pathognomonic of measles.</div><div class=\"graphic_reference\">Copyright Dr. Michael Bennish; reproduced with his permission.</div><div id=\"graphicVersion\">Graphic 57571 Version 3.0</div></div></div>"},"57572":{"type":"graphic_picture","displayName":"Myeloma cast I-light microscopy","title":"Myeloma cast: Light microscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Myeloma cast: Light microscopy</div><div class=\"cntnt\"><img style=\"width:377px; height:248px;\" src=\"images/NEPH/57572_Myeloma_cast_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power light micrograph shows PAS stain of tubular casts in myeloma kidney. The bottom two tubules contain casts composed of PAS-negative immunoglobulin light chains (small arrows).&nbsp;By comparison, the cast in the middle tubule (probably hyaline) is primarily composed of PAS-positive Tamm-Horsfall mucoprotein, the matrix of all casts (large arrow). Myeloma proteins are PAS negative because they contain few of the neutral sugars that are detected by this stain.</div><div class=\"graphic_footnotes\">PAS: period acid-Schiff.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 57572 Version 6.0</div></div></div>"},"57573":{"type":"graphic_table","displayName":"Chronic pain syndromes directly related to cancer","title":"Chronic pain syndromes directly related to cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chronic pain syndromes directly related to cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Nociceptive pain syndromes: Somatic </td> </tr> <tr> <td class=\"subtitle2_single\">Tumor-related bone pain </td> </tr> <tr> <td class=\"subtitle3_single\">Multifocal bone pain </td> </tr> <tr> <td class=\"indent2\">Bone metastases </td> </tr> <tr> <td class=\"indent2\">Bone marrow expansion (hematologic malignancies) </td> </tr> <tr> <td class=\"indent2\">Oncogenic hypophosphatemic osteomalacia </td> </tr> <tr> <td class=\"subtitle3_single\">Vertebral syndromes </td> </tr> <tr> <td class=\"indent2\">Atlanto-axial destruction and odontoid fracture </td> </tr> <tr> <td class=\"indent2\">C7-T1 syndrome </td> </tr> <tr> <td class=\"indent2\">T12-L1 syndrome </td> </tr> <tr> <td class=\"indent2\">Sacral syndrome</td> </tr> <tr> <td class=\"indent2\">Back pain secondary to spinal cord compression</td> </tr> <tr> <td class=\"subtitle3_single\">Pain syndromes related to pelvis and hip </td> </tr> <tr> <td class=\"indent2\">Pelvic metastases </td> </tr> <tr> <td class=\"indent2\">Hip joint syndrome </td> </tr> <tr> <td class=\"indent2\">Malignant piriformis syndrome</td> </tr> <tr> <td class=\"subtitle3_single\">Base of skull metastases </td> </tr> <tr> <td class=\"indent2\">Orbital syndrome </td> </tr> <tr> <td class=\"indent2\">Parasellar syndrome </td> </tr> <tr> <td class=\"indent2\">Middle cranial fossa syndrome </td> </tr> <tr> <td class=\"indent2\">Jugular foramen syndrome </td> </tr> <tr> <td class=\"indent2\">Occipital condyle syndrome </td> </tr> <tr> <td class=\"indent2\">Clivus syndrome </td> </tr> <tr> <td class=\"indent2\">Sphenoid sinus syndrome </td> </tr> <tr> <td class=\"subtitle2_single\">Tumor-related soft tissue pain </td> </tr> <tr> <td class=\"indent1\">Headache and facial pain </td> </tr> <tr> <td class=\"indent1\">Ear and eye pain syndromes </td> </tr> <tr> <td class=\"indent1\">Pleural pain </td> </tr> <tr> <td class=\"subtitle2_single\">Paraneoplastic pain syndromes </td> </tr> <tr> <td class=\"indent1\">Muscle cramps </td> </tr> <tr> <td class=\"indent1\">Hypertrophic osteoarthropathy </td> </tr> <tr> <td class=\"indent1\">Tumor-related gynecomastia (eg, in testicular neoplasms that secrete human chorionic gonadotropin) </td> </tr> <tr> <td class=\"indent1\">Paraneoplastic pemphigus </td> </tr> <tr> <td class=\"indent1\">Paraneoplastic Raynaud phenomenon </td> </tr> <tr> <td class=\"subtitle1_single\">Nociceptive pain syndromes: Visceral </td> </tr> <tr> <td>Hepatic distention syndrome</td> </tr> <tr> <td>Midline retroperitoneal syndrome</td> </tr> <tr> <td>Chronic intestinal obstruction</td> </tr> <tr> <td>Peritoneal carcinomatosis</td> </tr> <tr> <td>Malignant perineal pain</td> </tr> <tr> <td>Adrenal pain syndrome</td> </tr> <tr> <td>Ureteric obstruction</td> </tr> <tr> <td class=\"subtitle1_single\">Neuropathic pain syndromes </td> </tr> <tr> <td>Leptomeningeal metastases</td> </tr> <tr> <td>Malignant painful radiculopathy</td> </tr> <tr> <td class=\"subtitle2_single\">Painful cranial neuralgias </td> </tr> <tr> <td class=\"indent1\">Glossopharyngeal neuralgia </td> </tr> <tr> <td class=\"indent1\">Trigeminal neuralgia </td> </tr> <tr> <td class=\"subtitle2_single\">Radiculopathies</td> </tr> <tr> <td class=\"indent1\">Lumbosacral radiculopathy</td> </tr> <tr> <td class=\"indent1\">Cervical radiculopathy</td> </tr> <tr> <td class=\"indent1\">Thoracic radiculopathy</td> </tr> <tr> <td class=\"subtitle2_single\">Plexopathies </td> </tr> <tr> <td class=\"indent1\">Cervical plexopathy </td> </tr> <tr> <td class=\"indent1\">Malignant brachial plexopathy </td> </tr> <tr> <td class=\"indent1\">Malignant lumbosacral plexopathy </td> </tr> <tr> <td class=\"indent1\">Lower lumbosacral plexopathies, including sacral and coccygeal plexopathy and panplexopathy </td> </tr> <tr> <td class=\"subtitle2_single\">Painful peripheral mononeuropathies </td> </tr> <tr> <td class=\"subtitle2_single\">Paraneoplastic sensory neuropathy </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 57573 Version 2.0</div></div></div>"},"57574":{"type":"graphic_table","displayName":"FISTS violence screening","title":"FISTS violence screening questions for adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">FISTS violence screening questions for adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      \n\n      <td class=\"subtitle1_single\">Fights: How many fights have you been in in the past year? When was your last fight?</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Teens who have been in more than one physical fight in the preceding 12 months are at increased risk of violence-related injury.</td>\n\n    </tr>\n\n\n\n    <tr>\n\n      \n\n      <td class=\"subtitle1_single\">Injuries: Have you ever been injured in a fight? Have you ever injured anyone else?</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Multiple\nor serious previous injuries may indicate an increased risk of future\ninjury. Patients who have been injured may be more likely to carry\nweapons.</td>\n\n    </tr>\n\n\n\n    <tr>\n\n      \n\n      <td class=\"subtitle1_single\">Sexual violence: What happens when you and your boyfriend/girlfriend fight? Have you ever had sex against your will?</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Teen-dating violence is associated with future domestic violence.</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td class=\"subtitle1_single\">Threats: Have you ever been threatened?</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Teenagers who have been threatened with a weapon are at future risk of weapons-related injury.</td>\n\n    </tr>\n\n\n    <tr>\n\n      \n\n      <td class=\"subtitle1_single\">Self-defense: Have you ever carried a weapon to protect yourself?</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Teenagers who arm themselves in self-defense are at increased risk for violence-related injury.</td>\n\n    </tr>\n\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=52449&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>FIST_violence_screening.htm</title></head></div><div class=\"graphic_reference\">Adapted from Alpert E, Sege R, Bradshaw Y. Academic Medicine 1997; 72 (suppl):S41.</div><div id=\"graphicVersion\">Graphic 57574 Version 3.0</div></div></div>"},"57576":{"type":"graphic_table","displayName":"HPV types in VAIN","title":"HPV prevalence in vaginal lesions based on PCR or hybrid capture assays","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">HPV prevalence in vaginal lesions based on PCR or hybrid capture assays</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">N</td> <td class=\"subtitle1\">HPV (+)</td> <td class=\"subtitle1\">Number of HPV types</td> <td class=\"subtitle1\">HPV-16 (+)</td> <td class=\"subtitle1\">Multiple HPV infections</td> </tr> <tr> <td><strong>Vaginal cancer</strong></td> <td class=\"centered\">83</td> <td class=\"centered\">65.5 percent</td> <td class=\"centered\">2</td> <td class=\"centered\">55.4 percent</td> <td class=\"centered\">2.3 percent</td> </tr> <tr> <td><strong>VAIN 2/3</strong></td> <td class=\"centered\">166</td> <td class=\"centered\">92.6 percent</td> <td class=\"centered\">14</td> <td class=\"centered\">65.8 percent</td> <td class=\"centered\">12.6 percent</td> </tr> <tr> <td><strong>VAIN 1</strong></td> <td class=\"centered\">66</td> <td class=\"centered\">98.5 percent</td> <td class=\"centered\">21</td> <td class=\"centered\">17.9 percent</td> <td class=\"centered\">35 percent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HPV: human papillomavirus; PCR: polymerase chain reaction; VAIN: vaginal intraepithelial neoplasia.</div><div class=\"graphic_reference\">Data from: Smith JS, Backes DM, Hootes BE, et al. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors. Obstet Gynecol 2009; 113:917.</div><div id=\"graphicVersion\">Graphic 57576 Version 2.0</div></div></div>"},"57577":{"type":"graphic_picture","displayName":"Sebaceous hyperplasia","title":"Sebaceous hyperplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sebaceous hyperplasia</div><div class=\"cntnt\"><img style=\"width:396px; height:264px;\" src=\"images/PC/57577_Sebaceous_hyperplasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple yellowish papules are present on the forehead of this middle-aged patient.</div><div class=\"graphic_reference\">Reproduced with permission: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright ©2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 57577 Version 3.0</div></div></div>"},"57578":{"type":"graphic_diagnosticimage","displayName":"CT scan of pulmonary edema from near-drowning","title":"CT scan of pulmonary edema due to near-drowning","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan of pulmonary edema due to near-drowning</div><div class=\"cntnt\"><img style=\"width:368px; height:312px;\" src=\"images/PULM/57578_Ground_glass_drowning_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ground glass opacities are seen in both upper lobes. In the right lung, ground glass opacities abut the minor fissure and spare the middle lobe.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 57578 Version 2.0</div></div></div>"},"57579":{"type":"graphic_diagnosticimage","displayName":"Special EEG electrodes","title":"Position of special electrodes with respect to the underlying brain","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Position of special electrodes with respect to the underlying brain</div><div class=\"cntnt\"><img style=\"width:585px; height:308px;\" src=\"images/NEURO/57579_Special_EEG_electrodes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Standard temporal electrodes (F7/F8 and T7/T8) lie over the Sylvian fissure, and record infra- and suprasylvian regions. Special inferior temporal electrodes (F9/F10 and T9/T10) record the lateral temporal region. Superficial anterior temporal electrodes (T1/T2; usually positioned slightly anterior to what is shown here) record the anterior temporal region, as do mandibular notch electrodes (Mn1/Mn2). The inferior temporal region can be recorded by ear (A1/A2), sphenoidal (Sp1/Sp2) and nasopharyngeal electrodes (Np1/Np2).</div><div class=\"graphic_reference\">Courtesy of Lawrence J Hirsch, MD, Hiba Arif, MD, and Jeremy Moeller, MD.</div><div id=\"graphicVersion\">Graphic 57579 Version 4.0</div></div></div>"},"57580":{"type":"graphic_table","displayName":"Catheter size for pediatric hemodialysis","title":"Catheter size for hemodialysis according to the weight of the child","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Catheter size for hemodialysis according to the weight of the child</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Weight of child (kg)</td> <td class=\"subtitle1\">Catheter gauge (Fr)</td> <td class=\"subtitle1\">Catheter length (cm)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Double lumen</td> </tr> <tr> <td class=\"indent1\">3 to 12</td> <td>8</td> <td>12 or 18</td> </tr> <tr> <td class=\"indent1\">10 to 25</td> <td>10 or 12.5</td> <td>12 or 19</td> </tr> <tr> <td class=\"indent1\">15 to 30</td> <td>10 or 12.5</td> <td>19 or 28</td> </tr> <tr> <td class=\"indent1\">&#62;25</td> <td>14</td> <td>24</td> </tr> <tr> <td class=\"indent1\">&#62;30</td> <td>12 or 13.5</td> <td>23 or 26</td> </tr> <tr> <td class=\"indent1\">&#62;40</td> <td>12</td> <td>40</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Single lumen</td> </tr> <tr> <td class=\"indent1\">&#60;5</td> <td>6.5</td> <td>29 or 32</td> </tr> <tr> <td class=\"indent1\">&#62;10</td> <td>10</td> <td>36 or 40</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 57580 Version 4.0</div></div></div>"},"57581":{"type":"graphic_figure","displayName":"Estimated prevalence of non-acid reflux","title":"Estimated prevalence of non-acid reflux","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Estimated prevalence of non-acid reflux</div><div class=\"cntnt\"><img style=\"width:546px; height:316px;\" src=\"images/GAST/57581_Prop_sym_acid_reflux.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Estimated prevalence of GERD symptoms, persistent symptoms on PPI, and symptomatic non-acid reflux in the United States population (60-40 rule). Epidemiologic studies estimate that approximately 40 percent&nbsp;of the adult population in the United States experiences reflux symptoms at least once a week. Large clinical trials evaluating the efficacy of acid suppressive therapy in the treatment of GERD indicate that approximately 40 percent&nbsp;of GERD patients treated with PPI have persistent symptoms on therapy. Clinical investigations evaluating the association between persistent symptoms on PPI therapy with reflux episodes indicate that approximately 40 percent of patients have symptoms preceded by non-acid reflux. Based on this proportion, we estimate that roughly 19 million adults in the United States have symptomatic non-acid reflux.</div><div class=\"graphic_footnotes\">%: percent; GERD: gastroesophageal reflux disease; PPI: proton pump inhibitor.</div><div id=\"graphicVersion\">Graphic 57581 Version 2.0</div></div></div>"},"57582":{"type":"graphic_diagnosticimage","displayName":"Epiphrenic diverticulum Barium","title":"Epiphrenic diverticulum seen on barium swallow study","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Epiphrenic diverticulum seen on barium swallow study</div><div class=\"cntnt\"><img style=\"width:248px; height:288px;\" src=\"images/GAST/57582_Epiphrenic_diverticulum_Bar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Barium swallow study, performed in a patient with dysphagia and recurrent reflux, shows a large epiphrenic diverticulum (arrow) which has arisen immediately above a stricture (arrowhead) of the distal esophagus. This stricture was caused by chronic reflux esophagitis and the patient required an antireflux procedure, and resection of the stricture and diverticulum.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 57582 Version 4.0</div></div></div>"},"57583":{"type":"graphic_table","displayName":"NICHD criteria for category I II and III FHR tracings","title":"NICHD criteria for category I, II, and III FHR tracings","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NICHD criteria for category I, II, and III FHR tracings</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Category I</td> </tr> <tr> <td class=\"subtitle2_single\">All of the following criteria must be present. Tracings meeting these criteria are predictive of normal fetal acid-base balance at the time of observation.</td> </tr> <tr> <td class=\"indent1\">Baseline rate: 110 to 160 bpm</td> </tr> <tr> <td class=\"indent1\">Moderate baseline FHR variability</td> </tr> <tr> <td class=\"indent1\">No late or variable decelerations</td> </tr> <tr> <td class=\"indent1\">Early decelerations may be present or absent</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Accelerations may be present or absent</td> </tr> <tr> <td class=\"subtitle1_single\">Category III</td> </tr> <tr> <td class=\"subtitle2_single\">Category III tracings are predictive of abnormal fetal acid-base status at the time of observation. Prompt evaluation is indicated and most parturients will require expeditious intervention, such as provision of supplemental oxygen, change in position, treatment of hypotension, and discontinuation of any uterotonic drugs being administered. Category III tracings include either (1) or (2) below.</td> </tr> <tr> <td class=\"indent1\">(1) Absent baseline FHR variability and any of the following:</td> </tr> <tr> <td class=\"indent2\"> <ul class=\"decimal_heading\"> <li>Recurrent late decelerations </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul class=\"decimal_heading\"> <li>Recurrent variable decelerations </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul class=\"decimal_heading\"> <li>Bradycardia </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">(2) Sinusoidal pattern</td> </tr> <tr> <td class=\"subtitle1_single\">Category II</td> </tr> <tr> <td class=\"indent1\"><strong>FHR tracing does not meet criteria for either category I or III and is considered indeterminate.</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NICHD: National Institute of Child Health and Human Development; FHR: fetal heart rate; bpm: beats per minute.</div><div class=\"graphic_reference\">Data from: Macones GA, Hankins GD, Spong CY, et al. The 2008 National Institute of Child Health and Human Development Workshop Report on Electronic Fetal Monitoring: Update on Definitions, Interpretation, and Research Guidelines. Obstet Gynecol 2008; 112:661.</div><div id=\"graphicVersion\">Graphic 57583 Version 9.0</div></div></div>"},"57584":{"type":"graphic_table","displayName":"Paget disease breast surgery","title":"Treatment of Paget disease of the breast with surgery alone","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of Paget disease of the breast with surgery alone</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Study </td> <td class=\"subtitle1\">N </td> <td class=\"subtitle1\">Presentation </td> <td class=\"subtitle1\">Treatment </td> <td class=\"subtitle1\">Local Recurrence </td> <td class=\"subtitle1\">Median F/U (mos) </td> </tr> <tr> <td rowspan=\"2\">Polgar C; 2002 </td> <td rowspan=\"2\">33 </td> <td>No mass (30)</td> <td rowspan=\"2\">Cone excision only </td> <td rowspan=\"2\">11 (33 percent) </td> <td rowspan=\"2\">72 </td> </tr> <tr> <td>Mass (3)</td> </tr> <tr> <td rowspan=\"3\">Dixon AR; 1991 </td> <td>37</td> <td>No mass</td> <td>Simple mastectomy</td> <td>2 (5 percent)</td> <td>40</td> </tr> <tr> <td rowspan=\"2\">10 </td> <td>No mass</td> <td rowspan=\"2\">Nipple-areolar resection + resection underlying breast tissue/calcifications </td> <td rowspan=\"2\">4 (40 percent) </td> <td rowspan=\"2\">56 </td> </tr> <tr> <td>Calcifications adjacent to nipple on mammogram</td> </tr> <tr> <td rowspan=\"2\">Lagios MD; 1984 </td> <td rowspan=\"2\">5 </td> <td>No mass</td> <td>Nipple-areolar resection (n = 4)</td> <td>0 (0 percent)</td> <td rowspan=\"2\">50 </td> </tr> <tr> <td>Normal mammogram</td> <td>Partial nipple-areolar resection, (n = 1)</td> <td>1 (100 percent)</td> </tr> <tr> <td>Paone JF; 1981</td> <td>5</td> <td>No mass</td> <td>Nipple-areolar resection</td> <td>0 (0 percent)</td> <td>NR</td> </tr> </tbody></table></div><div class=\"graphic_reference\"><OL>&#xD;&#xA;<LI>Dixon AR, Galea MH, Ellis IO, et al. Paget's disease of the nipple. Br J Surg 1991; 78:722. </LI>&#xD;&#xA;<LI>Lagios MD, Westdahl PR, Rose MR, Concannon S. Paget's disease of the nipple. Alternative management in cases without or with minimal extent of underlying breast carcinoma. Cancer 1984; 54:545. </LI>&#xD;&#xA;<LI>Paone JF, Baker RR. Pathogenesis and treatment of Paget's disease of the breast. Cancer 1981; 48:825. </LI>&#xD;&#xA;<LI>Polgár C, Orosz Z, Kovács T, Fodor J. Breast-conserving therapy for Paget disease of the nipple: a prospective European Organization for Research and Treatment of Cancer study of 61 patients. Cancer 2002; 94:1904.</LI></OL></div><div id=\"graphicVersion\">Graphic 57584 Version 3.0</div></div></div>"},"57585":{"type":"graphic_figure","displayName":"Ultrafast CT scanner diagram","title":"Ultrafast CT scanner","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrafast CT scanner</div><div class=\"cntnt\"><img style=\"width:360px; height:225px;\" src=\"images/PULM/57585_Ultrafast_CT_scanner_diagra.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagram of ultrafast CT scanner, also called electron beam CT or fifth generation CT. An electron gun produces high energy electrons which are deflected and focused on four tungsten target rings by magnetic coils. The produced x-rays penetrate the patient and are intercepted by two arrays of detectors. No moving parts are present.</div><div class=\"graphic_reference\">Adapted from McCollough, CH, Morin, RL, Radiol Clin North Am 1994; 32:521</div><div id=\"graphicVersion\">Graphic 57585 Version 1.0</div></div></div>"},"57586":{"type":"graphic_picture","displayName":"Inflammatory morphea","title":"Inflammatory morphea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inflammatory morphea</div><div class=\"cntnt\"><img style=\"width:432px; height:243px;\" src=\"images/DERM/57586_Inflammatory_morphea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An active plaque in the inflammatory stage is present on the left. Note the violaceous border.</div><div id=\"graphicVersion\">Graphic 57586 Version 1.0</div></div></div>"},"57587":{"type":"graphic_diagnosticimage","displayName":"Gastric banding tubing around mesentery","title":"Gastric banding tubing around mesentery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric banding tubing around mesentery</div><div class=\"cntnt\"><img style=\"width:393px; height:443px;\" src=\"images/SURG/57587_Discon_tub_pull_sensation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This radiograph demonstrates the&nbsp;gastric banding tubing&nbsp;in the right lower quadrant in a&nbsp;patient who presented with&nbsp;right lower quadrant pulling sensation. The tubing is wrapped around the base of the small bowel mesentery, which was confirmed at&nbsp;the time of the operation.</div><div id=\"graphicVersion\">Graphic 57587 Version 7.0</div></div></div>"},"57588":{"type":"graphic_picture","displayName":"Abdominal port position","title":"Position of abdominal ports for laparascopic lymphadenectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Position of abdominal ports for laparascopic lymphadenectomy</div><div class=\"cntnt\"><img style=\"width:390px; height:262px;\" src=\"images/OBGYN/57588_Abdominal_port_position.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Ken Hatch, MD.</div><div id=\"graphicVersion\">Graphic 57588 Version 2.0</div></div></div>"},"57589":{"type":"graphic_table","displayName":"Lung abscess with CMI defects","title":"Lung abscess microbiology in patients with cell-mediated immune defects","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lung abscess microbiology in patients with cell-mediated immune defects</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Common</td> </tr> <tr> <td class=\"subtitle2_single\">Bacteria</td> </tr> <tr> <td class=\"indent1\"><em>Pseudomonas aeruginosa</em></td> </tr> <tr> <td class=\"indent1\">Enterobacteriaceae</td> </tr> <tr> <td class=\"indent1\"><em>Nocardia</em> spp</td> </tr> <tr> <td class=\"indent1\">Anaerobic bacteria and microaerophilic streptococci <span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">(eg, <em>Streptococcus milleri</em>)</span></td> </tr> <tr> <td class=\"indent1\"><em>Staphylococcus aureus</em></td> </tr> <tr> <td class=\"subtitle2_single\">Mycobacteria</td> </tr> <tr> <td class=\"indent1\"><em>M. tuberculosis</em></td> </tr> <tr> <td class=\"indent1\"><em>M. kansasii</em></td> </tr> <tr> <td class=\"subtitle2_single\">Fungi</td> </tr> <tr> <td class=\"indent1\"><em>Cryptococcus</em> spp</td> </tr> <tr> <td class=\"indent1\"><em>Aspergillus</em> spp</td> </tr> <tr> <td class=\"indent1\"><em>Histoplasma capsulatum</em></td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Uncommon</td> </tr> <tr> <td class=\"subtitle2_single\">Bacteria</td> </tr> <tr> <td class=\"indent1\"><em>Rhodococcus equi</em></td> </tr> <tr> <td class=\"indent1\"><em>Legionella</em> spp</td> </tr> <tr> <td class=\"subtitle2_single\">Mycobacteria</td> </tr> <tr> <td class=\"indent1\"><em>M. avium</em> complex</td> </tr> <tr> <td class=\"indent1\">Other nontuberculous mycobacteria</td> </tr> <tr> <td class=\"subtitle2_single\">Fungi</td> </tr> <tr> <td class=\"indent1\">Agents of mucormycosis&nbsp;</td> </tr> <tr> <td class=\"indent1\"><em>Blastomyces dermatitidis</em></td> </tr> <tr> <td class=\"indent1\"><em>Pneumocystis jirovecii</em> (formerly <em>P. carinii</em>)</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 57589 Version 4.0</div></div></div>"},"57590":{"type":"graphic_figure","displayName":"Pathogenesis Ebola Marburg","title":"Pathogenesis of Ebola and Marburg hemorrhagic fevers","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Pathogenesis of Ebola and Marburg hemorrhagic fevers</div><div class=\"cntnt\"><img style=\"width:540px; height:698px;\" src=\"images/ID/57590_Pathogenesis_ebola_marburg.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 57590 Version 4.0</div></div></div>"},"57593":{"type":"graphic_diagnosticimage","displayName":"Spic mass","title":"Mammogram spiculated mass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mammogram spiculated mass</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ONC/57593_Spic_mass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spot magnification view of a mammogram showing two small adjacent interconnected spiculated masses (red arrows). Pathology revealed tubular carcinoma. Tubular carcinoma characteristically appears spiculated on mammogram and is often associated with satellite lesions.</div><div class=\"graphic_reference\">Courtesy of Lisa E Esserman, MD.</div><div id=\"graphicVersion\">Graphic 57593 Version 2.0</div></div></div>"},"57594":{"type":"graphic_table","displayName":"WHO class gastric ca","title":"World Health Organization histological classification of gastric tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">World Health Organization histological classification of gastric tumors</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">&nbsp;</td>\n\t\t\t\t\t<td class=\"subtitle1\">SNOP code</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\" colspan=\"2\">Epithelial tumors</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle3_left\">Intraepithelial neoplasia - Adenoma</td>\n\t\t\t\t\t<td>8140/0</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle3_left\" colspan=\"2\">Carcinoma</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">Adenocarcinoma</td>\n\t\t\t\t\t<td>8140/3</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">Intestinal type</td>\n\t\t\t\t\t<td>8144/3</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">Diffuse type</td>\n\t\t\t\t\t<td>8145/3</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">Papillary adenocarcinoma</td>\n\t\t\t\t\t<td>8260/3</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">Tubular adenocarcinoma</td>\n\t\t\t\t\t<td>8211/3</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">Mucinous adenocarcinoma</td>\n\t\t\t\t\t<td>8480/3</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">Signet-ring cell carcinoma</td>\n\t\t\t\t\t<td>8490/3</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">Adenosquamous carcinoma</td>\n\t\t\t\t\t<td>8560/3</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">Squamous cell carcinoma</td>\n\t\t\t\t\t<td>8070/3</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">Small cell carcinoma</td>\n\t\t\t\t\t<td>8041/3</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">Undifferentiated carcinoma</td>\n\t\t\t\t\t<td>8020/3</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\" colspan=\"2\">Other</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle3_left\">Carcinoid (well differentiated endocrine neoplasm)</td>\n\t\t\t\t\t<td>8240/3</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\" colspan=\"2\">Non-epithelial tumors</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">Leiomyoma</td>\n\t\t\t\t\t<td>8890/0</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">Schwannoma</td>\n\t\t\t\t\t<td>9560/0</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">Granular cell tumour</td>\n\t\t\t\t\t<td>9580/0</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">Glomus tumour</td>\n\t\t\t\t\t<td>8711/0</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">Leiomyosarcoma</td>\n\t\t\t\t\t<td>8890/3</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent3\">GI stromal tumour</td>\n\t\t\t\t\t<td>8936/1</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent3\">Benign</td>\n\t\t\t\t\t<td>8936/0</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent3\">Uncertain malignant potential</td>\n\t\t\t\t\t<td>8936/1</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent3\">Malignant</td>\n\t\t\t\t\t<td>8936/3</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">Kaposi sarcoma</td>\n\t\t\t\t\t<td>9140/3</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\" colspan=\"2\">Other</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle3_left\" colspan=\"2\">Malignant lymphomas</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">Marginal zone B-cell lymphoma of MALT-type</td>\n\t\t\t\t\t<td>9699/3</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">Mantle cell lymphoma</td>\n\t\t\t\t\t<td>9673/3</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">Diffuse large B-cell lymphoma</td>\n\t\t\t\t\t<td>9680/3</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\" colspan=\"2\">Other</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div class=\"graphic_footnotes\">SNOP: systematized nomenclature of pathology.</div><div id=\"graphicVersion\">Graphic 57594 Version 1.0</div></div></div>"},"57597":{"type":"graphic_figure","displayName":"Model of the HFE protein","title":"Model of the HFE protein","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Model of the HFE protein</div><div class=\"cntnt\"><img style=\"width:492px; height:331px;\" src=\"images/HEME/57597_Model_of_the_HFE_protein.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hypothetical model of the HFE protein based upon its homology with MHC class I molecules. The HFE protein is a single polypeptide with three extracellular domains which would be analogous to the &#945;1, &#945;2, and &#945;3 domains of other MHC class I proteins. In contrast to other members of the MHC class I family, the &#945;1 and &#945;2 domains in the HFE protein are nonpolymorphic. &#946;2-microglobulin is a separate protein and would interact with the HFE gene product in a noncovalent manner in the &#945;3 homologous region. The HFE protein contains a membrane spanning region and a short cytoplasmic tail. The approximate locations of C282Y (the major mutation in hereditary hemochromatosis) and H63D are indicated.</div><div id=\"graphicVersion\">Graphic 57597 Version 1.0</div></div></div>"},"57598":{"type":"graphic_table","displayName":"Rx guide radiation exposure","title":"Treatment guidelines for radiation exposure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment guidelines for radiation exposure</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Variable</td>\n\n      <td class=\"subtitle1\"> Cytokines</td>\n\n      <td class=\"subtitle1\"> Antibiotics</td>\n\n      <td class=\"subtitle1\"> HCT</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">Less than 100\ncasualties</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Healthy, no other injuries</td>\n\n      <td colspan=\"1\" rowspan=\"2\">3 to 10*</td>\n\n      <td colspan=\"1\" rowspan=\"2\">2 to 10</td>\n\n      <td>Allo: 7 to 10</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      \n\n      \n\n      <td>Auto: 4 to 10</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Multiple injuries or burns</td>\n\n      <td>2 to 6</td>\n\n      <td>2 to 6</td>\n\n      <td>NA</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">More\nthan 100 casualties</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Healthy, no other injuries&nbsp;</td>\n\n      <td colspan=\"1\" rowspan=\"2\">3 to 7</td>\n\n      <td colspan=\"1\" rowspan=\"2\">2 to 7</td>\n\n      <td>Allo: 7 to 10</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      \n\n      \n\n      <td>Auto: 4 to 10</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Multiple injuries or burns</td>\n\n      <td>2 to 6</td>\n\n      <td>2 to 6</td>\n\n      <td>NA</td>\n\n    </tr>\n\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">7.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">8/26/2004 Perm requested Pull if no perm by 12.3 9/7/2004 Perm granted 6/3/2005 renewal requested 6/17/2005 they emailed for more info 6/28/2005 granted - need to note in each renewal the waselenko is the author since they don't carry over this info 7/24/2006 Renewal Requested 8/21/2006 bugged - informed that they only grant for one version at a time 8/21/2006 renewal granted (renew 15.1) 10/6/2006 renewal requested 10/11/2006 renewal granted for one year 11/28/2007--renewal requested. EM 1/8/2008--renewal granted. EM 12/30/2008--Requested renewal (JD). 1/14/2009--Renewal invoice recevied, to Susan; awaiting formal grant of permission (JD). 1/22/2009--Grant of permission received (JD). 2/4/2010--Renewal requested (JD). 2/12/2010--Renewal granted, paid on my AMEX (JD). The total fee of $&amp;quot;120.00&amp;quot;was originally charged to Radiation_tox_gastrointest Radiation_tox_hematopoietic Radiation_tox_cerebrovascular Radiation_biodosimetry Rx_guide_radiation_exposure Cytokines_radiation_exposure Military_triage_radiation</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=26606&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Rx_guide_radiation_exposure.htm</title></head></div><div class=\"graphic_footnotes\">HCT: hematopoietic cell transplantation; Allo: allogeneic HCT; Auto: autologous HCT; NA: not applicable; G-CSF: granulocyte colony-stimulating factor; GM-CSF: granulocyte-macroplage colony-stimulating factor.<br> * This table provides a consensus guideline for treatment with cytokines (eg, G-CSF, GM-CSF), antibiotics, and consideration for hematopoietic cell transplantation based upon whole body or significant partial body exposure doses, given in Gy units. See text for treatment details.</div><div class=\"graphic_reference\">Modified with permission from: Waselenko JK, MacVittie TJ, Blakely WF, et al. Medical management of the acute radiation syndrome: Recommendations of the strategic national stockpile radiation working group. Ann Intern Med 2004; 140:1037. Copyright © 2004 American College of Physicians.</div><div id=\"graphicVersion\">Graphic 57598 Version 15.0</div></div></div>"},"57599":{"type":"graphic_table","displayName":"LD resources","title":"Resources for health care providers, patients, and families of children with learning disabilities*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Resources for health care providers, patients, and families of children with learning disabilities*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Resource</td> <td class=\"subtitle1\">Description</td> </tr> <tr> <td> <p>American Academy of Pediatrics Council on School Health</p> <p><a href=\"http://www2.aap.org/sections/schoolhealth/\" target=\"_blank\">www2.aap.org/sections/schoolhealth</a></p> </td> <td>Provides technical assistance and resources to clinicians with an interest in school health</td> </tr> <tr> <td> <p>Council for Exceptional Children</p> <p><a href=\"http://www.cec.sped.org/\" target=\"_blank\">www.cec.sped.org</a></p> </td> <td>Provides advocacy and professional development and resources</td> </tr> <tr> <td> <p>Early Childhood Technical Assistance Center</p> <p><a href=\"http://ectacenter.org/idea/idea.asp\" target=\"_blank\">ectacenter.org/idea/idea.asp</a></p> </td> <td>Provides information and summaries of IDEA and the 2004 amendments to IDEA</td> </tr> <tr> <td> <p>Families and Advocates Partnership for Education</p> <p><a href=\"http://www.fape.org/\" target=\"_blank\">www.fape.org</a></p> </td> <td>Links to information about IDEA</td> </tr> <tr> <td> <p>Family Voices</p> <p><a href=\"http://www.familyvoices.org/\" target=\"_blank\">www.familyvoices.org</a></p> </td> <td>Provides information and advocacy for children with special needs</td> </tr> <tr> <td> <p>International Dyslexia Association</p> <p><a href=\"https://dyslexiaida.org/\" spellcheck=\"true\" target=\"_blank\">dyslexiaida.org</a></p> </td> <td>Provides comprehensive information, referral services, and advocacy</td> </tr> <tr> <td> <p>LD OnLine</p> <p><a href=\"http://www.ldonline.org/\" target=\"_blank\">www.ldonline.org</a></p> </td> <td>Provides information and advice about LD and attention deficit hyperactivity disorder for parents, teachers, and other professionals</td> </tr> <tr> <td> <p>LD Navigator</p> <p><a href=\"http://ldnavigator.ncld.org/\" target=\"_blank\">ldnavigator.ncld.org</a></p> </td> <td>Provides practical information about LD for health care professionals</td> </tr> <tr> <td> <p>The Learning Disabilities Association of America</p> <p><a href=\"http://ldaamerica.org/\" target=\"_blank\">www.ldaamerica.org</a></p> </td> <td>Provides advocacy</td> </tr> <tr> <td> <p>Medical Home Portal</p> <p><a href=\"http://www.medicalhomeportal.org/\" target=\"_blank\">www.medicalhomeportal.org</a></p> </td> <td>Provides information for parents and families and professionals (choose appropriate tab and select \"Education &#38; Schools\" from the menu)</td> </tr> <tr> <td> <p>National Center for Learning Disabilities (NCLD)</p> <p><a href=\"http://www.ncld.org/\" target=\"_blank\">www.ncld.org</a></p> </td> <td>Provides information to parents, professionals, and individuals with LD; promotes research and programs; and advocates for policies to strengthen educational rights and opportunities</td> </tr> <tr> <td> <p>Office of Special Education and Rehabilitative Services</p> <p><a href=\"http://www2.ed.gov/about/offices/list/osers/osep/index.html\" target=\"_blank\">www2.ed.gov/about/offices/list/osers/osep/index.html</a></p> </td> <td>Provides leadership and financial support to support children with disabilities</td> </tr> <tr> <td> <p>Parent Advocacy Coalition for Educational Rights</p> <p><a href=\"http://www.pacer.org/\" target=\"_blank\">www.pacer.org</a></p> </td> <td>Provides assistance to families, workshops, and information for parents and professionals</td> </tr> <tr> <td> <p>Regional Parent Technical Assistance Centers</p> <p><a href=\"http://www.parentcenterhub.org/parent-centers/rptacs/\">www.parentcenterhub.org/parent-centers/rptacs/</a></p> </td> <td>Works to fortify partnerships between parent centers and education systems at local, state, and national levels</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IDEA: Individuals with Disabilities Education Act; LD: learning disability.<br />* In this table, \"learning disability\" refers to a heterogeneous group of disorders characterized by the unexpected failure of an individual to acquire, retrieve, and use information competently, rather than intellectual disability (mental retardation).</div><div id=\"graphicVersion\">Graphic 57599 Version 13.0</div></div></div>"},"57600":{"type":"graphic_picture","displayName":"Hamstring stretch PI","title":"Hamstring stretch","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hamstring stretch</div><div class=\"cntnt\"><img style=\"width:324px; height:455px;\" src=\"images/PI/57600_Hamstring_stretch_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The hamstrings are the muscles in the back of the thigh, just above the back of the knee. To stretch them, you will need a stable stool that does not roll (or a stair) that is about knee height. Place hands on hips. Place the right heel on top of the stool, keeping the leg straight. Bend the left leg and slowly lean forward until you feel a stretch in the back of the right leg. Hold for 10 seconds. Rest. Repeat 10 times, then switch legs and repeat 10 times with the left leg on the stool or stair.</div><div id=\"graphicVersion\">Graphic 57600 Version 4.0</div></div></div>"},"57601":{"type":"graphic_figure","displayName":"Major branches of the ulnar nerve at the wrist","title":"Major branches of the ulnar nerve at the wrist","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Major branches of the ulnar nerve at the wrist</div><div class=\"cntnt\"><img style=\"width:481px; height:656px;\" src=\"images/NEURO/57601_Major_branches_ulnar_nerve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This illustration describes the major branches of the ulnar nerve at the wrist. The numbers 1 to 4 relate to the main sites of clinical syndrome associated with injury to the nerve:<br> <ol> <li>Main trunk of the nerve proximal to or within Guyon's canal. </li> <li>Deep motor branch proximal to the branches supplying the hypothenar muscles. </li> <li>Deep motor branch distal to the hypothenar muscles. </li> <li>Superficial branch (mainly sensory). </li> </ol></div><div id=\"graphicVersion\">Graphic 57601 Version 2.0</div></div></div>"},"57602":{"type":"graphic_figure","displayName":"Toll-like receptors: Organization and signaling pathways","title":"Toll-like receptors: Organization and signaling pathways","html":"<div class=\"graphic\"><div style=\"width: 745px\" class=\"figure\"><div class=\"ttl\">Toll-like receptors: Organization and signaling pathways</div><div class=\"cntnt\"><img style=\"width:725px; height:542px;\" src=\"images/ALLRG/57602_TLR_signaling.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">TLR signaling in conventional dendritic cells, macrophages, and plasmacytoid dendritic cells. TLR2 (TLR2 in association with TLR1 or TLR6), TLR4, TLR5, and TLR11 are localized on the cell surface for ligand recognition. TLR3, TLR7, and TLR9 are localized in the endosome, which is transported to the endosome via the endoplasmic reticulum (ER)-localized transporter protein UNC93B for ligand recognition in the lumen of endosome. All TLRs, except TLR3, recruit MyD88, while TLR1, TLR2, TLR4, and TLR6 recruit the additional adaptor TIRAP, which links the TIR domain with MyD88. TLR3 and TLR4 recruit TRIF. TLR4 requires the additional linker adaptor TRAM, which links the TIR domain of TLR4 with TRIF. Dendritic cells or macrophages stimulated with TLR1, TLR2, TLR5, TLR6, and TLR11 ligands initiate the MyD88-dependent pathway, whereas TLR3 ligands initiate the TRIF-dependent pathway. TLR4 activates both MyD88-dependent and TRIF-dependent pathways. In the MyD88-dependent pathway, MyD88 recruits the IRAK family of proteins and TRAF6. In turn, TRAF6 activates TAK1. The activated TAK1 activates the IKK complex, which activates NF-kappa-B subunits. The activated TAK1 also activates the MAPK pathway. In the TRIF-dependent pathway, TRIF interacts with RIP1 and TRAF6. Activated TRAF6 and RIP1 activate NF-kappa-B and mitogen-activated protein kinases (MAPKs). TRIF also interacts with TRAF3 and activates TBK1/IKKi, which activate IRF3 and IRF7. Plasmacytoid dendritic cells stimulated with TLR7 and TLR9 ligands activate NF-kappa-B and MAPKs via the MyD88-dependent pathway. To induce type 1 interferons, MyD88 associates with the IRAK family of proteins. IRAK1 and IKK-alpha activate IRF7. IRAK1 also interacts with TRAF3 and activates IRF7. The activated NF-kappa-B subunits and IRFs are translocated to the nucleus. NF-kappa-B and MAPKs initiate the transcription of inflammatory cytokine genes, whereas IRFs initiate the transcription of type 1 interferons.</div><div class=\"graphic_footnotes\">TLR: toll-like receptor; MyD88: myeloid differentiation primary response protein 88; IRAK: interleukin-1 receptor-associated kinase; TRAF: tumor necrosis factor (TNF) receptor-associated factor; TAK: transforming growth factor (TGF)-beta-activated protein kinase; IKK: inhibitor of NF-kappa-B kinase; MAP: mitogen-activated protein; NFkB: nuclear factor (NF)-kappa-B; TIRAP: toll/interleukin-1 (IL-1) receptor (TIR) domain-containing adapter protein; TRIF: TIR domain-containing adapter inducing interferon (IFN); TRAM: TRIF-related adapter molecule; RIP: receptor-interacting protein; TBK: TRAF family member-associated NF-kappa-B activator-binding kinase; IKKi: I-kappa-B kinase i; IRF: interferon regulatory factor; IFNs: interferons; UNC93B: UNC93 homolog B; IKK-alpha: inhibitor of nuclear factor kappa-B kinase subunit-alpha.</div><div class=\"graphic_reference\">Reproduced from: Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochem Biophys Res Commun 2009; 388:621. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 57602 Version 5.0</div></div></div>"},"57604":{"type":"graphic_picture","displayName":"Preseptal edema and erythema","title":"Preseptal edema and erythema","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Preseptal edema and erythema</div><div class=\"cntnt\"><img style=\"width:504px; height:438px;\" src=\"images/ID/57604_Orbital_cellulitis_photo_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This young girl has erythema and edema in the preseptal area, which could be caused by either orbital or preseptal infection.</div><div class=\"graphic_reference\">Reproduced with permission from: Fleisher GR, Ludwig W, Baskin MN. Atlas of Pediatric Emergency Medicine. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 57604 Version 5.0</div></div></div>"},"57607":{"type":"graphic_table","displayName":"TLS risk stratification","title":"Tumor lysis syndrome (TLS) prophylaxis recommendations based on TLS risk","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tumor lysis syndrome (TLS) prophylaxis recommendations based on TLS risk</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Low risk disease (LRD)</td> <td class=\"subtitle1_single\">Intermediate risk disease (IRD)</td> <td class=\"subtitle1_single\">High risk disease (HRD)</td> </tr> <tr> <td>Most solid tumors</td> <td>Rare, highly chemotherapy-sensitive solid tumors (eg, neuroblastoma, germ cell tumor, small-cell lung cancer) with bulky or advanced stage disease</td> <td>N/A</td> </tr> <tr> <td>MM</td> <td>Plasma cell leukemia</td> <td>N/A</td> </tr> <tr> <td>CML</td> <td>N/A</td> <td>N/A</td> </tr> <tr> <td>Indolent NHL</td> <td>N/A</td> <td>N/A</td> </tr> <tr> <td>HL</td> <td>N/A</td> <td>N/A</td> </tr> <tr> <td>CLL and WBC &#60;50 x 10<sup>9</sup>/L treated only with alkylating agents</td> <td>CLL treated with fludarabine, rituximab, or lenalidomide, or venetoclax and lymph node &#8805;5 cm<strong> or </strong>absolute lymphocyte count &#8805;25 x 10<sup><span style=\"font-size: 13px;\">9</span></sup>/L, and/or those with high WBC &#8805;50 x 10<sup>9</sup>/L</td> <td>CLL treated with venetoclax and lymph node &#8805;10 cm, <strong>or</strong> lymph node &#8805;5 cm<strong> and </strong>absolute lymphocyte count &#8805;25 x 10<sup><span style=\"font-size: 13px;\">9</span></sup>/L and elevated baseline uric acid.</td> </tr> <tr> <td rowspan=\"2\">AML and WBC &#60;25 x 10<sup>9</sup>/L and LDH &#60;2 x ULN</td> <td>AML with WBC 25 to 100 x 10<sup>9</sup>/L</td> <td rowspan=\"2\">AML and WBC &#8805;100 x 10<sup>9</sup>/L</td> </tr> <tr> <td>AML and WBC &#60;25 x 10<sup>9</sup>/L and LDH &#8805;2 x ULN</td> </tr> <tr> <td>Adult intermediate grade NHL and LDH within normal limits</td> <td>Adult T cell leukemia/lymphoma, diffuse large B-cell, transformed, and mantle cell lymphomas with LDH &#62; ULN, non-bulky</td> <td>Adult T cell leukemia/lymphoma, diffuse large B-cell, transformed, and mantle cell lymphomas with bulky disease and LDH &#8805;2 x ULN</td> </tr> <tr> <td>Adult ALCL</td> <td>Childhood ALCL stage III/IV</td> <td>N/A</td> </tr> <tr> <td>N/A</td> <td>Childhood intermediate grade NHL stage III/IV with LDH &#60;2 x ULN</td> <td>Stage III/IV childhood diffuse large B-cell lymphoma with LDH &#8805;2 x ULN</td> </tr> <tr> <td rowspan=\"2\">N/A</td> <td rowspan=\"2\">ALL and WBC &#60;100 x 10<sup>9</sup>/L and LDH &#60;2 x ULN</td> <td>Burkitt's leukemia</td> </tr> <tr> <td>Other ALL and WBC &#8805;100 x 10<sup>9</sup>/L and/or LDH &#8805;2 x ULN</td> </tr> <tr> <td>N/A</td> <td>Burkitt lymphoma and LDH &#60;2 x ULN</td> <td>Burkitt lymphoma stage III/IV and/or LDH &#8805;2 x ULN</td> </tr> <tr> <td>N/A</td> <td>Lymphoblastic lymphoma stage I/II and LDH &#60;2 x ULN</td> <td>Lymphoblastic lymphoma stage III/IV and/or LDH &#8805;2 x ULN</td> </tr> <tr> <td rowspan=\"2\">N/A</td> <td rowspan=\"2\">N/A</td> <td>Intermediate risk disease&nbsp;with renal dysfunction and/or renal involvement</td> </tr> <tr> <td>Intermediate risk disease&nbsp;with uric acid, potassium, and/or phosphate &#62; ULN</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"3\">Prophylaxis recommendations</td> </tr> <tr> <td>Monitoring</td> <td>Monitoring</td> <td>Monitoring</td> </tr> <tr> <td>Hydration</td> <td>Hydration</td> <td>Hydration</td> </tr> <tr> <td>&#177;Allopurinol</td> <td>Allopurinol</td> <td>Rasburicase*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">N/A: not applicable; MM: multiple myeloma; CML: chronic myeloid leukemia; NHL: non-Hodgkin lymphoma; HL: Hodgkin lymphoma; CLL: chronic lymphoid leukemia; WBC: white blood cell count; AML: acute myeloid leukemia; LDH: lactate dehydrogenase; ULN: upper limit of normal; ALCL: anaplastic large cell lymphoma; ALL: acute lymphoblastic leukemia.<br />* Contraindicated in patients with a history consistent with glucose-6 phosphate dehydrogenase. In these patients, rasburicase should be substituted with allopurinol.</div><div class=\"graphic_reference\">Cairo MS, Coiffier B, Reiter A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010; 149:578. Copyright &copy; 2010. Modified with permission of Blackwell Publishing Inc.</div><div id=\"graphicVersion\">Graphic 57607 Version 13.0</div></div></div>"},"57608":{"type":"graphic_table","displayName":"Acute wrist injury children and adolescents","title":"Causes of acute wrist injury in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of acute wrist injury in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Condition</td>\r\n            <td class=\"subtitle1\">Location</td>\r\n            <td class=\"subtitle1\">Clinical features</td>\r\n            <td class=\"subtitle1\">Radiographic findings</td>\r\n            <td class=\"subtitle1\">Associated activities</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Simple sprain</td>\r\n            <td>Dorsal</td>\r\n            <td>Mild pain or stiffness at full wrist flexion or extension or both, normal range of motion; resolves in two weeks</td>\r\n            <td>Wrist series is normal</td>\r\n            <td>&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Distal radius fracture</td>\r\n            <td>Radial</td>\r\n            <td>Common during adolescent growth spurt; point tenderness, swelling, ecchymosis, decreased grip strength</td>\r\n            <td>Fracture on standard wrist series</td>\r\n            <td>Impact sports; fall on extended wrist</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Scapholunate instability</td>\r\n            <td>Radial</td>\r\n            <td>Swelling, focal pain and tenderness, decreased range of motion, decreased grip strength, positive scaphoid stability test (but may not be able to tolerate)</td>\r\n            <td>Increased scapholunate distance on AP view; increased scapholunate angle on lateral view; but may be normal</td>\r\n            <td>Impact sports; racquet, stick, and club sports; fall on extended wrist</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Scaphoid (navicular) fracture</td>\r\n            <td>Radial, dorsal</td>\r\n            <td>Tenderness in anatomic snuffbox; decreased range of motion in flexion and extension; positive scaphoid compression test</td>\r\n            <td>Fracture may be seen on AP view with ulnar deviation; may need scaphoid series.&nbsp;Initial radiographs may not demonstrate fracture.&nbsp;When suspected, thumb spica splinting and repeat radiographs in 7 to 10 days&nbsp;should be performed. Bone scan or MRI&nbsp;can demonstrate fracture sooner when earlier diagnosis is necessary (eg, elite athletes).</td>\r\n            <td>Impact sports, particularly football; fall on extended wrist</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Midcarpal instability</td>\r\n            <td>Ulnar</td>\r\n            <td>Sulcus in the dorsal ulnar wrist border; painful clunk with active ulnar deviation</td>\r\n            <td>Dislocaton on standard wrist series</td>\r\n            <td>&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Distal ulnar fracture</td>\r\n            <td>Ulnar, dorsal</td>\r\n            <td>Usually occurs with distal radius fracture; associated with TFCC injury</td>\r\n            <td>Fracture on standard wrist series</td>\r\n            <td>Impact sports</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Triquetral fracture</td>\r\n            <td>Ulnar, dorsal</td>\r\n            <td>Point tenderness over the triquetrum or on the ulnar border, distal to the ulnar styloid</td>\r\n            <td>Fracture on standard wrist series</td>\r\n            <td>Impact sports</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Lunotriquetral ligament instability</td>\r\n            <td>Ulnar, dorsal</td>\r\n            <td>Tenderness of the lunotriquetral ligament in the ulnar snuff box; positive lunotriquetral shear test</td>\r\n            <td>Usually normal; may be step-off along proximal carpal row; associated with positive ulnar variance</td>\r\n            <td>Impact sports</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Triangular fibrocartilage complex (TFCC) tears</td>\r\n            <td>Ulnar, dorsal</td>\r\n            <td>Point tenderness over the lateral wrist just distal to the ulnar styloid; pain with forced ulnar deviation or TFCC compression test</td>\r\n            <td>Associated (but not diagnostic) findings: widening of DRUJ space, positive ulnar variance, fracture of ulnar styloid on AP; dislocation or subluxation on lateral. MRI with intra-articular contrast is most sensitive means of identifying TFCC injury</td>\r\n            <td>Impact sports; racquet, stick, and club sports; gymnastics</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Distal radioulnar joint (DRUJ) injury</td>\r\n            <td>Ulnar, dorsal</td>\r\n            <td>Pain with supination and pronation; positive DRUJ compression or piano key tests</td>\r\n            <td>Dislocation can be seen on plain radiographs and these should include AP and lateral views of the forearm to assess for an associated radial fracture (Galeazzi fracture); MRI may be necessary&nbsp;to identify&nbsp;instability</td>\r\n            <td>Impact sports; racquet, stick, and club sports; gymnastics</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Hamate hook fracture</td>\r\n            <td>Ulnar, palmar</td>\r\n            <td>Pain with sports but not daily activities; point tenderness over the hook of the hamate</td>\r\n            <td>Fracture best seen on 45&#176; supination oblique or carpal tunnel view or with CT</td>\r\n            <td>Racquet, stick, and club sports</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Pisiform fracture</td>\r\n            <td>Ulnar, palmar</td>\r\n            <td>Pain with palpation of the pisiform and hypothenar eminence</td>\r\n            <td>Fracture on standard wrist series</td>\r\n            <td>&nbsp;</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_lgnd\">CT: computed tomography; MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 57608 Version 3.0</div></div></div>"},"57610":{"type":"graphic_table","displayName":"DSDs with atypical genitalia","title":"Characteristics of selected disorders of sex development (DSD) presenting with atypical genitalia at birth","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of selected disorders of sex development (DSD) presenting with atypical genitalia at birth</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Diagnosis</td> <td class=\"subtitle1\">Prevalence (as a cause of atypical genitalia)</td> <td class=\"subtitle1\">Risk of adrenal crisis</td> <td class=\"subtitle1\">Projected gender identity and fertility</td> <td class=\"subtitle1\">Risk of gonadal tumor</td> <td class=\"subtitle1\">References</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">46,XX DSD</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Congenital adrenal hyperplasia (CAH)*</td> <td>Common (1:15,000)</td> <td>Yes (in most common forms)<sup>&#182; </sup></td> <td>Female; fertile&nbsp; <br /> (for 46,XX types of CAH)</td> <td>Yes<sup>&#916;</sup></td> <td>[1-6]</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Mixed gonadal dysgenesis </strong>(45,X/46,XY mosaicism<strong>&nbsp;</strong>with atypical genitalia)</td> <td>Rare </td> <td>No</td> <td>Usually male; infertile</td> <td>High<sup>&#9674;</sup></td> <td>[7,8]</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">46,XY DSD</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">5-alpha-reductase type 2 deficiency</td> <td>Very&nbsp;rare</td> <td>No</td> <td>Usually male; fertile</td> <td>Low<sup>&#9674;</sup></td> <td>[9-11]</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">17-beta-hydroxysteroid dehydrogenase type 3 deficiency</td> <td>Extremely&nbsp;rare</td> <td>No</td> <td>Usually male</td> <td>Intermediate<sup>&#9674;</sup></td> <td>[9,11,12]</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Disorders of incomplete or unknown androgen action:  <ul class=\"decimal_heading\"> <li>Partial androgen insensitivity </li> <li>Incomplete gonadal dysgenesis </li> </ul> </td> <td>Very rare</td> <td>No</td> <td>Unknown; infertile</td> <td> <p>Nonscrotal gonads: High<sup>&#9674;</sup></p> Scrotal gonads: Intermediate<sup>&#9674;</sup></td> <td>[13-15]</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">46,XY with severe genital anomaly (\"non-hormonal\" DSD):  <ul class=\"decimal_heading\"> <li>Micropenis </li> <li>Penile agenesis (ablatio penis) </li> <li>Cloacal exstrophy </li> </ul> </td> <td>Rare</td> <td>No</td> <td>Male</td> <td>Low<sup>&#9674;</sup></td> <td>[16-18]</td> </tr> <tr> <td class=\"subtitle2_left\">Ovotesticular DSD<sup>&#167;</sup></td> <td>Extremely&nbsp;rare </td> <td>No</td> <td>Unknown</td> <td>Unknown</td> <td>[3]</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Types of congenital adrenal hyperplasia (CAH) that may present with&nbsp;atypical genitalia&nbsp;in 46,<STRONG>XX</STRONG> infants are 21-hydroxylase deficiency (by far most common), 11-beta hydroxylase deficiency, P450 oxidoreductase deficiency, and 3-beta hydroxysteroid dehydrogenase type 2 deficiency. <br />¶ <FONT color=black>The risk of adrenal crisis refers primarily to CAH due to 21-hydroxylase deficiency or 11-beta hydroxylase deficiency. Adrenal crisis is not associated with 17-alpha hydroxylase deficiency, which is a rare cause of CAH affecting 46,XY infants.<br />Δ Females with poorly controlled CAH secondary to 21-hydroxylase deficiency appear to be at increased for ovarian adrenal rest tumors (OARTs).<SUP>[19]</SUP> There are rare forms of CAH (eg, 3-beta hydroxysteroid dehydrogenase deficiency) that present with atypical genitalia in 46,<STRONG>XY</STRONG> infants.&nbsp;These&nbsp;infants may have a risk of developing testicular adrenal rest tumors (TARTs).<SUP>[20,21]</SUP> These forms of CAH are discussed in UpToDate topics on uncommon congenital adrenal hyperplasias. <br />◊ The risk of gonadal tumor is characterized as \"high\" for risks around 30% and higher, \"intermediate\" for 5 to 30 percent, \"low\" for less than 5%. The \"low\" risk category is similar to the risk for individuals with cryptorchidism.<SUP>[3,4]</SUP><br />§&nbsp;Ovotesticular DSD refers to histologically confirmed presence of ovarian follicles and testicular&nbsp;tubules in the same individual. This disorder tends to raise difficult challenges regarding gender of rearing and reconstruction surgery. Most patients have a 46,XX karyotype, and fertility has been reported in those who have a functional ovary. The testicular tissue is usually dysgenetic, and fertility has not been reported in those raised as males. The risk of testicular tumor is probably low if the karyotype is 46,XX.<SUP>[4,22]</SUP> </FONT></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Berenbaum SA, Bailey JM. Effects on gender identity of prenatal androgens and genital appearance: evidence from girls with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2003; 88:1102.</LI>&#xD;&#xA;<LI>Dessens AB, Slijper FM, Drop SL. Gender dysphoria and gender change in chromosomal females with congenital adrenal hyperplasia. Arch Sex Behav 2005; 34:389.</LI>&#xD;&#xA;<LI>Lee PA, Houk CP, Ahmed SF, et al. Consensus statement on management of intersex disorders. International Consensus Conference on Intersex. Pediatrics 2006; 118:e488.</LI>&#xD;&#xA;<LI>Lee PA, Nordenström A, Houk CP, et al. Global Disorders of Sex Development Update since 2006: Perceptions, Approach and Care. Horm Res Paediatr 2016; 85:158.</LI>&#xD;&#xA;<LI>Meyer-Bahlburg HF, Dolezal C, Baker SW, New MI. Sexual orientation in women with classical or non-classical congenital adrenal hyperplasia as a function of degree of prenatal androgen excess. Arch Sex Behav 2008; 37:85.</LI>&#xD;&#xA;<LI>Meyer-Bahlburg HF, Dolezal C, Baker SW, et al. Gender development in women with congenital adrenal hyperplasia as a function of disorder severity. Arch Sex Behav 2006; 35:667.</LI>&#xD;&#xA;<LI>Martinerie L, Morel Y, Gay CL, et al. Impaired puberty, fertility, and final stature in 45,X/46,XY mixed gonadal dysgenetic patients raised as boys. Eur J Endocrinol 2012; 166:687.</LI>&#xD;&#xA;<LI>Szarras-Czapnik M, Lew-Starowicz Z, Zucker KJ. A psychosexual follow-up study of patients with mixed or partial gonadal dysgenesis. J Pediatr Adolesc Gynecol 2007; 20:333.</LI>&#xD;&#xA;<LI>Kolesinska Z, Ahmed SF, Niedziela M, et al. Changes over time in sex assignment for disorders of sex development. Pediatrics 2014; 134:e710.</LI>&#xD;&#xA;<LI>Imperato-McGinley, Peterson RE, Gautier T, Sturla E. Androgens and the evolution of male-gender identity among male pseudohermaphrodites with 5alpha-reductase deficiency. N Engl J Med, 1979. 300:1233.</LI>&#xD;&#xA;<LI>Cohen-Kettenis PT. Gender change in 46,XY persons with 5alpha-reductase-2 deficiency and 17beta-hydroxysteroid dehydrogenase-3 deficiency. Arch Sex Behav 2005; 34:399.</LI>&#xD;&#xA;<LI>Imperato-McGinley, Peterson RE, Stoller R, Goodwin WE. Male pseudohermaphroditism secondary to 17 beta-hydroxysteroid dehydrogenase deficiency: gender role change with puberty. J Clin Endocrinol Metab 1979; 49:391.</LI>&#xD;&#xA;<LI>Reiner WG. Gender identity and sex-of-rearing in children with disorders of sexual differentiation. J Pediatr Endocrinol Metab 2005; 18:549.</LI>&#xD;&#xA;<LI>Jurgensen M, Hiort O, Holterhus PM, Thyen U. Gender role behavior in children with XY karyotype and disorders of sex development. Horm Behav 2007; 51:443.</LI>&#xD;&#xA;<LI>Migeon CJ, Wisiewski AB, Gearhart JP, et al. Ambiguous genitalia with perineoscrotal hypospadias in 46,XY individuals: long-term medical, surgical, and psychosexual outcome. Pediatrics 2002; 110:e31.</LI>&#xD;&#xA;<LI>Meyer-Bahlburg. Gender identity outcome in female-raised 46,XY persons with penile agenesis, cloacal exstrophy of the bladder, or penile ablation. Arch Sex Behav 2005; 34:423.</LI>&#xD;&#xA;<LI>Reiner WG, Gearhart JP. Discordant sexual identity in some genetic males with cloacal exstrophy assigned to female sex at birth. N Engl J Med 2004; 350:333.</LI>&#xD;&#xA;<LI>Reiner WG, Kropp BP. A 7-year experience of genetic males with severe phallic inadequacy assigned female. J Urol 2004; 172:2395.</LI>&#xD;&#xA;<LI>Claahsen-van der Grinten HL, Hulsbergen-van de Kaa CA, Otten BJ.Ovarian adrenal rest tissue in congenital adrenal hyperplasia--a patient report.&nbsp; J Pediatr Endocrinol Metab. 2006; 19:177.&nbsp; </LI>&#xD;&#xA;<LI>Vukina J, Chism DD, Sharpless JL, et al. Metachronous Bilateral Testicular Leydig-Like Tumors Leading to the Diagnosis of Congenital Adrenal Hyperplasia (Adrenogenital Syndrome). Case Rep Pathol&nbsp;2015; 459318&nbsp;</LI>&#xD;&#xA;<LI>Claahsen-van der Grinten HL, Sweep FC, Blickman JG, et al. Prevalence of testicular adrenal rest tumours in male children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Eur J Endocrinol. 2007; 157:339.</LI>&#xD;&#xA;<LI>Nistal M, Paniagua R, Gonzalez-Peramato P, Reyes-Mugica M: Ovotesticular DSD (true hermaphroditism). Pediatr Dev Pathol 2015;18:345.</LI></OL></div><div id=\"graphicVersion\">Graphic 57610 Version 7.0</div></div></div>"},"57613":{"type":"graphic_picture","displayName":"Histoplasma blood smear","title":"<em>Histoplasma capsulatum</em> on blood smear","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\"><em>Histoplasma capsulatum</em> on blood smear</div><div class=\"cntnt\"><img style=\"width:540px; height:360px;\" src=\"images/ID/57613_Histoplasma_blood_smear_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><EM>Histoplasma capsulatum</EM> seen inside a white blood cell on a peripheral blood smear from a patient with disseminated histoplasmosis.</div><div class=\"graphic_reference\">Courtesy of Carol Kauffman, MD.</div><div id=\"graphicVersion\">Graphic 57613 Version 13.0</div></div></div>"},"57615":{"type":"graphic_picture","displayName":"Entamoeba histolytica trophozoite","title":"<em>Entamoeba histolytica</em> trophozoite: Microscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><em>Entamoeba histolytica</em> trophozoite: Microscopy</div><div class=\"cntnt\"><img style=\"width:300px; height:300px;\" src=\"images/ID/57615_Entamoeba_histo_troph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trophozoites of <EM>E. histolytica </EM>with ingested erythrocytes stained with trichrome.</div><div class=\"graphic_reference\">Centers for Disease Control and Prevention. http://www.dpd.cdc.gov/dpdx/html/ImageLibrary/Amebiasis_il.htm.</div><div id=\"graphicVersion\">Graphic 57615 Version 3.0</div></div></div>"},"57616":{"type":"graphic_algorithm","displayName":"Neutropenic fever sepsis algorithm","title":"Time-dependent algorithm for the initial assessment and management of cancer patients with neutropenic fever and suspected sepsis syndrome","html":"<div class=\"graphic\"><div style=\"width: 650px\" class=\"figure\"><div class=\"ttl\">Time-dependent algorithm for the initial assessment and management of cancer patients with neutropenic fever and suspected sepsis syndrome</div><div class=\"cntnt\"><img style=\"width:630px; height:832px;\" src=\"images/ID/57616_Neutropenic_fever_seps_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CVAD: central venous access device; Na: sodium; K: potassium; Cl: chloride; TCO<sub>2</sub>: total carbon dioxide; SIRS: systemic inflammatory response syndrome; LRT: lower respiratory tract; URT: upper respiratory tract; GI: gastrointestinal tract; GU: genitourinary tract; O<sub>2</sub>: oxygen; IV: intravenous; MASCC: Multinational Association for Supportive Care in Cancer; PO: per os (by mouth).<br />* The Northern Ireland Cancer Network states that neutropenic sepsis is a \"time-dependent\" condition, the successful management of which is dependent upon the early recognition of the likelihood that the cancer patient's problem represents a neutropenic fever/sepsis syndrome<sup>[1]</sup>. Since more than 70 percent of cancer treatment-related syndromes, including neutropenic fever, manifest within four to six weeks of systemic treatment<sup>[2]</sup>, the Northern Ireland Cancer Network has recommended a history of chemotherapy within the past six weeks as a sensitive discriminator to detect patients with neutropenic fever/sepsis syndromes by triage services in healthcare facilities<sup>[1]</sup>.<br />&para; SIRS is a clinical syndrome that is a form of dysregulated inflammation. The term SIRS has routinely been associated with both infectious processes (sepsis) and noninfectious insults, such as an autoimmune disorder, pancreatitis, vasculitis, thromboembolism, burns, or surgery. SIRS was previously defined as two or more abnormalities in temperature, heart rate, respiration, or white blood cell count<sup>[3]</sup>. However, in practice, its clinical definition and pathophysiology are nonequivocal such that SIRS and early sepsis cannot be readily distinguished. Thus, when SIRS is suspected it should prompt an evaluation for a septic focus.<br />&Delta; Hypoperfusion is defined by hypotension persisting after initial fluid challenge or blood lactate concentration &ge;4 mmol/L<sup>[4]</sup>. Refer to the UpToDate topic review on the definition of sepsis and SIRS for additional details.<br /><span class=\"lozenge\">&loz;</span> Goal-directed therapy for initial resuscitation includes the following: (a) central venous pressure 8 to 12 mmHg; (b) mean arterial pressure &ge;65 mmHg; (c) urine output &ge;0.5 mL/kg per hour; and (d) central venous (superior vena cava) oxygen saturation &ge;70 percent or mixed venous oxygen saturation &ge;65 percent<sup>[4]</sup>. Refer to the UpToDate topic review on evaluation and management of sepsis for additional details.<br />&sect; Sepsis is defined as the presence (probable or documented) of infection together with systemic manifestations of infection (eg, temperature &gt;38.3 or &lt;36&deg;C, heart rate &gt;90 beats/min, respiratory rate &gt;20 breaths/min, altered mental status, leukocytosis, arterial hypotension, arterial hypoxemia)<sup>[4]</sup>. Refer to the UpToDate topic review on the definition of sepsis and SIRS for the full diagnostic criteria for sepsis.<br />&yen; Patients at low risk for serious complications are defined as those who are expected to be neutropenic (absolute neutrophil count [ANC] &lt;500 cells/microL) for &le;7 days and those with no comorbidities or evidence of significant hepatic or renal dysfunction. High-risk patients are defined as those who are expected to be neutropenic (ANC &lt;500 cells/microL) for &gt;7 days; patients with neutropenic fever who have ongoing comorbidities or evidence of significant hepatic or renal dysfunction are also considered to be high risk, regardless of the duration of neutropenia. The Multinational Association for Supportive Care in Cancer (MASCC) risk index can also be used for determining risk. A MASCC score of &ge;21 predicts a low risk for medical complications of neutropenic fever syndromes that would require hospitalization and/or prolonged length of hospitalization. A score of &lt;21 predicts patients at high risk for such complications<sup>[5]</sup>. Refer to the text for more details regarding the definitions of low- and high-risk patients based upon clinical criteria and the MASCC risk score.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Bell MS, Scullen P, McParlan D, et al. Neutropenic Sepsis Guideline. In Edition Northern Ireland Cancer Network 2010; 1-11.</li>&#xD;&#xA;    <li>McKenzie H, Hayes L, White K, et al. Chemotherapy outpatients' unplanned presentations to hospital: a retrospective study. Support Care Cancer 2011; 19:963-969.</li>&#xD;&#xA;    <li>Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003; 29:530.</li>&#xD;&#xA;    <li>Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41:580.</li>&#xD;&#xA;    <li>Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000; 18:3038-3051.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 57616 Version 9.0</div></div></div>"},"57617":{"type":"graphic_table","displayName":"Disorders with annular skin lesions","title":"Examples of skin disorders that may present with annular lesions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of skin disorders that may present with annular lesions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Population commonly affected</td> <td class=\"subtitle1\">Common clinical features</td> <td class=\"subtitle1\">Pertinent histopathologic findings</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Peripheral scale</td> </tr> <tr> <td class=\"indent1\">Tinea corporis</td> <td>Children and adults</td> <td>Annular erythematous plaques with peripheral leading scale</td> <td>Hyphae in the stratum corneum; KOH preparation is preferred initial test</td> </tr> <tr> <td class=\"indent1\">Pityriasis rosea</td> <td>Children and young adults</td> <td>Thin erythematous plaques on trunk and proximal extremities in \"Christmas tree\" pattern; may have large initial lesion (herald patch)</td> <td>Focal parakeratosis, epidermal spongiosis, perivascular lymphohistiocytic infiltrate, RBC extravasation</td> </tr> <tr> <td class=\"indent1\">Superficial erythema annulare centrifugum</td> <td>Children and adults</td> <td>Erythematous plaques with trailing scale on face, trunk, or extremities</td> <td>Parakeratosis, spongiosis, superficial intense perivascular lymphohistiocytic infiltrate</td> </tr> <tr> <td class=\"indent1\">Porokeratosis</td> <td>Children and adults</td> <td>Plaque with very thin rim of scale at periphery; multiple clinical variants exist</td> <td>Cornoid lamella - thin column of parakeratosis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Vesicles</td> </tr> <tr> <td class=\"indent1\">Linear IgA bullous dermatosis</td> <td>Children and adults</td> <td>Annular clusters of tense bullae on an inflammatory base</td> <td>Subepidermal bullae with neutrophilic infiltrates; direct immunofluorescence reveals linear deposits of IgA at the DEJ</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Pustules</td> </tr> <tr> <td class=\"indent1\">Subcorneal pustular dermatosis</td> <td>Most common in adults over 40</td> <td>Intertriginous and flexural flaccid pustules and crusted plaques</td> <td>Subcorneal pustules with neutrophils</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Purpura</td> </tr> <tr> <td class=\"indent1\">Purpura annularis telangiectodes of Majocchi</td> <td>Most common in young women and female adolescents</td> <td>Round patches on the lower extremities that do not blanch with pressure</td> <td>Perivascular lymphocytic infiltrates and extravasated erythrocytes</td> </tr> <tr> <td class=\"indent1\">Acute hemorrhagic edema of infancy</td> <td>Children under the age of two</td> <td>Urticarial plaques progressing to purpuric plaques</td> <td>Leukocytoclastic vasculitis</td> </tr> <tr> <td class=\"indent1\">Henoch-Sch&#246;nlein purpura</td> <td>Children and adults</td> <td>Palpable purpura on the lower extremities; arthritis, abdominal pain, and hematuria may be present</td> <td>Leukocytoclastic vasculitis; direct immunofluorescence reveals IgA deposits in vessel walls</td> </tr> <tr> <td class=\"indent1\">Urticarial vasculitis</td> <td>Most common in adult women</td> <td>Urticarial plaques that last more than 24 hours with or without purpura or hyperpigmentation; burning sensations or pain may be present</td> <td>Leukocytoclastic vasculitis</td> </tr> <tr> <td class=\"indent1\">Traumatic purpura</td> <td>Children and adults</td> <td>Annular ecchymosis or purpura</td> <td>Hemorrhage</td> </tr> <tr> <td class=\"indent1\">Dependent purpura in annular inflammatory disorders</td> <td>Children and adults</td> <td>Annular purpura on lower abdomen and legs, non-purpuric primary lesions are often present elsewhere</td> <td>Dependent on the underlying disorder</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Expanding lesions</td> </tr> <tr> <td class=\"indent1\">Tinea corporis</td> <td colspan=\"3\">See \"Peripheral scale\" above</td> </tr> <tr> <td class=\"indent1\">Erythema migrans (Lyme disease)</td> <td>Children and adults</td> <td>Large erythematous plaque that rapidly expands</td> <td>Superficial and deep lymphocytic infiltrate with plasma cells and eosinophils; spirochetes are sometimes detectable</td> </tr> <tr> <td class=\"indent1\">Granuloma annulare</td> <td>Children and adults</td> <td>Non-scaly plaque with a dull erythematous color; often found on distal extremities</td> <td>Palisading granulomas or interstitial histiocytes plus increased mucin</td> </tr> <tr> <td class=\"indent1\">Superficial erythema annulare centrifugum</td> <td colspan=\"3\">See \"Peripheral scale\" above</td> </tr> <tr> <td class=\"indent1\">Deep erythema annulare centrifugum</td> <td>Children and adults</td> <td>Erythematous plaques without scale on face, trunk, or extremities</td> <td>Superficial and deep intense perivascular lymphocytic infiltrate</td> </tr> <tr> <td class=\"indent1\">Serum sickness-like reaction</td> <td colspan=\"3\">See \"Associated fever\" below</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Migratory</td> </tr> <tr> <td class=\"indent1\">Urticaria</td> <td>Children and adults</td> <td>Pink edematous plaques (wheals)</td> <td>Dermal edema, mild perivascular lymphocytic infiltrate with occasional eosinophils, mast cells, and neutrophils</td> </tr> <tr> <td class=\"indent1\">Erythema marginatum</td> <td>Most common in children; occurs in rheumatic fever due to group A streptococcal infection</td> <td>Erythematous, polycyclic patches or plaques that migrate within hours</td> <td>Superficial perivascular neutrophilic infiltrate with a few lymphocytes and eosinophils</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Photodistributed</td> </tr> <tr> <td class=\"indent1\">Subacute cutaneous lupus erythematosus</td> <td>Most common in adult women; approximately 50 percent meet criteria for SLE</td> <td>Erythematous, scaly plaques</td> <td>Lymphocytic interface dermatitis, dermal edema, mucin</td> </tr> <tr> <td class=\"indent1\">Lupus erythematosus tumidus</td> <td>Most common in adult women</td> <td>Erythematous plaques with minimal epidermal change</td> <td>Superficial and deep perivascular and periadnexal lymphocytic infiltrates with mucin</td> </tr> <tr> <td class=\"indent1\">Neonatal lupus erythematosus</td> <td>Infants up to four months of age</td> <td>Polycyclic erythematous plaques; may be accompanied by cardiac abnormalities</td> <td>Lymphocytic interface dermatitis, dermal edema, mucin</td> </tr> <tr> <td class=\"indent1\">Actinic lichen planus</td> <td>Most common in dark-skinned young adults; particularly those of Middle-Eastern descent</td> <td>Hyperpigmented plaques are often located on the face, forearms, or dorsal hands</td> <td>Hyperkeratosis, hypergranulosis, interface dermatitis; similar to classic lichen planus</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Acral</td> </tr> <tr> <td class=\"indent1\">Erythema multiforme</td> <td>Most frequent in young adults, but occurs at all ages; commonly associated with HSV</td> <td>Target and atypical target lesions with a predilection for acral sties; mucous membrane involvement is common</td> <td>Interface dermatitis, dense superficial lymphohistiocytic infiltrate in dermis, clefts and vesiculation</td> </tr> <tr> <td class=\"indent1\">Granuloma annulare</td> <td colspan=\"3\">See \"Expanding lesions\" above</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Genital</td> </tr> <tr> <td class=\"indent1\">Erythema multiforme</td> <td colspan=\"3\">See \"Acral\" above</td> </tr> <tr> <td class=\"indent1\">Circinate balanitis in reactive arthritis</td> <td>Most common in young men; associated with HLA-B27</td> <td>Moist annular or serpiginous papules or erosions; also may have conjunctivitis, urethritis, and arthritis</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Annular lichen planus</td> <td>Most common in men</td> <td>Annular plaques on the penis or scrotum; may also occur on nongenital body sites</td> <td>Hyperkeratosis, hypergranulosis, and interface dermatitis as in classic lichen planus; elastolysis in atrophic lesions</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Associated fever</td> </tr> <tr> <td class=\"indent1\">Acute febrile neutrophilic dermatosis (Sweet syndrome)</td> <td>Most common in adult females</td> <td>Erythematous, edematous, juicy plaques on upper body</td> <td>Dense neutrophilic infiltrate in superficial dermis, leukocytoclasis, prominent edema</td> </tr> <tr> <td class=\"indent1\">Serum sickness-like reaction</td> <td>Children and adults; often follows antibiotic therapy</td> <td>Urticarial plaques, usually slowly expanding and colliding with neighboring lesions to make polycyclic whealed plaques</td> <td>Leukocytoclastic vasculitis</td> </tr> <tr> <td class=\"indent1\">Acute hemorrhagic edema of infancy</td> <td colspan=\"3\">See \"Purpura\" above</td> </tr> <tr> <td class=\"indent1\">Kawasaki's disease</td> <td>Children under the age of five</td> <td> <p>Usually an exanthematous eruption, but occasionally presents with targetoid lesions</p> <p>Conjunctivitis, mucositis, acral edema, and lymphadenopathy may be present</p> </td> <td>Nonspecific findings such as edema in the superficial dermis, mild perivascular lymphocytic changes; vasculitis is rare</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">KOH: potassium hydroxide; RBC: red blood cell; DEJ: dermal-epidermal junction; SLE: systemic lupus erythematosus; HSV: herpes simplex virus.<br> * Annular lesions may present as an occasional finding in many other skin disorders, such as psoriasis, nummular dermatitis, seborrheic dermatitis, secondary syphilis, sarcoidosis, mycosis fungoides, and malignant skin tumors.</div><div id=\"graphicVersion\">Graphic 57617 Version 2.0</div></div></div>"},"57619":{"type":"graphic_picture","displayName":"Normal breast histology","title":"Normal male breast tissue","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal male breast tissue</div><div class=\"cntnt\"><img style=\"width:360px; height:237px;\" src=\"images/ENDO/57619_Normal_breast_light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal adult male breast tissue demonstrating a duct lined by a single layer of epithelial cells and surrounded by a loose stroma devoid of inflammatory infiltrate.</div><div class=\"graphic_reference\">Courtesy of Glenn D Braunstein, MD.</div><div id=\"graphicVersion\">Graphic 57619 Version 3.0</div></div></div>"},"57620":{"type":"graphic_table","displayName":"Diff dx hyperammonemia","title":"Differential diagnosis of hyperammonemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of hyperammonemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Reye syndrome</td> </tr> <tr> <td>Gastrointestinal bleeding</td> </tr> <tr> <td>Renal disease</td> </tr> <tr> <td>Urinary tract infection with a urease-producing organism (eg, <em>Proteus mirabilis</em>)</td> </tr> <tr> <td>Ureterosigmoidostomy</td> </tr> <tr> <td>Shock</td> </tr> <tr> <td>Severe muscle exertion/heavy exercise</td> </tr> <tr> <td>Cigarette smoking</td> </tr> <tr> <td>Transient hyperammonemia in newborns</td> </tr> <tr> <td>Certain inborn errors of metabolism (urea cycle defects and organic acidemia)</td> </tr> <tr> <td>Any cause of portosystemic shunting of blood</td> </tr> <tr> <td>Parenteral nutrition</td> </tr> <tr> <td>After high-dose chemotherapy</td> </tr> <tr> <td class=\"sublist1_start\">Drugs such as:</td> </tr> <tr> <td class=\"sublist1\">Valproic acid</td> </tr> <tr> <td class=\"sublist1\">Barbiturates</td> </tr> <tr> <td class=\"sublist1\">Narcotics</td> </tr> <tr> <td class=\"sublist1\">Diuretics</td> </tr> <tr> <td class=\"sublist1\">Alcohol</td> </tr> <tr> <td>Salicylate intoxication</td> </tr> <tr> <td>Systemic <em>Mycoplasma hominis </em>or <em>Ureasplasma</em> spp infection in lung transplant recipients</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 57620 Version 3.0</div></div></div>"},"57621":{"type":"graphic_figure","displayName":"Survival with HBV cirrhosis","title":"Survival in patients with cirrhosis from hepatitis B virus","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Survival in patients with cirrhosis from hepatitis B virus</div><div class=\"cntnt\"><img style=\"width:480px; height:314px;\" src=\"images/GAST/57621_Post_transplant_survival_HB.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Long-term survival in 98 patients with HBV-related cirrhosis with and without decompensated disease at study entry. Survival was markedly better in those with compensated cirrhosis (84 versus 14 percent).</div><div class=\"graphic_reference\">Data from DeJongh FE, Janssen JL, DeMan RA, et al, Gastroenterology 1992; 103:1630.</div><div id=\"graphicVersion\">Graphic 57621 Version 3.0</div></div></div>"},"57627":{"type":"graphic_table","displayName":"Revised IMWG diagnostic criteria MM SMM","title":"Revised International Myeloma Working Group diagnostic criteria for multiple myeloma and smoldering multiple myeloma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Revised International Myeloma Working Group diagnostic criteria for multiple myeloma and smoldering multiple myeloma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Definition of multiple myeloma</td> </tr> <tr> <td class=\"subtitle2_single\">Clonal bone marrow plasma cells &#8805;10% of biopsy-proven bony or extramedullary plasmacytoma* and any one or more of the following myeloma-defining events:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Evidence of end-organ damage that can be attributed to the underlying plasma cell proliferative disorder, specifically: <ul> <li>Hypercalcemia: serum calcium &#62;0.25 mmol/L (&#62;1 mg/dL) higher than the upper limit of normal or &#62;2.75 mmol/L (&#62;11 mg/dL) </li> <li>Renal insufficiency: creatinine clearance &#60;40 mL per min<sup>&#182;</sup> or serum creatinine &#62;177 &#181;mol/L (&#62;2 mg/dL) </li> <li>Anemia: hemoglobin value of &#62;20 g/L below the lower limit of normal, or a hemoglobin value &#60;100 g/L </li> <li>Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or PET-CT<sup>&#916;</sup> </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Any one or more of the following biomarkers of malignancy: <ul> <li>Clonal bone marrow plasma cell percentage* &#8805;60% </li> <li>Involved:uninvolved serum free light chain ratio<sup>&#9674;</sup> &#8805;100 </li> <li>&#62;1 focal lesions on MRI studies<sup>&#167;</sup> </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Definition of smoldering multiple myeloma</td> </tr> <tr> <td class=\"subtitle2_single\">Both criteria must be met:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Serum monoclonal protein (IgG or IgA) &#8805;30 g/L or urinary monoclonal protein &#8805;500 mg per 24 hours and/or clonal bone marrow plasma cells 10 to 60% </li> <li>Absence of myeloma defining events or amyloidosis </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Definition of monoclonal gammopathy of undetermined significance</td> </tr> <tr> <td class=\"subtitle2_single\">All three criteria must be met:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Serum monoclonal protein &#60;30 g/L </li> <li>Bone marrow plasma cells &#60;10% </li> <li>Absence of myeloma defining events or amyloidosis (or Waldenstr&#246;m macroglobulinemia in the case of IgM MGUS) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PET-CT: <SUP>18</SUP>F-fluorodeoxyglucose positron emission tomography with computed tomography.<br />* Clonality should be established by showing kappa/lambda-light-chain restriction on flow cytometry, immunohistochemistry, or immunofluorescence. Bone marrow plasma cell percentage should preferably be estimated from a core biopsy specimen; in case of a disparity between the aspirate and core biopsy, the highest value should be used.<br />¶ Measured or estimated by validated equations.<br />Δ If bone marrow has less than 10% clonal plasma cells, more than one bone lesion is required to distinguish from solitary plasmacytoma with minimal marrow involvement.<br /><FONT class=lozenge>◊</FONT> These values are based on the serum Freelite assay (The Binding Site Group, Birmingham, UK). The involved free light chain must be ≥100 mg/L.<br />§ Each focal lesion must be 5 mm or more in size.</div><div class=\"graphic_reference\">Original figure modified for this publication. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15:e538. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 57627 Version 13.0</div></div></div>"},"57629":{"type":"graphic_table","displayName":"Selected nonantimicrobial sulfonamides","title":"Selected nonantimicrobial sulfonamides (nonsulfonylarylamines and related drugs)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected nonantimicrobial sulfonamides (nonsulfonylarylamines and related drugs)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Loop diuretics</td> </tr> <tr> <td class=\"indent1\">Bumetanide*</td> </tr> <tr> <td class=\"indent1\">Furosemide*</td> </tr> <tr> <td class=\"indent1\">Torsemide*</td> </tr> <tr> <td class=\"subtitle1_single\">Thiazide and related diuretics</td> </tr> <tr> <td class=\"indent1\">Hydrochlorothiazide*</td> </tr> <tr> <td class=\"indent1\">Chlorothiazide*</td> </tr> <tr> <td class=\"indent1\">Chlorthalidone*</td> </tr> <tr> <td class=\"indent1\">Indapamide*</td> </tr> <tr> <td class=\"indent1\">Methyclothiazide*</td> </tr> <tr> <td class=\"indent1\">Metolazone*</td> </tr> <tr> <td class=\"subtitle1_single\">Sulfonylurea hypoglycemics</td> </tr> <tr> <td class=\"indent1\">Glyburide</td> </tr> <tr> <td class=\"indent1\">Glipizide</td> </tr> <tr> <td class=\"indent1\">Glimepiride</td> </tr> <tr> <td class=\"indent1\">Chlorpropamide</td> </tr> <tr> <td class=\"indent1\">Tolazamide</td> </tr> <tr> <td class=\"subtitle1_single\">Carbonic anhydrase inhibitors</td> </tr> <tr> <td class=\"indent1\">Acetazolamide*</td> </tr> <tr> <td class=\"indent1\">Brinzolamide ophthalmic*</td> </tr> <tr> <td class=\"indent1\">Dorzolamide ophthalmic*</td> </tr> <tr> <td class=\"indent1\">Methazolamide*</td> </tr> <tr> <td class=\"subtitle1_single\">HIV and HCV protease inhibitors<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Amprenavir*<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Fosamprenavir*<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Darunavir*<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Simeprevir*<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td class=\"indent1\">Celecoxib*</td> </tr> <tr> <td class=\"indent1\">Diazoxide*</td> </tr> <tr> <td class=\"indent1\">Ibutilide</td> </tr> <tr> <td class=\"indent1\">Probenecid<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Sotalol</td> </tr> <tr> <td class=\"indent1\"> <p><span class=\"red\">Sulfasalazine<sup>&#9674;</sup> (salazosulfapyridine, salazopyrin)</span></p> <span class=\"red\">NOTE: Use contraindicated in patients with a history of sulfonamide antibiotic hypersensitivity</span></td> </tr> <tr> <td class=\"indent1\">Sumatriptan</td> </tr> <tr> <td class=\"indent1\">Tipranavir*<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Topiramate</td> </tr> <tr> <td class=\"indent1\">Zonisamide*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus; HCV: chronic hepatitis C virus infection; G6PD: glucose-6-phosphate dehydrogenase.<br />* US Food and Drug Administration (FDA)-approved product information for this drug contains cautionary statement(s) regarding use in patients with history of allergy to sulfonamide drugs. Clear evidence of cross reactivity to nonantimicrobial drugs listed in this table among patients with a history of hypersensitivity to sulfonamide antibiotics is lacking, except sulfasalazine, which releases sulfapyridine (a sulfonamide antimicrobial). Refer to text.<br />¶ The HIV protease inhibitors darunavir, fosamprenavir, and tipranavir as well as the HCV protease inhibitor simeprevir contain sulfonamide moieties, but lack one or both essential functional groups implicated in sulfonamide antibiotic hypersensitivity (ie, N4 arylamine or N-containing ring substitution at N1) and do not appear to cross react. Refer to text.<br />Δ High risk in G6PD deficiency. See: <A href=\"http://www.g6pd.org/\" target=_blank>http://www.g6pd.org/</A>.<br /><FONT class=lozenge>◊</FONT> Releases sulfapyridine (a cross-reactive arylamine sulfonamide) in contact with gut flora. Use is contraindicated in patients with a significant allergy to sulfonamide antimicrobials.</div><div class=\"graphic_reference\">Prepared with data from: US Food and Drug Administration (FDA)-approved product information. US National Library of Medicine. (Available online at: <a href=\"http://dailymed.nlm.nih.gov/dailymed/about.cfm\" target=\"_blank\">http://dailymed.nlm.nih.gov/dailymed/about.cfm</a>). Accessed May 30, 2014.</div><div id=\"graphicVersion\">Graphic 57629 Version 8.0</div></div></div>"},"57632":{"type":"graphic_diagnosticimage","displayName":"Zollinger-Ellison syndrome","title":"Zollinger-Ellison syndrome: Appearance of gastric ulcers on upper GI series","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Zollinger-Ellison syndrome: Appearance of gastric ulcers on upper GI series</div><div class=\"cntnt\"><img style=\"width:331px; height:252px;\" src=\"images/ENDO/57632_Zollinger_Ellison_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper GI series performed in a patient with intractable epigastric pain demonstrates severe manifestations of Zollinger-Ellison syndrome&nbsp;with three different-sized ulcers (arrows) in the wall of the stomach. The patient had a high fasting serum gastrin concentration consistent with Zollinger-Ellison syndrome and a small duodenal wall gastrinoma was identified at surgery.</div><div class=\"graphic_footnotes\">GI: gastrointestinal.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 57632 Version 5.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal upper GI series</div><div class=\"cntnt\"><img style=\"width:286px; height:330px;\" src=\"images/GAST/81537_Normal_upper_GI_series.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal air-contrast upper gastrointestinal (GI)&nbsp;study showing normal gastric folds and small intestinal anatomy, and no masses.</div><div class=\"graphic_reference\">Courtesy of Paul C Schroy III, MD.</div><div id=\"graphicVersion\">Graphic 81537 Version 4.0</div></div></div>"},"57634":{"type":"graphic_diagnosticimage","displayName":"PIE with extension","title":"Pulmonary interstitial emphysema with extension to multiple extrapulmonary sites in a newborn infant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary interstitial emphysema with extension to multiple extrapulmonary sites in a newborn infant</div><div class=\"cntnt\"><img style=\"width:294px; height:347px;\" src=\"images/PEDS/57634_PIE_with_extension.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note pneumomediastinum, pneumopericardium, left pneumothorax, and subcutaneous emphysema.</div><div class=\"graphic_reference\">Courtesy of Gerardo Cabrera-Meza, MD.</div><div id=\"graphicVersion\">Graphic 57634 Version 3.0</div></div></div>"},"57635":{"type":"graphic_table","displayName":"Potential Rx in scleroderma","title":"New potential therapies for systemic sclerosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">New potential therapies for systemic sclerosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Agent/approach</td> <td class=\"subtitle1\">Mechanism</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Immune</td> </tr> <tr> <td class=\"indent1\">Rapamycin</td> <td>Blocks cytokine action responsible for T-cell activation/proliferation</td> <td>Possible benefit in a small trial</td> </tr> <tr> <td class=\"indent1\">Oral tolerance</td> <td>Induces regulatory suppression of specific immune response through oral administration of small amounts of antigen</td> <td>Proposed and ongoing studies include collagen (I) and topoisomerase</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Vascular</td> </tr> <tr> <td class=\"indent1\">Antioxidants</td> <td>Reduces free radical mediated endothelial damage and lipoprotein oxidation</td> <td>Benefit in open studies for nutrient antioxidants</td> </tr> <tr> <td class=\"indent1\">Superoxide dismutase</td> <td>Reduces free radical damage</td> <td>No evaluation yet</td> </tr> <tr> <td class=\"indent1\">Oral prostacyclin</td> <td>Vasodilation, also may modulate cytokine release</td> <td>Helps Raynaud in preliminary controlled trials but effect on digital ulceration unproven</td> </tr> <tr> <td class=\"indent1\">Endothelin antagonists</td> <td>Block ET-induced vasospasm</td> <td>Beneficial for pulmonary hypertension and may reduce the incidence of digital ulcers</td> </tr> <tr> <td class=\"indent1\">Losartan</td> <td>Angiotensin antagonist</td> <td>Benefit suggested for secondary Raynaud phenomenon</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Antifibrotic</td> </tr> <tr> <td class=\"indent1\">Anticytokine antibodies</td> <td>Blocks mediators of fibroblast activation (eg, TGFb, IL-6)</td> <td>Toxicity likely to be problematic</td> </tr> <tr> <td class=\"indent1\">Enzyme antagonists</td> <td>Lysal and prolyl hydroxylase inhibitors to block post-translational modification of collagen</td> <td>No data yet</td> </tr> <tr> <td class=\"indent1\">Pretranslational inhibition</td> <td>Block collagen gene transcription or mRNA translation using antisense nucleotides or gene therapy</td> <td>Hypothetical and dependent upon progress in understanding of collagen gene regulation</td> </tr> <tr> <td class=\"indent1\">Selective tyrosine kinase inhibitors</td> <td>Block myofibroblast differentiation and vascular proliferation</td> <td>Small studies of imatinib have suggested limited benefit but failed to show overall superiority over conventional therapy in diffuse SSc. More trials are needed.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ET: endothelin; TGFB: transforming growth factor beta; IL-6: interleukin-6; SSc: systemic sclerosis (scleroderma).</div><div id=\"graphicVersion\">Graphic 57635 Version 5.0</div></div></div>"},"57636":{"type":"graphic_table","displayName":"Electrocardiographic monitoring for syncope","title":"Electrocardiographic monitoring for syncope","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Electrocardiographic monitoring for syncope</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Recommendations</td> <td class=\"subtitle1\">Class*</td> <td class=\"subtitle1\">Level<sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Indications</td> </tr> <tr> <td class=\"indent1\">ECG monitoring is indicated in patients who have clinical or ECG features suggesting arrhythmic syncope (listed in the \"Risk stratification for syncope\" table). The duration (and technology) of monitoring should be selected according to the risk and the predicted recurrence rate of syncope:</td> <td>I</td> <td>B</td> </tr> <tr> <td class=\"indent2\">&#8226; Immediate in-hospital monitoring (in bed or telemetric) is indicated in high risk patients (as defined in the \"Risk stratification for syncope\" table)</td> <td>I</td> <td>C</td> </tr> <tr> <td class=\"indent2\">&#8226; Holter monitoring is indicated in patients who have very frequent syncope or pre-syncope (&#8805;one per week)</td> <td>I</td> <td>B</td> </tr> <tr> <td class=\"sublist3_start\" colspan=\"3\">&#8226; ILR is indicated in:</td> </tr> <tr> <td class=\"sublist3\">- An early phase of evaluation in patients with recurrent syncope of uncertain origin, absence of high risk criteria, and a high likelihood of recurrence within battery longevity of the device</td> <td class=\"sublist_other\">I</td> <td class=\"sublist_other\">B</td> </tr> <tr> <td class=\"sublist3\">- High risk patients (as defined in the \"Risk stratification for syncope\" table) in whom a comprehensive evaluation did not demonstrate a cause of syncope or lead to a specific treatment</td> <td class=\"sublist_other\">I</td> <td class=\"sublist_other\">B</td> </tr> <tr> <td class=\"indent2\">&#8226; ILR should be considered to assess the contribution of bradycardia before embarking on cardiac pacing in patients with suspected or certain reflex syncope presenting with frequent or traumatic syncopal episodes</td> <td>IIa</td> <td>B</td> </tr> <tr> <td class=\"indent2\">&#8226; External loop recorders should be considered in patients who have an inter-symptom interval &#8804;four weeks</td> <td>IIa</td> <td>B</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Diagnostic criteria</td> </tr> <tr> <td class=\"indent1\">ECG monitoring is diagnostic when a correlation between syncope and an arrhythmia (brady- or tachyarrhythmia) is detected</td> <td>I</td> <td>B</td> </tr> <tr> <td class=\"indent1\">In the absence of such correlation, ECG monitoring is diagnostic when periods of Mobitz II or III degree AV block or a ventricular pause &#62;3 s (with the possible exception of young trained persons, during sleep, medicated patients, or rate-controlled atrial fibrillation), or rapid prolonged paroxysmal SVT or VT are detected. The absence of arrhythmia during syncope excludes arrhythmic syncope.</td> <td>I</td> <td>C</td> </tr> <tr> <td class=\"indent1\">The ECG documentation of pre-syncope without any relevant arrhythmia is not an accurate surrogate for syncope</td> <td>III</td> <td>C</td> </tr> <tr> <td class=\"indent1\">Asymptomatic arrhythmias (other than those listed above) are not an accurate surrogate for syncope</td> <td>III</td> <td>C</td> </tr> <tr> <td class=\"indent1\">Sinus bradycardia (in the absence of syncope) is not an accurate surrogate for syncope</td> <td>III</td> <td>C</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AV: atrioventricular; ECG: electrocardiogram; ILR: implantable loop recorder; SVT: supraventricular tachyradia; VT: ventricular tachycardia.<br />* Class of recommendation.<br />&Delta; Level of evidence.</div><div class=\"graphic_reference\">Reproduced with permission from: European Heart Rhythm Association (EHRA), Heart Failure Association (HFA), Heart Rhythm Society (HRS), et al. Guidelines for the diagnosis and management of syncope (version 2009): the Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). Eur Heart J 2009; 30:2631. Copyright &copy; 2009 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 57636 Version 11.0</div></div></div>"},"57637":{"type":"graphic_picture","displayName":"Primary syphilis chancre","title":"Penile chancre of primary syphilis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Penile chancre of primary syphilis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ID/57637_Primary_syphilis_chancre.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 57637 Version 3.0</div></div></div>"},"57638":{"type":"graphic_table","displayName":"BASDAI","title":"Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>1.</strong> How would you describe the overall level of fatigue/tiredness you have experienced?</td> </tr> <tr> <td>none&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;0&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;1&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;2&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;3&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;4&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;5&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;6&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;7&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;8&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;9&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;10&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;very severe</td> </tr> <tr class=\"divider_top\"> <td><strong>2.</strong> How would you describe the overall level of AS <strong>neck, back, or hip pain</strong> you have had?</td> </tr> <tr> <td>none&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;0&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;1&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;2&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;3&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;4&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;5&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;6&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;7&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;8&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;9&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;10&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;very severe</td> </tr> <tr class=\"divider_top\"> <td><strong>3.</strong> How would you describe the overall level of pain/swelling you have had in joints <strong>other than</strong> neck, back, and hips?</td> </tr> <tr> <td>none&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;0&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;1&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;2&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;3&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;4&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;5&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;6&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;7&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;8&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;9&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;10&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;very severe</td> </tr> <tr class=\"divider_top\"> <td><strong>4.</strong> How would you describe the level of discomfort you have had from an area tender to touch or pressure?</td> </tr> <tr> <td>none&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;0&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;1&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;2&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;3&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;4&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;5&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;6&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;7&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;8&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;9&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;10&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;very severe</td> </tr> <tr class=\"divider_top\"> <td><strong>5.</strong> How would you describe the level of morning stiffness you have had from the time you wake up?</td> </tr> <tr> <td>none&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;0&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;1&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;2&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;3&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;4&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;5&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;6&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;7&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;8&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;9&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;10&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;very severe</td> </tr> <tr class=\"divider_top\"> <td><strong>6.</strong> How long does your morning stiffness last from the time you wake up?</td> </tr> <tr> <td>0 (0 hours)&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;1&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;2&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;3&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;4&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;5 (1 hour)&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;6&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;7&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;8&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;9&nbsp;&nbsp;&nbsp;|&nbsp;&nbsp;&nbsp;10 (2 or more hours)</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">15</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=90312&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_lgnd\">Calculation of BASDAI:<br> <ul> <li>Compute the mean of questions 5 and 6 </li> <li>Calculate the sum of the values of question 1-4 and add the result to the mean of questions 5 and 6 </li> <li>Divide the result by 5 </li> </ul></div><div class=\"graphic_reference\">Originally published in: Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21:2286. Reproduced with permission from: the Royal National Hospital for Rheumatic Diseases NHS Foundation Trust, Bath. <a href=\"http://www.rnhrd.nhs.uk/\" target=\"_blank\">www.rnhrd.nhs.uk</a>. Copyright © 1994.</div><div id=\"graphicVersion\">Graphic 57638 Version 3.0</div></div></div>"},"57639":{"type":"graphic_table","displayName":"Expanded disability status scale","title":"Expanded disability status scale and functional systems","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Expanded disability status scale and functional systems</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Functional systems (FS)</td> </tr> <tr> <td class=\"subtitle2_single\">Pyramidal functions</td> </tr> <tr> <td class=\"indent1\">0. Normal</td> </tr> <tr> <td class=\"indent1\">1. Abnormal signs without disability</td> </tr> <tr> <td class=\"indent1\">2. Minimal disability</td> </tr> <tr> <td class=\"indent1\">3. Mild or moderate paraparesis or hemiparesis; severe monoparesis</td> </tr> <tr> <td class=\"indent1\">4. Marked paraparesis or hemiparesis; moderate quadriparesis; or monoplegia</td> </tr> <tr> <td class=\"indent1\">5. Paraplegia, hemiplegia, or marked quadriparesis</td> </tr> <tr> <td class=\"indent1\">6. Quadriplegia</td> </tr> <tr> <td class=\"indent1\">V. Unknown</td> </tr> <tr> <td class=\"subtitle2_single\">Cerebellar functions</td> </tr> <tr> <td class=\"indent1\">0. Normal</td> </tr> <tr> <td class=\"indent1\">1. Abnormal signs without disability</td> </tr> <tr> <td class=\"indent1\">2. Mild ataxia</td> </tr> <tr> <td class=\"indent1\">3. Moderate truncal or limb ataxia</td> </tr> <tr> <td class=\"indent1\">4. Severe ataxia, all limbs</td> </tr> <tr> <td class=\"indent1\">5. Unable to perform coordinated movements due to ataxia</td> </tr> <tr> <td class=\"indent1\">V. Unknown</td> </tr> <tr> <td class=\"indent1\">X. Is used throughout after each number when weakness (grade 3 or more on pyramidal) interferes with testing</td> </tr> <tr> <td class=\"subtitle2_single\">Brain stem functions</td> </tr> <tr> <td class=\"indent1\">0. Normal</td> </tr> <tr> <td class=\"indent1\">1. Signs only</td> </tr> <tr> <td class=\"indent1\">2. Moderate nystagmus or other mild disability</td> </tr> <tr> <td class=\"indent1\">3. Severe nystagmus, marked extraocular weakness, or moderate disability of other cranial nerves</td> </tr> <tr> <td class=\"indent1\">4. Marked dysarthria or other marked disability</td> </tr> <tr> <td class=\"indent1\">5. Inability to swallow or speak</td> </tr> <tr> <td class=\"indent1\">V. Unknown</td> </tr> <tr> <td class=\"subtitle2_single\">Sensory functions</td> </tr> <tr> <td class=\"indent1\">0. Normal</td> </tr> <tr> <td class=\"indent1\">1. Vibration or figure-writing decrease only, in one or two limbs</td> </tr> <tr> <td class=\"indent1\">2. Mild decrease in touch or pain or position sense, and/or moderate decrease in vibration in one or two limbs; or vibratory (c/s figure writing) decrease alone in three or four limbs</td> </tr> <tr> <td class=\"indent1\">3. Moderate decrease in touch or pain or position sense, and/or essentially lost vibration in one or two limbs; or mild decrease in touch or pain and/or moderate decrease in all proprioceptive tests in three or four limbs</td> </tr> <tr> <td class=\"indent1\">4. Marked decrease in touch or pain or loss of proprioception, alone or combined, in one or two limbs; or moderate decrease in touch or pain and/or severe proprioceptive decrease in more than two limbs</td> </tr> <tr> <td class=\"indent1\">5. Loss (essentially) of sensation in one or two limbs; or moderate decrease in touch or pain and/or loss of proprioception for most of the body below the head</td> </tr> <tr> <td class=\"indent1\">6. Sensation essentially lost below the head</td> </tr> <tr> <td class=\"indent1\">V. Unknown</td> </tr> <tr> <td class=\"subtitle2_single\">Bowel and bladder functions</td> </tr> <tr> <td class=\"indent1\">0. Normal</td> </tr> <tr> <td class=\"indent1\">1. Mild urinary hesitancy, urgency, or retention</td> </tr> <tr> <td class=\"indent1\">2. Moderate hesitancy, urgency, retention of bowel or bladder, or rare urinary incontinence</td> </tr> <tr> <td class=\"indent1\">3. Frequent urinary incontinence</td> </tr> <tr> <td class=\"indent1\">4. In need of almost constant catheterization</td> </tr> <tr> <td class=\"indent1\">5. Loss of bladder function</td> </tr> <tr> <td class=\"indent1\">6. Loss of bowel and bladder function</td> </tr> <tr> <td class=\"indent1\">V. Unknown</td> </tr> <tr> <td class=\"subtitle2_single\">Visual (or optic) functions</td> </tr> <tr> <td class=\"indent1\">0. Normal</td> </tr> <tr> <td class=\"indent1\">1. Scotoma with visual acuity (corrected) better than 20/30</td> </tr> <tr> <td class=\"indent1\">2. Worse eye with scotoma with maximal visual acuity (corrected) of 20/30 to 20/59</td> </tr> <tr> <td class=\"indent1\">3. Worse eye with large scotoma, or moderate decrease in fields, but with maximal visual acuity (corrected) of 20/60 to 20/99</td> </tr> <tr> <td class=\"indent1\">4. Worse eye with marked decrease of fields and maximal visual acuity (corrected) of 20/100 to 20/200; grade 3 plus maximal acuity of better eye of 20/60 or less</td> </tr> <tr> <td class=\"indent1\">5. Worse eye with maximal visual acuity (corrected) less than 20/200; grade 4 plus maximal acuity of better eye of 20/60 or less</td> </tr> <tr> <td class=\"indent1\">6. Grade 5 plus maximal visual acuity of better eye of 20/60 or less</td> </tr> <tr> <td class=\"indent1\">V. Unknown</td> </tr> <tr> <td class=\"indent1\">X. Is added to grades 0 to 6 for presence of temporal pallor</td> </tr> <tr> <td class=\"subtitle2_single\">Cerebral (or mental) functions</td> </tr> <tr> <td class=\"indent1\">0. Normal</td> </tr> <tr> <td class=\"indent1\">1. Mood alteration only (Does not affect DSS score)</td> </tr> <tr> <td class=\"indent1\">2. Mild decrease in mentation</td> </tr> <tr> <td class=\"indent1\">3. Moderate decrease in mentation</td> </tr> <tr> <td class=\"indent1\">4. Marked decrease in mentation (chronic brain syndrome-moderate)</td> </tr> <tr> <td class=\"indent1\">5. Dementia or chronic brain syndrome-severe or incompetent</td> </tr> <tr> <td class=\"indent1\">V. Unknown</td> </tr> <tr> <td class=\"subtitle2_single\">Other functions</td> </tr> <tr> <td class=\"indent1\">0. None</td> </tr> <tr> <td class=\"indent1\">1. Any other neurologic findings attributed to MS (specify)</td> </tr> <tr> <td class=\"indent1\">V. Unknown</td> </tr> <tr> <td class=\"subtitle1_single\">Expanded Disability Status Scale (EDSS)</td> </tr> <tr> <td class=\"indent1\"><strong>0</strong> = Normal neurologic exam (all grade 0 in Functional Systems [FS]; Cerebral grade 1 acceptable)</td> </tr> <tr> <td class=\"indent1\"><strong>1.0</strong> = No disability, minimal signs in one FS (ie, grade 1 excluding Cerebral grade 1)</td> </tr> <tr> <td class=\"indent1\"><strong>1.5</strong> = No disability minimal signs in more than one FS (more than one grade 1 excluding Cerebral grade 1)</td> </tr> <tr> <td class=\"indent1\"><strong>2.0</strong> = Minimal disability in one FS (one FS grade 2, others 0 or 1)</td> </tr> <tr> <td class=\"indent1\"><strong>2.5</strong> = Minimal disability in two FS (two FS grade 2, others 0 or 1)</td> </tr> <tr> <td class=\"indent1\"><strong>3.0</strong> = Moderate disability in one FS (one FS grade 3, others 0 or l), or mild disability in three or four FS (three/four FS grade 2, others 0 or 1) though fully ambulatory</td> </tr> <tr> <td class=\"indent1\"><strong>3.5</strong> = Fully ambulatory but with moderate disability in one FS (one grade 3) and one or two FS grade 2; or two FS grade 3; or five FS grade 2 (others 0 or 1)</td> </tr> <tr> <td class=\"indent1\"><strong>4.0</strong> = Fully ambulatory without aid, self-sufficient, up and about some 12 hours a day despite relatively severe disability consisting of one FS grade 4 (others 0 or l), or combinations of lesser grades exceeding limits of previous steps. Able to walk without aid or rest some 500 meters.</td> </tr> <tr> <td class=\"indent1\"><strong>4.5</strong> = Fully ambulatory without aid, up and about much of the day, able to work a full day, may otherwise have some limitation of full activity or require minimal assistance; characterized by relatively severe disability, usually consisting of one FS grade 4 (others 0 or 1) or combinations of lesser grades exceeding limits of previous steps. Able to walk without aid or rest for some 300 meters.</td> </tr> <tr> <td class=\"indent1\"><strong>5.0</strong> = Ambulatory without aid or rest for about 200 meters; disability severe enough to impair full daily activities (eg, to work full day without special provisions). (Usual FS equivalents are one grade 5 alone, others 0 or 1; or combinations of lesser grades usually exceeding specifications for step 4.0.)</td> </tr> <tr> <td class=\"indent1\"><strong>5.5</strong> = Ambulatory without aid or rest for about 100 meters; disability severe enough to preclude full daily activities. (Usual FS equivalents are one grade 5 alone, others 0 or 1; or combinations of lesser grades usually exceeding those for step 4.0.)</td> </tr> <tr> <td class=\"indent1\"><strong>6.0</strong> = Intermittent or unilateral constant assistance (cane, crutch, or brace) required to walk about 100 meters with or without resting. (Usual FS equivalents are combinations with more than two FS grade 3+.)</td> </tr> <tr> <td class=\"indent1\"><strong>6.5</strong> = Constant bilateral assistance (canes, crutches, or braces) required to walk about 20 meters without resting. (Usual FS equivalents are combinations with more than two FS grade 3+.)</td> </tr> <tr> <td class=\"indent1\"><strong>7.0</strong> = Unable to walk beyond about 5 meters even with aid, essentially restricted to wheelchair; wheels self in standard wheelchair and transfers alone; up and about in w/c some 12 hours a day. (Usual FS equivalents are combinations with more than one FS grade 4+; very rarely, pyramidal grade 5 alone.)</td> </tr> <tr> <td class=\"indent1\"><strong>7.5</strong> = Unable to take more than a few steps; restricted to wheelchair; may need aid in transfer; wheels self but cannot carry on in standard wheelchair a full day; may require motorized wheelchair. (Usual FS equivalents are combinations with more than one FS grade 4+.)</td> </tr> <tr> <td class=\"indent1\"><strong>8.0</strong> = Essentially restricted to bed or chair or perambulated in wheelchair, but may be out of bed itself much of the day; retains many self-care functions; generally has effective use of arms. (Usual FS equivalents are combinations, generally grade 4+ in several systems.)</td> </tr> <tr> <td class=\"indent1\"><strong>8.5</strong> = Essentially restricted to bed much of the day; has some effective use of arm(s); retains some self-care functions. (Usual FS equivalents are combinations, generally 4+ in several systems.)</td> </tr> <tr> <td class=\"indent1\"><strong>9.0</strong> = Helpless bed patient; can communicate and eat. (Usual FS equivalents are combinations, mostly grade 4+.)</td> </tr> <tr> <td class=\"indent1\"><strong>9.5</strong> = Totally helpless bed patient; unable to communicate effectively or eat/swallow. (Usual FS equivalents are combinations, almost all grade 4+.)</td> </tr> <tr> <td class=\"indent1\"><strong>10</strong> = Death due to MS</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">10</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=98814&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_reference\">Reproduced with permission from: Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33:1444. Copyright © 1983 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 57639 Version 4.0</div></div></div>"},"57640":{"type":"graphic_diagnosticimage","displayName":"Chest x-ray of a pericardial effusion","title":"Chest x-ray of a pericardial effusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest x-ray of a pericardial effusion</div><div class=\"cntnt\"><img style=\"width:432px; height:333px;\" src=\"images/CARD/57640_CXR_perieff.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cardiomegaly due to a massive pericardial effusion. At least 200 mL of pericardial fluid must accumulate before the cardiac silhouette enlarges.</div><div class=\"graphic_reference\">Courtesy of Massimo Imazio, MD, FESC.</div><div id=\"graphicVersion\">Graphic 57640 Version 3.0</div></div></div>"},"57642":{"type":"graphic_picture","displayName":"Light microscopy chorioCA","title":"Choriocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Choriocarcinoma</div><div class=\"cntnt\"><img style=\"width:389px; height:260px;\" src=\"images/ONC/57642_Light_microscopy_chorioCA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a testicular choriocarcinoma. The central smaller cytotrophoblast cells with clear cytoplasm are surrounded by the much larger syncytiotrophoblastic giant cells (black arrow) that have huge, convoluted, pleomorphic nuclei and abundant eosinophilic cytoplasm.</div><div class=\"graphic_reference\">Courtesy of Michael Weinstein, MD, PhD.</div><div id=\"graphicVersion\">Graphic 57642 Version 1.0</div></div></div>"},"57644":{"type":"graphic_table","displayName":"Etiology pulmonary hypertension","title":"Etiology of pulmonary hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of pulmonary hypertension</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Cardiac</td> </tr> <tr> <td class=\"sublist1_start\">Increased pulmonary blood flow associated with left-to-right shunts at the atrial, ventricular, or great vessel level</td> </tr> <tr> <td class=\"sublist1\">Examples: atrial septal defect, patent ductus arteriosus, transposition of the great arteries, truncus arteriosus</td> </tr> <tr> <td class=\"sublist1_start\">Left-sided obstructive lesions associated with pulmonary venous congestion.</td> </tr> <tr> <td class=\"sublist1\">Examples: coarctation of aorta, aortic stenosis, mitral stenosis, pulmonary vein stenosis or atresia, cor triatriatum</td> </tr> <tr> <td>Cardiomyopathy</td> </tr> <tr> <td class=\"subtitle1_single\">Pulmonary</td> </tr> <tr> <td>Idiopathic: primary pulmonary hypertension, veno-occlusive disease.</td> </tr> <tr> <td class=\"sublist1_start\">Hypoxic vasoconstriction</td> </tr> <tr> <td class=\"sublist1\">Alveolar hypoventilation: sleep disorders, upper airway obstruction, neuromuscular disorder, chest wall deformity</td> </tr> <tr> <td class=\"sublist1\">Obstructive or restrictive lung disease: cystic fibrosis, bronchopulmonary dysplasia, interstitial fibrosis</td> </tr> <tr> <td class=\"sublist1\">Pneumonia</td> </tr> <tr> <td class=\"sublist1\">High altitude</td> </tr> <tr> <td>Pulmonary hypoplasia: primary, associated with congenital diaphragmatic hernia or renal dysplasia</td> </tr> <tr> <td>Peripheral pulmonary stenosis</td> </tr> <tr> <td>Persistent pulmonary hypertension of the newborn</td> </tr> <tr> <td class=\"subtitle1_single\">Thromboembolic</td> </tr> <tr> <td>Ventriculoatrial shunt, indwelling catheters, deep vein thrombosis</td> </tr> <tr> <td>Parasitic disease: filariasis, schistosomiasis</td> </tr> <tr> <td>Hematologic: sickle cell disease, polycythemia</td> </tr> <tr> <td class=\"subtitle1_single\">Hepatic disease</td> </tr> <tr> <td>Cirrhosis, portal hypertension</td> </tr> <tr> <td class=\"subtitle1_single\">Collagen vascular disease</td> </tr> <tr> <td>Scleroderma, systemic lupus erythematosus, rheumatoid arthritis, mixed connective tissue disease</td> </tr> <tr> <td class=\"subtitle1_single\">Granulomatous disease</td> </tr> <tr> <td>Sarcoidosis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Robert L Geggel, MD.</div><div id=\"graphicVersion\">Graphic 57644 Version 3.0</div></div></div>"},"57645":{"type":"graphic_table","displayName":"Health problems foster care","title":"Health problems of children in foster care","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Health problems of children in foster care</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Health problem</td>\n\t\t\t\t\t<td class=\"subtitle1\">Percent of foster care population</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Chronic medical problem</td>\n\t\t\t\t\t<td>35 to 60 percent</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Medically fragile or complex</td>\n\t\t\t\t\t<td>11 percent</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Mental health problem</td>\n\t\t\t\t\t<td>80 percent of children older than age 4 years</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Developmental delay</td>\n\t\t\t\t\t<td>60 percent of children younger than age 5 years</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Educational problems/special education</td>\n\t\t\t\t\t<td>45 percent</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Significant dental disease</td>\n\t\t\t\t\t<td>35 percent</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Family relationship problems</td>\n\t\t\t\t\t<td>100 percent</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 57645 Version 1.0</div></div></div>"},"57649":{"type":"graphic_table","displayName":"Radiation sensitivity syndromes","title":"Genetic syndromes associated with increased sensitivity to x-radiation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic syndromes associated with increased sensitivity to x-radiation</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Basal cell nevus syndrome (Gorlin's syndrome)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ataxia-telangiectasia (Louis-Bar syndrome)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Bloom's syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Fanconi's anemia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Rare variants of xeroderma pigmentosum, complementation group G</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Possibly Gardner's syndrome</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">11.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">11/9/2001-perm requested -jm; 12/18/2001 -perm granted, emailed contact to confirm we don't have to give them our password as stated in contract.  If so, give to ajeah and chris -jm; 12/24/2001 - email clarified, gave to chris and mailed back to mcgraw-hill - jm\r\n\r\n10/1/2003 renewal requested  11/20/2003 follow-up  11/21/2003 emailed her w/more info  12/8/2003 granted</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=47736&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Radiation_sensitivity_syndr.htm</title></head></div><div class=\"graphic_reference\">Reproduced with permission from: Malkinson FD. Radiobiology of the skin. In: Fitzpatrick's dermatology in general medicine, 5th ed, Freedberg IM, et al (Eds), McGraw Hill, New York 1999. P.1514. Copyright © 1999 McGraw-Hill.</div><div id=\"graphicVersion\">Graphic 57649 Version 2.0</div></div></div>"},"57650":{"type":"graphic_picture","displayName":"Flex atopic dermatitis PI","title":"Atopic dermatitis on the backs of the knees","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atopic dermatitis on the backs of the knees</div><div class=\"cntnt\"><img style=\"width:218px; height:324px;\" src=\"images/PI/57650_Flex_atopic_dermatitis_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atopic dermatitis often affects the crease of the skin where the leg bends.</div><div class=\"graphic_reference\">Courtesy of James C Shaw, MD.</div><div id=\"graphicVersion\">Graphic 57650 Version 1.0</div></div></div>"},"57651":{"type":"graphic_picture","displayName":"Capillary loop changes JDM","title":"Pre-ungual capillary loop changes in a patient with juvenile dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pre-ungual capillary loop changes in a patient with juvenile dermatomyositis</div><div class=\"cntnt\"><img style=\"width:360px; height:211px;\" src=\"images/PEDS/57651_Capillary_loop_changes_JDM.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Ross Petty, MD.</div><div id=\"graphicVersion\">Graphic 57651 Version 1.0</div></div></div>"},"57652":{"type":"graphic_table","displayName":"Predictors response lamivudine","title":"Predictors of response to lamivudine","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Predictors of response to lamivudine</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\t<tr>\n\t\n<td class=\"subtitle1_left\" colspan=\"5\">HBeAg seronconversion according to\nbaseline serum alanine aminotransferase levels</td>\n </tr>\n\n   <tr>\n\n      <td class=\"subtitle2\" colspan=\"1\" rowspan=\"2\">Pretreatment ALT level</td>\n\n      <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">Placebo</td>\n\n      <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">Lamivudine</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td class=\"subtitle3\">n</td>\n\n      <td class=\"subtitle3\">Percent</td>\n\n      <td class=\"subtitle3\">n</td>\n\n      <td class=\"subtitle3\">Percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>&#8804;1 X\nULN</td>\n\n      <td>0/25</td>\n\n      <td>0</td>\n\n      <td>1/53</td>\n\n      <td>2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>&#62;1 to &#8804;2\nX ULN</td>\n\n      <td>3/59</td>\n\n      <td>5</td>\n\n      <td>8/114</td>\n\n      <td>7</td>\n\n    </tr>\n\n    <tr>\n\n      <td>&#62;2 to &#60;5 X ULN</td>\n\n      <td>7/82</td>\n\n      <td>9</td>\n\n      <td>32/164</td>\n\n      <td>20</td>\n\n    </tr>\n\n    <tr>\n\n      <td>&#62;5 X ULN</td>\n\n      <td>4/26</td>\n\n      <td>15</td>\n\n      <td>25/60</td>\n\n      <td>42</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_left\" rowspan=\"1\" colspan=\"5\">Independent\npredictors of response to lamivudine&#8224;</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">Factor</td>\n\n      <td class=\"subtitle2\" rowspan=\"1\" colspan=\"3\">Odds\nratio (95 percent CI)</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\">Treatment (lamivudine versus placebo)</td>\n\n      <td colspan=\"3\" rowspan=\"1\">3.93 (2.21 to\n7.01)</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\">HAI score (per 1-unit increase)</td>\n\n      <td colspan=\"3\" rowspan=\"1\">1.17 (1.10 to\n1.24)</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\">ALT level (per 10-unit increase)</td>\n\n      <td colspan=\"3\" rowspan=\"1\">1.04 (1.02 to\n1.05)</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\">HBV-DNA level (per 10-unit increase)</td>\n\n      <td colspan=\"3\" rowspan=\"1\">0.99 (0.97 to\n1.00)</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">ULN: upper limit of normal.</div><div class=\"graphic_reference\">Data from: Perillo RP, Lai CL, Liaw YF, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36:186.</div><div id=\"graphicVersion\">Graphic 57652 Version 2.0</div></div></div>"},"57653":{"type":"graphic_diagnosticimage","displayName":"Color Doppler endometrial polyp","title":"Color Doppler sonogram of an endometrial polyp","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Color Doppler sonogram of an endometrial polyp</div><div class=\"cntnt\"><img style=\"width:466px; height:325px;\" src=\"images/OBGYN/57653_Color_Doppler_endometrial_p.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Saline infusion reveals a polypoid lesion emanating from the fundus. Color flow Doppler clearly identifies a central feeder vessel. Presence of such a feeder vessel can be used to make the diagnosis of polyp even in the absence of saline infusion.</div><div class=\"graphic_reference\">Courtesy of Steven Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 57653 Version 4.0</div></div></div>"},"57654":{"type":"graphic_diagnosticimage","displayName":"Paramet boost stgIIB cc","title":"Parametrial boost for cervical cancer","html":"<div class=\"graphic\"><div style=\"width: 607px\" class=\"figure\"><div class=\"ttl\">Parametrial boost for cervical cancer</div><div class=\"cntnt\"><img style=\"width:587px; height:197px;\" src=\"images/OBGYN/57654_Paramet_boost_stgIIB_cc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Treatment fields for a parametrial boost for a stage IIB cervical cancer.</div><div class=\"graphic_reference\">Courtesy of Kristin Bradley, MD and Derek McHaffie, MD.</div><div id=\"graphicVersion\">Graphic 57654 Version 2.0</div></div></div>"},"57655":{"type":"graphic_table","displayName":"Causes of acquired pure red cell aplasia","title":"Causes of acquired pure red cell aplasia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of acquired pure red cell aplasia</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Idiopathic</td> </tr> <tr> <td class=\"subtitle1_single\">Drugs</td> </tr> <tr> <td>Phenytoin</td> </tr> <tr> <td>Trimethoprim-sulfamethoxazole</td> </tr> <tr> <td>Zidovudine</td> </tr> <tr> <td>Chlorpropamide</td> </tr> <tr> <td>Recombinant human erythropoietins</td> </tr> <tr> <td>Mycophenolate mofetil</td> </tr> <tr> <td class=\"subtitle1_single\">Infection</td> </tr> <tr> <td>B19 parvovirus</td> </tr> <tr> <td>HIV</td> </tr> <tr> <td>Viral hepatitis</td> </tr> <tr> <td class=\"subtitle1_single\">Immune disorders</td> </tr> <tr> <td>Autoimmune hemolytic anemia</td> </tr> <tr> <td>Systemic lupus erythematosus</td> </tr> <tr> <td>Rheumatoid arthritis</td> </tr> <tr> <td>ABO-incompatible hematopoietic cell transplantation</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Lymphoid malignancies</td> </tr> <tr> <td>Chronic lymphocytic leukemia</td> </tr> <tr> <td>LGL leukemia</td> </tr> <tr> <td>Hodgkin lymphoma</td> </tr> <tr> <td>Non-Hodgkin lymphoma</td> </tr> <tr> <td>Myeloma</td> </tr> <tr> <td class=\"subtitle1_single\">Myeloid malignancies</td> </tr> <tr> <td>Chronic myeloid leukemia</td> </tr> <tr> <td>Agnogenic myeloid metaplasia with myelofibrosis</td> </tr> <tr> <td>Prodrome to myelodysplastic syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Other cancers </td> </tr> <tr> <td>Thymoma (10 to 15 percent of cases)</td> </tr> <tr> <td>Malignancies with chemotherapy-associated anemia treated with recombinant human erythropoietin</td> </tr> <tr> <td class=\"subtitle1_single\">Pregnancy</td> </tr> </tbody> </table> </td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">7</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=24968&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n<mso:Media_Notes msdt:dt=\"string\"></mso:Media_Notes>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div id=\"graphicVersion\">Graphic 57655 Version 3.0</div></div></div>"},"57656":{"type":"graphic_figure","displayName":"Primary stroke prevention in SCD","title":"Efficacy of red blood cell transfusion in preventing a first stroke in children with sickle cell disease","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Efficacy of red blood cell transfusion in preventing a first stroke in children with sickle cell disease</div><div class=\"cntnt\"><img style=\"width:478px; height:494px;\" src=\"images/HEME/57656_Prevent_first_CVA_sickle_ce.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier estimate of the probability of not having a stroke among 130 patients with sickle cell anemia at high risk of stroke as determined by transcranial Doppler; the patients were randomized to chronic long-term transfusion therapy or standard care. There was a significant benefit from transfusion therapy (p = 0.02). One patient in the standard-care group who had an intracerebral hematoma was excluded. The tick marks represent the lengths of observation in patients who did not have a stroke.</div><div class=\"graphic_reference\">Data from Adams, RJ, McKie, VC, Hsu, L, et al, N Engl J Med 1998; 339:5.</div><div id=\"graphicVersion\">Graphic 57656 Version 2.0</div></div></div>"},"57657":{"type":"graphic_diagnosticimage","displayName":"Fetal polymicrogyria","title":"Fetal polymicrogyria","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fetal polymicrogyria</div><div class=\"cntnt\"><img style=\"width:217px; height:234px;\" src=\"images/PEDS/57657_Fetal_polymicrogyria.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Third trimester fetus with diffusely dysmorphic sawtooth pattern of the gyri over the convexities compatible with polymicrogyria.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 57657 Version 1.0</div></div></div>"},"57658":{"type":"graphic_figure","displayName":"Temporomandibular joint TMJ anatomy","title":"Temporomandibular joint (TMJ) anatomy and associated musculature","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Temporomandibular joint (TMJ) anatomy and associated musculature</div><div class=\"cntnt\"><img style=\"width:478px; height:682px;\" src=\"images/PC/57658_Normal_jaw_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Temporomandibular joint (TMJ), associated muscles of mastication, and cervical muscles that connect the mandible and head and neck.</div><div id=\"graphicVersion\">Graphic 57658 Version 1.0</div></div></div>"},"57659":{"type":"graphic_table","displayName":"Differential diagnosis of cyclic vomiting syndrome","title":"Differential diagnosis of cyclic vomiting syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of cyclic vomiting syndrome</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Medications and toxic etiologies</td> </tr> <tr> <td class=\"sublist2_start\">Cancer chemotherapy</td> </tr> <tr> <td class=\"sublist2\">Severe-cisplatinum, dacarbazine, nitrogen mustard</td> </tr> <tr> <td class=\"sublist2\">Moderate-etoposide, methotrexate, cytarabine</td> </tr> <tr> <td class=\"sublist2\">Mild-fluorouracil, vinblastine, tamoxifen</td> </tr> <tr> <td class=\"sublist2_start\">Analgesics</td> </tr> <tr> <td class=\"sublist2\">Aspirin</td> </tr> <tr> <td class=\"sublist2\">Nonsteroidal antiinflammatory drugs</td> </tr> <tr> <td class=\"sublist2\">Auranofin</td> </tr> <tr> <td class=\"sublist2\">Antigout drugs</td> </tr> <tr> <td class=\"sublist2_start\">Cardiovascular medications</td> </tr> <tr> <td class=\"sublist2\">Digoxin</td> </tr> <tr> <td class=\"sublist2\">Antiarrhythmics</td> </tr> <tr> <td class=\"sublist2\">Antihypertensives</td> </tr> <tr> <td class=\"sublist2\">&#946;-blockers</td> </tr> <tr> <td class=\"sublist2\">Calcium channel antagonists</td> </tr> <tr> <td class=\"indent1\">Diuretics</td> </tr> <tr> <td class=\"sublist2_start\">Hormonal preparations/therapies</td> </tr> <tr> <td class=\"sublist2\">Oral antidiabetics</td> </tr> <tr> <td class=\"sublist2\">Oral contraceptives</td> </tr> <tr> <td class=\"sublist2_start\">Antibiotics/antivirals</td> </tr> <tr> <td class=\"sublist2\">Erythromycin</td> </tr> <tr> <td class=\"sublist2\">Tetracycline</td> </tr> <tr> <td class=\"sublist2\">Sulfonamides</td> </tr> <tr> <td class=\"sublist2\">Antituberculous drugs</td> </tr> <tr> <td class=\"sublist2\">Acyclovir</td> </tr> <tr> <td class=\"sublist2_start\">Gastrointestinal medications</td> </tr> <tr> <td class=\"sublist2\">Sulfasalazine</td> </tr> <tr> <td class=\"sublist2\">Azathioprine</td> </tr> <tr> <td class=\"sublist2_start\">Nicotine</td> </tr> <tr> <td class=\"sublist2\">CNS active</td> </tr> <tr> <td class=\"sublist2\">Narcotics</td> </tr> <tr> <td class=\"sublist2\">Antiparkinsonian drugs</td> </tr> <tr> <td class=\"sublist2\">Anticonvulsants</td> </tr> <tr> <td class=\"sublist2_start\">Antiasthmatics</td> </tr> <tr> <td class=\"sublist2\">Theophylline</td> </tr> <tr> <td class=\"indent1\">Radiation therapy</td> </tr> <tr> <td class=\"indent1\">Ethanol abuse</td> </tr> <tr> <td class=\"indent1\">Jamaican vomiting sickness</td> </tr> <tr> <td class=\"indent1\">Hypervitaminosis</td> </tr> <tr> <td class=\"indent1\">Cannabis hyperemesis syndrome</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Disorders of the gut and peritoneum</td> </tr> <tr> <td class=\"sublist2_start\">Mechanical obstruction</td> </tr> <tr> <td class=\"sublist2\">Gastric outlet obstruction</td> </tr> <tr> <td class=\"sublist2\">Small bowel obstruction</td> </tr> <tr> <td class=\"indent1\">Functional gastrointestinal disorders</td> </tr> <tr> <td class=\"indent1\">Gastroparesis</td> </tr> <tr> <td class=\"indent1\">Chronic intestinal pseudo-obstruction</td> </tr> <tr> <td class=\"indent1\">Nonulcer dyspepsia</td> </tr> <tr> <td class=\"indent1\">Irritable bowel syndrome</td> </tr> <tr> <td class=\"sublist2_start\">Gastrointestinal malignancies</td> </tr> <tr> <td class=\"sublist2\">Pancreatic adenocarcinoma</td> </tr> <tr> <td class=\"sublist2\">Inflammatory intraperitoneal disease</td> </tr> <tr> <td class=\"sublist2\">Peptic ulcer disease</td> </tr> <tr> <td class=\"sublist2\">Cholecystitis/cholelithiasis/biliary dyskinesia</td> </tr> <tr> <td class=\"sublist2\">Pancreatitis</td> </tr> <tr> <td class=\"sublist2\">Hepatitis</td> </tr> <tr> <td class=\"sublist2\">Crohn disease</td> </tr> <tr> <td class=\"sublist2\">Mesenteric ischemia</td> </tr> <tr> <td class=\"sublist2\">Retroperitoneal fibrosis</td> </tr> <tr> <td class=\"sublist2\">Mucosal metastases</td> </tr> <tr> <td class=\"sublist2\">Recurrent subacute appendicitis</td> </tr> <tr> <td class=\"sublist2\">Duodenal atresia/web/diverticulum</td> </tr> <tr> <td class=\"sublist2\">Choledochal cysts</td> </tr> <tr> <td class=\"sublist2\">Gastrointestinal infections (pinworms, <em>Blastocystis hominis</em>, <em>Entamoeba histolytica</em>, <em>Giardia</em>, <em>Gastrospirillum</em>)</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Neurological causes</td> </tr> <tr> <td class=\"sublist2_start\">Increased intracranial pressure</td> </tr> <tr> <td class=\"sublist2\">Malignancy</td> </tr> <tr> <td class=\"sublist2\">Hemorrhage</td> </tr> <tr> <td class=\"sublist2\">Infarction</td> </tr> <tr> <td class=\"sublist2\">Abscess</td> </tr> <tr> <td class=\"sublist2\">Meningitis</td> </tr> <tr> <td class=\"sublist2\">Congenital malformation</td> </tr> <tr> <td class=\"sublist2\">Hydrocephalus</td> </tr> <tr> <td class=\"sublist2\">Pseudotumor cerebri</td> </tr> <tr> <td class=\"indent1\">Seizure disorders</td> </tr> <tr> <td class=\"indent1\">Demyelinating disorders</td> </tr> <tr> <td class=\"indent1\">Emotional responses</td> </tr> <tr> <td class=\"sublist2_start\">Psychiatric disease</td> </tr> <tr> <td class=\"sublist2\">Psychogenic vomiting</td> </tr> <tr> <td class=\"sublist2\">Anxiety disorders</td> </tr> <tr> <td class=\"sublist2\">Depression</td> </tr> <tr> <td class=\"sublist2\">Pain</td> </tr> <tr> <td class=\"sublist2\">Anorexia nervosa</td> </tr> <tr> <td class=\"sublist2\">Bulimia nervosa</td> </tr> <tr> <td class=\"sublist2_start\">Labyrinthine disorders</td> </tr> <tr> <td class=\"sublist2\">Benign positional vertigo</td> </tr> <tr> <td class=\"sublist2\">Motion sickness</td> </tr> <tr> <td class=\"sublist2\">Labyrinthitis</td> </tr> <tr> <td class=\"sublist2\">Tumors</td> </tr> <tr> <td class=\"sublist2\">Meniere disease</td> </tr> <tr> <td class=\"sublist2\">Iatrogenic</td> </tr> <tr> <td class=\"sublist2\">Fluorescein angiography</td> </tr> <tr> <td class=\"sublist2\">Chronic sinusitis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Endocrinologic and metabolic causes</td> </tr> <tr> <td class=\"sublist2_start\">Other endocrine and metabolic</td> </tr> <tr> <td class=\"sublist2\">Uremia</td> </tr> <tr> <td class=\"sublist2\">Diabetic ketoacidosis</td> </tr> <tr> <td class=\"sublist2\">Hyperparathyroidism</td> </tr> <tr> <td class=\"sublist2\">Hypoparathyroidism</td> </tr> <tr> <td class=\"sublist2\">Hyperthyroidism</td> </tr> <tr> <td class=\"sublist2\">Addison's disease</td> </tr> <tr> <td class=\"sublist2\">Acute intermittent porphyria</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Postoperative nausea and vomiting</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous causes</td> </tr> <tr> <td class=\"sublist2_start\">Cardiac disease</td> </tr> <tr> <td class=\"sublist2\">Myocardial infarction</td> </tr> <tr> <td class=\"sublist2\">Heart failure</td> </tr> <tr> <td class=\"sublist2\">Radiofrequency ablation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Starvation</td> </tr> <tr> <td class=\"subtitle1_single\">Urologic/gynecologic disorders</td> </tr> <tr> <td class=\"indent1\">Urolithiasis</td> </tr> <tr> <td class=\"indent1\">Ureteropelvic junction obstruction</td> </tr> <tr> <td class=\"indent1\">Ovarian cyst</td> </tr> <tr> <td class=\"indent1\">Pregnancy</td> </tr> <tr> <td class=\"indent1\">Premenstrual syndrome</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Original table modified for this publication. Reproduced with permission from: the American Gastroenterological Association. Gastroenterology 2001; 120:263.</div><div id=\"graphicVersion\">Graphic 57659 Version 4.0</div></div></div>"},"57661":{"type":"graphic_diagnosticimage","displayName":"Crohn fistulae UGI","title":"Ileocecal fistulae in Crohn disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ileocecal fistulae in Crohn disease</div><div class=\"cntnt\"><img style=\"width:329px; height:292px;\" src=\"images/GAST/57661_Crohns_fistulae_UGI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small bowel follow through examination demonstrates nodular thickening of the terminal ileal mucosal folds in a patient with Crohn disease (arrow). Several fistulae extend from the terminal ileum to the adjacent cecum (arrowheads).</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 57661 Version 4.0</div></div></div>"},"57664":{"type":"graphic_form","displayName":"AAE emergency care","title":"Instructions for emergency care of acquired angioedema","html":"<div class=\"graphic\"><div style=\"width: 591px\" class=\"figure\"><div class=\"ttl\">Instructions for emergency care of acquired angioedema</div><div class=\"cntnt\"><img style=\"width:571px; height:709px;\" src=\"images/ALLRG/57664_AAEemergencycareed2.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 57664 Version 18.0</div></div></div>"},"57665":{"type":"graphic_diagnosticimage","displayName":"Nasal dermoid with intracranial extension","title":"Nasal dermoid with intracranial extension","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nasal dermoid with intracranial extension</div><div class=\"cntnt\"><img style=\"width:432px; height:321px;\" src=\"images/ALLRG/57665_Nasal_derm_intracranial_ext.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 57665 Version 2.0</div></div></div>"},"57666":{"type":"graphic_table","displayName":"Risk of breast and ovarian cancer for women with BRCA mutations ","title":"Lifetime risk of breast and ovarian cancer for women with <EM>BRCA </EM>mutations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lifetime risk of breast and ovarian cancer for women with <EM>BRCA </EM>mutations</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Lifetime risk of breast cancer</td> <td class=\"subtitle1\">Lifetime risk of ovarian cancer</td> </tr> <tr> <td><strong><em>BRCA1 </em>mutation</strong></td> <td>55 to 85 percent</td> <td>35 to 46 percent</td> </tr> <tr> <td><strong><em>BRCA2 </em>mutation</strong></td> <td>50 to 85 percent</td> <td>13 to 23 percent</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 57666 Version 2.0</div></div></div>"},"57667":{"type":"graphic_diagnosticimage","displayName":"Retrograde urethrogram with short stricture","title":"Retrograde urethrogram with short stricture","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Retrograde urethrogram with short stricture</div><div class=\"cntnt\"><img style=\"width:468px; height:351px;\" src=\"images/SURG/57667_Retro_urethro_short_strict.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 57667 Version 2.0</div></div></div>"},"57668":{"type":"graphic_picture","displayName":"Towel clamp closure of the abdomen","title":"Towel clamp closure of the abdomen","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Towel clamp closure of the abdomen</div><div class=\"cntnt\"><img style=\"width:298px; height:305px;\" src=\"images/SURG/57668_Towel_clamp_closure_abd.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 57668 Version 1.0</div></div></div>"},"57671":{"type":"graphic_diagnosticimage","displayName":"Osteochondritis dissecans","title":"Osteochondritis dissecans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Osteochondritis dissecans</div><div class=\"cntnt\"><img style=\"width:324px; height:325px;\" src=\"images/EM/57671_Osteochondritis_dissecans.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance imaging with lateral&nbsp; view of the talus (T1 weighted, gradient recovery sequence). The bone marrow is black whilst there is increased signal (mottled white area in the dome of the talus) secondary to osteochondral necrosis.</div><div class=\"graphic_reference\">Courtesy of the Department of Diagnostic Imaging, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 57671 Version 3.0</div></div></div>"},"57672":{"type":"graphic_figure","displayName":"Spermatic cord course","title":"Spermatic cord course","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Spermatic cord course</div><div class=\"cntnt\"><img style=\"width:513px; height:233px;\" src=\"images/PEDS/57672_Spermatic_cord_course.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This transverse section of the anterior abdominal wall demonstrates the structures that form the external and internal inguinal rings. The external inguinal ring is formed by the external oblique aponeurosis. The internal inguinal ring is located in the transversalis fascia and composed of the transversus abdominus and internal oblique muscles. The broad arrow represents the course of the spermatic cord.</div><div class=\"graphic_reference\">Adapted from O'Rahilly. Abdominal walls. In: Basic Human Anatomy, W.B. Saunders Company, Philadelphia 1983. p.230.</div><div id=\"graphicVersion\">Graphic 57672 Version 1.0</div></div></div>"},"57673":{"type":"graphic_picture","displayName":"Arsenical skin lesions","title":"Arsenical skin lesions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Arsenical skin lesions</div><div class=\"cntnt\"><img style=\"width:328px; height:210px;\" src=\"images/PC/57673_Arsenical_skin_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient shows multiple skin lesions associated with arsenic, including hyperkeratosis, suspected Bowen's disease, and nonhealing ulcers (suspected cancer).</div><div class=\"graphic_reference\">Reproduced with permission from Chakroborti, D, Mukherjee, SC, Pati, S, et al. Arsenic groundwater contamination in Middle Ganga Plain, Bihar, India: a future danger? Environ Health Perspect 2003; 111:1194.</div><div id=\"graphicVersion\">Graphic 57673 Version 2.0</div></div></div>"},"57674":{"type":"graphic_picture","displayName":"External rotation ankle stress test","title":"External rotation stress test","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">External rotation stress test</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/EM/57674_Ext_rotation_stress_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A provocative test for syndesmotic injury. The examiner supports the lateral fibula and tibia with one hand and gently forces external rotation with the other. Pain at the distal syndesmosis (area of pain indicated by the tip of the arrow) confirms distal syndesmotic ligamentous injury.</div><div class=\"graphic_reference\">Courtesy of Karen Maughan, MD.</div><div id=\"graphicVersion\">Graphic 57674 Version 3.0</div></div></div>"},"57676":{"type":"graphic_figure","displayName":"Cerebral autoregulation in hypertension","title":"Cerebral autoregulation in hypertension","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cerebral autoregulation in hypertension</div><div class=\"cntnt\"><img style=\"width:413px; height:304px;\" src=\"images/NEPH/57676_Cerebral_autoregulation_in.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of autoregulation of cerebral blood flow in normotensive and hypertensive subjects. In both groups, initial increases or decreases in mean arterial pressure are associated with maintenance of cerebral blood flow due to appropriate changes in arteriolar resistance. More marked changes in pressure are eventually associated with loss of autoregulation, leading to a reduction (with hypotension) or an elevation (with marked hypertension) in cerebral blood flow. These changes occur at higher pressures in patients with hypertension, presumably due to arteriolar thickening. Thus, aggressive antihypertensive therapy will produce cerebral ischemia at a higher mean arterial pressure in patients with underlying hypertension.</div><div class=\"graphic_reference\">Redrawn from: Kaplan, NM. Management of hypertensive emergencies. Lancet 1994; 344:1335.</div><div id=\"graphicVersion\">Graphic 57676 Version 3.0</div></div></div>"},"57679":{"type":"graphic_picture","displayName":"Histology nodular melanoma","title":"Nodular melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nodular melanoma</div><div class=\"cntnt\"><img style=\"width:375px; height:278px;\" src=\"images/ONC/57679_Histology_nodular_melanoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph of a nodular melanoma, demonstrating a large, pigmented dermal growth without an epidermal component.</div><div class=\"graphic_reference\">Courtesy of Vincent Liu, MD and April Wang Armstrong, MD.</div><div id=\"graphicVersion\">Graphic 57679 Version 1.0</div></div></div>"},"57680":{"type":"graphic_table","displayName":"AUA/IPSS","title":"American Urological Association (AUA) urinary symptom score/International Prostate Symptom Score (IPSS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American Urological Association (AUA) urinary symptom score/International Prostate Symptom Score (IPSS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Questions to be answered</td> <td class=\"subtitle1\">Not at all</td> <td class=\"subtitle1\">Less than 1 time in 5</td> <td class=\"subtitle1\">Less than half the time</td> <td class=\"subtitle1\">About half the time</td> <td class=\"subtitle1\">More than half the time</td> <td class=\"subtitle1\">Almost always</td> <td class=\"subtitle1\">Your score</td> </tr> <tr> <td>1. Over the past month, how often have you had a sensation of not emptying your bladder completely after you finished urinating?</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> <td>4</td> <td>5</td> <td>&nbsp;</td> </tr> <tr> <td>2. Over the past month, how often have you had to urinate again less than&nbsp;two hours after you finished urinating?</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> <td>4</td> <td>5</td> <td>&nbsp;</td> </tr> <tr> <td>3. Over the past month, how often have you found you stopped and started again several times when you urinated?</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> <td>4</td> <td>5</td> <td>&nbsp;</td> </tr> <tr> <td>4. Over the past month, how often have you found it difficult to postpone urination?</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> <td>4</td> <td>5</td> <td>&nbsp;</td> </tr> <tr> <td>5. Over the past month, how often have you had a weak urinary stream?</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> <td>4</td> <td>5</td> <td>&nbsp;</td> </tr> <tr> <td>6. Over the past month, how often have you had to push or strain to begin urination?</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> <td>4</td> <td>5</td> <td>&nbsp;</td> </tr> <tr> <td>7. Over the past month, how many times did you most typically get up to urinate from the time you went to bed at night until the time you got up in the morning?</td> <td>0 (none)</td> <td>1 (1 time)</td> <td>2 (2 times)</td> <td>3 (3 times)</td> <td>4 (4 times)</td> <td>5 (5 or more times)</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"7\" align=\"right\"><strong>Sum of numbers (AUA symptom score):</strong></td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"8\">Total score:</td> </tr> <tr> <td class=\"indent1\" colspan=\"8\">0 to 7: Mild symptoms</td> </tr> <tr> <td class=\"indent1\" colspan=\"8\">8 to 19: Moderate symptoms</td> </tr> <tr> <td class=\"indent1\" colspan=\"8\">20 to 35: Severe symptoms</td> </tr> <tr> <td class=\"subtitle1\">Quality of life due to urinary symptoms</td> <td class=\"subtitle1\">Delighted</td> <td class=\"subtitle1\">Pleased</td> <td class=\"subtitle1\">Mostly satisfied</td> <td class=\"subtitle1\">Mixed - about equally satisfied and unsatisfied</td> <td class=\"subtitle1\">Mostly dissatisfied</td> <td class=\"subtitle1\">Unhappy</td> <td class=\"subtitle1\">Terrible</td> </tr> <tr> <td>If you were to spend the rest of your life with your urinary condition the way it is now, how would you feel about that?</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> <td>4</td> <td>5</td> <td>6</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The AUA symptom score and the IPSS use the same questions and scale. The IPSS additionally includes the last&nbsp;disease-specific quality of life question.</div><div class=\"graphic_reference\">Modified with permission from: Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association Symptom Index for Benign Prostatic Hyperplasia. J Urol 1992; 148:1549. Copyright © 1992 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 57680 Version 10.0</div></div></div>"},"57681":{"type":"graphic_figure","displayName":"Enterobiasis life cycle","title":"Enterobiasis life cycle","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">Enterobiasis life cycle</div><div class=\"cntnt\"><img style=\"width:467px; height:533px;\" src=\"images/ID/57681_Enterobiasis_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Eggs are deposited on perianal folds <strong>(1)</strong>. Self-infection occurs by transferring infective eggs to the mouth with hands that have scratched the perianal area <strong>(2)</strong>. Person-to-person transmission can also occur through handling of contaminated clothes or bed linens. Enterobiasis may also be acquired through surfaces in the environment that are contaminated with pinworm eggs (eg, curtains, carpeting). Some small number of eggs may become airborne and inhaled. These would be swallowed and follow the same development as ingested eggs. Following ingestion of infective eggs, the larvae hatch in the small intestine <strong>(3)</strong> and the adults establish themselves in the colon <strong>(4)</strong>. The time interval from ingestion of infective eggs to oviposition by the adult females is about one month. The life span of the adults is about two months. Gravid females migrate nocturnally outside the anus and oviposit while crawling on the skin of the perianal area <strong>(5)</strong>. The larvae contained inside the eggs develop (the eggs become infective) in four to six hours under optimal conditions <strong>(1)</strong>. Retroinfection, or the migration of newly hatched larvae from the anal skin back into the rectum, may occur but the frequency with which this happens is unknown.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Enterobiasis. Available at: <A href=\"http://www.cdc.gov/dpdx/enterobiasis/index.html\">http://www.cdc.gov/dpdx/enterobiasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 57681 Version 3.0</div></div></div>"},"57682":{"type":"graphic_table","displayName":"Drugs causing cholestasis","title":"Drugs reported to cause chronic cholestasis and ductopenia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs reported to cause chronic cholestasis and ductopenia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Aceprometazine</td> </tr> <tr> <td>Ajmaline</td> </tr> <tr> <td>Allopurinol</td> </tr> <tr> <td>Amineptine</td> </tr> <tr> <td>Amoxicillin/clavulanic acid</td> </tr> <tr> <td>Ampicillin</td> </tr> <tr> <td>Androgenic anabolic steroids</td> </tr> <tr> <td>Azathioprine</td> </tr> <tr> <td>Azithromycin</td> </tr> <tr> <td>Barbiturates</td> </tr> <tr> <td>Carbamazepine</td> </tr> <tr> <td>Carbutamide</td> </tr> <tr> <td>Chlorothiazide</td> </tr> <tr> <td>Chlorpromazine</td> </tr> <tr> <td>Cimetidine</td> </tr> <tr> <td>Ciprofloxin</td> </tr> <tr> <td>Clindamycin</td> </tr> <tr> <td>Co-trimoxazole</td> </tr> <tr> <td>Cyamemazine</td> </tr> <tr> <td>Cyclohexylpropionate</td> </tr> <tr> <td>Cyproheptadine</td> </tr> <tr> <td>Erythomycin</td> </tr> <tr> <td>Flucloxacillin</td> </tr> <tr> <td>Glibenclamide</td> </tr> <tr> <td>Glycyrrhizin</td> </tr> <tr> <td>Haloperidol</td> </tr> <tr> <td>Ibuprofen</td> </tr> <tr> <td>Imipramine</td> </tr> <tr> <td>Meropenem</td> </tr> <tr> <td>Methyltestosterone</td> </tr> <tr> <td>Moxifloxacin</td> </tr> <tr> <td>Nevirapine</td> </tr> <tr> <td>Norandrostenolone</td> </tr> <tr> <td>Oestradiol</td> </tr> <tr> <td>Phenytoin</td> </tr> <tr> <td>Prochlorperazine</td> </tr> <tr> <td>Tetracyclines</td> </tr> <tr> <td>Thiabendazole</td> </tr> <tr> <td>Tiopronin</td> </tr> <tr> <td>Tolbutamide</td> </tr> <tr> <td>Trimethoprim-sulfamethoxazole</td> </tr> <tr> <td>Trioleandomycin</td> </tr> <tr> <td>Valproic acid</td> </tr> <tr> <td>Xenalamine</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: J Gastroenterol Hepatol 2000; 15:1232, J Hepatol 1997; 26S:31, Clin Liver Dis 2003; 7:311, and Korean J Hepatol 2005; 11:80.</div><div id=\"graphicVersion\">Graphic 57682 Version 2.0</div></div></div>"},"57684":{"type":"graphic_figure","displayName":"Lepore and Kenya hemoglobins","title":"Genesis of Lepore and Kenya hemoglobins","html":"<div class=\"graphic\"><div style=\"width: 479px\" class=\"figure\"><div class=\"ttl\">Genesis of Lepore and Kenya hemoglobins</div><div class=\"cntnt\"><img style=\"width:459px; height:310px;\" src=\"images/HEME/57684_Lepore_and_Kenya_hemoglobin.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These figures illustrate the unequal crossing-over which underlies the production of the Lepore and Kenya hemoglobins. For ease in understanding, each &quot;newly created&quot; gene has been given a separate color. Gene segments which are composed of joined portions from two different genes are shown in parentheses. Panel (A): unequal crossing-over between the beta gene locus of one chromosome and the delta gene locus of the other yields the genes for Lepore (red) and anti-Lepore (green) hemoglobins. Panel (B): unequal crossing-over between the beta gene locus of one chromosome and the A(gamma) gene locus of the other yields the genes for Kenya (red) and anti-Kenya (green) hemoglobins.</div><div class=\"graphic_reference\">Reproduced with permission from: Benz EJ, Jr. The hemoglobinopathies. In: Textbook of Internal Medicine, Kelly WN, DeVita VT (Eds), JB Lippincott, Philadelphia 1988. Copyright © 1988 Lippincott Williams &amp; Wilkins.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 57684 Version 6.0</div></div></div>"},"57685":{"type":"graphic_table","displayName":"Definition of prematurity based on birth weights","title":"Definition of prematurity based on birth weights","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definition of prematurity based on birth weights</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">Birth weight, grams</td>\r\n                    <td class=\"subtitle1\">Definition</td>\r\n                    <td class=\"subtitle1\">Abbreviation</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>&#60;2500</td>\r\n                    <td>Low birth weight</td>\r\n                    <td>LBW</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>&#60;1500</td>\r\n                    <td>Very low birth weight</td>\r\n                    <td>VLBW</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>&#60;1000</td>\r\n                    <td>Extremely low birth weight</td>\r\n                    <td>ELBW</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 57685 Version 2.0</div></div></div>"},"57687":{"type":"graphic_picture","displayName":"RB-ILD histology","title":"Respiratory bronchiolitis in patient with respiratory bronchiolitis-associated interstitial lung disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Respiratory bronchiolitis in patient with respiratory bronchiolitis-associated interstitial lung disease</div><div class=\"cntnt\"><img style=\"width:363px; height:411px;\" src=\"images/PULM/57687_RB-ILD_histology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Faintly pigmented alveolar macrophages fill the lumen of this respiratory bronchiole and the surrounding airspaces. There is a mild thickening of the wall of the respiratory bronchiole.</div><div id=\"graphicVersion\">Graphic 57687 Version 2.0</div></div></div>"},"57688":{"type":"graphic_table","displayName":"Etiology infectious arthritis","title":"Causes of infectious arthritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of infectious arthritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Organism</td> <td class=\"subtitle1\">Clinical clues</td> </tr> <tr> <td><em>Staphylococcus aureus</em></td> <td>Healthy adults, skin breakdown, previously damaged joint (eg, rheumatoid arthritis), prosthetic joint</td> </tr> <tr> <td>Strepotococcal species</td> <td>Healthy adults, splenic dysfunction</td> </tr> <tr> <td><em>Neisseria gonorrhoeae</em></td> <td>Healthy adults (particularly young, sexually active), associated tenosynovitis, vesicular pustules, late complement deficiency, negative synovial fluid culture and Gram stain</td> </tr> <tr> <td>Aerobic gram-negative bacteria</td> <td>Immunocompromised hosts, gastrointestinal infection</td> </tr> <tr> <td>Anaerobic gram-negative bacteria</td> <td>Immunocompromised hosts, gastrointestinal infection</td> </tr> <tr> <td>Brucellosis</td> <td>Zoonosis&nbsp;</td> </tr> <tr> <td>Mycobacterial species</td> <td>Immunocompromised hosts, recent travel to or residence in an endemic area</td> </tr> <tr> <td>Fungal species (sporotrichosis, <em>Cryptococcus</em>, blastomycosis, coccidioidomycosis)</td> <td>Immunocompromised hosts</td> </tr> <tr> <td>Spirochete (<em>Borellia burgdorferi</em>)</td> <td>Exposure to ticks, antecedent rash, knee joint involvement</td> </tr> <tr> <td><em>Mycoplasma hominis</em></td> <td>Immunocompromised hosts with prior urinary tract manipulation</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 57688 Version 7.0</div></div></div>"},"57690":{"type":"graphic_figure","displayName":"Eye anatomy in cross section","title":"Eye anatomy in cross section","html":"<div class=\"graphic\"><div style=\"width: 598px\" class=\"figure\"><div class=\"ttl\">Eye anatomy in cross section</div><div class=\"cntnt\"><img style=\"width:578px; height:551px;\" src=\"images/ID/57690_Eye_antmy_crss_ectn.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 57690 Version 5.0</div></div></div>"},"57692":{"type":"graphic_algorithm","displayName":"Arruda mapping algorithm localize accessory pathway","title":"Algorithm to localize accessory pathway in preexcitation syndrome","html":"<div class=\"graphic\"><div style=\"width: 585px\" class=\"figure\"><div class=\"ttl\">Algorithm to localize accessory pathway in preexcitation syndrome</div><div class=\"cntnt\"><img style=\"width:565px; height:323px;\" src=\"images/CARD/57692_Arruda_mapping_algorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mapping algorithm for localization of accessory pathway in the preexcitation syndrome using the morphology of the delta wave on the electrocardiogram.</div><div class=\"graphic_footnotes\">R/S: R-S wave ratio; +: positive &Delta;; &plusmn;: isoelectric &Delta;; -: negative &Delta; wave; Sens: sensitivity; Spec: specificity; PPV: positive predictive value; LL: left (L) lateral; LAL: L anterolateral; LP: L posterior; LPL: L posterolateral; LPS: L posteroseptal; RA: right (R) anterior; RAP: R anterior paraseptal; RAL: R anterolateral; RL: R lateral; RPL: R posterolateral; RP: R posterior; AS: R anteroseptal; MS: midseptal; RPS: R posteroseptal; CS/MCV: coronary sinus/middle cardiac vein; %: percent.</div><div class=\"graphic_reference\">Data from Arruda M, Wang X, McClelland J, et al, Pacing Clin Electrophysiol 1993; 16:865.</div><div id=\"graphicVersion\">Graphic 57692 Version 3.0</div></div></div>"},"57693":{"type":"graphic_figure","displayName":"HHV 6 infants young children","title":"Prevalence of human herpesvirus 6 (HHV-6) infection in young children","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Prevalence of human herpesvirus 6 (HHV-6) infection in young children</div><div class=\"cntnt\"><img style=\"width:493px; height:371px;\" src=\"images/ID/57693_HHV_6_infants_young_childre.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Geometric mean anti-HHV-6 antibody titers (blue) and the proportion with HHV-6 DNA detected by polymerase chain reaction in peripheral blood mononuclear cells (red) in 2427 infants and young children under the age of three years. Children with an acute febrile illness due to HHV-6 were excluded. HHV-6 DNA was detected in 10 percent of infants less than one month of age, which is consistent with perinatal transmission, and in 66 percent at one year. The rate of seroconversion was highest between 6 and 12 months of age; the high titers present in the first few months represent maternal antibodies.</div><div class=\"graphic_footnotes\">PCR: polymerase chain reaction.</div><div class=\"graphic_reference\">Adapted from: Hall CB, Long CE, Schnabel KC, et al. Human herpesvirus-6 infection in children. A prospective study of complications and reactivation. N Engl J Med 1994; 331:432.</div><div id=\"graphicVersion\">Graphic 57693 Version 3.0</div></div></div>"},"57697":{"type":"graphic_picture","displayName":"Central breast conserving surgery","title":"Central lumpectomy","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Central lumpectomy</div><div class=\"cntnt\"><img style=\"width:546px; height:365px;\" src=\"images/SURG/57697_Centrallumpectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Central breast conserving surgery.<br> (A) Parallelogram incision for central mastectomy.<br> (B) Completed central mastectomy.<br> (C) Closure of central mastectomy using parallelogram incision.</div><div class=\"graphic_reference\">Reproduced with permission from: Calhoun KE, Anderson BO. Oncoplastic surgery: Segmental resection for lumpectomies. In: Master Techniques in General Surgery: Breast Surgery, Bland KI, Klimberg SV (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 57697 Version 8.0</div></div></div>"},"57698":{"type":"graphic_figure","displayName":"Stress and sudden cardiac death","title":"Relationships between emotional stress, myocardial ischemia or infarction, and ventricular fibrillation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Relationships between emotional stress, myocardial ischemia or infarction, and ventricular fibrillation</div><div class=\"cntnt\"><img style=\"width:427px; height:326px;\" src=\"images/CARD/57698_Stress_and_sudden_cardiac_d.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 57698 Version 1.0</div></div></div>"},"57699":{"type":"graphic_diagnosticimage","displayName":"Leak after Roux-en-Y gastric bypass","title":"Leak after Roux-en-Y gastric bypass","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">Leak after Roux-en-Y gastric bypass</div><div class=\"cntnt\"><img style=\"width:570px; height:332px;\" src=\"images/SURG/57699_Leak_RouxenY_gastr_bypass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small amount of extraluminal contrast&nbsp;at gastrojejunal anastomosis.</div><div id=\"graphicVersion\">Graphic 57699 Version 5.0</div></div></div>"},"57700":{"type":"graphic_figure","displayName":"Manual reduction of paraphimosis","title":"Manual reduction of paraphimosis","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Manual reduction of paraphimosis</div><div class=\"cntnt\"><img style=\"width:487px; height:621px;\" src=\"images/EM/57700_Paraphim_manual_reduction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A)&nbsp;Compression of the swollen foreskin for several minutes. Alternatively osmotic agents (eg, granulated sugar, 50 percent dextrose, or 20 percent mannitol), ice, or compression bandages can be applied. <br />(B) Manual reduction of the constricted foreskin over the glans penis.<br />Refer to UpToDate topics on paraphimosis. </div><div class=\"graphic_reference\">Modified from: Chambers P. Paraphimosis reduction. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Philadelphia: Lippincott Williams &amp; Wilkins, 2007.</div><div id=\"graphicVersion\">Graphic 57700 Version 6.0</div></div></div>"},"57701":{"type":"graphic_table","displayName":"Major causes of thyroid nodules","title":"Causes of thyroid nodules","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of thyroid nodules</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Benign</td> </tr> <tr> <td>Multinodular (sporadic) goiter (\"colloid adenoma\")</td> </tr> <tr> <td>Hashimoto's (chronic lymphocytic) thyroiditis</td> </tr> <tr> <td>Cysts (colloid, simple, or hemorrhagic)</td> </tr> <tr> <td class=\"sublist1_start\">Follicular adenomas</td> </tr> <tr> <td class=\"sublist1\">Macrofollicular adenomas</td> </tr> <tr> <td class=\"sublist1\">Microfollicular or cellular adenomas</td> </tr> <tr> <td class=\"sublist1_start\">H&#252;rthle cell (oxyphil cell) adenomas</td> </tr> <tr> <td class=\"sublist1\">Macro- or microfollicular patterns</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Malignant</td> </tr> <tr> <td>Papillary carcinoma</td> </tr> <tr> <td class=\"sublist1_start\">Follicular carcinoma</td> </tr> <tr> <td class=\"sublist1\">Minimally or widely invasive</td> </tr> <tr> <td class=\"sublist1\">Oxyphilic (H&#252;rthle cell) type</td> </tr> <tr> <td class=\"sublist1\">Noninvasive follicular thyroid neoplasm&nbsp;<br /> with papillary-like nuclear features&nbsp;</td> </tr> <tr> <td>Medullary carcinoma</td> </tr> <tr> <td>Anaplastic carcinoma</td> </tr> <tr> <td>Primary thyroid lymphoma</td> </tr> <tr> <td>Metastatic carcinoma (breast, renal cell, others)</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 57701 Version 3.0</div></div></div>"},"57702":{"type":"graphic_picture","displayName":"Circumcision restraint PI","title":"Baby restraint for circumcision procedures","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Baby restraint for circumcision procedures</div><div class=\"cntnt\"><img style=\"width:567px; height:756px;\" src=\"images/PI/57702_Circumcision_restraint_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 57702 Version 2.0</div></div></div>"},"57705":{"type":"graphic_table","displayName":"Tips for using compression stockings PI","title":"Tips for using compression stockings","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tips for using compression stockings</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Here are tips for using compression stockings:</td> </tr> <tr> <td class=\"indent1\">&#8226; Wash new compression stockings before wearing them to reduce their stiffness and to make them easier to put on.</td> </tr> <tr> <td class=\"indent1\">&#8226; Put on stockings as early as possible in the morning after you bandage any sores you have because swelling is less in the morning. If you do not put the stockings on early, raise your legs for 20 to 30 minutes before putting the stockings on.</td> </tr> <tr> <td class=\"indent1\">&#8226; When putting on stockings, sit on a chair with firm back support (not on the bed).</td> </tr> <tr> <td class=\"indent1\">&#8226; Knee-high stockings can be put on using the \"heel-pocket-out method.\" The heel-pocket-out method to put on compression stockings is as follows:</td> </tr> <tr> <td class=\"indent2\">1. Turn the leg part of the stocking inside-out down to the heel.</td> </tr> <tr> <td class=\"indent2\">2. Put your foot into the stocking, hold onto the folded edge, and pull the stocking onto your foot and over the heel.</td> </tr> <tr> <td class=\"indent2\">3. Gently work the stocking up your leg by turning it right-side out.</td> </tr> <tr> <td>Some people find it helpful to wear rubber gloves to put their stockings on. This can make it easier to slide the stockings up the legs.</td> </tr> <tr> <td class=\"indent1\">&#8226; Heavy compression stockings may go on more easily if light silk pantyhose are worn under the compression stockings, or if you first put powder on your legs.</td> </tr> <tr> <td class=\"indent1\">&#8226; Skin moisturizers and treatments that are used to treat open sores can make the stockings dirty and wear them out. Wash the stockings each day after wearing them if possible. Stockings can be washed in cold water by hand. You can also wash them with cold water and a small amount of mild detergent in a washing machine. Hang the stockings up to dry, and do not dry them in a machine. Buying at least two pairs of stockings at a time will let you wear one pair while the other pair is drying.</td> </tr> <tr> <td>If you have an allergy to rubber (latex), you can buy compression stockings without elastic.</td> </tr> <tr> <td>If you are not able to pull on your stockings, talk with your doctor or nurse. There are different stockings you can use or devices that can help you put on stockings.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 57705 Version 5.0</div></div></div>"},"57709":{"type":"graphic_table","displayName":"Symptoms of Huntington disease","title":"Symptoms of Huntington disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms of Huntington disease</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Neurologic</td> </tr> <tr> <td class=\"indent1\">Chorea</td> </tr> <tr> <td class=\"indent1\">Dystonia</td> </tr> <tr> <td class=\"indent1\">Eye movement slowing</td> </tr> <tr> <td class=\"indent1\">Hyperreflexia</td> </tr> <tr> <td class=\"indent1\">Gait abnormality</td> </tr> <tr> <td class=\"indent1\">Myoclonus (rare)</td> </tr> <tr> <td class=\"indent1\">Parkinsonism (late stages)</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Psychiatric</td> </tr> <tr> <td class=\"indent1\">Apathy</td> </tr> <tr> <td class=\"indent1\">Irritability</td> </tr> <tr> <td class=\"indent1\">Depression</td> </tr> <tr> <td class=\"indent1\">Delusions</td> </tr> <tr> <td class=\"indent1\">Aggression</td> </tr> <tr> <td class=\"indent1\">Anxiety</td> </tr> <tr> <td class=\"indent1\">Disinhibition</td> </tr> <tr> <td class=\"indent1\">Paranoia</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Cognitive</td> </tr> <tr> <td class=\"indent1\">Poor judgment</td> </tr> <tr> <td class=\"indent1\">Inflexibility of thought</td> </tr> <tr> <td class=\"indent1\">Loss of insight</td> </tr> <tr> <td class=\"indent1\">Decreased concentration</td> </tr> <tr> <td class=\"indent1\">Memory loss</td> </tr> <tr> <td class=\"indent1\">Subcortical dementia</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 57709 Version 3.0</div></div></div>"},"57710":{"type":"graphic_diagnosticimage","displayName":"CRS NP CR rhinoscopy","title":"Radiographic and rhinoscopic features of CRS with NP","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiographic and rhinoscopic features of CRS with NP</div><div class=\"cntnt\"><img style=\"width:253px; height:468px;\" src=\"images/ALLRG/57710_CRS_NP_CR_rhinoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Coronal sinus CT scan showing evidence of prior functional endoscopic sinus surgery with persistence of polypoid mucosal thickening in both maxillary sinuses and polypoid opacification of the anterior ethmoid sinuses. B) Rhinoscopic photograph showing the typical appearance of polypoid regrowth in the left anterior ethmoid region.</div><div class=\"graphic_footnotes\">CRS: chronic rhinosinusitis: NP: nasal polyposis; CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Daniel Hamilos, MD</div><div id=\"graphicVersion\">Graphic 57710 Version 4.0</div></div></div>"},"57711":{"type":"graphic_figure","displayName":"Pudendal block","title":"Pudendal block","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Pudendal block</div><div class=\"cntnt\"><img style=\"width:470px; height:366px;\" src=\"images/OBGYN/57711_Pudendal_block.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 57711 Version 5.0</div></div></div>"},"57712":{"type":"graphic_table","displayName":"Dyspnea questionnaire PI","title":"Dyspnea questionnaire","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dyspnea questionnaire</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Please select up to three phrases that best describe your breathing discomfort. If you choose more than one phrase, please also note the phrase that most closely describes the sensation you feel. If none of these phrases applies, please write in your own description of your breathing discomfort.</td>\n</tr>\n<tr>\n<td>My breathing is shallow.</td>\n</tr>\n<tr>\n<td>I feel an urge to breathe more.</td>\n</tr>\n<tr>\n<td>My chest is constricted.</td>\n</tr>\n<tr>\n<td>My breathing requires effort.</td>\n</tr>\n<tr>\n<td>I feel a hunger for more air.</td>\n</tr>\n<tr>\n<td>I feel out of breath.</td>\n</tr>\n<tr>\n<td>I cannot get enough air.</td>\n</tr>\n<tr>\n<td>My breath does not go in all the way.</td>\n</tr>\n<tr>\n<td>My chest feels tight.</td>\n</tr>\n<tr>\n<td>My breathing requires work.</td>\n</tr>\n<tr>\n<td>I feel that I am smothering/suffocating.</td>\n</tr>\n<tr>\n<td>I feel that I cannot get a deep breath.</td>\n</tr>\n<tr>\n<td>I feel that I am breathing more.</td>\n</tr>\n<tr>\n<td>My breath does not go out all the way.</td>\n</tr>\n<tr>\n<td>My breathing is heavy.</td>\n</tr>\n<tr>\n<td>Other descriptions:</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 57712 Version 1.0</div></div></div>"},"57713":{"type":"graphic_algorithm","displayName":"Chronic diarrhea in children","title":"Chronic diarrhea in children","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Chronic diarrhea in children</div><div class=\"cntnt\"><img style=\"width:531px; height:250px;\" src=\"images/PEDS/57713_Diarrhea_chronic_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Symptoms typically &gt;1 month in duration.<br />¶ More likely in older children and adolescents.<br />Δ Only in infants.<br /><FONT class=lozenge>◊</FONT> More likely in infants and young children.</div><div id=\"graphicVersion\">Graphic 57713 Version 8.0</div></div></div>"},"57714":{"type":"graphic_picture","displayName":"Ossicular disruption","title":"Ossicular disruption","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ossicular disruption</div><div class=\"cntnt\"><img style=\"width:396px; height:276px;\" src=\"images/EM/57714_Ossicular_disruption_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intra-operative transcanal view of a traumatic ossicular disruption at the incudo-stapedial joint. (Stapes is not readily visualized in this image.)</div><div class=\"graphic_reference\">Courtesy of Adele Karen Evans, MD, FAAP and Steven D Handler MD, MBE.</div><div id=\"graphicVersion\">Graphic 57714 Version 3.0</div></div></div>"},"57715":{"type":"graphic_figure","displayName":"PD pressure gradient manometry","title":"Sphincter of Oddi manometry","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Sphincter of Oddi manometry</div><div class=\"cntnt\"><img style=\"width:521px; height:167px;\" src=\"images/GAST/57715_PD_pressure_gradient_manome.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Example of elevated basal sphincter of Oddi (SO) pressure and a pressure gradient between the pancreatic duct and duodenum obtained during manometric catheter pull-through of the pancreatic segment of the SO.</div><div class=\"graphic_reference\">Courtesy of Walter J Hogan, MD.</div><div id=\"graphicVersion\">Graphic 57715 Version 1.0</div></div></div>"},"57717":{"type":"graphic_table","displayName":"Immunogenicity RBC antigens","title":"Relative immunogenicity of the various red blood cell antigens","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Relative immunogenicity of the various red blood cell antigens</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Red blood cell antigen</td>\n\n      <td class=\"subtitle1\"> Relative immunogenicity*</td>\n\n    </tr>\n\n    <tr>\n\n      <td>A, B</td>\n\n      <td>100</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Rh(D)</td>\n\n      <td> 80</td>\n\n    </tr>\n\n    <tr>\n\n      <td>K</td>\n\n      <td> 10</td>\n\n    </tr>\n\n    <tr>\n\n      <td>c,E</td>\n\n      <td> 3</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Fy(a)</td>\n\n      <td> 0.4</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Jk(a)</td>\n\n      <td> 0.1</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* Defined as the percent of individuals negative for the antigen in question who will produce an antibody after receiving transfusion of a single unit of red cells positive for that antigen. Values are approximate.</div><div class=\"graphic_reference\">Revised after Calhoun, L and Petz, L. Erythrocyte antigens and antibodies. In: Williams' Hematology, 6th ed, Beutler, E, Lichtman, MA, Coller, BS, et al, (Eds), McGraw-Hill, New York, 2001. p.1846.</div><div id=\"graphicVersion\">Graphic 57717 Version 1.0</div></div></div>"},"57719":{"type":"graphic_diagnosticimage","displayName":"Pulm AVM PA gram III","title":"Multiple non-communicating arteriovenous malformations detected on a routine chest radiograph in asymptomatic patient","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multiple non-communicating arteriovenous malformations detected on a routine chest radiograph in asymptomatic patient</div><div class=\"cntnt\"><img style=\"width:309px; height:432px;\" src=\"images/PULM/57719_Pulm_AVM_PA_gram_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A right selective pulmonary arteriogram shows abnormally dilated and tortuous segmental and subsegmental pulmonary arteries without early venous drainage.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 57719 Version 2.0</div></div></div>"},"57722":{"type":"graphic_picture","displayName":"Langerhans histiocytosis skin 1","title":"Langerhans cell histiocytosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Langerhans cell histiocytosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/57722_Langerhans_histio_skin_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Yellow-brown and erythematous papules, erosions, and crusts are present on this infant with Langerhans cell histiocytosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 57722 Version 6.0</div></div></div>"},"57723":{"type":"graphic_table","displayName":"DKA rapid overview","title":"Emergent diabetic ketoacidosis (DKA) management in adults: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Emergent&nbsp;diabetic ketoacidosis (DKA)&nbsp;management in adults: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical features </td> </tr> <tr> <td>DKA usually evolves rapidly over a 24-hour period.</td> </tr> <tr> <td>Common, early signs of ketoacidosis include nausea, vomiting, abdominal pain, and hyperventilation. The earliest symptoms of marked hyperglycemia are polyuria, polydipsia, and weight loss.</td> </tr> <tr> <td>As hyperglycemia worsens, neurologic symptoms appear and may progress to include lethargy, focal deficits, obtundation, seizure, and coma.</td> </tr> <tr> <td>Common causes of DKA include: infection; noncompliance, inappropriate adjustment, or cessation of insulin; new-onset diabetes mellitus; and myocardial ischemia.</td> </tr> <tr> <td class=\"subtitle1_single\">Evaluation and laboratory findings </td> </tr> <tr> <td>Assess vital signs, cardiorespiratory status, and mental status.</td> </tr> <tr> <td>Assess volume status: vital signs, skin turgor, mucosa, urine output.</td> </tr> <tr> <td>Obtain the following studies: serum glucose, urinalysis and urine ketones, serum electrolytes, BUN and creatinine, plasma osmolality, mixed venous blood gas, electrocardiogram; add serum ketones if urine ketones present.</td> </tr> <tr> <td>DKA is characterized by hyperglycemia, an elevated anion gap* metabolic acidosis, and ketonemia. Dehydration and potassium deficits are often severe.</td> </tr> <tr> <td>Serum glucose is usually greater than 250 mg/dL (13.9 mmol/L) and less than 800 mg/dL (44.4 mmol/L). In certain instances (eg, insulin given prior to&nbsp;emergency department&nbsp;arrival), the glucose may be only mildly elevated.</td> </tr> <tr> <td>Additional testing is obtained based on clinical circumstances and may include: blood or urine cultures, lipase, chest x-ray.</td> </tr> <tr> <td class=\"subtitle1_single\">Management </td> </tr> <tr> <td>Stabilize the patient's airway, breathing, and circulation.</td> </tr> <tr> <td>Obtain large bore IV (&#8805;16 gauge) access; monitor using a cardiac monitor, capnography, and pulse oximetry.</td> </tr> <tr> <td>Monitor serum glucose hourly, and basic electrolytes and venous pH or bicarbonate every two to four hours until the patient is stable.</td> </tr> <tr> <td>Determine and treat any underlying cause of DKA (eg, pneumonia or urinary infection, myocardial ischemia).</td> </tr> <tr> <td class=\"subtitle2_single\">Replete ECF volume and free water deficits: </td> </tr> <tr> <td class=\"indent1\">&#8226; Give several liters of IV&nbsp;isotonic (0.9%) saline as rapidly as possible to patients with signs of shock. </td> </tr> <tr> <td class=\"indent1\">&#8226; Give IV isotonic (0.9%)&nbsp;saline at 15 to 20 mL/kg per hour (ie, 1 to 1.5 L per hour for an average-sized adult), in the absence of cardiac compromise, for the first few hours to hypovolemic patients without shock. </td> </tr> <tr> <td class=\"indent1\">&#8226; After intravascular volume is restored, give one-half isotonic (0.45%) saline at 4 to 14 mL/kg per hour if the corrected serum Na+<sup>&#182;</sup> is normal or elevated; isotonic saline is continued if the corrected serum Na+<sup>&#182;</sup> is reduced. </td> </tr> <tr> <td class=\"indent1\">&#8226; Add dextrose to the saline solution when the serum glucose reaches ~200 mg/dL (11.1 mmol/L). </td> </tr> <tr> <td class=\"subtitle2_single\">Replete potassium (K+) deficits: </td> </tr> <tr> <td class=\"indent1\">&#8226; Regardless of the initial measured serum K+, patients with DKA have a large total body K+ deficit. </td> </tr> <tr> <td class=\"indent1\">&#8226; If initial serum K+ is below 3.3 mEq/L, hold insulin and give&nbsp;potassium chloride&nbsp;20 to 40 mEq/hour IV until K+ concentration is above 3.3 mEq/L; rarely, additional potassium supplementation may be necessary to avoid life-threatening muscle weakness and cardiac arrhythmias.</td> </tr> <tr> <td class=\"indent1\">&#8226; If initial serum K+ is between 3.3 and 5.3 mEq/L, give&nbsp;potassium chloride&nbsp;20 to 30 mEq per liter IV fluid; maintain serum K+ between 4 to 5 mEq/L. </td> </tr> <tr> <td class=\"indent1\">&#8226; If initial serum K+ is above 5.3 mEq/L, do not give potassium; check serum K+ every 2 hours; delay administration of potassium chloride until serum K+ has fallen to 5 to 5.2 mEq/L.</td> </tr> <tr> <td class=\"subtitle2_single\">Give insulin: </td> </tr> <tr> <td class=\"indent1\">&#8226; Do not give insulin if initial serum K+ is below 3.3 mEq/L; replete K+ and fluid deficit first. </td> </tr> <tr> <td class=\"indent1\">&#8226; Give all patients without a serum K+ below 3.3 mEq/L regular insulin. Either of two regimens can be used: 0.1 units/kg IV bolus, then start a continuous IV infusion 0.1 units/kg per hour; <strong>OR</strong> do not give bolus and start a continuous IV infusion at a rate of 0.14 units/kg per hour.</td> </tr> <tr> <td class=\"indent1\">&#8226; If serum glucose does not fall by at least 50 to 70 mg/dL (2.8 to 3.9 mmol/L) in the first hour, double the rate of insulin infusion.</td> </tr> <tr> <td class=\"indent1\">&#8226; When the serum glucose reaches 200 mg/dL (11.1 mmol/L), it may be possible to decrease the infusion rate to 0.02 to 0.05 units/kg per hour.</td> </tr> <tr> <td class=\"indent1\">&#8226; Continue insulin infusion until ketoacidosis is resolved, serum glucose is below 200 mg/dL (11.1 mmol/L), and subcutaneous insulin is begun. </td> </tr> <tr> <td class=\"subtitle2_single\">Give sodium bicarbonate to patients with pH below 6.90: </td> </tr> <tr> <td class=\"indent1\">&#8226; If the arterial pH is below 6.90, give 100 mEq of sodium bicarbonate plus 20 mEq of potassium chloride in 400 mL sterile water over two hours; may be repeated if venous pH remains below 7.00.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DKA: diabetic ketoacidosis; BUN: blood urea nitrogen; IV: intravenous; ECF: extracellular fluid; Na: sodium;&nbsp;K: potassium.<br />* Patients with DKA usually present with a serum anion gap greater than 20 mEq/L (normal range approximately 3 to 10 mEq/L). However, the increase in anion gap is variable, being determined by several factors: the rate and duration of ketoacid production, the rate of metabolism of the ketoacids and their loss in the urine, and the volume of distribution of the ketoacid anions.<br />¶ Serum Na+ should be corrected for hyperglycemia; for each 100 mg/dL serum glucose exceeds 100 mg/dL (5.5 mmol/L), add 2 mEq to plasma Na+ for correction of Na+ value for hyperglycemia. A calculator to determine serum Na+ corrected for hyperglycemia is available separately in UpToDate.</div><div id=\"graphicVersion\">Graphic 57723 Version 4.0</div></div></div>"},"57724":{"type":"graphic_picture","displayName":"Hemifacial microsomia","title":"Hemifacial microsomia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hemifacial microsomia</div><div class=\"cntnt\"><img style=\"width:309px; height:396px;\" src=\"images/PEDS/57724_Hemifacial_microsomia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left-sided hemifacial microsomia. Bilateral hearing aids for mixed sensorineural and conductive loss.</div><div class=\"graphic_reference\">Reproduced with permission from: Gold DH, Weingeist TA. Color Atlas of the Eye in Systemic Disease. Baltimore: Lippincott Williams &amp; Wilkins, 2001. Copyright ©2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 57724 Version 2.0</div></div></div>"},"57725":{"type":"graphic_figure","displayName":"Musculoskeletal screen 4","title":"The pGALS musculoskeletal screen (continued)","html":"<div class=\"graphic\"><div style=\"width: 609px\" class=\"figure\"><div class=\"ttl\">The pGALS musculoskeletal screen (continued)</div><div class=\"cntnt\"><img style=\"width:589px; height:494px;\" src=\"images/PEDS/57725_Musculoskeletal_screen_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">pGALS: pediatric Gait Arms Legs Spine.</div><div class=\"graphic_reference\">Reproduced with permission from: Foster HE, Jandial S. pGALS - A Screening Examination of the Musculoskeletal System in School-Aged Children. Reports on the Rheumatic Diseases (Series 5), Hands On 15. Arthritis Research Campaign; 2008 June. Copyright &copy; 2008 Arthritis Research Campaign.</div><div id=\"graphicVersion\">Graphic 57725 Version 4.0</div></div></div>"},"57726":{"type":"graphic_waveform","displayName":"Intermediate case 17","title":"Intermediate case 17","html":"<div class=\"graphic normal\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Intermediate case 17</div><div class=\"cntnt\"><img style=\"width:506px; height:295px;\" src=\"images/CARD/57726_Intermediate_case_17.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 57726 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"57732":{"type":"graphic_table","displayName":"CCS stroke classification system","title":"Causative Classification System (CCS) of ischemic stroke etiology","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causative Classification System (CCS) of ischemic stroke etiology</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stroke mechanism</td> <td class=\"subtitle1\">Level of confidence</td> <td class=\"subtitle1\">Criteria</td> </tr> <tr> <td rowspan=\"7\"><strong>Large artery atherosclerosis</strong></td> <td rowspan=\"2\">Evident</td> <td>1. Either occlusive or stenotic (&#8805;50 percent diameter reduction or &#60;50 percent diameter reduction with plaque ulceration or thrombosis) vascular disease judged to be caused by atherosclerosis in the clinically relevant extracranial or intracranial arteries, <em>and</em></td> </tr> <tr> <td>2. The absence of acute infarction in vascular territories other than the stenotic or occluded artery</td> </tr> <tr> <td rowspan=\"3\">Probable</td> <td>1. History of &#8805;1 transient monocular blindness (TMB), TIA, or stroke from the territory of index artery affected by atherosclerosis within the last month, <em>or</em></td> </tr> <tr> <td>2. Evidence of near-occlusive stenosis or nonchronic complete occlusion judged to be caused by atherosclerosis in the clinically relevant extracranial or intracranial arteries (except for the vertebral arteries), <em>or</em></td> </tr> <tr> <td>3. The presence of ipsilateral and unilateral internal watershed infarctions or multiple, temporally separate, infarctions exclusively within the territory of the affected artery</td> </tr> <tr> <td rowspan=\"2\">Possible</td> <td>1. The presence of an atherosclerotic plaque protruding into the lumen and causing mild stenosis (&#60;50 percent) in the absence of any detectable plaque ulceration or thrombosis in a clinically relevant extracranial or intracranial artery and history of &#8805;2 TMB, TIA, or stroke from the territory of index artery affected by atherosclerosis, at least&nbsp;one event within the last month, <em>or</em></td> </tr> <tr> <td>2. Evidence for evident large artery atherosclerosis in the absence of complete diagnostic investigation for other mechanisms</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\"><strong>Cardio-aortic embolism</strong></td> <td>Evident</td> <td>The presence of a high-risk cardiac source of cerebral embolism</td> </tr> <tr> <td rowspan=\"2\">Probable</td> <td>1. Evidence of systemic embolism, <em>or</em></td> </tr> <tr> <td>2. The presence of multiple acute infarctions that have occurred closely related in time within both right and left anterior or both anterior and posterior circulations in the absence of occlusion or near-occlusive stenosis of all relevant vessels. Other diseases that can cause multifocal ischemic brain injury such as vasculitides, vasculopathies, and hemostatic or hemodynamic disturbances must not be present.</td> </tr> <tr> <td rowspan=\"2\">Possible</td> <td>1. The presence of a cardiac condition with low or uncertain primary risk of cerebral embolism, <em>or</em></td> </tr> <tr> <td>2. Evidence for evident cardio-aortic embolism in the absence of complete diagnostic investigation for other mechanisms</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\"><strong>Small artery occlusion</strong></td> <td>Evident</td> <td>Imaging evidence of a single and clinically relevant acute infarction &#60;20 mm in greatest diameter within the territory of basal or brainstem penetrating arteries in the absence of any other pathology in the parent artery at the site of the origin of the penetrating artery (focal atheroma, parent vessel dissection, vasculitis, vasospasm, etc)</td> </tr> <tr> <td rowspan=\"2\">Probable</td> <td>1. The presence of stereotypic lacunar transient ischemic attacks within the past week, <em>or</em></td> </tr> <tr> <td>2. The presence of a classical lacunar syndrome</td> </tr> <tr> <td rowspan=\"2\">Possible</td> <td>1. Presenting with a classical lacunar syndrome in the absence of imaging that is sensitive enough to detect small infarctions, <em>or</em></td> </tr> <tr> <td>2. Evidence for evident small artery occlusion in the absence of complete diagnostic investigation for other mechanisms</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\"><strong>Other causes</strong></td> <td>Evident</td> <td>The presence of a specific disease process that involves clinically appropriate brain arteries</td> </tr> <tr> <td>Probable</td> <td>A specific disease process that has occurred in clear and close temporal or spatial relationship to the onset of brain infarction such as arterial dissection, cardiac or arterial surgery, and cardiovascular interventions</td> </tr> <tr> <td>Possible</td> <td>Evidence for an evident other cause in the absence of complete diagnostic investigation for mechanisms listed above</td> </tr> <tr> <td rowspan=\"4\"><strong>Undetermined causes</strong></td> <td rowspan=\"3\">Unknown (no evident, probable, or possible criteria for the causes above)</td> <td> <p>Cryptogenic embolism:</p> <p>1. Angiographic evidence of abrupt cut-off consistent with a blood clot within otherwise angiographically normal looking intracranial arteries, <em>or</em></p> <p>2. Imaging evidence of complete recanalization of previously occluded artery, <em>or</em></p> <p>3. The presence of multiple acute infarctions that have occurred closely related in time without detectable abnormality in the relevant vessels</p> </td> </tr> <tr> <td>Other cryptogenic: Those not fulfilling the criteria for cryptogenic embolism</td> </tr> <tr> <td>Incomplete evaluation: The absence of diagnostic tests that, under the examiner's judgment, would have been essential to uncover the underlying etiology</td> </tr> <tr> <td>Unclassified</td> <td>The presence of &#62;1 evident mechanism in which there is either probable evidence for each, or no probable evidence to be able to establish a single cause</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Ay H, Benner T, Arsava EM. A computerized algorithm for etiologic classification of ischemic stroke: the Causative Classification of Stroke System. Stroke 2007; 38:2979.</div><div id=\"graphicVersion\">Graphic 57732 Version 4.0</div></div></div>"},"57733":{"type":"graphic_table","displayName":"Biochem clin feat MPS A","title":"Biochemical and clinical features of the mucopolysaccharidoses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Biochemical and clinical features of the mucopolysaccharidoses</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"14%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Common name</td> <td class=\"subtitle1\">Enzyme deficient</td> <td class=\"subtitle1\">Substrate accumulated</td> <td class=\"subtitle1\">Usual age at diagnosis</td> <td class=\"subtitle1\">Key distinct findings</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Skeletal disease, soft tissue storage, and a range of CNS disease</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">MPS I</td> <td>Hurler</td> <td rowspan=\"3\">Alpha-L-iduronidase</td> <td rowspan=\"3\">Heparan sulfate Dermatan sulfate</td> <td>1 to 2 years</td> <td>Developmental delay, severe coarse facies, hepatosplenomegaly, airway obstruction, dystosis multiplex, often placid and loving, death by age 10 years</td> </tr> <tr> <td>Hurler-Scheie</td> <td>1 to 5 years</td> <td>Micrognathia, toe walking, moderate coarse facies, possible normal intelligence, death by 20s</td> </tr> <tr> <td>Scheie</td> <td>3 to 15 years</td> <td>Aortic valve, joint disease, corneal clouding, normal facies, death in decades</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">MPS II</td> <td>Hunter severe</td> <td rowspan=\"2\">Iduronate sulfatase</td> <td rowspan=\"2\">Heparan sulfate Dermatan sulfate</td> <td>1 to 3 years</td> <td>No corneal clouding, physical disease similar to MPS I, aggressive behavior and developmental delay</td> </tr> <tr> <td>Hunter mild</td> <td>1 to 5 years</td> <td>Normal or near-normal intelligence</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">MPS VII</td> <td>Sly</td> <td rowspan=\"3\">Beta-glucoronidase</td> <td rowspan=\"3\">Heparan sulfate Dermatan sulfate</td> <td>Birth to 5 years</td> <td>Variable intermediate presentation similar to MPS I, death in teens</td> </tr> <tr> <td>Fetal hydrops</td> <td>In utero to birth</td> <td>Hydrops in utero</td> </tr> <tr> <td>Mild</td> <td>Teens to 20s</td> <td>Mild skeletal disease with death in decades</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Skeletal disease and soft tissue storage</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">MPS VI</td> <td>Maroteaux-Lamy severe</td> <td rowspan=\"2\">N-acetylgalacto- samine-4-sulfatase (arylsulfatase B)</td> <td rowspan=\"2\">Dermatan sulfate</td> <td>1 to 5 years</td> <td>Like MPS I without CNS disease, pachymeningitis cervicalis, death in teens and 20s</td> </tr> <tr> <td>Maroteaux-Lamy mild</td> <td>3 to 12 years</td> <td>Death in decades</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Skeletal, cartilage, and ligament disease primarily</td> </tr> <tr> <td class=\"indent1\">MPS IV A</td> <td>Morquio type A</td> <td>N-acetylgalactosamine-6-sulfatase</td> <td rowspan=\"2\">Keratan sulfate</td> <td rowspan=\"2\">1 to 5 years for severe forms</td> <td>Skeletal disease (similar to spondyloepiphysial dysplasia) with short stature, ligamentous laxity, corneal opacities</td> </tr> <tr> <td class=\"indent1\">MPS IV B</td> <td>Morquio type B</td> <td>Beta-galactosidase</td> <td>Skeletal disease with short stature</td> </tr> <tr> <td class=\"indent1\">MPS IX</td> <td>Natowicz syndrome</td> <td>Hyaluronidase</td> <td>Hyaluronan</td> <td>Only one case reported</td> <td>Nodular synovium, popliteal cyst, large joint effusion</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">CNS disease primarily, with less skeletal and soft tissue disease</td> </tr> <tr> <td class=\"indent1\">MPS III A</td> <td>Sanfilippo A</td> <td>Sulfamidase</td> <td>Heparan sulfate</td> <td>2 to 6 years</td> <td>Aggressive behavior followed by progressive neurologic decline</td> </tr> <tr> <td class=\"indent1\">MPS III B</td> <td>Sanfilippo B</td> <td>Alpha-N-acetylglucosaminidase</td> <td>Heparan sulfate</td> <td>2 to 6 years</td> <td>Aggressive behavior followed by progressive neurologic decline</td> </tr> <tr> <td class=\"indent1\">MPS III C</td> <td>Sanfilippo C</td> <td>GAC-acetylase</td> <td>Heparan sulfate</td> <td>2 to 6 years</td> <td>Aggressive behavior followed by progressive neurologic decline</td> </tr> <tr> <td class=\"indent1\">MPS III D</td> <td>Sanfilippo D</td> <td>N-acetylglucosamine-6-sulfatase</td> <td>Heparan sulfate</td> <td>2 to 6 years</td> <td>Aggressive behavior followed by progressive neurologic decline</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system; MPS: mucopolysaccharidoses.</div><div id=\"graphicVersion\">Graphic 57733 Version 6.0</div></div></div>"},"57734":{"type":"graphic_table","displayName":"Differential diagnosis of joint pain or swelling in children","title":"Differential diagnosis of joint pain or swelling in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of joint pain or swelling in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Single joint involvement </td> </tr> <tr> <td>Septic arthritis or osteomyelitis</td> </tr> <tr> <td>Juvenile idiopathic arthritis</td> </tr> <tr> <td>Lyme disease in endemic areas</td> </tr> <tr> <td>Reactive arthritis</td> </tr> <tr> <td>Hemarthrosis due to trauma, vascular malformation,&nbsp;or bleeding diathesis</td> </tr> <tr> <td>Malignancy such as acute lymphoblastic leukemia</td> </tr> <tr> <td class=\"subtitle1_single\">Multiple joint involvement </td> </tr> <tr> <td class=\"sublist1_start\">Acute rheumatic conditions</td> </tr> <tr> <td class=\"sublist1\">Systemic lupus erythematous </td> </tr> <tr> <td class=\"sublist1\">Juvenile dermatomyositis </td> </tr> <tr> <td class=\"sublist1\">Sarcoidosis </td> </tr> <tr> <td class=\"sublist1\">Sj&#246;gren's syndrome </td> </tr> <tr> <td class=\"sublist1\">Mixed connective tissue disease </td> </tr> <tr> <td class=\"sublist1\">IgA vasculitis (Henoch-Sch&#246;nlein purpura) </td> </tr> <tr> <td>Juvenile idiopathic arthritis</td> </tr> <tr> <td>Reactive arthritis</td> </tr> <tr> <td>Lyme disease</td> </tr> <tr> <td>Malignancy</td> </tr> <tr> <td>Immunodeficiency associated arthritis</td> </tr> <tr> <td>Inflammatory bowel associated arthritis</td> </tr> <tr> <td class=\"sublist1_start\">Other </td> </tr> <tr> <td class=\"sublist1\">Chronic recurrent multifocal osteomyelitis </td> </tr> <tr> <td class=\"sublist1\">Chronic infantile neurological cutaneous and arthritis syndrome (CINCA), also known as neonatal-onset multisystem inflammatory disease (NOMID) </td> </tr> <tr> <td class=\"subtitle1_single\">Prominent systemic features and joint pain </td> </tr> <tr> <td class=\"sublist1_start\">Acute rheumatic conditions</td> </tr> <tr> <td class=\"sublist1\">Systemic lupus erythematous </td> </tr> <tr> <td class=\"sublist1\">Mixed connective tissue disease </td> </tr> <tr> <td class=\"sublist1\">Kawasaki disease </td> </tr> <tr> <td class=\"sublist1\">IgA vasculitis (Henoch-Sch&#246;nlein purpura)</td> </tr> <tr> <td>Systemic juvenile idiopathic arthritis</td> </tr> <tr> <td>Macrophage activation syndrome</td> </tr> <tr> <td>Systemic vasculitis</td> </tr> <tr> <td>Malignancy such as neuroblastoma</td> </tr> <tr> <td>Reactive arthritis such as acute rheumatic fever</td> </tr> <tr> <td>Bacterial infection (tuberculosis, gonococcal infection, Lyme disease, and <em>Brucella</em> infection)</td> </tr> <tr> <td>Viral infection (Epstein-Barr and Hepatitis B virus)</td> </tr> <tr> <td>Parasitic infection (Malaria)</td> </tr> <tr> <td>Inflammatory bowel associated arthritis</td> </tr> <tr> <td class=\"sublist1_start\">Autoinflammatory disorders </td> </tr> <tr> <td class=\"sublist1\">Periodic fever syndromes </td> </tr> <tr> <td class=\"sublist1\">Chronic infantile neurological cutaneous and arthritis syndrome (CINCA), also known as neonatal-onset multisystem inflammatory disease (NOMID) </td> </tr> <tr> <td class=\"sublist1\">Cryopyrin-associated periodic syndromes (CAPS)</td> </tr> <tr> <td class=\"subtitle1_single\">Pain without joint swelling </td> </tr> <tr> <td class=\"sublist1_start\">Hip disease </td> </tr> <tr> <td class=\"sublist1\">Legg-Calv&#233;-Perthes disease </td> </tr> <tr> <td class=\"sublist1\">Slipped upper femoral epiphysis (slipped capital femoral epiphysis) </td> </tr> <tr> <td>Benign hypermobility syndrome</td> </tr> <tr> <td class=\"sublist1_start\">Inherited metabolic disorders </td> </tr> <tr> <td class=\"sublist1\">Gaucher disease </td> </tr> <tr> <td class=\"sublist1\">Sheie disease </td> </tr> <tr> <td class=\"sublist1_start\">Osteochondroses </td> </tr> <tr> <td class=\"sublist1\">Osgood-Schlatter disease </td> </tr> <tr> <td class=\"sublist1\">Scheuermann disease </td> </tr> <tr> <td class=\"sublist1_start\">Idiopathic pain syndromes </td> </tr> <tr> <td class=\"sublist1\">Growing pains </td> </tr> <tr> <td class=\"sublist1\">Complex regional pain syndrome </td> </tr> <tr> <td class=\"sublist1\">Fibromyalgia </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table includes the most common disorders to consider in the child with joint pain or swelling.</div><div class=\"graphic_footnotes\">IgA: immunoglobulin A.</div><div class=\"graphic_reference\">Courtesy of Yukiko Kimura, MD and Taunton R&nbsp;Southwood, MD, FRACP, FRCPA, FRCP, FRCPCH.</div><div id=\"graphicVersion\">Graphic 57734 Version 11.0</div></div></div>"},"57738":{"type":"graphic_table","displayName":"Laser treatment VAIN","title":"Laser treatment of vaginal intraepithelial neoplasia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laser treatment of vaginal intraepithelial neoplasia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\"><sup></sup>Author</td> <td class=\"subtitle1\">Year</td> <td class=\"subtitle1\">Patients treated</td> <td class=\"subtitle1\">Recurred after first treatment (percent)</td> <td class=\"subtitle1\">Follow-up range (months)</td> </tr> <tr> <td>Stafl<sup>[1]</sup></td> <td>1977</td> <td>8</td> <td>13</td> <td>3 to 12</td> </tr> <tr> <td>Petrilli<sup>[2]</sup></td> <td>1980</td> <td>10</td> <td>10</td> <td>2 to 12</td> </tr> <tr> <td>Capen<sup>[3]</sup></td> <td>1982</td> <td>15</td> <td>20</td> <td>4 to 28</td> </tr> <tr> <td>Townsend<sup>[4]</sup></td> <td>1982</td> <td>36</td> <td>22</td> <td>NR</td> </tr> <tr> <td>Jobson<sup>[5]</sup></td> <td>1983</td> <td>24</td> <td>17</td> <td>6 to 27</td> </tr> <tr> <td>Woodman<sup>[6]</sup></td> <td>1984</td> <td>14</td> <td>57</td> <td>6 to 60</td> </tr> <tr> <td>Curtin<sup>[7]</sup></td> <td>1985</td> <td>27</td> <td>11</td> <td>6 to 42</td> </tr> <tr> <td>Lenehan<sup>[8]</sup></td> <td>1986</td> <td>22</td> <td>50</td> <td>6 to 27</td> </tr> <tr> <td>Stuart<sup>[9]</sup></td> <td>1988</td> <td>22</td> <td>15</td> <td>6 to 38</td> </tr> <tr> <td>Ireland<sup>[10]</sup></td> <td>1988</td> <td>11</td> <td>45</td> <td>3 to 12</td> </tr> <tr> <td>Krebs<sup>[11]</sup></td> <td>1989</td> <td>22</td> <td>27</td> <td>12 to 84</td> </tr> <tr> <td>Audet-LaPointe<sup>[12]</sup></td> <td>1990</td> <td>32</td> <td>28</td> <td>7 to 85</td> </tr> <tr> <td>Hoffman<sup>[13]</sup></td> <td>1991</td> <td>26</td> <td>42</td> <td>11 to 56</td> </tr> <tr> <td>Diakomanolis<sup>[14]</sup></td> <td>1996</td> <td>25</td> <td>32</td> <td>35 to 82</td> </tr> <tr> <td>Sopracordevole<sup>[15]</sup></td> <td>1998</td> <td>24</td> <td>33</td> <td>3 to 12</td> </tr> <tr> <td>Campagnutta<sup>[16]</sup></td> <td>1999</td> <td>39</td> <td>67</td> <td>13 to 90</td> </tr> <tr> <td>Dodge<sup>[17]</sup></td> <td>2001</td> <td>42</td> <td>38</td> <td>&#62;7</td> </tr> <tr> <td>Perrotta<sup>[18]</sup></td> <td>2013</td> <td>21</td> <td>14</td> <td>12 to 78</td> </tr> <tr> <td>Gunderson<sup>[19]</sup></td> <td>2013</td> <td>34</td> <td>47</td> <td>1 to 194</td> </tr> <tr> <td>Piovano<sup>[20]</sup></td> <td>2015</td> <td>285&nbsp;</td> <td>25&nbsp;</td> <td>1 to 28&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NR: not reported.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Stafl A, et al. Am J Obstet Gynecol 1977; 128:128. </LI>&#xD;&#xA;<LI>Petrilli ES, et al. Am J Obstet Gynecol 1980; 138:321. </LI>&#xD;&#xA;<LI>Capen CV, et al. Am J Obstet Gynecol 1982; 15:973. </LI>&#xD;&#xA;<LI>Townsend DE, et al. Am J Obstet Gynecol 1982; 143:565. </LI>&#xD;&#xA;<LI>Jobson VW, et al. Obstet Gynecol 1983; 62:90. </LI>&#xD;&#xA;<LI>Woodman CB, et al. Br J Obstet Gynaecol 1984; 91:707. </LI>&#xD;&#xA;<LI>Curtin JP, et al. J Reprod Med 1985; 30:942. </LI>&#xD;&#xA;<LI>Lenehan PM, et al. Obstet Gynecol 1986; 68:333.</LI>&#xD;&#xA;<LI>Stuart GC, et al. Am J Obstet Gynecol 1988; 158:240. </LI>&#xD;&#xA;<LI>Ireland D, et al. Br J Obstet Gynaecol 1988; 95:973. </LI>&#xD;&#xA;<LI>Krebs HB. Obstet Gynecol 1989; 73:657. </LI>&#xD;&#xA;<LI>Audet-LaPointe P, et al. Gynecol Oncol 1990; 36:232. </LI>&#xD;&#xA;<LI>Hoffman MS, et al. Am J Obstet Gynecol 1991; 165:1342. </LI>&#xD;&#xA;<LI>Diakomanolis E, et al. Eur J Gynaecol Oncol 1996: 17:389. </LI>&#xD;&#xA;<LI>Sopracordevole F. et al. Minerva Ginecol&nbsp;1998; 50:507. </LI>&#xD;&#xA;<LI>Campagnutta E, et al. Clin Exp Obstet Gynecol 1999; 26:127. </LI>&#xD;&#xA;<LI>Dodge JA, et al. Gynecol Oncol 2001; 83:363. </LI>&#xD;&#xA;<LI>Perrotta M, et al. J Low Genit Tract Dis 2013; 17:23. </LI>&#xD;&#xA;<LI>Gunderson CC, et al. Am J Obstet Gynecol&nbsp;2013; 208:410<STRONG innerHtml>.</STRONG></LI>&#xD;&#xA;<LI>Piovano E, et al. Eur J Gynaecol Oncol 2015; 36:383.</LI></OL></div><div id=\"graphicVersion\">Graphic 57738 Version 5.0</div></div></div>"},"57739":{"type":"graphic_table","displayName":"Iron deficiency evolution","title":"Laboratory findings during the evolution of iron deficiency anemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory findings during the evolution of iron deficiency anemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Storage iron deficiency</td> <td class=\"subtitle1\">Iron-limited erythropoiesis</td> <td class=\"subtitle1\">Iron-deficiency anemia</td> </tr> <tr> <td>Hemoglobin</td> <td>Normal</td> <td>Normal</td> <td>Decreased</td> </tr> <tr> <td>Transferrin saturation*</td> <td>Normal</td> <td>Decreased</td> <td>Decreased</td> </tr> <tr> <td>Erythrocyte protoporphyrin</td> <td>Normal</td> <td>Increased</td> <td>Increased</td> </tr> <tr> <td>Plasma ferritin<sup>&#182;</sup></td> <td>Decreased</td> <td>Decreased</td> <td>Decreased</td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Reticulocyte hemoglobin content (CHr) or equivalent (Ret-He)</span>&nbsp;</td> <td>Normal&nbsp;</td> <td>Decreased</td> <td>Decreased</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Transferrin saturation is calculated as the serum iron/total iron binding capacity (SI/TIBC).<br />¶ Ferritin is an acute phase reactant, and serum levels are increased by liver disease, inflammation, and malignancy. In these settings, it is not a good reflection of iron stores.<br /></div><div id=\"graphicVersion\">Graphic 57739 Version 5.0</div></div></div>"},"57740":{"type":"graphic_waveform","displayName":"EMG neurogenic and myopathic","title":"Electromyography* comparing normal, neurogenic, and myopathic features","html":"<div class=\"graphic\"><div style=\"width: 595px\" class=\"figure\"><div class=\"ttl\">Electromyography* comparing normal, neurogenic, and myopathic features</div><div class=\"cntnt\"><img style=\"width:575px; height:353px;\" src=\"images/RHEUM/57740_EMG_neurogenic_and_myopathi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">1. At rest (spontaneous activity): a. fibrillations, b. positive sharp waves, c. fasciculation.<BR>2. Slight effort (motor unit potentials): d. giant polyphasic, e. BSAPS (brief-small-abundant polyphasic).<BR>3. Strong effort (interference pattern): f. full, g. reduced units, h. reduced amplitude.</div><div class=\"graphic_footnotes\">* helpful in selecting denervated muscles in radiculopathies (myotomal), mononeuropathies (distal to lesion), generalized neuropathies (distal muscles), and myopathies</div><div id=\"graphicVersion\">Graphic 57740 Version 3.0</div></div></div>"},"57741":{"type":"graphic_table","displayName":"ABCD rule of dermoscopy","title":"ABCD rule of dermoscopy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ABCD rule of dermoscopy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Score range</td> <td class=\"subtitle1\" colspan=\"2\">Criteria</td> <td class=\"subtitle1\">Points</td> <td class=\"subtitle1\">Multiply points by factor</td> <td class=\"subtitle1\">FDS* range</td> </tr> <tr> <td rowspan=\"3\">0-2</td> <td rowspan=\"3\"><strong>A</strong>symmetry</td> <td>No asymmetry</td> <td>0</td> <td rowspan=\"3\">x 1.3</td> <td rowspan=\"3\">0-2.6</td> </tr> <tr> <td>Mono-axial asymmetry</td> <td>1</td> </tr> <tr> <td>Bi-axial asymmetry</td> <td>2</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"9\">0-8</td> <td rowspan=\"9\"><strong>B</strong>order</td> <td>No sharp border</td> <td>0</td> <td rowspan=\"9\">x 0.1</td> <td rowspan=\"9\">0-0.8</td> </tr> <tr> <td>One segment with sharp border</td> <td>1</td> </tr> <tr> <td>Two segments with sharp border</td> <td>2</td> </tr> <tr> <td>Three segments with sharp border</td> <td>3</td> </tr> <tr> <td>Four segments with sharp border</td> <td>4</td> </tr> <tr> <td>Five segments with sharp border</td> <td>5</td> </tr> <tr> <td>Six segments with sharp border</td> <td>6</td> </tr> <tr> <td>Seven segments with sharp border</td> <td>7</td> </tr> <tr> <td>Eight segments with sharp border</td> <td>8</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\">1-6</td> <td rowspan=\"6\"><strong>C</strong>olor</td> <td>White</td> <td>1</td> <td rowspan=\"6\">x 0.5</td> <td rowspan=\"6\">0.5-3</td> </tr> <tr> <td>Red</td> <td>1</td> </tr> <tr> <td>Light brown</td> <td>1</td> </tr> <tr> <td>Dark brown</td> <td>1</td> </tr> <tr> <td>Blue-gray</td> <td>1</td> </tr> <tr> <td>Black</td> <td>1</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">1-5</td> <td rowspan=\"5\"><strong>D</strong>ermoscopic structure</td> <td>Network</td> <td>1</td> <td rowspan=\"5\">x 0.5</td> <td rowspan=\"5\">0.5-2.5</td> </tr> <tr> <td>Aggregated globules</td> <td>1</td> </tr> <tr> <td>Dots</td> <td>1</td> </tr> <tr> <td>Structureless areas</td> <td>1</td> </tr> <tr> <td>Branched streaks</td> <td>1</td> </tr> <tr class=\"divider_top\"> <td colspan=\"5\" align=\"right\"><strong>FDS range:</strong></td> <td><strong>1-8.9</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* FDS: final dermoscopy score. &lt;4.75 = benign; 4.75 to 5.45 = suspicious; &gt;5.45 = malignant.</div><div class=\"graphic_reference\">Original table modified for this publication. Nachbar F, Stolz W, Merkle T, et al. The ABCD rule of dermatoscopy. High prospective value in the diagnosis of doubtful melanocytic skin lesions. J Am Acad Dermatol 1994; 30:551. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 57741 Version 4.0</div></div></div>"},"57744":{"type":"graphic_picture","displayName":"Halo nevus 2","title":"Halo nevus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Halo nevus</div><div class=\"cntnt\"><img style=\"width:380px; height:273px;\" src=\"images/DERM/57744_Halo_nevus_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An inflamed compound nevus is encircled by a white halo of depigmentation.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 57744 Version 2.0</div></div></div>"},"57745":{"type":"graphic_table","displayName":"MDMA-ecstasy-intoxication - Rapid overview","title":"MDMA (ecstasy) intoxication in adolescents and adults: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">MDMA (ecstasy) intoxication in adolescents and adults: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span style=\"color: #ff0000;\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">Clinical features</td> </tr> <tr> <td>MDMA is a serotonergic amphetamine that generally causes feelings of euphoria, empathy, excitement, and wellbeing</td> </tr> <tr> <td>Patients with MDMA toxicity may exhibit CNS agitation, hypertension, tachycardia, and hyperthermia</td> </tr> <tr> <td>MDMA intoxication can cause severe hyponatremia, seizures, and obtundation. Serotonin syndrome can occur.</td> </tr> <tr> <td class=\"subtitle1_single\">Laboratory evaluation</td> </tr> <tr> <td class=\"sublist1_start\">Obtain the following:</td> </tr> <tr> <td class=\"sublist1\">Fingerstick glucose, electrocardiogram, acetaminophen and aspirin levels, and pregnancy test (when appropriate)</td> </tr> <tr> <td class=\"sublist1\">Basic chemistries, to assess serum sodium and creatinine</td> </tr> <tr> <td class=\"sublist1\">Creatinine kinase, for evidence of rhabdomyolysis</td> </tr> <tr> <td class=\"sublist1\">Liver function testing and coagulation profiles in severely ill patients</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td>Secure airway, breathing, and circulation: standard rapid sequence medications may be used; treat severe hypertension initially with benzodiazepines (eg, lorazepam, 1 to 2 mg IV push, may repeat as needed; or in the absence of IV access midazolam 3 to 5 mg intramuscularly, may repeat as needed)</td> </tr> <tr> <td>Give one dose of activated charcoal (1 g/kg; maximum dose 50 g) for ingestions less than one hour if airway protected</td> </tr> <tr> <td>Agitation and/or seizures: give benzodiazepines (eg, lorazepam 1 to 2 mg IV push or midazolam 3 to 5 mg IM; may repeat as needed); <strong>DO NOT</strong> give butyrophenones (eg, haloperidol); <strong>DO NOT</strong> give phenytoin</td> </tr> <tr> <td>Chest pain: give oxygen, aspirin and nitroglycerin if chest pain does not respond to benzodiazepines; <strong>DO NOT</strong> administer beta-blocking agents</td> </tr> <tr> <td>Hyperthermia: active external cooling, benzodiazepines; <strong>DO NOT</strong> give antipyretics</td> </tr> <tr> <td>Hyponatremia: fluid restriction if hyponatremia is mild or moderate (above 115 mEq/dL)</td> </tr> <tr> <td>Hyponatremia with persistent seizure: benzodiazepines (eg, lorazepam 1 to 2 mg IV push or midazolam 3 to 5 mg IM; may repeat as needed); hypertonic saline (3 percent or 513 mEq/L), if serum sodium 115 mEq/dL or less, give 100 mL as IV bolus; if seizures persist, give one or two additional doses of 100 mL, with each dose given over 10 minutes; <strong>DO NOT</strong> give additional hypertonic or normal saline; monitor serum sodium closely; <strong>DO NOT</strong> give phenytoin</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MDMA: 3,4-methylenedioxymethamphetamine.</div><div id=\"graphicVersion\">Graphic 57745 Version 13.0</div></div></div>"},"57746":{"type":"graphic_figure","displayName":"NB lung fluid clearance","title":"Resorption of alveolar fluid at birth: Cellular mechanisms","html":"<div class=\"graphic\"><div style=\"width: 634px\" class=\"figure\"><div class=\"ttl\">Resorption of alveolar fluid at birth: Cellular mechanisms</div><div class=\"cntnt\"><img style=\"width:614px; height:310px;\" src=\"images/PEDS/57746_NB_lung_fluid_clearance.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Na enters the cell through the apical surface of both ATI and ATII cells via amiloride-sensitive epithelial Na channels (ENaC), both highly selective channels (HSC) and nonselective channels (NSC), and via cyclic nucleotide gated channels (seen only in ATI cells). Electroneutrality is conserved with chloride movement through cystic fibrosis transmembrane conductance regulator (CFTR) or through chloride channels (CLC) in ATI and ATII cells, and/or paracellularly through tight junctions. The increase in cell Na stimulates Na-K-ATPase activity on the basolateral aspect of the cell membrane, which drives out three Na ions in exchange for two K ions, a process that can be blocked by the cardiac glycoside ouabain. If the net ion movement is from the apical surface to the interstitium, an osmotic gradient would be created, which would in turn direct water transport in the same direction, either through aquaporins or by diffusion.</div><div class=\"graphic_reference\">Reprinted with permission from: Jain L. Respiratory morbidity in late-preterm infants: prevention is better than cure. Am J Perinatol 2008; 25:75. Copyright &#169; 2008 Thieme Medical Publishers, Inc.</div><div id=\"graphicVersion\">Graphic 57746 Version 8.0</div></div></div>"},"57748":{"type":"graphic_diagnosticimage","displayName":"Untreated early ankylosis","title":"Panoramic radiograph: Ankylosis of second primary molar","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Panoramic radiograph: Ankylosis of second primary molar</div><div class=\"cntnt\"><img style=\"width:401px; height:255px;\" src=\"images/PEDS/57748_Untreated_early_ankylosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This panoramic radiograph shows the result of untreated early ankylosis of the secondary primary molar that resulted in severe submergence of the primary teeth and displacement of the permanent premolar (see arrows).</div><div class=\"graphic_reference\">Reproduced with permission from: Wright JT. Pediatr Clin North Am 2000; 47:975. Copyright WB Saunders 2000.</div><div id=\"graphicVersion\">Graphic 57748 Version 6.0</div></div></div>"},"57752":{"type":"graphic_movie","displayName":"Partial anomalous pulmonary venous connection","title":"Partial anomalous pulmonary vein connection to the innominate vein","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Partial anomalous pulmonary vein connection to the innominate vein</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/57752_PAPVenouscnnctnvid.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:727px; height:492px;\" src=\"images/CARD/57752_PAPVenouscnnctnimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A catheter injects contrast into the left pulmonary artery. The left upper lobe segment drains to a vertical vein that connects to the distal innominate vein before returning to the right atrium.</div><div class=\"graphic_footnotes\">SVC: superior vena cava.</div><div class=\"graphic_reference\">Courtesy of Dr. Brian Soriano.</div><div id=\"graphicVersion\">Graphic 57752 Version 4.0</div></div></div>"},"57755":{"type":"graphic_table","displayName":"Severity of bone marrow failure in FA","title":"Severity of bone marrow failure in patients with Fanconi anemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Severity of bone marrow&nbsp;failure in patients with Fanconi anemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Absolute neutrophil count<br /> (per microL)</td> <td class=\"subtitle1\">Platelet count<br /> (per microL)</td> <td class=\"subtitle1\">Hemoglobin concentration<br /> (g/dL)</td> </tr> <tr> <td><strong>Mild</strong></td> <td class=\"centered\">&#8805;1000</td> <td class=\"centered\">&#8805;50,000</td> <td class=\"centered\">&#8805;10</td> </tr> <tr> <td><strong>Moderate</strong></td> <td class=\"centered\">500 to 1000</td> <td class=\"centered\">30,000 to &#60;50,000</td> <td class=\"centered\">8 to 10</td> </tr> <tr> <td><strong>Severe</strong></td> <td class=\"centered\">&#60;500</td> <td class=\"centered\">&#60;30,000</td> <td class=\"centered\">&#60;8</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate for additional information regarding the severity of bone marrow failure and its implications for treatment.</div><div class=\"graphic_reference\">Adapted from Fanconi anemia: Guidelines for diagnosis and management, 3rd edition. Eiler ME, Frohnmayer D, Frohnmayer L, et al, Eds, Eugene OR, 2008. Available at: http://www.fanconi.org/images/uploads/other/Guidelines_for_Diagnosis_and_Management.pdf.</div><div id=\"graphicVersion\">Graphic 57755 Version 7.0</div></div></div>"},"57756":{"type":"graphic_picture","displayName":"Use of the scoliometer","title":"Use of the scoliometer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Use of the scoliometer</div><div class=\"cntnt\"><img style=\"width:417px; height:267px;\" src=\"images/PEDS/57756_Use_of_the_scoliometer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The scoliometer is run along the patient's spine from caudad to cephalad while the patient is in the position assumed for the Adams forward bend test. In the above photograph, the right thoracic prominence causes the right side of the scoliometer to deviate upward and the ball to deviate to the left. The angle of trunk rotation can also be measured with a scoliometer app on a smartphone.</div><div class=\"graphic_reference\">Courtesy of Susan A Scherl, MD.</div><div id=\"graphicVersion\">Graphic 57756 Version 3.0</div></div></div>"},"57758":{"type":"graphic_algorithm","displayName":"Management of acute epicondylitis algorithm","title":"Management of acute epicondylitis algorithm","html":"<div class=\"graphic\"><div style=\"width: 597px\" class=\"figure\"><div class=\"ttl\">Management of acute epicondylitis algorithm</div><div class=\"cntnt\"><img style=\"width:577px; height:627px;\" src=\"images/EM/57758_Epicondylitis_acute_algo.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 57758 Version 3.0</div></div></div>"},"57759":{"type":"graphic_table","displayName":"Clin features panc neoplasm","title":"Key demographic and clinical features of patients with pancreatic cystic neoplasms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key demographic and clinical features of patients with pancreatic cystic neoplasms</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Serous cystic tumor</td> <td class=\"subtitle1\">Mucinous neoplasm</td> <td class=\"subtitle1\">Main-duct intraductal papillary mucinous neoplasm</td> <td class=\"subtitle1\">Branch-duct intraductal papillary mucinous neoplasm</td> <td class=\"subtitle1\">Solid pseudopapillary neoplasm</td> </tr> <tr> <td><strong>Age of presentation</strong></td> <td>Variable, usually 5th to 7th decade</td> <td>Variable, usually 5th to 7th decade</td> <td>Variable, usually 5th to 7th decade</td> <td>Variable, usually 5th to 7th decade</td> <td>Usually 2nd to 3rd decade</td> </tr> <tr> <td><strong>Gender distribution</strong></td> <td>Females &#62; males</td> <td>Almost exclusively females</td> <td>Females = males</td> <td>Females = males</td> <td>Females &#62; males</td> </tr> <tr> <td><strong>Typical clinical presentation</strong></td> <td>Incidental or abdominal pain or mass effect</td> <td>Incidental or abdominal pain or malignancy related</td> <td>Incidental or pancreatitis or pancreatic insufficiency or malignancy related</td> <td>Incidental or pancreatitis or malignancy related</td> <td>Incidental or abdominal pain or mass effect</td> </tr> <tr> <td><strong>Typical imaging characteristics</strong></td> <td> <p>Microcystic/ honeycomb appearance</p> <p>Oligocystic appearance less common</p> </td> <td> <p>Unilocular or septated cyst +/- wall calcifications</p> <p>Solid component, if present, may suggest malignancy</p> </td> <td> <p>Dilated main pancreatic duct +/- parenchymal atrophy</p> <p>Solid component, if present, may suggest malignancy</p> </td> <td> <p>Dilated pancreatic duct branch or branches</p> <p>Solid component, if present, may suggest malignancy</p> </td> <td>Solid and cystic mass +/- calcifications</td> </tr> <tr> <td><strong>Typical aspirate characteristic</strong></td> <td>Thin, often bloody</td> <td>Viscous</td> <td>Viscous</td> <td>Viscous or thin</td> <td>Bloody</td> </tr> <tr> <td><strong>Typical cytology findings</strong></td> <td>Cuboidal cells that stain positive for glycogen; yield &#60;50%</td> <td> <p>Columnar cells with variable atypia</p> <p>Stains positive for mucin; yield &#60;50%</p> <p>High yield from solid component for malignancy</p> </td> <td> <p>Columnar cells with variable atypia</p> <p>Stains positive for mucin; yield &#60;50%</p> <p>High yield from solid component for malignancy</p> </td> <td> <p>Columnar cells with variable atypia</p> <p>Stains positive for mucin; yield &#60;50%</p> <p>High yield from solid component for malignancy</p> </td> <td> <p>Characteristic branching papillae with myxoid stroma</p> <p>High yield from solid component</p> </td> </tr> <tr> <td><strong>Typical carcinoembryonic antigen (CEA) level</strong></td> <td>&#60;5 to 20 ng/mL in majority of lesions</td> <td>&#62;200 ng/mL in approximately 75% of lesions</td> <td>&#62;200 ng/mL in approximately 75% of lesions</td> <td>&#62;200 ng/mL in approximately 75% of lesions</td> <td>Insufficient data</td> </tr> <tr> <td><strong>Typical DNA analysis</strong></td> <td>Allelic loss affecting chromosome 3p and VHL mutation specific</td> <td> <p>K-ras mutation specific (&#62;90%), not sensitive (&#60;50%)</p> <p>High DNA amount or high-amplitude allelic loss seen in malignancy</p> </td> <td> <p>K-ras and GNAS mutation specific (&#62;90%), not sensitive (&#60;50%)</p> <p>High DNA amount or high-amplitude allelic loss seen in malignancy</p> </td> <td> <p>K-ras and GNAS mutation specific (&#62;90%), not sensitive (&#60;50%)</p> <p>High DNA amount or high-amplitude allelic loss seen in malignancy</p> </td> <td>CTNNB1 mutation specific</td> </tr> <tr> <td><strong>Relative malignant potential</strong></td> <td>Negligible</td> <td>Moderate</td> <td>High</td> <td>Low to moderate</td> <td>Moderate to high</td> </tr> <tr> <td><strong>Treatment</strong></td> <td>Resect if symptomatic</td> <td>Resection</td> <td>Resection and post-resection surveillance</td> <td> <p>Closely monitor or resect</p> <p>Post-resection surveillance required</p> </td> <td>Resection</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified from: <br /><OL>&#xD;&#xA;<LI>Khalid A, Brugge WR. ACG practice guidelines for the diagnosis and management of neoplastic pancreatic cysts. Am J Gastroenterol 2007; 102:2339. </LI>&#xD;&#xA;<LI>Wu J, Jiao Y, Dal Molin M, et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A 2011; 108:21188.</LI></OL></div><div id=\"graphicVersion\">Graphic 57759 Version 7.0</div></div></div>"},"57760":{"type":"graphic_figure","displayName":"Uterus position","title":"Normal variations in uterine position","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal variations in uterine position</div><div class=\"cntnt\"><img style=\"width:449px; height:506px;\" src=\"images/OBGYN/57760_Uterus_position_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Position of the uterus:<br> (A) Anteverted and markedly anteflexed.<br> (B) Anteverted and anteflexed.<br> (C) Retroverted and retroflexed.<br> (D) Retroverted and markedly retroflexed.</div><div class=\"graphic_reference\">Reproduced with permission from: Lippincott Williams &amp; Wilkins. Copyright &#169; 2008.</div><div id=\"graphicVersion\">Graphic 57760 Version 4.0</div></div></div>"},"57761":{"type":"graphic_table","displayName":"Doses asthma control meds other than ICS for kids","title":"Usual doses for long-term asthma controller medications other than inhaled glucocorticoids in children*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Usual doses for long-term asthma controller medications other than inhaled glucocorticoids in children*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"15%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Dose form</td> <td class=\"subtitle1\">0 to 4 years</td> <td class=\"subtitle1\">5 to 11 years</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Leukotriene receptor antagonists (LTRAs)<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Montelukast</td> <td> <p>4 mg or 5 mg chewable tablet</p> 4 mg granule packets</td> <td>4 mg once daily at bedtime (1 to 5 years of age)</td> <td>5 mg once daily at bedtime (6 to 14 years of age)</td> <td>When LTRA treatment is indicated, montelukast is preferred.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Zafirlukast</td> <td>10 mg tablet</td> <td>Safety and efficacy not established</td> <td>10 mg twice per day on empty stomach</td> <td> <p>Zafirlukast has potential drug interactions and a small risk of hepatotoxicity.</p> Food decreases bioavailability of zafirlukast; take at least one hour before or two hours after meals.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Combined inhaled glucocorticoids and long-acting beta agonists (LABAs)<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Fluticasone-salmeterol</td> <td>DPI 100 mcg/50 mcg</td> <td rowspan=\"2\">Safety and efficacy not established</td> <td>One inhalation twice a day</td> <td rowspan=\"2\"> <p>Most children &#60;4 years of age cannot provide sufficient inspiratory flow for adequate lung delivery of DPI.</p> Do not exceed dose shown.</td> </tr> <tr> <td>MDI 45 mcg/21 mcg</td> <td>Two puffs twice per day</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Budesonide-formoterol</td> <td>HFA MDI 80 mcg/4.5 mcg</td> <td>Safety and efficacy not established</td> <td>One to two puffs twice per day</td> <td> <p>Onset of formoterol is similar to albuterol.</p> <p>There have been no clinical trials in children &#60;4 years of age.</p> Do not exceed dose shown.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Systemic glucocorticoids</td> </tr> <tr> <td class=\"indent1\">Methylprednisolone</td> <td class=\"divider_bottom\" rowspan=\"3\">For detail, refer to Lexicomp drug specific monographs included with UpToDate</td> <td class=\"divider_bottom\" rowspan=\"3\">0.25 to 2 mg/kg orally per day or every other day given in the morning. Titrate to the lowest acceptable dose that maintains control.</td> <td class=\"divider_bottom\" rowspan=\"3\">0.25 to 2 mg/kg orally per day or every other day given in the morning. Titrate to the lowest acceptable dose that maintains control.</td> <td class=\"divider_bottom\" rowspan=\"3\"> <p><strong>(Applies to all three glucocorticoids)</strong></p> <p>Due to their toxic effects, systemic glucocorticoids should be used only rarely for long-term control of asthma, ie, in those few patients with poorly-controlled severe persistent asthma despite compliance with maximized ICS and other pharmacologic and preventive therapies. Refer to topic.</p> The use and dosing of systemic glucocorticoids for the treatment of acute asthma exacerbations is reviewed elsewhere. Refer to separate topic reviews on acute asthma exacerbation in children, emergency department, and inpatient management.</td> </tr> <tr> <td class=\"indent1\">Prednisolone</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Prednisone</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Chromones</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Cromolyn sodium (sodium cromoglycate)</td> <td>5 mg/puff CFC free MDI (not available in the United States)<sup>&#9674;</sup></td> <td>Safety and efficacy not established</td> <td>Two puffs four times per day</td> <td class=\"divider_bottom\" rowspan=\"3\"> <p>Less effective than ICS in children. Add-on to ICS is not recommended. Refer to topic.</p> <p>Four- to six-week trial may be needed to determine maximum benefit. May cause bronchospasm. Premedication with bronchodilator may be needed.</p> <p>Use of spacer device may substantially decrease amount of drug delivered.</p> Once control is achieved, the frequency of dosing may be reduced.</td> </tr> <tr> <td>20 mg/ampule solution for nebulization</td> <td> <p>20 mg four times per day</p> Safety and efficacy not established in children aged &#60;2 years</td> <td>20 mg four times per day</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Nedocromil</td> <td>2 mg/puff CFC free inhaler (not available in the United States)<sup>&#9674;</sup></td> <td>Safety and efficacy not established in children aged &#60;6 years</td> <td>Two puffs four times per day</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Anti-IgE therapy: Refer to separate topic on anti-IgE therapy</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Methylxanthines</td> </tr> <tr> <td class=\"indent1\">Theophylline</td> <td>Liquids, sustained-release tablets and capsules</td> <td> <p>Starting dose for patients without risk factors for decreased theophylline clearance ~10 mg/kg per day (initial maximum 300 mg per day).</p> <p class=\"sublist1_start\">Usual maximum following titration:</p> <p class=\"sublist1\">&#60;1 year of age: 0.2 x (age in weeks) + 5 = dose in mg/kg per day</p> <p class=\"sublist1\">&#8805;1 year of age: 16 mg/kg per day (maximum 600 mg per day)</p> </td> <td> <p>Starting dose for patients without risk factors for decreased theophylline clearance ~10 mg/kg/day (initial maximum 300 mg per day).</p> <p class=\"sublist1_start\">Usual maximum following titration:</p> <p class=\"sublist1\">16 mg/kg/day (maximum 600 mg per day)</p> </td> <td> <p>Due to risk of toxic effects, requirement of frequent serum concentration monitoring, and significant drug-drug interactions, theophylline is infrequently used.</p> <p>Monitoring and dose adjustment is required to maintain peak serum levels of 5 to 15 mcg/mL at steady-state.</p> For additional information including approach to dose adjustment, refer to topic on theophylline use in asthma.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LTRA: leukotriene receptor antagonists; LABA: long-acting beta agonists; DPI: dry-powder inhaler; MDI: metered-dose inhaler; HFA: hydrofluoroalkane (inhaler propellant); ICS: inhaled glucocorticoid; CFC: chlorofluorocarbon.<br />* Doses are provided for those products that have been approved by the US Food and Drug Administration or have sufficient clinical trial safety and efficacy data in the appropriate age ranges to support their use.<br />¶ Zileuton is available in the United States and some other countries. Its use is not recommended in children.<br />Δ LABA should only be used in combination products with inhaled glucocorticoids. Other ICS-LABA combination products are available. Some ICS-LABA combination inhalers may be approved for use in children in countries other than the United States.<br /><FONT class=lozenge>◊</FONT> Chromone DPI and MDI inhalers with different strengths than those listed in this table are available in some countries other than the United States. Consult local product information.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</li>&#xD;&#xA;    <li>Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Updated 2012. Available at <a href=\"http://www.ginasthma.org/\" target=\"_blank\">www.ginasthma.org</a>.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 57761 Version 6.0</div></div></div>"},"57764":{"type":"graphic_figure","displayName":"Codons","title":"Codon structure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Codon structure</div><div class=\"cntnt\"><img style=\"width:382px; height:370px;\" src=\"images/PC/57764_Codons.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The genetic code.</div><div id=\"graphicVersion\">Graphic 57764 Version 3.0</div></div></div>"},"57765":{"type":"graphic_picture","displayName":"Lentigo maligna melanoma 4","title":"Lentigo maligna melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lentigo maligna melanoma</div><div class=\"cntnt\"><img style=\"width:380px; height:396px;\" src=\"images/DERM/57765_Lent_malig_melan_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lentigo maligna melanoma on the left cheek of a 68-year-old man with characteristic nodule signifying dermal invasion in the precursor surrounding in situ lesion (lentigo maligna).</div><div id=\"graphicVersion\">Graphic 57765 Version 1.0</div></div></div>"},"57766":{"type":"graphic_diagnosticimage","displayName":"Clonorchiasis sonogram","title":"Clonorchiasis sonogram","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Clonorchiasis sonogram</div><div class=\"cntnt\"><img style=\"width:548px; height:400px;\" src=\"images/ID/57766_Clonorchiasis_sonogram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Liver sonograms of clonorchiasis.<br> (A) In a 57-year-old man, transverse scan of the left hepatic lobe, showing mild dilatation of the intrahepatic bile ducts (arrows).<br> (B) In a 56-year-old man with the increased periductal echogenicity (arrows) along the dilated intrahepatic bile ducts.<br> (C) Oblique scan of the gallbladder of a heavily-infected Chinese man with several floating echogenic foci (arrows), which probably indicate worms or desquamated materials.<br> (D) Mild dilatation of the intrahepatic bile ducts in the central liver of a cured 60-year-old man.</div><div class=\"graphic_reference\">Reproduced with permission from: Choi D, Hong ST. Imaging diagnosis of clonorchiasis. Korean J Parasitol 2007; 45:77. Copyright &#169; 2007 Korean Society for Parasitology.</div><div id=\"graphicVersion\">Graphic 57766 Version 1.0</div></div></div>"},"57768":{"type":"graphic_movie","displayName":"VSD short axis color Doppler echo","title":"Echocardiogram (short-axis view) of a membranous ventricular septal defect","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echocardiogram (short-axis view) of a membranous ventricular septal defect</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/57768_shaxcvsdconv.mp4\" style=\"width:328px;height:248px\"></div><img style=\"width:265px; height:437px;\" src=\"images/CARD/57768_shaxcvsd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The short-axis view from the 2D echocardiogram with color flow Doppler shows a ventricular septal defect of the membranous part of the interventricular septum with shunting of blood primarily in systole and a smaller amount in diastole.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 57768 Version 4.0</div></div></div>"},"57770":{"type":"graphic_figure","displayName":"Schematic of the breast and regional lymph nodes","title":"Schematic of the breast and regional lymph nodes","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Schematic of the breast and regional lymph nodes</div><div class=\"cntnt\"><img style=\"width:462px; height:468px;\" src=\"images/ONC/57770_Breast_reg_lymph_nodes_ed.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 57770 Version 12.0</div></div></div>"},"57772":{"type":"graphic_table","displayName":"Progn strat adv HCC","title":"Prognostic stratifications for advanced hepatocellular carcinoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prognostic stratifications for advanced hepatocellular carcinoma</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\" colspan=\"3\">\r\n  \r\n   Multivariate Cox model and the points assigned to each category of prognostic factors in the new prognostic score system\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"2\">\r\n  \r\n   Characteristics\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   Point\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle3_left\" colspan=\"3\">\r\n  \r\n   Patient characteristics\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" rowspan=\"2\">\r\n  \r\n   Ascites\r\n  \r\n   </td>\r\n  \r\n   <td>Yes</td>\r\n  \r\n   <td>2</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>No</td>\r\n  \r\n   <td>0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" rowspan=\"2\">\r\n  \r\n   Abdominal pain\r\n  \r\n   </td>\r\n  \r\n   <td>Yes</td>\r\n  \r\n   <td>2</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>No</td>\r\n  \r\n   <td>0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" rowspan=\"2\">\r\n  \r\n   Weight loss\r\n  \r\n   </td>\r\n  \r\n   <td>Yes</td>\r\n  \r\n   <td>2</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>No</td>\r\n  \r\n   <td>0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" rowspan=\"3\">\r\n  \r\n   Child-Pugh grade\r\n  \r\n   </td>\r\n  \r\n   <td>C</td>\r\n  \r\n   <td>5</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>B</td>\r\n  \r\n   <td>2</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>A</td>\r\n  \r\n   <td>0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle3_left\" colspan=\"3\">\r\n  \r\n   Biochemistry\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" rowspan=\"2\">\r\n  \r\n   Serum alkaline phosphatase (ALP), int. unit/L\r\n  \r\n   </td>\r\n  \r\n   <td>&#62;200</td>\r\n  \r\n   <td>3</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8804;200</td>\r\n  \r\n   <td>0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" rowspan=\"3\">\r\n  \r\n   Total bilirubin\r\n  \r\n   </td>\r\n  \r\n   <td>&#62;50 int. unit/L (2.9 mg/dL)</td>\r\n  \r\n   <td>3</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#62;33 - &#8804;50 int. unit/l (1.9 mg/dL - 2.9 mg/dL)</td>\r\n  \r\n   <td>1</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8804;33 int unit/L (1.9 mg/dL)</td>\r\n  \r\n   <td>0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" rowspan=\"2\">\r\n  \r\n   Urea\r\n  \r\n   </td>\r\n  \r\n   <td>&#62;8.9 mmol/L (&#62;25 mg/dL)</td>\r\n  \r\n   <td>2</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8804;8.9 mmol/L (&#8804;25 mg/dL)</td>\r\n  \r\n   <td>0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle3_left\" colspan=\"3\">\r\n  \r\n   Tumor characteristics\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" rowspan=\"2\">\r\n  \r\n   Portal vein thrombosis\r\n  \r\n   </td>\r\n  \r\n   <td>Yes</td>\r\n  \r\n   <td>3</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>No</td>\r\n  \r\n   <td>0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" rowspan=\"3\">\r\n  \r\n   Tumor size\r\n  \r\n   </td>\r\n  \r\n   <td>Diffuse</td>\r\n  \r\n   <td>4</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#62;5 cm</td>\r\n  \r\n   <td>3</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8804;5 cm</td>\r\n  \r\n   <td>0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" rowspan=\"2\">\r\n  \r\n   Lung metastases\r\n  \r\n   </td>\r\n  \r\n   <td>Yes</td>\r\n  \r\n   <td>3</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>No</td>\r\n  \r\n   <td>0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" rowspan=\"2\">\r\n  \r\n   Serum alpha-fetoprotein (AFP), ng/mL\r\n  \r\n   </td>\r\n  \r\n   <td>&#62;400</td>\r\n  \r\n   <td>4</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8804;400</td>\r\n  \r\n   <td>0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\" colspan=\"3\">\r\n  \r\n   Probability of patients surviving at least 3 months estimated by the advanced liver cancer prognostic system score\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   Prognosis\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   Score\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   3-month survival rate, %\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"3\">\r\n  \r\n   Good\r\n  \r\n   </td>\r\n  \r\n   <td>0-2</td>\r\n  \r\n   <td>&#62;81</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>3-6</td>\r\n  \r\n   <td>72-80</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>7-8</td>\r\n  \r\n   <td>66-69</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"4\">\r\n  \r\n   Intermediate\r\n  \r\n   </td>\r\n  \r\n   <td>9</td>\r\n  \r\n   <td>63</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>10-12</td>\r\n  \r\n   <td>51-59</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>13-14</td>\r\n  \r\n   <td>42-47</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>15</td>\r\n  \r\n   <td>38</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"4\">\r\n  \r\n   Poor\r\n  \r\n   </td>\r\n  \r\n   <td>16</td>\r\n  \r\n   <td>33</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>17-19</td>\r\n  \r\n   <td>21-29</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>20-22</td>\r\n  \r\n   <td>10-17</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8805;23</td>\r\n  \r\n   <td>&#60;10</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_footnotes\">int. unit: international unit.</div><div class=\"graphic_reference\">Reproduced with permission from: Yau T, Yao TJ, Chan P, et al. A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trials. Cancer 2008; 113:2742. Copyright &#169; 2008 John Wiley &amp; Sons, Inc.</div><div id=\"graphicVersion\">Graphic 57772 Version 4.0</div></div></div>"},"57774":{"type":"graphic_figure","displayName":"Colostomy PI","title":"Colostomy","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Colostomy</div><div class=\"cntnt\"><img style=\"width:457px; height:563px;\" src=\"images/PI/57774_Colostomy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture&nbsp;shows a colostomy, which&nbsp;is necessary in some people with severe diverticulitis or Crohn disease, or&nbsp;who are being treated for&nbsp;colon cancer. In some people, the colostomy is temporary. In other people, the colostomy is permanent.</div><div id=\"graphicVersion\">Graphic 57774 Version 6.0</div></div></div>"},"57777":{"type":"graphic_figure","displayName":"Ureter entering bladder","title":"Ureteral insertion into the bladder","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ureteral insertion into the bladder</div><div class=\"cntnt\"><img style=\"width:404px; height:364px;\" src=\"images/OBGYN/57777_Ureter_entering_bladder.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">As the ureter is traced down through the parametrium, the parametrium is divided superior and lateral to the ureter and mobilized medially, until the actual insertion of the ureter into the bladder can be seen.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 57777 Version 2.0</div></div></div>"},"57778":{"type":"graphic_figure","displayName":"DHR assay","title":"Flow cytometric measurement of neutrophil respiratory burst","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Flow cytometric measurement of neutrophil respiratory burst</div><div class=\"cntnt\"><img style=\"width:498px; height:252px;\" src=\"images/ALLRG/57778_DHR_assay.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Neutrophils stimulated with phorbol ester stimulation generate reactive oxygen radicals that cause oxidation of the fluorescent dye DHR 123. Defective oxidation is observed in individuals with CGD. Bimodal expression pattern of DHR 123 oxidation indicates carrier status.</div><div class=\"graphic_footnotes\">CGD: chronic granulomatous disease; DHR: dihydrorhodamine.</div><div id=\"graphicVersion\">Graphic 57778 Version 3.0</div></div></div>"},"57780":{"type":"graphic_picture","displayName":"Diffuse panbronchiolitis Lung","title":"Diffuse panbronchiolitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diffuse panbronchiolitis</div><div class=\"cntnt\"><img style=\"width:366px; height:245px;\" src=\"images/PULM/57780_Diffuse_panbronchiolitis_Lu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Collection of foamy macrophages in alveolar spaces adjacent to a bronchiole compromised by diffuse panbronchiolitis (hematoxylin and eosin stain).</div><div class=\"graphic_reference\">Courtesy of Talmadge E King, Jr, MD.</div><div id=\"graphicVersion\">Graphic 57780 Version 1.0</div></div></div>"},"57781":{"type":"graphic_figure","displayName":"Normal impulse conduction","title":"Schema of normal impulse conduction in the heart","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Schema of normal impulse conduction in the heart</div><div class=\"cntnt\"><img style=\"width:550px; height:332px;\" src=\"images/CARD/57781_Normal_impulse_conduction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The sinoatrial node (SAN) generates an action potential that is conducted through the right and left atria, resulting in atrial contraction. The impulse is then conducted through the atrioventricular node (AVN), activating the ventricular myocardium, resulting in contraction of the right and left ventricle.</div><div class=\"graphic_footnotes\">SVC: superior vena cava; IVC: inferior vena cava; PV: pulmonary veins; LAA: left atrial appendage; RAA: right atrial appendage.</div><div id=\"graphicVersion\">Graphic 57781 Version 2.0</div></div></div>"},"57782":{"type":"graphic_picture","displayName":"Unmyelinated sensory axons","title":"Unmyelinated sensory axons","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Unmyelinated sensory axons</div><div class=\"cntnt\"><img style=\"width:504px; height:370px;\" src=\"images/NEURO/57782_Unmyelinated_sensory_axons.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Unmyelinated sensory axons are seen extending from the dermal-epidermal junction towards the surface in this biopsy from a normal subject (40x).</div><div class=\"graphic_reference\">Courtesy of&nbsp;A. Gordon Smith, MD</div><div id=\"graphicVersion\">Graphic 57782 Version 3.0</div></div></div>"},"57783":{"type":"graphic_picture","displayName":"Solar urticaria","title":"Solar urticaria induced by ultraviolet A light","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Solar urticaria induced by ultraviolet A light</div><div class=\"cntnt\"><img style=\"width:521px; height:240px;\" src=\"images/ALLRG/57783_Solar_urticaria_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Shoulder before sun exposure.<br> (B) Shoulder after 15 minutes of sun exposure through a glass window. The glass window filters out ultraviolet B light.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 57783 Version 3.0</div></div></div>"},"57784":{"type":"graphic_table","displayName":"Seasons of viral CNS infection","title":"Seasonal incidence of viral CNS infections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Seasonal incidence of viral CNS infections</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t\t<tbody>\n\t\t\t<tr>\n\t\t\t\t<td class=\"subtitle1\">Peak time of year</td>\n\n\t\t\t\t<td class=\"subtitle1\">Aseptic meningitis</td>\n\n\t\t\t\t<td class=\"subtitle1\">Viral encephalitis</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Summer/fall</td>\n\n\t\t\t\t<td class=\"sublist1_start\"><p>Enteroviruses:</p>\n\t\t\t\t<p>Coxsackie</p>\n\t\t\t\t<p>Echovirus</p>\n\t\t\t\t<p>Poliovirus</p></td>\n\n\t\t\t\t<td><p>West Nile virus</p>\n\t\t\t\t<p>St Louis encephalitis virus</p>\n\t\t\t\t<p>Eastern equine encephalitis virus</p>\n\t\t\t\t<p>California encephalitis viruses</p>\n\t\t\t\t<p>Western equine encephalitis virus</p></td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Winter/spring</td>\n\n\t\t\t\t<td><p>Mumps</p><br />\n\t\t\t\t<p>Lymphocytic choriomeningitis virus</p></td>\n\n\t\t\t\t<td><p>Measles</p><br />\n\t\t\t\t<p>Mumps</p></td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Any season</td>\n\n\t\t\t\t<td><p>Herpes simplex virus type 2</p><p> HIV infection</p></td>\n\n\t\t\t\t<td><p>Herpes simplex virus type 1</p><p> HIV infection</p></td>\n\t\t\t</tr>\n\t\t</tbody>\n\t</table></div><div id=\"graphicVersion\">Graphic 57784 Version 1.0</div></div></div>"},"57785":{"type":"graphic_waveform","displayName":"Doppler pulmonic stenosis","title":"Doppler of pulmonary stenosis before and after balloon valvuloplasty","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Doppler of pulmonary stenosis before and after balloon valvuloplasty</div><div class=\"cntnt\"><img style=\"width:365px; height:269px;\" src=\"images/CARD/57785_Dopplerpulmonicstenosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Doppler signal is directed through the suprasternal notch. Prior to valvuloplasty (panel 1) the estimated peak systolic gradient is 35 to 40 mmHg; however, the Doppler underestimates the peak gradient because sampling of flow may not be axial. After valvuloplasty (panel 2), there is a decrease in peak velocity to 2 m/sec, and the estimated gradient is 16 mmHg.</div><div id=\"graphicVersion\">Graphic 57785 Version 4.0</div></div></div>"},"57787":{"type":"graphic_diagnosticimage","displayName":"Blount disease radiograph","title":"Blount disease radiograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Blount disease radiograph</div><div class=\"cntnt\"><img style=\"width:396px; height:381px;\" src=\"images/PEDS/57787_Blount_disease_radiograph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiograph of a patient with bilateral Blount disease showing characteristic medial beaking and downward slope of the proximal tibia metaphysis (arrows).</div><div class=\"graphic_reference\">Courtesy of Scott Rosenfeld, MD.</div><div id=\"graphicVersion\">Graphic 57787 Version 3.0</div></div></div>"},"57788":{"type":"graphic_table","displayName":"Diagnostic studies in IPH","title":"Principal and ancillary diagnostic studies in idiopathic pulmonary hemosiderosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Principal and ancillary diagnostic studies in idiopathic pulmonary hemosiderosis</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td class=\"container\"><table cellspacing=\"0\">\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   General diagnostic studies\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pulmonary function tests including DLCO</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>High resolution CT-scanning (HRCT) of thorax</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pulmonary perfusion and ventilation scintigraphy</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pulmonary radioscintigraphy with radio-labeled RBCs</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Sputum examination for hemosiderin-laden macrophages</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Screening for coagulation defects</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Plasma immunoglobulins (IgG, IgA, IgM, lgE)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Plasma antinuclear antibodies (ANA)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Plasma antidouble stranded DNA antibodies (anti-dsDNA)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Plasma antineutrophil cytoplasmic antibodies (ANCA)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Plasma antiglomerular basement membrane antibodies</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Plasma antiphospholipid antibodies (IgG, IgA)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Plasma rheumatoid factors (IgA, IgM)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Plasma IgA anti tissue transglutaminase and endomysial antibodies</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Plasma antireticulin antibodies</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Plasma anticow's milk antibodies (IgG, IgE)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Plasma cryoglobulins</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Plasma complement levels</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Blood eosinophils</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Urine analysis for protein, hemoglobin, RBC casts</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Skin prick test with appropriate antigens</td>\r\n  \r\n   </tr>\r\n  \r\n   </table></td>\r\n  \r\n   <td class=\"container\"><table cellspacing=\"0\">\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Evaluation for anemia\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Erythrocyte indices</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Serum transferrin saturation</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Serum ferritin</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Plasma cobalamine</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Erythrocyte folate</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Tests for hemolysis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Tests for hemoglobinopathy</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Examination for gastrointestinal, urinary, genital tract bleeding</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Bone marrow biopsy</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Flexible fiberoptic bronchoscopy\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Bronchoalveolar lavage</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Transbronchial forceps lung biopsy</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Lung biopsy for\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Light microscopy</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Perl's Prussian blue stain</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Immunofluorescence or immunohistochemistry</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Electron microscopy</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   In selected patients\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Skin biopsy (leukocytoclastic vasculitis)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Jejunal biopsy (celiac disease)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Renal biopsy (glomerulonephritis)</td>\r\n  \r\n   </tr>\r\n  \r\n   </table></td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 57788 Version 1.0</div></div></div>"},"57791":{"type":"graphic_table","displayName":"Disorders associated with secondary mast cell activation","title":"Disease states associated with secondary mast cell activation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disease states associated with secondary mast cell activation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Potential mechanisms</td> </tr> <tr> <td>Atopic diseases</td> <td>Allergen-specific IgE</td> </tr> <tr> <td>Chronic autoimmune urticaria</td> <td>Anti-IgE or anti-Fc-epsilon-RI autoantibodies</td> </tr> <tr> <td>Autoimmunity</td> <td>IgG receptor, complement</td> </tr> <tr> <td>Chronic infections</td> <td>TLRs, IgG, complement</td> </tr> <tr> <td>Drug allergy</td> <td>Specific receptors, complement, IgE</td> </tr> <tr> <td>Physical stimuli</td> <td>Direct mast cell activation</td> </tr> <tr> <td>Neoplasms</td> <td>Complement, cytokines</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgE: immunoglobulin E; Fc-epsilon-RI: high affinity receptor for IgE on mast cells; IgG: immunoglobulin G; TLRs: toll-like receptors.</div><div id=\"graphicVersion\">Graphic 57791 Version 7.0</div></div></div>"},"57792":{"type":"graphic_figure","displayName":"Global incidence of gastric cancer in men","title":"Global incidence of gastric cancer in men*","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Global incidence of gastric cancer in men*</div><div class=\"cntnt\"><img style=\"width:514px; height:340px;\" src=\"images/GAST/57792_Global_gast_canc_incid_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* The highest rates occur in Eastern Asia, South America, and Eastern Europe.</div><div class=\"graphic_reference\">Stewart B, Keihues P. World Cancer Report, International Agency for Research on Cancer Press, Lyon France 2003. p.194.</div><div id=\"graphicVersion\">Graphic 57792 Version 4.0</div></div></div>"},"57793":{"type":"graphic_picture","displayName":"Planar xanthomas in PBC","title":"Planar xanthomas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Planar xanthomas</div><div class=\"cntnt\"><img style=\"width:361px; height:241px;\" src=\"images/GAST/57793_Planar_xanthomas_in_PBC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral planar xanthomas in the palms of a 35-year-old woman with primary biliary cholangitis. Xanthomas started in the creases and expanded. At the time that the xanthomas began to form, the serum bilriubin level was 18.6 mg/dL and serum cholesterol concentration was 970 mg/dL (25.2 mmol/l).</div><div class=\"graphic_reference\">Courtesy of Marshall M Kaplan, MD.</div><div id=\"graphicVersion\">Graphic 57793 Version 2.0</div></div></div>"},"57795":{"type":"graphic_figure","displayName":"Comparison of effectiveness of contraceptive methods","title":"Comparing effectiveness of contraceptive methods","html":"<div class=\"graphic\"><div style=\"width: 714px\" class=\"figure\"><div class=\"ttl\">Comparing effectiveness of contraceptive methods</div><div class=\"cntnt\"><img style=\"width:694px; height:628px;\" src=\"images/OBGYN/57795_Compeffcontracmeth.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Condoms should always be used to reduce the risk of sexually transmitted infections.<br />Other methods of contraception: &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>Lactational amenorrhea method&nbsp;– LAM is a highly effective, <STRONG>temporary</STRONG> method of contraception</LI>&#xD;&#xA;<LI>Emergency contraception&nbsp;– Emergency contraceptive pills or a copper IUD after unprotected intercourse substantially reduces risk of pregnancy</LI></UL></div><div class=\"graphic_footnotes\">LNG: levonorgestrel.<br />* The percentages indicate the number out of every 100 women who experienced an unintended pregnancy within the first year of typical use of each contraceptive method.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>World Health Organization (WHO) Department of Reproductive Health and Research, Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs (CCP). Knowledge for health project. Family planning: a global handbook for providers (2011 update), CPP and WHO, Baltimore MD, Geneva, Switzerland, 2011.</li>&#xD;&#xA;    <li>Trussell J. Contraceptive failure in the United States. Contraception 2011; 83:397.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced from: U.S. Selected Practice Recommendations for Contraceptive Use, 2013: Adapted from the World Health Organization Selected Practice Recommendations for Contraceptive Use, 2nd Edition. MMWR Morb Mortal Wkly Rep 2013; 62:1.</div><div id=\"graphicVersion\">Graphic 57795 Version 6.0</div></div></div>"},"57796":{"type":"graphic_picture","displayName":"Skin patch PI","title":"Birth control skin patch","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Birth control skin patch</div><div class=\"cntnt\"><img style=\"width:504px; height:336px;\" src=\"images/PI/57796_Ortho_Evra_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin patches like this one deliver hormones into the body that help prevent pregnancy.</div><div class=\"graphic_reference\">Reproduced with permission from: www.orthoevra.com. Copyright &copy; 2006.</div><div id=\"graphicVersion\">Graphic 57796 Version 7.0</div></div></div>"},"57798":{"type":"graphic_figure","displayName":"Box and whiskers plot","title":"Box and whiskers plot","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Box and whiskers plot</div><div class=\"cntnt\"><img style=\"width:374px; height:254px;\" src=\"images/PC/57798_Box_and_whiskers_plot.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A box and whiskers plot is a graphical depiction of the interquartile range, a measure of dispersion of the data.</div><div id=\"graphicVersion\">Graphic 57798 Version 2.0</div></div></div>"},"57799":{"type":"graphic_picture","displayName":"Ginkgo biloba","title":"Ginkgo biloba","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ginkgo biloba</div><div class=\"cntnt\"><img style=\"width:324px; height:487px;\" src=\"images/PC/57799_Ginkgo_biloba.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Martin Wall/herbslides.com.</div><div id=\"graphicVersion\">Graphic 57799 Version 1.0</div></div></div>"},"57800":{"type":"graphic_table","displayName":"Photosensitive disorders","title":"Photosensitive disorders: Clinical features","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Photosensitive disorders: Clinical features</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Sex</td> <td class=\"subtitle1\">Age of onset</td> <td class=\"subtitle1\">Timeline of eruption</td> <td class=\"subtitle1\">Location</td> <td class=\"subtitle1\">Common lesion morphology and symptoms</td> <td class=\"subtitle1\">Family history</td> <td class=\"subtitle1\">Action spectrum</td> <td class=\"subtitle1\">Phototesting</td> <td class=\"subtitle1\">Laboratory findings</td> <td class=\"subtitle1\">Duration/ resolution</td> <td class=\"subtitle1\">Key features</td> </tr> <tr> <td><strong>Polymorphous light eruption</strong></td> <td>F&#62;M</td> <td>First three decades</td> <td>Hours after sun exposure, lasts days to weeks; most conspicuous in spring; improves during summer</td> <td>Sun-exposed areas</td> <td>Pruritic papules, papulovesicles, plaques.</td> <td>May be present</td> <td>UVA, UVB, visible</td> <td>Normal MED; provocative phototesting may induce lesions</td> <td>&nbsp;</td> <td>Recurrent over the course of years, may improve over time</td> <td>Most common photodermatosis; \"hardening\" phenomenon may occur</td> </tr> <tr class=\"divider_top\"> <td><strong>Juvenile spring eruption</strong></td> <td>M&#62;F</td> <td>Primarily childhood; also may be seen in young adults</td> <td>As with PMLE</td> <td>Classically, helices of ears</td> <td>Erythematous papules, bullae.</td> <td>May be present</td> <td>UVA?</td> <td>As with PMLE</td> <td>&nbsp;</td> <td>Recurrent over years, may improve with age</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td><strong>Actinic prurigo</strong></td> <td>F&#62;M, M&#62;F reported in adult onset in Asia</td> <td> <p>Childhood;</p> <p>adult-onset may occur in Asians</p> </td> <td>Persistent during summer; may also be present year round</td> <td>Sun-exposed areas, may also affect unexposed areas</td> <td>Pruritic papulonodules, crusts, excoriations, lichenification, cheilitis.</td> <td>Yes, in up to 50%</td> <td>UVA&#62;UVB</td> <td>60% with reduced MED, 60 to 70% with positive provocative phototests</td> <td>&nbsp;</td> <td>Improves in adolescence, but also may persist</td> <td>More common in American Indians and Mestizos. May have ocular findings. </td> </tr> <tr class=\"divider_top\"> <td><strong>Hydroa vacciniforme</strong></td> <td>Slight M&#62;F</td> <td>Childhood</td> <td>Hours after sun exposure</td> <td>Face, dorsal hands</td> <td>Erythematous macules, papules, vesicles, crusts.</td> <td>Rarely positive</td> <td>Likely UVA</td> <td>May show reduced MED to UVA in some cases</td> <td>&nbsp;</td> <td>Usually resolves by adolescence/young adulthood, but may persist</td> <td>Lymphoproliferative disease association with severe cases</td> </tr> <tr class=\"divider_top\"> <td><strong>Chronic actinic dermatitis</strong></td> <td>M&#62;F</td> <td>Older, but may be seen in younger patients</td> <td>Persistent; worsens in summer, may have findings year round</td> <td>Sun-exposed areas</td> <td>Eczematous patches, lichenification, may see palmoplantar involvement.</td> <td>&nbsp;</td> <td>UVA, UVB, visible light</td> <td>Decreased MEDs to UVA, UVB, or visible light</td> <td>May see S&#233;zary cells in severe cases</td> <td>Persists for years, may resolve</td> <td>Often coexistent contact dermatitis</td> </tr> <tr class=\"divider_top\"> <td><strong>Solar urticaria</strong></td> <td>F&#62;M</td> <td>Young or mid-adulthood</td> <td>Appears within minutes, individual lesions resolve within 24 hours</td> <td>Sun-exposed areas</td> <td>Urticarial plaques (hives), occasional systemic symptoms.</td> <td>&nbsp;</td> <td>UVA, UVB, visible light</td> <td>Normal MEDs, urticaria are induced within minutes of phototesting</td> <td>&nbsp;</td> <td>Persists for years, may resolve</td> <td>\"Hardening\" phenomenon may occur</td> </tr> <tr class=\"divider_top\"> <td><strong>Phototoxicity</strong></td> <td>M = F</td> <td>Any age</td> <td>Appears within hours of sun exposure, can occur after first dose of drug</td> <td>Sun-exposed areas</td> <td>Exacerbated sunburn appearance.</td> <td>&nbsp;</td> <td>UVA</td> <td>In systemic phototoxicity, MED for UVA decreased, UVB and visible light MEDs normal</td> <td>&nbsp;</td> <td>Resolves when drug discontinued and cleared from body</td> <td>Can occur in anyone</td> </tr> <tr class=\"divider_top\"> <td><strong>Photoallergy</strong></td> <td>M = F</td> <td>Any age</td> <td>Appears&nbsp;one to&nbsp;two days after exposure to sun and inciting agent in sensitized individual</td> <td>Sun-exposed areas</td> <td>Pruritic, eczematous lesions.</td> <td>&nbsp;</td> <td>UVA</td> <td>In systemic photoallergy, MED for UVA decreased, UVB and visible light MEDs normal</td> <td>&nbsp;</td> <td>Resolves with discontinuation of inciting agent</td> <td>Usually due to topical agents</td> </tr> <tr class=\"divider_top\"> <td><strong>Erythropoietic protoporphyria</strong></td> <td>M = F, versus slight M&#62;F</td> <td>Onset in early childhood</td> <td>Symptoms begin within minutes of sun exposure, improves in winter</td> <td>Nose, cheeks, hands</td> <td>Burning and stinging, pain, pruritus. Erythema, edema, pupura. Heals with atrophic, wax-like scars; wrinkled knuckles.</td> <td>Common (siblings), autosomal recessive or pseudo-dominant</td> <td>Soret band (400 to 410 nm)</td> <td>Often normal, some patients may note stinging sensation or lesions</td> <td>Elevated erythrocyte protoporphyrin level</td> <td>Chronic</td> <td>May develop liver disease</td> </tr> <tr class=\"divider_top\"> <td><strong>Porphyria cutanea tarda</strong></td> <td>M = F</td> <td>Middle age, may occur earlier</td> <td>&nbsp;</td> <td>Sun-exposed areas</td> <td>Skin fragility, bullae, crusts, scarring. Hypertrichosis, hyperpigmentation, sclerodermoid changes.</td> <td>Sporadic in Type I, autosomal dominant in Type II</td> <td>Soret band (400 to 410 nm)</td> <td>&nbsp;</td> <td>Elevated porphyrins in urine and stool</td> <td>Chronic, symptoms improve with sun protection, removal of triggers, phlebotomy, antimalarials</td> <td>Often associated with hepatitis C</td> </tr> <tr class=\"divider_top\"> <td><strong>Pseudoporphyria</strong></td> <td>&nbsp;F&#62;M</td> <td> <p>Any age; 10% of children taking naproxene</p> </td> <td>&nbsp;</td> <td>Sun-exposed areas</td> <td>Skin fragility, bullae, crusts, scarring, milia.</td> <td>Negative</td> <td>UVA</td> <td>&nbsp;</td> <td>Normal porphyrin levels</td> <td>Symptoms resolve with sun protection, avoidance of tanning bed use, and&nbsp;discontinuation of the causative medications</td> <td>May be caused by medications, renal failure and hemodialysis, and excessive tanning bed use</td> </tr> <tr class=\"divider_top\"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">F: female; M: male; UV: ultraviolet; MED: minimal erythema dose; PMLE: polymorphus light eruption.</div><div id=\"graphicVersion\">Graphic 57800 Version 12.0</div></div></div>"},"57801":{"type":"graphic_figure","displayName":"Zones of the prostate gland","title":"Zones of the prostate gland","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Zones of the prostate gland</div><div class=\"cntnt\"><img style=\"width:535px; height:471px;\" src=\"images/SURG/57801_Prostate_zone.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The bulk of the prostate gland is contained within the peripheral zone. The transition zone is the site of benign prostatic hypertrophy. The majority of prostate cancers originate in the peripheral zone, whereas only 5 and 10 percent originate from the central and transition zones, respectively.</div><div id=\"graphicVersion\">Graphic 57801 Version 2.0</div></div></div>"},"57803":{"type":"graphic_picture","displayName":"Boy with measles","title":"Boy with measles","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Boy with measles</div><div class=\"cntnt\"><img style=\"width:143px; height:200px;\" src=\"images/ID/57803_Boy_with_measles.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Source: Centers for Disease Control and Prevention.</div><div id=\"graphicVersion\">Graphic 57803 Version 3.0</div></div></div>"},"57806":{"type":"graphic_table","displayName":"Systemic therapy regimens for high-grade gliomas","title":"Systemic therapy regimens used for high-grade gliomas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Systemic therapy regimens used for high-grade gliomas</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td rowspan=\"2\">Bevacizumab&nbsp;</td> <td>10 mg/kg days 1, 15&nbsp;</td> <td>Every&nbsp;4 weeks&nbsp;</td> </tr> <tr> <td>15 mg/kg days 1,&nbsp;22&nbsp;</td> <td>Every&nbsp;6 weeks&nbsp;</td> </tr> <tr> <td>Carmustine (BCNU)</td> <td>150 to 200 mg/m2 day 1</td> <td>Every 6 weeks</td> </tr> <tr> <td>Lomustine (CCNU)</td> <td>90 to 110 mg/m2 day 1&nbsp;</td> <td>Every 6 weeks&nbsp;</td> </tr> <tr> <td rowspan=\"3\">PCV [1]</td> <td>Procarbazine 100 mg/m2 days 1 to 10</td> <td rowspan=\"3\">Every 6 to 8 weeks</td> </tr> <tr> <td>Lomustine 100 mg/m2 day 1</td> </tr> <tr> <td>Vincristine 1.5 mg/m2 (maximum 2 mg) day 1</td> </tr> <tr> <td rowspan=\"3\">PCV [2, 3]</td> <td>Procarbazine 60 mg/m2 days 8 to 21</td> <td rowspan=\"3\">Every 6 to 8 weeks</td> </tr> <tr> <td>Lomustine 100 mg/m2 day 1</td> </tr> <tr> <td>Vincristine 1.5 mg/m2 (maximum 2 mg) days 8 and 29</td> </tr> <tr> <td>Temozolomide (standard)&nbsp;</td> <td>150 to 200 mg/m2 daily for five days </td> <td>Every 4 weeks</td> </tr> <tr> <td rowspan=\"3\">Temozolomide (dose intensified)&nbsp;</td> <td>150 mg/m2 daily days 1 to 7, 15 to 21</td> <td>Every 4 weeks</td> </tr> <tr> <td>75 to 100 mg/m2 daily days 1 to 21&nbsp;</td> <td>Every 4 weeks</td> </tr> <tr> <td>50 mg/m2 daily continuous&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td rowspan=\"2\">Adjuvant temozolomide [4]</td> <td>75 mg/m2 daily during RT</td> <td rowspan=\"2\">&nbsp;</td> </tr> <tr> <td>Up to six cycles of 150 to 200 mg/m2 daily for 5 days, every 28 days</td> </tr> </tbody></table></div><div class=\"graphic_reference\">1. Medical Research Council trial. J Clin Oncol 2001; 19:509.<br />2. Levin, VA, et al. Int J Radiat Oncol Biol Phys 1990; 18:321.<br />3. van den Bent, MJ, et al. Neurology 1998; 51:1140.<br />4. Stupp, R, et al. N Engl J Med 2005; 352:987.</div><div id=\"graphicVersion\">Graphic 57806 Version 2.0</div></div></div>"},"57807":{"type":"graphic_picture","displayName":"Cafe-au-lait macule","title":"Large café-au-lait macule","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Large caf&#233;-au-lait macule</div><div class=\"cntnt\"><img style=\"width:396px; height:326px;\" src=\"images/PEDS/57807_Cafe-au-lait_macule.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large caf&#233;-au-lait macule on the flank of a young child with neurofibromatosis type 1.</div><div class=\"graphic_reference\">Courtesy of the Yale Dermatology Residents' Slide Collection.</div><div id=\"graphicVersion\">Graphic 57807 Version 2.0</div></div></div>"},"57808":{"type":"graphic_table","displayName":"Monitoring type 1 GD","title":"Minimum recommended initial assessment and monitoring recommendations for patients with nonneuronopathic Gaucher disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Minimum recommended initial assessment and monitoring recommendations for patients with nonneuronopathic Gaucher disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Initial assessment and ongoing monitoring</td> <td class=\"subtitle1\" colspan=\"2\">Frequency*</td> </tr> <tr> <td class=\"subtitle2\">Not receiving ERT</td> <td class=\"subtitle2\">Receiving ERT, has not achieved goals</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Physical examination</strong></td> <td>Every 6 months</td> <td>Every 6 to 12 months</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Blood tests</td> </tr> <tr> <td class=\"indent1\">Hemoglobin</td> <td>Every 12 months</td> <td>Every 3 months</td> </tr> <tr> <td class=\"indent1\">Platelets</td> <td>Every 12 months</td> <td>Every 3 months</td> </tr> <tr> <td class=\"indent1\">Chitotriosidase, PARC/CCL18, HDL</td> <td>Every 12 months</td> <td>Every 3 months</td> </tr> <tr> <td class=\"indent1\">Beta-glucosidase and mutation analysis</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Antibody sample<sup>&#182;</sup></td> <td>Not necessary</td> <td>Optional sample after 6 months of therapy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Serum immunoelectrophoresis<sup>&#916;</sup></td> <td>Every 12 to 24 months in patients &#62;50 years</td> <td>Every 12 to 24 months in patients &#62;50 years</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Radiographs</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Visceral</td> </tr> <tr> <td class=\"indent2\">Spleen volume (MRI or US)</td> <td>Every 12 to 24 months</td> <td>Every 12 months</td> </tr> <tr> <td class=\"indent2\">Liver volume (MRI or US)</td> <td>Every 12 to 24 months</td> <td>Every 12 months</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Skeletal</td> </tr> <tr> <td class=\"sublist3_start\" colspan=\"3\">MRI</td> </tr> <tr> <td class=\"sublist3\">Spine (sagittal T1-weighted)<sup>&#916;</sup></td> <td class=\"sublist_other\">Every 24 months</td> <td class=\"sublist_other\">Every 12 months</td> </tr> <tr> <td class=\"sublist3\">Femora (coronal T1- and T2-weighted)</td> <td class=\"sublist_other\">Every 24 months (T1- and T2-weighted)</td> <td class=\"sublist_other\">Every 12 month (T1- and T2-weighted)</td> </tr> <tr> <td class=\"sublist3_start\" colspan=\"3\">Plain radiographs<sup>&#9674;</sup></td> </tr> <tr> <td class=\"sublist3\">Children: Pelvis, long bones, spine<sup>&#167;</sup></td> <td class=\"sublist_other\">Every 12 to 24 months</td> <td class=\"sublist_other\">Every 12 months</td> </tr> <tr> <td class=\"sublist3\">Adult: Lateral spine; AP of entire femora<sup>&#165;</sup></td> <td class=\"sublist_other\">Every 12 to 24 months</td> <td class=\"sublist_other\">Every 12 months</td> </tr> <tr> <td class=\"indent2\">DXA spine and hips</td> <td>Every 12 to 24 months</td> <td>Every 12 months</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Cardiopulmonary</td> </tr> <tr> <td class=\"sublist3_start\" colspan=\"3\">Children:</td> </tr> <tr> <td class=\"sublist3\">Forced vital capacity</td> <td class=\"sublist_other\" rowspan=\"5\">Repeat if abnormal at baseline or if symptoms develop</td> <td class=\"sublist_other\" rowspan=\"5\">Repeat if abnormal at baseline or if symptoms develop</td> </tr> <tr> <td class=\"sublist3\">Peak expiratory flow rate</td> </tr> <tr> <td class=\"sublist3\">High-resolution chest computed tomography</td> </tr> <tr> <td class=\"sublist3\">Echocardiography</td> </tr> <tr> <td class=\"sublist3\">Electrocardiogram</td> </tr> <tr> <td class=\"sublist3_start\" colspan=\"3\">Adults (&#62;18 years):</td> </tr> <tr> <td class=\"sublist3\">Electrocardiogram</td> <td class=\"sublist_other\" rowspan=\"3\"> <p>Every 12 to 24 months for those with borderline or above normal pulmonary pressures at baseline</p> Consider repeating every two to three years if baseline is normal</td> <td class=\"sublist_other\" rowspan=\"3\">Annual evaluation if signs/symptoms of cardiopulmonary disease are present</td> </tr> <tr> <td class=\"sublist3\">Chest radiograph</td> </tr> <tr> <td class=\"sublist3\">Doppler echocardiogram (right ventricular systolic pressure)</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Other</td> </tr> <tr> <td class=\"indent2\">Pain</td> <td>Every 12 months</td> <td>Every 6 to 12 months</td> </tr> <tr> <td class=\"indent2\">Quality of life</td> <td>Every 12 months</td> <td>Every 12 months</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Validated disease severity score</td> <td>Every 12 months</td> <td>Every 12 months</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Additional tests<sup>&#135;</sup></td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">White blood count, prothrombin time, activated partial thromboplastin time, iron, iron-binding capacity, ferritin, vitamin B12, aspartate aminotransferase, and/or alanine aminotransferase; alkaline phosphatase; calcium, phosphorous, albumin, total protein, total and direct bilirubin; hepatitis profile, serum immunoelectrophoresis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ERT: enzyme-replacement therapy; PARC/CCL18: pulmonary and activation-regulated chemokine/chemokine (C-C motif) ligand 18; HDL: high-density lipoprotein; MRI: magnetic resonance imaging; US: ultrasonography; DXA: dual-energy x-ray absorptiometry.<br />* The entire assessment should be performed at baseline and every 12 to 24 months in patients who are receiving ERT and have achieved therapeutic goals. DXA should be performed every 24 months in these patients. The entire assessment also should be performed at the time of dose change or the development of a significant complication.<br />¶ To be stored and tested only if clinically indicated.<br />Δ Only in children.<br /><FONT class=lozenge>◊</FONT> Sites not included here should be evaluated if symptoms develop.<br />§ Plain radiographs of the spine only when patient is symptomatic (eg, back pain), disease is severe, there is poor growth, or kyphosis.<br />¥ Optional in absence of new symptoms or evidence of disease progression.<br />‡ Additional tests to be considered and followed appropriately depending upon patient's age and clinical status.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Grabowski GA, Andria G, Baldellou A, et al. Pediatric nonneuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements. Eur J Pediatr 2004; 163:58. </li>&#xD;&#xA;    <li>Baldellou A, Andria G, Campbell PE, et al. Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr 2004; 163:67. </li>&#xD;&#xA;    <li>Charrow J, Andersson HC, Kaplan P, et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr 2004; 144:112. </li>&#xD;&#xA;    <li>Weinreb NJ, Aggio MC, Andersson HC, et al. Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol 2004; 41:15. </li>&#xD;&#xA;    <li>Rosenbloom BE, Weinreb NJ, Zimran A, et al. Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood 2005; 105:4569. </li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 57808 Version 9.0</div></div></div>"},"57811":{"type":"graphic_figure","displayName":"Bones and ligaments of the pelvis","title":"Bones and ligaments of the pelvis","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Bones and ligaments of the pelvis</div><div class=\"cntnt\"><img style=\"width:482px; height:707px;\" src=\"images/EM/57811_Pelvicboneligaments.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The joints of the adult pelvic girdle include the sacroiliac joints and the pubic symphysis. The lumbosacral and sacrococcygeal are joints of the axial skeleton directly related to the pelvic girdle.<br />(B and C) The ligaments of the pelvis are shown.</div><div class=\"graphic_footnotes\">* Inferior pelvic aperture.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AR. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 57811 Version 13.0</div></div></div>"},"57812":{"type":"graphic_diagnosticimage","displayName":"C difficile colitis CT","title":"<EM>Clostridium difficile </EM>colitis – Computed tomography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Clostridium difficile </EM>colitis – Computed tomography</div><div class=\"cntnt\"><img style=\"width:299px; height:288px;\" src=\"images/GAST/57812_CdifficilecolitisCT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) scan shows marked thickening of the wall of the sigmoid colon (arrows). This appearance is not specific for pseudomembranous colitis and may be seen with any form of colitis.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 57812 Version 5.0</div></div></div>"},"57813":{"type":"graphic_diagnosticimage","displayName":"Periesophageal lymph nodes EUS","title":"Benign and malignant periesophageal lymph nodes","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Benign and malignant periesophageal lymph nodes</div><div class=\"cntnt\"><img style=\"width:536px; height:258px;\" src=\"images/GAST/57813_Periesophageallymphnodes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic ultrasound images showing a benign (left panel) and malignant (right panel) appearing periesophageal lymph node in a patient with histologically proven esophageal adenocarcinoma. Characteristics of the benign lymph node are its mixed echogenicity, irregular border, elongated shape, and &lt;10 mm width. In contrast, the malignant lymph node is echopoor, has a smooth border, has a round shape, and is &gt;10 mm in width.</div><div class=\"graphic_reference\">Courtesy of Enrique Vazquez-Sequeiros, MD, and Maurits J Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 57813 Version 3.0</div></div></div>"},"57814":{"type":"graphic_figure","displayName":"Transperineal fistula repair3","title":"Transverse transperineal approach to a rectovaginal fistula located about the sphincter complex","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transverse transperineal approach to a rectovaginal fistula located about the sphincter complex</div><div class=\"cntnt\"><img style=\"width:407px; height:407px;\" src=\"images/OBGYN/57814_Transperineal_fistula_rep2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The fistula tract is excised.</div><div id=\"graphicVersion\">Graphic 57814 Version 1.0</div></div></div>"},"57816":{"type":"graphic_picture","displayName":"Tinea pedis manuum","title":"Tinea pedis and tinea manuum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tinea pedis and tinea manuum</div><div class=\"cntnt\"><img style=\"width:432px; height:300px;\" src=\"images/PC/57816_Tinea_pedis_manuum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image shows concomitant tinea pedis and tinea manuum, also known as the &quot;two feet, one hand&quot; presentation.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 57816 Version 3.0</div></div></div>"},"57818":{"type":"graphic_table","displayName":"Indications for TBNA","title":"Indications for transbronchial needle aspiration","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for transbronchial needle aspiration</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"sublist1_start\">Mediastinal and/or hilar lymphadenopathy</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">To establish a histologic diagnosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">To stage known or suspected bronchogenic carcinoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Endobronchial lesions</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Especially useful in cases of necrotic tumor, hemorrhagic tumor, or to define the line of surgical resection (see text)</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Extrinsic compression of the airway by a peribronchial process</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Submucosal disease</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Peripheral nodules/masses</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Follow-up of small-cell tumors, lymphoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Diagnosis and/or drainage of mediastinal cysts and/or mediastinal abscesses</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from Minai, OA, Dasgupta, A, Mehta, AC. Transbronchial needle aspiration of central and peripheral lesions. In: Bolliger, CT, Mathur, PN (Eds), Progress in Respiratory Research-Interventional Bronchoscopy. Karger, Basel, Switzerland, 1999.</div><div id=\"graphicVersion\">Graphic 57818 Version 1.0</div></div></div>"},"57819":{"type":"graphic_picture","displayName":"Acquired ichthyosis 1","title":"Acquired ichthyosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Acquired ichthyosis</div><div class=\"cntnt\"><img style=\"width:504px; height:402px;\" src=\"images/DERM/57819_Acquired_ichthyosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adherent, &quot;fish-like&quot; scales are present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 57819 Version 4.0</div></div></div>"},"57820":{"type":"graphic_picture","displayName":"Laerdal trachlight handle","title":"Laerdal trachlight handle","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Laerdal trachlight handle</div><div class=\"cntnt\"><img style=\"width:504px; height:456px;\" src=\"images/EM/57820_Laerdal_trachlight_handle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Trachlight handle.<br> (B) Infant trachlight.<br> (C) Pediatric trachlight.<br> (D) Adult trachlight.<br> (E) The wand and rigid internal stylet combination has been attached to the handle and a cuffed endotracheal (ET) tube has been loaded on to the wand. The ET tube adapter is connected to the handle.</div><div class=\"graphic_reference\">Reproduced with permission from: Murphy MF, Hung OR. Lighted stylet intubation. In: Walls RM, Murphy MF (eds). Manual of Emergency Airway Management, 3rd edition. Lippincott Williams &amp; Wilkins, Philadelphia, 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 57820 Version 5.0</div></div></div>"},"57822":{"type":"graphic_movie","displayName":"Classical whooping","title":"Classical whooping cough with lots of whooping","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Classical whooping cough with lots of whooping</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/57822_Classicalwhoopingconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:252px; height:372px;\" src=\"images/CARD/57822_Classicalwhooping.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: http://www.whoopingcough.net/symptoms.htm. Copyright © 2010 Dr. Doug Jenkinson.</div><div id=\"graphicVersion\">Graphic 57822 Version 2.0</div></div></div>"},"57824":{"type":"graphic_picture","displayName":"Photo birth 4","title":"Delivery sequence from crowning through birth of the newborn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Delivery sequence from crowning through birth of the newborn</div><div class=\"cntnt\"><img style=\"width:432px; height:318px;\" src=\"images/OBGYN/57824_Photo_birth_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cardinal movement of extension.</div><div class=\"graphic_reference\">Reproduced with permission from: Wolters Kluwer. Copyright &#169;2009.</div><div id=\"graphicVersion\">Graphic 57824 Version 1.0</div></div></div>"},"57827":{"type":"graphic_picture","displayName":"Fundic gland polyp CPC Endosc","title":"Gastric fundic gland polyp","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric fundic gland polyp</div><div class=\"cntnt\"><img style=\"width:307px; height:320px;\" src=\"images/GAST/57827_Fundic_gland_polyp_CPC_Endo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper endoscopy showing a small polyp in the gastric fundus proven to be a fundic gland polyp after it was removed.</div><div class=\"graphic_reference\">Courtesy of Myron Falchuk, MD and Andres Gelrud, MD.</div><div id=\"graphicVersion\">Graphic 57827 Version 1.0</div></div></div>"},"57828":{"type":"graphic_table","displayName":"ACC AHA CV risk noncard surgery","title":"ACC/AHA guideline summary: Cardiac risk stratification for noncardiac surgical procedures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACC/AHA guideline summary: Cardiac risk stratification for noncardiac surgical procedures</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">High risk (reported risk of cardiac death or nonfatal myocardial infarction [MI] often greater than 5%)</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Aortic and other major vascular surgery </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Peripheral artery surgery </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Intermediate risk (reported risk of cardiac death or nonfatal MI generally 1 to 5%)</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Carotid endarterectomy </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Head and neck surgery </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Intraperitoneal and intrathoracic surgery </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Orthopedic surgery </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Prostate surgery </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Low risk* (reported risk of cardiac death or nonfatal MI generally less than 1%)</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Ambulatory surgery<sup>&#182;</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Endoscopic procedures </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Superficial procedures </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Cataract surgery </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Breast surgery </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Do not generally require further preoperative cardiac testing.<br />&para; Ambulatory surgery refers to surgery in patients who are admitted on the day of an operation or procedure, and return home on the same day.</div><div class=\"graphic_reference\">Data from: Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. J Am Coll Cardiol 2007; 50:e159.</div><div id=\"graphicVersion\">Graphic 57828 Version 10.0</div></div></div>"},"57830":{"type":"graphic_figure","displayName":"Lynch syndrome cancer risk","title":"Lynch syndrome cancer risk","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Lynch syndrome cancer risk</div><div class=\"cntnt\"><img style=\"width:456px; height:438px;\" src=\"images/OBGYN/57830_Lynch_syndrome_cancer_risk.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lifetime risk for colon, endometrial, and ovarian cancer in individuals compared with the general population.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Koornstra JJ, Mourits MJ, Sijmons RH, et al. Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol 2009; 10:400.</li>&#xD;&#xA;    <li>Barrow E, Robinson L, Alduaij W, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet 2009; 75:141.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 57830 Version 4.0</div></div></div>"},"57831":{"type":"graphic_picture","displayName":"ALL lymphoblasts in peripheral blood","title":"Lymphoblasts in acute lymphoblastic leukemia ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphoblasts in acute lymphoblastic leukemia </div><div class=\"cntnt\"><img style=\"width:360px; height:233px;\" src=\"images/HEME/57831_Lymphoblasts_FAB_L1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blood smear showing small lymphoblasts with rare nucleoli and vacuoles, as seen in acute lymphocytic leukemia (ALL). </div><div class=\"graphic_reference\">Courtesy of Robert Baehner, MD.</div><div id=\"graphicVersion\">Graphic 57831 Version 4.0</div></div></div>"},"57832":{"type":"graphic_figure","displayName":"Curves from unacceptable FVC","title":"Unacceptable spirometry","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Unacceptable spirometry</div><div class=\"cntnt\"><img style=\"width:250px; height:220px;\" src=\"images/PULM/57832_Curves_from_unacceptable_FV.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flow-volume curve patterns from unacceptable forced vital capacity maneuvers. Curve A (red) hesitating start; curve B (blue) submaximal blast (poor peak flow effort); curve C (green) excessive coughing at the beginning of the maneuver; curve D (orange) premature termination of effort.</div><div class=\"graphic_footnotes\">FVC: forced vital capacity.</div><div id=\"graphicVersion\">Graphic 57832 Version 2.0</div></div></div>"},"57833":{"type":"graphic_table","displayName":"Reference range eNO","title":"Reference ranges derived from the multivariate model in normal subjects","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Reference ranges derived from the multivariate model in normal subjects</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Atopy status*</td>\n\t\t\t\t\t<td class=\"subtitle1\">Smoking status</td>\n\t\t\t\t\t<td class=\"subtitle1\">Reference range for F<small>E</small><sub>NO</sub> (ppb)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1_start\" colspan=\"3\">Female</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\" rowspan=\"3\">No atopy</td>\n\t\t\t\t\t<td class=\"sublist_other\">Current smoker</td>\n\t\t\t\t\t<td class=\"sublist_other\">5.9-30.5</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist_other\">Ex-smoker</td>\n\t\t\t\t\t<td class=\"sublist_other\">6.4-32.2</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist_other\">Nonsmoker</td>\n\t\t\t\t\t<td class=\"sublist_other\">7.5-37.4</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\" rowspan=\"3\">Atopy</td>\n\t\t\t\t\t<td class=\"sublist_other\">Current smoker</td>\n\t\t\t\t\t<td class=\"sublist_other\">6.9-36.4</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist_other\">Ex-smoker</td>\n\t\t\t\t\t<td class=\"sublist_other\">7.6-38.5</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist_other\">Nonsmoker</td>\n\t\t\t\t\t<td class=\"sublist_other\">8.8-44.6</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1_start\" colspan=\"3\">Male</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\" rowspan=\"3\">No atopy</td>\n\t\t\t\t\t<td class=\"sublist_other\">Current smoker</td>\n\t\t\t\t\t<td class=\"sublist_other\">7.5-38.4</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist_other\">Ex-smoker</td>\n\t\t\t\t\t<td class=\"sublist_other\">8.1-40.8</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist_other\">Nonsmoker</td>\n\t\t\t\t\t<td class=\"sublist_other\">9.5-47.4</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\" rowspan=\"3\">Atopy</td>\n\t\t\t\t\t<td class=\"sublist_other\">Current smoker</td>\n\t\t\t\t\t<td class=\"sublist_other\">8.8-45.9</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist_other\">Ex-smoker</td>\n\t\t\t\t\t<td class=\"sublist_other\">9.6-48.6</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist_other\">Nonsmoker</td>\n\t\t\t\t\t<td class=\"sublist_other\">11.2-56.5</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div class=\"graphic_footnotes\">F<small>E</small><sub>NO</sub>: fraction of nitric oxide in expired breath.<br> * Atopy: a positive skin prick test to at least one common allergen.</div><div class=\"graphic_reference\">Reproduced with permission from: Travers, J, Marsh, S, Aldington, S, et al. Reference ranges for exhaled nitric oxide derived from a random community survey of adults. Am J Respir Crit Care Med 2007; 176:238. Copyright &#169;2007 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 57833 Version 1.0</div></div></div>"},"57836":{"type":"graphic_picture","displayName":"Molluscum and eczema","title":"Molluscum contagiosum in a patient with atopic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Molluscum contagiosum in a patient with atopic dermatitis</div><div class=\"cntnt\"><img style=\"width:432px; height:286px;\" src=\"images/DERM/57836_Molluscum_and_eczema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lesions are present on a background of atopic dermatitis of the flexural creases.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 57836 Version 2.0</div></div></div>"},"57840":{"type":"graphic_figure","displayName":"CSF secretion reabsorption","title":"Cerebrospinal fluid (CSF) formation and reabsorption","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Cerebrospinal fluid (CSF) formation and reabsorption</div><div class=\"cntnt\"><img style=\"width:542px; height:709px;\" src=\"images/ID/57840_CSF_secretion_reabsorption.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 57840 Version 3.0</div></div></div>"},"57841":{"type":"graphic_picture","displayName":"Light micrograph showing membranous nephropathy","title":"Light micrograph showing membranous nephropathy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light micrograph showing membranous nephropathy</div><div class=\"cntnt\"><img style=\"width:395px; height:254px;\" src=\"images/NEPH/57841_Membranous_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of membranous nephropathy, showing diffuse thickening of the glomerular basement membrane (long arrows) with essentially normal cellularity. Note how the thickness of the glomerular capillary walls is much greater than that of the adjacent tubular basement membranes (short arrow). There are also areas of mesangial expansion (asterisks). Immunofluorescence microscopy (showing granular IgG deposition) and electron microscopy (showing subepithelial deposits) are generally required to confirm the diagnosis.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 57841 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal glomerulus</div><div class=\"cntnt\"><img style=\"width:396px; height:253px;\" src=\"images/NEPH/75094_Normal_glomerulus_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 75094 Version 4.0</div></div></div>"},"57842":{"type":"graphic_figure","displayName":"pupillary reflex pathway","title":"Parasympathetic innervation and the pupillary reflex pathway","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Parasympathetic innervation and the pupillary reflex pathway</div><div class=\"cntnt\"><img style=\"width:548px; height:387px;\" src=\"images/NEURO/57842_pupillary_reflex_pathway.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Martin, TJ, Corbett, JJ. The Pupil. In: Neuro-ophthalmology: the requisites in ophthalmology, Krachmer, JH (Ed), Mosby, St. Louis 2000. Copyright &#169;2000 Elsevier.</div><div id=\"graphicVersion\">Graphic 57842 Version 1.0</div></div></div>"},"57843":{"type":"graphic_table","displayName":"NCI CTCAE v5 infusion-related reactions","title":"NCI CTCAE v5.0 infusion-related reactions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 infusion-related reactions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Infusion related reaction</td> <td>Mild transient reaction; infusion interruption not indicated; intervention not indicated</td> <td>Therapy or infusion interruption indicated but responds promptly to symptomatic treatment (eg, antihistamines, NSAIDs, narcotics [opioids], intravenous fluids); prophylactic medication indicated for less than or equal to 24 hours</td> <td>Prolonged (eg, not rapidly responsive to symptomatic medication and/or brief interruption of infusion); recurrence of symptoms following initial improvement; hospitalization indicated for other clinical sequelae</td> <td>Life-threatening consequences; urgent intervention indicated</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Infusion-related reaction is characterized by adverse reaction to the infusion of pharmacological or biological substances.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; NSAIDs: nonsteroidal anti-inflammatory drugs.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <A spellcheck=true href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=_blank>https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</A> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 57843 Version 8.0</div></div></div>"},"57844":{"type":"graphic_picture","displayName":"Urine in acute intermittent porphyria ","title":"Urine in acute intermittent porphyria","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urine in acute intermittent porphyria</div><div class=\"cntnt\"><img style=\"width:294px; height:455px;\" src=\"images/HEME/57844_Urine_in_AIP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photograph of urine from a normal subject (left) and a subject with acute intermittent porphyria (middle). The colors are compared with a dilute aqueous solution of red wine (right).</div><div class=\"graphic_footnotes\">AIP: acute intermittant porphyria</div><div class=\"graphic_reference\">Provided by Shigeru Sassa, MD, PhD.</div><div id=\"graphicVersion\">Graphic 57844 Version 3.0</div></div></div>"},"57845":{"type":"graphic_table","displayName":"Side effects of amiodarone","title":"Type and incidence of major side effects associated with amiodarone therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Type and incidence of major side effects associated with amiodarone therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Side effect</td> <td class=\"subtitle1\">Incidence, percent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Lung</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Cough, especially with infiltrates on chest radiography and reduced DLCO</td> <td>5 to 15 (&#62;400 mg/day)</td> </tr> <tr> <td>1 to 2 (&#8804;400 mg/day)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Thyroid</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Hypothyroidism and hyperthyroidism</td> <td>2 to 24</td> </tr> <tr> <td>3 to 4 (&#8804;400 mg/day)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Heart</td> </tr> <tr> <td class=\"indent1\">Bradycardia and atrioventricular block</td> <td>3 to 5</td> </tr> <tr> <td class=\"indent1\">Proarrhythmia</td> <td>&#60;1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Liver</td> </tr> <tr> <td class=\"indent1\">Serum AST or ALT more than two times normal</td> <td>15 to 50 </td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td>1 to 2 (&#8804;400 mg/day)</td> </tr> <tr> <td class=\"indent1\">Hepatitis and cirrhosis</td> <td>&#60;3</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Eye</td> </tr> <tr> <td class=\"indent1\">Corneal microdeposits</td> <td>&#62;90</td> </tr> <tr> <td class=\"indent1\">Halo vision, especially at night</td> <td>&#60;5</td> </tr> <tr> <td class=\"indent1\">Optic neuritis</td> <td>1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Skin</td> </tr> <tr> <td class=\"indent1\">Photosensitivity</td> <td>25 to 75</td> </tr> <tr> <td class=\"indent1\">Blue discoloration</td> <td>&#60;10</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Gastrointestinal tract</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Nausea, anorexia, and constipation</td> <td>30</td> </tr> <tr> <td>4 to 5 (&#8804;400 mg/day)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Central nervous system</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Varied manifestations including ataxia, paresthesias, peripheral neuropathy, sleep disturbance, impaired memory, and tremor</td> <td>3 to 30</td> </tr> <tr> <td>4 to 5 (&#8804;400 mg/day)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Genitourinary tract</td> </tr> <tr> <td class=\"indent1\">Epididymitis and erectile dysfunction</td> <td>&#60;1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DLCO: diffusing capacity for carbon monoxide; AST: aspartate aminotransferase; ALT: alanine aminotransferase.</div><div class=\"graphic_reference\">Data from: Goldschlager N, Epstein AE, Naccarelli G, et al. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med 2000; 160:1741; Vorperian VR, Havighurst TC, Miller S, et al. Adverse effects of low dose amiodarone: A meta-analysis. J Am Coll Cardiol 1997; 30:791; and Harjai KJ, Licata AA. Effects of amiodarone on thyroid function. Ann Intern Med 1997; 126:63.</div><div id=\"graphicVersion\">Graphic 57845 Version 5.0</div></div></div>"},"57846":{"type":"graphic_picture","displayName":"Botulinum toxin injection sites for peau d orange chin","title":"Example of botulinum toxin injection sites for peau d'orange chin","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Example of botulinum toxin injection sites for peau d'orange chin</div><div class=\"cntnt\"><img style=\"width:502px; height:324px;\" src=\"images/DERM/57846_Inject_sites_pea_dorang_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Injections are placed into the mentalis muscles.</div><div id=\"graphicVersion\">Graphic 57846 Version 3.0</div></div></div>"},"57847":{"type":"graphic_figure","displayName":"Auricle anatomy","title":"Auricle anatomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Auricle anatomy</div><div class=\"cntnt\"><img style=\"width:439px; height:424px;\" src=\"images/EM/57847_Auricle_anatomy_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">External ear. Auricle.</div><div class=\"graphic_reference\">Reproduced with permission from: Atlas of Human Anatomy. Copyright &copy; 2008 Anatomical Chart Co.</div><div id=\"graphicVersion\">Graphic 57847 Version 2.0</div></div></div>"},"57848":{"type":"graphic_diagnosticimage","displayName":"Popliteal arteriogram","title":"Arteriogram of the popliteal artery","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Arteriogram of the popliteal artery</div><div class=\"cntnt\"><img style=\"width:527px; height:561px;\" src=\"images/EM/57848_Popliteal_artery_A_gram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anterior view of an angiogram of the popliteal artery and branches. Note that the circumflex fibular artery supplies a hypervascular lesion in the popliteal fossa.</div><div class=\"graphic_reference\">Reproduced with permission from: Uflacker, R. Atlas Of Vascular Anatomy: An Angiographic Approach, Second Edition. Philadelphia: Lippincott Williams &amp; Wilkins. Copyright © 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 57848 Version 3.0</div></div></div>"},"57850":{"type":"graphic_table","displayName":"Types of hysterectomy","title":"Types of hysterectomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Types of hysterectomy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">Subtotal/supracervical</td> </tr> <tr> <td class=\"indent1\">Subtotal/supracervical hysterectomy. The uterus is removed. The superior portion of the cervix is amputated, the remainder of the cervix is conserved. Intrafascial hysterectomy is a subtype of subtotal hysterectomy in which the uterosacral ligaments are conserved.<sup>[1]</sup></td> </tr> <tr> <td class=\"subtitle2_left\">Piver-Rutledge-Smith Classification<sup><span style=\"font-size: 13px;\">[2]</span></sup></td> </tr> <tr> <td class=\"subtitle2_left\">Class l</td> </tr> <tr> <td class=\"indent1\">Extrafascial hysterectomy. The fascia of the cervix and lower uterine segment, which is rich in lymphatics, is removed with the uterus.</td> </tr> <tr> <td class=\"subtitle2_left\">Class ll</td> </tr> <tr> <td class=\"indent1\">Modified radical hysterectomy. The uterine artery is ligated where it crosses over the ureter and the uterosacral and cardinal ligaments are divided midway towards their attachment to the sacrum and pelvic sidewall, respectively. The upper one-third of the vagina is resected.</td> </tr> <tr> <td class=\"subtitle2_left\">Class lll</td> </tr> <tr> <td class=\"indent1\">Radical hysterectomy. The uterine artery is ligated at its origin from the superior vesical or internal iliac artery. Uterosacral and cardinal ligaments are resected at their attachments to the sacrum and pelvic sidewall. The upper one-half of the vagina is resected.</td> </tr> <tr> <td class=\"subtitle2_left\">Class lV</td> </tr> <tr> <td class=\"indent1\">Radical hysterectomy. The ureter is completely dissected from the vesicouterine ligament, the superior vesical artery is sacrificed, and three-fourths of the vagina is resected.</td> </tr> <tr> <td class=\"subtitle2_left\">Class V</td> </tr> <tr> <td class=\"indent1\">Radical hysterectomy. There is additional resection of a portion of the bladder or distal ureter with ureteral reimplantation into the bladder.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Semm K. Hysterectomy via laparotomy or pelviscopy. A new CASH method without colpotomy (German). Geburtshilfe Frauenheilkd 1991; 51:996. </LI>&#xD;&#xA;<LI>Piver MS. Five classes of extended hysterectomy for women with cervical cancer. Obstet Gynecol 1974; 44:265. </LI></OL></div><div id=\"graphicVersion\">Graphic 57850 Version 7.0</div></div></div>"},"57851":{"type":"graphic_picture","displayName":"Deep partial-thickness burn","title":"Deep partial-thickness burn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Deep partial-thickness burn</div><div class=\"cntnt\"><img style=\"width:382px; height:271px;\" src=\"images/EM/57851_Deeppartialthicknessburn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Easily unroofed blisters that do not blanch with pressure and have a waxy appearance typify deep partial-thickness burns.</div><div class=\"graphic_reference\">Courtesy of Eric D Morgan, MD,&nbsp;and William F Miser, MD.</div><div id=\"graphicVersion\">Graphic 57851 Version 4.0</div></div></div>"},"57853":{"type":"graphic_diagnosticimage","displayName":"Inspissated stool rectum","title":"Plain abdominal radiograph showing inspissated stool","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Plain abdominal radiograph showing inspissated stool</div><div class=\"cntnt\"><img style=\"width:453px; height:392px;\" src=\"images/PULM/57853_Inspissated_stool_rectum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pellets of stool, which lack the geometric appearance of drug packets, are predominantly present in rectum.</div><div class=\"graphic_reference\">Courtesy of Stephen Traub, MD.</div><div id=\"graphicVersion\">Graphic 57853 Version 2.0</div></div></div>"},"57854":{"type":"graphic_figure","displayName":"Tracheal bronchus types","title":"Different types of tracheal bronchus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Different types of tracheal bronchus</div><div class=\"cntnt\"><img style=\"width:344px; height:144px;\" src=\"images/PULM/57854_Tracheal_bronchus_types.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(a) normal, (b) blind ending diverticulum, (c) supernumerary bronchus, (d) displaced bronchus, (e) replaced right upper lobe bronchus.</div><div id=\"graphicVersion\">Graphic 57854 Version 2.0</div></div></div>"},"57856":{"type":"graphic_diagnosticimage","displayName":"Guide for odontoid cervical spine x-ray","title":"Guide for odontoid cervical spine x-ray","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Guide for odontoid cervical spine x-ray</div><div class=\"cntnt\"><img style=\"width:490px; height:643px;\" src=\"images/EM/57856_Guide_odont_cerv_spine_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Mower WR, Hoffman JR, Mahadevan SV. Cervical spine fractures. In: Harwood-Nuss Clinical Practice of Emergency Medicine, 5th ed, Wolfson AB (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 57856 Version 6.0</div></div></div>"},"57858":{"type":"graphic_movie","displayName":"Mitral valve prolapse with patient standing","title":"Mitral valve prolapse as heard with the patient standing","html":"<div class=\"graphic normal\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Mitral valve prolapse as heard with the patient standing</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/57858_mvpstandconv.mp4\" style=\"width:580px;height:480px\"></div><img style=\"width:569px; height:293px;\" src=\"images/CARD/57858_mvpstand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram and phonocardiogram of mitral valve prolapse as heard at the apex. S1 (mitral and tricuspid valve closure) is followed by a mid systolic click resulting from the prolapse of the mitral valve. After the prolapse occurs, there is the mid systolic murmur of mitral regurgitation. With standing, there is a decrease in venous return, a decrease in left ventricular volume, and the mitral valve prolapses earlier in systole. Consequently, the mitral regurgitation murmur is lengthened.</div><div class=\"graphic_reference\">Provided by John M Criley, MD, The Physiological Origins of Heart Sounds and Murmurs, Little, Brown, Boston, 1996, 1-800-527-0145. This program contains a complete interactive tutorial integrating over 200 heart sounds and murmurs with cineangiographic, echo-Doppler, and hemodynamic motion picture sequences.</div><div id=\"graphicVersion\">Graphic 57858 Version 5.0</div></div></div>"},"57862":{"type":"graphic_table","displayName":"Causes of spinal cord infarct","title":"Causes of spinal cord infarction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of spinal cord infarction</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Aorta disease, procedures</td> </tr> <tr> <td class=\"indent1\">Aortic surgery</td> </tr> <tr> <td class=\"indent1\">Thoracic endovascular aortic repair (TEVAR)</td> </tr> <tr> <td class=\"indent1\">Aortic dissection</td> </tr> <tr> <td class=\"indent1\">Traumatic rupture of the aorta</td> </tr> <tr> <td class=\"indent1\">Aortic thrombosis</td> </tr> <tr> <td class=\"indent1\">Aortic aneurysm</td> </tr> <tr> <td class=\"indent1\">Coarctation of the aorta</td> </tr> <tr> <td class=\"indent1\">Aortography</td> </tr> <tr> <td class=\"subtitle1_single\">Systemic hypoperfusion</td> </tr> <tr> <td class=\"indent1\">Cardiac arrest</td> </tr> <tr> <td class=\"indent1\">Systemic bleeding</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiogenic embolism</td> </tr> <tr> <td class=\"indent1\">Atrial myxoma</td> </tr> <tr> <td class=\"indent1\">Mitral valve disease</td> </tr> <tr> <td class=\"indent1\">Patent foramen ovale</td> </tr> <tr> <td class=\"indent1\">Bacterial endocarditis</td> </tr> <tr> <td class=\"indent1\">Cardiac catheterization</td> </tr> <tr> <td class=\"subtitle1_single\">Vasculitis</td> </tr> <tr> <td class=\"indent1\">Systemic lupus erythematosus</td> </tr> <tr> <td class=\"indent1\">Polyarteritis nodosa</td> </tr> <tr> <td class=\"indent1\">Behcet syndrome</td> </tr> <tr> <td class=\"indent1\">Giant cell arteritis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Infection</td> </tr> <tr> <td class=\"indent1\">Bacterial meningitis</td> </tr> <tr> <td class=\"indent1\">Syphilis</td> </tr> <tr> <td class=\"indent1\">Mucormycosis</td> </tr> <tr> <td class=\"subtitle1_single\">Hematologic disease</td> </tr> <tr> <td class=\"indent1\">Hypercoagulable conditions</td> </tr> <tr> <td class=\"indent1\">Sickle cell anemia</td> </tr> <tr> <td class=\"subtitle1_single\">Non-aortic surgeries</td> </tr> <tr> <td class=\"subtitle1_single\">Spine disease</td> </tr> <tr> <td class=\"indent1\">Spine surgery</td> </tr> <tr> <td class=\"indent1\">Cervical spondylosis</td> </tr> <tr> <td class=\"indent1\">Fibrocartilaginous embolism</td> </tr> <tr> <td class=\"indent1\">Epidural steroid injections</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\">Cocaine abuse</td> </tr> <tr> <td class=\"indent1\">Vertebral artery dissection</td> </tr> <tr> <td class=\"indent1\">Spinal vascular malformation</td> </tr> <tr> <td class=\"indent1\">Decompression sickness</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 57862 Version 7.0</div></div></div>"},"57864":{"type":"graphic_diagnosticimage","displayName":"Vascular malformation 9h","title":"Pelvic ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pelvic ultrasound</div><div class=\"cntnt\"><img style=\"width:313px; height:266px;\" src=\"images/OBGYN/57864_Vascular_malformation_9h.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pelvic ultrasound after uterine artery embolization no longer demonstrates the abnormal intrauterine vascular structures within the uterus (arrows), which were present before uterine artery embolization. The patient's uterine bleeding was stopped immediately after the embolization.</div><div id=\"graphicVersion\">Graphic 57864 Version 2.0</div></div></div>"},"57865":{"type":"graphic_figure","displayName":"Megakaryocyte number and volume","title":"Megakaryocyte number and volume in megakaryocyte disorders","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Megakaryocyte number and volume in megakaryocyte disorders</div><div class=\"cntnt\"><img style=\"width:507px; height:264px;\" src=\"images/HEME/57865_Megakaryocyte_number_and_vo.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow analysis was performed in normal subjects and patients with a variety of hematological conditions: hypoplastic bone marrow states (Hypo), B12 deficiency (B12 def), congestive splenomegaly (Congest), immune thrombocytopenia (ITP), chronic inflammation (Inflam), and essential thrombocythemia (ET). Left panel: The number of megakaryocytes was reduced below normal only in hypoplastic bone marrow states and was variably increased in all other conditions examined. Right panel: Megakaryocyte volume was reduced below normal only in B12 deficiency and chronic inflammation, and was variably elevated in all other conditions. </div><div class=\"graphic_reference\">Data from: Harker LA, Finch CA. J Clin Invest 1969; 48:963.</div><div id=\"graphicVersion\">Graphic 57865 Version 3.0</div></div></div>"},"57866":{"type":"graphic_figure","displayName":"Arterial dissection","title":"The progression of a dissection, thrombus development, and total vessel occlusion","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">The progression of a dissection, thrombus development, and total vessel occlusion</div><div class=\"cntnt\"><img style=\"width:526px; height:285px;\" src=\"images/NEURO/57866_Arterial_dissection.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dr. Mounzer Kassab.</div><div id=\"graphicVersion\">Graphic 57866 Version 2.0</div></div></div>"},"57867":{"type":"graphic_diagnosticimage","displayName":"Ultrasound images of in situ intrauterine device","title":"Ultrasound images of in situ intrauterine devices: Normal position (A-D) and abnormal position (E-F)","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Ultrasound images of in situ intrauterine devices: Normal position (A-D) and abnormal position (E-F)</div><div class=\"cntnt\"><img style=\"width:462px; height:647px;\" src=\"images/OBGYN/57867_US_imgs_insitu_intr_device.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Transabdominal ultrasound shows the normal appearance of the shaft of an intrauterine contraceptive device (IUD) in good position in the endometrial cavity.<br> (B) Transvaginal scan shows the shaft of the IUD in good position. Note the echogenic string of the IUD in the cervix.<br> (C) View of the fundus shows the cross bars of the IUD in good position.<br> (D) Three-dimensional (3D) reconstructed image shows IUD in good position.<br> (E) In a different patient, transvaginal ultrasound shows low position of IUD, which is located in the cervix.<br> (F) When an IUD is known to be present, but has not been seen on an ultrasound examination, a KUB is helpful. In this case, the IUD is in the right pelvis (arrow).</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 57867 Version 3.0</div></div></div>"},"57868":{"type":"graphic_picture","displayName":"Contact dermatitis histology","title":"Histopathology of allergic contact dermatitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Histopathology of allergic contact dermatitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/57868_Contact_dermatitis_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Epidermal spongiosis and spongiotic vesicles (arrows) are present in this biopsy of allergic contact dermatitis from poison ivy. Infiltrating lymphocytes are apparent in the epidermis, where they effect the cell-mediated delayed hypersensitivity reaction.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin R, Strayer DS. Rubin's Pathology: Clinicopathologic Foundations of Medicine, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &#169; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 57868 Version 2.0</div></div></div>"},"57870":{"type":"graphic_picture","displayName":"Renal Bx congenital NS of the Finnish type - tubular changes","title":"Renal Bx congenital NS of the Finnish type - tubular changes","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Renal Bx congenital NS of the Finnish type - tubular changes</div><div class=\"cntnt\"><img style=\"width:540px; height:364px;\" src=\"images/PEDS/57870_Renal_Bx_Finn_tubular_chang.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Renal biopsy from an infant with congenital nephrotic syndrome (NS) of the Finnish type due to mutations in the <EM>NPHS1</EM> gene that encodes nephrin, a transmembrane protein located at the slit diaphragm of the glomerular podocytes. The most striking histologic finding is the irregular microcystic dilatation of proximal tubule.</div><div id=\"graphicVersion\">Graphic 57870 Version 4.0</div></div></div>"},"57871":{"type":"graphic_picture","displayName":"Phytophotodermatitis 2","title":"Phytophotodermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Phytophotodermatitis</div><div class=\"cntnt\"><img style=\"width:396px; height:371px;\" src=\"images/DERM/57871_Phytophotodermatitis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After making lemonade during an outdoor excursion trip, this 38-year-old female presented with erythematous linear and angulated patches and crusts on the face.</div><div class=\"graphic_reference\">Copyright © Shahbaz A Janjua, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 57871 Version 5.0</div></div></div>"},"57872":{"type":"graphic_algorithm","displayName":"Neuromuscular respir failure","title":"Pathophysiology of neuromuscular respiratory failure","html":"<div class=\"graphic\"><div style=\"width: 597px\" class=\"figure\"><div class=\"ttl\">Pathophysiology of neuromuscular respiratory failure</div><div class=\"cntnt\"><img style=\"width:577px; height:319px;\" src=\"images/PULM/57872_Neuromuscular_respir_failur.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">V/Q: ventilation/perfusion; VC: vital capacity; TV: tidal volume.</div><div id=\"graphicVersion\">Graphic 57872 Version 3.0</div></div></div>"},"57873":{"type":"graphic_waveform","displayName":"Assessing intrinsic PEEP","title":"Intrinsic positive end-expiratory pressure (PEEPi)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intrinsic positive end-expiratory pressure (PEEPi)</div><div class=\"cntnt\"><img style=\"width:328px; height:358px;\" src=\"images/PULM/57873_OccludingexpiratoryportC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Recordings of airway pressure (P<sub>aw</sub>), flow, and volume in a patient receiving controlled mechanical ventilation. After the third breath, the airway was occluded at end-expiration using the end-expiratory hold function on the ventilator. During the period of zero flow, pressure in the alveoli and ventilator circuit equilibrate, and the plateau pressure reflects auto or intrinsic positive end-expiratory pressure (PEEPi), indicated by the arrow.</div><div class=\"graphic_reference\">Reproduced with permission from: Tobin MJ, Van de Graaff WB. Monitoring of lung mechanics and work of breathing. In: Tobin MJ, ed. Principles and practice of mechanical ventilation. New York: McGraw Hill, Inc, 1994: 967.</div><div id=\"graphicVersion\">Graphic 57873 Version 4.0</div></div></div>"},"57874":{"type":"graphic_table","displayName":"Richmond sedation scale","title":"Richmond agitation-sedation scale (RASS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Richmond agitation-sedation scale (RASS)</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n      <td class=\"subtitle1\">Score</td>\n      <td class=\"subtitle1\">Term</td>\n      <td class=\"subtitle1\">Description</td>\n    </tr>\n\n    <tr>\n      <td>+4</td>\n      <td>Combative</td>\n      <td>Overtly combative or violent, immediate danger to staff</td>\n    </tr>\n\n    <tr>\n      <td>+3</td>\n      <td>Very agitated</td>\n      <td>Pulls on or removes tubes or catheters, aggressive behavior toward staff</td>\n    </tr>\n\n    <tr>\n      <td>+2</td>\n      <td>Agitated</td>\n      <td>Frequent nonpurposeful movement or patient-ventilator dyssynchrony</td>\n    </tr>\n\n    <tr>\n      <td>+1</td>\n      <td>Restless</td>\n      <td>Anxious or apprehensive but movements not aggressive or vigorous</td>\n    </tr>\n\n    <tr>\n      <td>0</td>\n      <td>Alert and calm</td>\n      <td>&nbsp;</td>\n    </tr>\n\n    <tr>\n      <td>-1</td>\n      <td>Drowsy</td>\n      <td>Not fully alert, sustained (&#62;10 seconds) awakening, eye contact to voice</td>\n    </tr>\n\n    <tr>\n      <td>-2</td>\n      <td>Light sedation</td>\n      <td>Briefly (&#60;10 seconds) awakens with eye contact to voice</td>\n    </tr>\n\n    <tr>\n      <td>-3</td>\n      <td>Moderate sedation</td>\n      <td>Any movement (but no eye contact) to voice</td>\n    </tr>\n\n    <tr>\n      <td>-4</td>\n      <td>Deep sedation</td>\n      <td>No response to voice, any movement to physical stimulation</td>\n    </tr>\n\n    <tr>\n      <td>-5</td>\n      <td>Unarousable</td>\n      <td>No response to voice or physical stimulation</td>\n    </tr>\n\n    <tr>\n      <td colspan=\"3\"  class=\"subtitle1\">Procedure</td>\n    </tr>\n\n    <tr>\n      <td>1.</td>\n      <td colspan=\"2\">Observe patient. Is patient alert and calm (score 0)?</td>\n    </tr>\n\n    <tr>\n      <td rowspan=\"2\">2.</td>\n      <td colspan=\"2\">Does patient have behavior that is consistent with restlessness or agitation?</td>\n    </tr>\n\n    <tr>\n      <td colspan=\"2\">Assign score +1 to +4 using the criteria listed above.</td>\n    </tr>\n\n    <tr>\n      <td rowspan=\"4\">3.</td>\n      <td colspan=\"2\">If patient is not alert, in a loud speaking voice state patient's name and direct patient to open\neyes and look at speaker. Repeat once if necessary. Can prompt patient to continue looking at speaker.</td>\n    </tr>\n\n    <tr>\n      <td colspan=\"2\">Patient has eye opening and eye contact, which is sustained for more than 10 seconds (score -1).</td>\n    </tr>\n\n    <tr>\n      <td colspan=\"2\" >Patient has eye opening and eye contact, but this is not sustained for 10 seconds (score -2).</td>\n    </tr>\n\n    <tr>\n      <td colspan=\"2\" >Patient has any movement in response to voice, excluding eye contact (score -3).</td>\n    </tr>\n\n    <tr>\n      <td rowspan=\"3\">4.</td>\n      <td colspan=\"2\" >If patient does not respond to voice, physically stimulate patient by shaking shoulder and then rubbing sternum if there is no response.</td>\n    </tr>\n\n    <tr>\n      <td colspan=\"2\" >Patient has any movement to physical stimulation (score -4).</td>\n    </tr>\n\n    <tr>\n      <td colspan=\"2\" >Patient has no response to voice or physical stimulation (score -5).</td>\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Sessler, C, Gosnell, M, Grap, MJ, et al. The Richmond agitation-sedation scale. Validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med 2002; 166:1338. Copyright &#169; 2002 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 57874 Version 1.0</div></div></div>"},"57875":{"type":"graphic_diagnosticimage","displayName":"Tuberculosis pleurisy II PA","title":"Pleural calcifications due to chronic tuberculous pleurisy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pleural calcifications due to chronic tuberculous pleurisy</div><div class=\"cntnt\"><img style=\"width:324px; height:327px;\" src=\"images/PULM/57875_TuberculosispleurisyIIPA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chronic tuberculous pleurisy with extensive pleural calcifications and restriction of the right lung, accounting for the small right hemithorax and the cardiomediastinal shift to the right. Right-sided parenchymal lung scars and left-sided nodular calcified granulomata are also evident.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 57875 Version 4.0</div></div></div>"},"57877":{"type":"graphic_table","displayName":"Comorbidity anorexia nervosa with other mental disorders","title":"Lifetime comorbidity of anorexia nervosa with other mental disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lifetime comorbidity of anorexia nervosa with other mental disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Mental disorder</td> <td class=\"subtitle1\" colspan=\"2\">Percent of anorexia nervosa patients with a comorbid disorder</td> </tr> <tr> <td class=\"subtitle2\">Nationally representative survey</td> <td class=\"subtitle2\">Clinical settings</td> </tr> <tr> <td colspan=\"3\"><strong>Anxiety disorders</strong></td> </tr> <tr> <td class=\"indent1\">Specific phobias</td> <td class=\"centered\">27</td> <td class=\"centered\">14</td> </tr> <tr> <td class=\"indent1\">Social anxiety disorder</td> <td class=\"centered\">25</td> <td class=\"centered\">22</td> </tr> <tr> <td class=\"indent1\">Generalized anxiety disorder</td> <td class=\"centered\">7</td> <td class=\"centered\">13</td> </tr> <tr> <td class=\"indent1\">Agoraphobia</td> <td class=\"centered\">5</td> <td class=\"centered\">3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Panic disorder</td> <td class=\"centered\">3</td> <td class=\"centered\">9</td> </tr> <tr> <td colspan=\"3\"><strong>Mood disorders</strong></td> </tr> <tr> <td class=\"indent1\">Unipolar major depression</td> <td class=\"centered\">39</td> <td class=\"centered\">71</td> </tr> <tr> <td class=\"indent1\">Persistent depressive disorder</td> <td class=\"centered\">13</td> <td class=\"centered\">&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Bipolar I or II disorder</td> <td class=\"centered\">3</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td colspan=\"3\"><strong>Disruptive, impulse control, and conduct disorders</strong></td> </tr> <tr> <td class=\"indent1\">Oppositional-defiant disorder</td> <td class=\"centered\">11</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"indent1\">Conduct disorder</td> <td class=\"centered\">10</td> <td class=\"centered\">&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Intermittent explosive disorder</td> <td class=\"centered\">5</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td colspan=\"3\"><strong>Substance use disorders</strong></td> </tr> <tr> <td class=\"indent1\">Alcohol abuse or dependence</td> <td class=\"centered\">25</td> <td class=\"centered\">17</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Illicit drug abuse or dependence</td> <td class=\"centered\">18</td> <td class=\"centered\">11</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Attention-deficit/hyperactivity disorder</strong></td> <td class=\"centered\">16</td> <td class=\"centered\">&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Posttraumatic stress disorder</strong></td> <td class=\"centered\">12</td> <td class=\"centered\">5</td> </tr> <tr> <td><strong>Obsessive-compulsive disorder</strong></td> <td class=\"centered\">0</td> <td class=\"centered\">35</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:<br /><ol>&#xD;&#xA;    <li>Bulik CM, Klump KL, Thornton L, et al. Alcohol use disorder comorbidity in eating disorders: a multicenter study. J Clin Psychiatry 2004; 65:1000. </li>&#xD;&#xA;    <li>Fern&aacute;ndez-Aranda F, Pinheiro AP, Thornton LM, et al. Impulse control disorders in women with eating disorders. Psychiatry Res 2008; 157:147. </li>&#xD;&#xA;    <li>Fern&aacute;ndez-Aranda F, Pinheiro AP, Tozzi F, et al. Symptom profile of major depressive disorder in women with eating disorders. Aust N Z J Psychiatry 2007; 41:24. </li>&#xD;&#xA;    <li>Hudson JI, Hiripi E, Pope HG Jr, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry 2007; 61:348. </li>&#xD;&#xA;    <li>Kaye WH, Bulik CM, Thornton L, et al. Comorbidity of anxiety disorders with anorexia and bulimia nervosa. Am J Psychiatry 2004; 161:2215. </li>&#xD;&#xA;    <li>Root TL, Pinheiro AP, Thornton L, et al. Substance use disorders in women with anorexia nervosa. Int J Eat Disord 2010; 43:14. </li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 57877 Version 6.0</div></div></div>"},"57878":{"type":"graphic_figure","displayName":"Basic knee anatomy PI","title":"Right knee","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right knee</div><div class=\"cntnt\"><img style=\"width:427px; height:438px;\" src=\"images/PI/57878_Basic_knee_anatomy_PI_ed.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 57878 Version 2.0</div></div></div>"},"57879":{"type":"graphic_table","displayName":"Differential diagnosis of painless scrotal mass in children","title":"Differential diagnosis of painless scrotal mass in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of painless scrotal mass in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Mass </td> <td class=\"subtitle1\">Palpation </td> <td class=\"subtitle1\">Transilluminates? </td> <td class=\"subtitle1\">Increases with Valsalva maneuver? </td> </tr> <tr> <td>Tumor</td> <td>Firm</td> <td>No</td> <td>No</td> </tr> <tr> <td>Varicocele</td> <td>\"Bag of worms\"</td> <td>No</td> <td>Yes</td> </tr> <tr> <td>Noncommunicating hydrocele</td> <td>Fluid-filled</td> <td>Yes</td> <td>No</td> </tr> <tr> <td>Communicating hydrocele</td> <td>Fluid-filled</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td>Inguinal hernia without incarceration</td> <td>Nontender, reducible mass&nbsp;</td> <td>No&nbsp;</td> <td>Yes</td> </tr> <tr> <td>Scrotal edema (insect bite or sign of generalized edema)</td> <td>Bilateral scrotal swelling, soft</td> <td>No</td> <td>No</td> </tr> <tr> <td>Spermatocele</td> <td>Small, soft, and localized cyst</td> <td>Yes</td> <td>No</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>Kapphahn C, Schlossberger N. Diagnostic approach to scrotal masses. Adolescent Health Update 1992; 5:1.</LI></OL></div><div id=\"graphicVersion\">Graphic 57879 Version 4.0</div></div></div>"},"57880":{"type":"graphic_figure","displayName":"How to swaddle PI","title":"How to swaddle a baby","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">How to swaddle a baby</div><div class=\"cntnt\"><img style=\"width:534px; height:578px;\" src=\"images/PI/57880_How_to_swaddle_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Swaddling a baby can help stop crying or fussing. To swaddle a baby:<br /><OL>&#xD;&#xA;<LI>Put your baby on a large blanket that has the top corner folded down (as shown in A). </LI>&#xD;&#xA;<LI>Bring the left arm down (as shown in B). Wrap the cloth over the arm and chest and tuck it under the right side of the baby (as shown in C).</LI>&#xD;&#xA;<LI>Bring the right arm down. Wrap the cloth over the baby's arm and chest and tuck it under the left side of the baby (as shown in D).</LI>&#xD;&#xA;<LI>Twist or fold the bottom end of the cloth and tuck it behind the baby, ensuring that both legs are bent up and out (as shown in E and F). It is important to leave room for the hips to move. </LI></OL></div><div id=\"graphicVersion\">Graphic 57880 Version 7.0</div></div></div>"},"57882":{"type":"graphic_table","displayName":"Rome IV constipation child","title":"Rome IV criteria for the diagnosis of functional constipation in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rome&nbsp;IV criteria for the diagnosis of functional constipation in children</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Infants and toddlers up to 4 years old</td> </tr> <tr> <td class=\"sublist1_start\">At least two of the following present for at least one month</td> </tr> <tr> <td class=\"sublist1\">Two or fewer defecations per week</td> </tr> <tr> <td class=\"sublist1\">History of excessive stool retention&nbsp;</td> </tr> <tr> <td class=\"sublist1\">History of painful or hard bowel movements&nbsp;</td> </tr> <tr> <td class=\"sublist1\">History of large-diameter stools </td> </tr> <tr> <td class=\"sublist1\">Presence of a large fecal mass in the rectum</td> </tr> <tr> <td class=\"sublist1_start\">In toilet-trained children, the following additional criteria may be used:</td> </tr> <tr> <td class=\"sublist1\">At least one episode/week of incontinence after the acquisition of toileting skills</td> </tr> <tr> <td class=\"sublist1\">History of large-diameter stools that may obstruct the toilet</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Children with developmental age of at least 4 years</td> </tr> <tr> <td class=\"sublist1_start\">At least two of the following present at least once per week for at least&nbsp;one month*</td> </tr> <tr> <td class=\"sublist1\">Two or fewer defecations in the toilet per week</td> </tr> <tr> <td class=\"sublist1\">At least one episode of fecal incontinence per week</td> </tr> <tr> <td class=\"sublist1\">History of retentive posturing or excessive volitional stool retention</td> </tr> <tr> <td class=\"sublist1\">History of painful or hard bowel movements</td> </tr> <tr> <td class=\"sublist1\">Presence of a large fecal mass in the rectum</td> </tr> <tr> <td class=\"sublist1\">History of large-diameter stools that may obstruct the toilet</td> </tr> <tr> <td class=\"sublist1_start\">The symptoms cannot be fully explained by&nbsp;another medical condition.&nbsp;</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* In addition, the symptoms are insufficient to fulfill the diagnostic criteria of irritable bowel syndrome.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Benninga MA, Faure C, Hyman PE, et al. Childhood Functional Gastrointestinal Disorders: Neonate/Toddler. Gastroenterology 2016. </LI>&#xD;&#xA;<LI>Hyams JS, Di Lorenzo C, Saps M, et al. Functional Disorders: Children and Adolescents. Gastroenterology 2016.</LI></OL></div><div id=\"graphicVersion\">Graphic 57882 Version 4.0</div></div></div>"},"57883":{"type":"graphic_picture","displayName":"Delivery of PDT","title":"Photodynamic therapy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Photodynamic therapy</div><div class=\"cntnt\"><img style=\"width:306px; height:311px;\" src=\"images/PULM/57883_Delivery_of_PDT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The same patient photographed during the delivery of photodynamic therapy. The field appears diffusely red to orange, and the tip of the cylindrical diffuser is embedded in the tumor.</div><div class=\"graphic_reference\">Courtesy of Armin Ernst, MD.</div><div id=\"graphicVersion\">Graphic 57883 Version 2.0</div></div></div>"},"57884":{"type":"graphic_diagnosticimage","displayName":"Acute cholangitis MRCP","title":"Acute cholangitis MRCP","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute cholangitis MRCP</div><div class=\"cntnt\"><img style=\"width:396px; height:398px;\" src=\"images/GAST/57884_Acute_cholangitis_MRCP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 64-year-old man presented to the emergency department complaining of severe right upper quadrant abdominal pain, nausea, vomiting, and fevers. Laboratory data revealed an elevated white blood cell count with a left shift, elevated liver function tests including bilirubin, and elevated pancreatic enzymes. A right upper quadrant ultrasound revealed a dilated bile duct with possible stones in the bile duct and gallbladder. Magnetic resonance cholangiopancreatography (MRCP) was performed and revealed multiple filling defects in the common bile duct and cystic duct (arrows).</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD.</div><div id=\"graphicVersion\">Graphic 57884 Version 2.0</div></div></div>"},"57887":{"type":"graphic_algorithm","displayName":"Formation of extravillous trophoblast","title":"Formation of extravillous trophoblast (EVT)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Formation of extravillous trophoblast (EVT)</div><div class=\"cntnt\"><img style=\"width:376px; height:281px;\" src=\"images/OBGYN/57887_Extravillous_trophobl_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The interstital EVT invades decidua and myometrium, where it anchors the conceptus and forms a continuous shell around it at the level of the decidua. Endovascular EVTs are associated with spiral arteries, either within the vessel wall (intramural) or replacing endothelium (intra-arterial). EVTs transform the narrow spiral arteries to wide uteroplacental arteries, which distribute blood into a low resistance vascular network.</div><div id=\"graphicVersion\">Graphic 57887 Version 5.0</div></div></div>"},"57888":{"type":"graphic_picture","displayName":"Necrotizing funisitis","title":"Necrotizing funisitis - \"barber pole\" umbilical cord","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Necrotizing funisitis - &quot;barber pole&quot; umbilical cord</div><div class=\"cntnt\"><img style=\"width:432px; height:256px;\" src=\"images/OBGYN/57888_Necrotizing_funisitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 57888 Version 1.0</div></div></div>"},"57890":{"type":"graphic_figure","displayName":"Heme biosynthetic pathway","title":"Biosynthetic pathway of heme","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Biosynthetic pathway of heme</div><div class=\"cntnt\"><img style=\"width:531px; height:501px;\" src=\"images/HEME/57890_Heme_biosynthetic_pathway.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates the biochemical steps in the formation of heme, starting with glycine and succinyl CoA and ending with the insertion of iron into protoporphyrin IX to form heme. Each of the eight enzymatic steps involved in this process is shown as a number inside of a circle, and the locations (ie, mitochondrial or cytoplasmic) where these steps take place are also shown.</div><div class=\"graphic_footnotes\">A: acetate; P: propionate; M: methyl; V: vinyl.</div><div id=\"graphicVersion\">Graphic 57890 Version 4.0</div></div></div>"},"57892":{"type":"graphic_figure","displayName":"Pathogenesis acne vulgaris","title":"Pathogenesis of follicular distention, rupture, and inflammation in acne vulgaris","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Pathogenesis of follicular distention, rupture, and inflammation in acne vulgaris</div><div class=\"cntnt\"><img style=\"width:518px; height:796px;\" src=\"images/PC/57892_Pathogenesis_acne_vulgaris.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acne is a disease of the follicular canal of a sebaceous folicle. A compact stratum corneum and a thickened granular layer in the infrainfundibulum are the beginning of the formation of a comedo. Microcomedones (A) and closed (B) and open (C) comedones form. Excessive sebum secretion occurs, and the bacterium <EM>Cutibacterium</EM> (formerly <EM>Propionibacterium</EM>) <EM>acnes</EM> proliferates. The organism produces chemotactic factors, leading to neutrophil migration into the intact comedo. Neutrophilic enzymes are released and the comedo ruptures, inducing a cycle of chemotaxis and intense neutrophilic inflammation (D and E).</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin E, MD and Farber JL, MD. Pathology, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 1999. Copyright ©1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 57892 Version 3.0</div></div></div>"},"57893":{"type":"graphic_picture","displayName":"Extensive hidradenitis suppurativa with multiple sinus tracts","title":"Extensive hidradenitis suppurativa with multiple sinus tracts","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Extensive hidradenitis suppurativa with multiple sinus tracts</div><div class=\"cntnt\"><img style=\"width:396px; height:397px;\" src=\"images/SURG/57893_Addsinusdiscoverededt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows the initial surgical unroofing of the inflamed hidradenitis suppurativa inflamed nodule, the lateral extension of the sinus tract, and an additional inferior lateral sinus tract. Gentle probing with blunt scissors has identified another sinus tract that requires unroofing with beveled skin edges.</div><div class=\"graphic_reference\">Reproduced with permission from: F William Danby, MD, FRCPC, FAAD. Copyright © 2011.</div><div id=\"graphicVersion\">Graphic 57893 Version 4.0</div></div></div>"},"57894":{"type":"graphic_picture","displayName":"Erythema multiforme on extremity","title":"Erythema multiforme","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema multiforme</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/57894_Erythema_multi_extrem_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple typical target lesions are present on this extremity.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 57894 Version 6.0</div></div></div>"},"57900":{"type":"graphic_figure","displayName":"Determinants VO2max","title":"Determinants of VO<sub>2</sub>max in the Fick equation","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Determinants of VO<sub>2</sub>max in the Fick equation</div><div class=\"cntnt\"><img style=\"width:457px; height:361px;\" src=\"images/CARD/57900_Determinants_VO2_max.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">VO<sub>2</sub>: oxygen (O<sub>2</sub>) uptake; SV: stroke volume; HR: heart rate; PiO<sub>2</sub>: partial pressure inspired O<sub>2</sub>: FiO<sub>2</sub> x Patmospheric; CaO<sub>2</sub>: arterial oxygen content; CvO<sub>2</sub>: mixed venous oxygen content.</div><div id=\"graphicVersion\">Graphic 57900 Version 4.0</div></div></div>"},"57901":{"type":"graphic_figure","displayName":"Abdominal hysterectomy PI","title":"Types of abdominal hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Types of abdominal hysterectomy</div><div class=\"cntnt\"><img style=\"width:540px; height:762px;\" src=\"images/PI/57901_Abdom_hysterectomy_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In an abdominal hysterectomy, the doctor removes the uterus through an opening in the belly. If it is a \"total hysterectomy\" the doctor also removes the cervix. If it is a \"subtotal\" or \"supracervical\" hysterectomy, the doctor removes the uterus but leaves the cervix in place. To do this surgery, doctors sometimes make a horizontal cut (from left to right) at the bikini line. Sometimes they instead make a vertical cut from top to bottom. As part of a hysterectomy, doctors sometimes also remove the ovaries and the tubes that connect the ovaries to the uterus (fallopian tubes). This is called \"salpingo-oophorectomy.\"</div><div id=\"graphicVersion\">Graphic 57901 Version 5.0</div></div></div>"},"57902":{"type":"graphic_diagnosticimage","displayName":"Axial MRI Sturge-Weber","title":"Sturge-Weber syndrome axial MRI","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Sturge-Weber syndrome axial MRI</div><div class=\"cntnt\"><img style=\"width:466px; height:252px;\" src=\"images/PEDS/57902_Axial_MRI_Sturge-Weber.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial brain MRI of child with Sturge-Weber syndrome demonstrating atrophy of the left hemisphere and contrast enhancement of the surface of the left hemisphere, particularly prominent over the occipital lobe. The left hemisphere is indicated by a white arrow in both images.</div><div class=\"graphic_reference\">Courtesy of John Bodensteiner, MD.</div><div id=\"graphicVersion\">Graphic 57902 Version 4.0</div></div></div>"},"57903":{"type":"graphic_diagnosticimage","displayName":"Connected Roux-en-O misconstruction","title":"Connected Roux-en-O misconstruction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Connected Roux-en-O misconstruction</div><div class=\"cntnt\"><img style=\"width:443px; height:653px;\" src=\"images/SURG/57903_Connrouxenomisconstr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">60-year-old man with connected Roux-en-O misconstruction.<br />(A) Representative axial CT scan through upper abdomen shows nonspecific mild dilatation of upper abdominal bowel loops (thick arrows). Ileum (thin arrow) and colon (arrowheads) are unremarkable. Gastrojejunostomy tube placed in excluded gastric segment is partially evident within transverse duodenum.<br />(B) Patient was given medium-density barium in serial patient-controlled swallows during fluoroscopic observation. Early spot image of gastric pouch (thick arrow) shows patent proximal anastomosis (paired thin arrows) and normal-caliber alimentary limb (arrowheads). Small collection of contrast material lateral to pouch (single thin arrow) is residual contrast agent from earlier anastomotic leak that had healed.<br />(C) Fluoroscopic spot image of alimentary limb during initial filling shows normal bowel caliber. Mild indentation of alimentary limb as it goes through transverse mesocolon (arrow) is evident. Residual enteric contrast material from previous CT examination faintly opacifies colon.<br />(D) Fluoroscopic spot image of distal alimentary limb shows mild to moderate dilatation of limb. Antegrade contrast flow is by gravity only with no peristaltic activity observed. Most contrast material has reached distal alimentary limb (arrowheads).<br />(E) Fifteen-minute-delayed fluoroscopic spot image of alimentary limb shows retrograde peristalsis (arrows) with return of considerable amount of contrast material into dilated proximal alimentary limb (arrowheads). Fluoroscopy showed contrast material eventually reaching gastric pouch (not shown).</div><div class=\"graphic_reference\">Reprinted with the permission of the American Journal of Roentgenology. Mitchell MT, Gasparaitis AE, Alverdy JC. Imaging findings in roux-en-o and other misconstructions: Rare but serious complications of roux-en-y gastric bypass surgery. AJR Am J Roentgenol 2008; 190:367. Copyright &copy; 2008 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 57903 Version 9.0</div></div></div>"},"57905":{"type":"graphic_figure","displayName":"Agenesis lower vagina complete","title":"Agenesis (atresia) of the lower vagina","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Agenesis (atresia) of the lower vagina</div><div class=\"cntnt\"><img style=\"width:406px; height:329px;\" src=\"images/OBGYN/57905_Agenesis_lower_vagina_compl.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 57905 Version 10.0</div></div></div>"},"57906":{"type":"graphic_figure","displayName":"Anatomy mitral valve leaflets","title":"Anatomy of the mitral valve leaflets","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomy of the mitral valve leaflets</div><div class=\"cntnt\"><img style=\"width:423px; height:384px;\" src=\"images/CARD/57906_Anatomymitralvalveleafle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anatomic diagram illustrates the relative size, length, and postion of the anterior (A) and posterior (P) leaflets of the mitral valve. In particular, the A leaflet has a long margain to base dimension and a greater length than the shorter P leaflet; in spite of these differences, their surface areas are equal. The A leaflet is in continuity with the posterior aortic root (Ao) and is therefore called the aortic leaflet. The P leaflet is in continuity with the posterior left ventricular wall (PLVW) and is known as the mural leaflet.</div><div id=\"graphicVersion\">Graphic 57906 Version 2.0</div></div></div>"},"57907":{"type":"graphic_diagnosticimage","displayName":"Newborn clavicle fracture","title":"Newborn with left mid clavicle fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Newborn with left mid clavicle fracture</div><div class=\"cntnt\"><img style=\"width:432px; height:267px;\" src=\"images/PEDS/57907_Newborn_clavicle_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Rajvee Shah, MD.</div><div id=\"graphicVersion\">Graphic 57907 Version 2.0</div></div></div>"},"57908":{"type":"graphic_table","displayName":"Hyperinflation and auto PEEP","title":"Determinants of dynamic pulmonary hyperinflation and auto-PEEP","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Determinants of dynamic pulmonary hyperinflation and auto-PEEP</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\">Internal</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle2_single\">Respiratory mechanics</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Flow resistance</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Expiratory flow limitation</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Respiratory system compliance</td></tr>\n     \t\t\t\t\t<tr><td class=\"subtitle2_single\">Breathing\npattern</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Frequency of breathing</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">T<sub>I</sub>/T<sub>TOT</sub></td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Tidal volume</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">External</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle2_single\">Added flow resistance</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Fine bore endotracheal tube</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Ventilator tubing and devices</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle2_single\">Ventilator setting</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Frequency</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">I:E ratio</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Inflation volume</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">End-inspiratory\npause</td></tr></tbody></table></td>\n\n    </tr>\n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">T<sub>I</sub>: inspiratory time, T<sub>TOT</sub>: total cycle time.</div><div class=\"graphic_reference\">Adapted from Rossi, A, Polese, G, Brandi, G, et al, Intensive Care Med 1995; 21:522.</div><div id=\"graphicVersion\">Graphic 57908 Version 1.0</div></div></div>"},"57910":{"type":"graphic_picture","displayName":"Lichen sclerosus in a 10 year old prepubertal girl","title":"Lichen sclerosus in a 10-year-old prepubertal girl","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen sclerosus in a 10-year-old prepubertal girl</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/EM/57910_Lichensclerprepubgirl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Figure-of-eight pattern of vulvar and perianal hypopigmentation in a 10-year-old girl with lichen sclerosus.</div><div class=\"graphic_reference\">Reproduced with permission from: Paradise JE. Vaginal bleeding. In: Textbook of Pediatric Emergency Medicine, 6th ed, Fleisher GF, Ludwig S (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 57910 Version 9.0</div></div></div>"},"57911":{"type":"graphic_picture","displayName":"Pityriasis lichenoides et varioliformis acuta","title":"Pityriasis lichenoides et varioliformis acuta","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pityriasis lichenoides et varioliformis acuta</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/57911_Pityr_lichenoid_varioliform.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple inflammatory papules are present. Some lesions demonstrate necrosis and crusting.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 57911 Version 3.0</div></div></div>"},"57912":{"type":"graphic_table","displayName":"TEE aortic rupture v dissection","title":"Transesophageal echocardiography criteria for distinguishing aortic rupture and dissection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Transesophageal echocardiography criteria for distinguishing aortic rupture and dissection</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Aortic rupture</td> <td class=\"subtitle1\">Aortic dissection</td> </tr> <tr> <td><strong>Size/contour</strong></td> <td>&#8594; or &#8593; / asymmetric</td> <td>&#8593; / symmetric</td> </tr> <tr> <td><strong>Intraluminal flap</strong></td> <td>Thick (\"medial flap\")</td> <td>Thin (\"intimal flap\")</td> </tr> <tr> <td><strong>Entry tear</strong></td> <td>No</td> <td>Frequent</td> </tr> <tr> <td><strong>Thrombus</strong></td> <td>No</td> <td>Yes (false lumen)</td> </tr> <tr> <td><strong>Blood flow velocity (color Doppler)</strong></td> <td>Similar</td> <td>Different (slower in the false lumen)</td> </tr> <tr> <td><strong>Aliasing (mosaic of colors)</strong></td> <td>Yes (surrounding the torn aortic wall)</td> <td>Unusual (near an intimal tear)</td> </tr> <tr> <td><strong>Spatial extension</strong></td> <td>Limited (aortic isthmus)</td> <td>Variable (anatomical type)</td> </tr> <tr> <td><strong>Hemomediastinum</strong></td> <td>Frequent (large)</td> <td>Infrequent</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 57912 Version 3.0</div></div></div>"},"57913":{"type":"graphic_figure","displayName":"Liver disease in pregnancy","title":"Clinical characteristics of liver diseases in pregnancy","html":"<div class=\"graphic\"><div style=\"width: 769px\" class=\"figure\"><div class=\"ttl\">Clinical characteristics of liver diseases in pregnancy</div><div class=\"cntnt\"><img style=\"width:749px; height:513px;\" src=\"images/GAST/57913_Liver_disease_in_pregnancy.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HELLP syndrome&nbsp;likely represents a form of&nbsp;preeclampsia with severe features. </div><div class=\"graphic_footnotes\">PP: postpartum; ALT: alanine aminotransferase; HELLP: hemolysis, elevated liver enzymes, low platelets; AST: aspartate aminotransferase; LDH: lactate dehydrogenase; WBC: white blood cell; INR: international normalized ratio.</div><div id=\"graphicVersion\">Graphic 57913 Version 5.0</div></div></div>"},"57914":{"type":"graphic_picture","displayName":"Gram-negative diplococci","title":"<EM>Neisseria gonorrhoeae</EM> stain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Neisseria gonorrhoeae</EM> stain</div><div class=\"cntnt\"><img style=\"width:432px; height:292px;\" src=\"images/ID/57914_Gram_negative_diplococci.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram stain of <EM>Neisseria gonorrhoeae</EM> in urethral exudate.</div><div class=\"graphic_reference\">Reproduced with permission from: McClatchey KD, MD, DDS. Clinical Laboratory Medicine, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2002. Copyright © 2002 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 57914 Version 4.0</div></div></div>"},"57916":{"type":"graphic_table","displayName":"2010 TNM staging stomach CA","title":"TNM staging for gastric cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">TNM staging for gastric cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr> <td>TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td>T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td>Tis</td> <td colspan=\"3\">Carcinoma in situ: intraepithelial tumor without invasion of the lamina propria</td> </tr> <tr> <td class=\"sublist1_start\">T1</td> <td class=\"sublist_other_start\" colspan=\"3\">Tumor invades lamina propria, muscularis mucosae, or submucosa</td> </tr> <tr> <td class=\"sublist1\">T1a</td> <td class=\"sublist_other\" colspan=\"3\">Tumor invades lamina propria or muscularis mucosae</td> </tr> <tr> <td class=\"sublist1\">T1b</td> <td class=\"sublist_other\" colspan=\"3\">Tumor invades submucosa</td> </tr> <tr> <td class=\"sublist1_start\">T2</td> <td class=\"sublist_other_start\" colspan=\"3\">Tumor invades muscularis propria*</td> </tr> <tr> <td>T3</td> <td colspan=\"3\">Tumor penetrates subserosal connective tissue without invasion of visceral peritoneum or adjacent structures<sup>&#182;&#916;</sup></td> </tr> <tr> <td class=\"sublist1_start\">T4</td> <td class=\"sublist_other_start\" colspan=\"3\">Tumor invades serosa (visceral peritoneum) or adjacent structures<sup>&#182;&#916;</sup></td> </tr> <tr> <td class=\"sublist1\">T4a</td> <td class=\"sublist_other\" colspan=\"3\">Tumor invades serosa (visceral peritoneum)</td> </tr> <tr> <td class=\"sublist1\">T4b</td> <td class=\"sublist_other\" colspan=\"3\">Tumor invades adjacent structures</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr> <td>NX</td> <td colspan=\"3\">Regional lymph node(s) cannot be assessed</td> </tr> <tr> <td>N0</td> <td colspan=\"3\">No regional lymph node metastasis<sup>&#9674;</sup></td> </tr> <tr> <td>N1</td> <td colspan=\"3\">Metastasis in 1-2 regional lymph nodes</td> </tr> <tr> <td>N2</td> <td colspan=\"3\">Metastasis in 3-6 regional lymph nodes</td> </tr> <tr> <td class=\"sublist1_start\">N3</td> <td class=\"sublist_other_start\" colspan=\"3\">Metastasis in seven or more regional lymph nodes</td> </tr> <tr> <td class=\"sublist1\">N3a</td> <td class=\"sublist_other\" colspan=\"3\">Metastasis in 7-15 regional lymph nodes</td> </tr> <tr> <td class=\"sublist1\">N3b</td> <td class=\"sublist_other\" colspan=\"3\">Metastasis in 16 or more regional lymph nodes</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr> <td>M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr> <td>M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Anatomic stage/prognostic groups</td> </tr> <tr> <td>Stage 0</td> <td>Tis</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage IA</td> <td>T1</td> <td>N0</td> <td>M0</td> </tr> <tr> <td rowspan=\"2\">Stage IB</td> <td>T2</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>T1</td> <td>N1</td> <td>M0</td> </tr> <tr> <td rowspan=\"3\">Stage IIA</td> <td>T3</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>T2</td> <td>N1</td> <td>M0</td> </tr> <tr> <td>T1</td> <td>N2</td> <td>M0</td> </tr> <tr> <td rowspan=\"4\">Stage IIB</td> <td>T4a</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>T3</td> <td>N1</td> <td>M0</td> </tr> <tr> <td>T2</td> <td>N2</td> <td>M0</td> </tr> <tr> <td>T1</td> <td>N3</td> <td>M0</td> </tr> <tr> <td rowspan=\"3\">Stage IIIA</td> <td>T4a</td> <td>N1</td> <td>M0</td> </tr> <tr> <td>T3</td> <td>N2</td> <td>M0</td> </tr> <tr> <td>T2</td> <td>N3</td> <td>M0</td> </tr> <tr> <td rowspan=\"4\">Stage IIIB</td> <td>T4b</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>T4b</td> <td>N1</td> <td>M0</td> </tr> <tr> <td>T4a</td> <td>N2</td> <td>M0</td> </tr> <tr> <td>T3</td> <td>N3</td> <td>M0</td> </tr> <tr> <td rowspan=\"3\">Stage IIIC</td> <td>T4b</td> <td>N2</td> <td>M0</td> </tr> <tr> <td>T4b</td> <td>N3</td> <td>M0</td> </tr> <tr> <td>T4a</td> <td>N3</td> <td>M0</td> </tr> <tr> <td>Stage IV</td> <td>Any T</td> <td>Any N</td> <td>M1</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Note: cTNM is the clinical classification, pTNM is the pathologic classification.</div><div class=\"graphic_footnotes\">* A tumor may penetrate the muscularis propria with extension into the gastrocolic or gastrohepatic ligaments, or into the greater or lesser omentum, without perforation of the visceral peritoneum covering these structures. In this case, the tumor is classified T3. If there is perforation of the visceral peritoneum covering the gastric ligaments or the omentum, the tumor should be classified T4.<br />¶&nbsp;The adjacent structures of the stomach include the spleen, transverse colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small intestine, and retroperitoneum.<br />Δ Intramural extension to the duodenum or esophagus is classified by the depth of the greatest invasion in any of these sites, including the stomach.<br /><FONT class=lozenge>◊</FONT> A designation of pN0 should be used if all examined lymph nodes are negative, regardless of the total number removed and examined.</div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 57916 Version 15.0</div></div></div>"},"57918":{"type":"graphic_picture","displayName":"Fingertip testing PI","title":"Fingertip testing","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Fingertip testing</div><div class=\"cntnt\"><img style=\"width:468px; height:350px;\" src=\"images/PI/57918_Fingertip_testing_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The sides of the fingers have fewer nerve endings than the middle of the fingertips. It might not hurt as much to use the sides of your fingers to test your blood sugar.</div><div id=\"graphicVersion\">Graphic 57918 Version 3.0</div></div></div>"},"57919":{"type":"graphic_figure","displayName":"T4 metabolism","title":"T4 metabolism in nonthyroidal illness","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">T4 metabolism in nonthyroidal illness</div><div class=\"cntnt\"><img style=\"width:560px; height:270px;\" src=\"images/ENDO/57919_Thyroxine_metabolism.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The inhibition of 5'-monodeiodinase in nonthyroidal illness leads to decreased conversion of T4 to T3 and reduced metabolism of rT3.</div><div class=\"graphic_footnotes\">T4: thyroxine; T3: triiodothyronine; T2: diiodothyronine; rT3: reverse triiodothyronine.</div><div id=\"graphicVersion\">Graphic 57919 Version 4.0</div></div></div>"},"57920":{"type":"graphic_picture","displayName":"Hybridization silence","title":"Hybridization silence of Faecalibacterium prausnitzii","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hybridization silence of Faecalibacterium prausnitzii</div><div class=\"cntnt\"><img style=\"width:432px; height:271px;\" src=\"images/GAST/57920_Hybridization_silence.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hybridization silence of Faecalibacterium prausnitzii in a patient with idiopathic diarrhea (orange fluorescence, x200). Bacteria are suppressed at the center of stool whereas their concentration and fluorescence at the surface are well preserved.</div><div class=\"graphic_reference\">Courtesy of Alexander Swidsinski, MD, and Vera Loening-Baucke, MD.</div><div id=\"graphicVersion\">Graphic 57920 Version 2.0</div></div></div>"},"57922":{"type":"graphic_picture","displayName":"Dry powder inhalers","title":"Examples of various dry powder inhalers","html":"<div class=\"graphic\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">Examples of various dry powder inhalers</div><div class=\"cntnt\"><img style=\"width:566px; height:460px;\" src=\"images/PULM/57922_Dry_powder_inhalers_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With these devices, the patient inhales the medication in the form of a fine powder rather than an aerosol. (A) Aerolizer*, (B) HandiHaler, (C) Neohaler, (D) Tobi Podhaler, (E) Flexhaler, (F) Diskus, (G) Twisthaler, (H) Ellipta. With single-dose devices, a powder-filled capsule is placed in the device for each dose. With multiple-dose devices, medication for multiple doses (often a month's supply) is contained within the device.</div><div class=\"graphic_footnotes\">* Available in some countries, but not the United States.</div><div class=\"graphic_reference\">Panels A, B, E, F, and G: Courtesy of Dean Hess, RRT, PhD.<br />Panel C: Image used with permission. Copyright &copy; 2012 Novartis Pharmaceuticals Corporation.<br />Panel D: Image used with permission. Copyright &copy; 2013 Novartis Pharmaceuticals Corporation.<br />Panel H: Reproduced with permission. Copyright &copy; 2014 GlaxoSmithKline. All rights reserved.</div><div id=\"graphicVersion\">Graphic 57922 Version 7.0</div></div></div>"},"57923":{"type":"graphic_picture","displayName":"Lap hernia still C","title":"Lap hernia still C","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lap hernia still C</div><div class=\"cntnt\"><img style=\"width:416px; height:338px;\" src=\"images/SURG/57923_Lap_hernia_still_C.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 57923 Version 3.0</div></div></div>"},"57924":{"type":"graphic_picture","displayName":"Pemphigus vulgaris - oral","title":"Pemphigus vulgaris - oral lesions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pemphigus vulgaris - oral lesions</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/57924_Pemphigus_vulgar_oral.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erosions on the&nbsp;palate in a patient with pemphigus vulgaris.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 57924 Version 4.0</div></div></div>"},"57925":{"type":"graphic_picture","displayName":"Acne nodules","title":"Acne nodules","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acne nodules</div><div class=\"cntnt\"><img style=\"width:432px; height:330px;\" src=\"images/DERM/57925_Acne_nodules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe nodular acne on the forehead.</div><div id=\"graphicVersion\">Graphic 57925 Version 1.0</div></div></div>"},"57926":{"type":"graphic_diagnosticimage","displayName":"Transphyseal fracture","title":"Transphyseal fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transphyseal fracture</div><div class=\"cntnt\"><img style=\"width:305px; height:597px;\" src=\"images/EM/57926_Transphysealfx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A) Group A - AP view of a small infant who had a swollen left elbow after a difficult delivery. The displacement medially of the proximal radius and ulna (arrows) helps to make the diagnosis of a displaced total distal humeral physis. Panel B) Normal elbow for comparison. Panel C) Group B - AP view showing the posteromedial displacement of the distal fragment (arrows). The relationship between the ossification center of the lateral condyle and the proximal radius has been maintained. Panel D) Group C - AP view with marked medial displacement of the distal fragment. Panel E) Group C - lateral view of the same patient showing posterior displacement of the distal fragment. There is also a large metaphyseal fragment associated with the distal fragment (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Glotzbecker MP, Kasser JR. Distal Humeral Physeal, Medial Condyle, Lateral Epicondylar, and Other Uncommon Elbow Fractures. In: Rockwood and Wilkins' Fractures in Children, 8th ed, Flynn jM, Skaggs DL, Waters PM (Eds), Lippincott Williams &amp; Wilkins 2014. Copyright © 2014 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 57926 Version 13.0</div></div></div>"},"57927":{"type":"graphic_diagnosticimage","displayName":"Biologic lung volume reduction","title":"CT images of biologic lung volume reduction","html":"<div class=\"graphic\"><div style=\"width: 575px\" class=\"figure\"><div class=\"ttl\">CT images of biologic lung volume reduction</div><div class=\"cntnt\"><img style=\"width:555px; height:629px;\" src=\"images/PULM/57927_Bio_lung_vol_reduction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal computer tomography images obtained in the supine position at full lung inflation showing treatment site at baseline (pretreatment) and 6 weeks after low-dose (patients 1 to 4) and high-dose (patients 5 to 8) biologic lung volume reduction therapy. Numbering on the scans corresponds to treated sites showing evidence of scarring reactions.</div><div class=\"graphic_footnotes\">BioLVR: biologic lung volume reduction; HD: high dose; LD: low dose; CT: computed tomography.</div><div class=\"graphic_reference\">Reprinted with permission of the American Thoracic Society. Copyright &copy; 2009 American Thoracic Society. Criner GJ, Pint-Olata V, Strange C, et al. Biologic lung volume reduction in advanced upper lobe emphysema: Phase 2 results. Am J Respir Crit Care Med 2009; 179:791. Official journal of the American Thoracic Society. Diane Gern, Publisher.</div><div id=\"graphicVersion\">Graphic 57927 Version 8.0</div></div></div>"},"57928":{"type":"graphic_picture","displayName":"Normal coronary artery OCT","title":"Normal coronary artery as visualized by intracoronary OCT","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Normal coronary artery as visualized by intracoronary OCT</div><div class=\"cntnt\"><img style=\"width:583px; height:352px;\" src=\"images/CARD/57928_Normal_coronary_artery_OCT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Cross sectional view of the coronary artery. The coronary lumen is signal-poor and black, whereas the vessel is visualized using sepia false color scale. The normal artery wall shows three-layer appearance. (IC) OCT imaging catheter in the center of the lumen; asterisk indicates the angioplasty guide wire artefact.<br> (B) Magnification (2.8x) showing three layer appearance of the normal vessel wall corresponding to the intma (I) which appears signal rich, bright yellow; the media (M) which appears signal-poor, dark and the adventitia (A) which appears signal-rich, bright yellow, peri-adventitial tissue is visible (PAT).</div><div class=\"graphic_footnotes\">OCT: St. Jude/Lightlab Imaging C7XR.</div><div class=\"graphic_reference\">Courtesy of Dr. Evelyn Regar, Thoraxcenter.</div><div id=\"graphicVersion\">Graphic 57928 Version 3.0</div></div></div>"},"57931":{"type":"graphic_figure","displayName":"Clinical course HAV infection","title":"Course of hepatitis A","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Course of hepatitis A</div><div class=\"cntnt\"><img style=\"width:487px; height:332px;\" src=\"images/GAST/57931_Clncl_crs_HAV_infct.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Timeline for hepatitis A manifestations.</div><div class=\"graphic_footnotes\">ALT: alanine transaminase; HAV: hepatitis A virus; Ig: immunoglobulin.</div><div class=\"graphic_reference\">Reproduced from: American Medical Association; American Nurses Association-American Nurses Foundation; Centers for Disease Control and Prevention; Center for Food Safety and Applied Nutrition, Food and Drug Administration; Food Safety and Inspection Service, US Department of Agriculture. Diagnosis and management of foodborne illnesses: a primer for physicians and other health care professionals. MMWR Recomm Rep 2004; 53(RR-4):1.</div><div id=\"graphicVersion\">Graphic 57931 Version 4.0</div></div></div>"},"57932":{"type":"graphic_picture","displayName":"Debrided Vibrio vulnificus infection","title":"<EM>Vibrio vulnificus</EM> lesions following debridement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Vibrio vulnificus</EM> lesions following debridement</div><div class=\"cntnt\"><img style=\"width:395px; height:259px;\" src=\"images/ID/57932_Debrided_V_vulnificus_infec.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Appearance of the hand of the immunocompromised patient with bullous <EM>Vibrio vulnificus</EM> skin infection after surgical debridement.</div><div class=\"graphic_reference\">Courtesy of Rolando E Saenz, MD.</div><div id=\"graphicVersion\">Graphic 57932 Version 4.0</div></div></div>"},"57933":{"type":"graphic_diagnosticimage","displayName":"Abdominal scintigram with leak","title":"Abdominal scintigram showing a peritoneal leak in a peritoneal dialysis patient","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Abdominal scintigram showing a peritoneal leak in a peritoneal dialysis patient</div><div class=\"cntnt\"><img style=\"width:353px; height:465px;\" src=\"images/NEPH/57933_Abdom_scintigram_leak.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A)&nbsp;Fifteen-minute activity within the peritoneal cavity. At&nbsp;two hours (B and C), leakage of dialysate occurs into the mid-lower anterior abdominal wall. Small leakage into the scrotum (D) at&nbsp;two hours is also demonstrable with high-intensity scintiphoto.</div><div class=\"graphic_footnotes\">P: pubis; S: scrotum.</div><div class=\"graphic_reference\">Reproduced with permission from: Walker JV, Fish MB. Scintigraphic detection of abdominal wall and diaphragmatic peritoneal leaks in patients on continuous ambulatory peritoneal dialysis. J Nucl Med 1988; 29:1596. Copyright &copy; 1988 Society of Nuclear Medicine.</div><div id=\"graphicVersion\">Graphic 57933 Version 6.0</div></div></div>"},"57935":{"type":"graphic_diagnosticimage","displayName":"Ultrasound hydronephrosis","title":"Ultrasound demonstrating hydronephrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound demonstrating hydronephrosis</div><div class=\"cntnt\"><img style=\"width:396px; height:290px;\" src=\"images/NEPH/57935_Ultrasound.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Longitudinal sonogram of a hydronephrotic left kidney showing dilatation of the minor and major calyces and the pelvis.</div><div class=\"graphic_reference\">Courtesy of W Charles O'Neill, MD.</div><div id=\"graphicVersion\">Graphic 57935 Version 3.0</div></div></div>"},"57936":{"type":"graphic_picture","displayName":"Vacuum suction pressure","title":"Vacuum delivery pressure","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Vacuum delivery pressure</div><div class=\"cntnt\"><img style=\"width:540px; height:360px;\" src=\"images/OBGYN/57936_Vacuum_suction_pressure.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Aron Schuftan, MD. &#169; Aron Schuftan, MD.</div><div id=\"graphicVersion\">Graphic 57936 Version 1.0</div></div></div>"},"57937":{"type":"graphic_picture","displayName":"Abnormal pancreaticobiliary junction II","title":"Abnormal pancreaticobiliary junction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Abnormal pancreaticobiliary junction</div><div class=\"cntnt\"><img style=\"width:360px; height:509px;\" src=\"images/GAST/57937_Anomalous_pancbil_junctio1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic retrograde cholangiopancreatography in an adult with obstructive jaundice demonstrates an abnormal pancreaticobiliary junction with a malignant biliary stricture replacing the cystic duct insertion. There is no evidence of a biliary cyst.</div><div class=\"graphic_reference\">Courtesy of Mark D Topazian, MD.</div><div id=\"graphicVersion\">Graphic 57937 Version 3.0</div></div></div>"},"57938":{"type":"graphic_table","displayName":"Allo SCT in CR2 ALL","title":"Leukemia-free survival after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia in second or greater complete remission","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Leukemia-free survival after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia in second or greater complete remission</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Study</td>\n\n      <td class=\"subtitle1\">Number of patients</td>\n\n      <td class=\"subtitle1\">Probability of relapse, percent</td>\n\n      <td class=\"subtitle1\">LFS at &#62;3 years, percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>IBMTR, 1989</td>\n\n      <td>208 (high risk)</td>\n\n      <td> 56</td>\n\n      <td>22 (4 years)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>IBMTR, 1989</td>\n\n      <td>97 (standard risk)</td>\n\n      <td>49</td>\n\n      <td>36 (4 years)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Barrett, AJ, 1989</td>\n\n      <td>391</td>\n\n      <td>52</td>\n\n      <td>26 (5 years)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Gratwohl, A, 1990</td>\n\n      <td>348</td>\n\n      <td>NR</td>\n\n      <td>32</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Blume, KG, 1990</td>\n\n      <td>49</td>\n\n      <td>41</td>\n\n      <td>46</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Wingard, JR, 1990</td>\n\n      <td>36</td>\n\n      <td>26</td>\n\n      <td>43 (5 years)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Doney, K, 1991</td>\n\n      <td>48</td>\n\n      <td>64</td>\n\n      <td>15 (5 years)</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">All series except IBMTR include both children and adults.</div><div id=\"graphicVersion\">Graphic 57938 Version 2.0</div></div></div>"},"57940":{"type":"graphic_diagnosticimage","displayName":"Tendon erosion sonogram","title":"Longitudinal sonogram of the Achilles tendon in a patient with enthesitis due to ankylosing spondylitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Longitudinal sonogram of the Achilles tendon in a patient with enthesitis due to ankylosing spondylitis</div><div class=\"cntnt\"><img style=\"width:504px; height:298px;\" src=\"images/RHEUM/57940_Tendon_erosion_sonogram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This longitudinal sonogram of the Achilles tendon (T) in a patient with ankylosing spondylitis shows a swollen tendon enthesis with decreased echogenicity and a large bony erosion (arrows) in the calcaneus (C).</div><div class=\"graphic_reference\">Courtesy of George AW Bruyn, MD, PhD.</div><div id=\"graphicVersion\">Graphic 57940 Version 2.0</div></div></div>"},"57941":{"type":"graphic_table","displayName":"Presenting features acquired TTP","title":"Presenting features of 78 consecutive patients with acquired TTP","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Presenting features of&nbsp;78 consecutive patients with acquired TTP</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Signs and symptoms</td> <td class=\"subtitle1\">Number affected*</td> </tr> <tr> <td>Microangiopathic hemolytic anemia (MAHA)</td> <td>78&nbsp;(100 percent)</td> </tr> <tr> <td>Thrombocytopenia</td> <td>78&nbsp;(100 percent)</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Neurologic abnormalities</td> </tr> <tr> <td class=\"sublist1\">Severe (coma, stroke, seizure, focal signs)</td> <td class=\"sublist_other\">41&nbsp;(53 percent)</td> </tr> <tr> <td class=\"sublist1\">Minor (confusion, headache, etc)</td> <td class=\"sublist_other\">21 (27 percent)</td> </tr> <tr> <td class=\"sublist1\">No neurologic abnormalities</td> <td class=\"sublist_other\">16&nbsp;(20 percent)</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Renal abnormalities</td> </tr> <tr> <td class=\"sublist1\">Acute renal failure<sup><span style=\"font-size: 13px;\">&#182;</span></sup></td> <td class=\"sublist_other\">4&nbsp;(5 percent)</td> </tr> <tr> <td class=\"sublist1\">Renal insufficiency</td> <td class=\"sublist_other\">37&nbsp;(47 percent)</td> </tr> <tr> <td class=\"sublist1\">Normal renal function</td> <td class=\"sublist_other\">37&nbsp;(47 percent)</td> </tr> <tr> <td>Fever</td> <td>8 (10 percent)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate topic on the clinical manifestations and diagnosis of acquired TTP for additional details.</div><div class=\"graphic_footnotes\">TTP: thrombotic thrombocytopenic purpura; MAHA: microangiopathic hemolytic anemia.<br />* Data are from the day of diagnosis, defined as the day of the first plasma exchange treatment. ADAMTS13 activity was&nbsp;&lt;10 percent of normal in all cases.<br />¶ Acute renal failure&nbsp;was defined as an increased serum creatinine of ≥0.5 mg/dL/day for two consecutive days or a serum creatinine of ≥4.0 mg/dL with hemodialysis. <br /></div><div class=\"graphic_reference\">Data from: Page EE, Kremer Hovinga JA, Terrell DR, et al. Thrombotic thrombocytopenic purpura: Diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Advances 2017; 1:590.</div><div id=\"graphicVersion\">Graphic 57941 Version 9.0</div></div></div>"},"57942":{"type":"graphic_figure","displayName":"Innervation of the kidney","title":"Schematic depiction of the innervation of the kidney","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schematic depiction of the innervation of the kidney</div><div class=\"cntnt\"><img style=\"width:382px; height:596px;\" src=\"images/NEPH/57942_Innervationkidney.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sympathetic, parasympathetic, and sensory enervation supplying the kidney. The solid line represents the sympathetic component. The dotted line reflects the parasympathetic nerve supply. Afferent (sensory) fibers are represented by the dashed line and travel with the autonomic nerves.</div><div class=\"graphic_reference\">Reproduced with permission from: Willard FH. Autonomic Nervous System. In: Foundations of Osteopathic Medicine, 3rd Edition, Chile A (Ed). Philadelphia: Lippincott Williams &amp; Wilkins, 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 57942 Version 12.0</div></div></div>"},"57943":{"type":"graphic_figure","displayName":"Kidney injury grades","title":"Kidney injury grades according to the AAST","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Kidney injury grades according to the AAST</div><div class=\"cntnt\"><img style=\"width:540px; height:632px;\" src=\"images/EM/57943_Kidneyinjurygrades.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AAST: American Association for the Surgery of Trauma. </div><div class=\"graphic_reference\">Redrawn and reproduced with permission from: Moore, EE, Shackford, SR, Pachter, HL, et al. Organ injury scaling: spleen, liver, and kidney. J Trauma 1989; 29:1664. Copyright © 1989 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 57943 Version 10.0</div></div></div>"},"57945":{"type":"graphic_table","displayName":"Performance status measure","title":"Karnofsky and Eastern Cooperative Oncology Group (ECOG) performance status measures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Karnofsky and Eastern Cooperative Oncology Group (ECOG) performance status measures</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Karnofsky</td> </tr> <tr> <td class=\"subtitle2\">Score</td> <td class=\"subtitle2\">Definition</td> </tr> <tr> <td class=\"centered\">100</td> <td>Normal, no complaints, no evidence of disease</td> </tr> <tr> <td class=\"centered\">90</td> <td>Able to carry on normal activity, minor signs or symptoms of disease</td> </tr> <tr> <td class=\"centered\">80</td> <td>Normal activity with effort, some signs or symptoms of disease</td> </tr> <tr> <td class=\"centered\">70</td> <td>Cares for self, unable to carry on normal activity or to do active work</td> </tr> <tr> <td class=\"centered\">60</td> <td>Requires occasional assistance but is able to care for most needs</td> </tr> <tr> <td class=\"centered\">50</td> <td>Requires considerable assistance and frequent medical care</td> </tr> <tr> <td class=\"centered\">40</td> <td>Disabled, requires special care and assistance</td> </tr> <tr> <td class=\"centered\">30</td> <td>Severely disabled, hospitalization is indicated, although death is not imminent</td> </tr> <tr> <td class=\"centered\">20</td> <td>Hospitalization is necessary, very sick, active supportive treatment necessary</td> </tr> <tr> <td class=\"centered\">10</td> <td>Moribund, fatal processes progressing rapidly</td> </tr> <tr> <td class=\"centered\">0</td> <td>Dead</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">ECOG</td> </tr> <tr> <td class=\"subtitle2\">Score</td> <td class=\"subtitle2\">Definition</td> </tr> <tr> <td class=\"centered\">0</td> <td>Fully active; no performance restrictions</td> </tr> <tr> <td class=\"centered\">1</td> <td>Strenuous physical activity restricted; fully ambulatory and able to carry out light work</td> </tr> <tr> <td class=\"centered\">2</td> <td>Capable of all self-care but unable to carry out any work activities. Up and about &#62;50% of waking hours.</td> </tr> <tr> <td class=\"centered\">3</td> <td>Capable of only limited self-care; confined to bed or chair &#62;50% of waking hours</td> </tr> <tr> <td class=\"centered\">4</td> <td>Completely disabled; cannot carry out any self-care; totally confined to bed or chair</td> </tr> <tr> <td class=\"centered\">5</td> <td>Dead</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 57945 Version 6.0</div></div></div>"},"57946":{"type":"graphic_picture","displayName":"Apert syndrome syndactyly 1","title":"Apert syndrome: Syndactyly of the hand","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Apert syndrome: Syndactyly of the hand</div><div class=\"cntnt\"><img style=\"width:504px; height:198px;\" src=\"images/PEDS/57946_Apert_syndrome_syndactyly_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Dorsal view of partial thumb-index syndactyly (with complete, complicated finger syndactyly). <br />(B) Palmar view of partial thumb-index syndactyly.</div><div class=\"graphic_reference\">Reproduced with permission from: Strickland JW, Graham TJ. Master Techniques in Orthopeadic Surgery: The Hand, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. Copyright ©2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 57946 Version 2.0</div></div></div>"},"57949":{"type":"graphic_figure","displayName":"M mode mitral stenosis I","title":"Mitral stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mitral stenosis</div><div class=\"cntnt\"><img style=\"width:241px; height:223px;\" src=\"images/CARD/57949_M_mode_mitral_stenosis_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">M-mode echocardiogram shows moderate mitral stenosis with concordant motion of the anterior and posterior mitral valve (MV) leaflets which are thickened and a reduced E-F slope, indicating a pressure gradient between the left atrium and ventricle during diastole.</div><div class=\"graphic_reference\">Provided by Thomas Binder, MD, et al. Interactive Echocardiography. A Clinical Atlas. Futura, 1997.</div><div id=\"graphicVersion\">Graphic 57949 Version 1.0</div></div></div>"},"57950":{"type":"graphic_diagnosticimage","displayName":"Panlobular emphysema","title":"Panlobular emphysema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Panlobular emphysema</div><div class=\"cntnt\"><img style=\"width:375px; height:326px;\" src=\"images/PULM/57950_Panlobular_emphysema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HRCT shows a paucity of vascular structures in both lower lobes, most evident in the anterior-basal segment of the right lower lobe.</div><div class=\"graphic_footnotes\">HRCT: high resolution computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 57950 Version 3.0</div></div></div>"},"57952":{"type":"graphic_table","displayName":"Clinical features of Adies syndrome","title":"Clinical features of Adie's syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of Adie's syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Percent prevalence</td> </tr> <tr> <td>Unilateral</td> <td class=\"centered\">80*</td> </tr> <tr> <td>Reduced deep tendon reflexes</td> <td class=\"centered\">89</td> </tr> <tr> <td>Sector palsy (if residual light reaction)</td> <td class=\"centered\">100</td> </tr> <tr> <td>Accommodative paresis</td> <td class=\"centered\">66</td> </tr> <tr> <td>Cholinergic supersensitivity</td> <td class=\"centered\">80</td> </tr> <tr> <td>Decreased regional corneal sensation</td> <td class=\"centered\">90</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* 4 percent per year will become bilateral.</div><div class=\"graphic_reference\">Reproduced with permission from: Thompson HS. Adie's syndrome: Some new observations. Trans Am Ophthalmol Soc 1977; 75:587. Copyright &copy; 1977 American Ophthalmalogic Society.</div><div id=\"graphicVersion\">Graphic 57952 Version 3.0</div></div></div>"},"57953":{"type":"graphic_picture","displayName":"Uncircumcised penis","title":"Uncircumcised penis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uncircumcised penis</div><div class=\"cntnt\"><img style=\"width:432px; height:283px;\" src=\"images/OBGYN/57953_Uncircumcised_penis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of David G Weismiller, MD.</div><div id=\"graphicVersion\">Graphic 57953 Version 1.0</div></div></div>"},"57954":{"type":"graphic_picture","displayName":"Paraneoplastic plane xanthomas","title":"Plane xanthomas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plane xanthomas</div><div class=\"cntnt\"><img style=\"width:323px; height:315px;\" src=\"images/ONC/57954_Paraneoplastic_plane_xantho.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Yellowish-reddish, slightly elevated plaques on the neck (arrows), noticeable mainly because of the accentuation of the skin texture in a normolipemic patient with lymphomas. Plane xanthomas occur most commonly on the upper trunk and neck and also occur in individuals with myeloma.</div><div class=\"graphic_reference\">Reproduced with permission from Color Atlas and Synopsis of Clinical Dermatology, 3rd edition, Fitzpatrick, et al (Eds), McGraw-Hill, New York 1997. Copyright &#169; 1997 The McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 57954 Version 1.0</div></div></div>"},"57955":{"type":"graphic_algorithm","displayName":"Basic management of LUTS in men","title":"Basic management of LUTS in men","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Basic management of LUTS in men</div><div class=\"cntnt\"><img style=\"width:554px; height:723px;\" src=\"images/PC/57955_BasicmanagementLUTSmen.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">LUTS: lower urinary tract symptoms; DRE: digital rectal examination; PSA: prostate-specific antigen.<br />* When life expectancy is &gt;10 years and if the diagnosis of prostate cancer can modify the management.<br />¶ When significant nocturia is a predominant symptom.<br />Δ Assess and start treatment before referral.<br /><FONT class=lozenge>◊</FONT> In practice, advise patients with symptoms to aim for a urine output of about 1 liter/24 hours.</div><div class=\"graphic_reference\">Reproduced with permission from: Abrams, P, Chapple, C, Khoury, S, et al. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol 2009; 181:1779. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 57955 Version 2.0</div></div></div>"},"57956":{"type":"graphic_picture","displayName":"Occluding exostosis of the external auditory canal","title":"Occluding exostosis of the external auditory canal","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Occluding exostosis of the external auditory canal</div><div class=\"cntnt\"><img style=\"width:324px; height:296px;\" src=\"images/PC/57956_Occluding_exostosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surgical intervention with removal of the exostosis is performed when the exostoses become so large that they occlude the canal, and infections begin to develop because of retained skin and cerumen.</div><div class=\"graphic_reference\">Reprinted with permission from Nikolas H Blevins, MD</div><div id=\"graphicVersion\">Graphic 57956 Version 2.0</div></div></div>"},"57957":{"type":"graphic_picture","displayName":"Pyogenic granuloma dermoscopy","title":"Pyogenic granuloma","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Pyogenic granuloma</div><div class=\"cntnt\"><img style=\"width:583px; height:232px;\" src=\"images/DERM/57957_Pyogenic_granuloma_derm_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clinical (left) and dermoscopic (right) image of pyogenic granuloma. On dermoscopy, pyogenic granulomas typically appear as pink homogeneous papules with a white collarette and white intersecting lines representing the fibrous septa seen at histopathology. In a minority of cases, as in the one shown in this picture, a bluish homogeneous structure can be seen. These cases are often clinically and dermoscopically misdiagnosed as melanomas.</div><div class=\"graphic_reference\">Reproduced with permission from: Dr. Ashfaq Marghoob.</div><div id=\"graphicVersion\">Graphic 57957 Version 1.0</div></div></div>"},"57958":{"type":"graphic_table","displayName":"Use of cephalosporins in patients with positive skin tests PCN","title":"Use of cephalosporins in patients with positive skin tests to penicillin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Use of cephalosporins in patients with positive skin tests to penicillin</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Study</td> <td class=\"subtitle1\">Number of patients</td> <td class=\"subtitle1\">Number of reactions (%)</td> <td class=\"subtitle1\">Cephalosporin skin testing</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td>Girard (1968)<sup>[1]</sup></td> <td class=\"centered\">23</td> <td class=\"centered\">2 (8.7)</td> <td class=\"centered\">No</td> <td>Both reactions to cephaloridine</td> </tr> <tr> <td>Assem (1974)<sup>[2]</sup></td> <td class=\"centered\">3</td> <td class=\"centered\">3 (100)</td> <td class=\"centered\">No</td> <td>All reactions to cephaloridine</td> </tr> <tr> <td>Warrington (1978)<sup>[3]</sup></td> <td class=\"centered\">3</td> <td class=\"centered\">0</td> <td class=\"centered\">Yes</td> <td>&nbsp;</td> </tr> <tr> <td>Solley (1982)<sup>[4]</sup></td> <td class=\"centered\">27</td> <td class=\"centered\">0</td> <td class=\"centered\">No</td> <td>&nbsp;</td> </tr> <tr> <td>Saxon (1987)<sup>[5]</sup></td> <td class=\"centered\">62</td> <td class=\"centered\">1 (1.6)</td> <td class=\"centered\">No</td> <td>Cephalosporin not noted</td> </tr> <tr> <td>Blanca (1989)<sup>[6]</sup></td> <td class=\"centered\">16</td> <td class=\"centered\">2 (12.5)</td> <td class=\"centered\">No</td> <td>Both reactions to cefamandole</td> </tr> <tr> <td>Shepherd (1993)<sup>[7]</sup></td> <td class=\"centered\">9</td> <td class=\"centered\">0</td> <td class=\"centered\">No</td> <td>&nbsp;</td> </tr> <tr> <td>Audicana (1994)<sup>[8]</sup></td> <td class=\"centered\">12</td> <td class=\"centered\">0</td> <td class=\"centered\">Yes</td> <td>&nbsp;</td> </tr> <tr> <td>Pichichero (1998)<sup>[9]</sup></td> <td class=\"centered\">39</td> <td class=\"centered\">2 (5.1)</td> <td class=\"centered\">No</td> <td>Reaction to cefaclor and ?</td> </tr> <tr> <td>Novalbos (2001)<sup>[10]</sup></td> <td class=\"centered\">23</td> <td class=\"centered\">0</td> <td class=\"centered\">Yes</td> <td>&nbsp;</td> </tr> <tr> <td>Macy (2002)<sup>[11]</sup></td> <td class=\"centered\">42</td> <td class=\"centered\">1 (2.4)</td> <td class=\"centered\">No</td> <td>Reaction to cefixime</td> </tr> <tr> <td>Romano (2004)<sup>[12]</sup></td> <td class=\"centered\">75</td> <td class=\"centered\">0</td> <td class=\"centered\">Yes</td> <td>&nbsp;</td> </tr> <tr> <td>Greenberger (2005)<sup>[13]</sup></td> <td class=\"centered\">6</td> <td class=\"centered\">0</td> <td class=\"centered\">No</td> <td>&nbsp;</td> </tr> <tr> <td>Park (2010)<sup>[14]</sup></td> <td class=\"centered\">85</td> <td class=\"centered\">2 (2.4)</td> <td class=\"centered\">No</td> <td>Reactions to cefazolin, cephalexin</td> </tr> <tr class=\"divider_bottom\"> <td>Ahmed (2012)<sup>[15]</sup></td> <td class=\"centered\">21&nbsp;</td> <td class=\"centered\">0&nbsp;</td> <td class=\"centered\">No&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Total</strong></td> <td class=\"centered\"><strong>446</strong></td> <td class=\"centered\"><strong>13 (2.9)</strong></td> <td class=\"centered\"><strong>&nbsp;</strong></td> <td><strong>&nbsp;</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Summary of penicillin skin test-positive patients challenged with cephalosporins, excluding patients selectively allergic to amoxicillin or ampicillin (skin test-positive to an aminopenicillin, but negative to penicillin G-derived major and minor determinants).</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Girard JP. Common antigenic determinants of penicillin G, ampicillin and the cephalosporins demonstrated in men. Int Arch Allergy Appl Immunol 1968; 33:428. </LI>&#xD;&#xA;<LI>Assem ES, Vickers MR. Tests for penicillin allergy in man. II. The immunological cross-reaction between penicillins and cephalosporins. Immunology 1974; 27:255. </LI>&#xD;&#xA;<LI>Warrington RJ, Simons FE, Ho HW, Gorski BA. Diagnosis of penicillin allergy by skin testing: the Manitoba experience. Can Med Assoc J 1978; 118:787. </LI>&#xD;&#xA;<LI>Solley, GO, Gleich GJ, Van Dellen RG. Penicillin allergy: Clinical experience with a battery of skin-test reagents. J Allergy Clin Immunol 1982; 69:238. </LI>&#xD;&#xA;<LI>Saxon A, Beall GN, Rohr AS, Adelman DC. Immediate hypersensitivity reactions to beta-lactam antibiotics. Ann Intern Med 1987; 107:204. </LI>&#xD;&#xA;<LI>Blanca M, Fernandez J, Miranda A, et al. Cross-reactivity between penicillins and cephalosporins: Clinical and immunologic studies. J Allergy Clin Immunol 1989; 83:381. </LI>&#xD;&#xA;<LI>Shepherd GM, Burton DA. Administration of cephalosporin antibiotics to patients with a history of penicillin allergy. J Allergy Clin Immunol 1993; 91:262 </LI>&#xD;&#xA;<LI>Audicana M, Bernaola G, Urrutia I, et al. Allergic reactions to betalactams: studies in a group of patients allergic to penicillin and evaluation of cross-reactivity with cephalosporin. Allergy 1994; 49:108. </LI>&#xD;&#xA;<LI>Pichichero ME, Pichichero DM. Diagnosis of penicillin, amoxicillin, and cephalosporin allergy: reliability of examination assessed by skin testing and oral challenge. J Pediatr 1998; 132:137. </LI>&#xD;&#xA;<LI>Novalbos A, Sastre J, Cuesta J, et al. Lack of allergic cross-reactivity to cephalosporins among patients allergic to penicillins. Clin Exp Allergy 2001; 31:438. </LI>&#xD;&#xA;<LI>Macy E, Burchette RJ. Oral antibiotic adverse reactions after penicillin skin testing: multi-year follow-up. Allergy 2002; 57:1151. </LI>&#xD;&#xA;<LI>Romano A, Guéant-Rodriguez RM, Viola M, et al. Cross-reactivity and tolerability of cephalosporins in patients with immediate hypersensitivity to penicillins. Ann Intern Med 2004; 141:16. </LI>&#xD;&#xA;<LI>Greenberger PA, Klemens JC. Utility of penicillin major and minor determinants for identification of allergic reactions to cephalosporins. J Allergy Clin Immunol 2005; 115:S182 </LI>&#xD;&#xA;<LI>Park MA, Koch CA, Klemawesch P, et al. Increased adverse drug reactions to cephalosporins in penicillin allergy patients with positive penicillin skin test. Int Arch Allergy Immunol 2010; 153:268. </LI>&#xD;&#xA;<LI>Ahmed KA, Fox SJ, Frigas E, Park MA. Clinical outcome in the use of cephalosporins in pediatric patients with a history of penicillin allergy. Int Arch Allergy Immunol 2012; 158:405.</LI></OL></div><div id=\"graphicVersion\">Graphic 57958 Version 9.0</div></div></div>"},"57959":{"type":"graphic_algorithm","displayName":"Evaluation breast enlargement in adults","title":"Evaluation of an adult patient with breast enlargement","html":"<div class=\"graphic\"><div style=\"width: 1012px\" class=\"figure\"><div class=\"ttl\">Evaluation of an adult patient with breast enlargement</div><div class=\"cntnt\"><img style=\"width:992px; height:634px;\" src=\"images/ENDO/57959_Evl_breast_enlargement_adlt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Algorithm for interpretation of serum hormone levels and suggestions for further evaluation of patients with gynecomastia.</div><div class=\"graphic_footnotes\">Neg H&amp;P: Negative history and physical exam; T: testosterone; LH: luteinizing hormone; E2: estradiol; hCG: human chorionic gonadotropin; NI: normal; TSH: thyroid-stimulating hormone; T<SUB>4</SUB>: thyroxine; CT: computed tomography; MRI: magnetic resonance imaging; SHBG: sex hormone-binding globulin.<br />* Negative history and physical exam (ie, not undergoing pubertal transition; no history of medications associated with gynecomastia; no evidence of hyperthyroidism, adrenal or testicular masses, or liver or kidney disease).<br />¶ In some patients with early primary hypogonadism, the T level may be in the lower half of the normal range.<br />Δ In hyperthyroidism, SHBG is elevated, which leads to an increase in total T. In addition, free T can be lowered slightly, leading to higher LH levels that are not totally compensated for.</div><div id=\"graphicVersion\">Graphic 57959 Version 5.0</div></div></div>"},"57960":{"type":"graphic_figure","displayName":"CBD and PD pressures manometry","title":"Comparison of pressures in the pancreatic and common duct segments of the sphincter of Oddi","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Comparison of pressures in the pancreatic and common duct segments of the sphincter of Oddi</div><div class=\"cntnt\"><img style=\"width:516px; height:255px;\" src=\"images/GAST/57960_CBD_and_PD_pressures_manome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sphincter of Oddi manometry. Comparison of the sphincter of Oddi (SO) pressures obtained from both the pancreatic segment (PD) and common duct (CBD) segment of the SO during catheter pull-through of the sphincter in the same patient. The pressures are equivalent. (BM refers to &quot;black marks&quot; noted on the catheter.)</div><div class=\"graphic_reference\">Courtesy of Walter J Hogan, MD.</div><div id=\"graphicVersion\">Graphic 57960 Version 1.0</div></div></div>"},"57961":{"type":"graphic_diagnosticimage","displayName":"Cervical pregnancy","title":"Cervical pregnancy","html":"<div class=\"graphic\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Cervical pregnancy</div><div class=\"cntnt\"><img style=\"width:592px; height:490px;\" src=\"images/OBGYN/57961_Cervical_pregnancy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three views of cervical ectopic pregnancy obtained at different field of views. (Panel A) A gestational sac is seen in the cervix (G). Closer inspection shows a yolk sac and tiny embryo (Panel B) with cardiac activity (Panel C).</div><div class=\"graphic_footnotes\">FHR: fetal heart rate.</div><div class=\"graphic_reference\">Courtesy of Tejas S Mehta, MD, MPH.</div><div id=\"graphicVersion\">Graphic 57961 Version 4.0</div></div></div>"},"57962":{"type":"graphic_table","displayName":"AASLD treatment guidelines HH","title":"Treatment of hereditary hemochromatosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of hereditary hemochromatosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>One phlebotomy (500 mL) once every one or two weeks</td> </tr> <tr> <td>Check hematocrit (Hct) prior to each phlebotomy; do not allow Hct to fall by more than 20 percent of prior level</td> </tr> <tr> <td>Check serum ferritin every 10 to 12 phlebotomies</td> </tr> <tr> <td>Stop frequent phlebotomy when ferritin reaches 50 to 100 mcg/L</td> </tr> <tr> <td>Continue phlebotomies at intervals to keep ferritin between 50 and 100 mcg/L</td> </tr> <tr> <td>Avoid vitamin C and iron supplements; dietary adjustments are unnecessary</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Excerpted from: Bacon BR, Adams PC, Kowdley KV, et al. Diagnosis and managment of hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:328.</div><div id=\"graphicVersion\">Graphic 57962 Version 5.0</div></div></div>"},"57963":{"type":"graphic_table","displayName":"Assessing O2 need inflight","title":"Determination of need for in-flight supplemental oxygen","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Determination of need for in-flight supplemental oxygen</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">SpO<sub>2</sub> at rest breathing ambient air at sea level</td> <td class=\"subtitle1\">Further evaluation needed</td> <td class=\"subtitle1\">Supplemental oxygen needed in-flight</td> </tr> <tr> <td>&#62;95 percent</td> <td>No</td> <td>No</td> </tr> <tr> <td>92 to 95 percent without risk factors*</td> <td>No</td> <td>No</td> </tr> <tr> <td>92 to 95 percent with risk factors*</td> <td>Yes<sup>&#182;</sup></td> <td>Depends on further evaluation</td> </tr> <tr> <td>&#60;92 percent</td> <td>No</td> <td>Yes</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SpO<sub>2</sub>: oxygen saturation measured by pulse oximetry.<br />* Risk factors include: Hypercapnia, forced expiratory volume in one second (FEV<sub>1</sub>) &lt;50 percent of predicted, lung cancer, restrictive respiratory disease due to interstitial lung disease, chest wall abnormality, or respiratory muscle weakness, cerebrovascular or cardiac disease, exacerbation of chronic lung disease requiring hospitalization within the prior six weeks, pulmonary hypertension, previous dyspnea or chest pain during air travel, or inability to walk further than 50 m without distress.<br />&para; Further evaluation includes use of oximetry measurement during a six minute walk test, a regression equation or hypoxia altitude simulation testing for prediction of in-flight arterial partial pressure of oxygen (PaO<sub>2</sub>). See text for details.</div><div id=\"graphicVersion\">Graphic 57963 Version 3.0</div></div></div>"},"57964":{"type":"graphic_picture","displayName":"Early DAD micrograph","title":"Early diffuse alveolar damage","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Early diffuse alveolar damage</div><div class=\"cntnt\"><img style=\"width:302px; height:198px;\" src=\"images/PULM/57964_Early_DAD_micrograph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph shows early diffuse alveolar damage with minimal alveolar septal thickening, hyperplasia of pneumocytes, and eosinophilic hyaline membranes (arrow).</div><div class=\"graphic_reference\">Courtesy of Jeffrey L Myers, MD.</div><div id=\"graphicVersion\">Graphic 57964 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal lung</div><div class=\"cntnt\"><img style=\"width:360px; height:330px;\" src=\"images/PULM/80140_Normal_lung_High.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power photomicrograph shows alveoli containing capillaries within a narrow interstitium. The alveoli are lined with thin, elongated type I pneumocytes (arrow) and smaller numbers of cuboidal type II pneumocytes (dashed arrow).</div><div class=\"graphic_reference\">Courtesy of Steven E Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 80140 Version 2.0</div></div></div>"},"57966":{"type":"graphic_table","displayName":"Use of SCOOP system III","title":"Patient management tips for the SCOOP transtracheal oxygen system - III","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patient management tips for the SCOOP transtracheal oxygen system - III</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Phase</td> <td class=\"subtitle1\">Goal</td> <td class=\"subtitle1\">Management strategy</td> </tr> <tr> <td class=\"centered\" rowspan=\"13\">III</td> <td>Assure patient compliance</td> <td>Spend sufficient time teaching to prevent later problems. Teach the patient to wear a nasal cannula when cleaning the catheter. Demonstrate correct technique for cleaning with normal saline instillation and use of the cleaning rod. Watch a return demonstration. Provide written teaching materials and phone access to health care providers for problem solving, concerns.</td> </tr> <tr> <td>Teach signs and symptoms of mucus ball formation</td> <td>Teach the patient to promptly report signs and symptoms that suggest formation of mucus balls: (1) whistling or \"pop-off\" of the humidifier from back pressure; (2) persistent, severe cough or change in cough; (3) unexplained dyspnea, wheezing or hoarseness; (4) hemoptysis; and (5) perception that the catheter is \"fixed in place\" in the tract.</td> </tr> <tr> <td rowspan=\"4\">Teach cough techniques which assist in preventing mucus ball formation</td> <td class=\"sublist1_start\">Use cough techniques to maximize airflow during expiration, increase force of the \"glottic blast\" and help loosen mucus from the catheter:</td> </tr> <tr> <td class=\"sublist1\">Sit in chair, feet on floor, pillow against abdomen</td> </tr> <tr> <td class=\"sublist1\">Take 3 to 4 slow deep breaths in through mouth, out nose</td> </tr> <tr> <td class=\"sublist1\">Inhale deeply and cough forcefully while exhaling and bending forward with pillow pressed against abdomen</td> </tr> <tr> <td rowspan=\"4\">Titrate care and followup based on risk of mucus ball formation</td> <td>Monitor progress with phone calls. Periodic phone calls allow closer patient monitoring.</td> </tr> <tr> <td><strong>LOW RISK:</strong> (TTO flow &#60;1 L/min, no secretion problem, good cough.) Call third day and as needed. After TTO hookup, advise twice daily cleaning. Use a humidifier on the stationary oxygen source. Schedule return visit one week after hookup. Strip catheter and adjust future visits and cleaning protocol based on clinical course.</td> </tr> <tr> <td><strong>MODERATE RISK:</strong> (TTO flow 2 to 4 L/min, some mucus, good cough.) Call third day and as needed. After TTO hookup, advise cleaning two to three times daily. Use a humidifier on the stationary oxygen source. Schedule return visits one and two weeks after hookup. Strip catheter at this visit and adjust future visits and cleaning protocol based on clinical course.</td> </tr> <tr> <td><strong>HIGH RISK:</strong> (TTO flow &#62;5 L/min, large amounts of secretions, poor cough.) Call third day and as needed. After TTO hookup, advise cleaning four times daily. Use a servo-controlled heated humidifier to provide 100 percent humidity. Schedule return visits three days and one week after hookup. Strip catheter and adjust future visits and cleaning protocol based on clinical course.</td> </tr> <tr> <td>Prevent catheter displacement</td> <td>Place a small strip of OpSite or other clear tape over the chain on each side of the flange for the first two weeks of catheter use. Teach the patient to keep the oxygen delivery tubing under upper body clothing at all times. At night, place the tubing under a t-shirt or cloth belt. This helps to prevent accidental displacement.</td> </tr> <tr> <td>Reinsert displaced catherter into the tract</td> <td>Instruct the patient to keep a tube of water-soluble lubricant available. If displacement occurs, the patient may be able to clean and replace the catheter. If unsuccessful after two attempts, instruct the patient to call the clinic and return for assistance. The longer the catheter is out of the tract, the more difficult it will be to replace.</td> </tr> <tr> <td>Maintain O<sub>2</sub> delivery if problems develop</td> <td>Teach the patient to keep a carrying kit for supplies (nasal cannula, normal saline, mirror, etc) available at all times. The patient can use the nasal cannula if there is any doubt about correct function. Instruct the patient to call if the problem cannot be resolved.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TTO: transtracheal oxygen; O<sub>2</sub>: oxygen.</div><div class=\"graphic_reference\">Adapted from: Hoffman LA, Wesmiller SW. Transtracheal oxygen. In: Portable Oxygen Therapy: Including Oxygen Conserving Methodology, Tiep BL (Ed), Mount Kisco, NY, 1991.</div><div id=\"graphicVersion\">Graphic 57966 Version 5.0</div></div></div>"},"57967":{"type":"graphic_diagnosticimage","displayName":"Ultrasound image of umbilical cord pseudocyst and angiomyxoma","title":"Prenatal ultrasound image of umbilical cord pseudocyst and angiomyxoma","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound image of umbilical cord pseudocyst and angiomyxoma</div><div class=\"cntnt\"><img style=\"width:480px; height:345px;\" src=\"images/OBGYN/57967_US_umb_cord_pseudo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Giant umbilical cord pseudocyst (C) associated with an angiomyxoma (asterisk). Intrauterine aspiration had been performed twice, with reaccumulation of the cystic fluid.</div><div class=\"graphic_reference\">Reproduced with permission from: Edgardo Corral, MD.</div><div id=\"graphicVersion\">Graphic 57967 Version 4.0</div></div></div>"},"57968":{"type":"graphic_table","displayName":"Irritant patch test reactions","title":"Irritant patch test reactions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Irritant patch test reactions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr> <td>Erythematous</td> <td>Characterized by sharp cut-offs at the patch test site. Seen with fragrance mix, carbamate mix.</td> </tr> <tr> <td>Follicular</td> <td>Follicular papules as opposed to micro vesicles. Seen with nickel, cobalt.</td> </tr> <tr> <td>Pustular</td> <td>More common in atopic individuals<sup>[1]</sup>. Can be seen with metal salts (eg, nickel). Occasionally can be seen with true allergic reactions.</td> </tr> <tr> <td>Soap irritation</td> <td>Glazed erythematous appearance. Seen when testing soaps and shampoos.</td> </tr> <tr> <td>Bullous/necrotic</td> <td>Seen with high concentrations of caustic materials including gasoline, kerosene.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reference:<br /><ol>&#xD;&#xA;    <li>Hjorth N. Diagnostic patch testing. In: Dermatoxicology and pharmacology, Marzulli F, Maibach HI (Eds), John Wiley and Sons, New York 1977. p.344. </li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 57968 Version 4.0</div></div></div>"},"57969":{"type":"graphic_table","displayName":"Management strep TSS","title":"Rapid empiric management of streptococcal toxic shock syndrome in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rapid empiric management of streptococcal toxic shock syndrome in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Diagnosis </td> </tr> <tr> <td>Isolation of GAS from a normally sterile site (eg, blood cerebrospinal, pleural, or peritoneal fluid, tissue biopsy, or surgical wound)</td> </tr> <tr> <td><strong>and</strong> hypotension</td> </tr> <tr> <td><strong>plus</strong> evidence of failure of two of more organ systems:</td> </tr> <tr> <td>Renal failure</td> </tr> <tr> <td>Coagulopathy</td> </tr> <tr> <td>Liver involvement</td> </tr> <tr> <td>Adult respiratory distress syndrome</td> </tr> <tr> <td>Erythematous macular rash</td> </tr> <tr> <td>Soft tissue necrosis</td> </tr> <tr> <td class=\"subtitle1_single\">Management </td> </tr> <tr> <td class=\"subtitle2_single\">Hemodynamic support </td> </tr> <tr> <td class=\"indent1\">Massive amounts of intravenous fluids </td> </tr> <tr> <td class=\"indent1\">Vasopressors (eg, dopamine and/or norepinephrine) </td> </tr> <tr> <td class=\"subtitle2_single\">Surgical therapy </td> </tr> <tr> <td class=\"indent1\">Prompt and aggressive exploration and debridement of suspected sites of infection </td> </tr> <tr> <td class=\"indent1\">Consider surgical intervention in patients who have fever and excruciating pain, particularly with soft tissue swelling or formation of violaceous vesicles or bullae </td> </tr> <tr> <td class=\"subtitle2_single\">Empiric antibiotics </td> </tr> <tr> <td class=\"indent1\">Immediately begin empiric antibiotics, following culture of blood and suspected site of infection, with broad-spectrum antibiotics including: </td> </tr> <tr> <td class=\"indent1\">Clindamycin (900 mg IV every eight hours) </td> </tr> <tr> <td class=\"indent1\"><strong>plus</strong> one of the following: </td> </tr> <tr> <td class=\"indent1\">A carbapenem (eg, imipenem 500 mg every six hours <strong>or</strong> meropenem 1 g every eight hours) <strong>or</strong> </td> </tr> <tr> <td class=\"indent1\">A combination drug containing a penicillin plus beta-lactamase inhibitor 1 g every eight hours) (eg, ticarcillin-clavulanate 3.1 g every four hours <strong>or</strong> piperacillin-tazobactam 4.5 g every six hours) </td> </tr> <tr> <td class=\"subtitle2_single\">Tailored antibiotics (eg, once diagnosis of toxic shock syndrome due to GAS is established) </td> </tr> <tr> <td class=\"indent1\">Clindamycin (900 mg IV every eight hours) <strong>plus</strong> </td> </tr> <tr> <td class=\"indent1\">Penicillin G (4 million units IV every four hours) </td> </tr> <tr> <td class=\"subtitle2_single\">Intravenous immune globulin </td> </tr> <tr> <td class=\"indent1\">Treatment with intravenous immune globulin (1 g/kg day one, followed by 0.5 g/kg days two and three) </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GAS: group A <EM innerHtml>Streptococcus</EM>; IV: intravenous.</div><div id=\"graphicVersion\">Graphic 57969 Version 4.0</div></div></div>"},"57970":{"type":"graphic_table","displayName":"Prev PICC cath infection","title":"Prevention of infection with peripherally inserted central venous catheters","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevention of infection with peripherally inserted central venous catheters</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Replacement and relocation of catheter</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Do not routinely replace peripherally inserted central venous catheters (PICC).</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Replacement of catheter-site dressing</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">Replace dressing when the catheter is removed or replaced, or when the dressing becomes damp, loosened, or soiled. Replace dressings more frequently in diaphoretic patients.</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      <td colspan=\"1\">There is no need to remove a gauze or opaque dressing if the patient has no clinical signs of infection.</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Replacement of administration sets</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Replace administration sets, including secondary sets and add-on devices, no more frequently than at 72-hour intervals, unless clinically indicated.</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      <td colspan=\"1\">Replace tubing used to administer blood, blood products, or lipid emulsions within 24 hours of initiating the infusion. <strong>No recommendation*</strong> for replacement of tubing used for intermittent infusions.</td>\n\n\n    </tr>\n\n\n\n    <tr>\n\n      <td colspan=\"1\">Replace tubing used to administer propofol infusions every 6 or 12 hours, depending on its use.</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Hang time for parenteral fluids</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Complete infusion of lipids or lipid-containing parenteral nutrition fluids (eg, 3-in-1 solutions) within 24 hours of hanging the fluid. When lipid emulsions are given alone, complete the infusion within 12 hours of hanging the emulsion.</td>\n\n\n    </tr>\n\n\n\n    <tr>\n\n      <td>Complete infusion of blood or blood products within four hours of hanging the blood.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td><strong>No recommendation*</strong> for the hang time of intravenous fluids, including nonlipid-containing parenteral nutrition fluids.</td>\n\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">*&#160;No recommendation is made when there is insufficient data in the literature.</div><div id=\"graphicVersion\">Graphic 57970 Version 1.0</div></div></div>"},"57971":{"type":"graphic_table","displayName":"Cancer screening in transplant","title":"Suggested guidelines for cancer screening in patients undergoing solid organ transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested guidelines for cancer screening in patients undergoing solid organ transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Cancer type</td> <td class=\"subtitle1\">Recommendation</td> </tr> <tr> <td>Breast</td> <td>Women 50 to 69 years: annual screening mammography with or without clinical breast examination; age 40 to 49 years: the benefit of screening is less certain and should be left to the decision of the&nbsp;clinician and patient; &#8805;70 years of age: annual screening is appropriate as long as estimated life exectancy is &#8805;8 years.</td> </tr> <tr> <td>Skin</td> <td>Monthly self-examination;&nbsp;clinician examination annually, with early referral for suspected lesions.</td> </tr> <tr> <td>Cervical</td> <td>All women &#8805;18 years old and sexually active girls &#60;18 years old should undergo an annual pelvic examination and Pap smear.</td> </tr> <tr> <td>Anogenital</td> <td>Yearly physical examination of the anogenital area, including pelvic examination and cytologic studies for women. Insufficient evidence to recommend for or against screening anoscopy and biopsies of anal epithelium.</td> </tr> <tr> <td>KS/other sarcomas</td> <td>Examination of skin, conjunctivae, and oropharyngeal mucosa annually; patients at higher risk (ethnicity, geographic area of residence or serologic positivity for HHV) may benefit from more frequent screening.</td> </tr> <tr> <td>Prostate</td> <td>Annual screening with digital rectal examination and PSA recommended for men &#8805;age 50 years&nbsp;if their estimated life expectancy is at least 10 years. If positive family history or African-American race, may start annual screening earlier (eg, age 45 years).</td> </tr> <tr> <td>Colorectal</td> <td>Starting at age 50 years: annual FOBT and either sigmoidoscopy every five years or colonoscopy every 10 years*.</td> </tr> <tr> <td>PTLD</td> <td>Complete history and physical examination every three months, particularly in the first posttransplant year; patients at increased risk of PTLND may benefit from more frequent screening.</td> </tr> <tr> <td>Lung</td> <td>Not recommended.</td> </tr> <tr> <td>HCC</td> <td>For patients with chronic hepatitis B or C and cirrhosis, serum AFP and liver ultrasound every 6 to 12 months.</td> </tr> <tr> <td>Renal cell</td> <td>Screening via cytologic or radiographic means is not recommended, except possibly for patients with a history of analgesic abuse.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">KS: Kaposi sarcoma; PSA: prostate specific antigen; HHV-8: human herpesvirus 8; FOBT: fecal occult blood testing; PTLD: posttransplant lymphoproliferative disorder; HCC: hepatocellular cancer; AFP: alpha-fetoprotein.<br />* At some institutions, screening is started at age 40 years&nbsp;or five years after transplant, whichever comes first.</div><div class=\"graphic_reference\">Modified from: Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000; 11 Suppl 15:S1.</div><div id=\"graphicVersion\">Graphic 57971 Version 5.0</div></div></div>"},"57972":{"type":"graphic_movie","displayName":"Pericardial effusion with tamponade 4 chamber view","title":"Pericardial effusion","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pericardial effusion</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/57972_4chpeff2conv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:266px; height:410px;\" src=\"images/CARD/57972_4chpeff2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Parasternal four-chamber view from a two-dimensional echocardiogram shows a massive pericardial effusion (PE) in a patient with hemodynamic compromise and tamponade physiology. The effusion surrounds the left ventricle (LV) and right ventricle (RV) which is severely compressed.</div><div class=\"graphic_footnotes\">RA: right atrium; LA: left atrium.</div><div class=\"graphic_reference\">Courtesy of Ralph Shabetai, MD.</div><div id=\"graphicVersion\">Graphic 57972 Version 3.0</div></div></div>"},"57973":{"type":"graphic_table","displayName":"Criteria schwannomatosis","title":"Criteria for the diagnosis of schwannomatosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for the diagnosis of schwannomatosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Criteria for definite schwannomatosis</td> </tr> <tr> <td class=\"sublist1_start\">A. Age &#62;30 years and all of the following:</td> </tr> <tr> <td class=\"sublist1\">&#8226; Two or more nonintradermal schwannomas, at least one with histologic confirmation</td> </tr> <tr> <td class=\"sublist1\">&#8226; Diagnostic criteria for NF2 not fulfilled</td> </tr> <tr> <td class=\"sublist1\">&#8226; No evidence of vestibular tumor on high-quality MRI scan</td> </tr> <tr> <td class=\"sublist1\">&#8226; No first-degree relative with NF2</td> </tr> <tr> <td class=\"sublist1\">&#8226; No known constitutional NF2 mutation</td> </tr> <tr> <td class=\"indent2\"><strong>OR</strong></td> </tr> <tr> <td>B. One pathologically confirmed nonvestibular schwannoma plus a first-degree relative who meets above criteria</td> </tr> <tr> <td class=\"subtitle1_single\">Criteria for possible schwannomatosis</td> </tr> <tr> <td class=\"sublist1_start\">A. Age &#60;30 years and all of the following:</td> </tr> <tr> <td class=\"sublist1\">&#8226; Two or more nonintradermal schwannomas, at least one with histologic confirmation</td> </tr> <tr> <td class=\"sublist1\">&#8226; Diagnostic criteria for NF2 not fulfilled</td> </tr> <tr> <td class=\"sublist1\">&#8226; No evidence of vestibular tumor on high-quality MRI scan</td> </tr> <tr> <td class=\"sublist1\">&#8226; No first-degree relative with NF2</td> </tr> <tr> <td class=\"sublist1\">&#8226; No known constitutional NF2 mutation</td> </tr> <tr> <td class=\"indent2\"><strong>OR</strong></td> </tr> <tr> <td class=\"sublist1_start\">B. Age &#62;45 years and all of the following:</td> </tr> <tr> <td class=\"sublist1\">&#8226; Two or more nonintradermal schwannomas, at least one with histologic confirmation</td> </tr> <tr> <td class=\"sublist1\">&#8226; No symptoms of 8th cranial nerve dysfunction</td> </tr> <tr> <td class=\"sublist1\">&#8226; No first-degree relative with NF2</td> </tr> <tr> <td class=\"sublist1\">&#8226; No known constitutional NF2 mutation</td> </tr> <tr> <td class=\"indent2\"><strong>OR</strong></td> </tr> <tr> <td>C. Radiographic evidence of a nonvestibular schwannoma and first degree relative meeting criteria for definite schwannomatosis</td> </tr> <tr> <td class=\"subtitle1_single\">Criteria for segmental schwannomatosis</td> </tr> <tr> <td>Meets criteria for either definite or possible schwannomatosis and schwannomas limited to one limb or &#8804;5 contiguous spine segments</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified with permission from: MacCollin M, Chiocca EA, Evans DG, et al. Diagnostic criteria for schwannomatosis. Neurology 2005; 64:1838. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins. Criteria updated based on revisions in: Baser ME, Friedman JM, Evans DG. Increasing the specificity of diagnostic criteria for schwannomatosis. Neurology 2006; 66:730.</div><div id=\"graphicVersion\">Graphic 57973 Version 7.0</div></div></div>"},"57975":{"type":"graphic_table","displayName":"Celiac screening in children","title":"Prevalence of celiac disease in 17,201 Italian school children (age 6 to 15)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevalence of celiac disease in 17,201 Italian school children (age 6 to 15)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Percent positive</td> </tr> <tr> <td>IgG and/or IgA antigliadin antibodies</td> <td>7.50</td> </tr> <tr> <td>IgA antigliadin and/or IgA endomysial antibodies</td> <td>0.65</td> </tr> <tr> <td>Intestinal biopsy performed</td> <td>0.57</td> </tr> <tr> <td>Villous atrophy seen on biopsy</td> <td>0.44</td> </tr> <tr> <td>Not biopsied but clinically celiac</td> <td>0.04</td> </tr> <tr> <td>Previously known celiac</td> <td>0.06</td> </tr> <tr class=\"divider_top\"> <td><strong>TOTAL with diagnosis of celiac disease</strong></td> <td><strong>0.54</strong></td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Catassi C, Fabiani E, R&#228;tsch IM, et al. The coeliac iceberg in Italy: a multicentre antigliadin antibodies screening for coeliac disease in school-age subjects. Acta Paediatr 1996; 412(Suppl):29.</div><div id=\"graphicVersion\">Graphic 57975 Version 3.0</div></div></div>"},"57977":{"type":"graphic_figure","displayName":"Hymen anatomic variations","title":"Anatomic variations of the normal hymen","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Anatomic variations of the normal hymen</div><div class=\"cntnt\"><img style=\"width:537px; height:285px;\" src=\"images/OBGYN/57977_Hymen_anatomic_variations.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Modified from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012.</div><div id=\"graphicVersion\">Graphic 57977 Version 11.0</div></div></div>"},"57979":{"type":"graphic_table","displayName":"Resuscitative measures for category II and III FHR tracings","title":"Various intrauterine resuscitative measures for Category II and/or III tracings","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Various intrauterine resuscitative measures for Category II and/or III tracings</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Goal</td> <td class=\"subtitle1\">Associated FHR abnormality*</td> <td class=\"subtitle1\">Potential intervention(s)<sup>&#916;</sup></td> </tr> <tr> <td rowspan=\"4\">Promote fetal oxygenation and improve uteroplacental blood flow</td> <td rowspan=\"4\"> <ul> <li>Recurrent late decelerations </li> <li>Prolonged decelerations or bradycardia </li> <li>Minimal or absent FHR variability </li> </ul> </td> <td>Place mother in a lateral position (either left or right)</td> </tr> <tr> <td>Administer oxygen</td> </tr> <tr> <td>Give IV fluid bolus</td> </tr> <tr> <td>Reduce uterine contraction frequency</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Reduce uterine activity</td> <td rowspan=\"2\"> <ul> <li>Tachysystole with Category II or III tracing </li> </ul> </td> <td>Discontinue oxytocin or cervical ripening agents</td> </tr> <tr> <td>Administer tocolytic medication (eg, terbutaline)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Alleviate umbilical cord compression</td> <td rowspan=\"3\"> <ul> <li>Recurrent variable decelerations </li> <li>Prolonged decelerations or bradycardia </li> </ul> </td> <td>Reposition mother (left or right lateral, hands and knees)</td> </tr> <tr> <td>Perform amnioinfusion</td> </tr> <tr> <td>If umbilical cord prolapse is noted, elevate the presenting fetal part while preparing for operative delivery</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Evaluation for the underlying suspected cause(s) is also an important step in management of abnormal FHR tracings.<br />&Delta; Depending on the suspected underlying cause(s) of FHR abnormality, combining multiple interventions simultaneously may be appropriate and potentially more effective than doing individually or serially.<sup>[1]</sup></div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Simpson KR, James DC. Efficacy of intrauterine resuscitation techniques in improving fetal oxygen status during labor. Obstet Gynecol 2005; 105:1362.</li>&#xD;&#xA;</ol>&#xD;&#xA;<br />Modified and reproduced with permission from: ACOG Practice Bulletin #116. Management of intrapartum fetal heart rate tracings. Obstet Gynecol 2010; 116:1232. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 57979 Version 10.0</div></div></div>"},"57980":{"type":"graphic_diagnosticimage","displayName":"TEE pulmonic valve and pulmonary artery","title":"Pulmonic valve and pulmonary arteries on transesophageal echocardiogram","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Pulmonic valve and pulmonary arteries on transesophageal echocardiogram</div><div class=\"cntnt\"><img style=\"width:509px; height:214px;\" src=\"images/CARD/57980_TEE_pulmonic_valve_pul_arte.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A: Vertical (90º) imaging plane shows the pulmonic valve (PV), main pulmonary artery (PA), and the right (RPA) and left pulmonary arteries (LPA). Panel B: With further anterior rotation (panel B), the right ventricle (RV), tricuspid valve (TV), right (RA) and left atria (LA), interatrial septum, and aortic valve (AoV) are well seen.</div><div class=\"graphic_reference\">Courtesy of Warren Manning, MD.</div><div id=\"graphicVersion\">Graphic 57980 Version 3.0</div></div></div>"},"57981":{"type":"graphic_algorithm","displayName":"Prehospital chest pain STEMI flow sheets","title":"Example of prehospital chest pain and STEMI flow sheets","html":"<div class=\"graphic\"><div style=\"width: 643px\" class=\"figure\"><div class=\"ttl\">Example of prehospital chest pain and STEMI flow sheets</div><div class=\"cntnt\"><img style=\"width:623px; height:797px;\" src=\"images/EM/57981_Prehospit_chest_pain_STEMI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">AMI: acute myocardial infarction; COPD: chronic obstructive pulmonary disease; ECG: electrocardiogram; EMS: emergency medical system; EMT: emergency medical technician (B: basic EMT); NS: normal saline; P: paramedic;&#160;SBP: systolic blood pressure; STEMI: ST elevetion myocardial infarction</div><div class=\"graphic_reference\">Courtesy of Henderson McGinnis, MD.</div><div id=\"graphicVersion\">Graphic 57981 Version 1.0</div></div></div>"},"57982":{"type":"graphic_picture","displayName":"Atopic dermatitis antecubital","title":"Atopic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atopic dermatitis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/57982_Atopic_dermatitis_antecubit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A slightly lichenified, erythematous patch and excoriations are present in the antecubital fold.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 57982 Version 5.0</div></div></div>"},"57983":{"type":"graphic_picture","displayName":"External rotation test","title":"External rotation test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">External rotation test</div><div class=\"cntnt\"><img style=\"width:440px; height:479px;\" src=\"images/EM/57983_External_rotation_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The infraspinatus muscle is primarily responsible for external rotation of the shoulder. The muscle can be tested by having the patient attempt to externally rotate against resistance, as shown in the photograph above. The shoulder is held in adduction and the elbow bent to 90 degrees during testing.</div><div id=\"graphicVersion\">Graphic 57983 Version 2.0</div></div></div>"},"57987":{"type":"graphic_figure","displayName":"Fire ant mound","title":"Fire ant mound","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Fire ant mound</div><div class=\"cntnt\"><img style=\"width:499px; height:401px;\" src=\"images/ALLRG/57987_Fire_ant_mound.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The fire ant mound consists of a series of interlocking galleries, tunnels, and chambers that extend downward into the ground. Galleries can extend anywhere from&nbsp;one to three&nbsp;feet into the soil, usually forming an inverted cone. Foraging tunnels just below the soil surface extend several yards out from the mound with periodic exits from which workers emerge to search for food on the soil surface.</div><div class=\"graphic_reference\">Reproduced with permission from: Vinson SB, Sorensen, AA. Imported fire ants: Life history and impact. Texas Department of Agriculture 1986. Copyright © 1986 Texas Department of Agriculture.</div><div id=\"graphicVersion\">Graphic 57987 Version 2.0</div></div></div>"},"57988":{"type":"graphic_table","displayName":"WHO immunologic classification for HIV","title":"WHO immunological classification for established HIV infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">WHO immunological classification for established HIV infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">HIV-associated immunodeficiency</td> <td class=\"subtitle1\" colspan=\"4\">Age-related CD4 values</td> </tr> <tr> <td class=\"subtitle2\">&#60;11 months (CD4 percent)</td> <td class=\"subtitle2\">12 to 35 months (CD4 percent)</td> <td class=\"subtitle2\">36 to 59 months (CD4 percent)</td> <td class=\"subtitle2\">&#62;5 years (absolute number per mm<sup>3</sup> or CD4 percent)</td> </tr> <tr> <td>None or not significant</td> <td>&#62;35</td> <td>&#62;30</td> <td>&#62;25</td> <td>&#62;500</td> </tr> <tr> <td>Mild</td> <td>30 to 35</td> <td>25 to 30</td> <td>20 to 25</td> <td>350 to 499</td> </tr> <tr> <td>Moderate</td> <td>25 to 29</td> <td>20 to 24</td> <td>15 to 19</td> <td>200 to 349</td> </tr> <tr> <td>Severe</td> <td>&#60;25</td> <td>&#60;20</td> <td>&#60;15</td> <td>&#60;200 or &#60;15 percent</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">CD4 cells expressed as number of cells per mm<sup>3</sup> or percentage of total lymphocytes.</div><div class=\"graphic_footnotes\">WHO: World Health Organization; HIV: human immunodeficiency virus.<BR></div><div class=\"graphic_reference\">Reproduced with permission from: WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. World Health Organization, Geneva, Switzerland, 2007. Copyright © 2007 World Health Organization. <a href=\"http://www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf\">http://www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf</a>.</div><div id=\"graphicVersion\">Graphic 57988 Version 4.0</div></div></div>"},"57989":{"type":"graphic_picture","displayName":"Macular degeneration view PI","title":"How age-related macular degeneration affects vision","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">How age-related macular degeneration affects vision</div><div class=\"cntnt\"><img style=\"width:514px; height:215px;\" src=\"images/PI/57989_Macular_degener_view_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Age-related macular degeneration can make certain spots look blurry, especially in the center of where you are looking.</div><div class=\"graphic_reference\">Reproduced from: the National Eye Institute. Available at: <a href=\"http://www.nei.nih.gov/health/examples/\" target=\"_blank\">http://www.nei.nih.gov/health/examples/</a>.</div><div id=\"graphicVersion\">Graphic 57989 Version 2.0</div></div></div>"},"57990":{"type":"graphic_picture","displayName":"Superficial basal cell carcinoma","title":"Superficial basal cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superficial basal cell carcinoma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/57990_Superfic_basal_cell_carcin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This erythematous, slightly scaly patch is representative of a superficial basal cell carcinoma.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 57990 Version 4.0</div></div></div>"},"57991":{"type":"graphic_table","displayName":"Melanoma recur temporal pattern","title":"Recurrence patterns over time for patients with locoregional recurrence on the melanoma intergroup trial","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recurrence patterns over time for patients with locoregional recurrence on the melanoma intergroup trial</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Type of recurrence</td> <td class=\"subtitle1\" rowspan=\"2\">Number of patients recurring</td> <td class=\"subtitle1\" colspan=\"3\">Percentage of patients recurring according to duration of follow-up, in years</td> </tr> <tr> <td class=\"subtitle2\">Years 1 and 2</td> <td class=\"subtitle2\">Years 3 and 4</td> <td class=\"subtitle2\">Years 5 or more</td> </tr> <tr> <td>Local</td> <td class=\"centered\">28</td> <td class=\"centered\">14</td> <td class=\"centered\">42</td> <td class=\"centered\">42</td> </tr> <tr> <td>In transit metastases</td> <td class=\"centered\">47</td> <td class=\"centered\">19</td> <td class=\"centered\">30</td> <td class=\"centered\">51</td> </tr> <tr> <td>Regional nodal</td> <td class=\"centered\">98</td> <td class=\"centered\">17</td> <td class=\"centered\">31</td> <td class=\"centered\">51</td> </tr> <tr> <td>Distant</td> <td class=\"centered\">158</td> <td class=\"centered\">18</td> <td class=\"centered\">40</td> <td class=\"centered\">29</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Karakousis CP, et al. Ann Surg Oncol 1996; 3:466.</div><div id=\"graphicVersion\">Graphic 57991 Version 4.0</div></div></div>"},"57992":{"type":"graphic_table","displayName":"Drug and toxin related acid base disorder","title":"Agents that result in acid-base disturbances*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Agents that result in acid-base disturbances*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Acid-base disturbances</td> <td class=\"subtitle1\">Drug or toxin</td> </tr> <tr> <td>Respiratory alkalosis</td> <td>Aspirin (early)</td> </tr> <tr> <td rowspan=\"10\">Metabolic acidosis</td> <td>Methanol (delayed)</td> </tr> <tr> <td>Paraldehyde, phenformin</td> </tr> <tr> <td>Iron, isoniazid</td> </tr> <tr> <td>Lactate (cyanide, carbon monoxide, theophylline, methemoglobin inducers)</td> </tr> <tr> <td>Ethanol&nbsp;</td> </tr> <tr> <td>Ethylene glycol (delayed)</td> </tr> <tr> <td>Salicylates</td> </tr> <tr> <td>Toluene</td> </tr> <tr> <td>Ibuprofen</td> </tr> <tr> <td>Metformin</td> </tr> <tr> <td rowspan=\"4\">Respiratory acidosis</td> <td>Barbiturates</td> </tr> <tr> <td>Opiates</td> </tr> <tr> <td>Combinations of sedative-hypnotics</td> </tr> <tr> <td>Neuromuscular blocking agents</td> </tr> <tr> <td rowspan=\"2\">Metabolic alkalosis</td> <td>Diuretics</td> </tr> <tr> <td>Milk alkali syndrome</td> </tr> <tr> <td>Combined respiratory alkalosis and metabolic acidosis</td> <td>Aspirin</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from Fulop, M. J Emerg Med 1998; 16:97; and Rutecki, GW, Whittier, FC. Consultant 1991; 44.</div><div id=\"graphicVersion\">Graphic 57992 Version 3.0</div></div></div>"},"57993":{"type":"graphic_table","displayName":"Noninfectious causes of arthritis in children","title":"Noninfectious causes of arthritis/arthralgia in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Noninfectious causes of arthritis/arthralgia in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Noninfectious arthritis </td> <td class=\"subtitle1\">&nbsp; </td> </tr> <tr> <td>Hemarthrosis</td> <td>May be the first presentation of bleeding disorder</td> </tr> <tr> <td>Inflammatory bowel disease</td> <td>Extra-articular manifestations include abdominal pain, diarrhea, growth failure, weight loss, rectal bleeding, perianal skin tags, and dermatologic findings (eg, erythema nodosum, pyoderma gangrenosum)</td> </tr> <tr> <td>Juvenile idiopathic arthritis</td> <td>Joints are warm and markedly swollen, but not especially painful (patient remains ambulatory); the hip is rarely the initial joint; gradual onset of symptoms</td> </tr> <tr> <td>Psoriatic arthritis</td> <td>Positive family history, nail pitting, psoriatic rash; painful tendon or ligament insertions (enthesitis)</td> </tr> <tr> <td>Kawasaki disease</td> <td>Fever; conjunctivitis; erythema of the lips and oral mucosa; rash; extremity changes; lymphadenopathy</td> </tr> <tr> <td>Serum sickness</td> <td>Rash (usually urticarial); fever; lymphadenopathy; polyarthralgia or polyarthritis, beginning one to two weeks after exposure to the inciting agent; usually involves the metacarpophalangeal joints, knees, wrists, ankles, and shoulders; swelling and erythema are uncommon</td> </tr> <tr> <td>Henoch-Sch&#246;nlein purpura</td> <td>Palpable purpura; arthritis/arthralgia; abdominal pain; renal disease</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 57993 Version 5.0</div></div></div>"},"57996":{"type":"graphic_diagnosticimage","displayName":"Ovarian cancer ultrasound","title":"Malignant ovarian mass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Malignant ovarian mass</div><div class=\"cntnt\"><img style=\"width:331px; height:252px;\" src=\"images/PC/57996_Ovarian_cancer_ultrasound.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound image of a complex, malignant ovarian mass (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Jorge Londono, MD.</div><div id=\"graphicVersion\">Graphic 57996 Version 3.0</div></div></div>"},"57999":{"type":"graphic_movie","displayName":"Aortic regurgitation long axis echocardiogram","title":"Aortic regurgitation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aortic regurgitation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/57999_aorlngecconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:319px; height:482px;\" src=\"images/CARD/57999_aorlngec.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Long-axis view of 2-D echocardiogram of bicuspid aortic valve showing dilated left ventricle and thickening of aortic valve leaflets.</div><div id=\"graphicVersion\">Graphic 57999 Version 2.0</div></div></div>"}};